seer cancer statistics review 1975-2016...hispanic f 2000-16 .4*0 .4*0 .4*0 u.s. cancer mortality c,...

42
SEER Cancer Statistics Review 1975-2016 National Cancer Institute Joinpoint Regression Program Version 4.7, February 2019, National Cancer Institute. (https://surveillance.cancer.gov/joinpoint/). The APC is the Annual Percent Change based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130). a Trends are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta). b Trends are from the SEER 21 areas (SEER 9 areas, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts). c Trends are from US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. d The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint. e API - Asian/Pacific Islander, AI/AN - American Indian/Alaska Native, NH - Non-Hispanic f Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. g Data for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties. * The APC/AAPC is significantly different from zero (p<.05). - Joinpoint regression line analysis could not be performed on data series. JP Trend 1 JP Trend 2 JP Trend 3 JP Trend 4 JP Trend 5 JP Trend 6 AAPC d Years APC Years APC Years APC Years APC Years APC Years APC 2007-16 2012-16 SEER 9 Delay-Adjusted Incidence a , 1975-2016 All Races 1975-91 3.6* 1991-07 0.7* 2007-16 -0.6* -0.6* -0.6* White 1975-90 3.8* 1990-07 0.8* 2007-16 -0.7* -0.7* -0.7* Black 1975-95 4.5* 1995-16 0.2 0.2 0.2 SEER 21 Delay-Adjusted Incidence b , 2000-2016 All Races 2000-08 0.7* 2008-16 -0.5* -0.4* -0.5* White 2000-07 1.0* 2007-16 -0.4* -0.4* -0.4* White NH ef 2000-07 1.0* 2007-16 -0.4* -0.4* -0.4* Black 2000-16 0.3* 0.3* 0.3* Black NH ef 2000-16 0.4* 0.4* 0.4* API e 2000-16 0.3 0.3 0.3 AI/AN eg 2000-16 0.1 0.1 0.1 Hispanic f 2000-16 0.2 0.2 0.2 U.S. Cancer Mortality c , 1975-2016 All Races 1975-91 2.5* 1991-97 1.6* 1997-06 -3.1* 2006-16 -2.2* -2.2* -2.2* White 1975-91 2.5* 1991-97 1.6* 1997-06 -3.1* 2006-16 -2.2* -2.2* -2.2* Black 1975-96 2.6* 1996-16 -2.3* -2.3* -2.3* U.S. Cancer Mortality c , 2000-2016 All Races 2000-05 -3.3* 2005-16 -2.3* -2.3* -2.3* White 2000-04 -3.6* 2004-16 -2.3* -2.3* -2.3* White NH ef 2000-05 -3.4* 2005-16 -2.3* -2.3* -2.3* Black 2000-16 -2.0* -2.0* -2.0* Black NH ef 2000-16 -1.9* -1.9* -1.9* API e 2000-16 -1.7* -1.7* -1.7* AI/AN eg 2000-16 -2.1* -2.1* -2.1* Hispanic f 2000-16 -1.7* -1.7* -1.7* Table 19.1 Non-Hodgkin Lymphoma Trends in SEER Incidence ab and U.S. Mortality c Using the Joinpoint Regression Program, 1975-2016 With up to Five Joinpoints, 2000-2016 With up to Three Joinpoints, Both Sexes by Race/Ethnicity

Upload: others

Post on 13-Jul-2020

0 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Regression Program Version 47 February 2019 National Cancer Institute (httpssurveillancecancergovjoinpoint)The APC is the Annual Percent Change based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

a Trends are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)b Trends are from the SEER 21 areas (SEER 9 areas Los Angeles Alaska Native Registry Rural Georgia California excluding

SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York and Massachusetts)c Trends are from US Mortality Files National Center for Health Statistics Centers for Disease Control and Preventiond The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpointe API - AsianPacific Islander AIAN - American IndianAlaska Native NH - Non-Hispanicf Hispanic and Non-Hispanic are not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska

Natives Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registryg Data for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) counties The APCAAPC is significantly different from zero (plt05)- Joinpoint regression line analysis could not be performed on data series

JP Trend 1 JP Trend 2 JP Trend 3 JP Trend 4 JP Trend 5 JP Trend 6 AAPCd

Years APC Years APC Years APC Years APC Years APC Years APC 2007-16 2012-16

SEER 9 Delay-Adjusted Incidencea 1975-2016

All Races 1975-91 36 1991-07 07 2007-16 -06 -06 -06

White 1975-90 38 1990-07 08 2007-16 -07 -07 -07

Black 1975-95 45 1995-16 02 02 02

SEER 21 Delay-Adjusted Incidenceb 2000-2016

All Races 2000-08 07 2008-16 -05 -04 -05

White 2000-07 10 2007-16 -04 -04 -04

White NHef 2000-07 10 2007-16 -04 -04 -04

Black 2000-16 03 03 03

Black NHef 2000-16 04 04 04

APIe 2000-16 03 03 03

AIANeg 2000-16 01 01 01

Hispanicf 2000-16 02 02 02

US Cancer Mortalityc 1975-2016

All Races 1975-91 25 1991-97 16 1997-06 -31 2006-16 -22 -22 -22

White 1975-91 25 1991-97 16 1997-06 -31 2006-16 -22 -22 -22

Black 1975-96 26 1996-16 -23 -23 -23

US Cancer Mortalityc 2000-2016

All Races 2000-05 -33 2005-16 -23 -23 -23

White 2000-04 -36 2004-16 -23 -23 -23

White NHef 2000-05 -34 2005-16 -23 -23 -23

Black 2000-16 -20 -20 -20

Black NHef 2000-16 -19 -19 -19

APIe 2000-16 -17 -17 -17

AIANeg 2000-16 -21 -21 -21

Hispanicf 2000-16 -17 -17 -17

Table 191

Non-Hodgkin Lymphoma

Trends in SEER Incidenceab and US Mortalityc Using the Joinpoint Regression Program

1975-2016 With up to Five Joinpoints 2000-2016 With up to Three Joinpoints

Both Sexes by RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Regression Program Version 47 February 2019 National Cancer Institute (httpssurveillancecancergovjoinpoint)The APC is the Annual Percent Change based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

a Trends are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)b Trends are from the SEER 21 areas (SEER 9 areas Los Angeles Alaska Native Registry Rural Georgia California excluding

SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York and Massachusetts)c Trends are from US Mortality Files National Center for Health Statistics Centers for Disease Control and Preventiond The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpointe API - AsianPacific Islander AIAN - American IndianAlaska Native NH - Non-Hispanicf Hispanic and Non-Hispanic are not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska

Natives Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registryg Data for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) counties The APCAAPC is significantly different from zero (plt05)- Joinpoint regression line analysis could not be performed on data series

JP Trend 1 JP Trend 2 JP Trend 3 JP Trend 4 JP Trend 5 JP Trend 6 AAPCd

Years APC Years APC Years APC Years APC Years APC Years APC 2007-16 2012-16

SEER 9 Delay-Adjusted Incidencea 1975-2016

All Races 1975-91 42 1991-10 04 2010-16 -09 -05 -09

White 1975-90 44 1990-08 06 2008-16 -07 -05 -07

Black 1975-94 54 1994-16 -02 -02 -02

SEER 21 Delay-Adjusted Incidenceb 2000-2016

All Races 2000-08 09 2008-16 -05 -04 -05

White 2000-07 12 2007-16 -04 -04 -04

White NHef 2000-07 13 2007-16 -03 -03 -03

Black 2000-16 02 02 02

Black NHef 2000-16 02 02 02

APIe 2000-16 04 04 04

AIANeg 2000-16 -06 -06 -06

Hispanicf 2000-16 00 00 00

US Cancer Mortalityc 1975-2016

All Races 1975-91 27 1991-97 16 1997-06 -28 2006-16 -20 -20 -20

White 1975-91 26 1991-97 16 1997-06 -28 2006-16 -20 -20 -20

Black 1975-96 27 1996-16 -24 -24 -24

US Cancer Mortalityc 2000-2016

All Races 2000-06 -29 2006-16 -20 -20 -20

White 2000-06 -30 2006-16 -20 -20 -20

White NHef 2000-06 -30 2006-16 -20 -20 -20

Black 2000-16 -19 -19 -19

Black NHef 2000-16 -19 -19 -19

APIe 2000-16 -15 -15 -15

AIANeg 2000-16 -04 -04 -04

Hispanicf 2000-16 -14 -14 -14

Table 192

Non-Hodgkin Lymphoma

Trends in SEER Incidenceab and US Mortalityc Using the Joinpoint Regression Program

1975-2016 With up to Five Joinpoints 2000-2016 With up to Three Joinpoints

Males by RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Regression Program Version 47 February 2019 National Cancer Institute (httpssurveillancecancergovjoinpoint)The APC is the Annual Percent Change based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

a Trends are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)b Trends are from the SEER 21 areas (SEER 9 areas Los Angeles Alaska Native Registry Rural Georgia California excluding

SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York and Massachusetts)c Trends are from US Mortality Files National Center for Health Statistics Centers for Disease Control and Preventiond The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpointe API - AsianPacific Islander AIAN - American IndianAlaska Native NH - Non-Hispanicf Hispanic and Non-Hispanic are not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska

Natives Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registryg Data for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) counties The APCAAPC is significantly different from zero (plt05)- Joinpoint regression line analysis could not be performed on data series

JP Trend 1 JP Trend 2 JP Trend 3 JP Trend 4 JP Trend 5 JP Trend 6 AAPCd

Years APC Years APC Years APC Years APC Years APC Years APC 2007-16 2012-16

SEER 9 Delay-Adjusted Incidencea 1975-2016

All Races 1975-88 30 1988-04 14 2004-16 -07 -07 -07

White 1975-88 31 1988-04 14 2004-16 -06 -06 -06

Black 1975-04 29 2004-16 -06 -06 -06

SEER 21 Delay-Adjusted Incidenceb 2000-2016

All Races 2000-04 13 2004-16 -04 -04 -04

White 2000-06 08 2006-16 -05 -05 -05

White NHef 2000-06 08 2006-16 -05 -05 -05

Black 2000-16 05 05 05

Black NHef 2000-16 05 05 05

APIe 2000-16 03 03 03

AIANeg 2000-16 07 07 07

Hispanicf 2000-16 04 04 04

US Cancer Mortalityc 1975-2016

All Races 1975-94 22 1994-97 10 1997-08 -33 2008-16 -25 -26 -25

White 1975-97 21 1997-04 -38 2004-16 -27 -27 -27

Black 1975-96 27 1996-16 -22 -22 -22

US Cancer Mortalityc 2000-2016

All Races 2000-04 -39 2004-16 -27 -27 -27

White 2000-03 -44 2003-16 -27 -27 -27

White NHef 2000-03 -45 2003-16 -27 -27 -27

Black 2000-16 -21 -21 -21

Black NHef 2000-16 -20 -20 -20

APIe 2000-16 -19 -19 -19

AIANeg 2000-16 -37 -37 -37

Hispanicf 2000-16 -21 -21 -21

Table 193

Non-Hodgkin Lymphoma

Trends in SEER Incidenceab and US Mortalityc Using the Joinpoint Regression Program

1975-2016 With up to Five Joinpoints 2000-2016 With up to Three Joinpoints

Females by RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Reference Cancer Incidence Rates Adjusted for Reporting DelayIndividual rates for diagnosis years 1975-1979 available in web browser version of Cancer Statistics Review

a SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

- Delay-adjusted rate is not shown for observed rates based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

Year of Diagnosis1975-1979 1160 1344 1018 1209 1393 1068 696 874 5521980 1262 1501 1081 1298 1528 1122 870 1074 7201981 1358 1590 1181 1406 1634 1235 742 1059 4981982 1339 1556 1161 1402 1642 1205 1027 1022 10011983 1399 1662 1195 1463 1752 1240 1028 1088 9621984 1519 1829 1279 1597 1910 1355 946 1252 6921985 1551 1839 1316 1628 1925 1385 995 1196 8431986 1590 1943 1300 1683 2059 1375 1066 1313 8521987 1674 2078 1342 1770 2215 1400 1035 1043 9951988 1726 2136 1408 1822 2245 1490 1158 1579 8491989 1736 2165 1384 1836 2304 1450 1159 1410 9721990 1851 2297 1481 1934 2396 1549 1392 1763 11021991 1881 2374 1461 1970 2481 1532 1403 1881 10291992 1862 2304 1494 1956 2394 1584 1368 1887 9651993 1885 2347 1500 1965 2432 1570 1423 1937 9971994 1995 2496 1579 2067 2558 1654 1448 2152 8861995 1999 2542 1545 2070 2618 1604 1676 2363 11431996 1942 2424 1548 2027 2520 1621 1554 1925 12391997 2000 2453 1646 2090 2522 1749 1640 2426 10861998 1962 2296 1686 2061 2401 1778 1449 1696 12541999 1997 2459 1636 2095 2554 1732 1441 1842 11372000 1981 2434 1613 2099 2571 1712 1393 1823 10742001 2002 2440 1646 2082 2547 1706 1605 1844 13922002 2023 2420 1710 2134 2552 1798 1448 1710 12512003 2078 2506 1753 2191 2633 1848 1637 2006 13782004 2140 2589 1795 2235 2685 1885 1860 2418 14552005 2088 2563 1709 2202 2674 1820 1673 1995 14102006 2052 2475 1724 2178 2608 1839 1639 2102 12942007 2126 2612 1739 2255 2755 1845 1583 1935 13172008 2097 2580 1703 2185 2687 1768 1694 1899 15082009 2097 2528 1747 2204 2669 1814 1540 1867 12992010 2151 2676 1724 2250 2758 1831 1781 2343 13342011 1996 2450 1637 2093 2564 1716 1472 1769 12512012 2049 2511 1674 2147 2618 1757 1682 1926 14652013 1993 2438 1630 2101 2559 1719 1586 1838 13932014 2047 2531 1651 2172 2653 1777 1545 2042 11522015 2037 2521 1643 2161 2652 1754 1550 1998 12062016 1984 2403 1640 2078 2499 1726 1686 1980 1433

Table 194Non-Hodgkin Lymphoma

Delay-adjusted SEER Incidencea Rates by Year Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Individual rates for diagnosis years 1975-1979 available in web browser version of Cancer Statistics Reviewa SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)

Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

Year of Diagnosis1975-2016 1846 2267 1513 1925 2357 1581 1414 1769 11351975-1979 1160 1344 1018 1209 1393 1068 696 874 5521980 1262 1501 1081 1298 1528 1122 870 1074 7201981 1358 1590 1181 1406 1634 1235 742 1059 4981982 1339 1556 1161 1402 1642 1205 1027 1022 10011983 1399 1662 1195 1463 1752 1240 1028 1088 9621984 1519 1829 1279 1597 1910 1355 946 1252 6921985 1551 1839 1316 1628 1925 1385 995 1196 8431986 1590 1943 1300 1683 2059 1375 1066 1313 8521987 1674 2078 1342 1770 2215 1400 1035 1043 9951988 1726 2136 1408 1822 2245 1490 1158 1579 8491989 1736 2165 1384 1836 2304 1450 1159 1410 9721990 1851 2297 1481 1934 2396 1549 1392 1763 11021991 1881 2374 1461 1970 2481 1532 1403 1881 10291992 1862 2304 1494 1956 2394 1584 1368 1887 9651993 1885 2347 1500 1965 2432 1570 1423 1937 9971994 1995 2496 1579 2067 2558 1654 1448 2152 8861995 1999 2542 1545 2070 2618 1604 1676 2363 11431996 1942 2424 1548 2027 2520 1621 1554 1925 12391997 2000 2453 1646 2090 2522 1749 1640 2426 10861998 1962 2296 1686 2061 2401 1778 1449 1696 12541999 1997 2459 1636 2095 2554 1732 1441 1842 11372000 1981 2434 1613 2099 2571 1712 1393 1823 10742001 2002 2440 1646 2082 2547 1706 1605 1844 13922002 2023 2420 1710 2134 2552 1798 1448 1710 12512003 2078 2506 1753 2191 2633 1848 1637 2006 13782004 2140 2589 1795 2235 2685 1885 1860 2418 14552005 2088 2563 1709 2202 2674 1820 1673 1995 14102006 2052 2475 1724 2178 2608 1839 1639 2102 12942007 2126 2612 1739 2255 2755 1845 1583 1935 13172008 2093 2575 1700 2180 2681 1765 1689 1894 15032009 2089 2520 1741 2195 2659 1806 1531 1856 12912010 2141 2662 1715 2237 2742 1820 1767 2323 13232011 1982 2433 1626 2076 2544 1702 1455 1749 12372012 2031 2489 1659 2125 2591 1739 1658 1897 14442013 1973 2414 1613 2076 2529 1699 1558 1807 13682014 2020 2497 1629 2138 2612 1749 1512 1998 11282015 2003 2478 1615 2118 2600 1718 1510 1947 11742016 1936 2344 1600 2018 2428 1676 1625 1909 1382

Table 195Non-Hodgkin Lymphoma

Age-adjusted SEER Incidencea Rates by Year Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Individual rates for years of death 1975-1979 available in web browser version of Cancer Statistics Reviewa US Mortality Files National Center for Health Statistics Centers for Disease Control and Prevention

Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

Year of Death1975-2016 701 880 570 732 915 596 478 613 3801975-1979 580 708 484 602 733 503 375 483 2921980 623 747 529 647 774 552 399 515 3121981 616 738 527 640 766 547 398 500 3251982 655 798 549 683 829 574 412 523 3291983 666 811 558 692 839 585 430 579 3231984 676 815 575 705 850 601 419 528 3391985 706 880 580 734 917 602 462 557 3871986 731 898 605 759 925 633 495 664 3701987 726 881 610 756 912 638 473 630 3621988 752 928 624 782 959 653 501 682 3721989 783 973 643 812 1004 671 533 710 4071990 787 997 634 816 1032 658 539 713 4171991 819 1015 674 850 1052 700 570 717 4611992 822 1030 669 853 1066 696 564 723 4451993 825 1014 686 857 1045 717 569 753 4401994 863 1075 710 900 1120 741 554 682 4561995 872 1081 716 909 1121 749 579 762 4451996 875 1094 714 909 1129 746 621 825 4741997 888 1103 725 921 1135 757 634 845 4871998 869 1085 710 903 1127 738 599 750 4891999 832 1036 685 867 1071 718 565 744 4412000 817 1020 670 854 1063 701 520 661 4172001 791 998 642 821 1031 668 561 728 4472002 765 966 619 797 1004 644 541 688 4412003 738 940 592 769 981 613 494 583 4272004 709 894 573 738 928 596 501 623 4132005 695 887 556 724 922 579 477 611 3812006 674 848 544 701 878 566 492 627 3932007 659 836 526 686 867 549 452 577 3622008 641 820 509 671 856 533 431 548 3452009 630 812 493 656 842 513 449 615 3412010 614 783 485 637 811 504 457 584 3642011 603 785 464 629 817 483 436 574 3402012 591 762 461 617 795 480 426 538 3482013 571 738 444 595 767 462 411 527 3332014 565 726 443 589 755 460 418 528 3422015 547 713 418 569 741 434 404 519 3212016 537 691 417 562 721 436 383 481 311

Table 196Non-Hodgkin Lymphoma

Age-adjusted US Deatha Rates by Year Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a SEER 21 areas Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)unless noted

b US Mortality Files National Center for Health Statistics Centers for Disease Control and PreventionRates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) unless noted

c Rates are per 100000 and are age-adjusted to the world (WHO 2000-2025) standard million- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER IncidenceAge at DiagnosisAge-Adjusted Rates 2012-2016All ages 196 239 162 206 250 170 147 177 124Under 65 94 111 78 96 113 80 91 109 7665 and over 904 1126 743 966 1199 794 532 646 461

All ages (WHO world std)c 147 177 122 154 184 127 117 140 98

Age-Specific Rates 2012-2016lt1 - - - - - - - - -1-4 08 11 05 08 11 06 06 07 -5-9 12 17 07 13 18 07 10 13 0810-14 15 20 10 14 19 10 16 21 1115-19 21 27 14 20 26 14 20 28 1220-24 27 32 22 26 31 21 28 35 2025-29 35 40 29 34 39 28 41 48 3430-34 49 56 42 48 54 41 56 67 4735-39 72 85 59 71 83 58 81 98 6640-44 99 117 80 99 117 80 108 128 9045-49 145 168 122 147 169 125 156 190 12750-54 222 256 189 229 264 194 217 250 18755-59 312 366 261 326 379 274 277 332 23060-64 445 522 376 470 548 396 363 426 31165-69 629 742 528 667 781 564 447 522 39070-74 833 997 697 890 1058 746 522 640 43975-79 1044 1287 855 1124 1384 918 588 692 52080-84 1193 1522 966 1280 1631 1031 650 791 57385+ 1079 1499 861 1146 1589 915 508 685 434

US MortalityAge at DeathAge-Adjusted Rates 2012-2016All ages 56 73 44 59 76 45 41 52 33Under 65 13 17 10 13 17 09 16 21 1265 and over 352 453 279 372 477 295 210 265 176

All ages (WHO world std)c 30 39 23 31 40 23 25 32 20

Age-Specific Rates 2012-2016lt1 - - - - - - - - -1-4 00 01 - 00 01 - - - -5-9 01 01 00 00 01 - 01 - -10-14 01 01 01 01 01 01 - - -15-19 01 02 01 01 02 01 02 02 -20-24 02 03 02 02 03 02 04 04 0325-29 04 05 03 03 04 02 05 07 0430-34 05 07 04 05 06 03 09 12 0635-39 07 09 05 06 08 04 11 14 0940-44 11 14 08 10 13 08 18 21 1545-49 18 23 13 17 22 13 24 32 1750-54 31 41 21 31 41 21 37 49 2655-59 53 71 37 54 72 36 58 74 4460-64 90 118 64 92 121 64 90 116 6965-69 142 184 105 149 192 109 116 146 9370-74 244 309 188 256 324 197 167 214 13375-79 374 473 294 397 501 312 220 275 18480-84 567 725 455 600 764 481 321 405 27485+ 751 994 624 795 1049 662 360 457 320

Table 197Non-Hodgkin Lymphoma

SEER Incidencea and US Deathb Rates Age-Adjusted and Age-Specific Rates by Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on End Results data from a series of hospital registries and one population-based registryb SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)

Based on follow-up of patients into 2016 Expected survival rates are derived from the US Annual Life Tablesc SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER programBased on follow-up of patients into 2016

d Period survival provides a 2015 estimate of survival by piecing together the most recent conditional survival estimatesfrom several cohorts It is computed here using three year calendar blocks (2010-2012 0-1 year survival)(2009-2011 1-2 year survival) (2008-2010 2-3 year survival) (2007-2009 3-4 year survival) (2006-2008 4-5 years survival)

e Stage at diagnosis is classified using SEER Summary Stage 2000 Stage distribution percentages may not sum to 100 due to roundingf The difference between 1975-1977 and 2009-2015 is statistically significant (plt05)g The standard error is between 5 and 10 percentage pointsh The standard error is greater than 10 percentage points- Statistic could not be calculated due to fewer than 25 cases during the time period

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

5-Year Relative Survival (Percent)Year of Diagnosis1960-1963a - - - 31 31 31 - - -1970-1973a - - - 41 39 43 - - -1975-1977b 465 456 475 468 463 473 486 426 553g

1978-1980b 479 461 498 479 462 495 511 469 5671981-1983b 506 503 509 508 505 511 495 492 4981984-1986b 516 501 534 521 507 537 468 445 4991987-1989b 509 476 549 513 482 552 457 413 5101990-1992b 507 467 557 515 476 564 422 384 4761993-1995b 526 487 575 533 498 577 425 359 5491996-1998b 588 570 610 595 577 615 547 531 5721999-2001b 640 614 670 650 628 676 558 490 6382002-2004b 698 686 712 710 701 721 636 611 6662005-2008b 716 706 727 728 719 738 625 578 6752009-2015b 747f 739f 757f 757f 748f 767f 695f 670f 724f

5-Year Period Survival (Percent)cd

2015 722 705 743 726 708 747 671 641 703

Stage Distribution () 2009-2015ce

All StagesNumber of cases 97737 53606 44131 80120 44109 36011 8184 4388 3796Percent 100 100 100 100 100 100 100 100 100Localized 27 27 29 27 26 28 28 25 31Regional 15 15 15 15 15 15 15 15 15Distant 50 51 48 51 52 49 51 54 48UnstagedUnknown 8 7 8 7 7 8 6 6 7

5-Year Relative Survival (Percent) 2009-2015c

Age at DiagnosisAges lt45 840 820 870 855 836 885 735 708 776Ages 45-54 810 777 859 826 795 872 687 639 750Ages 55-64 770 742 809 781 754 818 678 620 749Ages 65-74 725 706 747 731 711 755 656 623 682Ages 75+ 554 539 568 557 538 574 482 449 500Ages lt65 800 773 838 812 787 849 701 659 759Ages 65+ 638 627 649 641 628 655 584 562 598

StageeAll Stages 720 707 737 724 711 740 665 637 698Localized 840 830 850 843 833 852 810 766 850Regional 750 751 749 755 756 755 689 698 678Distant 648 633 668 657 642 677 580 557 610UnstagedUnknown 703 686 723 679 662 698 659 648 666

Table 198Non-Hodgkin Lymphoma

5-Year Relative and Period Survival (Percent) by Race Sex Diagnosis Year and Age

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Expected survival rates are derived from the US Annual Life Tables

1975- 1980- 1985- 1990-1979 1984 1989 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Survival Time

1-year 702 730 713 704 703 733 756 767 774 773 787 810 803 811 817 810 816 841 839 844 834 842 844 834 8452-year 602 637 628 622 618 659 685 700 710 714 733 760 757 760 773 769 775 790 795 796 797 800 800 7953-year 546 585 582 577 575 621 649 664 669 679 701 731 731 735 748 745 750 762 773 774 775 779 7794-year 505 546 543 544 547 587 621 636 645 655 681 712 716 715 730 726 732 744 756 752 756 7675-year 468 507 510 516 520 561 594 609 621 638 660 693 700 701 716 705 712 728 741 742 7426-year 436 475 483 492 499 541 571 583 595 621 647 680 683 688 704 688 701 718 721 7237-year 408 450 458 470 479 522 552 564 577 605 629 663 671 672 685 672 688 702 7108-year 385 428 434 450 464 504 529 552 563 589 613 651 658 666 670 661 674 6909-year 366 408 415 435 453 493 515 535 548 576 600 640 648 649 652 651 66110-year 350 389 398 421 443 481 501 522 537 563 589 632 633 638 634 63711-year 335 374 385 406 434 466 488 511 525 548 581 618 621 630 63112-year 324 360 369 395 423 457 481 501 512 535 568 600 615 61713-year 314 348 358 383 415 449 469 492 500 520 561 593 60214-year 302 335 347 372 406 443 456 485 488 513 549 58315-year 289 322 335 365 398 437 447 474 478 505 54016-year 279 312 328 356 393 437 433 472 470 49217-year 274 304 321 349 388 428 428 469 45818-year 268 296 314 341 378 420 419 46319-year 260 288 306 333 370 413 41220-year 252 280 301 329 359 408

Table 199Non-Hodgkin Lymphoma

SEERa Relative Survival (Percent)By Year of Diagnosis

All Races Males and Females

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Expected survival rates are derived from the US Annual Life Tables

1975- 1980- 1985- 1990-1979 1984 1989 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Survival Time

1-year 694 727 689 671 666 712 747 749 758 765 776 806 797 801 811 810 814 836 828 838 838 841 834 830 8352-year 594 637 605 582 583 636 672 682 691 703 713 752 749 755 762 765 778 779 781 788 798 793 786 7913-year 534 580 557 537 545 598 638 645 644 668 679 720 726 726 731 736 754 751 757 766 776 769 7644-year 493 539 516 504 515 561 610 620 615 639 657 700 709 701 711 713 734 734 737 743 756 7575-year 455 501 482 476 485 537 583 592 590 617 635 679 689 688 699 689 710 721 724 735 7426-year 426 466 455 456 469 510 561 565 562 602 620 667 669 676 684 670 696 715 706 7177-year 399 442 431 436 449 491 542 544 546 587 601 652 658 655 668 651 682 696 6968-year 378 420 410 418 433 474 520 533 536 567 582 637 645 649 650 634 665 6869-year 357 401 391 402 423 465 504 514 523 553 572 628 633 632 636 618 65210-year 340 380 377 392 416 455 489 503 515 542 560 617 617 620 613 60911-year 328 363 364 381 407 437 477 494 508 527 547 603 605 612 61212-year 319 352 351 372 395 427 472 482 498 515 537 589 601 59613-year 307 342 343 361 389 419 456 467 491 501 531 582 59114-year 295 330 332 350 378 414 444 461 480 496 521 57215-year 281 319 324 344 368 409 435 453 473 488 51216-year 272 308 316 333 361 409 426 453 471 47417-year 265 300 308 326 358 403 420 449 46218-year 261 294 302 320 350 396 410 44219-year 256 287 294 313 342 391 40320-year 250 280 291 309 332 387

Table 1910Non-Hodgkin Lymphoma

SEERa Relative Survival (Percent)By Year of Diagnosis

All Races Males

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Expected survival rates are derived from the US Annual Life Tables

1975- 1980- 1985- 1990-1979 1984 1989 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Survival Time

1-year 710 734 741 747 752 759 767 786 792 782 801 814 810 821 825 809 819 847 854 851 830 843 856 838 8572-year 611 637 656 672 664 688 701 720 734 727 758 769 765 767 786 774 772 804 812 807 796 810 817 7993-year 559 589 611 627 616 649 662 684 700 692 727 744 736 746 768 756 746 774 791 786 774 791 7974-year 519 553 576 595 590 619 634 653 681 674 710 725 724 730 751 739 729 757 778 764 755 7805-year 482 514 544 567 565 591 608 629 658 664 688 708 713 716 736 724 715 735 763 751 7426-year 446 484 517 539 540 580 583 603 635 643 679 695 699 701 727 708 707 722 738 7317-year 417 458 490 512 520 560 563 586 615 626 663 674 687 692 704 698 694 709 7268-year 392 437 463 491 505 542 539 573 596 615 649 667 672 684 693 692 684 6949-year 374 416 443 476 492 529 528 557 578 603 633 654 664 669 671 688 67110-year 360 399 424 458 480 514 516 542 562 588 625 648 651 658 659 66911-year 342 385 409 438 469 503 500 529 547 573 621 636 640 651 65312-year 329 368 390 425 460 494 493 523 529 560 606 613 632 64013-year 321 353 376 411 449 486 485 518 510 543 598 606 61514-year 310 340 365 400 442 479 470 512 497 532 582 59615-year 297 326 349 391 436 472 460 498 483 525 57416-year 287 316 342 385 435 467 441 492 468 51317-year 282 306 336 378 428 459 438 490 45218-year 274 298 327 367 413 449 428 48519-year 265 288 321 358 407 439 42220-year 254 280 312 353 395 433

Table 1911Non-Hodgkin Lymphoma

SEERa Relative Survival (Percent)By Year of Diagnosis

All Races Females

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 5222 2506 2704 3176 3627 3994 4570 4729 5325 5260 5263 5562 5775 6226 6401 6704 6998 7072 11154

SEER 9 except 4285 2088 2267 2603 2819 3091 3507 3694 4159 4249 4364 4515 4818 5209 5398 5628 5841 6015 9363SF-Oakland

San Francisco- 937 418 437 573 808 903 1063 1035 1166 1011 899 1047 957 1017 1003 1076 1157 1057 1791Oakland SMSAc

San Francisco 245 96 123 210 326 393 467 410 450 354 213 256 220 283 219 216 240 225 362CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 134 155 161 183 201 215 234 233 252 244 238 244 246 258 254 255 255 245 244

SEER 9 except 132 154 161 181 188 201 217 218 236 236 235 236 244 256 254 253 252 247 243SF-Oakland

San Francisco- 147 158 160 194 267 285 317 305 335 288 252 286 256 266 256 263 268 235 246Oakland SMSAc

San Francisco 143 144 176 293 444 519 610 523 574 448 274 325 269 354 265 257 273 252 246CityCounty

Table 1912

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males All Ages

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males All Ages

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 0-19 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 223 87 108 91 94 84 100 89 120 105 104 119 127 107 106 143 134 155 240

SEER 9 except 191 78 95 82 80 76 86 74 107 84 93 100 115 90 87 114 119 129 198SF-Oakland

San Francisco- 32 9 13 9 14 8 14 15 13 21 11 19 12 17 19 29 15 26 42Oakland SMSAc

San Francisco 9 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 5 lt4 6 lt4CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 12 12 16 14 14 13 15 13 17 14 14 15 16 14 13 18 17 20 20

SEER 9 except 12 13 16 14 14 13 15 12 17 13 14 15 17 13 13 16 17 19 19SF-Oakland

San Francisco- 14 10 15 10 16 09 15 16 13 21 11 18 12 17 19 28 14 25 27Oakland SMSAc

San Francisco 23 - - - - - - - - - - - - - - 40 - 49 -CityCounty

Table 1913

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 0-19

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 0-19

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 20-54 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 1463 687 723 958 1211 1413 1766 1830 2089 1770 1608 1696 1623 1722 1655 1693 1674 1596 2242

SEER 9 except 1208 563 588 730 827 923 1195 1294 1483 1325 1269 1327 1308 1410 1383 1401 1402 1328 1848SF-Oakland

San Francisco- 255 124 135 228 384 490 571 536 606 445 339 369 315 312 272 292 272 268 394Oakland SMSAc

San Francisco 58 29 34 105 215 288 333 303 317 225 105 115 111 111 86 75 73 71 98CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 69 79 82 104 124 136 159 156 169 138 121 124 117 123 116 118 116 111 104

SEER 9 except 69 78 81 97 103 109 131 134 144 123 115 116 112 119 115 116 115 110 103SF-Oakland

San Francisco- 69 84 89 139 226 264 295 267 298 213 156 164 139 141 123 130 118 114 110Oakland SMSAc

San Francisco 67 88 94 272 565 715 813 724 744 510 230 252 239 248 194 162 152 145 129CityCounty

Table 1914

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 20-54

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 20-54

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 55+ and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 3536 1732 1873 2127 2322 2497 2704 2810 3116 3385 3551 3747 4025 4397 4640 4868 5190 5321 8672

SEER 9 except 2886 1447 1584 1791 1912 2092 2226 2326 2569 2840 3002 3088 3395 3709 3928 4113 4320 4558 7317SF-Oakland

San Francisco- 650 285 289 336 410 405 478 484 547 545 549 659 630 688 712 755 870 763 1355Oakland SMSAc

San Francisco 178 65 88 104 109 105 132 106 130 126 106 141 108 169 131 136 164 148 261CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 451 522 540 596 633 673 701 706 761 800 811 831 858 900 901 891 899 862 871

SEER 9 except 440 521 544 601 620 667 687 692 744 797 813 813 858 901 904 891 888 874 874SF-Oakland

San Francisco- 508 528 520 571 702 703 773 783 854 821 800 932 855 894 888 890 959 800 860Oakland SMSAc

San Francisco 482 446 598 727 739 757 934 747 914 872 727 934 690 1047 764 769 889 776 826CityCounty

Table 1915

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 55+

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 55+

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 003 006 217 072 Asian 0 001 003 005 183 072

10 002 005 011 218 073 Pacific 10 002 004 009 184 073

20 003 009 021 217 073 Islander 20 003 007 015 182 073

30 006 018 042 216 073 30 005 013 029 180 073

40 012 037 082 213 074 40 008 024 057 176 073

50 025 072 139 206 074 50 017 049 101 170 073

60 049 120 177 191 075 60 034 087 139 158 072

70 080 144 - 160 072 70 056 112 - 133 068

80 085 - - 106 062 80 066 - - 091 056

White 0 001 003 006 227 075 American 0 001 002 003 116 049

10 002 005 011 228 076 Indian 10 002 002 005 117 050

20 003 009 021 227 076 Alaska 20 001 003 008 116 050

30 006 018 043 226 077 Nativea 30 003 007 022 117 051

40 012 038 085 223 077 40 004 019 041 117 052

50 026 075 147 217 078 50 016 038 078 118 053

60 052 127 187 201 078 60 024 067 105 109 055

70 085 153 - 169 076 70 048 091 - 096 055

80 090 - - 111 065 80 057 - - 064 043

Black 0 001 002 006 138 042 Hispanicb 0 001 002 005 222 073

10 002 005 011 140 043 10 001 004 009 223 074

20 003 010 022 139 043 20 003 008 019 222 074

30 006 019 041 137 043 30 005 016 040 221 074

40 013 035 068 133 043 40 011 035 078 218 074

50 023 057 093 125 043 50 024 068 133 211 074

60 037 076 102 110 042 60 046 114 173 195 074

70 047 078 - 087 038 70 075 140 - 164 070

80 044 - - 057 032 80 081 - - 112 057

Table 1916

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Both Sexes 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 004 007 243 081 Asian 0 001 003 006 213 085

10 002 006 013 244 082 Pacific 10 002 005 011 213 086

20 004 010 024 243 082 Islander 20 003 009 018 211 086

30 007 021 049 243 083 30 006 015 034 210 086

40 014 042 094 240 084 40 009 028 067 205 086

50 029 082 158 233 085 50 019 059 117 199 086

60 057 139 203 219 086 60 041 101 161 187 085

70 095 170 - 188 084 70 066 131 - 159 082

80 105 - - 130 073 80 080 - - 114 069

White 0 001 004 007 254 085 American 0 001 003 004 104 057

10 002 006 013 255 086 Indian 10 002 003 006 105 058

20 004 010 024 254 086 Alaska 20 001 004 008 103 058

30 007 020 049 253 087 Nativea 30 003 008 021 104 059

40 014 043 097 251 088 40 005 018 038 105 060

50 030 086 167 244 089 50 014 035 071 105 062

60 059 147 215 230 090 60 023 062 094 099 065

70 101 180 - 198 088 70 046 084 - 090 066

80 112 - - 136 076 80 053 - - 061 053

Black 0 001 003 007 152 046 Hispanicb 0 001 003 005 238 083

10 002 006 014 154 047 10 002 005 011 239 084

20 004 012 027 153 047 20 003 009 021 238 084

30 008 023 048 152 047 30 006 018 043 238 084

40 016 042 079 148 047 40 012 037 083 235 085

50 027 066 105 138 047 50 026 073 145 228 085

60 043 087 114 123 045 60 050 126 189 214 085

70 054 088 - 099 042 70 086 157 - 185 081

80 053 - - 070 036 80 094 - - 131 066

Table 1917

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Males 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 002 004 193 064 Asian 0 001 002 004 159 063

10 001 004 009 195 064 Pacific 10 001 004 008 160 063

20 003 007 017 194 064 Islander 20 002 006 013 159 063

30 005 015 036 192 065 30 004 011 025 157 063

40 010 031 071 189 065 40 007 021 048 153 063

50 022 062 120 182 065 50 014 042 087 148 063

60 042 103 154 168 065 60 028 074 122 136 062

70 067 123 - 138 063 70 049 099 - 114 058

80 071 - - 090 054 80 057 - - 075 047

White 0 001 002 004 203 067 American 0 000 001 002 128 043

10 001 004 009 204 067 Indian 10 001 001 004 129 044

20 002 007 017 203 067 Alaska 20 001 003 007 128 044

30 005 015 037 201 067 Nativea 30 002 006 023 129 044

40 010 032 074 198 068 40 004 021 044 129 045

50 022 065 127 192 068 50 017 042 085 129 046

60 044 109 163 177 068 60 026 072 113 118 047

70 072 130 - 146 066 70 050 097 - 102 046

80 075 - - 094 056 80 060 - - 066 037

Black 0 000 002 004 126 040 Hispanicb 0 001 002 004 210 065

10 001 004 009 128 040 10 001 004 008 211 066

20 003 008 018 127 040 20 002 007 017 211 066

30 005 015 034 125 040 30 004 014 036 209 066

40 010 029 058 122 040 40 010 032 073 206 066

50 020 049 083 115 040 50 022 064 123 198 066

60 032 068 094 102 039 60 043 104 161 182 065

70 041 071 - 080 036 70 066 127 - 149 062

80 039 - - 051 030 80 073 - - 100 051

Table 1918

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Females 2014-2016 By RaceEthnicity

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

The AAPC is the Average Annual Percent Change over the time interval The AAPCs are calculated bythe Joinpoint Regression Program Version 47 February 2019 National Cancer Institute

- Statistic not shown Rate based on less than 16 cases for the time intervalTrend based on less than 10 cases for at least one year within the time interval

a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) Trendsare based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico SeattleUtah and AtlantaThe SEER 21 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the AlaskaNative Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts

c The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 3 Joinpoints overdiagnosis years 2000-2016

d The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 5 Joinpoints overdiagnosis years 1975-2016

e Hispanic and Non-Hispanic are not mutually exclusive from whites blacks AsianPacificIslanders and American IndiansAlaska Natives Incidence data for Hispanics and Non-Hispanicsare based on NHIA and exclude cases from the Alaska Native Registry

f Incidence data for American IndianAlaska Native are based on the PurchasedReferred CareDelivery Area (PRCDA) counties

g US Mortality Files National Center for Health Statistics CDCh The 2007-2016 mortality AAPCs are based on a Joinpoint analysis using years of death 2000-2016 The APC is significantly different from zero (plt05)

SEER Incidence SEER 21 Areasb SEER 21 Areasb SEER 9 Areasb

Rate 2012-2016 Trend 2007-2016c Trend 2007-2016d

Rate per 100000 persons AAPC () AAPC ()

Total Males Females Total Males Females Total Males Females RaceEthnicity

All Races 196 239 162 -07 -09 -08 -09 -07 -08

White 206 250 170 -08 -11 -09 -09 -08 -08White Hispanice 183 212 161 -08 -03 -05 - - -White Non-Hispanice 210 256 172 -08 -06 -10 - - -

Black 147 177 124 01 00 03 00 -04 -09

AsianPacific Islander 134 164 110 00 00 -01 - - -

Amer IndAlaska Natf 113 120 106 -05 -12 00 - - -

Hispanice 179 207 157 -05 -02 03 - - -

US Mortalityg Rate 2012-2016 Trend 2007-2016h

Rate per 100000 persons AAPC ()

Total Males Females Total Males FemalesRaceEthnicity

All Races 56 73 44 -23 -20 -27

White 59 76 45 -23 -20 -27White Hispanice 51 65 40 -16 -13 -20White Non-Hispanice 59 76 46 -23 -20 -27

Black 41 52 33 -20 -19 -21

AsianPacific Islander 39 49 31 -17 -15 -19

Amer IndAlaska NatTotal US 31 40 24 -32 -20 -45PRCDA Counties 44 58 33 -21 -04 -37Non-PRCDA Counties 17 21 14 -54 -50 -60

Hispanice 48 61 38 -17 -14 -21

Table 1919Non-Hodgkin Lymphoma

SEER Incidence and US MortalityAge-Adjusted Rates and Trendsa

By RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Incidence Ratesa 2012-2016

California 1844 2241 1515 1938 2349 1591 1390 1639 1182Greater Bay Area 1957 2381 1600 2144 2601 1755 1628 1828 1436San Francisco-Oakland 1956 2421 1570 2174 2660 1765 1603 1816 1408San Jose-Monterey 1962 2311 1660 2097 2503 1742 1800 1891 1646

Los Angeles 1804 2176 1505 1951 2331 1637 1357 1659 1139Greater California 1822 2220 1489 1876 2286 1529 1314 1534 1113

Connecticut 2116 2607 1733 2154 2642 1771 1386 1829 1051Detroit 2132 2636 1742 2290 2850 1847 1620 1905 1409Georgia 1826 2244 1487 1936 2346 1588 1462 1833 1187Atlanta 1925 2381 1555 2119 2567 1736 1601 2034 1272Rural Georgia 1584 1790 1401 1953 2298 1567 807 - 988Greater Georgia 1784 2186 1459 1872 2274 1537 1380 1703 1146

Hawaii 1660 2024 1349 1958 2275 1593 - - -Idaho 1922 2267 1616 1920 2262 1618 - - -Iowa 2134 2601 1756 2148 2612 1773 1352 1602 1100Kentucky 2039 2505 1666 2070 2538 1693 1403 1788 1112Louisiana 1944 2352 1614 2106 2537 1744 1469 1769 1237Massachusetts 1810 2181 1518 1830 2214 1524 1452 1655 1299New Jersey 2155 2607 1804 2285 2765 1905 1387 1621 1222New Mexico 1550 1739 1387 1580 1798 1394 875 - -New York 2152 2620 1788 2306 2792 1915 1545 1852 1333Seattle-Puget Sound 2116 2627 1695 2177 2667 1766 1631 1973 1316Utah 1843 2233 1498 1862 2258 1513 2089 - -

SEER 9 Areasb 1992 2444 1623 2095 2551 1716 1573 1914 1298SEER 13 Areasb 1946 2373 1597 2064 2502 1700 1519 1853 1258SEER 18 Areasb 1933 2354 1590 2031 2464 1671 1449 1751 1214SEER 21 Areasb 1963 2388 1620 2061 2498 1702 1471 1771 1245

Table 1920Non-Hodgkin Lymphoma

Age-Adjusted SEER Incidence Ratesa

By Registry Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control and PreventionRates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and AtlantaThe SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Death Ratesa 2012-2016

California 533 677 423 570 726 449 417 480 367Greater Bay Area 505 671 376 561 756 408 410 491 331San Francisco-Oakland 503 667 376 555 742 409 416 490 343San Jose-Monterey 511 681 377 573 781 407 - - -

Los Angeles 541 670 443 589 728 481 424 503 371Greater California 539 682 429 564 716 447 416 455 384

Connecticut 533 705 407 547 717 421 350 510 244Detroit 639 822 505 693 895 542 443 528 384Georgia 533 697 411 580 747 450 376 503 286Atlanta 492 659 372 533 728 388 397 506 317Rural Georgia 559 731 388 670 813 507 - - -Greater Georgia 549 712 426 595 755 470 363 500 266

Hawaii 475 620 352 545 649 412 - - -Idaho 635 775 510 641 782 516 - - -Iowa 638 845 484 642 848 488 - - -Kentucky 642 886 460 655 904 470 401 557 284Louisiana 608 814 451 651 863 485 461 623 340Massachusetts 523 659 423 541 682 436 347 410 297New Jersey 545 721 419 585 780 443 372 466 314New Mexico 488 585 405 493 595 406 - - -New York 535 702 412 575 752 441 390 514 313Seattle-Puget Sound 585 749 463 604 769 480 490 562 397Utah 542 670 433 551 681 440 - - -

SEER 9 Areasb 555 719 430 586 758 454 414 522 333SEER 13 Areasb 549 705 429 586 753 457 419 521 342SEER 18 Areasb 554 717 431 589 761 456 409 518 329SEER 21 Areasb 550 712 428 584 754 453 401 513 322

Total US 562 725 436 586 755 454 408 518 330

Table 1921Non-Hodgkin Lymphoma

Age-Adjusted SEER Death Ratesa

By Registry Race and Sex

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 562 002

High Five StatesMichigan 645 011 01(0112) 1479Kentucky 642 016 02(0118) 1424Iowa 638 018 03(0120) 1367Indiana 638 013 04(0117) 1361Idaho 635 027 05(0126) 1303

Low Five StatesNevada 511 019 47(2251) -899Colorado 491 014 48(3851) -1257New Mexico 488 020 49(2851) -1317Hawaii 475 024 50(3051) -1542c

DC 444 039 51(2351) -2097c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 545 014 28(1847) -291 Montana 559 030 25(0250) -042Alaska 525 047 43(0151) -654 Nebraska 563 023 22(0548) 026Arizona 512 012 46(2950) -886 Nevada 511 019 47(2251) -899Arkansas 555 018 26(1247) -113 New Hampshire 562 027 23(0349) 014California 533 005 40(2645) -508 New Jersey 545 010 29(2045) -301Colorado 491 014 48(3851) -1257 New Mexico 488 020 49(2851) -1317Connecticut 533 016 39(1949) -505 New York 535 007 37(2446) -478Delaware 628 033 08(0139) 1174 North Carolina 541 010 35(2146) -363DC 444 039 51(2351) -2097c North Dakota 561 037 24(0151) -007Florida 535 006 38(2545) -479 Ohio 616 009 10(0220) 969Georgia 533 011 41(2248) -511 Oklahoma 630 017 06(0121) 1226Hawaii 475 024 50(3051) -1542c Oregon 612 016 11(0124) 903Idaho 635 027 05(0126) 1303 Pennsylvania 603 009 16(0622) 729Illinois 566 009 20(1634) 085 Rhode Island 542 029 32(0651) -350Indiana 638 013 04(0117) 1361 South Carolina 542 014 31(1847) -347Iowa 638 018 03(0120) 1367 South Dakota 541 033 36(0451) -364Kansas 585 019 19(0439) 420 Tennessee 629 013 07(0119) 1198Kentucky 642 016 02(0118) 1424 Texas 546 007 27(2142) -277Louisiana 608 016 14(0125) 826 Utah 542 022 33(1250) -352Maine 609 026 13(0137) 852 Vermont 605 040 15(0148) 770Maryland 524 013 44(2349) -663 Virginia 544 011 30(2046) -319Massachusetts 523 012 45(2549) -687 Washington 599 013 17(0425) 665Michigan 645 011 01(0112) 1479 West Virginia 612 022 12(0132) 894Minnesota 617 014 09(0122) 984 Wisconsin 590 013 18(0629) 507Mississippi 531 018 42(1850) -551 Wyoming 564 043 21(0151) 050Missouri 542 012 34(1947) -354

Table 1922Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males and Females

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 725 003

High Five StatesKentucky 886 030 01(0112) 2213c

Iowa 845 032 02(0120) 1647c

Michigan 842 019 03(0114) 1615c

Indiana 839 024 04(0116) 1567c

Delaware 824 058 05(0144) 1364

Low Five StatesArizona 635 019 47(3251) -1244Alaska 630 075 48(0251) -1311Hawaii 620 041 49(1951) -1452DC 614 071 50(0551) -1535c

New Mexico 585 033 51(3451) -1928c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 688 025 36(1649) -513 Montana 709 050 26(0251) -218Alaska 630 075 48(0251) -1311 Nebraska 737 040 20(0248) 165Arizona 635 019 47(3251) -1244 Nevada 653 032 44(1951) -994Arkansas 721 031 22(0747) -061 New Hampshire 710 046 25(0451) -210California 677 009 41(2846) -666 New Jersey 721 018 21(1441) -059Colorado 643 024 46(2451) -1133 New Mexico 585 033 51(3451) -1928c

Connecticut 705 028 28(1248) -273 New York 702 012 30(1943) -323Delaware 824 058 05(0144) 1364 North Carolina 709 018 27(1644) -221DC 614 071 50(0551) -1535c North Dakota 682 061 39(0251) -598Florida 683 011 37(2446) -585 Ohio 800 017 09(0320) 1029Georgia 697 019 34(1746) -387 Oklahoma 806 030 08(0126) 1109Hawaii 620 041 49(1951) -1452 Oregon 794 028 12(0128) 947Idaho 775 045 16(0146) 692 Pennsylvania 783 015 15(0523) 794Illinois 739 016 19(1235) 190 Rhode Island 649 050 45(1051) -1050Indiana 839 024 04(0116) 1567c South Carolina 681 025 40(1850) -604Iowa 845 032 02(0120) 1647c South Dakota 701 056 31(0251) -332Kansas 713 032 24(0948) -174 Tennessee 820 023 06(0120) 1311Kentucky 886 030 01(0112) 2213c Texas 698 012 32(2043) -368Louisiana 814 029 07(0122) 1222 Utah 670 036 42(1351) -754Maine 754 045 18(0148) 395 Vermont 794 069 11(0149) 950Maryland 682 023 38(1849) -588 Virginia 694 020 35(1847) -429Massachusetts 659 020 43(2450) -910 Washington 790 022 13(0224) 897Michigan 842 019 03(0114) 1615c West Virginia 774 038 17(0142) 675Minnesota 797 025 10(0224) 995 Wisconsin 786 023 14(0227) 844Mississippi 717 034 23(0748) -110 Wyoming 698 071 33(0151) -377Missouri 702 022 29(1646) -319

Table 1923Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 436 002

High Five StatesIdaho 510 033 01(0139) 1697c

Maine 497 031 02(0141) 1396Michigan 495 012 03(0119) 1340Oklahoma 492 020 04(0128) 1276Indiana 492 016 05(0123) 1270

Low Five StatesMississippi 404 021 47(1351) -731Nevada 382 022 48(2051) -1237Colorado 369 016 49(3451) -1540c

Hawaii 352 027 50(2551) -1932c

DC 323 044 51(1551) -2601c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 440 017 24(0547) 099 Montana 435 036 27(0151) -034Alaska 414 058 38(0151) -500 Nebraska 435 027 26(0249) -032Arizona 407 014 44(2049) -664 Nevada 382 022 48(2051) -1237Arkansas 428 021 31(0649) -181 New Hampshire 454 032 19(0149) 400California 423 006 34(2244) -313 New Jersey 419 012 37(1848) -397Colorado 369 016 49(3451) -1540c New Mexico 405 025 46(0951) -706Connecticut 407 018 45(1550) -669 New York 412 008 39(2548) -554Delaware 473 039 12(0150) 855 North Carolina 420 012 35(1848) -374DC 323 044 51(1551) -2601c North Dakota 471 045 13(0150) 809Florida 412 007 40(2548) -564 Ohio 478 011 10(0123) 967Georgia 411 012 43(2049) -582 Oklahoma 492 020 04(0128) 1276Hawaii 352 027 50(2551) -1932c Oregon 465 019 15(0141) 668Idaho 510 033 01(0139) 1697c Pennsylvania 467 010 14(0427) 714Illinois 439 010 25(1341) 074 Rhode Island 455 035 18(0150) 434Indiana 492 016 05(0123) 1270 South Carolina 432 017 30(0947) -102Iowa 484 021 08(0135) 1087 South Dakota 411 039 42(0151) -580Kansas 486 023 06(0137) 1143 Tennessee 484 015 09(0126) 1087Kentucky 460 018 17(0241) 544 Texas 427 008 32(1944) -213Louisiana 451 018 21(0345) 333 Utah 433 026 28(0250) -081Maine 497 031 02(0141) 1396 Vermont 461 047 16(0151) 578Maryland 411 015 41(1749) -576 Virginia 432 013 29(1246) -092Massachusetts 423 014 33(1548) -303 Washington 452 015 20(0541) 360Michigan 495 012 03(0119) 1340 West Virginia 486 027 07(0143) 1141Minnesota 475 017 11(0132) 901 Wisconsin 443 015 23(0645) 156Mississippi 404 021 47(1351) -731 Wyoming 445 051 22(0151) 192Missouri 419 014 36(1549) -396

Table 1924Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Females

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 Areas (excluding the AlaskaNative Registry) and 112016 US population estimates based on the average of 2015 and 2016 population estimates from theUS Bureau of the CensusPrevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 24 years

b Maximum limited-duration prevalence is 24 years for 1992-2016 datac Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groupsd Cases diagnosed more than 24 years ago were estimated using the completeness index method (Capocaccia et al 1997

Merrill et al 2000)e Complete prevalence is obtained by summing 0 to lt24 and gt=24- Statistic not shown Statistic based on fewer than 5 cases estimated alive in SEER for the time interval+ Not available

Years Since Diagnosis 0 to lt5 5 to lt10 10 to lt15 15 to lt20 20 to lt24 0 to lt24b gt=24d Completee

Race Sex

All Races Both Sexes 248946 177490 117326 69109 31890 644761 49943 694704Males 135137 94173 60159 36020 16581 342069 25489 367558Females 113809 83317 57167 33089 15309 302692 24454 327146

White Both Sexes 213764 154454 101984 60537 28026 558765 49625 620368Males 116527 82172 52535 31627 14543 297404 26526 330121Females 97237 72282 49448 28910 13483 261361 23099 290247

Black Both Sexes 20500 13640 9750 5271 2215 51376 4115 55491Males 10712 7188 4768 2684 1174 26526 1911 28437Females 9789 6452 4981 2587 1041 24850 2204 27054

Asian Both Sexes 8405 5210 3415 1867 844 19741 + +Pacific Males 4548 2661 1757 1013 407 10386 + +Islander Females 3856 2549 1657 855 437 9355 + +

Hispanic Both Sexes 21339 14049 8272 4881 2136 50676 + +Males 10918 7243 4331 2617 1094 26202 + +Females 10421 6805 3941 2264 1043 24474 + +

Age Specific (Crude) Age-Adjustedc Age at Prevalence All Ages 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ All Ages

Race Sex

All Races Both Sexes 02001 00035 00139 00283 00538 01121 02352 04640 08181 10224 01738Males 02156 00044 00189 00354 00625 01293 02710 05243 09364 12449 02023Females 01850 00026 00087 00208 00450 00952 02010 04094 07196 08856 01498

White Both Sexes 02216 00035 00143 00289 00534 01148 02427 04858 08597 10738 01807Males 02380 00045 00198 00359 00622 01317 02790 05442 09778 13060 02095Females 02054 00025 00085 00214 00442 00976 02072 04317 07593 09285 01560

Black Both Sexes 01139 00029 00113 00265 00599 01027 02010 03340 05117 05333 01251Males 01226 00029 00140 00351 00696 01223 02333 03969 05849 06055 01457Females 01059 00030 00086 00178 00510 00853 01728 02836 04608 04976 01088

Asian Both Sexes 00970 00039 00133 00207 00353 00680 01409 02692 04470 06094 01032Pacific Males 01065 00044 00175 00240 00398 00744 01640 03072 05516 07472 01222Islander Females 00882 00033 00092 00175 00312 00623 01209 02384 03629 05207 00880

Hispanic Both Sexes 00887 00030 00117 00206 00398 00850 01769 03632 05888 07209 01294Males 00908 00035 00147 00256 00455 00932 01924 03940 06326 08003 01420Females 00866 00024 00086 00151 00337 00766 01616 03360 05552 06719 01185

Table 1925Non-Hodgkin Lymphoma

Estimated United States Cancer Prevalence Countsa on January 1 2016By RaceEthnicity Sex and Years Since Diagnosis

Estimated prevalence percenta on January 1 2016 of the SEER population diagnosed in the previous 24 yearsBy Age at Prevalence RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 372 452924 -05 62 18862 04 247 189692 -05 1657 244370 -05

1 Hodgkin Lymphoma 28 32262 -17 13 3927 -06 33 22556 -15 39 5779 -31

2 Non-Hodgkin lymphoma 336 409991 -03 48 14693 04 210 163591 -03 1572 231707 -042(a) Non-Hodgkin lymphoma B-cell 311 380349 -01 39 11836 14 190 148768 -02 1491 219745 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 15 16631 20 31 9416 10 07 5203 39 14 2012 252(a) 2 Mature Non-Hodgkin lymphoma B-cell 280 343965 -04 07 2271 30 174 137225 -05 1387 204469 -042(a) 21 ChronicSmallProlymphocytic 69 85601 -13 00 35 - 35 29103 -11 382 56463 -14

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 61 75061 -15 00 30 - 31 25339 -13 336 49692 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 311 19 - - - 00 72 - 02 234 262(a) 213 Mantle-cell lymphoma 08 10229 03 - - - 04 3692 02 44 6537 04

2(a) 22 Lymphoplasmacytic lymphoma 07 8651 00 - - - 03 2590 -11 41 6059 04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 03 3667 -03 - - - 01 1132 -18 17 2533 022(a) 222 Waldenstrom macroglubulinemia 04 4984 03 - - - 02 1458 -07 24 3526 06

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 72 87188 00 03 925 26 48 36480 -02 339 49783 022(a) 231 DLBCL NOSc 71 85899 -01 03 861 12 46 35469 -05 337 49569 012(a) 232 Intravascular large B-cell 00 162 - - - - 00 63 - 01 99 -

lymphoma2(a) 233 Primary effusion lymphoma 00 181 27 - - - 00 126 - 00 55 -2(a) 234 Mediastinal large B-cell 01 946 116 00 64 - 01 822 111 00 60 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 04 4692 -26 03 1028 32 04 2618 -43 07 1046 -432(a) 25 Marginal-zone lymphoma (MZL) 22 26534 00 00 137 13 14 11049 05 104 15348 -042(a) 251 Splenic MZL 02 2418 04 - - - 01 889 -08 10 1529 102(a) 252 Extranodal MZL MALTc type 13 15979 06 00 92 - 09 7148 11 59 8739 032(a) 253 Nodal MZL 07 8137 -15 00 45 - 04 3012 -05 34 5080 -20

2(a) 26 Follicular lymphoma 35 43582 -21 00 119 - 28 21725 -25 147 21738 -182(a) 27 Hairy-cell leukemia 03 3712 -16 - - - 03 2311 -19 09 1401 -122(a) 28 Plasma cell neoplasms 68 83957 08 00 24 - 39 31325 12 358 52608 062(a) 281 Plasmacytoma 04 4879 -04 00 16 - 03 2362 -06 17 2501 -032(a) 282 Multiple myeloma 64 79078 09 - - - 36 28963 14 341 50107 07

plasma-cell leukemia2(a) 29 Heavy chain disease 00 48 - - - - 00 24 - 00 23 -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 16 19753 33 00 149 27 08 6340 37 90 13264 32

Table 1926All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 23 27222 01 08 2502 18 19 13933 03 73 10787 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 616 - 01 293 - 00 272 - 00 51 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 22 26531 11 07 2207 75 19 13621 12 73 10703 -042(b) 21 Mycosis fungoidesSezary syndrome 06 6969 18 01 213 84 06 4080 23 18 2676 052(b) 211 Mycosis fungoides 06 6739 17 01 213 84 05 3990 22 17 2536 042(b) 212 Sezary syndrome 00 230 46 - - - 00 90 - 01 140 -

2(b) 22 Peripheral T-cell lymphoma 12 14531 -10 02 534 07 10 7159 -09 46 6838 -122(b) 221 Peripheral T-cell lymphoma NOSc 04 5393 -01 00 86 - 03 2489 04 19 2818 -042(b) 222 Angioimmunoblastic T-cell lymphoma 02 1902 02 - - - 01 699 -09 08 1201 072(b) 223 Subcutaneous panniculitis- 00 176 44 00 31 - 00 111 - 00 34 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 2523 -36 01 291 00 02 1450 -33 05 782 -54

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 139 - - - - 00 98 - 00 28 -2(b) 226 Enteropathy-type T-cell lymphoma 00 186 -02 - - - 00 84 - 01 101 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 2963 -07 00 59 - 02 1575 01 09 1329 -142(b) 228 Primary cutaneous anaplastic 01 1249 -41 00 51 - 01 653 -49 04 545 -39

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 03 3417 96 05 1428 101 02 1474 99 03 515 672(b) 24 NKcT-cell lymphoma nasal-type 01 985 02 00 26 - 01 659 00 02 300 05

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 120 - - - - 00 54 - 00 65 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 509 30 - - - 00 195 -05 02 309 442(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 75 - - - - 00 40 - 00 33 -2(c) Non-Hodgkin lymphoma unknown lineage 02 2420 -274 01 355 - 01 890 -216 08 1175 -2792(c) 1 Precursor lymphoblastic leukemia 01 814 -283 01 343 - 00 238 - 02 233 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 95 - - - - 00 25 - 00 69 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 1511 -274 - - - 01 627 -202 06 873 -319

lineage2() 1 Total precursor lymphomaleukemiad 16 18061 -07 33 10052 -15 08 5713 06 15 2296 -01

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 762 273 00 20 - 00 339 227 03 403 -lymphoma

4 Lymphoid neoplasm NOSc 08 9909 -55 01 222 113 04 3206 -59 43 6481 -59

Table 1926 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 461 253152 -05 70 10973 05 294 110367 -07 2122 131812 -05

1 Hodgkin Lymphoma 31 17710 -17 13 2118 -03 36 12525 -16 48 3067 -31

2 Non-Hodgkin lymphoma 419 229772 -03 56 8711 05 252 95756 -05 2017 125305 -032(a) Non-Hodgkin lymphoma B-cell 387 212247 -02 44 6786 15 227 86941 -04 1908 118520 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 16 8999 24 33 5123 11 08 2888 46 16 988 292(a) 2 Mature Non-Hodgkin lymphoma B-cell 351 192801 -05 10 1558 28 210 80417 -08 1783 110826 -042(a) 21 ChronicSmallProlymphocytic 96 52411 -15 00 21 - 47 18927 -14 539 33463 -15

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 82 44988 -17 00 19 - 40 16143 -16 464 28826 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 193 -02 - - - 00 46 - 02 145 052(a) 213 Mantle-cell lymphoma 13 7230 -01 - - - 07 2738 -01 72 4492 -01

2(a) 22 Lymphoplasmacytic lymphoma 10 5082 -05 - - - 04 1524 -08 58 3558 -04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 04 2062 -08 - - - 02 616 -12 23 1446 -072(a) 222 Waldenstrom macroglubulinemia 06 3020 -02 - - - 02 908 -06 34 2112 -02

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 88 48128 01 03 554 22 59 21824 -06 418 25750 052(a) 231 DLBCL NOSc 87 47520 00 03 519 03 57 21366 -08 416 25635 042(a) 232 Intravascular large B-cell 00 75 - - - - 00 31 - 01 44 -

lymphoma2(a) 233 Primary effusion lymphoma 00 167 26 - - - 00 123 - 01 44 -2(a) 234 Mediastinal large B-cell 01 366 155 00 35 - 01 304 142 00 27 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 06 3388 -22 05 775 31 06 1969 -46 10 644 -192(a) 25 Marginal-zone lymphoma (MZL) 22 12351 -02 01 98 - 14 5177 -02 114 7076 -012(a) 251 Splenic MZL 02 1164 14 - - - 01 434 18 12 730 112(a) 252 Extranodal MZL MALTc type 13 7268 07 00 62 - 09 3267 04 63 3939 102(a) 253 Nodal MZL 07 3919 -23 00 36 - 04 1476 -22 39 2407 -23

2(a) 26 Follicular lymphoma 39 21788 -19 01 100 - 30 11210 -25 165 10478 -152(a) 27 Hairy-cell leukemia 05 2984 -18 - - - 05 1908 -20 17 1076 -152(a) 28 Plasma cell neoplasms 85 46642 07 - - - 45 17864 11 462 28769 052(a) 281 Plasmacytoma 05 2997 -08 - - - 04 1509 -16 24 1484 -012(a) 282 Multiple myeloma 80 43645 08 - - - 41 16355 13 439 27285 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 27 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 20 10447 34 01 105 - 10 3636 40 110 6706 32

Table 1927All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 29 16118 00 11 1730 14 23 8235 02 98 6153 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 430 - 01 208 - 01 188 - 01 34 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 28 15642 11 10 1521 71 22 8022 11 97 6099 -032(b) 21 Mycosis fungoidesSezary syndrome 07 3962 19 01 135 - 06 2261 21 25 1566 092(b) 211 Mycosis fungoides 07 3831 20 01 135 - 06 2213 21 23 1483 092(b) 212 Sezary syndrome 00 131 - - - - 00 48 - 01 83 -

2(b) 22 Peripheral T-cell lymphoma 15 8438 -13 02 318 -09 12 4248 -12 62 3872 -132(b) 221 Peripheral T-cell lymphoma NOSc 06 3159 -05 00 49 - 04 1520 02 26 1590 -082(b) 222 Angioimmunoblastic T-cell lymphoma 02 1024 19 - - - 01 415 11 10 607 232(b) 223 Subcutaneous panniculitis- 00 68 - - - - 00 39 - 00 16 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 03 1549 -39 01 184 -01 02 888 -43 08 477 -45

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 98 - - - - 00 69 - 00 18 -2(b) 226 Enteropathy-type T-cell lymphoma 00 105 - - - - 00 50 - 01 54 -2(b) 227 Cutaneous T-cell lymphoma NOSc 03 1696 -12 00 32 - 02 894 -03 12 770 -172(b) 228 Primary cutaneous anaplastic 01 739 -48 00 26 - 01 373 -49 05 340 -49

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 04 2253 97 07 1047 92 03 940 98 04 266 1022(b) 24 NKcT-cell lymphoma nasal-type 01 638 -05 00 18 - 01 435 -03 03 185 -06

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 58 - - - - 00 22 - 01 36 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 01 293 45 - - - 00 116 - 03 174 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 46 - - - - 00 25 - 00 20 -2(c) Non-Hodgkin lymphoma unknown lineage 03 1407 -232 01 195 - 02 580 -184 10 632 -2302(c) 1 Precursor lymphoblastic leukemia 01 474 -228 01 187 - 00 134 - 02 153 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 49 - - - - - - - 01 36 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 02 884 -239 - - - 01 433 -175 07 443 -

lineage2() 1 Total precursor lymphomaleukemiad 18 9903 -06 35 5518 -17 09 3210 09 19 1175 05

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 435 271 - - - 01 215 - 03 207 -lymphoma

4 Lymphoid neoplasm NOSc 10 5235 -59 01 131 - 05 1871 -65 54 3233 -61

Table 1927 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 301 199772 -05 53 7889 02 202 79325 -02 1322 112558 -08

1 Hodgkin Lymphoma 24 14552 -16 12 1809 -10 29 10031 -14 32 2712 -32

2 Non-Hodgkin lymphoma 269 180219 -03 40 5982 03 170 67835 00 1251 106402 -062(a) Non-Hodgkin lymphoma B-cell 250 168102 -01 34 5050 13 154 61827 02 1190 101225 -042(a) 1 Precursor Non-Hodgkin lymphoma B-cell 14 7632 16 29 4293 09 06 2315 29 12 1024 202(a) 2 Mature Non-Hodgkin lymphoma B-cell 223 151164 -04 05 713 35 141 56808 -01 1102 93643 -072(a) 21 ChronicSmallProlymphocytic 48 33190 -13 - - - 24 10176 -05 268 23000 -16

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 43 30073 -15 - - - 22 9196 -06 243 20866 -19

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 118 - - - - 00 26 - 01 89 -2(a) 213 Mantle-cell lymphoma 04 2999 11 - - - 02 954 10 24 2045 12

2(a) 22 Lymphoplasmacytic lymphoma 05 3569 04 - - - 03 1066 -16 30 2501 11Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 02 1605 01 - - - 01 516 -25 13 1087 112(a) 222 Waldenstrom macroglubulinemia 03 1964 06 - - - 01 550 -08 17 1414 11

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 58 39060 00 02 371 33 38 14656 03 283 24033 -032(a) 231 DLBCL NOSc 57 38379 -02 02 342 27 36 14103 -01 282 23934 -032(a) 232 Intravascular large B-cell 00 87 - - - - 00 32 - 01 55 -

lymphoma2(a) 233 Primary effusion lymphoma - - - - - - - - - - - -2(a) 234 Mediastinal large B-cell 01 580 91 00 29 - 02 518 93 00 33 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 02 1304 -34 02 253 38 02 649 -37 05 402 -852(a) 25 Marginal-zone lymphoma (MZL) 21 14183 01 00 39 - 15 5872 12 98 8272 -062(a) 251 Splenic MZL 02 1254 -07 - - - 01 455 -32 10 799 072(a) 252 Extranodal MZL MALTc type 13 8711 06 00 30 - 10 3881 17 57 4800 -032(a) 253 Nodal MZL 06 4218 -07 - - - 04 1536 11 32 2673 -18

2(a) 26 Follicular lymphoma 33 21794 -24 00 19 - 27 10515 -25 134 11260 -222(a) 27 Hairy-cell leukemia 01 728 -12 - - - 01 403 -11 04 325 -122(a) 28 Plasma cell neoplasms 55 37315 08 - - - 33 13461 15 282 23839 052(a) 281 Plasmacytoma 03 1882 00 - - - 02 853 12 12 1017 -092(a) 282 Multiple myeloma 52 35433 09 - - - 30 12608 15 270 22822 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 21 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 14 9306 32 00 44 - 07 2704 32 76 6558 31

Table 1928All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 17 11104 01 05 772 29 15 5698 05 55 4634 -112(b) 1 Precursor Non-Hodgkin lymphoma T-cell 00 186 - 01 85 - 00 84 - 00 17 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 17 10889 09 05 686 83 15 5599 12 54 4604 -092(b) 21 Mycosis fungoidesSezary syndrome 05 3007 15 01 78 - 05 1819 26 13 1110 -042(b) 211 Mycosis fungoides 05 2908 12 01 78 - 05 1777 23 12 1053 -072(b) 212 Sezary syndrome 00 99 - - - - 00 42 - 01 57 -

2(b) 22 Peripheral T-cell lymphoma 09 6093 -08 01 216 30 08 2911 -06 35 2966 -142(b) 221 Peripheral T-cell lymphoma NOSc 03 2234 03 00 37 - 03 969 07 14 1228 -012(b) 222 Angioimmunoblastic T-cell lymphoma 01 878 -22 - - - 01 284 -39 07 594 -152(b) 223 Subcutaneous panniculitis- 00 108 - 00 18 - 00 72 - 00 18 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 974 -33 01 107 - 02 562 -19 04 305 -77

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 41 - - - - 00 29 - - - -2(b) 226 Enteropathy-type T-cell lymphoma 00 81 - - - - 00 34 - 01 47 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 1267 00 00 27 - 02 681 07 07 559 -102(b) 228 Primary cutaneous anaplastic 01 510 -34 00 25 - 01 280 -50 02 205 -33

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 02 1164 96 03 381 127 01 534 97 03 249 302(b) 24 NKcT-cell lymphoma nasal-type 01 347 11 - - - 01 224 - 01 115 -

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 62 - - - - 00 32 - 00 29 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 216 03 - - - 00 79 - 02 135 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 29 - - - - - - - - - -2(c) Non-Hodgkin lymphoma unknown lineage 02 1013 -341 01 160 - 01 310 - 06 543 -2(c) 1 Precursor lymphoblastic leukemia 01 340 - 01 156 - 00 104 - 01 80 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 46 - - - - - - - 00 33 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 627 - - - - 01 194 - 05 430 -

lineage2() 1 Total precursor lymphomaleukemiad 14 8158 -09 31 4534 -13 07 2503 02 13 1121 -11

3 Composite Hodgkin lymphoma and Non-Hodgkin 00 327 - - - - 00 124 - 02 196 -lymphoma

4 Lymphoid neoplasm NOSc 07 4674 -52 01 91 - 03 1335 -51 36 3248 -58

Table 1928 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 2: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Regression Program Version 47 February 2019 National Cancer Institute (httpssurveillancecancergovjoinpoint)The APC is the Annual Percent Change based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

a Trends are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)b Trends are from the SEER 21 areas (SEER 9 areas Los Angeles Alaska Native Registry Rural Georgia California excluding

SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York and Massachusetts)c Trends are from US Mortality Files National Center for Health Statistics Centers for Disease Control and Preventiond The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpointe API - AsianPacific Islander AIAN - American IndianAlaska Native NH - Non-Hispanicf Hispanic and Non-Hispanic are not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska

Natives Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registryg Data for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) counties The APCAAPC is significantly different from zero (plt05)- Joinpoint regression line analysis could not be performed on data series

JP Trend 1 JP Trend 2 JP Trend 3 JP Trend 4 JP Trend 5 JP Trend 6 AAPCd

Years APC Years APC Years APC Years APC Years APC Years APC 2007-16 2012-16

SEER 9 Delay-Adjusted Incidencea 1975-2016

All Races 1975-91 42 1991-10 04 2010-16 -09 -05 -09

White 1975-90 44 1990-08 06 2008-16 -07 -05 -07

Black 1975-94 54 1994-16 -02 -02 -02

SEER 21 Delay-Adjusted Incidenceb 2000-2016

All Races 2000-08 09 2008-16 -05 -04 -05

White 2000-07 12 2007-16 -04 -04 -04

White NHef 2000-07 13 2007-16 -03 -03 -03

Black 2000-16 02 02 02

Black NHef 2000-16 02 02 02

APIe 2000-16 04 04 04

AIANeg 2000-16 -06 -06 -06

Hispanicf 2000-16 00 00 00

US Cancer Mortalityc 1975-2016

All Races 1975-91 27 1991-97 16 1997-06 -28 2006-16 -20 -20 -20

White 1975-91 26 1991-97 16 1997-06 -28 2006-16 -20 -20 -20

Black 1975-96 27 1996-16 -24 -24 -24

US Cancer Mortalityc 2000-2016

All Races 2000-06 -29 2006-16 -20 -20 -20

White 2000-06 -30 2006-16 -20 -20 -20

White NHef 2000-06 -30 2006-16 -20 -20 -20

Black 2000-16 -19 -19 -19

Black NHef 2000-16 -19 -19 -19

APIe 2000-16 -15 -15 -15

AIANeg 2000-16 -04 -04 -04

Hispanicf 2000-16 -14 -14 -14

Table 192

Non-Hodgkin Lymphoma

Trends in SEER Incidenceab and US Mortalityc Using the Joinpoint Regression Program

1975-2016 With up to Five Joinpoints 2000-2016 With up to Three Joinpoints

Males by RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Regression Program Version 47 February 2019 National Cancer Institute (httpssurveillancecancergovjoinpoint)The APC is the Annual Percent Change based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

a Trends are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)b Trends are from the SEER 21 areas (SEER 9 areas Los Angeles Alaska Native Registry Rural Georgia California excluding

SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York and Massachusetts)c Trends are from US Mortality Files National Center for Health Statistics Centers for Disease Control and Preventiond The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpointe API - AsianPacific Islander AIAN - American IndianAlaska Native NH - Non-Hispanicf Hispanic and Non-Hispanic are not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska

Natives Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registryg Data for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) counties The APCAAPC is significantly different from zero (plt05)- Joinpoint regression line analysis could not be performed on data series

JP Trend 1 JP Trend 2 JP Trend 3 JP Trend 4 JP Trend 5 JP Trend 6 AAPCd

Years APC Years APC Years APC Years APC Years APC Years APC 2007-16 2012-16

SEER 9 Delay-Adjusted Incidencea 1975-2016

All Races 1975-88 30 1988-04 14 2004-16 -07 -07 -07

White 1975-88 31 1988-04 14 2004-16 -06 -06 -06

Black 1975-04 29 2004-16 -06 -06 -06

SEER 21 Delay-Adjusted Incidenceb 2000-2016

All Races 2000-04 13 2004-16 -04 -04 -04

White 2000-06 08 2006-16 -05 -05 -05

White NHef 2000-06 08 2006-16 -05 -05 -05

Black 2000-16 05 05 05

Black NHef 2000-16 05 05 05

APIe 2000-16 03 03 03

AIANeg 2000-16 07 07 07

Hispanicf 2000-16 04 04 04

US Cancer Mortalityc 1975-2016

All Races 1975-94 22 1994-97 10 1997-08 -33 2008-16 -25 -26 -25

White 1975-97 21 1997-04 -38 2004-16 -27 -27 -27

Black 1975-96 27 1996-16 -22 -22 -22

US Cancer Mortalityc 2000-2016

All Races 2000-04 -39 2004-16 -27 -27 -27

White 2000-03 -44 2003-16 -27 -27 -27

White NHef 2000-03 -45 2003-16 -27 -27 -27

Black 2000-16 -21 -21 -21

Black NHef 2000-16 -20 -20 -20

APIe 2000-16 -19 -19 -19

AIANeg 2000-16 -37 -37 -37

Hispanicf 2000-16 -21 -21 -21

Table 193

Non-Hodgkin Lymphoma

Trends in SEER Incidenceab and US Mortalityc Using the Joinpoint Regression Program

1975-2016 With up to Five Joinpoints 2000-2016 With up to Three Joinpoints

Females by RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Reference Cancer Incidence Rates Adjusted for Reporting DelayIndividual rates for diagnosis years 1975-1979 available in web browser version of Cancer Statistics Review

a SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

- Delay-adjusted rate is not shown for observed rates based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

Year of Diagnosis1975-1979 1160 1344 1018 1209 1393 1068 696 874 5521980 1262 1501 1081 1298 1528 1122 870 1074 7201981 1358 1590 1181 1406 1634 1235 742 1059 4981982 1339 1556 1161 1402 1642 1205 1027 1022 10011983 1399 1662 1195 1463 1752 1240 1028 1088 9621984 1519 1829 1279 1597 1910 1355 946 1252 6921985 1551 1839 1316 1628 1925 1385 995 1196 8431986 1590 1943 1300 1683 2059 1375 1066 1313 8521987 1674 2078 1342 1770 2215 1400 1035 1043 9951988 1726 2136 1408 1822 2245 1490 1158 1579 8491989 1736 2165 1384 1836 2304 1450 1159 1410 9721990 1851 2297 1481 1934 2396 1549 1392 1763 11021991 1881 2374 1461 1970 2481 1532 1403 1881 10291992 1862 2304 1494 1956 2394 1584 1368 1887 9651993 1885 2347 1500 1965 2432 1570 1423 1937 9971994 1995 2496 1579 2067 2558 1654 1448 2152 8861995 1999 2542 1545 2070 2618 1604 1676 2363 11431996 1942 2424 1548 2027 2520 1621 1554 1925 12391997 2000 2453 1646 2090 2522 1749 1640 2426 10861998 1962 2296 1686 2061 2401 1778 1449 1696 12541999 1997 2459 1636 2095 2554 1732 1441 1842 11372000 1981 2434 1613 2099 2571 1712 1393 1823 10742001 2002 2440 1646 2082 2547 1706 1605 1844 13922002 2023 2420 1710 2134 2552 1798 1448 1710 12512003 2078 2506 1753 2191 2633 1848 1637 2006 13782004 2140 2589 1795 2235 2685 1885 1860 2418 14552005 2088 2563 1709 2202 2674 1820 1673 1995 14102006 2052 2475 1724 2178 2608 1839 1639 2102 12942007 2126 2612 1739 2255 2755 1845 1583 1935 13172008 2097 2580 1703 2185 2687 1768 1694 1899 15082009 2097 2528 1747 2204 2669 1814 1540 1867 12992010 2151 2676 1724 2250 2758 1831 1781 2343 13342011 1996 2450 1637 2093 2564 1716 1472 1769 12512012 2049 2511 1674 2147 2618 1757 1682 1926 14652013 1993 2438 1630 2101 2559 1719 1586 1838 13932014 2047 2531 1651 2172 2653 1777 1545 2042 11522015 2037 2521 1643 2161 2652 1754 1550 1998 12062016 1984 2403 1640 2078 2499 1726 1686 1980 1433

Table 194Non-Hodgkin Lymphoma

Delay-adjusted SEER Incidencea Rates by Year Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Individual rates for diagnosis years 1975-1979 available in web browser version of Cancer Statistics Reviewa SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)

Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

Year of Diagnosis1975-2016 1846 2267 1513 1925 2357 1581 1414 1769 11351975-1979 1160 1344 1018 1209 1393 1068 696 874 5521980 1262 1501 1081 1298 1528 1122 870 1074 7201981 1358 1590 1181 1406 1634 1235 742 1059 4981982 1339 1556 1161 1402 1642 1205 1027 1022 10011983 1399 1662 1195 1463 1752 1240 1028 1088 9621984 1519 1829 1279 1597 1910 1355 946 1252 6921985 1551 1839 1316 1628 1925 1385 995 1196 8431986 1590 1943 1300 1683 2059 1375 1066 1313 8521987 1674 2078 1342 1770 2215 1400 1035 1043 9951988 1726 2136 1408 1822 2245 1490 1158 1579 8491989 1736 2165 1384 1836 2304 1450 1159 1410 9721990 1851 2297 1481 1934 2396 1549 1392 1763 11021991 1881 2374 1461 1970 2481 1532 1403 1881 10291992 1862 2304 1494 1956 2394 1584 1368 1887 9651993 1885 2347 1500 1965 2432 1570 1423 1937 9971994 1995 2496 1579 2067 2558 1654 1448 2152 8861995 1999 2542 1545 2070 2618 1604 1676 2363 11431996 1942 2424 1548 2027 2520 1621 1554 1925 12391997 2000 2453 1646 2090 2522 1749 1640 2426 10861998 1962 2296 1686 2061 2401 1778 1449 1696 12541999 1997 2459 1636 2095 2554 1732 1441 1842 11372000 1981 2434 1613 2099 2571 1712 1393 1823 10742001 2002 2440 1646 2082 2547 1706 1605 1844 13922002 2023 2420 1710 2134 2552 1798 1448 1710 12512003 2078 2506 1753 2191 2633 1848 1637 2006 13782004 2140 2589 1795 2235 2685 1885 1860 2418 14552005 2088 2563 1709 2202 2674 1820 1673 1995 14102006 2052 2475 1724 2178 2608 1839 1639 2102 12942007 2126 2612 1739 2255 2755 1845 1583 1935 13172008 2093 2575 1700 2180 2681 1765 1689 1894 15032009 2089 2520 1741 2195 2659 1806 1531 1856 12912010 2141 2662 1715 2237 2742 1820 1767 2323 13232011 1982 2433 1626 2076 2544 1702 1455 1749 12372012 2031 2489 1659 2125 2591 1739 1658 1897 14442013 1973 2414 1613 2076 2529 1699 1558 1807 13682014 2020 2497 1629 2138 2612 1749 1512 1998 11282015 2003 2478 1615 2118 2600 1718 1510 1947 11742016 1936 2344 1600 2018 2428 1676 1625 1909 1382

Table 195Non-Hodgkin Lymphoma

Age-adjusted SEER Incidencea Rates by Year Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Individual rates for years of death 1975-1979 available in web browser version of Cancer Statistics Reviewa US Mortality Files National Center for Health Statistics Centers for Disease Control and Prevention

Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

Year of Death1975-2016 701 880 570 732 915 596 478 613 3801975-1979 580 708 484 602 733 503 375 483 2921980 623 747 529 647 774 552 399 515 3121981 616 738 527 640 766 547 398 500 3251982 655 798 549 683 829 574 412 523 3291983 666 811 558 692 839 585 430 579 3231984 676 815 575 705 850 601 419 528 3391985 706 880 580 734 917 602 462 557 3871986 731 898 605 759 925 633 495 664 3701987 726 881 610 756 912 638 473 630 3621988 752 928 624 782 959 653 501 682 3721989 783 973 643 812 1004 671 533 710 4071990 787 997 634 816 1032 658 539 713 4171991 819 1015 674 850 1052 700 570 717 4611992 822 1030 669 853 1066 696 564 723 4451993 825 1014 686 857 1045 717 569 753 4401994 863 1075 710 900 1120 741 554 682 4561995 872 1081 716 909 1121 749 579 762 4451996 875 1094 714 909 1129 746 621 825 4741997 888 1103 725 921 1135 757 634 845 4871998 869 1085 710 903 1127 738 599 750 4891999 832 1036 685 867 1071 718 565 744 4412000 817 1020 670 854 1063 701 520 661 4172001 791 998 642 821 1031 668 561 728 4472002 765 966 619 797 1004 644 541 688 4412003 738 940 592 769 981 613 494 583 4272004 709 894 573 738 928 596 501 623 4132005 695 887 556 724 922 579 477 611 3812006 674 848 544 701 878 566 492 627 3932007 659 836 526 686 867 549 452 577 3622008 641 820 509 671 856 533 431 548 3452009 630 812 493 656 842 513 449 615 3412010 614 783 485 637 811 504 457 584 3642011 603 785 464 629 817 483 436 574 3402012 591 762 461 617 795 480 426 538 3482013 571 738 444 595 767 462 411 527 3332014 565 726 443 589 755 460 418 528 3422015 547 713 418 569 741 434 404 519 3212016 537 691 417 562 721 436 383 481 311

Table 196Non-Hodgkin Lymphoma

Age-adjusted US Deatha Rates by Year Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a SEER 21 areas Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)unless noted

b US Mortality Files National Center for Health Statistics Centers for Disease Control and PreventionRates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) unless noted

c Rates are per 100000 and are age-adjusted to the world (WHO 2000-2025) standard million- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER IncidenceAge at DiagnosisAge-Adjusted Rates 2012-2016All ages 196 239 162 206 250 170 147 177 124Under 65 94 111 78 96 113 80 91 109 7665 and over 904 1126 743 966 1199 794 532 646 461

All ages (WHO world std)c 147 177 122 154 184 127 117 140 98

Age-Specific Rates 2012-2016lt1 - - - - - - - - -1-4 08 11 05 08 11 06 06 07 -5-9 12 17 07 13 18 07 10 13 0810-14 15 20 10 14 19 10 16 21 1115-19 21 27 14 20 26 14 20 28 1220-24 27 32 22 26 31 21 28 35 2025-29 35 40 29 34 39 28 41 48 3430-34 49 56 42 48 54 41 56 67 4735-39 72 85 59 71 83 58 81 98 6640-44 99 117 80 99 117 80 108 128 9045-49 145 168 122 147 169 125 156 190 12750-54 222 256 189 229 264 194 217 250 18755-59 312 366 261 326 379 274 277 332 23060-64 445 522 376 470 548 396 363 426 31165-69 629 742 528 667 781 564 447 522 39070-74 833 997 697 890 1058 746 522 640 43975-79 1044 1287 855 1124 1384 918 588 692 52080-84 1193 1522 966 1280 1631 1031 650 791 57385+ 1079 1499 861 1146 1589 915 508 685 434

US MortalityAge at DeathAge-Adjusted Rates 2012-2016All ages 56 73 44 59 76 45 41 52 33Under 65 13 17 10 13 17 09 16 21 1265 and over 352 453 279 372 477 295 210 265 176

All ages (WHO world std)c 30 39 23 31 40 23 25 32 20

Age-Specific Rates 2012-2016lt1 - - - - - - - - -1-4 00 01 - 00 01 - - - -5-9 01 01 00 00 01 - 01 - -10-14 01 01 01 01 01 01 - - -15-19 01 02 01 01 02 01 02 02 -20-24 02 03 02 02 03 02 04 04 0325-29 04 05 03 03 04 02 05 07 0430-34 05 07 04 05 06 03 09 12 0635-39 07 09 05 06 08 04 11 14 0940-44 11 14 08 10 13 08 18 21 1545-49 18 23 13 17 22 13 24 32 1750-54 31 41 21 31 41 21 37 49 2655-59 53 71 37 54 72 36 58 74 4460-64 90 118 64 92 121 64 90 116 6965-69 142 184 105 149 192 109 116 146 9370-74 244 309 188 256 324 197 167 214 13375-79 374 473 294 397 501 312 220 275 18480-84 567 725 455 600 764 481 321 405 27485+ 751 994 624 795 1049 662 360 457 320

Table 197Non-Hodgkin Lymphoma

SEER Incidencea and US Deathb Rates Age-Adjusted and Age-Specific Rates by Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on End Results data from a series of hospital registries and one population-based registryb SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)

Based on follow-up of patients into 2016 Expected survival rates are derived from the US Annual Life Tablesc SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER programBased on follow-up of patients into 2016

d Period survival provides a 2015 estimate of survival by piecing together the most recent conditional survival estimatesfrom several cohorts It is computed here using three year calendar blocks (2010-2012 0-1 year survival)(2009-2011 1-2 year survival) (2008-2010 2-3 year survival) (2007-2009 3-4 year survival) (2006-2008 4-5 years survival)

e Stage at diagnosis is classified using SEER Summary Stage 2000 Stage distribution percentages may not sum to 100 due to roundingf The difference between 1975-1977 and 2009-2015 is statistically significant (plt05)g The standard error is between 5 and 10 percentage pointsh The standard error is greater than 10 percentage points- Statistic could not be calculated due to fewer than 25 cases during the time period

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

5-Year Relative Survival (Percent)Year of Diagnosis1960-1963a - - - 31 31 31 - - -1970-1973a - - - 41 39 43 - - -1975-1977b 465 456 475 468 463 473 486 426 553g

1978-1980b 479 461 498 479 462 495 511 469 5671981-1983b 506 503 509 508 505 511 495 492 4981984-1986b 516 501 534 521 507 537 468 445 4991987-1989b 509 476 549 513 482 552 457 413 5101990-1992b 507 467 557 515 476 564 422 384 4761993-1995b 526 487 575 533 498 577 425 359 5491996-1998b 588 570 610 595 577 615 547 531 5721999-2001b 640 614 670 650 628 676 558 490 6382002-2004b 698 686 712 710 701 721 636 611 6662005-2008b 716 706 727 728 719 738 625 578 6752009-2015b 747f 739f 757f 757f 748f 767f 695f 670f 724f

5-Year Period Survival (Percent)cd

2015 722 705 743 726 708 747 671 641 703

Stage Distribution () 2009-2015ce

All StagesNumber of cases 97737 53606 44131 80120 44109 36011 8184 4388 3796Percent 100 100 100 100 100 100 100 100 100Localized 27 27 29 27 26 28 28 25 31Regional 15 15 15 15 15 15 15 15 15Distant 50 51 48 51 52 49 51 54 48UnstagedUnknown 8 7 8 7 7 8 6 6 7

5-Year Relative Survival (Percent) 2009-2015c

Age at DiagnosisAges lt45 840 820 870 855 836 885 735 708 776Ages 45-54 810 777 859 826 795 872 687 639 750Ages 55-64 770 742 809 781 754 818 678 620 749Ages 65-74 725 706 747 731 711 755 656 623 682Ages 75+ 554 539 568 557 538 574 482 449 500Ages lt65 800 773 838 812 787 849 701 659 759Ages 65+ 638 627 649 641 628 655 584 562 598

StageeAll Stages 720 707 737 724 711 740 665 637 698Localized 840 830 850 843 833 852 810 766 850Regional 750 751 749 755 756 755 689 698 678Distant 648 633 668 657 642 677 580 557 610UnstagedUnknown 703 686 723 679 662 698 659 648 666

Table 198Non-Hodgkin Lymphoma

5-Year Relative and Period Survival (Percent) by Race Sex Diagnosis Year and Age

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Expected survival rates are derived from the US Annual Life Tables

1975- 1980- 1985- 1990-1979 1984 1989 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Survival Time

1-year 702 730 713 704 703 733 756 767 774 773 787 810 803 811 817 810 816 841 839 844 834 842 844 834 8452-year 602 637 628 622 618 659 685 700 710 714 733 760 757 760 773 769 775 790 795 796 797 800 800 7953-year 546 585 582 577 575 621 649 664 669 679 701 731 731 735 748 745 750 762 773 774 775 779 7794-year 505 546 543 544 547 587 621 636 645 655 681 712 716 715 730 726 732 744 756 752 756 7675-year 468 507 510 516 520 561 594 609 621 638 660 693 700 701 716 705 712 728 741 742 7426-year 436 475 483 492 499 541 571 583 595 621 647 680 683 688 704 688 701 718 721 7237-year 408 450 458 470 479 522 552 564 577 605 629 663 671 672 685 672 688 702 7108-year 385 428 434 450 464 504 529 552 563 589 613 651 658 666 670 661 674 6909-year 366 408 415 435 453 493 515 535 548 576 600 640 648 649 652 651 66110-year 350 389 398 421 443 481 501 522 537 563 589 632 633 638 634 63711-year 335 374 385 406 434 466 488 511 525 548 581 618 621 630 63112-year 324 360 369 395 423 457 481 501 512 535 568 600 615 61713-year 314 348 358 383 415 449 469 492 500 520 561 593 60214-year 302 335 347 372 406 443 456 485 488 513 549 58315-year 289 322 335 365 398 437 447 474 478 505 54016-year 279 312 328 356 393 437 433 472 470 49217-year 274 304 321 349 388 428 428 469 45818-year 268 296 314 341 378 420 419 46319-year 260 288 306 333 370 413 41220-year 252 280 301 329 359 408

Table 199Non-Hodgkin Lymphoma

SEERa Relative Survival (Percent)By Year of Diagnosis

All Races Males and Females

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Expected survival rates are derived from the US Annual Life Tables

1975- 1980- 1985- 1990-1979 1984 1989 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Survival Time

1-year 694 727 689 671 666 712 747 749 758 765 776 806 797 801 811 810 814 836 828 838 838 841 834 830 8352-year 594 637 605 582 583 636 672 682 691 703 713 752 749 755 762 765 778 779 781 788 798 793 786 7913-year 534 580 557 537 545 598 638 645 644 668 679 720 726 726 731 736 754 751 757 766 776 769 7644-year 493 539 516 504 515 561 610 620 615 639 657 700 709 701 711 713 734 734 737 743 756 7575-year 455 501 482 476 485 537 583 592 590 617 635 679 689 688 699 689 710 721 724 735 7426-year 426 466 455 456 469 510 561 565 562 602 620 667 669 676 684 670 696 715 706 7177-year 399 442 431 436 449 491 542 544 546 587 601 652 658 655 668 651 682 696 6968-year 378 420 410 418 433 474 520 533 536 567 582 637 645 649 650 634 665 6869-year 357 401 391 402 423 465 504 514 523 553 572 628 633 632 636 618 65210-year 340 380 377 392 416 455 489 503 515 542 560 617 617 620 613 60911-year 328 363 364 381 407 437 477 494 508 527 547 603 605 612 61212-year 319 352 351 372 395 427 472 482 498 515 537 589 601 59613-year 307 342 343 361 389 419 456 467 491 501 531 582 59114-year 295 330 332 350 378 414 444 461 480 496 521 57215-year 281 319 324 344 368 409 435 453 473 488 51216-year 272 308 316 333 361 409 426 453 471 47417-year 265 300 308 326 358 403 420 449 46218-year 261 294 302 320 350 396 410 44219-year 256 287 294 313 342 391 40320-year 250 280 291 309 332 387

Table 1910Non-Hodgkin Lymphoma

SEERa Relative Survival (Percent)By Year of Diagnosis

All Races Males

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Expected survival rates are derived from the US Annual Life Tables

1975- 1980- 1985- 1990-1979 1984 1989 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Survival Time

1-year 710 734 741 747 752 759 767 786 792 782 801 814 810 821 825 809 819 847 854 851 830 843 856 838 8572-year 611 637 656 672 664 688 701 720 734 727 758 769 765 767 786 774 772 804 812 807 796 810 817 7993-year 559 589 611 627 616 649 662 684 700 692 727 744 736 746 768 756 746 774 791 786 774 791 7974-year 519 553 576 595 590 619 634 653 681 674 710 725 724 730 751 739 729 757 778 764 755 7805-year 482 514 544 567 565 591 608 629 658 664 688 708 713 716 736 724 715 735 763 751 7426-year 446 484 517 539 540 580 583 603 635 643 679 695 699 701 727 708 707 722 738 7317-year 417 458 490 512 520 560 563 586 615 626 663 674 687 692 704 698 694 709 7268-year 392 437 463 491 505 542 539 573 596 615 649 667 672 684 693 692 684 6949-year 374 416 443 476 492 529 528 557 578 603 633 654 664 669 671 688 67110-year 360 399 424 458 480 514 516 542 562 588 625 648 651 658 659 66911-year 342 385 409 438 469 503 500 529 547 573 621 636 640 651 65312-year 329 368 390 425 460 494 493 523 529 560 606 613 632 64013-year 321 353 376 411 449 486 485 518 510 543 598 606 61514-year 310 340 365 400 442 479 470 512 497 532 582 59615-year 297 326 349 391 436 472 460 498 483 525 57416-year 287 316 342 385 435 467 441 492 468 51317-year 282 306 336 378 428 459 438 490 45218-year 274 298 327 367 413 449 428 48519-year 265 288 321 358 407 439 42220-year 254 280 312 353 395 433

Table 1911Non-Hodgkin Lymphoma

SEERa Relative Survival (Percent)By Year of Diagnosis

All Races Females

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 5222 2506 2704 3176 3627 3994 4570 4729 5325 5260 5263 5562 5775 6226 6401 6704 6998 7072 11154

SEER 9 except 4285 2088 2267 2603 2819 3091 3507 3694 4159 4249 4364 4515 4818 5209 5398 5628 5841 6015 9363SF-Oakland

San Francisco- 937 418 437 573 808 903 1063 1035 1166 1011 899 1047 957 1017 1003 1076 1157 1057 1791Oakland SMSAc

San Francisco 245 96 123 210 326 393 467 410 450 354 213 256 220 283 219 216 240 225 362CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 134 155 161 183 201 215 234 233 252 244 238 244 246 258 254 255 255 245 244

SEER 9 except 132 154 161 181 188 201 217 218 236 236 235 236 244 256 254 253 252 247 243SF-Oakland

San Francisco- 147 158 160 194 267 285 317 305 335 288 252 286 256 266 256 263 268 235 246Oakland SMSAc

San Francisco 143 144 176 293 444 519 610 523 574 448 274 325 269 354 265 257 273 252 246CityCounty

Table 1912

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males All Ages

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males All Ages

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 0-19 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 223 87 108 91 94 84 100 89 120 105 104 119 127 107 106 143 134 155 240

SEER 9 except 191 78 95 82 80 76 86 74 107 84 93 100 115 90 87 114 119 129 198SF-Oakland

San Francisco- 32 9 13 9 14 8 14 15 13 21 11 19 12 17 19 29 15 26 42Oakland SMSAc

San Francisco 9 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 5 lt4 6 lt4CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 12 12 16 14 14 13 15 13 17 14 14 15 16 14 13 18 17 20 20

SEER 9 except 12 13 16 14 14 13 15 12 17 13 14 15 17 13 13 16 17 19 19SF-Oakland

San Francisco- 14 10 15 10 16 09 15 16 13 21 11 18 12 17 19 28 14 25 27Oakland SMSAc

San Francisco 23 - - - - - - - - - - - - - - 40 - 49 -CityCounty

Table 1913

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 0-19

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 0-19

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 20-54 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 1463 687 723 958 1211 1413 1766 1830 2089 1770 1608 1696 1623 1722 1655 1693 1674 1596 2242

SEER 9 except 1208 563 588 730 827 923 1195 1294 1483 1325 1269 1327 1308 1410 1383 1401 1402 1328 1848SF-Oakland

San Francisco- 255 124 135 228 384 490 571 536 606 445 339 369 315 312 272 292 272 268 394Oakland SMSAc

San Francisco 58 29 34 105 215 288 333 303 317 225 105 115 111 111 86 75 73 71 98CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 69 79 82 104 124 136 159 156 169 138 121 124 117 123 116 118 116 111 104

SEER 9 except 69 78 81 97 103 109 131 134 144 123 115 116 112 119 115 116 115 110 103SF-Oakland

San Francisco- 69 84 89 139 226 264 295 267 298 213 156 164 139 141 123 130 118 114 110Oakland SMSAc

San Francisco 67 88 94 272 565 715 813 724 744 510 230 252 239 248 194 162 152 145 129CityCounty

Table 1914

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 20-54

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 20-54

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 55+ and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 3536 1732 1873 2127 2322 2497 2704 2810 3116 3385 3551 3747 4025 4397 4640 4868 5190 5321 8672

SEER 9 except 2886 1447 1584 1791 1912 2092 2226 2326 2569 2840 3002 3088 3395 3709 3928 4113 4320 4558 7317SF-Oakland

San Francisco- 650 285 289 336 410 405 478 484 547 545 549 659 630 688 712 755 870 763 1355Oakland SMSAc

San Francisco 178 65 88 104 109 105 132 106 130 126 106 141 108 169 131 136 164 148 261CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 451 522 540 596 633 673 701 706 761 800 811 831 858 900 901 891 899 862 871

SEER 9 except 440 521 544 601 620 667 687 692 744 797 813 813 858 901 904 891 888 874 874SF-Oakland

San Francisco- 508 528 520 571 702 703 773 783 854 821 800 932 855 894 888 890 959 800 860Oakland SMSAc

San Francisco 482 446 598 727 739 757 934 747 914 872 727 934 690 1047 764 769 889 776 826CityCounty

Table 1915

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 55+

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 55+

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 003 006 217 072 Asian 0 001 003 005 183 072

10 002 005 011 218 073 Pacific 10 002 004 009 184 073

20 003 009 021 217 073 Islander 20 003 007 015 182 073

30 006 018 042 216 073 30 005 013 029 180 073

40 012 037 082 213 074 40 008 024 057 176 073

50 025 072 139 206 074 50 017 049 101 170 073

60 049 120 177 191 075 60 034 087 139 158 072

70 080 144 - 160 072 70 056 112 - 133 068

80 085 - - 106 062 80 066 - - 091 056

White 0 001 003 006 227 075 American 0 001 002 003 116 049

10 002 005 011 228 076 Indian 10 002 002 005 117 050

20 003 009 021 227 076 Alaska 20 001 003 008 116 050

30 006 018 043 226 077 Nativea 30 003 007 022 117 051

40 012 038 085 223 077 40 004 019 041 117 052

50 026 075 147 217 078 50 016 038 078 118 053

60 052 127 187 201 078 60 024 067 105 109 055

70 085 153 - 169 076 70 048 091 - 096 055

80 090 - - 111 065 80 057 - - 064 043

Black 0 001 002 006 138 042 Hispanicb 0 001 002 005 222 073

10 002 005 011 140 043 10 001 004 009 223 074

20 003 010 022 139 043 20 003 008 019 222 074

30 006 019 041 137 043 30 005 016 040 221 074

40 013 035 068 133 043 40 011 035 078 218 074

50 023 057 093 125 043 50 024 068 133 211 074

60 037 076 102 110 042 60 046 114 173 195 074

70 047 078 - 087 038 70 075 140 - 164 070

80 044 - - 057 032 80 081 - - 112 057

Table 1916

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Both Sexes 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 004 007 243 081 Asian 0 001 003 006 213 085

10 002 006 013 244 082 Pacific 10 002 005 011 213 086

20 004 010 024 243 082 Islander 20 003 009 018 211 086

30 007 021 049 243 083 30 006 015 034 210 086

40 014 042 094 240 084 40 009 028 067 205 086

50 029 082 158 233 085 50 019 059 117 199 086

60 057 139 203 219 086 60 041 101 161 187 085

70 095 170 - 188 084 70 066 131 - 159 082

80 105 - - 130 073 80 080 - - 114 069

White 0 001 004 007 254 085 American 0 001 003 004 104 057

10 002 006 013 255 086 Indian 10 002 003 006 105 058

20 004 010 024 254 086 Alaska 20 001 004 008 103 058

30 007 020 049 253 087 Nativea 30 003 008 021 104 059

40 014 043 097 251 088 40 005 018 038 105 060

50 030 086 167 244 089 50 014 035 071 105 062

60 059 147 215 230 090 60 023 062 094 099 065

70 101 180 - 198 088 70 046 084 - 090 066

80 112 - - 136 076 80 053 - - 061 053

Black 0 001 003 007 152 046 Hispanicb 0 001 003 005 238 083

10 002 006 014 154 047 10 002 005 011 239 084

20 004 012 027 153 047 20 003 009 021 238 084

30 008 023 048 152 047 30 006 018 043 238 084

40 016 042 079 148 047 40 012 037 083 235 085

50 027 066 105 138 047 50 026 073 145 228 085

60 043 087 114 123 045 60 050 126 189 214 085

70 054 088 - 099 042 70 086 157 - 185 081

80 053 - - 070 036 80 094 - - 131 066

Table 1917

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Males 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 002 004 193 064 Asian 0 001 002 004 159 063

10 001 004 009 195 064 Pacific 10 001 004 008 160 063

20 003 007 017 194 064 Islander 20 002 006 013 159 063

30 005 015 036 192 065 30 004 011 025 157 063

40 010 031 071 189 065 40 007 021 048 153 063

50 022 062 120 182 065 50 014 042 087 148 063

60 042 103 154 168 065 60 028 074 122 136 062

70 067 123 - 138 063 70 049 099 - 114 058

80 071 - - 090 054 80 057 - - 075 047

White 0 001 002 004 203 067 American 0 000 001 002 128 043

10 001 004 009 204 067 Indian 10 001 001 004 129 044

20 002 007 017 203 067 Alaska 20 001 003 007 128 044

30 005 015 037 201 067 Nativea 30 002 006 023 129 044

40 010 032 074 198 068 40 004 021 044 129 045

50 022 065 127 192 068 50 017 042 085 129 046

60 044 109 163 177 068 60 026 072 113 118 047

70 072 130 - 146 066 70 050 097 - 102 046

80 075 - - 094 056 80 060 - - 066 037

Black 0 000 002 004 126 040 Hispanicb 0 001 002 004 210 065

10 001 004 009 128 040 10 001 004 008 211 066

20 003 008 018 127 040 20 002 007 017 211 066

30 005 015 034 125 040 30 004 014 036 209 066

40 010 029 058 122 040 40 010 032 073 206 066

50 020 049 083 115 040 50 022 064 123 198 066

60 032 068 094 102 039 60 043 104 161 182 065

70 041 071 - 080 036 70 066 127 - 149 062

80 039 - - 051 030 80 073 - - 100 051

Table 1918

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Females 2014-2016 By RaceEthnicity

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

The AAPC is the Average Annual Percent Change over the time interval The AAPCs are calculated bythe Joinpoint Regression Program Version 47 February 2019 National Cancer Institute

- Statistic not shown Rate based on less than 16 cases for the time intervalTrend based on less than 10 cases for at least one year within the time interval

a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) Trendsare based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico SeattleUtah and AtlantaThe SEER 21 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the AlaskaNative Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts

c The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 3 Joinpoints overdiagnosis years 2000-2016

d The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 5 Joinpoints overdiagnosis years 1975-2016

e Hispanic and Non-Hispanic are not mutually exclusive from whites blacks AsianPacificIslanders and American IndiansAlaska Natives Incidence data for Hispanics and Non-Hispanicsare based on NHIA and exclude cases from the Alaska Native Registry

f Incidence data for American IndianAlaska Native are based on the PurchasedReferred CareDelivery Area (PRCDA) counties

g US Mortality Files National Center for Health Statistics CDCh The 2007-2016 mortality AAPCs are based on a Joinpoint analysis using years of death 2000-2016 The APC is significantly different from zero (plt05)

SEER Incidence SEER 21 Areasb SEER 21 Areasb SEER 9 Areasb

Rate 2012-2016 Trend 2007-2016c Trend 2007-2016d

Rate per 100000 persons AAPC () AAPC ()

Total Males Females Total Males Females Total Males Females RaceEthnicity

All Races 196 239 162 -07 -09 -08 -09 -07 -08

White 206 250 170 -08 -11 -09 -09 -08 -08White Hispanice 183 212 161 -08 -03 -05 - - -White Non-Hispanice 210 256 172 -08 -06 -10 - - -

Black 147 177 124 01 00 03 00 -04 -09

AsianPacific Islander 134 164 110 00 00 -01 - - -

Amer IndAlaska Natf 113 120 106 -05 -12 00 - - -

Hispanice 179 207 157 -05 -02 03 - - -

US Mortalityg Rate 2012-2016 Trend 2007-2016h

Rate per 100000 persons AAPC ()

Total Males Females Total Males FemalesRaceEthnicity

All Races 56 73 44 -23 -20 -27

White 59 76 45 -23 -20 -27White Hispanice 51 65 40 -16 -13 -20White Non-Hispanice 59 76 46 -23 -20 -27

Black 41 52 33 -20 -19 -21

AsianPacific Islander 39 49 31 -17 -15 -19

Amer IndAlaska NatTotal US 31 40 24 -32 -20 -45PRCDA Counties 44 58 33 -21 -04 -37Non-PRCDA Counties 17 21 14 -54 -50 -60

Hispanice 48 61 38 -17 -14 -21

Table 1919Non-Hodgkin Lymphoma

SEER Incidence and US MortalityAge-Adjusted Rates and Trendsa

By RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Incidence Ratesa 2012-2016

California 1844 2241 1515 1938 2349 1591 1390 1639 1182Greater Bay Area 1957 2381 1600 2144 2601 1755 1628 1828 1436San Francisco-Oakland 1956 2421 1570 2174 2660 1765 1603 1816 1408San Jose-Monterey 1962 2311 1660 2097 2503 1742 1800 1891 1646

Los Angeles 1804 2176 1505 1951 2331 1637 1357 1659 1139Greater California 1822 2220 1489 1876 2286 1529 1314 1534 1113

Connecticut 2116 2607 1733 2154 2642 1771 1386 1829 1051Detroit 2132 2636 1742 2290 2850 1847 1620 1905 1409Georgia 1826 2244 1487 1936 2346 1588 1462 1833 1187Atlanta 1925 2381 1555 2119 2567 1736 1601 2034 1272Rural Georgia 1584 1790 1401 1953 2298 1567 807 - 988Greater Georgia 1784 2186 1459 1872 2274 1537 1380 1703 1146

Hawaii 1660 2024 1349 1958 2275 1593 - - -Idaho 1922 2267 1616 1920 2262 1618 - - -Iowa 2134 2601 1756 2148 2612 1773 1352 1602 1100Kentucky 2039 2505 1666 2070 2538 1693 1403 1788 1112Louisiana 1944 2352 1614 2106 2537 1744 1469 1769 1237Massachusetts 1810 2181 1518 1830 2214 1524 1452 1655 1299New Jersey 2155 2607 1804 2285 2765 1905 1387 1621 1222New Mexico 1550 1739 1387 1580 1798 1394 875 - -New York 2152 2620 1788 2306 2792 1915 1545 1852 1333Seattle-Puget Sound 2116 2627 1695 2177 2667 1766 1631 1973 1316Utah 1843 2233 1498 1862 2258 1513 2089 - -

SEER 9 Areasb 1992 2444 1623 2095 2551 1716 1573 1914 1298SEER 13 Areasb 1946 2373 1597 2064 2502 1700 1519 1853 1258SEER 18 Areasb 1933 2354 1590 2031 2464 1671 1449 1751 1214SEER 21 Areasb 1963 2388 1620 2061 2498 1702 1471 1771 1245

Table 1920Non-Hodgkin Lymphoma

Age-Adjusted SEER Incidence Ratesa

By Registry Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control and PreventionRates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and AtlantaThe SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Death Ratesa 2012-2016

California 533 677 423 570 726 449 417 480 367Greater Bay Area 505 671 376 561 756 408 410 491 331San Francisco-Oakland 503 667 376 555 742 409 416 490 343San Jose-Monterey 511 681 377 573 781 407 - - -

Los Angeles 541 670 443 589 728 481 424 503 371Greater California 539 682 429 564 716 447 416 455 384

Connecticut 533 705 407 547 717 421 350 510 244Detroit 639 822 505 693 895 542 443 528 384Georgia 533 697 411 580 747 450 376 503 286Atlanta 492 659 372 533 728 388 397 506 317Rural Georgia 559 731 388 670 813 507 - - -Greater Georgia 549 712 426 595 755 470 363 500 266

Hawaii 475 620 352 545 649 412 - - -Idaho 635 775 510 641 782 516 - - -Iowa 638 845 484 642 848 488 - - -Kentucky 642 886 460 655 904 470 401 557 284Louisiana 608 814 451 651 863 485 461 623 340Massachusetts 523 659 423 541 682 436 347 410 297New Jersey 545 721 419 585 780 443 372 466 314New Mexico 488 585 405 493 595 406 - - -New York 535 702 412 575 752 441 390 514 313Seattle-Puget Sound 585 749 463 604 769 480 490 562 397Utah 542 670 433 551 681 440 - - -

SEER 9 Areasb 555 719 430 586 758 454 414 522 333SEER 13 Areasb 549 705 429 586 753 457 419 521 342SEER 18 Areasb 554 717 431 589 761 456 409 518 329SEER 21 Areasb 550 712 428 584 754 453 401 513 322

Total US 562 725 436 586 755 454 408 518 330

Table 1921Non-Hodgkin Lymphoma

Age-Adjusted SEER Death Ratesa

By Registry Race and Sex

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 562 002

High Five StatesMichigan 645 011 01(0112) 1479Kentucky 642 016 02(0118) 1424Iowa 638 018 03(0120) 1367Indiana 638 013 04(0117) 1361Idaho 635 027 05(0126) 1303

Low Five StatesNevada 511 019 47(2251) -899Colorado 491 014 48(3851) -1257New Mexico 488 020 49(2851) -1317Hawaii 475 024 50(3051) -1542c

DC 444 039 51(2351) -2097c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 545 014 28(1847) -291 Montana 559 030 25(0250) -042Alaska 525 047 43(0151) -654 Nebraska 563 023 22(0548) 026Arizona 512 012 46(2950) -886 Nevada 511 019 47(2251) -899Arkansas 555 018 26(1247) -113 New Hampshire 562 027 23(0349) 014California 533 005 40(2645) -508 New Jersey 545 010 29(2045) -301Colorado 491 014 48(3851) -1257 New Mexico 488 020 49(2851) -1317Connecticut 533 016 39(1949) -505 New York 535 007 37(2446) -478Delaware 628 033 08(0139) 1174 North Carolina 541 010 35(2146) -363DC 444 039 51(2351) -2097c North Dakota 561 037 24(0151) -007Florida 535 006 38(2545) -479 Ohio 616 009 10(0220) 969Georgia 533 011 41(2248) -511 Oklahoma 630 017 06(0121) 1226Hawaii 475 024 50(3051) -1542c Oregon 612 016 11(0124) 903Idaho 635 027 05(0126) 1303 Pennsylvania 603 009 16(0622) 729Illinois 566 009 20(1634) 085 Rhode Island 542 029 32(0651) -350Indiana 638 013 04(0117) 1361 South Carolina 542 014 31(1847) -347Iowa 638 018 03(0120) 1367 South Dakota 541 033 36(0451) -364Kansas 585 019 19(0439) 420 Tennessee 629 013 07(0119) 1198Kentucky 642 016 02(0118) 1424 Texas 546 007 27(2142) -277Louisiana 608 016 14(0125) 826 Utah 542 022 33(1250) -352Maine 609 026 13(0137) 852 Vermont 605 040 15(0148) 770Maryland 524 013 44(2349) -663 Virginia 544 011 30(2046) -319Massachusetts 523 012 45(2549) -687 Washington 599 013 17(0425) 665Michigan 645 011 01(0112) 1479 West Virginia 612 022 12(0132) 894Minnesota 617 014 09(0122) 984 Wisconsin 590 013 18(0629) 507Mississippi 531 018 42(1850) -551 Wyoming 564 043 21(0151) 050Missouri 542 012 34(1947) -354

Table 1922Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males and Females

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 725 003

High Five StatesKentucky 886 030 01(0112) 2213c

Iowa 845 032 02(0120) 1647c

Michigan 842 019 03(0114) 1615c

Indiana 839 024 04(0116) 1567c

Delaware 824 058 05(0144) 1364

Low Five StatesArizona 635 019 47(3251) -1244Alaska 630 075 48(0251) -1311Hawaii 620 041 49(1951) -1452DC 614 071 50(0551) -1535c

New Mexico 585 033 51(3451) -1928c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 688 025 36(1649) -513 Montana 709 050 26(0251) -218Alaska 630 075 48(0251) -1311 Nebraska 737 040 20(0248) 165Arizona 635 019 47(3251) -1244 Nevada 653 032 44(1951) -994Arkansas 721 031 22(0747) -061 New Hampshire 710 046 25(0451) -210California 677 009 41(2846) -666 New Jersey 721 018 21(1441) -059Colorado 643 024 46(2451) -1133 New Mexico 585 033 51(3451) -1928c

Connecticut 705 028 28(1248) -273 New York 702 012 30(1943) -323Delaware 824 058 05(0144) 1364 North Carolina 709 018 27(1644) -221DC 614 071 50(0551) -1535c North Dakota 682 061 39(0251) -598Florida 683 011 37(2446) -585 Ohio 800 017 09(0320) 1029Georgia 697 019 34(1746) -387 Oklahoma 806 030 08(0126) 1109Hawaii 620 041 49(1951) -1452 Oregon 794 028 12(0128) 947Idaho 775 045 16(0146) 692 Pennsylvania 783 015 15(0523) 794Illinois 739 016 19(1235) 190 Rhode Island 649 050 45(1051) -1050Indiana 839 024 04(0116) 1567c South Carolina 681 025 40(1850) -604Iowa 845 032 02(0120) 1647c South Dakota 701 056 31(0251) -332Kansas 713 032 24(0948) -174 Tennessee 820 023 06(0120) 1311Kentucky 886 030 01(0112) 2213c Texas 698 012 32(2043) -368Louisiana 814 029 07(0122) 1222 Utah 670 036 42(1351) -754Maine 754 045 18(0148) 395 Vermont 794 069 11(0149) 950Maryland 682 023 38(1849) -588 Virginia 694 020 35(1847) -429Massachusetts 659 020 43(2450) -910 Washington 790 022 13(0224) 897Michigan 842 019 03(0114) 1615c West Virginia 774 038 17(0142) 675Minnesota 797 025 10(0224) 995 Wisconsin 786 023 14(0227) 844Mississippi 717 034 23(0748) -110 Wyoming 698 071 33(0151) -377Missouri 702 022 29(1646) -319

Table 1923Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 436 002

High Five StatesIdaho 510 033 01(0139) 1697c

Maine 497 031 02(0141) 1396Michigan 495 012 03(0119) 1340Oklahoma 492 020 04(0128) 1276Indiana 492 016 05(0123) 1270

Low Five StatesMississippi 404 021 47(1351) -731Nevada 382 022 48(2051) -1237Colorado 369 016 49(3451) -1540c

Hawaii 352 027 50(2551) -1932c

DC 323 044 51(1551) -2601c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 440 017 24(0547) 099 Montana 435 036 27(0151) -034Alaska 414 058 38(0151) -500 Nebraska 435 027 26(0249) -032Arizona 407 014 44(2049) -664 Nevada 382 022 48(2051) -1237Arkansas 428 021 31(0649) -181 New Hampshire 454 032 19(0149) 400California 423 006 34(2244) -313 New Jersey 419 012 37(1848) -397Colorado 369 016 49(3451) -1540c New Mexico 405 025 46(0951) -706Connecticut 407 018 45(1550) -669 New York 412 008 39(2548) -554Delaware 473 039 12(0150) 855 North Carolina 420 012 35(1848) -374DC 323 044 51(1551) -2601c North Dakota 471 045 13(0150) 809Florida 412 007 40(2548) -564 Ohio 478 011 10(0123) 967Georgia 411 012 43(2049) -582 Oklahoma 492 020 04(0128) 1276Hawaii 352 027 50(2551) -1932c Oregon 465 019 15(0141) 668Idaho 510 033 01(0139) 1697c Pennsylvania 467 010 14(0427) 714Illinois 439 010 25(1341) 074 Rhode Island 455 035 18(0150) 434Indiana 492 016 05(0123) 1270 South Carolina 432 017 30(0947) -102Iowa 484 021 08(0135) 1087 South Dakota 411 039 42(0151) -580Kansas 486 023 06(0137) 1143 Tennessee 484 015 09(0126) 1087Kentucky 460 018 17(0241) 544 Texas 427 008 32(1944) -213Louisiana 451 018 21(0345) 333 Utah 433 026 28(0250) -081Maine 497 031 02(0141) 1396 Vermont 461 047 16(0151) 578Maryland 411 015 41(1749) -576 Virginia 432 013 29(1246) -092Massachusetts 423 014 33(1548) -303 Washington 452 015 20(0541) 360Michigan 495 012 03(0119) 1340 West Virginia 486 027 07(0143) 1141Minnesota 475 017 11(0132) 901 Wisconsin 443 015 23(0645) 156Mississippi 404 021 47(1351) -731 Wyoming 445 051 22(0151) 192Missouri 419 014 36(1549) -396

Table 1924Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Females

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 Areas (excluding the AlaskaNative Registry) and 112016 US population estimates based on the average of 2015 and 2016 population estimates from theUS Bureau of the CensusPrevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 24 years

b Maximum limited-duration prevalence is 24 years for 1992-2016 datac Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groupsd Cases diagnosed more than 24 years ago were estimated using the completeness index method (Capocaccia et al 1997

Merrill et al 2000)e Complete prevalence is obtained by summing 0 to lt24 and gt=24- Statistic not shown Statistic based on fewer than 5 cases estimated alive in SEER for the time interval+ Not available

Years Since Diagnosis 0 to lt5 5 to lt10 10 to lt15 15 to lt20 20 to lt24 0 to lt24b gt=24d Completee

Race Sex

All Races Both Sexes 248946 177490 117326 69109 31890 644761 49943 694704Males 135137 94173 60159 36020 16581 342069 25489 367558Females 113809 83317 57167 33089 15309 302692 24454 327146

White Both Sexes 213764 154454 101984 60537 28026 558765 49625 620368Males 116527 82172 52535 31627 14543 297404 26526 330121Females 97237 72282 49448 28910 13483 261361 23099 290247

Black Both Sexes 20500 13640 9750 5271 2215 51376 4115 55491Males 10712 7188 4768 2684 1174 26526 1911 28437Females 9789 6452 4981 2587 1041 24850 2204 27054

Asian Both Sexes 8405 5210 3415 1867 844 19741 + +Pacific Males 4548 2661 1757 1013 407 10386 + +Islander Females 3856 2549 1657 855 437 9355 + +

Hispanic Both Sexes 21339 14049 8272 4881 2136 50676 + +Males 10918 7243 4331 2617 1094 26202 + +Females 10421 6805 3941 2264 1043 24474 + +

Age Specific (Crude) Age-Adjustedc Age at Prevalence All Ages 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ All Ages

Race Sex

All Races Both Sexes 02001 00035 00139 00283 00538 01121 02352 04640 08181 10224 01738Males 02156 00044 00189 00354 00625 01293 02710 05243 09364 12449 02023Females 01850 00026 00087 00208 00450 00952 02010 04094 07196 08856 01498

White Both Sexes 02216 00035 00143 00289 00534 01148 02427 04858 08597 10738 01807Males 02380 00045 00198 00359 00622 01317 02790 05442 09778 13060 02095Females 02054 00025 00085 00214 00442 00976 02072 04317 07593 09285 01560

Black Both Sexes 01139 00029 00113 00265 00599 01027 02010 03340 05117 05333 01251Males 01226 00029 00140 00351 00696 01223 02333 03969 05849 06055 01457Females 01059 00030 00086 00178 00510 00853 01728 02836 04608 04976 01088

Asian Both Sexes 00970 00039 00133 00207 00353 00680 01409 02692 04470 06094 01032Pacific Males 01065 00044 00175 00240 00398 00744 01640 03072 05516 07472 01222Islander Females 00882 00033 00092 00175 00312 00623 01209 02384 03629 05207 00880

Hispanic Both Sexes 00887 00030 00117 00206 00398 00850 01769 03632 05888 07209 01294Males 00908 00035 00147 00256 00455 00932 01924 03940 06326 08003 01420Females 00866 00024 00086 00151 00337 00766 01616 03360 05552 06719 01185

Table 1925Non-Hodgkin Lymphoma

Estimated United States Cancer Prevalence Countsa on January 1 2016By RaceEthnicity Sex and Years Since Diagnosis

Estimated prevalence percenta on January 1 2016 of the SEER population diagnosed in the previous 24 yearsBy Age at Prevalence RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 372 452924 -05 62 18862 04 247 189692 -05 1657 244370 -05

1 Hodgkin Lymphoma 28 32262 -17 13 3927 -06 33 22556 -15 39 5779 -31

2 Non-Hodgkin lymphoma 336 409991 -03 48 14693 04 210 163591 -03 1572 231707 -042(a) Non-Hodgkin lymphoma B-cell 311 380349 -01 39 11836 14 190 148768 -02 1491 219745 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 15 16631 20 31 9416 10 07 5203 39 14 2012 252(a) 2 Mature Non-Hodgkin lymphoma B-cell 280 343965 -04 07 2271 30 174 137225 -05 1387 204469 -042(a) 21 ChronicSmallProlymphocytic 69 85601 -13 00 35 - 35 29103 -11 382 56463 -14

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 61 75061 -15 00 30 - 31 25339 -13 336 49692 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 311 19 - - - 00 72 - 02 234 262(a) 213 Mantle-cell lymphoma 08 10229 03 - - - 04 3692 02 44 6537 04

2(a) 22 Lymphoplasmacytic lymphoma 07 8651 00 - - - 03 2590 -11 41 6059 04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 03 3667 -03 - - - 01 1132 -18 17 2533 022(a) 222 Waldenstrom macroglubulinemia 04 4984 03 - - - 02 1458 -07 24 3526 06

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 72 87188 00 03 925 26 48 36480 -02 339 49783 022(a) 231 DLBCL NOSc 71 85899 -01 03 861 12 46 35469 -05 337 49569 012(a) 232 Intravascular large B-cell 00 162 - - - - 00 63 - 01 99 -

lymphoma2(a) 233 Primary effusion lymphoma 00 181 27 - - - 00 126 - 00 55 -2(a) 234 Mediastinal large B-cell 01 946 116 00 64 - 01 822 111 00 60 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 04 4692 -26 03 1028 32 04 2618 -43 07 1046 -432(a) 25 Marginal-zone lymphoma (MZL) 22 26534 00 00 137 13 14 11049 05 104 15348 -042(a) 251 Splenic MZL 02 2418 04 - - - 01 889 -08 10 1529 102(a) 252 Extranodal MZL MALTc type 13 15979 06 00 92 - 09 7148 11 59 8739 032(a) 253 Nodal MZL 07 8137 -15 00 45 - 04 3012 -05 34 5080 -20

2(a) 26 Follicular lymphoma 35 43582 -21 00 119 - 28 21725 -25 147 21738 -182(a) 27 Hairy-cell leukemia 03 3712 -16 - - - 03 2311 -19 09 1401 -122(a) 28 Plasma cell neoplasms 68 83957 08 00 24 - 39 31325 12 358 52608 062(a) 281 Plasmacytoma 04 4879 -04 00 16 - 03 2362 -06 17 2501 -032(a) 282 Multiple myeloma 64 79078 09 - - - 36 28963 14 341 50107 07

plasma-cell leukemia2(a) 29 Heavy chain disease 00 48 - - - - 00 24 - 00 23 -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 16 19753 33 00 149 27 08 6340 37 90 13264 32

Table 1926All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 23 27222 01 08 2502 18 19 13933 03 73 10787 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 616 - 01 293 - 00 272 - 00 51 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 22 26531 11 07 2207 75 19 13621 12 73 10703 -042(b) 21 Mycosis fungoidesSezary syndrome 06 6969 18 01 213 84 06 4080 23 18 2676 052(b) 211 Mycosis fungoides 06 6739 17 01 213 84 05 3990 22 17 2536 042(b) 212 Sezary syndrome 00 230 46 - - - 00 90 - 01 140 -

2(b) 22 Peripheral T-cell lymphoma 12 14531 -10 02 534 07 10 7159 -09 46 6838 -122(b) 221 Peripheral T-cell lymphoma NOSc 04 5393 -01 00 86 - 03 2489 04 19 2818 -042(b) 222 Angioimmunoblastic T-cell lymphoma 02 1902 02 - - - 01 699 -09 08 1201 072(b) 223 Subcutaneous panniculitis- 00 176 44 00 31 - 00 111 - 00 34 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 2523 -36 01 291 00 02 1450 -33 05 782 -54

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 139 - - - - 00 98 - 00 28 -2(b) 226 Enteropathy-type T-cell lymphoma 00 186 -02 - - - 00 84 - 01 101 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 2963 -07 00 59 - 02 1575 01 09 1329 -142(b) 228 Primary cutaneous anaplastic 01 1249 -41 00 51 - 01 653 -49 04 545 -39

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 03 3417 96 05 1428 101 02 1474 99 03 515 672(b) 24 NKcT-cell lymphoma nasal-type 01 985 02 00 26 - 01 659 00 02 300 05

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 120 - - - - 00 54 - 00 65 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 509 30 - - - 00 195 -05 02 309 442(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 75 - - - - 00 40 - 00 33 -2(c) Non-Hodgkin lymphoma unknown lineage 02 2420 -274 01 355 - 01 890 -216 08 1175 -2792(c) 1 Precursor lymphoblastic leukemia 01 814 -283 01 343 - 00 238 - 02 233 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 95 - - - - 00 25 - 00 69 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 1511 -274 - - - 01 627 -202 06 873 -319

lineage2() 1 Total precursor lymphomaleukemiad 16 18061 -07 33 10052 -15 08 5713 06 15 2296 -01

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 762 273 00 20 - 00 339 227 03 403 -lymphoma

4 Lymphoid neoplasm NOSc 08 9909 -55 01 222 113 04 3206 -59 43 6481 -59

Table 1926 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 461 253152 -05 70 10973 05 294 110367 -07 2122 131812 -05

1 Hodgkin Lymphoma 31 17710 -17 13 2118 -03 36 12525 -16 48 3067 -31

2 Non-Hodgkin lymphoma 419 229772 -03 56 8711 05 252 95756 -05 2017 125305 -032(a) Non-Hodgkin lymphoma B-cell 387 212247 -02 44 6786 15 227 86941 -04 1908 118520 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 16 8999 24 33 5123 11 08 2888 46 16 988 292(a) 2 Mature Non-Hodgkin lymphoma B-cell 351 192801 -05 10 1558 28 210 80417 -08 1783 110826 -042(a) 21 ChronicSmallProlymphocytic 96 52411 -15 00 21 - 47 18927 -14 539 33463 -15

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 82 44988 -17 00 19 - 40 16143 -16 464 28826 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 193 -02 - - - 00 46 - 02 145 052(a) 213 Mantle-cell lymphoma 13 7230 -01 - - - 07 2738 -01 72 4492 -01

2(a) 22 Lymphoplasmacytic lymphoma 10 5082 -05 - - - 04 1524 -08 58 3558 -04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 04 2062 -08 - - - 02 616 -12 23 1446 -072(a) 222 Waldenstrom macroglubulinemia 06 3020 -02 - - - 02 908 -06 34 2112 -02

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 88 48128 01 03 554 22 59 21824 -06 418 25750 052(a) 231 DLBCL NOSc 87 47520 00 03 519 03 57 21366 -08 416 25635 042(a) 232 Intravascular large B-cell 00 75 - - - - 00 31 - 01 44 -

lymphoma2(a) 233 Primary effusion lymphoma 00 167 26 - - - 00 123 - 01 44 -2(a) 234 Mediastinal large B-cell 01 366 155 00 35 - 01 304 142 00 27 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 06 3388 -22 05 775 31 06 1969 -46 10 644 -192(a) 25 Marginal-zone lymphoma (MZL) 22 12351 -02 01 98 - 14 5177 -02 114 7076 -012(a) 251 Splenic MZL 02 1164 14 - - - 01 434 18 12 730 112(a) 252 Extranodal MZL MALTc type 13 7268 07 00 62 - 09 3267 04 63 3939 102(a) 253 Nodal MZL 07 3919 -23 00 36 - 04 1476 -22 39 2407 -23

2(a) 26 Follicular lymphoma 39 21788 -19 01 100 - 30 11210 -25 165 10478 -152(a) 27 Hairy-cell leukemia 05 2984 -18 - - - 05 1908 -20 17 1076 -152(a) 28 Plasma cell neoplasms 85 46642 07 - - - 45 17864 11 462 28769 052(a) 281 Plasmacytoma 05 2997 -08 - - - 04 1509 -16 24 1484 -012(a) 282 Multiple myeloma 80 43645 08 - - - 41 16355 13 439 27285 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 27 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 20 10447 34 01 105 - 10 3636 40 110 6706 32

Table 1927All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 29 16118 00 11 1730 14 23 8235 02 98 6153 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 430 - 01 208 - 01 188 - 01 34 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 28 15642 11 10 1521 71 22 8022 11 97 6099 -032(b) 21 Mycosis fungoidesSezary syndrome 07 3962 19 01 135 - 06 2261 21 25 1566 092(b) 211 Mycosis fungoides 07 3831 20 01 135 - 06 2213 21 23 1483 092(b) 212 Sezary syndrome 00 131 - - - - 00 48 - 01 83 -

2(b) 22 Peripheral T-cell lymphoma 15 8438 -13 02 318 -09 12 4248 -12 62 3872 -132(b) 221 Peripheral T-cell lymphoma NOSc 06 3159 -05 00 49 - 04 1520 02 26 1590 -082(b) 222 Angioimmunoblastic T-cell lymphoma 02 1024 19 - - - 01 415 11 10 607 232(b) 223 Subcutaneous panniculitis- 00 68 - - - - 00 39 - 00 16 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 03 1549 -39 01 184 -01 02 888 -43 08 477 -45

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 98 - - - - 00 69 - 00 18 -2(b) 226 Enteropathy-type T-cell lymphoma 00 105 - - - - 00 50 - 01 54 -2(b) 227 Cutaneous T-cell lymphoma NOSc 03 1696 -12 00 32 - 02 894 -03 12 770 -172(b) 228 Primary cutaneous anaplastic 01 739 -48 00 26 - 01 373 -49 05 340 -49

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 04 2253 97 07 1047 92 03 940 98 04 266 1022(b) 24 NKcT-cell lymphoma nasal-type 01 638 -05 00 18 - 01 435 -03 03 185 -06

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 58 - - - - 00 22 - 01 36 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 01 293 45 - - - 00 116 - 03 174 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 46 - - - - 00 25 - 00 20 -2(c) Non-Hodgkin lymphoma unknown lineage 03 1407 -232 01 195 - 02 580 -184 10 632 -2302(c) 1 Precursor lymphoblastic leukemia 01 474 -228 01 187 - 00 134 - 02 153 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 49 - - - - - - - 01 36 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 02 884 -239 - - - 01 433 -175 07 443 -

lineage2() 1 Total precursor lymphomaleukemiad 18 9903 -06 35 5518 -17 09 3210 09 19 1175 05

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 435 271 - - - 01 215 - 03 207 -lymphoma

4 Lymphoid neoplasm NOSc 10 5235 -59 01 131 - 05 1871 -65 54 3233 -61

Table 1927 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 301 199772 -05 53 7889 02 202 79325 -02 1322 112558 -08

1 Hodgkin Lymphoma 24 14552 -16 12 1809 -10 29 10031 -14 32 2712 -32

2 Non-Hodgkin lymphoma 269 180219 -03 40 5982 03 170 67835 00 1251 106402 -062(a) Non-Hodgkin lymphoma B-cell 250 168102 -01 34 5050 13 154 61827 02 1190 101225 -042(a) 1 Precursor Non-Hodgkin lymphoma B-cell 14 7632 16 29 4293 09 06 2315 29 12 1024 202(a) 2 Mature Non-Hodgkin lymphoma B-cell 223 151164 -04 05 713 35 141 56808 -01 1102 93643 -072(a) 21 ChronicSmallProlymphocytic 48 33190 -13 - - - 24 10176 -05 268 23000 -16

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 43 30073 -15 - - - 22 9196 -06 243 20866 -19

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 118 - - - - 00 26 - 01 89 -2(a) 213 Mantle-cell lymphoma 04 2999 11 - - - 02 954 10 24 2045 12

2(a) 22 Lymphoplasmacytic lymphoma 05 3569 04 - - - 03 1066 -16 30 2501 11Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 02 1605 01 - - - 01 516 -25 13 1087 112(a) 222 Waldenstrom macroglubulinemia 03 1964 06 - - - 01 550 -08 17 1414 11

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 58 39060 00 02 371 33 38 14656 03 283 24033 -032(a) 231 DLBCL NOSc 57 38379 -02 02 342 27 36 14103 -01 282 23934 -032(a) 232 Intravascular large B-cell 00 87 - - - - 00 32 - 01 55 -

lymphoma2(a) 233 Primary effusion lymphoma - - - - - - - - - - - -2(a) 234 Mediastinal large B-cell 01 580 91 00 29 - 02 518 93 00 33 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 02 1304 -34 02 253 38 02 649 -37 05 402 -852(a) 25 Marginal-zone lymphoma (MZL) 21 14183 01 00 39 - 15 5872 12 98 8272 -062(a) 251 Splenic MZL 02 1254 -07 - - - 01 455 -32 10 799 072(a) 252 Extranodal MZL MALTc type 13 8711 06 00 30 - 10 3881 17 57 4800 -032(a) 253 Nodal MZL 06 4218 -07 - - - 04 1536 11 32 2673 -18

2(a) 26 Follicular lymphoma 33 21794 -24 00 19 - 27 10515 -25 134 11260 -222(a) 27 Hairy-cell leukemia 01 728 -12 - - - 01 403 -11 04 325 -122(a) 28 Plasma cell neoplasms 55 37315 08 - - - 33 13461 15 282 23839 052(a) 281 Plasmacytoma 03 1882 00 - - - 02 853 12 12 1017 -092(a) 282 Multiple myeloma 52 35433 09 - - - 30 12608 15 270 22822 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 21 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 14 9306 32 00 44 - 07 2704 32 76 6558 31

Table 1928All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 17 11104 01 05 772 29 15 5698 05 55 4634 -112(b) 1 Precursor Non-Hodgkin lymphoma T-cell 00 186 - 01 85 - 00 84 - 00 17 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 17 10889 09 05 686 83 15 5599 12 54 4604 -092(b) 21 Mycosis fungoidesSezary syndrome 05 3007 15 01 78 - 05 1819 26 13 1110 -042(b) 211 Mycosis fungoides 05 2908 12 01 78 - 05 1777 23 12 1053 -072(b) 212 Sezary syndrome 00 99 - - - - 00 42 - 01 57 -

2(b) 22 Peripheral T-cell lymphoma 09 6093 -08 01 216 30 08 2911 -06 35 2966 -142(b) 221 Peripheral T-cell lymphoma NOSc 03 2234 03 00 37 - 03 969 07 14 1228 -012(b) 222 Angioimmunoblastic T-cell lymphoma 01 878 -22 - - - 01 284 -39 07 594 -152(b) 223 Subcutaneous panniculitis- 00 108 - 00 18 - 00 72 - 00 18 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 974 -33 01 107 - 02 562 -19 04 305 -77

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 41 - - - - 00 29 - - - -2(b) 226 Enteropathy-type T-cell lymphoma 00 81 - - - - 00 34 - 01 47 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 1267 00 00 27 - 02 681 07 07 559 -102(b) 228 Primary cutaneous anaplastic 01 510 -34 00 25 - 01 280 -50 02 205 -33

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 02 1164 96 03 381 127 01 534 97 03 249 302(b) 24 NKcT-cell lymphoma nasal-type 01 347 11 - - - 01 224 - 01 115 -

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 62 - - - - 00 32 - 00 29 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 216 03 - - - 00 79 - 02 135 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 29 - - - - - - - - - -2(c) Non-Hodgkin lymphoma unknown lineage 02 1013 -341 01 160 - 01 310 - 06 543 -2(c) 1 Precursor lymphoblastic leukemia 01 340 - 01 156 - 00 104 - 01 80 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 46 - - - - - - - 00 33 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 627 - - - - 01 194 - 05 430 -

lineage2() 1 Total precursor lymphomaleukemiad 14 8158 -09 31 4534 -13 07 2503 02 13 1121 -11

3 Composite Hodgkin lymphoma and Non-Hodgkin 00 327 - - - - 00 124 - 02 196 -lymphoma

4 Lymphoid neoplasm NOSc 07 4674 -52 01 91 - 03 1335 -51 36 3248 -58

Table 1928 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 3: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Regression Program Version 47 February 2019 National Cancer Institute (httpssurveillancecancergovjoinpoint)The APC is the Annual Percent Change based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

a Trends are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)b Trends are from the SEER 21 areas (SEER 9 areas Los Angeles Alaska Native Registry Rural Georgia California excluding

SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York and Massachusetts)c Trends are from US Mortality Files National Center for Health Statistics Centers for Disease Control and Preventiond The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpointe API - AsianPacific Islander AIAN - American IndianAlaska Native NH - Non-Hispanicf Hispanic and Non-Hispanic are not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska

Natives Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registryg Data for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) counties The APCAAPC is significantly different from zero (plt05)- Joinpoint regression line analysis could not be performed on data series

JP Trend 1 JP Trend 2 JP Trend 3 JP Trend 4 JP Trend 5 JP Trend 6 AAPCd

Years APC Years APC Years APC Years APC Years APC Years APC 2007-16 2012-16

SEER 9 Delay-Adjusted Incidencea 1975-2016

All Races 1975-88 30 1988-04 14 2004-16 -07 -07 -07

White 1975-88 31 1988-04 14 2004-16 -06 -06 -06

Black 1975-04 29 2004-16 -06 -06 -06

SEER 21 Delay-Adjusted Incidenceb 2000-2016

All Races 2000-04 13 2004-16 -04 -04 -04

White 2000-06 08 2006-16 -05 -05 -05

White NHef 2000-06 08 2006-16 -05 -05 -05

Black 2000-16 05 05 05

Black NHef 2000-16 05 05 05

APIe 2000-16 03 03 03

AIANeg 2000-16 07 07 07

Hispanicf 2000-16 04 04 04

US Cancer Mortalityc 1975-2016

All Races 1975-94 22 1994-97 10 1997-08 -33 2008-16 -25 -26 -25

White 1975-97 21 1997-04 -38 2004-16 -27 -27 -27

Black 1975-96 27 1996-16 -22 -22 -22

US Cancer Mortalityc 2000-2016

All Races 2000-04 -39 2004-16 -27 -27 -27

White 2000-03 -44 2003-16 -27 -27 -27

White NHef 2000-03 -45 2003-16 -27 -27 -27

Black 2000-16 -21 -21 -21

Black NHef 2000-16 -20 -20 -20

APIe 2000-16 -19 -19 -19

AIANeg 2000-16 -37 -37 -37

Hispanicf 2000-16 -21 -21 -21

Table 193

Non-Hodgkin Lymphoma

Trends in SEER Incidenceab and US Mortalityc Using the Joinpoint Regression Program

1975-2016 With up to Five Joinpoints 2000-2016 With up to Three Joinpoints

Females by RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Reference Cancer Incidence Rates Adjusted for Reporting DelayIndividual rates for diagnosis years 1975-1979 available in web browser version of Cancer Statistics Review

a SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

- Delay-adjusted rate is not shown for observed rates based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

Year of Diagnosis1975-1979 1160 1344 1018 1209 1393 1068 696 874 5521980 1262 1501 1081 1298 1528 1122 870 1074 7201981 1358 1590 1181 1406 1634 1235 742 1059 4981982 1339 1556 1161 1402 1642 1205 1027 1022 10011983 1399 1662 1195 1463 1752 1240 1028 1088 9621984 1519 1829 1279 1597 1910 1355 946 1252 6921985 1551 1839 1316 1628 1925 1385 995 1196 8431986 1590 1943 1300 1683 2059 1375 1066 1313 8521987 1674 2078 1342 1770 2215 1400 1035 1043 9951988 1726 2136 1408 1822 2245 1490 1158 1579 8491989 1736 2165 1384 1836 2304 1450 1159 1410 9721990 1851 2297 1481 1934 2396 1549 1392 1763 11021991 1881 2374 1461 1970 2481 1532 1403 1881 10291992 1862 2304 1494 1956 2394 1584 1368 1887 9651993 1885 2347 1500 1965 2432 1570 1423 1937 9971994 1995 2496 1579 2067 2558 1654 1448 2152 8861995 1999 2542 1545 2070 2618 1604 1676 2363 11431996 1942 2424 1548 2027 2520 1621 1554 1925 12391997 2000 2453 1646 2090 2522 1749 1640 2426 10861998 1962 2296 1686 2061 2401 1778 1449 1696 12541999 1997 2459 1636 2095 2554 1732 1441 1842 11372000 1981 2434 1613 2099 2571 1712 1393 1823 10742001 2002 2440 1646 2082 2547 1706 1605 1844 13922002 2023 2420 1710 2134 2552 1798 1448 1710 12512003 2078 2506 1753 2191 2633 1848 1637 2006 13782004 2140 2589 1795 2235 2685 1885 1860 2418 14552005 2088 2563 1709 2202 2674 1820 1673 1995 14102006 2052 2475 1724 2178 2608 1839 1639 2102 12942007 2126 2612 1739 2255 2755 1845 1583 1935 13172008 2097 2580 1703 2185 2687 1768 1694 1899 15082009 2097 2528 1747 2204 2669 1814 1540 1867 12992010 2151 2676 1724 2250 2758 1831 1781 2343 13342011 1996 2450 1637 2093 2564 1716 1472 1769 12512012 2049 2511 1674 2147 2618 1757 1682 1926 14652013 1993 2438 1630 2101 2559 1719 1586 1838 13932014 2047 2531 1651 2172 2653 1777 1545 2042 11522015 2037 2521 1643 2161 2652 1754 1550 1998 12062016 1984 2403 1640 2078 2499 1726 1686 1980 1433

Table 194Non-Hodgkin Lymphoma

Delay-adjusted SEER Incidencea Rates by Year Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Individual rates for diagnosis years 1975-1979 available in web browser version of Cancer Statistics Reviewa SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)

Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

Year of Diagnosis1975-2016 1846 2267 1513 1925 2357 1581 1414 1769 11351975-1979 1160 1344 1018 1209 1393 1068 696 874 5521980 1262 1501 1081 1298 1528 1122 870 1074 7201981 1358 1590 1181 1406 1634 1235 742 1059 4981982 1339 1556 1161 1402 1642 1205 1027 1022 10011983 1399 1662 1195 1463 1752 1240 1028 1088 9621984 1519 1829 1279 1597 1910 1355 946 1252 6921985 1551 1839 1316 1628 1925 1385 995 1196 8431986 1590 1943 1300 1683 2059 1375 1066 1313 8521987 1674 2078 1342 1770 2215 1400 1035 1043 9951988 1726 2136 1408 1822 2245 1490 1158 1579 8491989 1736 2165 1384 1836 2304 1450 1159 1410 9721990 1851 2297 1481 1934 2396 1549 1392 1763 11021991 1881 2374 1461 1970 2481 1532 1403 1881 10291992 1862 2304 1494 1956 2394 1584 1368 1887 9651993 1885 2347 1500 1965 2432 1570 1423 1937 9971994 1995 2496 1579 2067 2558 1654 1448 2152 8861995 1999 2542 1545 2070 2618 1604 1676 2363 11431996 1942 2424 1548 2027 2520 1621 1554 1925 12391997 2000 2453 1646 2090 2522 1749 1640 2426 10861998 1962 2296 1686 2061 2401 1778 1449 1696 12541999 1997 2459 1636 2095 2554 1732 1441 1842 11372000 1981 2434 1613 2099 2571 1712 1393 1823 10742001 2002 2440 1646 2082 2547 1706 1605 1844 13922002 2023 2420 1710 2134 2552 1798 1448 1710 12512003 2078 2506 1753 2191 2633 1848 1637 2006 13782004 2140 2589 1795 2235 2685 1885 1860 2418 14552005 2088 2563 1709 2202 2674 1820 1673 1995 14102006 2052 2475 1724 2178 2608 1839 1639 2102 12942007 2126 2612 1739 2255 2755 1845 1583 1935 13172008 2093 2575 1700 2180 2681 1765 1689 1894 15032009 2089 2520 1741 2195 2659 1806 1531 1856 12912010 2141 2662 1715 2237 2742 1820 1767 2323 13232011 1982 2433 1626 2076 2544 1702 1455 1749 12372012 2031 2489 1659 2125 2591 1739 1658 1897 14442013 1973 2414 1613 2076 2529 1699 1558 1807 13682014 2020 2497 1629 2138 2612 1749 1512 1998 11282015 2003 2478 1615 2118 2600 1718 1510 1947 11742016 1936 2344 1600 2018 2428 1676 1625 1909 1382

Table 195Non-Hodgkin Lymphoma

Age-adjusted SEER Incidencea Rates by Year Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Individual rates for years of death 1975-1979 available in web browser version of Cancer Statistics Reviewa US Mortality Files National Center for Health Statistics Centers for Disease Control and Prevention

Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

Year of Death1975-2016 701 880 570 732 915 596 478 613 3801975-1979 580 708 484 602 733 503 375 483 2921980 623 747 529 647 774 552 399 515 3121981 616 738 527 640 766 547 398 500 3251982 655 798 549 683 829 574 412 523 3291983 666 811 558 692 839 585 430 579 3231984 676 815 575 705 850 601 419 528 3391985 706 880 580 734 917 602 462 557 3871986 731 898 605 759 925 633 495 664 3701987 726 881 610 756 912 638 473 630 3621988 752 928 624 782 959 653 501 682 3721989 783 973 643 812 1004 671 533 710 4071990 787 997 634 816 1032 658 539 713 4171991 819 1015 674 850 1052 700 570 717 4611992 822 1030 669 853 1066 696 564 723 4451993 825 1014 686 857 1045 717 569 753 4401994 863 1075 710 900 1120 741 554 682 4561995 872 1081 716 909 1121 749 579 762 4451996 875 1094 714 909 1129 746 621 825 4741997 888 1103 725 921 1135 757 634 845 4871998 869 1085 710 903 1127 738 599 750 4891999 832 1036 685 867 1071 718 565 744 4412000 817 1020 670 854 1063 701 520 661 4172001 791 998 642 821 1031 668 561 728 4472002 765 966 619 797 1004 644 541 688 4412003 738 940 592 769 981 613 494 583 4272004 709 894 573 738 928 596 501 623 4132005 695 887 556 724 922 579 477 611 3812006 674 848 544 701 878 566 492 627 3932007 659 836 526 686 867 549 452 577 3622008 641 820 509 671 856 533 431 548 3452009 630 812 493 656 842 513 449 615 3412010 614 783 485 637 811 504 457 584 3642011 603 785 464 629 817 483 436 574 3402012 591 762 461 617 795 480 426 538 3482013 571 738 444 595 767 462 411 527 3332014 565 726 443 589 755 460 418 528 3422015 547 713 418 569 741 434 404 519 3212016 537 691 417 562 721 436 383 481 311

Table 196Non-Hodgkin Lymphoma

Age-adjusted US Deatha Rates by Year Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a SEER 21 areas Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)unless noted

b US Mortality Files National Center for Health Statistics Centers for Disease Control and PreventionRates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) unless noted

c Rates are per 100000 and are age-adjusted to the world (WHO 2000-2025) standard million- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER IncidenceAge at DiagnosisAge-Adjusted Rates 2012-2016All ages 196 239 162 206 250 170 147 177 124Under 65 94 111 78 96 113 80 91 109 7665 and over 904 1126 743 966 1199 794 532 646 461

All ages (WHO world std)c 147 177 122 154 184 127 117 140 98

Age-Specific Rates 2012-2016lt1 - - - - - - - - -1-4 08 11 05 08 11 06 06 07 -5-9 12 17 07 13 18 07 10 13 0810-14 15 20 10 14 19 10 16 21 1115-19 21 27 14 20 26 14 20 28 1220-24 27 32 22 26 31 21 28 35 2025-29 35 40 29 34 39 28 41 48 3430-34 49 56 42 48 54 41 56 67 4735-39 72 85 59 71 83 58 81 98 6640-44 99 117 80 99 117 80 108 128 9045-49 145 168 122 147 169 125 156 190 12750-54 222 256 189 229 264 194 217 250 18755-59 312 366 261 326 379 274 277 332 23060-64 445 522 376 470 548 396 363 426 31165-69 629 742 528 667 781 564 447 522 39070-74 833 997 697 890 1058 746 522 640 43975-79 1044 1287 855 1124 1384 918 588 692 52080-84 1193 1522 966 1280 1631 1031 650 791 57385+ 1079 1499 861 1146 1589 915 508 685 434

US MortalityAge at DeathAge-Adjusted Rates 2012-2016All ages 56 73 44 59 76 45 41 52 33Under 65 13 17 10 13 17 09 16 21 1265 and over 352 453 279 372 477 295 210 265 176

All ages (WHO world std)c 30 39 23 31 40 23 25 32 20

Age-Specific Rates 2012-2016lt1 - - - - - - - - -1-4 00 01 - 00 01 - - - -5-9 01 01 00 00 01 - 01 - -10-14 01 01 01 01 01 01 - - -15-19 01 02 01 01 02 01 02 02 -20-24 02 03 02 02 03 02 04 04 0325-29 04 05 03 03 04 02 05 07 0430-34 05 07 04 05 06 03 09 12 0635-39 07 09 05 06 08 04 11 14 0940-44 11 14 08 10 13 08 18 21 1545-49 18 23 13 17 22 13 24 32 1750-54 31 41 21 31 41 21 37 49 2655-59 53 71 37 54 72 36 58 74 4460-64 90 118 64 92 121 64 90 116 6965-69 142 184 105 149 192 109 116 146 9370-74 244 309 188 256 324 197 167 214 13375-79 374 473 294 397 501 312 220 275 18480-84 567 725 455 600 764 481 321 405 27485+ 751 994 624 795 1049 662 360 457 320

Table 197Non-Hodgkin Lymphoma

SEER Incidencea and US Deathb Rates Age-Adjusted and Age-Specific Rates by Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on End Results data from a series of hospital registries and one population-based registryb SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)

Based on follow-up of patients into 2016 Expected survival rates are derived from the US Annual Life Tablesc SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER programBased on follow-up of patients into 2016

d Period survival provides a 2015 estimate of survival by piecing together the most recent conditional survival estimatesfrom several cohorts It is computed here using three year calendar blocks (2010-2012 0-1 year survival)(2009-2011 1-2 year survival) (2008-2010 2-3 year survival) (2007-2009 3-4 year survival) (2006-2008 4-5 years survival)

e Stage at diagnosis is classified using SEER Summary Stage 2000 Stage distribution percentages may not sum to 100 due to roundingf The difference between 1975-1977 and 2009-2015 is statistically significant (plt05)g The standard error is between 5 and 10 percentage pointsh The standard error is greater than 10 percentage points- Statistic could not be calculated due to fewer than 25 cases during the time period

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

5-Year Relative Survival (Percent)Year of Diagnosis1960-1963a - - - 31 31 31 - - -1970-1973a - - - 41 39 43 - - -1975-1977b 465 456 475 468 463 473 486 426 553g

1978-1980b 479 461 498 479 462 495 511 469 5671981-1983b 506 503 509 508 505 511 495 492 4981984-1986b 516 501 534 521 507 537 468 445 4991987-1989b 509 476 549 513 482 552 457 413 5101990-1992b 507 467 557 515 476 564 422 384 4761993-1995b 526 487 575 533 498 577 425 359 5491996-1998b 588 570 610 595 577 615 547 531 5721999-2001b 640 614 670 650 628 676 558 490 6382002-2004b 698 686 712 710 701 721 636 611 6662005-2008b 716 706 727 728 719 738 625 578 6752009-2015b 747f 739f 757f 757f 748f 767f 695f 670f 724f

5-Year Period Survival (Percent)cd

2015 722 705 743 726 708 747 671 641 703

Stage Distribution () 2009-2015ce

All StagesNumber of cases 97737 53606 44131 80120 44109 36011 8184 4388 3796Percent 100 100 100 100 100 100 100 100 100Localized 27 27 29 27 26 28 28 25 31Regional 15 15 15 15 15 15 15 15 15Distant 50 51 48 51 52 49 51 54 48UnstagedUnknown 8 7 8 7 7 8 6 6 7

5-Year Relative Survival (Percent) 2009-2015c

Age at DiagnosisAges lt45 840 820 870 855 836 885 735 708 776Ages 45-54 810 777 859 826 795 872 687 639 750Ages 55-64 770 742 809 781 754 818 678 620 749Ages 65-74 725 706 747 731 711 755 656 623 682Ages 75+ 554 539 568 557 538 574 482 449 500Ages lt65 800 773 838 812 787 849 701 659 759Ages 65+ 638 627 649 641 628 655 584 562 598

StageeAll Stages 720 707 737 724 711 740 665 637 698Localized 840 830 850 843 833 852 810 766 850Regional 750 751 749 755 756 755 689 698 678Distant 648 633 668 657 642 677 580 557 610UnstagedUnknown 703 686 723 679 662 698 659 648 666

Table 198Non-Hodgkin Lymphoma

5-Year Relative and Period Survival (Percent) by Race Sex Diagnosis Year and Age

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Expected survival rates are derived from the US Annual Life Tables

1975- 1980- 1985- 1990-1979 1984 1989 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Survival Time

1-year 702 730 713 704 703 733 756 767 774 773 787 810 803 811 817 810 816 841 839 844 834 842 844 834 8452-year 602 637 628 622 618 659 685 700 710 714 733 760 757 760 773 769 775 790 795 796 797 800 800 7953-year 546 585 582 577 575 621 649 664 669 679 701 731 731 735 748 745 750 762 773 774 775 779 7794-year 505 546 543 544 547 587 621 636 645 655 681 712 716 715 730 726 732 744 756 752 756 7675-year 468 507 510 516 520 561 594 609 621 638 660 693 700 701 716 705 712 728 741 742 7426-year 436 475 483 492 499 541 571 583 595 621 647 680 683 688 704 688 701 718 721 7237-year 408 450 458 470 479 522 552 564 577 605 629 663 671 672 685 672 688 702 7108-year 385 428 434 450 464 504 529 552 563 589 613 651 658 666 670 661 674 6909-year 366 408 415 435 453 493 515 535 548 576 600 640 648 649 652 651 66110-year 350 389 398 421 443 481 501 522 537 563 589 632 633 638 634 63711-year 335 374 385 406 434 466 488 511 525 548 581 618 621 630 63112-year 324 360 369 395 423 457 481 501 512 535 568 600 615 61713-year 314 348 358 383 415 449 469 492 500 520 561 593 60214-year 302 335 347 372 406 443 456 485 488 513 549 58315-year 289 322 335 365 398 437 447 474 478 505 54016-year 279 312 328 356 393 437 433 472 470 49217-year 274 304 321 349 388 428 428 469 45818-year 268 296 314 341 378 420 419 46319-year 260 288 306 333 370 413 41220-year 252 280 301 329 359 408

Table 199Non-Hodgkin Lymphoma

SEERa Relative Survival (Percent)By Year of Diagnosis

All Races Males and Females

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Expected survival rates are derived from the US Annual Life Tables

1975- 1980- 1985- 1990-1979 1984 1989 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Survival Time

1-year 694 727 689 671 666 712 747 749 758 765 776 806 797 801 811 810 814 836 828 838 838 841 834 830 8352-year 594 637 605 582 583 636 672 682 691 703 713 752 749 755 762 765 778 779 781 788 798 793 786 7913-year 534 580 557 537 545 598 638 645 644 668 679 720 726 726 731 736 754 751 757 766 776 769 7644-year 493 539 516 504 515 561 610 620 615 639 657 700 709 701 711 713 734 734 737 743 756 7575-year 455 501 482 476 485 537 583 592 590 617 635 679 689 688 699 689 710 721 724 735 7426-year 426 466 455 456 469 510 561 565 562 602 620 667 669 676 684 670 696 715 706 7177-year 399 442 431 436 449 491 542 544 546 587 601 652 658 655 668 651 682 696 6968-year 378 420 410 418 433 474 520 533 536 567 582 637 645 649 650 634 665 6869-year 357 401 391 402 423 465 504 514 523 553 572 628 633 632 636 618 65210-year 340 380 377 392 416 455 489 503 515 542 560 617 617 620 613 60911-year 328 363 364 381 407 437 477 494 508 527 547 603 605 612 61212-year 319 352 351 372 395 427 472 482 498 515 537 589 601 59613-year 307 342 343 361 389 419 456 467 491 501 531 582 59114-year 295 330 332 350 378 414 444 461 480 496 521 57215-year 281 319 324 344 368 409 435 453 473 488 51216-year 272 308 316 333 361 409 426 453 471 47417-year 265 300 308 326 358 403 420 449 46218-year 261 294 302 320 350 396 410 44219-year 256 287 294 313 342 391 40320-year 250 280 291 309 332 387

Table 1910Non-Hodgkin Lymphoma

SEERa Relative Survival (Percent)By Year of Diagnosis

All Races Males

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Expected survival rates are derived from the US Annual Life Tables

1975- 1980- 1985- 1990-1979 1984 1989 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Survival Time

1-year 710 734 741 747 752 759 767 786 792 782 801 814 810 821 825 809 819 847 854 851 830 843 856 838 8572-year 611 637 656 672 664 688 701 720 734 727 758 769 765 767 786 774 772 804 812 807 796 810 817 7993-year 559 589 611 627 616 649 662 684 700 692 727 744 736 746 768 756 746 774 791 786 774 791 7974-year 519 553 576 595 590 619 634 653 681 674 710 725 724 730 751 739 729 757 778 764 755 7805-year 482 514 544 567 565 591 608 629 658 664 688 708 713 716 736 724 715 735 763 751 7426-year 446 484 517 539 540 580 583 603 635 643 679 695 699 701 727 708 707 722 738 7317-year 417 458 490 512 520 560 563 586 615 626 663 674 687 692 704 698 694 709 7268-year 392 437 463 491 505 542 539 573 596 615 649 667 672 684 693 692 684 6949-year 374 416 443 476 492 529 528 557 578 603 633 654 664 669 671 688 67110-year 360 399 424 458 480 514 516 542 562 588 625 648 651 658 659 66911-year 342 385 409 438 469 503 500 529 547 573 621 636 640 651 65312-year 329 368 390 425 460 494 493 523 529 560 606 613 632 64013-year 321 353 376 411 449 486 485 518 510 543 598 606 61514-year 310 340 365 400 442 479 470 512 497 532 582 59615-year 297 326 349 391 436 472 460 498 483 525 57416-year 287 316 342 385 435 467 441 492 468 51317-year 282 306 336 378 428 459 438 490 45218-year 274 298 327 367 413 449 428 48519-year 265 288 321 358 407 439 42220-year 254 280 312 353 395 433

Table 1911Non-Hodgkin Lymphoma

SEERa Relative Survival (Percent)By Year of Diagnosis

All Races Females

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 5222 2506 2704 3176 3627 3994 4570 4729 5325 5260 5263 5562 5775 6226 6401 6704 6998 7072 11154

SEER 9 except 4285 2088 2267 2603 2819 3091 3507 3694 4159 4249 4364 4515 4818 5209 5398 5628 5841 6015 9363SF-Oakland

San Francisco- 937 418 437 573 808 903 1063 1035 1166 1011 899 1047 957 1017 1003 1076 1157 1057 1791Oakland SMSAc

San Francisco 245 96 123 210 326 393 467 410 450 354 213 256 220 283 219 216 240 225 362CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 134 155 161 183 201 215 234 233 252 244 238 244 246 258 254 255 255 245 244

SEER 9 except 132 154 161 181 188 201 217 218 236 236 235 236 244 256 254 253 252 247 243SF-Oakland

San Francisco- 147 158 160 194 267 285 317 305 335 288 252 286 256 266 256 263 268 235 246Oakland SMSAc

San Francisco 143 144 176 293 444 519 610 523 574 448 274 325 269 354 265 257 273 252 246CityCounty

Table 1912

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males All Ages

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males All Ages

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 0-19 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 223 87 108 91 94 84 100 89 120 105 104 119 127 107 106 143 134 155 240

SEER 9 except 191 78 95 82 80 76 86 74 107 84 93 100 115 90 87 114 119 129 198SF-Oakland

San Francisco- 32 9 13 9 14 8 14 15 13 21 11 19 12 17 19 29 15 26 42Oakland SMSAc

San Francisco 9 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 5 lt4 6 lt4CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 12 12 16 14 14 13 15 13 17 14 14 15 16 14 13 18 17 20 20

SEER 9 except 12 13 16 14 14 13 15 12 17 13 14 15 17 13 13 16 17 19 19SF-Oakland

San Francisco- 14 10 15 10 16 09 15 16 13 21 11 18 12 17 19 28 14 25 27Oakland SMSAc

San Francisco 23 - - - - - - - - - - - - - - 40 - 49 -CityCounty

Table 1913

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 0-19

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 0-19

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 20-54 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 1463 687 723 958 1211 1413 1766 1830 2089 1770 1608 1696 1623 1722 1655 1693 1674 1596 2242

SEER 9 except 1208 563 588 730 827 923 1195 1294 1483 1325 1269 1327 1308 1410 1383 1401 1402 1328 1848SF-Oakland

San Francisco- 255 124 135 228 384 490 571 536 606 445 339 369 315 312 272 292 272 268 394Oakland SMSAc

San Francisco 58 29 34 105 215 288 333 303 317 225 105 115 111 111 86 75 73 71 98CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 69 79 82 104 124 136 159 156 169 138 121 124 117 123 116 118 116 111 104

SEER 9 except 69 78 81 97 103 109 131 134 144 123 115 116 112 119 115 116 115 110 103SF-Oakland

San Francisco- 69 84 89 139 226 264 295 267 298 213 156 164 139 141 123 130 118 114 110Oakland SMSAc

San Francisco 67 88 94 272 565 715 813 724 744 510 230 252 239 248 194 162 152 145 129CityCounty

Table 1914

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 20-54

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 20-54

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 55+ and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 3536 1732 1873 2127 2322 2497 2704 2810 3116 3385 3551 3747 4025 4397 4640 4868 5190 5321 8672

SEER 9 except 2886 1447 1584 1791 1912 2092 2226 2326 2569 2840 3002 3088 3395 3709 3928 4113 4320 4558 7317SF-Oakland

San Francisco- 650 285 289 336 410 405 478 484 547 545 549 659 630 688 712 755 870 763 1355Oakland SMSAc

San Francisco 178 65 88 104 109 105 132 106 130 126 106 141 108 169 131 136 164 148 261CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 451 522 540 596 633 673 701 706 761 800 811 831 858 900 901 891 899 862 871

SEER 9 except 440 521 544 601 620 667 687 692 744 797 813 813 858 901 904 891 888 874 874SF-Oakland

San Francisco- 508 528 520 571 702 703 773 783 854 821 800 932 855 894 888 890 959 800 860Oakland SMSAc

San Francisco 482 446 598 727 739 757 934 747 914 872 727 934 690 1047 764 769 889 776 826CityCounty

Table 1915

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 55+

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 55+

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 003 006 217 072 Asian 0 001 003 005 183 072

10 002 005 011 218 073 Pacific 10 002 004 009 184 073

20 003 009 021 217 073 Islander 20 003 007 015 182 073

30 006 018 042 216 073 30 005 013 029 180 073

40 012 037 082 213 074 40 008 024 057 176 073

50 025 072 139 206 074 50 017 049 101 170 073

60 049 120 177 191 075 60 034 087 139 158 072

70 080 144 - 160 072 70 056 112 - 133 068

80 085 - - 106 062 80 066 - - 091 056

White 0 001 003 006 227 075 American 0 001 002 003 116 049

10 002 005 011 228 076 Indian 10 002 002 005 117 050

20 003 009 021 227 076 Alaska 20 001 003 008 116 050

30 006 018 043 226 077 Nativea 30 003 007 022 117 051

40 012 038 085 223 077 40 004 019 041 117 052

50 026 075 147 217 078 50 016 038 078 118 053

60 052 127 187 201 078 60 024 067 105 109 055

70 085 153 - 169 076 70 048 091 - 096 055

80 090 - - 111 065 80 057 - - 064 043

Black 0 001 002 006 138 042 Hispanicb 0 001 002 005 222 073

10 002 005 011 140 043 10 001 004 009 223 074

20 003 010 022 139 043 20 003 008 019 222 074

30 006 019 041 137 043 30 005 016 040 221 074

40 013 035 068 133 043 40 011 035 078 218 074

50 023 057 093 125 043 50 024 068 133 211 074

60 037 076 102 110 042 60 046 114 173 195 074

70 047 078 - 087 038 70 075 140 - 164 070

80 044 - - 057 032 80 081 - - 112 057

Table 1916

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Both Sexes 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 004 007 243 081 Asian 0 001 003 006 213 085

10 002 006 013 244 082 Pacific 10 002 005 011 213 086

20 004 010 024 243 082 Islander 20 003 009 018 211 086

30 007 021 049 243 083 30 006 015 034 210 086

40 014 042 094 240 084 40 009 028 067 205 086

50 029 082 158 233 085 50 019 059 117 199 086

60 057 139 203 219 086 60 041 101 161 187 085

70 095 170 - 188 084 70 066 131 - 159 082

80 105 - - 130 073 80 080 - - 114 069

White 0 001 004 007 254 085 American 0 001 003 004 104 057

10 002 006 013 255 086 Indian 10 002 003 006 105 058

20 004 010 024 254 086 Alaska 20 001 004 008 103 058

30 007 020 049 253 087 Nativea 30 003 008 021 104 059

40 014 043 097 251 088 40 005 018 038 105 060

50 030 086 167 244 089 50 014 035 071 105 062

60 059 147 215 230 090 60 023 062 094 099 065

70 101 180 - 198 088 70 046 084 - 090 066

80 112 - - 136 076 80 053 - - 061 053

Black 0 001 003 007 152 046 Hispanicb 0 001 003 005 238 083

10 002 006 014 154 047 10 002 005 011 239 084

20 004 012 027 153 047 20 003 009 021 238 084

30 008 023 048 152 047 30 006 018 043 238 084

40 016 042 079 148 047 40 012 037 083 235 085

50 027 066 105 138 047 50 026 073 145 228 085

60 043 087 114 123 045 60 050 126 189 214 085

70 054 088 - 099 042 70 086 157 - 185 081

80 053 - - 070 036 80 094 - - 131 066

Table 1917

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Males 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 002 004 193 064 Asian 0 001 002 004 159 063

10 001 004 009 195 064 Pacific 10 001 004 008 160 063

20 003 007 017 194 064 Islander 20 002 006 013 159 063

30 005 015 036 192 065 30 004 011 025 157 063

40 010 031 071 189 065 40 007 021 048 153 063

50 022 062 120 182 065 50 014 042 087 148 063

60 042 103 154 168 065 60 028 074 122 136 062

70 067 123 - 138 063 70 049 099 - 114 058

80 071 - - 090 054 80 057 - - 075 047

White 0 001 002 004 203 067 American 0 000 001 002 128 043

10 001 004 009 204 067 Indian 10 001 001 004 129 044

20 002 007 017 203 067 Alaska 20 001 003 007 128 044

30 005 015 037 201 067 Nativea 30 002 006 023 129 044

40 010 032 074 198 068 40 004 021 044 129 045

50 022 065 127 192 068 50 017 042 085 129 046

60 044 109 163 177 068 60 026 072 113 118 047

70 072 130 - 146 066 70 050 097 - 102 046

80 075 - - 094 056 80 060 - - 066 037

Black 0 000 002 004 126 040 Hispanicb 0 001 002 004 210 065

10 001 004 009 128 040 10 001 004 008 211 066

20 003 008 018 127 040 20 002 007 017 211 066

30 005 015 034 125 040 30 004 014 036 209 066

40 010 029 058 122 040 40 010 032 073 206 066

50 020 049 083 115 040 50 022 064 123 198 066

60 032 068 094 102 039 60 043 104 161 182 065

70 041 071 - 080 036 70 066 127 - 149 062

80 039 - - 051 030 80 073 - - 100 051

Table 1918

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Females 2014-2016 By RaceEthnicity

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

The AAPC is the Average Annual Percent Change over the time interval The AAPCs are calculated bythe Joinpoint Regression Program Version 47 February 2019 National Cancer Institute

- Statistic not shown Rate based on less than 16 cases for the time intervalTrend based on less than 10 cases for at least one year within the time interval

a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) Trendsare based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico SeattleUtah and AtlantaThe SEER 21 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the AlaskaNative Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts

c The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 3 Joinpoints overdiagnosis years 2000-2016

d The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 5 Joinpoints overdiagnosis years 1975-2016

e Hispanic and Non-Hispanic are not mutually exclusive from whites blacks AsianPacificIslanders and American IndiansAlaska Natives Incidence data for Hispanics and Non-Hispanicsare based on NHIA and exclude cases from the Alaska Native Registry

f Incidence data for American IndianAlaska Native are based on the PurchasedReferred CareDelivery Area (PRCDA) counties

g US Mortality Files National Center for Health Statistics CDCh The 2007-2016 mortality AAPCs are based on a Joinpoint analysis using years of death 2000-2016 The APC is significantly different from zero (plt05)

SEER Incidence SEER 21 Areasb SEER 21 Areasb SEER 9 Areasb

Rate 2012-2016 Trend 2007-2016c Trend 2007-2016d

Rate per 100000 persons AAPC () AAPC ()

Total Males Females Total Males Females Total Males Females RaceEthnicity

All Races 196 239 162 -07 -09 -08 -09 -07 -08

White 206 250 170 -08 -11 -09 -09 -08 -08White Hispanice 183 212 161 -08 -03 -05 - - -White Non-Hispanice 210 256 172 -08 -06 -10 - - -

Black 147 177 124 01 00 03 00 -04 -09

AsianPacific Islander 134 164 110 00 00 -01 - - -

Amer IndAlaska Natf 113 120 106 -05 -12 00 - - -

Hispanice 179 207 157 -05 -02 03 - - -

US Mortalityg Rate 2012-2016 Trend 2007-2016h

Rate per 100000 persons AAPC ()

Total Males Females Total Males FemalesRaceEthnicity

All Races 56 73 44 -23 -20 -27

White 59 76 45 -23 -20 -27White Hispanice 51 65 40 -16 -13 -20White Non-Hispanice 59 76 46 -23 -20 -27

Black 41 52 33 -20 -19 -21

AsianPacific Islander 39 49 31 -17 -15 -19

Amer IndAlaska NatTotal US 31 40 24 -32 -20 -45PRCDA Counties 44 58 33 -21 -04 -37Non-PRCDA Counties 17 21 14 -54 -50 -60

Hispanice 48 61 38 -17 -14 -21

Table 1919Non-Hodgkin Lymphoma

SEER Incidence and US MortalityAge-Adjusted Rates and Trendsa

By RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Incidence Ratesa 2012-2016

California 1844 2241 1515 1938 2349 1591 1390 1639 1182Greater Bay Area 1957 2381 1600 2144 2601 1755 1628 1828 1436San Francisco-Oakland 1956 2421 1570 2174 2660 1765 1603 1816 1408San Jose-Monterey 1962 2311 1660 2097 2503 1742 1800 1891 1646

Los Angeles 1804 2176 1505 1951 2331 1637 1357 1659 1139Greater California 1822 2220 1489 1876 2286 1529 1314 1534 1113

Connecticut 2116 2607 1733 2154 2642 1771 1386 1829 1051Detroit 2132 2636 1742 2290 2850 1847 1620 1905 1409Georgia 1826 2244 1487 1936 2346 1588 1462 1833 1187Atlanta 1925 2381 1555 2119 2567 1736 1601 2034 1272Rural Georgia 1584 1790 1401 1953 2298 1567 807 - 988Greater Georgia 1784 2186 1459 1872 2274 1537 1380 1703 1146

Hawaii 1660 2024 1349 1958 2275 1593 - - -Idaho 1922 2267 1616 1920 2262 1618 - - -Iowa 2134 2601 1756 2148 2612 1773 1352 1602 1100Kentucky 2039 2505 1666 2070 2538 1693 1403 1788 1112Louisiana 1944 2352 1614 2106 2537 1744 1469 1769 1237Massachusetts 1810 2181 1518 1830 2214 1524 1452 1655 1299New Jersey 2155 2607 1804 2285 2765 1905 1387 1621 1222New Mexico 1550 1739 1387 1580 1798 1394 875 - -New York 2152 2620 1788 2306 2792 1915 1545 1852 1333Seattle-Puget Sound 2116 2627 1695 2177 2667 1766 1631 1973 1316Utah 1843 2233 1498 1862 2258 1513 2089 - -

SEER 9 Areasb 1992 2444 1623 2095 2551 1716 1573 1914 1298SEER 13 Areasb 1946 2373 1597 2064 2502 1700 1519 1853 1258SEER 18 Areasb 1933 2354 1590 2031 2464 1671 1449 1751 1214SEER 21 Areasb 1963 2388 1620 2061 2498 1702 1471 1771 1245

Table 1920Non-Hodgkin Lymphoma

Age-Adjusted SEER Incidence Ratesa

By Registry Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control and PreventionRates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and AtlantaThe SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Death Ratesa 2012-2016

California 533 677 423 570 726 449 417 480 367Greater Bay Area 505 671 376 561 756 408 410 491 331San Francisco-Oakland 503 667 376 555 742 409 416 490 343San Jose-Monterey 511 681 377 573 781 407 - - -

Los Angeles 541 670 443 589 728 481 424 503 371Greater California 539 682 429 564 716 447 416 455 384

Connecticut 533 705 407 547 717 421 350 510 244Detroit 639 822 505 693 895 542 443 528 384Georgia 533 697 411 580 747 450 376 503 286Atlanta 492 659 372 533 728 388 397 506 317Rural Georgia 559 731 388 670 813 507 - - -Greater Georgia 549 712 426 595 755 470 363 500 266

Hawaii 475 620 352 545 649 412 - - -Idaho 635 775 510 641 782 516 - - -Iowa 638 845 484 642 848 488 - - -Kentucky 642 886 460 655 904 470 401 557 284Louisiana 608 814 451 651 863 485 461 623 340Massachusetts 523 659 423 541 682 436 347 410 297New Jersey 545 721 419 585 780 443 372 466 314New Mexico 488 585 405 493 595 406 - - -New York 535 702 412 575 752 441 390 514 313Seattle-Puget Sound 585 749 463 604 769 480 490 562 397Utah 542 670 433 551 681 440 - - -

SEER 9 Areasb 555 719 430 586 758 454 414 522 333SEER 13 Areasb 549 705 429 586 753 457 419 521 342SEER 18 Areasb 554 717 431 589 761 456 409 518 329SEER 21 Areasb 550 712 428 584 754 453 401 513 322

Total US 562 725 436 586 755 454 408 518 330

Table 1921Non-Hodgkin Lymphoma

Age-Adjusted SEER Death Ratesa

By Registry Race and Sex

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 562 002

High Five StatesMichigan 645 011 01(0112) 1479Kentucky 642 016 02(0118) 1424Iowa 638 018 03(0120) 1367Indiana 638 013 04(0117) 1361Idaho 635 027 05(0126) 1303

Low Five StatesNevada 511 019 47(2251) -899Colorado 491 014 48(3851) -1257New Mexico 488 020 49(2851) -1317Hawaii 475 024 50(3051) -1542c

DC 444 039 51(2351) -2097c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 545 014 28(1847) -291 Montana 559 030 25(0250) -042Alaska 525 047 43(0151) -654 Nebraska 563 023 22(0548) 026Arizona 512 012 46(2950) -886 Nevada 511 019 47(2251) -899Arkansas 555 018 26(1247) -113 New Hampshire 562 027 23(0349) 014California 533 005 40(2645) -508 New Jersey 545 010 29(2045) -301Colorado 491 014 48(3851) -1257 New Mexico 488 020 49(2851) -1317Connecticut 533 016 39(1949) -505 New York 535 007 37(2446) -478Delaware 628 033 08(0139) 1174 North Carolina 541 010 35(2146) -363DC 444 039 51(2351) -2097c North Dakota 561 037 24(0151) -007Florida 535 006 38(2545) -479 Ohio 616 009 10(0220) 969Georgia 533 011 41(2248) -511 Oklahoma 630 017 06(0121) 1226Hawaii 475 024 50(3051) -1542c Oregon 612 016 11(0124) 903Idaho 635 027 05(0126) 1303 Pennsylvania 603 009 16(0622) 729Illinois 566 009 20(1634) 085 Rhode Island 542 029 32(0651) -350Indiana 638 013 04(0117) 1361 South Carolina 542 014 31(1847) -347Iowa 638 018 03(0120) 1367 South Dakota 541 033 36(0451) -364Kansas 585 019 19(0439) 420 Tennessee 629 013 07(0119) 1198Kentucky 642 016 02(0118) 1424 Texas 546 007 27(2142) -277Louisiana 608 016 14(0125) 826 Utah 542 022 33(1250) -352Maine 609 026 13(0137) 852 Vermont 605 040 15(0148) 770Maryland 524 013 44(2349) -663 Virginia 544 011 30(2046) -319Massachusetts 523 012 45(2549) -687 Washington 599 013 17(0425) 665Michigan 645 011 01(0112) 1479 West Virginia 612 022 12(0132) 894Minnesota 617 014 09(0122) 984 Wisconsin 590 013 18(0629) 507Mississippi 531 018 42(1850) -551 Wyoming 564 043 21(0151) 050Missouri 542 012 34(1947) -354

Table 1922Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males and Females

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 725 003

High Five StatesKentucky 886 030 01(0112) 2213c

Iowa 845 032 02(0120) 1647c

Michigan 842 019 03(0114) 1615c

Indiana 839 024 04(0116) 1567c

Delaware 824 058 05(0144) 1364

Low Five StatesArizona 635 019 47(3251) -1244Alaska 630 075 48(0251) -1311Hawaii 620 041 49(1951) -1452DC 614 071 50(0551) -1535c

New Mexico 585 033 51(3451) -1928c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 688 025 36(1649) -513 Montana 709 050 26(0251) -218Alaska 630 075 48(0251) -1311 Nebraska 737 040 20(0248) 165Arizona 635 019 47(3251) -1244 Nevada 653 032 44(1951) -994Arkansas 721 031 22(0747) -061 New Hampshire 710 046 25(0451) -210California 677 009 41(2846) -666 New Jersey 721 018 21(1441) -059Colorado 643 024 46(2451) -1133 New Mexico 585 033 51(3451) -1928c

Connecticut 705 028 28(1248) -273 New York 702 012 30(1943) -323Delaware 824 058 05(0144) 1364 North Carolina 709 018 27(1644) -221DC 614 071 50(0551) -1535c North Dakota 682 061 39(0251) -598Florida 683 011 37(2446) -585 Ohio 800 017 09(0320) 1029Georgia 697 019 34(1746) -387 Oklahoma 806 030 08(0126) 1109Hawaii 620 041 49(1951) -1452 Oregon 794 028 12(0128) 947Idaho 775 045 16(0146) 692 Pennsylvania 783 015 15(0523) 794Illinois 739 016 19(1235) 190 Rhode Island 649 050 45(1051) -1050Indiana 839 024 04(0116) 1567c South Carolina 681 025 40(1850) -604Iowa 845 032 02(0120) 1647c South Dakota 701 056 31(0251) -332Kansas 713 032 24(0948) -174 Tennessee 820 023 06(0120) 1311Kentucky 886 030 01(0112) 2213c Texas 698 012 32(2043) -368Louisiana 814 029 07(0122) 1222 Utah 670 036 42(1351) -754Maine 754 045 18(0148) 395 Vermont 794 069 11(0149) 950Maryland 682 023 38(1849) -588 Virginia 694 020 35(1847) -429Massachusetts 659 020 43(2450) -910 Washington 790 022 13(0224) 897Michigan 842 019 03(0114) 1615c West Virginia 774 038 17(0142) 675Minnesota 797 025 10(0224) 995 Wisconsin 786 023 14(0227) 844Mississippi 717 034 23(0748) -110 Wyoming 698 071 33(0151) -377Missouri 702 022 29(1646) -319

Table 1923Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 436 002

High Five StatesIdaho 510 033 01(0139) 1697c

Maine 497 031 02(0141) 1396Michigan 495 012 03(0119) 1340Oklahoma 492 020 04(0128) 1276Indiana 492 016 05(0123) 1270

Low Five StatesMississippi 404 021 47(1351) -731Nevada 382 022 48(2051) -1237Colorado 369 016 49(3451) -1540c

Hawaii 352 027 50(2551) -1932c

DC 323 044 51(1551) -2601c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 440 017 24(0547) 099 Montana 435 036 27(0151) -034Alaska 414 058 38(0151) -500 Nebraska 435 027 26(0249) -032Arizona 407 014 44(2049) -664 Nevada 382 022 48(2051) -1237Arkansas 428 021 31(0649) -181 New Hampshire 454 032 19(0149) 400California 423 006 34(2244) -313 New Jersey 419 012 37(1848) -397Colorado 369 016 49(3451) -1540c New Mexico 405 025 46(0951) -706Connecticut 407 018 45(1550) -669 New York 412 008 39(2548) -554Delaware 473 039 12(0150) 855 North Carolina 420 012 35(1848) -374DC 323 044 51(1551) -2601c North Dakota 471 045 13(0150) 809Florida 412 007 40(2548) -564 Ohio 478 011 10(0123) 967Georgia 411 012 43(2049) -582 Oklahoma 492 020 04(0128) 1276Hawaii 352 027 50(2551) -1932c Oregon 465 019 15(0141) 668Idaho 510 033 01(0139) 1697c Pennsylvania 467 010 14(0427) 714Illinois 439 010 25(1341) 074 Rhode Island 455 035 18(0150) 434Indiana 492 016 05(0123) 1270 South Carolina 432 017 30(0947) -102Iowa 484 021 08(0135) 1087 South Dakota 411 039 42(0151) -580Kansas 486 023 06(0137) 1143 Tennessee 484 015 09(0126) 1087Kentucky 460 018 17(0241) 544 Texas 427 008 32(1944) -213Louisiana 451 018 21(0345) 333 Utah 433 026 28(0250) -081Maine 497 031 02(0141) 1396 Vermont 461 047 16(0151) 578Maryland 411 015 41(1749) -576 Virginia 432 013 29(1246) -092Massachusetts 423 014 33(1548) -303 Washington 452 015 20(0541) 360Michigan 495 012 03(0119) 1340 West Virginia 486 027 07(0143) 1141Minnesota 475 017 11(0132) 901 Wisconsin 443 015 23(0645) 156Mississippi 404 021 47(1351) -731 Wyoming 445 051 22(0151) 192Missouri 419 014 36(1549) -396

Table 1924Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Females

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 Areas (excluding the AlaskaNative Registry) and 112016 US population estimates based on the average of 2015 and 2016 population estimates from theUS Bureau of the CensusPrevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 24 years

b Maximum limited-duration prevalence is 24 years for 1992-2016 datac Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groupsd Cases diagnosed more than 24 years ago were estimated using the completeness index method (Capocaccia et al 1997

Merrill et al 2000)e Complete prevalence is obtained by summing 0 to lt24 and gt=24- Statistic not shown Statistic based on fewer than 5 cases estimated alive in SEER for the time interval+ Not available

Years Since Diagnosis 0 to lt5 5 to lt10 10 to lt15 15 to lt20 20 to lt24 0 to lt24b gt=24d Completee

Race Sex

All Races Both Sexes 248946 177490 117326 69109 31890 644761 49943 694704Males 135137 94173 60159 36020 16581 342069 25489 367558Females 113809 83317 57167 33089 15309 302692 24454 327146

White Both Sexes 213764 154454 101984 60537 28026 558765 49625 620368Males 116527 82172 52535 31627 14543 297404 26526 330121Females 97237 72282 49448 28910 13483 261361 23099 290247

Black Both Sexes 20500 13640 9750 5271 2215 51376 4115 55491Males 10712 7188 4768 2684 1174 26526 1911 28437Females 9789 6452 4981 2587 1041 24850 2204 27054

Asian Both Sexes 8405 5210 3415 1867 844 19741 + +Pacific Males 4548 2661 1757 1013 407 10386 + +Islander Females 3856 2549 1657 855 437 9355 + +

Hispanic Both Sexes 21339 14049 8272 4881 2136 50676 + +Males 10918 7243 4331 2617 1094 26202 + +Females 10421 6805 3941 2264 1043 24474 + +

Age Specific (Crude) Age-Adjustedc Age at Prevalence All Ages 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ All Ages

Race Sex

All Races Both Sexes 02001 00035 00139 00283 00538 01121 02352 04640 08181 10224 01738Males 02156 00044 00189 00354 00625 01293 02710 05243 09364 12449 02023Females 01850 00026 00087 00208 00450 00952 02010 04094 07196 08856 01498

White Both Sexes 02216 00035 00143 00289 00534 01148 02427 04858 08597 10738 01807Males 02380 00045 00198 00359 00622 01317 02790 05442 09778 13060 02095Females 02054 00025 00085 00214 00442 00976 02072 04317 07593 09285 01560

Black Both Sexes 01139 00029 00113 00265 00599 01027 02010 03340 05117 05333 01251Males 01226 00029 00140 00351 00696 01223 02333 03969 05849 06055 01457Females 01059 00030 00086 00178 00510 00853 01728 02836 04608 04976 01088

Asian Both Sexes 00970 00039 00133 00207 00353 00680 01409 02692 04470 06094 01032Pacific Males 01065 00044 00175 00240 00398 00744 01640 03072 05516 07472 01222Islander Females 00882 00033 00092 00175 00312 00623 01209 02384 03629 05207 00880

Hispanic Both Sexes 00887 00030 00117 00206 00398 00850 01769 03632 05888 07209 01294Males 00908 00035 00147 00256 00455 00932 01924 03940 06326 08003 01420Females 00866 00024 00086 00151 00337 00766 01616 03360 05552 06719 01185

Table 1925Non-Hodgkin Lymphoma

Estimated United States Cancer Prevalence Countsa on January 1 2016By RaceEthnicity Sex and Years Since Diagnosis

Estimated prevalence percenta on January 1 2016 of the SEER population diagnosed in the previous 24 yearsBy Age at Prevalence RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 372 452924 -05 62 18862 04 247 189692 -05 1657 244370 -05

1 Hodgkin Lymphoma 28 32262 -17 13 3927 -06 33 22556 -15 39 5779 -31

2 Non-Hodgkin lymphoma 336 409991 -03 48 14693 04 210 163591 -03 1572 231707 -042(a) Non-Hodgkin lymphoma B-cell 311 380349 -01 39 11836 14 190 148768 -02 1491 219745 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 15 16631 20 31 9416 10 07 5203 39 14 2012 252(a) 2 Mature Non-Hodgkin lymphoma B-cell 280 343965 -04 07 2271 30 174 137225 -05 1387 204469 -042(a) 21 ChronicSmallProlymphocytic 69 85601 -13 00 35 - 35 29103 -11 382 56463 -14

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 61 75061 -15 00 30 - 31 25339 -13 336 49692 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 311 19 - - - 00 72 - 02 234 262(a) 213 Mantle-cell lymphoma 08 10229 03 - - - 04 3692 02 44 6537 04

2(a) 22 Lymphoplasmacytic lymphoma 07 8651 00 - - - 03 2590 -11 41 6059 04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 03 3667 -03 - - - 01 1132 -18 17 2533 022(a) 222 Waldenstrom macroglubulinemia 04 4984 03 - - - 02 1458 -07 24 3526 06

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 72 87188 00 03 925 26 48 36480 -02 339 49783 022(a) 231 DLBCL NOSc 71 85899 -01 03 861 12 46 35469 -05 337 49569 012(a) 232 Intravascular large B-cell 00 162 - - - - 00 63 - 01 99 -

lymphoma2(a) 233 Primary effusion lymphoma 00 181 27 - - - 00 126 - 00 55 -2(a) 234 Mediastinal large B-cell 01 946 116 00 64 - 01 822 111 00 60 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 04 4692 -26 03 1028 32 04 2618 -43 07 1046 -432(a) 25 Marginal-zone lymphoma (MZL) 22 26534 00 00 137 13 14 11049 05 104 15348 -042(a) 251 Splenic MZL 02 2418 04 - - - 01 889 -08 10 1529 102(a) 252 Extranodal MZL MALTc type 13 15979 06 00 92 - 09 7148 11 59 8739 032(a) 253 Nodal MZL 07 8137 -15 00 45 - 04 3012 -05 34 5080 -20

2(a) 26 Follicular lymphoma 35 43582 -21 00 119 - 28 21725 -25 147 21738 -182(a) 27 Hairy-cell leukemia 03 3712 -16 - - - 03 2311 -19 09 1401 -122(a) 28 Plasma cell neoplasms 68 83957 08 00 24 - 39 31325 12 358 52608 062(a) 281 Plasmacytoma 04 4879 -04 00 16 - 03 2362 -06 17 2501 -032(a) 282 Multiple myeloma 64 79078 09 - - - 36 28963 14 341 50107 07

plasma-cell leukemia2(a) 29 Heavy chain disease 00 48 - - - - 00 24 - 00 23 -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 16 19753 33 00 149 27 08 6340 37 90 13264 32

Table 1926All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 23 27222 01 08 2502 18 19 13933 03 73 10787 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 616 - 01 293 - 00 272 - 00 51 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 22 26531 11 07 2207 75 19 13621 12 73 10703 -042(b) 21 Mycosis fungoidesSezary syndrome 06 6969 18 01 213 84 06 4080 23 18 2676 052(b) 211 Mycosis fungoides 06 6739 17 01 213 84 05 3990 22 17 2536 042(b) 212 Sezary syndrome 00 230 46 - - - 00 90 - 01 140 -

2(b) 22 Peripheral T-cell lymphoma 12 14531 -10 02 534 07 10 7159 -09 46 6838 -122(b) 221 Peripheral T-cell lymphoma NOSc 04 5393 -01 00 86 - 03 2489 04 19 2818 -042(b) 222 Angioimmunoblastic T-cell lymphoma 02 1902 02 - - - 01 699 -09 08 1201 072(b) 223 Subcutaneous panniculitis- 00 176 44 00 31 - 00 111 - 00 34 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 2523 -36 01 291 00 02 1450 -33 05 782 -54

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 139 - - - - 00 98 - 00 28 -2(b) 226 Enteropathy-type T-cell lymphoma 00 186 -02 - - - 00 84 - 01 101 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 2963 -07 00 59 - 02 1575 01 09 1329 -142(b) 228 Primary cutaneous anaplastic 01 1249 -41 00 51 - 01 653 -49 04 545 -39

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 03 3417 96 05 1428 101 02 1474 99 03 515 672(b) 24 NKcT-cell lymphoma nasal-type 01 985 02 00 26 - 01 659 00 02 300 05

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 120 - - - - 00 54 - 00 65 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 509 30 - - - 00 195 -05 02 309 442(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 75 - - - - 00 40 - 00 33 -2(c) Non-Hodgkin lymphoma unknown lineage 02 2420 -274 01 355 - 01 890 -216 08 1175 -2792(c) 1 Precursor lymphoblastic leukemia 01 814 -283 01 343 - 00 238 - 02 233 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 95 - - - - 00 25 - 00 69 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 1511 -274 - - - 01 627 -202 06 873 -319

lineage2() 1 Total precursor lymphomaleukemiad 16 18061 -07 33 10052 -15 08 5713 06 15 2296 -01

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 762 273 00 20 - 00 339 227 03 403 -lymphoma

4 Lymphoid neoplasm NOSc 08 9909 -55 01 222 113 04 3206 -59 43 6481 -59

Table 1926 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 461 253152 -05 70 10973 05 294 110367 -07 2122 131812 -05

1 Hodgkin Lymphoma 31 17710 -17 13 2118 -03 36 12525 -16 48 3067 -31

2 Non-Hodgkin lymphoma 419 229772 -03 56 8711 05 252 95756 -05 2017 125305 -032(a) Non-Hodgkin lymphoma B-cell 387 212247 -02 44 6786 15 227 86941 -04 1908 118520 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 16 8999 24 33 5123 11 08 2888 46 16 988 292(a) 2 Mature Non-Hodgkin lymphoma B-cell 351 192801 -05 10 1558 28 210 80417 -08 1783 110826 -042(a) 21 ChronicSmallProlymphocytic 96 52411 -15 00 21 - 47 18927 -14 539 33463 -15

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 82 44988 -17 00 19 - 40 16143 -16 464 28826 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 193 -02 - - - 00 46 - 02 145 052(a) 213 Mantle-cell lymphoma 13 7230 -01 - - - 07 2738 -01 72 4492 -01

2(a) 22 Lymphoplasmacytic lymphoma 10 5082 -05 - - - 04 1524 -08 58 3558 -04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 04 2062 -08 - - - 02 616 -12 23 1446 -072(a) 222 Waldenstrom macroglubulinemia 06 3020 -02 - - - 02 908 -06 34 2112 -02

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 88 48128 01 03 554 22 59 21824 -06 418 25750 052(a) 231 DLBCL NOSc 87 47520 00 03 519 03 57 21366 -08 416 25635 042(a) 232 Intravascular large B-cell 00 75 - - - - 00 31 - 01 44 -

lymphoma2(a) 233 Primary effusion lymphoma 00 167 26 - - - 00 123 - 01 44 -2(a) 234 Mediastinal large B-cell 01 366 155 00 35 - 01 304 142 00 27 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 06 3388 -22 05 775 31 06 1969 -46 10 644 -192(a) 25 Marginal-zone lymphoma (MZL) 22 12351 -02 01 98 - 14 5177 -02 114 7076 -012(a) 251 Splenic MZL 02 1164 14 - - - 01 434 18 12 730 112(a) 252 Extranodal MZL MALTc type 13 7268 07 00 62 - 09 3267 04 63 3939 102(a) 253 Nodal MZL 07 3919 -23 00 36 - 04 1476 -22 39 2407 -23

2(a) 26 Follicular lymphoma 39 21788 -19 01 100 - 30 11210 -25 165 10478 -152(a) 27 Hairy-cell leukemia 05 2984 -18 - - - 05 1908 -20 17 1076 -152(a) 28 Plasma cell neoplasms 85 46642 07 - - - 45 17864 11 462 28769 052(a) 281 Plasmacytoma 05 2997 -08 - - - 04 1509 -16 24 1484 -012(a) 282 Multiple myeloma 80 43645 08 - - - 41 16355 13 439 27285 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 27 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 20 10447 34 01 105 - 10 3636 40 110 6706 32

Table 1927All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 29 16118 00 11 1730 14 23 8235 02 98 6153 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 430 - 01 208 - 01 188 - 01 34 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 28 15642 11 10 1521 71 22 8022 11 97 6099 -032(b) 21 Mycosis fungoidesSezary syndrome 07 3962 19 01 135 - 06 2261 21 25 1566 092(b) 211 Mycosis fungoides 07 3831 20 01 135 - 06 2213 21 23 1483 092(b) 212 Sezary syndrome 00 131 - - - - 00 48 - 01 83 -

2(b) 22 Peripheral T-cell lymphoma 15 8438 -13 02 318 -09 12 4248 -12 62 3872 -132(b) 221 Peripheral T-cell lymphoma NOSc 06 3159 -05 00 49 - 04 1520 02 26 1590 -082(b) 222 Angioimmunoblastic T-cell lymphoma 02 1024 19 - - - 01 415 11 10 607 232(b) 223 Subcutaneous panniculitis- 00 68 - - - - 00 39 - 00 16 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 03 1549 -39 01 184 -01 02 888 -43 08 477 -45

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 98 - - - - 00 69 - 00 18 -2(b) 226 Enteropathy-type T-cell lymphoma 00 105 - - - - 00 50 - 01 54 -2(b) 227 Cutaneous T-cell lymphoma NOSc 03 1696 -12 00 32 - 02 894 -03 12 770 -172(b) 228 Primary cutaneous anaplastic 01 739 -48 00 26 - 01 373 -49 05 340 -49

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 04 2253 97 07 1047 92 03 940 98 04 266 1022(b) 24 NKcT-cell lymphoma nasal-type 01 638 -05 00 18 - 01 435 -03 03 185 -06

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 58 - - - - 00 22 - 01 36 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 01 293 45 - - - 00 116 - 03 174 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 46 - - - - 00 25 - 00 20 -2(c) Non-Hodgkin lymphoma unknown lineage 03 1407 -232 01 195 - 02 580 -184 10 632 -2302(c) 1 Precursor lymphoblastic leukemia 01 474 -228 01 187 - 00 134 - 02 153 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 49 - - - - - - - 01 36 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 02 884 -239 - - - 01 433 -175 07 443 -

lineage2() 1 Total precursor lymphomaleukemiad 18 9903 -06 35 5518 -17 09 3210 09 19 1175 05

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 435 271 - - - 01 215 - 03 207 -lymphoma

4 Lymphoid neoplasm NOSc 10 5235 -59 01 131 - 05 1871 -65 54 3233 -61

Table 1927 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 301 199772 -05 53 7889 02 202 79325 -02 1322 112558 -08

1 Hodgkin Lymphoma 24 14552 -16 12 1809 -10 29 10031 -14 32 2712 -32

2 Non-Hodgkin lymphoma 269 180219 -03 40 5982 03 170 67835 00 1251 106402 -062(a) Non-Hodgkin lymphoma B-cell 250 168102 -01 34 5050 13 154 61827 02 1190 101225 -042(a) 1 Precursor Non-Hodgkin lymphoma B-cell 14 7632 16 29 4293 09 06 2315 29 12 1024 202(a) 2 Mature Non-Hodgkin lymphoma B-cell 223 151164 -04 05 713 35 141 56808 -01 1102 93643 -072(a) 21 ChronicSmallProlymphocytic 48 33190 -13 - - - 24 10176 -05 268 23000 -16

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 43 30073 -15 - - - 22 9196 -06 243 20866 -19

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 118 - - - - 00 26 - 01 89 -2(a) 213 Mantle-cell lymphoma 04 2999 11 - - - 02 954 10 24 2045 12

2(a) 22 Lymphoplasmacytic lymphoma 05 3569 04 - - - 03 1066 -16 30 2501 11Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 02 1605 01 - - - 01 516 -25 13 1087 112(a) 222 Waldenstrom macroglubulinemia 03 1964 06 - - - 01 550 -08 17 1414 11

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 58 39060 00 02 371 33 38 14656 03 283 24033 -032(a) 231 DLBCL NOSc 57 38379 -02 02 342 27 36 14103 -01 282 23934 -032(a) 232 Intravascular large B-cell 00 87 - - - - 00 32 - 01 55 -

lymphoma2(a) 233 Primary effusion lymphoma - - - - - - - - - - - -2(a) 234 Mediastinal large B-cell 01 580 91 00 29 - 02 518 93 00 33 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 02 1304 -34 02 253 38 02 649 -37 05 402 -852(a) 25 Marginal-zone lymphoma (MZL) 21 14183 01 00 39 - 15 5872 12 98 8272 -062(a) 251 Splenic MZL 02 1254 -07 - - - 01 455 -32 10 799 072(a) 252 Extranodal MZL MALTc type 13 8711 06 00 30 - 10 3881 17 57 4800 -032(a) 253 Nodal MZL 06 4218 -07 - - - 04 1536 11 32 2673 -18

2(a) 26 Follicular lymphoma 33 21794 -24 00 19 - 27 10515 -25 134 11260 -222(a) 27 Hairy-cell leukemia 01 728 -12 - - - 01 403 -11 04 325 -122(a) 28 Plasma cell neoplasms 55 37315 08 - - - 33 13461 15 282 23839 052(a) 281 Plasmacytoma 03 1882 00 - - - 02 853 12 12 1017 -092(a) 282 Multiple myeloma 52 35433 09 - - - 30 12608 15 270 22822 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 21 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 14 9306 32 00 44 - 07 2704 32 76 6558 31

Table 1928All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 17 11104 01 05 772 29 15 5698 05 55 4634 -112(b) 1 Precursor Non-Hodgkin lymphoma T-cell 00 186 - 01 85 - 00 84 - 00 17 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 17 10889 09 05 686 83 15 5599 12 54 4604 -092(b) 21 Mycosis fungoidesSezary syndrome 05 3007 15 01 78 - 05 1819 26 13 1110 -042(b) 211 Mycosis fungoides 05 2908 12 01 78 - 05 1777 23 12 1053 -072(b) 212 Sezary syndrome 00 99 - - - - 00 42 - 01 57 -

2(b) 22 Peripheral T-cell lymphoma 09 6093 -08 01 216 30 08 2911 -06 35 2966 -142(b) 221 Peripheral T-cell lymphoma NOSc 03 2234 03 00 37 - 03 969 07 14 1228 -012(b) 222 Angioimmunoblastic T-cell lymphoma 01 878 -22 - - - 01 284 -39 07 594 -152(b) 223 Subcutaneous panniculitis- 00 108 - 00 18 - 00 72 - 00 18 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 974 -33 01 107 - 02 562 -19 04 305 -77

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 41 - - - - 00 29 - - - -2(b) 226 Enteropathy-type T-cell lymphoma 00 81 - - - - 00 34 - 01 47 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 1267 00 00 27 - 02 681 07 07 559 -102(b) 228 Primary cutaneous anaplastic 01 510 -34 00 25 - 01 280 -50 02 205 -33

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 02 1164 96 03 381 127 01 534 97 03 249 302(b) 24 NKcT-cell lymphoma nasal-type 01 347 11 - - - 01 224 - 01 115 -

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 62 - - - - 00 32 - 00 29 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 216 03 - - - 00 79 - 02 135 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 29 - - - - - - - - - -2(c) Non-Hodgkin lymphoma unknown lineage 02 1013 -341 01 160 - 01 310 - 06 543 -2(c) 1 Precursor lymphoblastic leukemia 01 340 - 01 156 - 00 104 - 01 80 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 46 - - - - - - - 00 33 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 627 - - - - 01 194 - 05 430 -

lineage2() 1 Total precursor lymphomaleukemiad 14 8158 -09 31 4534 -13 07 2503 02 13 1121 -11

3 Composite Hodgkin lymphoma and Non-Hodgkin 00 327 - - - - 00 124 - 02 196 -lymphoma

4 Lymphoid neoplasm NOSc 07 4674 -52 01 91 - 03 1335 -51 36 3248 -58

Table 1928 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 4: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Reference Cancer Incidence Rates Adjusted for Reporting DelayIndividual rates for diagnosis years 1975-1979 available in web browser version of Cancer Statistics Review

a SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

- Delay-adjusted rate is not shown for observed rates based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

Year of Diagnosis1975-1979 1160 1344 1018 1209 1393 1068 696 874 5521980 1262 1501 1081 1298 1528 1122 870 1074 7201981 1358 1590 1181 1406 1634 1235 742 1059 4981982 1339 1556 1161 1402 1642 1205 1027 1022 10011983 1399 1662 1195 1463 1752 1240 1028 1088 9621984 1519 1829 1279 1597 1910 1355 946 1252 6921985 1551 1839 1316 1628 1925 1385 995 1196 8431986 1590 1943 1300 1683 2059 1375 1066 1313 8521987 1674 2078 1342 1770 2215 1400 1035 1043 9951988 1726 2136 1408 1822 2245 1490 1158 1579 8491989 1736 2165 1384 1836 2304 1450 1159 1410 9721990 1851 2297 1481 1934 2396 1549 1392 1763 11021991 1881 2374 1461 1970 2481 1532 1403 1881 10291992 1862 2304 1494 1956 2394 1584 1368 1887 9651993 1885 2347 1500 1965 2432 1570 1423 1937 9971994 1995 2496 1579 2067 2558 1654 1448 2152 8861995 1999 2542 1545 2070 2618 1604 1676 2363 11431996 1942 2424 1548 2027 2520 1621 1554 1925 12391997 2000 2453 1646 2090 2522 1749 1640 2426 10861998 1962 2296 1686 2061 2401 1778 1449 1696 12541999 1997 2459 1636 2095 2554 1732 1441 1842 11372000 1981 2434 1613 2099 2571 1712 1393 1823 10742001 2002 2440 1646 2082 2547 1706 1605 1844 13922002 2023 2420 1710 2134 2552 1798 1448 1710 12512003 2078 2506 1753 2191 2633 1848 1637 2006 13782004 2140 2589 1795 2235 2685 1885 1860 2418 14552005 2088 2563 1709 2202 2674 1820 1673 1995 14102006 2052 2475 1724 2178 2608 1839 1639 2102 12942007 2126 2612 1739 2255 2755 1845 1583 1935 13172008 2097 2580 1703 2185 2687 1768 1694 1899 15082009 2097 2528 1747 2204 2669 1814 1540 1867 12992010 2151 2676 1724 2250 2758 1831 1781 2343 13342011 1996 2450 1637 2093 2564 1716 1472 1769 12512012 2049 2511 1674 2147 2618 1757 1682 1926 14652013 1993 2438 1630 2101 2559 1719 1586 1838 13932014 2047 2531 1651 2172 2653 1777 1545 2042 11522015 2037 2521 1643 2161 2652 1754 1550 1998 12062016 1984 2403 1640 2078 2499 1726 1686 1980 1433

Table 194Non-Hodgkin Lymphoma

Delay-adjusted SEER Incidencea Rates by Year Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Individual rates for diagnosis years 1975-1979 available in web browser version of Cancer Statistics Reviewa SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)

Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

Year of Diagnosis1975-2016 1846 2267 1513 1925 2357 1581 1414 1769 11351975-1979 1160 1344 1018 1209 1393 1068 696 874 5521980 1262 1501 1081 1298 1528 1122 870 1074 7201981 1358 1590 1181 1406 1634 1235 742 1059 4981982 1339 1556 1161 1402 1642 1205 1027 1022 10011983 1399 1662 1195 1463 1752 1240 1028 1088 9621984 1519 1829 1279 1597 1910 1355 946 1252 6921985 1551 1839 1316 1628 1925 1385 995 1196 8431986 1590 1943 1300 1683 2059 1375 1066 1313 8521987 1674 2078 1342 1770 2215 1400 1035 1043 9951988 1726 2136 1408 1822 2245 1490 1158 1579 8491989 1736 2165 1384 1836 2304 1450 1159 1410 9721990 1851 2297 1481 1934 2396 1549 1392 1763 11021991 1881 2374 1461 1970 2481 1532 1403 1881 10291992 1862 2304 1494 1956 2394 1584 1368 1887 9651993 1885 2347 1500 1965 2432 1570 1423 1937 9971994 1995 2496 1579 2067 2558 1654 1448 2152 8861995 1999 2542 1545 2070 2618 1604 1676 2363 11431996 1942 2424 1548 2027 2520 1621 1554 1925 12391997 2000 2453 1646 2090 2522 1749 1640 2426 10861998 1962 2296 1686 2061 2401 1778 1449 1696 12541999 1997 2459 1636 2095 2554 1732 1441 1842 11372000 1981 2434 1613 2099 2571 1712 1393 1823 10742001 2002 2440 1646 2082 2547 1706 1605 1844 13922002 2023 2420 1710 2134 2552 1798 1448 1710 12512003 2078 2506 1753 2191 2633 1848 1637 2006 13782004 2140 2589 1795 2235 2685 1885 1860 2418 14552005 2088 2563 1709 2202 2674 1820 1673 1995 14102006 2052 2475 1724 2178 2608 1839 1639 2102 12942007 2126 2612 1739 2255 2755 1845 1583 1935 13172008 2093 2575 1700 2180 2681 1765 1689 1894 15032009 2089 2520 1741 2195 2659 1806 1531 1856 12912010 2141 2662 1715 2237 2742 1820 1767 2323 13232011 1982 2433 1626 2076 2544 1702 1455 1749 12372012 2031 2489 1659 2125 2591 1739 1658 1897 14442013 1973 2414 1613 2076 2529 1699 1558 1807 13682014 2020 2497 1629 2138 2612 1749 1512 1998 11282015 2003 2478 1615 2118 2600 1718 1510 1947 11742016 1936 2344 1600 2018 2428 1676 1625 1909 1382

Table 195Non-Hodgkin Lymphoma

Age-adjusted SEER Incidencea Rates by Year Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Individual rates for years of death 1975-1979 available in web browser version of Cancer Statistics Reviewa US Mortality Files National Center for Health Statistics Centers for Disease Control and Prevention

Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

Year of Death1975-2016 701 880 570 732 915 596 478 613 3801975-1979 580 708 484 602 733 503 375 483 2921980 623 747 529 647 774 552 399 515 3121981 616 738 527 640 766 547 398 500 3251982 655 798 549 683 829 574 412 523 3291983 666 811 558 692 839 585 430 579 3231984 676 815 575 705 850 601 419 528 3391985 706 880 580 734 917 602 462 557 3871986 731 898 605 759 925 633 495 664 3701987 726 881 610 756 912 638 473 630 3621988 752 928 624 782 959 653 501 682 3721989 783 973 643 812 1004 671 533 710 4071990 787 997 634 816 1032 658 539 713 4171991 819 1015 674 850 1052 700 570 717 4611992 822 1030 669 853 1066 696 564 723 4451993 825 1014 686 857 1045 717 569 753 4401994 863 1075 710 900 1120 741 554 682 4561995 872 1081 716 909 1121 749 579 762 4451996 875 1094 714 909 1129 746 621 825 4741997 888 1103 725 921 1135 757 634 845 4871998 869 1085 710 903 1127 738 599 750 4891999 832 1036 685 867 1071 718 565 744 4412000 817 1020 670 854 1063 701 520 661 4172001 791 998 642 821 1031 668 561 728 4472002 765 966 619 797 1004 644 541 688 4412003 738 940 592 769 981 613 494 583 4272004 709 894 573 738 928 596 501 623 4132005 695 887 556 724 922 579 477 611 3812006 674 848 544 701 878 566 492 627 3932007 659 836 526 686 867 549 452 577 3622008 641 820 509 671 856 533 431 548 3452009 630 812 493 656 842 513 449 615 3412010 614 783 485 637 811 504 457 584 3642011 603 785 464 629 817 483 436 574 3402012 591 762 461 617 795 480 426 538 3482013 571 738 444 595 767 462 411 527 3332014 565 726 443 589 755 460 418 528 3422015 547 713 418 569 741 434 404 519 3212016 537 691 417 562 721 436 383 481 311

Table 196Non-Hodgkin Lymphoma

Age-adjusted US Deatha Rates by Year Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a SEER 21 areas Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)unless noted

b US Mortality Files National Center for Health Statistics Centers for Disease Control and PreventionRates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) unless noted

c Rates are per 100000 and are age-adjusted to the world (WHO 2000-2025) standard million- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER IncidenceAge at DiagnosisAge-Adjusted Rates 2012-2016All ages 196 239 162 206 250 170 147 177 124Under 65 94 111 78 96 113 80 91 109 7665 and over 904 1126 743 966 1199 794 532 646 461

All ages (WHO world std)c 147 177 122 154 184 127 117 140 98

Age-Specific Rates 2012-2016lt1 - - - - - - - - -1-4 08 11 05 08 11 06 06 07 -5-9 12 17 07 13 18 07 10 13 0810-14 15 20 10 14 19 10 16 21 1115-19 21 27 14 20 26 14 20 28 1220-24 27 32 22 26 31 21 28 35 2025-29 35 40 29 34 39 28 41 48 3430-34 49 56 42 48 54 41 56 67 4735-39 72 85 59 71 83 58 81 98 6640-44 99 117 80 99 117 80 108 128 9045-49 145 168 122 147 169 125 156 190 12750-54 222 256 189 229 264 194 217 250 18755-59 312 366 261 326 379 274 277 332 23060-64 445 522 376 470 548 396 363 426 31165-69 629 742 528 667 781 564 447 522 39070-74 833 997 697 890 1058 746 522 640 43975-79 1044 1287 855 1124 1384 918 588 692 52080-84 1193 1522 966 1280 1631 1031 650 791 57385+ 1079 1499 861 1146 1589 915 508 685 434

US MortalityAge at DeathAge-Adjusted Rates 2012-2016All ages 56 73 44 59 76 45 41 52 33Under 65 13 17 10 13 17 09 16 21 1265 and over 352 453 279 372 477 295 210 265 176

All ages (WHO world std)c 30 39 23 31 40 23 25 32 20

Age-Specific Rates 2012-2016lt1 - - - - - - - - -1-4 00 01 - 00 01 - - - -5-9 01 01 00 00 01 - 01 - -10-14 01 01 01 01 01 01 - - -15-19 01 02 01 01 02 01 02 02 -20-24 02 03 02 02 03 02 04 04 0325-29 04 05 03 03 04 02 05 07 0430-34 05 07 04 05 06 03 09 12 0635-39 07 09 05 06 08 04 11 14 0940-44 11 14 08 10 13 08 18 21 1545-49 18 23 13 17 22 13 24 32 1750-54 31 41 21 31 41 21 37 49 2655-59 53 71 37 54 72 36 58 74 4460-64 90 118 64 92 121 64 90 116 6965-69 142 184 105 149 192 109 116 146 9370-74 244 309 188 256 324 197 167 214 13375-79 374 473 294 397 501 312 220 275 18480-84 567 725 455 600 764 481 321 405 27485+ 751 994 624 795 1049 662 360 457 320

Table 197Non-Hodgkin Lymphoma

SEER Incidencea and US Deathb Rates Age-Adjusted and Age-Specific Rates by Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on End Results data from a series of hospital registries and one population-based registryb SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)

Based on follow-up of patients into 2016 Expected survival rates are derived from the US Annual Life Tablesc SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER programBased on follow-up of patients into 2016

d Period survival provides a 2015 estimate of survival by piecing together the most recent conditional survival estimatesfrom several cohorts It is computed here using three year calendar blocks (2010-2012 0-1 year survival)(2009-2011 1-2 year survival) (2008-2010 2-3 year survival) (2007-2009 3-4 year survival) (2006-2008 4-5 years survival)

e Stage at diagnosis is classified using SEER Summary Stage 2000 Stage distribution percentages may not sum to 100 due to roundingf The difference between 1975-1977 and 2009-2015 is statistically significant (plt05)g The standard error is between 5 and 10 percentage pointsh The standard error is greater than 10 percentage points- Statistic could not be calculated due to fewer than 25 cases during the time period

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

5-Year Relative Survival (Percent)Year of Diagnosis1960-1963a - - - 31 31 31 - - -1970-1973a - - - 41 39 43 - - -1975-1977b 465 456 475 468 463 473 486 426 553g

1978-1980b 479 461 498 479 462 495 511 469 5671981-1983b 506 503 509 508 505 511 495 492 4981984-1986b 516 501 534 521 507 537 468 445 4991987-1989b 509 476 549 513 482 552 457 413 5101990-1992b 507 467 557 515 476 564 422 384 4761993-1995b 526 487 575 533 498 577 425 359 5491996-1998b 588 570 610 595 577 615 547 531 5721999-2001b 640 614 670 650 628 676 558 490 6382002-2004b 698 686 712 710 701 721 636 611 6662005-2008b 716 706 727 728 719 738 625 578 6752009-2015b 747f 739f 757f 757f 748f 767f 695f 670f 724f

5-Year Period Survival (Percent)cd

2015 722 705 743 726 708 747 671 641 703

Stage Distribution () 2009-2015ce

All StagesNumber of cases 97737 53606 44131 80120 44109 36011 8184 4388 3796Percent 100 100 100 100 100 100 100 100 100Localized 27 27 29 27 26 28 28 25 31Regional 15 15 15 15 15 15 15 15 15Distant 50 51 48 51 52 49 51 54 48UnstagedUnknown 8 7 8 7 7 8 6 6 7

5-Year Relative Survival (Percent) 2009-2015c

Age at DiagnosisAges lt45 840 820 870 855 836 885 735 708 776Ages 45-54 810 777 859 826 795 872 687 639 750Ages 55-64 770 742 809 781 754 818 678 620 749Ages 65-74 725 706 747 731 711 755 656 623 682Ages 75+ 554 539 568 557 538 574 482 449 500Ages lt65 800 773 838 812 787 849 701 659 759Ages 65+ 638 627 649 641 628 655 584 562 598

StageeAll Stages 720 707 737 724 711 740 665 637 698Localized 840 830 850 843 833 852 810 766 850Regional 750 751 749 755 756 755 689 698 678Distant 648 633 668 657 642 677 580 557 610UnstagedUnknown 703 686 723 679 662 698 659 648 666

Table 198Non-Hodgkin Lymphoma

5-Year Relative and Period Survival (Percent) by Race Sex Diagnosis Year and Age

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Expected survival rates are derived from the US Annual Life Tables

1975- 1980- 1985- 1990-1979 1984 1989 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Survival Time

1-year 702 730 713 704 703 733 756 767 774 773 787 810 803 811 817 810 816 841 839 844 834 842 844 834 8452-year 602 637 628 622 618 659 685 700 710 714 733 760 757 760 773 769 775 790 795 796 797 800 800 7953-year 546 585 582 577 575 621 649 664 669 679 701 731 731 735 748 745 750 762 773 774 775 779 7794-year 505 546 543 544 547 587 621 636 645 655 681 712 716 715 730 726 732 744 756 752 756 7675-year 468 507 510 516 520 561 594 609 621 638 660 693 700 701 716 705 712 728 741 742 7426-year 436 475 483 492 499 541 571 583 595 621 647 680 683 688 704 688 701 718 721 7237-year 408 450 458 470 479 522 552 564 577 605 629 663 671 672 685 672 688 702 7108-year 385 428 434 450 464 504 529 552 563 589 613 651 658 666 670 661 674 6909-year 366 408 415 435 453 493 515 535 548 576 600 640 648 649 652 651 66110-year 350 389 398 421 443 481 501 522 537 563 589 632 633 638 634 63711-year 335 374 385 406 434 466 488 511 525 548 581 618 621 630 63112-year 324 360 369 395 423 457 481 501 512 535 568 600 615 61713-year 314 348 358 383 415 449 469 492 500 520 561 593 60214-year 302 335 347 372 406 443 456 485 488 513 549 58315-year 289 322 335 365 398 437 447 474 478 505 54016-year 279 312 328 356 393 437 433 472 470 49217-year 274 304 321 349 388 428 428 469 45818-year 268 296 314 341 378 420 419 46319-year 260 288 306 333 370 413 41220-year 252 280 301 329 359 408

Table 199Non-Hodgkin Lymphoma

SEERa Relative Survival (Percent)By Year of Diagnosis

All Races Males and Females

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Expected survival rates are derived from the US Annual Life Tables

1975- 1980- 1985- 1990-1979 1984 1989 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Survival Time

1-year 694 727 689 671 666 712 747 749 758 765 776 806 797 801 811 810 814 836 828 838 838 841 834 830 8352-year 594 637 605 582 583 636 672 682 691 703 713 752 749 755 762 765 778 779 781 788 798 793 786 7913-year 534 580 557 537 545 598 638 645 644 668 679 720 726 726 731 736 754 751 757 766 776 769 7644-year 493 539 516 504 515 561 610 620 615 639 657 700 709 701 711 713 734 734 737 743 756 7575-year 455 501 482 476 485 537 583 592 590 617 635 679 689 688 699 689 710 721 724 735 7426-year 426 466 455 456 469 510 561 565 562 602 620 667 669 676 684 670 696 715 706 7177-year 399 442 431 436 449 491 542 544 546 587 601 652 658 655 668 651 682 696 6968-year 378 420 410 418 433 474 520 533 536 567 582 637 645 649 650 634 665 6869-year 357 401 391 402 423 465 504 514 523 553 572 628 633 632 636 618 65210-year 340 380 377 392 416 455 489 503 515 542 560 617 617 620 613 60911-year 328 363 364 381 407 437 477 494 508 527 547 603 605 612 61212-year 319 352 351 372 395 427 472 482 498 515 537 589 601 59613-year 307 342 343 361 389 419 456 467 491 501 531 582 59114-year 295 330 332 350 378 414 444 461 480 496 521 57215-year 281 319 324 344 368 409 435 453 473 488 51216-year 272 308 316 333 361 409 426 453 471 47417-year 265 300 308 326 358 403 420 449 46218-year 261 294 302 320 350 396 410 44219-year 256 287 294 313 342 391 40320-year 250 280 291 309 332 387

Table 1910Non-Hodgkin Lymphoma

SEERa Relative Survival (Percent)By Year of Diagnosis

All Races Males

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Expected survival rates are derived from the US Annual Life Tables

1975- 1980- 1985- 1990-1979 1984 1989 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Survival Time

1-year 710 734 741 747 752 759 767 786 792 782 801 814 810 821 825 809 819 847 854 851 830 843 856 838 8572-year 611 637 656 672 664 688 701 720 734 727 758 769 765 767 786 774 772 804 812 807 796 810 817 7993-year 559 589 611 627 616 649 662 684 700 692 727 744 736 746 768 756 746 774 791 786 774 791 7974-year 519 553 576 595 590 619 634 653 681 674 710 725 724 730 751 739 729 757 778 764 755 7805-year 482 514 544 567 565 591 608 629 658 664 688 708 713 716 736 724 715 735 763 751 7426-year 446 484 517 539 540 580 583 603 635 643 679 695 699 701 727 708 707 722 738 7317-year 417 458 490 512 520 560 563 586 615 626 663 674 687 692 704 698 694 709 7268-year 392 437 463 491 505 542 539 573 596 615 649 667 672 684 693 692 684 6949-year 374 416 443 476 492 529 528 557 578 603 633 654 664 669 671 688 67110-year 360 399 424 458 480 514 516 542 562 588 625 648 651 658 659 66911-year 342 385 409 438 469 503 500 529 547 573 621 636 640 651 65312-year 329 368 390 425 460 494 493 523 529 560 606 613 632 64013-year 321 353 376 411 449 486 485 518 510 543 598 606 61514-year 310 340 365 400 442 479 470 512 497 532 582 59615-year 297 326 349 391 436 472 460 498 483 525 57416-year 287 316 342 385 435 467 441 492 468 51317-year 282 306 336 378 428 459 438 490 45218-year 274 298 327 367 413 449 428 48519-year 265 288 321 358 407 439 42220-year 254 280 312 353 395 433

Table 1911Non-Hodgkin Lymphoma

SEERa Relative Survival (Percent)By Year of Diagnosis

All Races Females

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 5222 2506 2704 3176 3627 3994 4570 4729 5325 5260 5263 5562 5775 6226 6401 6704 6998 7072 11154

SEER 9 except 4285 2088 2267 2603 2819 3091 3507 3694 4159 4249 4364 4515 4818 5209 5398 5628 5841 6015 9363SF-Oakland

San Francisco- 937 418 437 573 808 903 1063 1035 1166 1011 899 1047 957 1017 1003 1076 1157 1057 1791Oakland SMSAc

San Francisco 245 96 123 210 326 393 467 410 450 354 213 256 220 283 219 216 240 225 362CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 134 155 161 183 201 215 234 233 252 244 238 244 246 258 254 255 255 245 244

SEER 9 except 132 154 161 181 188 201 217 218 236 236 235 236 244 256 254 253 252 247 243SF-Oakland

San Francisco- 147 158 160 194 267 285 317 305 335 288 252 286 256 266 256 263 268 235 246Oakland SMSAc

San Francisco 143 144 176 293 444 519 610 523 574 448 274 325 269 354 265 257 273 252 246CityCounty

Table 1912

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males All Ages

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males All Ages

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 0-19 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 223 87 108 91 94 84 100 89 120 105 104 119 127 107 106 143 134 155 240

SEER 9 except 191 78 95 82 80 76 86 74 107 84 93 100 115 90 87 114 119 129 198SF-Oakland

San Francisco- 32 9 13 9 14 8 14 15 13 21 11 19 12 17 19 29 15 26 42Oakland SMSAc

San Francisco 9 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 5 lt4 6 lt4CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 12 12 16 14 14 13 15 13 17 14 14 15 16 14 13 18 17 20 20

SEER 9 except 12 13 16 14 14 13 15 12 17 13 14 15 17 13 13 16 17 19 19SF-Oakland

San Francisco- 14 10 15 10 16 09 15 16 13 21 11 18 12 17 19 28 14 25 27Oakland SMSAc

San Francisco 23 - - - - - - - - - - - - - - 40 - 49 -CityCounty

Table 1913

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 0-19

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 0-19

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 20-54 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 1463 687 723 958 1211 1413 1766 1830 2089 1770 1608 1696 1623 1722 1655 1693 1674 1596 2242

SEER 9 except 1208 563 588 730 827 923 1195 1294 1483 1325 1269 1327 1308 1410 1383 1401 1402 1328 1848SF-Oakland

San Francisco- 255 124 135 228 384 490 571 536 606 445 339 369 315 312 272 292 272 268 394Oakland SMSAc

San Francisco 58 29 34 105 215 288 333 303 317 225 105 115 111 111 86 75 73 71 98CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 69 79 82 104 124 136 159 156 169 138 121 124 117 123 116 118 116 111 104

SEER 9 except 69 78 81 97 103 109 131 134 144 123 115 116 112 119 115 116 115 110 103SF-Oakland

San Francisco- 69 84 89 139 226 264 295 267 298 213 156 164 139 141 123 130 118 114 110Oakland SMSAc

San Francisco 67 88 94 272 565 715 813 724 744 510 230 252 239 248 194 162 152 145 129CityCounty

Table 1914

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 20-54

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 20-54

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 55+ and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 3536 1732 1873 2127 2322 2497 2704 2810 3116 3385 3551 3747 4025 4397 4640 4868 5190 5321 8672

SEER 9 except 2886 1447 1584 1791 1912 2092 2226 2326 2569 2840 3002 3088 3395 3709 3928 4113 4320 4558 7317SF-Oakland

San Francisco- 650 285 289 336 410 405 478 484 547 545 549 659 630 688 712 755 870 763 1355Oakland SMSAc

San Francisco 178 65 88 104 109 105 132 106 130 126 106 141 108 169 131 136 164 148 261CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 451 522 540 596 633 673 701 706 761 800 811 831 858 900 901 891 899 862 871

SEER 9 except 440 521 544 601 620 667 687 692 744 797 813 813 858 901 904 891 888 874 874SF-Oakland

San Francisco- 508 528 520 571 702 703 773 783 854 821 800 932 855 894 888 890 959 800 860Oakland SMSAc

San Francisco 482 446 598 727 739 757 934 747 914 872 727 934 690 1047 764 769 889 776 826CityCounty

Table 1915

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 55+

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 55+

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 003 006 217 072 Asian 0 001 003 005 183 072

10 002 005 011 218 073 Pacific 10 002 004 009 184 073

20 003 009 021 217 073 Islander 20 003 007 015 182 073

30 006 018 042 216 073 30 005 013 029 180 073

40 012 037 082 213 074 40 008 024 057 176 073

50 025 072 139 206 074 50 017 049 101 170 073

60 049 120 177 191 075 60 034 087 139 158 072

70 080 144 - 160 072 70 056 112 - 133 068

80 085 - - 106 062 80 066 - - 091 056

White 0 001 003 006 227 075 American 0 001 002 003 116 049

10 002 005 011 228 076 Indian 10 002 002 005 117 050

20 003 009 021 227 076 Alaska 20 001 003 008 116 050

30 006 018 043 226 077 Nativea 30 003 007 022 117 051

40 012 038 085 223 077 40 004 019 041 117 052

50 026 075 147 217 078 50 016 038 078 118 053

60 052 127 187 201 078 60 024 067 105 109 055

70 085 153 - 169 076 70 048 091 - 096 055

80 090 - - 111 065 80 057 - - 064 043

Black 0 001 002 006 138 042 Hispanicb 0 001 002 005 222 073

10 002 005 011 140 043 10 001 004 009 223 074

20 003 010 022 139 043 20 003 008 019 222 074

30 006 019 041 137 043 30 005 016 040 221 074

40 013 035 068 133 043 40 011 035 078 218 074

50 023 057 093 125 043 50 024 068 133 211 074

60 037 076 102 110 042 60 046 114 173 195 074

70 047 078 - 087 038 70 075 140 - 164 070

80 044 - - 057 032 80 081 - - 112 057

Table 1916

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Both Sexes 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 004 007 243 081 Asian 0 001 003 006 213 085

10 002 006 013 244 082 Pacific 10 002 005 011 213 086

20 004 010 024 243 082 Islander 20 003 009 018 211 086

30 007 021 049 243 083 30 006 015 034 210 086

40 014 042 094 240 084 40 009 028 067 205 086

50 029 082 158 233 085 50 019 059 117 199 086

60 057 139 203 219 086 60 041 101 161 187 085

70 095 170 - 188 084 70 066 131 - 159 082

80 105 - - 130 073 80 080 - - 114 069

White 0 001 004 007 254 085 American 0 001 003 004 104 057

10 002 006 013 255 086 Indian 10 002 003 006 105 058

20 004 010 024 254 086 Alaska 20 001 004 008 103 058

30 007 020 049 253 087 Nativea 30 003 008 021 104 059

40 014 043 097 251 088 40 005 018 038 105 060

50 030 086 167 244 089 50 014 035 071 105 062

60 059 147 215 230 090 60 023 062 094 099 065

70 101 180 - 198 088 70 046 084 - 090 066

80 112 - - 136 076 80 053 - - 061 053

Black 0 001 003 007 152 046 Hispanicb 0 001 003 005 238 083

10 002 006 014 154 047 10 002 005 011 239 084

20 004 012 027 153 047 20 003 009 021 238 084

30 008 023 048 152 047 30 006 018 043 238 084

40 016 042 079 148 047 40 012 037 083 235 085

50 027 066 105 138 047 50 026 073 145 228 085

60 043 087 114 123 045 60 050 126 189 214 085

70 054 088 - 099 042 70 086 157 - 185 081

80 053 - - 070 036 80 094 - - 131 066

Table 1917

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Males 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 002 004 193 064 Asian 0 001 002 004 159 063

10 001 004 009 195 064 Pacific 10 001 004 008 160 063

20 003 007 017 194 064 Islander 20 002 006 013 159 063

30 005 015 036 192 065 30 004 011 025 157 063

40 010 031 071 189 065 40 007 021 048 153 063

50 022 062 120 182 065 50 014 042 087 148 063

60 042 103 154 168 065 60 028 074 122 136 062

70 067 123 - 138 063 70 049 099 - 114 058

80 071 - - 090 054 80 057 - - 075 047

White 0 001 002 004 203 067 American 0 000 001 002 128 043

10 001 004 009 204 067 Indian 10 001 001 004 129 044

20 002 007 017 203 067 Alaska 20 001 003 007 128 044

30 005 015 037 201 067 Nativea 30 002 006 023 129 044

40 010 032 074 198 068 40 004 021 044 129 045

50 022 065 127 192 068 50 017 042 085 129 046

60 044 109 163 177 068 60 026 072 113 118 047

70 072 130 - 146 066 70 050 097 - 102 046

80 075 - - 094 056 80 060 - - 066 037

Black 0 000 002 004 126 040 Hispanicb 0 001 002 004 210 065

10 001 004 009 128 040 10 001 004 008 211 066

20 003 008 018 127 040 20 002 007 017 211 066

30 005 015 034 125 040 30 004 014 036 209 066

40 010 029 058 122 040 40 010 032 073 206 066

50 020 049 083 115 040 50 022 064 123 198 066

60 032 068 094 102 039 60 043 104 161 182 065

70 041 071 - 080 036 70 066 127 - 149 062

80 039 - - 051 030 80 073 - - 100 051

Table 1918

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Females 2014-2016 By RaceEthnicity

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

The AAPC is the Average Annual Percent Change over the time interval The AAPCs are calculated bythe Joinpoint Regression Program Version 47 February 2019 National Cancer Institute

- Statistic not shown Rate based on less than 16 cases for the time intervalTrend based on less than 10 cases for at least one year within the time interval

a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) Trendsare based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico SeattleUtah and AtlantaThe SEER 21 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the AlaskaNative Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts

c The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 3 Joinpoints overdiagnosis years 2000-2016

d The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 5 Joinpoints overdiagnosis years 1975-2016

e Hispanic and Non-Hispanic are not mutually exclusive from whites blacks AsianPacificIslanders and American IndiansAlaska Natives Incidence data for Hispanics and Non-Hispanicsare based on NHIA and exclude cases from the Alaska Native Registry

f Incidence data for American IndianAlaska Native are based on the PurchasedReferred CareDelivery Area (PRCDA) counties

g US Mortality Files National Center for Health Statistics CDCh The 2007-2016 mortality AAPCs are based on a Joinpoint analysis using years of death 2000-2016 The APC is significantly different from zero (plt05)

SEER Incidence SEER 21 Areasb SEER 21 Areasb SEER 9 Areasb

Rate 2012-2016 Trend 2007-2016c Trend 2007-2016d

Rate per 100000 persons AAPC () AAPC ()

Total Males Females Total Males Females Total Males Females RaceEthnicity

All Races 196 239 162 -07 -09 -08 -09 -07 -08

White 206 250 170 -08 -11 -09 -09 -08 -08White Hispanice 183 212 161 -08 -03 -05 - - -White Non-Hispanice 210 256 172 -08 -06 -10 - - -

Black 147 177 124 01 00 03 00 -04 -09

AsianPacific Islander 134 164 110 00 00 -01 - - -

Amer IndAlaska Natf 113 120 106 -05 -12 00 - - -

Hispanice 179 207 157 -05 -02 03 - - -

US Mortalityg Rate 2012-2016 Trend 2007-2016h

Rate per 100000 persons AAPC ()

Total Males Females Total Males FemalesRaceEthnicity

All Races 56 73 44 -23 -20 -27

White 59 76 45 -23 -20 -27White Hispanice 51 65 40 -16 -13 -20White Non-Hispanice 59 76 46 -23 -20 -27

Black 41 52 33 -20 -19 -21

AsianPacific Islander 39 49 31 -17 -15 -19

Amer IndAlaska NatTotal US 31 40 24 -32 -20 -45PRCDA Counties 44 58 33 -21 -04 -37Non-PRCDA Counties 17 21 14 -54 -50 -60

Hispanice 48 61 38 -17 -14 -21

Table 1919Non-Hodgkin Lymphoma

SEER Incidence and US MortalityAge-Adjusted Rates and Trendsa

By RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Incidence Ratesa 2012-2016

California 1844 2241 1515 1938 2349 1591 1390 1639 1182Greater Bay Area 1957 2381 1600 2144 2601 1755 1628 1828 1436San Francisco-Oakland 1956 2421 1570 2174 2660 1765 1603 1816 1408San Jose-Monterey 1962 2311 1660 2097 2503 1742 1800 1891 1646

Los Angeles 1804 2176 1505 1951 2331 1637 1357 1659 1139Greater California 1822 2220 1489 1876 2286 1529 1314 1534 1113

Connecticut 2116 2607 1733 2154 2642 1771 1386 1829 1051Detroit 2132 2636 1742 2290 2850 1847 1620 1905 1409Georgia 1826 2244 1487 1936 2346 1588 1462 1833 1187Atlanta 1925 2381 1555 2119 2567 1736 1601 2034 1272Rural Georgia 1584 1790 1401 1953 2298 1567 807 - 988Greater Georgia 1784 2186 1459 1872 2274 1537 1380 1703 1146

Hawaii 1660 2024 1349 1958 2275 1593 - - -Idaho 1922 2267 1616 1920 2262 1618 - - -Iowa 2134 2601 1756 2148 2612 1773 1352 1602 1100Kentucky 2039 2505 1666 2070 2538 1693 1403 1788 1112Louisiana 1944 2352 1614 2106 2537 1744 1469 1769 1237Massachusetts 1810 2181 1518 1830 2214 1524 1452 1655 1299New Jersey 2155 2607 1804 2285 2765 1905 1387 1621 1222New Mexico 1550 1739 1387 1580 1798 1394 875 - -New York 2152 2620 1788 2306 2792 1915 1545 1852 1333Seattle-Puget Sound 2116 2627 1695 2177 2667 1766 1631 1973 1316Utah 1843 2233 1498 1862 2258 1513 2089 - -

SEER 9 Areasb 1992 2444 1623 2095 2551 1716 1573 1914 1298SEER 13 Areasb 1946 2373 1597 2064 2502 1700 1519 1853 1258SEER 18 Areasb 1933 2354 1590 2031 2464 1671 1449 1751 1214SEER 21 Areasb 1963 2388 1620 2061 2498 1702 1471 1771 1245

Table 1920Non-Hodgkin Lymphoma

Age-Adjusted SEER Incidence Ratesa

By Registry Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control and PreventionRates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and AtlantaThe SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Death Ratesa 2012-2016

California 533 677 423 570 726 449 417 480 367Greater Bay Area 505 671 376 561 756 408 410 491 331San Francisco-Oakland 503 667 376 555 742 409 416 490 343San Jose-Monterey 511 681 377 573 781 407 - - -

Los Angeles 541 670 443 589 728 481 424 503 371Greater California 539 682 429 564 716 447 416 455 384

Connecticut 533 705 407 547 717 421 350 510 244Detroit 639 822 505 693 895 542 443 528 384Georgia 533 697 411 580 747 450 376 503 286Atlanta 492 659 372 533 728 388 397 506 317Rural Georgia 559 731 388 670 813 507 - - -Greater Georgia 549 712 426 595 755 470 363 500 266

Hawaii 475 620 352 545 649 412 - - -Idaho 635 775 510 641 782 516 - - -Iowa 638 845 484 642 848 488 - - -Kentucky 642 886 460 655 904 470 401 557 284Louisiana 608 814 451 651 863 485 461 623 340Massachusetts 523 659 423 541 682 436 347 410 297New Jersey 545 721 419 585 780 443 372 466 314New Mexico 488 585 405 493 595 406 - - -New York 535 702 412 575 752 441 390 514 313Seattle-Puget Sound 585 749 463 604 769 480 490 562 397Utah 542 670 433 551 681 440 - - -

SEER 9 Areasb 555 719 430 586 758 454 414 522 333SEER 13 Areasb 549 705 429 586 753 457 419 521 342SEER 18 Areasb 554 717 431 589 761 456 409 518 329SEER 21 Areasb 550 712 428 584 754 453 401 513 322

Total US 562 725 436 586 755 454 408 518 330

Table 1921Non-Hodgkin Lymphoma

Age-Adjusted SEER Death Ratesa

By Registry Race and Sex

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 562 002

High Five StatesMichigan 645 011 01(0112) 1479Kentucky 642 016 02(0118) 1424Iowa 638 018 03(0120) 1367Indiana 638 013 04(0117) 1361Idaho 635 027 05(0126) 1303

Low Five StatesNevada 511 019 47(2251) -899Colorado 491 014 48(3851) -1257New Mexico 488 020 49(2851) -1317Hawaii 475 024 50(3051) -1542c

DC 444 039 51(2351) -2097c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 545 014 28(1847) -291 Montana 559 030 25(0250) -042Alaska 525 047 43(0151) -654 Nebraska 563 023 22(0548) 026Arizona 512 012 46(2950) -886 Nevada 511 019 47(2251) -899Arkansas 555 018 26(1247) -113 New Hampshire 562 027 23(0349) 014California 533 005 40(2645) -508 New Jersey 545 010 29(2045) -301Colorado 491 014 48(3851) -1257 New Mexico 488 020 49(2851) -1317Connecticut 533 016 39(1949) -505 New York 535 007 37(2446) -478Delaware 628 033 08(0139) 1174 North Carolina 541 010 35(2146) -363DC 444 039 51(2351) -2097c North Dakota 561 037 24(0151) -007Florida 535 006 38(2545) -479 Ohio 616 009 10(0220) 969Georgia 533 011 41(2248) -511 Oklahoma 630 017 06(0121) 1226Hawaii 475 024 50(3051) -1542c Oregon 612 016 11(0124) 903Idaho 635 027 05(0126) 1303 Pennsylvania 603 009 16(0622) 729Illinois 566 009 20(1634) 085 Rhode Island 542 029 32(0651) -350Indiana 638 013 04(0117) 1361 South Carolina 542 014 31(1847) -347Iowa 638 018 03(0120) 1367 South Dakota 541 033 36(0451) -364Kansas 585 019 19(0439) 420 Tennessee 629 013 07(0119) 1198Kentucky 642 016 02(0118) 1424 Texas 546 007 27(2142) -277Louisiana 608 016 14(0125) 826 Utah 542 022 33(1250) -352Maine 609 026 13(0137) 852 Vermont 605 040 15(0148) 770Maryland 524 013 44(2349) -663 Virginia 544 011 30(2046) -319Massachusetts 523 012 45(2549) -687 Washington 599 013 17(0425) 665Michigan 645 011 01(0112) 1479 West Virginia 612 022 12(0132) 894Minnesota 617 014 09(0122) 984 Wisconsin 590 013 18(0629) 507Mississippi 531 018 42(1850) -551 Wyoming 564 043 21(0151) 050Missouri 542 012 34(1947) -354

Table 1922Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males and Females

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 725 003

High Five StatesKentucky 886 030 01(0112) 2213c

Iowa 845 032 02(0120) 1647c

Michigan 842 019 03(0114) 1615c

Indiana 839 024 04(0116) 1567c

Delaware 824 058 05(0144) 1364

Low Five StatesArizona 635 019 47(3251) -1244Alaska 630 075 48(0251) -1311Hawaii 620 041 49(1951) -1452DC 614 071 50(0551) -1535c

New Mexico 585 033 51(3451) -1928c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 688 025 36(1649) -513 Montana 709 050 26(0251) -218Alaska 630 075 48(0251) -1311 Nebraska 737 040 20(0248) 165Arizona 635 019 47(3251) -1244 Nevada 653 032 44(1951) -994Arkansas 721 031 22(0747) -061 New Hampshire 710 046 25(0451) -210California 677 009 41(2846) -666 New Jersey 721 018 21(1441) -059Colorado 643 024 46(2451) -1133 New Mexico 585 033 51(3451) -1928c

Connecticut 705 028 28(1248) -273 New York 702 012 30(1943) -323Delaware 824 058 05(0144) 1364 North Carolina 709 018 27(1644) -221DC 614 071 50(0551) -1535c North Dakota 682 061 39(0251) -598Florida 683 011 37(2446) -585 Ohio 800 017 09(0320) 1029Georgia 697 019 34(1746) -387 Oklahoma 806 030 08(0126) 1109Hawaii 620 041 49(1951) -1452 Oregon 794 028 12(0128) 947Idaho 775 045 16(0146) 692 Pennsylvania 783 015 15(0523) 794Illinois 739 016 19(1235) 190 Rhode Island 649 050 45(1051) -1050Indiana 839 024 04(0116) 1567c South Carolina 681 025 40(1850) -604Iowa 845 032 02(0120) 1647c South Dakota 701 056 31(0251) -332Kansas 713 032 24(0948) -174 Tennessee 820 023 06(0120) 1311Kentucky 886 030 01(0112) 2213c Texas 698 012 32(2043) -368Louisiana 814 029 07(0122) 1222 Utah 670 036 42(1351) -754Maine 754 045 18(0148) 395 Vermont 794 069 11(0149) 950Maryland 682 023 38(1849) -588 Virginia 694 020 35(1847) -429Massachusetts 659 020 43(2450) -910 Washington 790 022 13(0224) 897Michigan 842 019 03(0114) 1615c West Virginia 774 038 17(0142) 675Minnesota 797 025 10(0224) 995 Wisconsin 786 023 14(0227) 844Mississippi 717 034 23(0748) -110 Wyoming 698 071 33(0151) -377Missouri 702 022 29(1646) -319

Table 1923Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 436 002

High Five StatesIdaho 510 033 01(0139) 1697c

Maine 497 031 02(0141) 1396Michigan 495 012 03(0119) 1340Oklahoma 492 020 04(0128) 1276Indiana 492 016 05(0123) 1270

Low Five StatesMississippi 404 021 47(1351) -731Nevada 382 022 48(2051) -1237Colorado 369 016 49(3451) -1540c

Hawaii 352 027 50(2551) -1932c

DC 323 044 51(1551) -2601c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 440 017 24(0547) 099 Montana 435 036 27(0151) -034Alaska 414 058 38(0151) -500 Nebraska 435 027 26(0249) -032Arizona 407 014 44(2049) -664 Nevada 382 022 48(2051) -1237Arkansas 428 021 31(0649) -181 New Hampshire 454 032 19(0149) 400California 423 006 34(2244) -313 New Jersey 419 012 37(1848) -397Colorado 369 016 49(3451) -1540c New Mexico 405 025 46(0951) -706Connecticut 407 018 45(1550) -669 New York 412 008 39(2548) -554Delaware 473 039 12(0150) 855 North Carolina 420 012 35(1848) -374DC 323 044 51(1551) -2601c North Dakota 471 045 13(0150) 809Florida 412 007 40(2548) -564 Ohio 478 011 10(0123) 967Georgia 411 012 43(2049) -582 Oklahoma 492 020 04(0128) 1276Hawaii 352 027 50(2551) -1932c Oregon 465 019 15(0141) 668Idaho 510 033 01(0139) 1697c Pennsylvania 467 010 14(0427) 714Illinois 439 010 25(1341) 074 Rhode Island 455 035 18(0150) 434Indiana 492 016 05(0123) 1270 South Carolina 432 017 30(0947) -102Iowa 484 021 08(0135) 1087 South Dakota 411 039 42(0151) -580Kansas 486 023 06(0137) 1143 Tennessee 484 015 09(0126) 1087Kentucky 460 018 17(0241) 544 Texas 427 008 32(1944) -213Louisiana 451 018 21(0345) 333 Utah 433 026 28(0250) -081Maine 497 031 02(0141) 1396 Vermont 461 047 16(0151) 578Maryland 411 015 41(1749) -576 Virginia 432 013 29(1246) -092Massachusetts 423 014 33(1548) -303 Washington 452 015 20(0541) 360Michigan 495 012 03(0119) 1340 West Virginia 486 027 07(0143) 1141Minnesota 475 017 11(0132) 901 Wisconsin 443 015 23(0645) 156Mississippi 404 021 47(1351) -731 Wyoming 445 051 22(0151) 192Missouri 419 014 36(1549) -396

Table 1924Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Females

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 Areas (excluding the AlaskaNative Registry) and 112016 US population estimates based on the average of 2015 and 2016 population estimates from theUS Bureau of the CensusPrevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 24 years

b Maximum limited-duration prevalence is 24 years for 1992-2016 datac Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groupsd Cases diagnosed more than 24 years ago were estimated using the completeness index method (Capocaccia et al 1997

Merrill et al 2000)e Complete prevalence is obtained by summing 0 to lt24 and gt=24- Statistic not shown Statistic based on fewer than 5 cases estimated alive in SEER for the time interval+ Not available

Years Since Diagnosis 0 to lt5 5 to lt10 10 to lt15 15 to lt20 20 to lt24 0 to lt24b gt=24d Completee

Race Sex

All Races Both Sexes 248946 177490 117326 69109 31890 644761 49943 694704Males 135137 94173 60159 36020 16581 342069 25489 367558Females 113809 83317 57167 33089 15309 302692 24454 327146

White Both Sexes 213764 154454 101984 60537 28026 558765 49625 620368Males 116527 82172 52535 31627 14543 297404 26526 330121Females 97237 72282 49448 28910 13483 261361 23099 290247

Black Both Sexes 20500 13640 9750 5271 2215 51376 4115 55491Males 10712 7188 4768 2684 1174 26526 1911 28437Females 9789 6452 4981 2587 1041 24850 2204 27054

Asian Both Sexes 8405 5210 3415 1867 844 19741 + +Pacific Males 4548 2661 1757 1013 407 10386 + +Islander Females 3856 2549 1657 855 437 9355 + +

Hispanic Both Sexes 21339 14049 8272 4881 2136 50676 + +Males 10918 7243 4331 2617 1094 26202 + +Females 10421 6805 3941 2264 1043 24474 + +

Age Specific (Crude) Age-Adjustedc Age at Prevalence All Ages 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ All Ages

Race Sex

All Races Both Sexes 02001 00035 00139 00283 00538 01121 02352 04640 08181 10224 01738Males 02156 00044 00189 00354 00625 01293 02710 05243 09364 12449 02023Females 01850 00026 00087 00208 00450 00952 02010 04094 07196 08856 01498

White Both Sexes 02216 00035 00143 00289 00534 01148 02427 04858 08597 10738 01807Males 02380 00045 00198 00359 00622 01317 02790 05442 09778 13060 02095Females 02054 00025 00085 00214 00442 00976 02072 04317 07593 09285 01560

Black Both Sexes 01139 00029 00113 00265 00599 01027 02010 03340 05117 05333 01251Males 01226 00029 00140 00351 00696 01223 02333 03969 05849 06055 01457Females 01059 00030 00086 00178 00510 00853 01728 02836 04608 04976 01088

Asian Both Sexes 00970 00039 00133 00207 00353 00680 01409 02692 04470 06094 01032Pacific Males 01065 00044 00175 00240 00398 00744 01640 03072 05516 07472 01222Islander Females 00882 00033 00092 00175 00312 00623 01209 02384 03629 05207 00880

Hispanic Both Sexes 00887 00030 00117 00206 00398 00850 01769 03632 05888 07209 01294Males 00908 00035 00147 00256 00455 00932 01924 03940 06326 08003 01420Females 00866 00024 00086 00151 00337 00766 01616 03360 05552 06719 01185

Table 1925Non-Hodgkin Lymphoma

Estimated United States Cancer Prevalence Countsa on January 1 2016By RaceEthnicity Sex and Years Since Diagnosis

Estimated prevalence percenta on January 1 2016 of the SEER population diagnosed in the previous 24 yearsBy Age at Prevalence RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 372 452924 -05 62 18862 04 247 189692 -05 1657 244370 -05

1 Hodgkin Lymphoma 28 32262 -17 13 3927 -06 33 22556 -15 39 5779 -31

2 Non-Hodgkin lymphoma 336 409991 -03 48 14693 04 210 163591 -03 1572 231707 -042(a) Non-Hodgkin lymphoma B-cell 311 380349 -01 39 11836 14 190 148768 -02 1491 219745 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 15 16631 20 31 9416 10 07 5203 39 14 2012 252(a) 2 Mature Non-Hodgkin lymphoma B-cell 280 343965 -04 07 2271 30 174 137225 -05 1387 204469 -042(a) 21 ChronicSmallProlymphocytic 69 85601 -13 00 35 - 35 29103 -11 382 56463 -14

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 61 75061 -15 00 30 - 31 25339 -13 336 49692 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 311 19 - - - 00 72 - 02 234 262(a) 213 Mantle-cell lymphoma 08 10229 03 - - - 04 3692 02 44 6537 04

2(a) 22 Lymphoplasmacytic lymphoma 07 8651 00 - - - 03 2590 -11 41 6059 04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 03 3667 -03 - - - 01 1132 -18 17 2533 022(a) 222 Waldenstrom macroglubulinemia 04 4984 03 - - - 02 1458 -07 24 3526 06

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 72 87188 00 03 925 26 48 36480 -02 339 49783 022(a) 231 DLBCL NOSc 71 85899 -01 03 861 12 46 35469 -05 337 49569 012(a) 232 Intravascular large B-cell 00 162 - - - - 00 63 - 01 99 -

lymphoma2(a) 233 Primary effusion lymphoma 00 181 27 - - - 00 126 - 00 55 -2(a) 234 Mediastinal large B-cell 01 946 116 00 64 - 01 822 111 00 60 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 04 4692 -26 03 1028 32 04 2618 -43 07 1046 -432(a) 25 Marginal-zone lymphoma (MZL) 22 26534 00 00 137 13 14 11049 05 104 15348 -042(a) 251 Splenic MZL 02 2418 04 - - - 01 889 -08 10 1529 102(a) 252 Extranodal MZL MALTc type 13 15979 06 00 92 - 09 7148 11 59 8739 032(a) 253 Nodal MZL 07 8137 -15 00 45 - 04 3012 -05 34 5080 -20

2(a) 26 Follicular lymphoma 35 43582 -21 00 119 - 28 21725 -25 147 21738 -182(a) 27 Hairy-cell leukemia 03 3712 -16 - - - 03 2311 -19 09 1401 -122(a) 28 Plasma cell neoplasms 68 83957 08 00 24 - 39 31325 12 358 52608 062(a) 281 Plasmacytoma 04 4879 -04 00 16 - 03 2362 -06 17 2501 -032(a) 282 Multiple myeloma 64 79078 09 - - - 36 28963 14 341 50107 07

plasma-cell leukemia2(a) 29 Heavy chain disease 00 48 - - - - 00 24 - 00 23 -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 16 19753 33 00 149 27 08 6340 37 90 13264 32

Table 1926All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 23 27222 01 08 2502 18 19 13933 03 73 10787 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 616 - 01 293 - 00 272 - 00 51 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 22 26531 11 07 2207 75 19 13621 12 73 10703 -042(b) 21 Mycosis fungoidesSezary syndrome 06 6969 18 01 213 84 06 4080 23 18 2676 052(b) 211 Mycosis fungoides 06 6739 17 01 213 84 05 3990 22 17 2536 042(b) 212 Sezary syndrome 00 230 46 - - - 00 90 - 01 140 -

2(b) 22 Peripheral T-cell lymphoma 12 14531 -10 02 534 07 10 7159 -09 46 6838 -122(b) 221 Peripheral T-cell lymphoma NOSc 04 5393 -01 00 86 - 03 2489 04 19 2818 -042(b) 222 Angioimmunoblastic T-cell lymphoma 02 1902 02 - - - 01 699 -09 08 1201 072(b) 223 Subcutaneous panniculitis- 00 176 44 00 31 - 00 111 - 00 34 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 2523 -36 01 291 00 02 1450 -33 05 782 -54

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 139 - - - - 00 98 - 00 28 -2(b) 226 Enteropathy-type T-cell lymphoma 00 186 -02 - - - 00 84 - 01 101 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 2963 -07 00 59 - 02 1575 01 09 1329 -142(b) 228 Primary cutaneous anaplastic 01 1249 -41 00 51 - 01 653 -49 04 545 -39

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 03 3417 96 05 1428 101 02 1474 99 03 515 672(b) 24 NKcT-cell lymphoma nasal-type 01 985 02 00 26 - 01 659 00 02 300 05

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 120 - - - - 00 54 - 00 65 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 509 30 - - - 00 195 -05 02 309 442(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 75 - - - - 00 40 - 00 33 -2(c) Non-Hodgkin lymphoma unknown lineage 02 2420 -274 01 355 - 01 890 -216 08 1175 -2792(c) 1 Precursor lymphoblastic leukemia 01 814 -283 01 343 - 00 238 - 02 233 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 95 - - - - 00 25 - 00 69 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 1511 -274 - - - 01 627 -202 06 873 -319

lineage2() 1 Total precursor lymphomaleukemiad 16 18061 -07 33 10052 -15 08 5713 06 15 2296 -01

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 762 273 00 20 - 00 339 227 03 403 -lymphoma

4 Lymphoid neoplasm NOSc 08 9909 -55 01 222 113 04 3206 -59 43 6481 -59

Table 1926 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 461 253152 -05 70 10973 05 294 110367 -07 2122 131812 -05

1 Hodgkin Lymphoma 31 17710 -17 13 2118 -03 36 12525 -16 48 3067 -31

2 Non-Hodgkin lymphoma 419 229772 -03 56 8711 05 252 95756 -05 2017 125305 -032(a) Non-Hodgkin lymphoma B-cell 387 212247 -02 44 6786 15 227 86941 -04 1908 118520 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 16 8999 24 33 5123 11 08 2888 46 16 988 292(a) 2 Mature Non-Hodgkin lymphoma B-cell 351 192801 -05 10 1558 28 210 80417 -08 1783 110826 -042(a) 21 ChronicSmallProlymphocytic 96 52411 -15 00 21 - 47 18927 -14 539 33463 -15

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 82 44988 -17 00 19 - 40 16143 -16 464 28826 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 193 -02 - - - 00 46 - 02 145 052(a) 213 Mantle-cell lymphoma 13 7230 -01 - - - 07 2738 -01 72 4492 -01

2(a) 22 Lymphoplasmacytic lymphoma 10 5082 -05 - - - 04 1524 -08 58 3558 -04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 04 2062 -08 - - - 02 616 -12 23 1446 -072(a) 222 Waldenstrom macroglubulinemia 06 3020 -02 - - - 02 908 -06 34 2112 -02

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 88 48128 01 03 554 22 59 21824 -06 418 25750 052(a) 231 DLBCL NOSc 87 47520 00 03 519 03 57 21366 -08 416 25635 042(a) 232 Intravascular large B-cell 00 75 - - - - 00 31 - 01 44 -

lymphoma2(a) 233 Primary effusion lymphoma 00 167 26 - - - 00 123 - 01 44 -2(a) 234 Mediastinal large B-cell 01 366 155 00 35 - 01 304 142 00 27 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 06 3388 -22 05 775 31 06 1969 -46 10 644 -192(a) 25 Marginal-zone lymphoma (MZL) 22 12351 -02 01 98 - 14 5177 -02 114 7076 -012(a) 251 Splenic MZL 02 1164 14 - - - 01 434 18 12 730 112(a) 252 Extranodal MZL MALTc type 13 7268 07 00 62 - 09 3267 04 63 3939 102(a) 253 Nodal MZL 07 3919 -23 00 36 - 04 1476 -22 39 2407 -23

2(a) 26 Follicular lymphoma 39 21788 -19 01 100 - 30 11210 -25 165 10478 -152(a) 27 Hairy-cell leukemia 05 2984 -18 - - - 05 1908 -20 17 1076 -152(a) 28 Plasma cell neoplasms 85 46642 07 - - - 45 17864 11 462 28769 052(a) 281 Plasmacytoma 05 2997 -08 - - - 04 1509 -16 24 1484 -012(a) 282 Multiple myeloma 80 43645 08 - - - 41 16355 13 439 27285 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 27 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 20 10447 34 01 105 - 10 3636 40 110 6706 32

Table 1927All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 29 16118 00 11 1730 14 23 8235 02 98 6153 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 430 - 01 208 - 01 188 - 01 34 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 28 15642 11 10 1521 71 22 8022 11 97 6099 -032(b) 21 Mycosis fungoidesSezary syndrome 07 3962 19 01 135 - 06 2261 21 25 1566 092(b) 211 Mycosis fungoides 07 3831 20 01 135 - 06 2213 21 23 1483 092(b) 212 Sezary syndrome 00 131 - - - - 00 48 - 01 83 -

2(b) 22 Peripheral T-cell lymphoma 15 8438 -13 02 318 -09 12 4248 -12 62 3872 -132(b) 221 Peripheral T-cell lymphoma NOSc 06 3159 -05 00 49 - 04 1520 02 26 1590 -082(b) 222 Angioimmunoblastic T-cell lymphoma 02 1024 19 - - - 01 415 11 10 607 232(b) 223 Subcutaneous panniculitis- 00 68 - - - - 00 39 - 00 16 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 03 1549 -39 01 184 -01 02 888 -43 08 477 -45

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 98 - - - - 00 69 - 00 18 -2(b) 226 Enteropathy-type T-cell lymphoma 00 105 - - - - 00 50 - 01 54 -2(b) 227 Cutaneous T-cell lymphoma NOSc 03 1696 -12 00 32 - 02 894 -03 12 770 -172(b) 228 Primary cutaneous anaplastic 01 739 -48 00 26 - 01 373 -49 05 340 -49

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 04 2253 97 07 1047 92 03 940 98 04 266 1022(b) 24 NKcT-cell lymphoma nasal-type 01 638 -05 00 18 - 01 435 -03 03 185 -06

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 58 - - - - 00 22 - 01 36 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 01 293 45 - - - 00 116 - 03 174 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 46 - - - - 00 25 - 00 20 -2(c) Non-Hodgkin lymphoma unknown lineage 03 1407 -232 01 195 - 02 580 -184 10 632 -2302(c) 1 Precursor lymphoblastic leukemia 01 474 -228 01 187 - 00 134 - 02 153 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 49 - - - - - - - 01 36 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 02 884 -239 - - - 01 433 -175 07 443 -

lineage2() 1 Total precursor lymphomaleukemiad 18 9903 -06 35 5518 -17 09 3210 09 19 1175 05

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 435 271 - - - 01 215 - 03 207 -lymphoma

4 Lymphoid neoplasm NOSc 10 5235 -59 01 131 - 05 1871 -65 54 3233 -61

Table 1927 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 301 199772 -05 53 7889 02 202 79325 -02 1322 112558 -08

1 Hodgkin Lymphoma 24 14552 -16 12 1809 -10 29 10031 -14 32 2712 -32

2 Non-Hodgkin lymphoma 269 180219 -03 40 5982 03 170 67835 00 1251 106402 -062(a) Non-Hodgkin lymphoma B-cell 250 168102 -01 34 5050 13 154 61827 02 1190 101225 -042(a) 1 Precursor Non-Hodgkin lymphoma B-cell 14 7632 16 29 4293 09 06 2315 29 12 1024 202(a) 2 Mature Non-Hodgkin lymphoma B-cell 223 151164 -04 05 713 35 141 56808 -01 1102 93643 -072(a) 21 ChronicSmallProlymphocytic 48 33190 -13 - - - 24 10176 -05 268 23000 -16

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 43 30073 -15 - - - 22 9196 -06 243 20866 -19

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 118 - - - - 00 26 - 01 89 -2(a) 213 Mantle-cell lymphoma 04 2999 11 - - - 02 954 10 24 2045 12

2(a) 22 Lymphoplasmacytic lymphoma 05 3569 04 - - - 03 1066 -16 30 2501 11Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 02 1605 01 - - - 01 516 -25 13 1087 112(a) 222 Waldenstrom macroglubulinemia 03 1964 06 - - - 01 550 -08 17 1414 11

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 58 39060 00 02 371 33 38 14656 03 283 24033 -032(a) 231 DLBCL NOSc 57 38379 -02 02 342 27 36 14103 -01 282 23934 -032(a) 232 Intravascular large B-cell 00 87 - - - - 00 32 - 01 55 -

lymphoma2(a) 233 Primary effusion lymphoma - - - - - - - - - - - -2(a) 234 Mediastinal large B-cell 01 580 91 00 29 - 02 518 93 00 33 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 02 1304 -34 02 253 38 02 649 -37 05 402 -852(a) 25 Marginal-zone lymphoma (MZL) 21 14183 01 00 39 - 15 5872 12 98 8272 -062(a) 251 Splenic MZL 02 1254 -07 - - - 01 455 -32 10 799 072(a) 252 Extranodal MZL MALTc type 13 8711 06 00 30 - 10 3881 17 57 4800 -032(a) 253 Nodal MZL 06 4218 -07 - - - 04 1536 11 32 2673 -18

2(a) 26 Follicular lymphoma 33 21794 -24 00 19 - 27 10515 -25 134 11260 -222(a) 27 Hairy-cell leukemia 01 728 -12 - - - 01 403 -11 04 325 -122(a) 28 Plasma cell neoplasms 55 37315 08 - - - 33 13461 15 282 23839 052(a) 281 Plasmacytoma 03 1882 00 - - - 02 853 12 12 1017 -092(a) 282 Multiple myeloma 52 35433 09 - - - 30 12608 15 270 22822 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 21 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 14 9306 32 00 44 - 07 2704 32 76 6558 31

Table 1928All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 17 11104 01 05 772 29 15 5698 05 55 4634 -112(b) 1 Precursor Non-Hodgkin lymphoma T-cell 00 186 - 01 85 - 00 84 - 00 17 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 17 10889 09 05 686 83 15 5599 12 54 4604 -092(b) 21 Mycosis fungoidesSezary syndrome 05 3007 15 01 78 - 05 1819 26 13 1110 -042(b) 211 Mycosis fungoides 05 2908 12 01 78 - 05 1777 23 12 1053 -072(b) 212 Sezary syndrome 00 99 - - - - 00 42 - 01 57 -

2(b) 22 Peripheral T-cell lymphoma 09 6093 -08 01 216 30 08 2911 -06 35 2966 -142(b) 221 Peripheral T-cell lymphoma NOSc 03 2234 03 00 37 - 03 969 07 14 1228 -012(b) 222 Angioimmunoblastic T-cell lymphoma 01 878 -22 - - - 01 284 -39 07 594 -152(b) 223 Subcutaneous panniculitis- 00 108 - 00 18 - 00 72 - 00 18 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 974 -33 01 107 - 02 562 -19 04 305 -77

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 41 - - - - 00 29 - - - -2(b) 226 Enteropathy-type T-cell lymphoma 00 81 - - - - 00 34 - 01 47 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 1267 00 00 27 - 02 681 07 07 559 -102(b) 228 Primary cutaneous anaplastic 01 510 -34 00 25 - 01 280 -50 02 205 -33

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 02 1164 96 03 381 127 01 534 97 03 249 302(b) 24 NKcT-cell lymphoma nasal-type 01 347 11 - - - 01 224 - 01 115 -

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 62 - - - - 00 32 - 00 29 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 216 03 - - - 00 79 - 02 135 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 29 - - - - - - - - - -2(c) Non-Hodgkin lymphoma unknown lineage 02 1013 -341 01 160 - 01 310 - 06 543 -2(c) 1 Precursor lymphoblastic leukemia 01 340 - 01 156 - 00 104 - 01 80 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 46 - - - - - - - 00 33 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 627 - - - - 01 194 - 05 430 -

lineage2() 1 Total precursor lymphomaleukemiad 14 8158 -09 31 4534 -13 07 2503 02 13 1121 -11

3 Composite Hodgkin lymphoma and Non-Hodgkin 00 327 - - - - 00 124 - 02 196 -lymphoma

4 Lymphoid neoplasm NOSc 07 4674 -52 01 91 - 03 1335 -51 36 3248 -58

Table 1928 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 5: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Individual rates for diagnosis years 1975-1979 available in web browser version of Cancer Statistics Reviewa SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)

Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

Year of Diagnosis1975-2016 1846 2267 1513 1925 2357 1581 1414 1769 11351975-1979 1160 1344 1018 1209 1393 1068 696 874 5521980 1262 1501 1081 1298 1528 1122 870 1074 7201981 1358 1590 1181 1406 1634 1235 742 1059 4981982 1339 1556 1161 1402 1642 1205 1027 1022 10011983 1399 1662 1195 1463 1752 1240 1028 1088 9621984 1519 1829 1279 1597 1910 1355 946 1252 6921985 1551 1839 1316 1628 1925 1385 995 1196 8431986 1590 1943 1300 1683 2059 1375 1066 1313 8521987 1674 2078 1342 1770 2215 1400 1035 1043 9951988 1726 2136 1408 1822 2245 1490 1158 1579 8491989 1736 2165 1384 1836 2304 1450 1159 1410 9721990 1851 2297 1481 1934 2396 1549 1392 1763 11021991 1881 2374 1461 1970 2481 1532 1403 1881 10291992 1862 2304 1494 1956 2394 1584 1368 1887 9651993 1885 2347 1500 1965 2432 1570 1423 1937 9971994 1995 2496 1579 2067 2558 1654 1448 2152 8861995 1999 2542 1545 2070 2618 1604 1676 2363 11431996 1942 2424 1548 2027 2520 1621 1554 1925 12391997 2000 2453 1646 2090 2522 1749 1640 2426 10861998 1962 2296 1686 2061 2401 1778 1449 1696 12541999 1997 2459 1636 2095 2554 1732 1441 1842 11372000 1981 2434 1613 2099 2571 1712 1393 1823 10742001 2002 2440 1646 2082 2547 1706 1605 1844 13922002 2023 2420 1710 2134 2552 1798 1448 1710 12512003 2078 2506 1753 2191 2633 1848 1637 2006 13782004 2140 2589 1795 2235 2685 1885 1860 2418 14552005 2088 2563 1709 2202 2674 1820 1673 1995 14102006 2052 2475 1724 2178 2608 1839 1639 2102 12942007 2126 2612 1739 2255 2755 1845 1583 1935 13172008 2093 2575 1700 2180 2681 1765 1689 1894 15032009 2089 2520 1741 2195 2659 1806 1531 1856 12912010 2141 2662 1715 2237 2742 1820 1767 2323 13232011 1982 2433 1626 2076 2544 1702 1455 1749 12372012 2031 2489 1659 2125 2591 1739 1658 1897 14442013 1973 2414 1613 2076 2529 1699 1558 1807 13682014 2020 2497 1629 2138 2612 1749 1512 1998 11282015 2003 2478 1615 2118 2600 1718 1510 1947 11742016 1936 2344 1600 2018 2428 1676 1625 1909 1382

Table 195Non-Hodgkin Lymphoma

Age-adjusted SEER Incidencea Rates by Year Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Individual rates for years of death 1975-1979 available in web browser version of Cancer Statistics Reviewa US Mortality Files National Center for Health Statistics Centers for Disease Control and Prevention

Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

Year of Death1975-2016 701 880 570 732 915 596 478 613 3801975-1979 580 708 484 602 733 503 375 483 2921980 623 747 529 647 774 552 399 515 3121981 616 738 527 640 766 547 398 500 3251982 655 798 549 683 829 574 412 523 3291983 666 811 558 692 839 585 430 579 3231984 676 815 575 705 850 601 419 528 3391985 706 880 580 734 917 602 462 557 3871986 731 898 605 759 925 633 495 664 3701987 726 881 610 756 912 638 473 630 3621988 752 928 624 782 959 653 501 682 3721989 783 973 643 812 1004 671 533 710 4071990 787 997 634 816 1032 658 539 713 4171991 819 1015 674 850 1052 700 570 717 4611992 822 1030 669 853 1066 696 564 723 4451993 825 1014 686 857 1045 717 569 753 4401994 863 1075 710 900 1120 741 554 682 4561995 872 1081 716 909 1121 749 579 762 4451996 875 1094 714 909 1129 746 621 825 4741997 888 1103 725 921 1135 757 634 845 4871998 869 1085 710 903 1127 738 599 750 4891999 832 1036 685 867 1071 718 565 744 4412000 817 1020 670 854 1063 701 520 661 4172001 791 998 642 821 1031 668 561 728 4472002 765 966 619 797 1004 644 541 688 4412003 738 940 592 769 981 613 494 583 4272004 709 894 573 738 928 596 501 623 4132005 695 887 556 724 922 579 477 611 3812006 674 848 544 701 878 566 492 627 3932007 659 836 526 686 867 549 452 577 3622008 641 820 509 671 856 533 431 548 3452009 630 812 493 656 842 513 449 615 3412010 614 783 485 637 811 504 457 584 3642011 603 785 464 629 817 483 436 574 3402012 591 762 461 617 795 480 426 538 3482013 571 738 444 595 767 462 411 527 3332014 565 726 443 589 755 460 418 528 3422015 547 713 418 569 741 434 404 519 3212016 537 691 417 562 721 436 383 481 311

Table 196Non-Hodgkin Lymphoma

Age-adjusted US Deatha Rates by Year Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a SEER 21 areas Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)unless noted

b US Mortality Files National Center for Health Statistics Centers for Disease Control and PreventionRates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) unless noted

c Rates are per 100000 and are age-adjusted to the world (WHO 2000-2025) standard million- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER IncidenceAge at DiagnosisAge-Adjusted Rates 2012-2016All ages 196 239 162 206 250 170 147 177 124Under 65 94 111 78 96 113 80 91 109 7665 and over 904 1126 743 966 1199 794 532 646 461

All ages (WHO world std)c 147 177 122 154 184 127 117 140 98

Age-Specific Rates 2012-2016lt1 - - - - - - - - -1-4 08 11 05 08 11 06 06 07 -5-9 12 17 07 13 18 07 10 13 0810-14 15 20 10 14 19 10 16 21 1115-19 21 27 14 20 26 14 20 28 1220-24 27 32 22 26 31 21 28 35 2025-29 35 40 29 34 39 28 41 48 3430-34 49 56 42 48 54 41 56 67 4735-39 72 85 59 71 83 58 81 98 6640-44 99 117 80 99 117 80 108 128 9045-49 145 168 122 147 169 125 156 190 12750-54 222 256 189 229 264 194 217 250 18755-59 312 366 261 326 379 274 277 332 23060-64 445 522 376 470 548 396 363 426 31165-69 629 742 528 667 781 564 447 522 39070-74 833 997 697 890 1058 746 522 640 43975-79 1044 1287 855 1124 1384 918 588 692 52080-84 1193 1522 966 1280 1631 1031 650 791 57385+ 1079 1499 861 1146 1589 915 508 685 434

US MortalityAge at DeathAge-Adjusted Rates 2012-2016All ages 56 73 44 59 76 45 41 52 33Under 65 13 17 10 13 17 09 16 21 1265 and over 352 453 279 372 477 295 210 265 176

All ages (WHO world std)c 30 39 23 31 40 23 25 32 20

Age-Specific Rates 2012-2016lt1 - - - - - - - - -1-4 00 01 - 00 01 - - - -5-9 01 01 00 00 01 - 01 - -10-14 01 01 01 01 01 01 - - -15-19 01 02 01 01 02 01 02 02 -20-24 02 03 02 02 03 02 04 04 0325-29 04 05 03 03 04 02 05 07 0430-34 05 07 04 05 06 03 09 12 0635-39 07 09 05 06 08 04 11 14 0940-44 11 14 08 10 13 08 18 21 1545-49 18 23 13 17 22 13 24 32 1750-54 31 41 21 31 41 21 37 49 2655-59 53 71 37 54 72 36 58 74 4460-64 90 118 64 92 121 64 90 116 6965-69 142 184 105 149 192 109 116 146 9370-74 244 309 188 256 324 197 167 214 13375-79 374 473 294 397 501 312 220 275 18480-84 567 725 455 600 764 481 321 405 27485+ 751 994 624 795 1049 662 360 457 320

Table 197Non-Hodgkin Lymphoma

SEER Incidencea and US Deathb Rates Age-Adjusted and Age-Specific Rates by Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on End Results data from a series of hospital registries and one population-based registryb SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)

Based on follow-up of patients into 2016 Expected survival rates are derived from the US Annual Life Tablesc SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER programBased on follow-up of patients into 2016

d Period survival provides a 2015 estimate of survival by piecing together the most recent conditional survival estimatesfrom several cohorts It is computed here using three year calendar blocks (2010-2012 0-1 year survival)(2009-2011 1-2 year survival) (2008-2010 2-3 year survival) (2007-2009 3-4 year survival) (2006-2008 4-5 years survival)

e Stage at diagnosis is classified using SEER Summary Stage 2000 Stage distribution percentages may not sum to 100 due to roundingf The difference between 1975-1977 and 2009-2015 is statistically significant (plt05)g The standard error is between 5 and 10 percentage pointsh The standard error is greater than 10 percentage points- Statistic could not be calculated due to fewer than 25 cases during the time period

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

5-Year Relative Survival (Percent)Year of Diagnosis1960-1963a - - - 31 31 31 - - -1970-1973a - - - 41 39 43 - - -1975-1977b 465 456 475 468 463 473 486 426 553g

1978-1980b 479 461 498 479 462 495 511 469 5671981-1983b 506 503 509 508 505 511 495 492 4981984-1986b 516 501 534 521 507 537 468 445 4991987-1989b 509 476 549 513 482 552 457 413 5101990-1992b 507 467 557 515 476 564 422 384 4761993-1995b 526 487 575 533 498 577 425 359 5491996-1998b 588 570 610 595 577 615 547 531 5721999-2001b 640 614 670 650 628 676 558 490 6382002-2004b 698 686 712 710 701 721 636 611 6662005-2008b 716 706 727 728 719 738 625 578 6752009-2015b 747f 739f 757f 757f 748f 767f 695f 670f 724f

5-Year Period Survival (Percent)cd

2015 722 705 743 726 708 747 671 641 703

Stage Distribution () 2009-2015ce

All StagesNumber of cases 97737 53606 44131 80120 44109 36011 8184 4388 3796Percent 100 100 100 100 100 100 100 100 100Localized 27 27 29 27 26 28 28 25 31Regional 15 15 15 15 15 15 15 15 15Distant 50 51 48 51 52 49 51 54 48UnstagedUnknown 8 7 8 7 7 8 6 6 7

5-Year Relative Survival (Percent) 2009-2015c

Age at DiagnosisAges lt45 840 820 870 855 836 885 735 708 776Ages 45-54 810 777 859 826 795 872 687 639 750Ages 55-64 770 742 809 781 754 818 678 620 749Ages 65-74 725 706 747 731 711 755 656 623 682Ages 75+ 554 539 568 557 538 574 482 449 500Ages lt65 800 773 838 812 787 849 701 659 759Ages 65+ 638 627 649 641 628 655 584 562 598

StageeAll Stages 720 707 737 724 711 740 665 637 698Localized 840 830 850 843 833 852 810 766 850Regional 750 751 749 755 756 755 689 698 678Distant 648 633 668 657 642 677 580 557 610UnstagedUnknown 703 686 723 679 662 698 659 648 666

Table 198Non-Hodgkin Lymphoma

5-Year Relative and Period Survival (Percent) by Race Sex Diagnosis Year and Age

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Expected survival rates are derived from the US Annual Life Tables

1975- 1980- 1985- 1990-1979 1984 1989 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Survival Time

1-year 702 730 713 704 703 733 756 767 774 773 787 810 803 811 817 810 816 841 839 844 834 842 844 834 8452-year 602 637 628 622 618 659 685 700 710 714 733 760 757 760 773 769 775 790 795 796 797 800 800 7953-year 546 585 582 577 575 621 649 664 669 679 701 731 731 735 748 745 750 762 773 774 775 779 7794-year 505 546 543 544 547 587 621 636 645 655 681 712 716 715 730 726 732 744 756 752 756 7675-year 468 507 510 516 520 561 594 609 621 638 660 693 700 701 716 705 712 728 741 742 7426-year 436 475 483 492 499 541 571 583 595 621 647 680 683 688 704 688 701 718 721 7237-year 408 450 458 470 479 522 552 564 577 605 629 663 671 672 685 672 688 702 7108-year 385 428 434 450 464 504 529 552 563 589 613 651 658 666 670 661 674 6909-year 366 408 415 435 453 493 515 535 548 576 600 640 648 649 652 651 66110-year 350 389 398 421 443 481 501 522 537 563 589 632 633 638 634 63711-year 335 374 385 406 434 466 488 511 525 548 581 618 621 630 63112-year 324 360 369 395 423 457 481 501 512 535 568 600 615 61713-year 314 348 358 383 415 449 469 492 500 520 561 593 60214-year 302 335 347 372 406 443 456 485 488 513 549 58315-year 289 322 335 365 398 437 447 474 478 505 54016-year 279 312 328 356 393 437 433 472 470 49217-year 274 304 321 349 388 428 428 469 45818-year 268 296 314 341 378 420 419 46319-year 260 288 306 333 370 413 41220-year 252 280 301 329 359 408

Table 199Non-Hodgkin Lymphoma

SEERa Relative Survival (Percent)By Year of Diagnosis

All Races Males and Females

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Expected survival rates are derived from the US Annual Life Tables

1975- 1980- 1985- 1990-1979 1984 1989 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Survival Time

1-year 694 727 689 671 666 712 747 749 758 765 776 806 797 801 811 810 814 836 828 838 838 841 834 830 8352-year 594 637 605 582 583 636 672 682 691 703 713 752 749 755 762 765 778 779 781 788 798 793 786 7913-year 534 580 557 537 545 598 638 645 644 668 679 720 726 726 731 736 754 751 757 766 776 769 7644-year 493 539 516 504 515 561 610 620 615 639 657 700 709 701 711 713 734 734 737 743 756 7575-year 455 501 482 476 485 537 583 592 590 617 635 679 689 688 699 689 710 721 724 735 7426-year 426 466 455 456 469 510 561 565 562 602 620 667 669 676 684 670 696 715 706 7177-year 399 442 431 436 449 491 542 544 546 587 601 652 658 655 668 651 682 696 6968-year 378 420 410 418 433 474 520 533 536 567 582 637 645 649 650 634 665 6869-year 357 401 391 402 423 465 504 514 523 553 572 628 633 632 636 618 65210-year 340 380 377 392 416 455 489 503 515 542 560 617 617 620 613 60911-year 328 363 364 381 407 437 477 494 508 527 547 603 605 612 61212-year 319 352 351 372 395 427 472 482 498 515 537 589 601 59613-year 307 342 343 361 389 419 456 467 491 501 531 582 59114-year 295 330 332 350 378 414 444 461 480 496 521 57215-year 281 319 324 344 368 409 435 453 473 488 51216-year 272 308 316 333 361 409 426 453 471 47417-year 265 300 308 326 358 403 420 449 46218-year 261 294 302 320 350 396 410 44219-year 256 287 294 313 342 391 40320-year 250 280 291 309 332 387

Table 1910Non-Hodgkin Lymphoma

SEERa Relative Survival (Percent)By Year of Diagnosis

All Races Males

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Expected survival rates are derived from the US Annual Life Tables

1975- 1980- 1985- 1990-1979 1984 1989 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Survival Time

1-year 710 734 741 747 752 759 767 786 792 782 801 814 810 821 825 809 819 847 854 851 830 843 856 838 8572-year 611 637 656 672 664 688 701 720 734 727 758 769 765 767 786 774 772 804 812 807 796 810 817 7993-year 559 589 611 627 616 649 662 684 700 692 727 744 736 746 768 756 746 774 791 786 774 791 7974-year 519 553 576 595 590 619 634 653 681 674 710 725 724 730 751 739 729 757 778 764 755 7805-year 482 514 544 567 565 591 608 629 658 664 688 708 713 716 736 724 715 735 763 751 7426-year 446 484 517 539 540 580 583 603 635 643 679 695 699 701 727 708 707 722 738 7317-year 417 458 490 512 520 560 563 586 615 626 663 674 687 692 704 698 694 709 7268-year 392 437 463 491 505 542 539 573 596 615 649 667 672 684 693 692 684 6949-year 374 416 443 476 492 529 528 557 578 603 633 654 664 669 671 688 67110-year 360 399 424 458 480 514 516 542 562 588 625 648 651 658 659 66911-year 342 385 409 438 469 503 500 529 547 573 621 636 640 651 65312-year 329 368 390 425 460 494 493 523 529 560 606 613 632 64013-year 321 353 376 411 449 486 485 518 510 543 598 606 61514-year 310 340 365 400 442 479 470 512 497 532 582 59615-year 297 326 349 391 436 472 460 498 483 525 57416-year 287 316 342 385 435 467 441 492 468 51317-year 282 306 336 378 428 459 438 490 45218-year 274 298 327 367 413 449 428 48519-year 265 288 321 358 407 439 42220-year 254 280 312 353 395 433

Table 1911Non-Hodgkin Lymphoma

SEERa Relative Survival (Percent)By Year of Diagnosis

All Races Females

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 5222 2506 2704 3176 3627 3994 4570 4729 5325 5260 5263 5562 5775 6226 6401 6704 6998 7072 11154

SEER 9 except 4285 2088 2267 2603 2819 3091 3507 3694 4159 4249 4364 4515 4818 5209 5398 5628 5841 6015 9363SF-Oakland

San Francisco- 937 418 437 573 808 903 1063 1035 1166 1011 899 1047 957 1017 1003 1076 1157 1057 1791Oakland SMSAc

San Francisco 245 96 123 210 326 393 467 410 450 354 213 256 220 283 219 216 240 225 362CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 134 155 161 183 201 215 234 233 252 244 238 244 246 258 254 255 255 245 244

SEER 9 except 132 154 161 181 188 201 217 218 236 236 235 236 244 256 254 253 252 247 243SF-Oakland

San Francisco- 147 158 160 194 267 285 317 305 335 288 252 286 256 266 256 263 268 235 246Oakland SMSAc

San Francisco 143 144 176 293 444 519 610 523 574 448 274 325 269 354 265 257 273 252 246CityCounty

Table 1912

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males All Ages

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males All Ages

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 0-19 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 223 87 108 91 94 84 100 89 120 105 104 119 127 107 106 143 134 155 240

SEER 9 except 191 78 95 82 80 76 86 74 107 84 93 100 115 90 87 114 119 129 198SF-Oakland

San Francisco- 32 9 13 9 14 8 14 15 13 21 11 19 12 17 19 29 15 26 42Oakland SMSAc

San Francisco 9 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 5 lt4 6 lt4CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 12 12 16 14 14 13 15 13 17 14 14 15 16 14 13 18 17 20 20

SEER 9 except 12 13 16 14 14 13 15 12 17 13 14 15 17 13 13 16 17 19 19SF-Oakland

San Francisco- 14 10 15 10 16 09 15 16 13 21 11 18 12 17 19 28 14 25 27Oakland SMSAc

San Francisco 23 - - - - - - - - - - - - - - 40 - 49 -CityCounty

Table 1913

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 0-19

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 0-19

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 20-54 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 1463 687 723 958 1211 1413 1766 1830 2089 1770 1608 1696 1623 1722 1655 1693 1674 1596 2242

SEER 9 except 1208 563 588 730 827 923 1195 1294 1483 1325 1269 1327 1308 1410 1383 1401 1402 1328 1848SF-Oakland

San Francisco- 255 124 135 228 384 490 571 536 606 445 339 369 315 312 272 292 272 268 394Oakland SMSAc

San Francisco 58 29 34 105 215 288 333 303 317 225 105 115 111 111 86 75 73 71 98CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 69 79 82 104 124 136 159 156 169 138 121 124 117 123 116 118 116 111 104

SEER 9 except 69 78 81 97 103 109 131 134 144 123 115 116 112 119 115 116 115 110 103SF-Oakland

San Francisco- 69 84 89 139 226 264 295 267 298 213 156 164 139 141 123 130 118 114 110Oakland SMSAc

San Francisco 67 88 94 272 565 715 813 724 744 510 230 252 239 248 194 162 152 145 129CityCounty

Table 1914

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 20-54

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 20-54

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 55+ and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 3536 1732 1873 2127 2322 2497 2704 2810 3116 3385 3551 3747 4025 4397 4640 4868 5190 5321 8672

SEER 9 except 2886 1447 1584 1791 1912 2092 2226 2326 2569 2840 3002 3088 3395 3709 3928 4113 4320 4558 7317SF-Oakland

San Francisco- 650 285 289 336 410 405 478 484 547 545 549 659 630 688 712 755 870 763 1355Oakland SMSAc

San Francisco 178 65 88 104 109 105 132 106 130 126 106 141 108 169 131 136 164 148 261CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 451 522 540 596 633 673 701 706 761 800 811 831 858 900 901 891 899 862 871

SEER 9 except 440 521 544 601 620 667 687 692 744 797 813 813 858 901 904 891 888 874 874SF-Oakland

San Francisco- 508 528 520 571 702 703 773 783 854 821 800 932 855 894 888 890 959 800 860Oakland SMSAc

San Francisco 482 446 598 727 739 757 934 747 914 872 727 934 690 1047 764 769 889 776 826CityCounty

Table 1915

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 55+

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 55+

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 003 006 217 072 Asian 0 001 003 005 183 072

10 002 005 011 218 073 Pacific 10 002 004 009 184 073

20 003 009 021 217 073 Islander 20 003 007 015 182 073

30 006 018 042 216 073 30 005 013 029 180 073

40 012 037 082 213 074 40 008 024 057 176 073

50 025 072 139 206 074 50 017 049 101 170 073

60 049 120 177 191 075 60 034 087 139 158 072

70 080 144 - 160 072 70 056 112 - 133 068

80 085 - - 106 062 80 066 - - 091 056

White 0 001 003 006 227 075 American 0 001 002 003 116 049

10 002 005 011 228 076 Indian 10 002 002 005 117 050

20 003 009 021 227 076 Alaska 20 001 003 008 116 050

30 006 018 043 226 077 Nativea 30 003 007 022 117 051

40 012 038 085 223 077 40 004 019 041 117 052

50 026 075 147 217 078 50 016 038 078 118 053

60 052 127 187 201 078 60 024 067 105 109 055

70 085 153 - 169 076 70 048 091 - 096 055

80 090 - - 111 065 80 057 - - 064 043

Black 0 001 002 006 138 042 Hispanicb 0 001 002 005 222 073

10 002 005 011 140 043 10 001 004 009 223 074

20 003 010 022 139 043 20 003 008 019 222 074

30 006 019 041 137 043 30 005 016 040 221 074

40 013 035 068 133 043 40 011 035 078 218 074

50 023 057 093 125 043 50 024 068 133 211 074

60 037 076 102 110 042 60 046 114 173 195 074

70 047 078 - 087 038 70 075 140 - 164 070

80 044 - - 057 032 80 081 - - 112 057

Table 1916

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Both Sexes 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 004 007 243 081 Asian 0 001 003 006 213 085

10 002 006 013 244 082 Pacific 10 002 005 011 213 086

20 004 010 024 243 082 Islander 20 003 009 018 211 086

30 007 021 049 243 083 30 006 015 034 210 086

40 014 042 094 240 084 40 009 028 067 205 086

50 029 082 158 233 085 50 019 059 117 199 086

60 057 139 203 219 086 60 041 101 161 187 085

70 095 170 - 188 084 70 066 131 - 159 082

80 105 - - 130 073 80 080 - - 114 069

White 0 001 004 007 254 085 American 0 001 003 004 104 057

10 002 006 013 255 086 Indian 10 002 003 006 105 058

20 004 010 024 254 086 Alaska 20 001 004 008 103 058

30 007 020 049 253 087 Nativea 30 003 008 021 104 059

40 014 043 097 251 088 40 005 018 038 105 060

50 030 086 167 244 089 50 014 035 071 105 062

60 059 147 215 230 090 60 023 062 094 099 065

70 101 180 - 198 088 70 046 084 - 090 066

80 112 - - 136 076 80 053 - - 061 053

Black 0 001 003 007 152 046 Hispanicb 0 001 003 005 238 083

10 002 006 014 154 047 10 002 005 011 239 084

20 004 012 027 153 047 20 003 009 021 238 084

30 008 023 048 152 047 30 006 018 043 238 084

40 016 042 079 148 047 40 012 037 083 235 085

50 027 066 105 138 047 50 026 073 145 228 085

60 043 087 114 123 045 60 050 126 189 214 085

70 054 088 - 099 042 70 086 157 - 185 081

80 053 - - 070 036 80 094 - - 131 066

Table 1917

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Males 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 002 004 193 064 Asian 0 001 002 004 159 063

10 001 004 009 195 064 Pacific 10 001 004 008 160 063

20 003 007 017 194 064 Islander 20 002 006 013 159 063

30 005 015 036 192 065 30 004 011 025 157 063

40 010 031 071 189 065 40 007 021 048 153 063

50 022 062 120 182 065 50 014 042 087 148 063

60 042 103 154 168 065 60 028 074 122 136 062

70 067 123 - 138 063 70 049 099 - 114 058

80 071 - - 090 054 80 057 - - 075 047

White 0 001 002 004 203 067 American 0 000 001 002 128 043

10 001 004 009 204 067 Indian 10 001 001 004 129 044

20 002 007 017 203 067 Alaska 20 001 003 007 128 044

30 005 015 037 201 067 Nativea 30 002 006 023 129 044

40 010 032 074 198 068 40 004 021 044 129 045

50 022 065 127 192 068 50 017 042 085 129 046

60 044 109 163 177 068 60 026 072 113 118 047

70 072 130 - 146 066 70 050 097 - 102 046

80 075 - - 094 056 80 060 - - 066 037

Black 0 000 002 004 126 040 Hispanicb 0 001 002 004 210 065

10 001 004 009 128 040 10 001 004 008 211 066

20 003 008 018 127 040 20 002 007 017 211 066

30 005 015 034 125 040 30 004 014 036 209 066

40 010 029 058 122 040 40 010 032 073 206 066

50 020 049 083 115 040 50 022 064 123 198 066

60 032 068 094 102 039 60 043 104 161 182 065

70 041 071 - 080 036 70 066 127 - 149 062

80 039 - - 051 030 80 073 - - 100 051

Table 1918

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Females 2014-2016 By RaceEthnicity

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

The AAPC is the Average Annual Percent Change over the time interval The AAPCs are calculated bythe Joinpoint Regression Program Version 47 February 2019 National Cancer Institute

- Statistic not shown Rate based on less than 16 cases for the time intervalTrend based on less than 10 cases for at least one year within the time interval

a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) Trendsare based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico SeattleUtah and AtlantaThe SEER 21 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the AlaskaNative Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts

c The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 3 Joinpoints overdiagnosis years 2000-2016

d The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 5 Joinpoints overdiagnosis years 1975-2016

e Hispanic and Non-Hispanic are not mutually exclusive from whites blacks AsianPacificIslanders and American IndiansAlaska Natives Incidence data for Hispanics and Non-Hispanicsare based on NHIA and exclude cases from the Alaska Native Registry

f Incidence data for American IndianAlaska Native are based on the PurchasedReferred CareDelivery Area (PRCDA) counties

g US Mortality Files National Center for Health Statistics CDCh The 2007-2016 mortality AAPCs are based on a Joinpoint analysis using years of death 2000-2016 The APC is significantly different from zero (plt05)

SEER Incidence SEER 21 Areasb SEER 21 Areasb SEER 9 Areasb

Rate 2012-2016 Trend 2007-2016c Trend 2007-2016d

Rate per 100000 persons AAPC () AAPC ()

Total Males Females Total Males Females Total Males Females RaceEthnicity

All Races 196 239 162 -07 -09 -08 -09 -07 -08

White 206 250 170 -08 -11 -09 -09 -08 -08White Hispanice 183 212 161 -08 -03 -05 - - -White Non-Hispanice 210 256 172 -08 -06 -10 - - -

Black 147 177 124 01 00 03 00 -04 -09

AsianPacific Islander 134 164 110 00 00 -01 - - -

Amer IndAlaska Natf 113 120 106 -05 -12 00 - - -

Hispanice 179 207 157 -05 -02 03 - - -

US Mortalityg Rate 2012-2016 Trend 2007-2016h

Rate per 100000 persons AAPC ()

Total Males Females Total Males FemalesRaceEthnicity

All Races 56 73 44 -23 -20 -27

White 59 76 45 -23 -20 -27White Hispanice 51 65 40 -16 -13 -20White Non-Hispanice 59 76 46 -23 -20 -27

Black 41 52 33 -20 -19 -21

AsianPacific Islander 39 49 31 -17 -15 -19

Amer IndAlaska NatTotal US 31 40 24 -32 -20 -45PRCDA Counties 44 58 33 -21 -04 -37Non-PRCDA Counties 17 21 14 -54 -50 -60

Hispanice 48 61 38 -17 -14 -21

Table 1919Non-Hodgkin Lymphoma

SEER Incidence and US MortalityAge-Adjusted Rates and Trendsa

By RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Incidence Ratesa 2012-2016

California 1844 2241 1515 1938 2349 1591 1390 1639 1182Greater Bay Area 1957 2381 1600 2144 2601 1755 1628 1828 1436San Francisco-Oakland 1956 2421 1570 2174 2660 1765 1603 1816 1408San Jose-Monterey 1962 2311 1660 2097 2503 1742 1800 1891 1646

Los Angeles 1804 2176 1505 1951 2331 1637 1357 1659 1139Greater California 1822 2220 1489 1876 2286 1529 1314 1534 1113

Connecticut 2116 2607 1733 2154 2642 1771 1386 1829 1051Detroit 2132 2636 1742 2290 2850 1847 1620 1905 1409Georgia 1826 2244 1487 1936 2346 1588 1462 1833 1187Atlanta 1925 2381 1555 2119 2567 1736 1601 2034 1272Rural Georgia 1584 1790 1401 1953 2298 1567 807 - 988Greater Georgia 1784 2186 1459 1872 2274 1537 1380 1703 1146

Hawaii 1660 2024 1349 1958 2275 1593 - - -Idaho 1922 2267 1616 1920 2262 1618 - - -Iowa 2134 2601 1756 2148 2612 1773 1352 1602 1100Kentucky 2039 2505 1666 2070 2538 1693 1403 1788 1112Louisiana 1944 2352 1614 2106 2537 1744 1469 1769 1237Massachusetts 1810 2181 1518 1830 2214 1524 1452 1655 1299New Jersey 2155 2607 1804 2285 2765 1905 1387 1621 1222New Mexico 1550 1739 1387 1580 1798 1394 875 - -New York 2152 2620 1788 2306 2792 1915 1545 1852 1333Seattle-Puget Sound 2116 2627 1695 2177 2667 1766 1631 1973 1316Utah 1843 2233 1498 1862 2258 1513 2089 - -

SEER 9 Areasb 1992 2444 1623 2095 2551 1716 1573 1914 1298SEER 13 Areasb 1946 2373 1597 2064 2502 1700 1519 1853 1258SEER 18 Areasb 1933 2354 1590 2031 2464 1671 1449 1751 1214SEER 21 Areasb 1963 2388 1620 2061 2498 1702 1471 1771 1245

Table 1920Non-Hodgkin Lymphoma

Age-Adjusted SEER Incidence Ratesa

By Registry Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control and PreventionRates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and AtlantaThe SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Death Ratesa 2012-2016

California 533 677 423 570 726 449 417 480 367Greater Bay Area 505 671 376 561 756 408 410 491 331San Francisco-Oakland 503 667 376 555 742 409 416 490 343San Jose-Monterey 511 681 377 573 781 407 - - -

Los Angeles 541 670 443 589 728 481 424 503 371Greater California 539 682 429 564 716 447 416 455 384

Connecticut 533 705 407 547 717 421 350 510 244Detroit 639 822 505 693 895 542 443 528 384Georgia 533 697 411 580 747 450 376 503 286Atlanta 492 659 372 533 728 388 397 506 317Rural Georgia 559 731 388 670 813 507 - - -Greater Georgia 549 712 426 595 755 470 363 500 266

Hawaii 475 620 352 545 649 412 - - -Idaho 635 775 510 641 782 516 - - -Iowa 638 845 484 642 848 488 - - -Kentucky 642 886 460 655 904 470 401 557 284Louisiana 608 814 451 651 863 485 461 623 340Massachusetts 523 659 423 541 682 436 347 410 297New Jersey 545 721 419 585 780 443 372 466 314New Mexico 488 585 405 493 595 406 - - -New York 535 702 412 575 752 441 390 514 313Seattle-Puget Sound 585 749 463 604 769 480 490 562 397Utah 542 670 433 551 681 440 - - -

SEER 9 Areasb 555 719 430 586 758 454 414 522 333SEER 13 Areasb 549 705 429 586 753 457 419 521 342SEER 18 Areasb 554 717 431 589 761 456 409 518 329SEER 21 Areasb 550 712 428 584 754 453 401 513 322

Total US 562 725 436 586 755 454 408 518 330

Table 1921Non-Hodgkin Lymphoma

Age-Adjusted SEER Death Ratesa

By Registry Race and Sex

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 562 002

High Five StatesMichigan 645 011 01(0112) 1479Kentucky 642 016 02(0118) 1424Iowa 638 018 03(0120) 1367Indiana 638 013 04(0117) 1361Idaho 635 027 05(0126) 1303

Low Five StatesNevada 511 019 47(2251) -899Colorado 491 014 48(3851) -1257New Mexico 488 020 49(2851) -1317Hawaii 475 024 50(3051) -1542c

DC 444 039 51(2351) -2097c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 545 014 28(1847) -291 Montana 559 030 25(0250) -042Alaska 525 047 43(0151) -654 Nebraska 563 023 22(0548) 026Arizona 512 012 46(2950) -886 Nevada 511 019 47(2251) -899Arkansas 555 018 26(1247) -113 New Hampshire 562 027 23(0349) 014California 533 005 40(2645) -508 New Jersey 545 010 29(2045) -301Colorado 491 014 48(3851) -1257 New Mexico 488 020 49(2851) -1317Connecticut 533 016 39(1949) -505 New York 535 007 37(2446) -478Delaware 628 033 08(0139) 1174 North Carolina 541 010 35(2146) -363DC 444 039 51(2351) -2097c North Dakota 561 037 24(0151) -007Florida 535 006 38(2545) -479 Ohio 616 009 10(0220) 969Georgia 533 011 41(2248) -511 Oklahoma 630 017 06(0121) 1226Hawaii 475 024 50(3051) -1542c Oregon 612 016 11(0124) 903Idaho 635 027 05(0126) 1303 Pennsylvania 603 009 16(0622) 729Illinois 566 009 20(1634) 085 Rhode Island 542 029 32(0651) -350Indiana 638 013 04(0117) 1361 South Carolina 542 014 31(1847) -347Iowa 638 018 03(0120) 1367 South Dakota 541 033 36(0451) -364Kansas 585 019 19(0439) 420 Tennessee 629 013 07(0119) 1198Kentucky 642 016 02(0118) 1424 Texas 546 007 27(2142) -277Louisiana 608 016 14(0125) 826 Utah 542 022 33(1250) -352Maine 609 026 13(0137) 852 Vermont 605 040 15(0148) 770Maryland 524 013 44(2349) -663 Virginia 544 011 30(2046) -319Massachusetts 523 012 45(2549) -687 Washington 599 013 17(0425) 665Michigan 645 011 01(0112) 1479 West Virginia 612 022 12(0132) 894Minnesota 617 014 09(0122) 984 Wisconsin 590 013 18(0629) 507Mississippi 531 018 42(1850) -551 Wyoming 564 043 21(0151) 050Missouri 542 012 34(1947) -354

Table 1922Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males and Females

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 725 003

High Five StatesKentucky 886 030 01(0112) 2213c

Iowa 845 032 02(0120) 1647c

Michigan 842 019 03(0114) 1615c

Indiana 839 024 04(0116) 1567c

Delaware 824 058 05(0144) 1364

Low Five StatesArizona 635 019 47(3251) -1244Alaska 630 075 48(0251) -1311Hawaii 620 041 49(1951) -1452DC 614 071 50(0551) -1535c

New Mexico 585 033 51(3451) -1928c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 688 025 36(1649) -513 Montana 709 050 26(0251) -218Alaska 630 075 48(0251) -1311 Nebraska 737 040 20(0248) 165Arizona 635 019 47(3251) -1244 Nevada 653 032 44(1951) -994Arkansas 721 031 22(0747) -061 New Hampshire 710 046 25(0451) -210California 677 009 41(2846) -666 New Jersey 721 018 21(1441) -059Colorado 643 024 46(2451) -1133 New Mexico 585 033 51(3451) -1928c

Connecticut 705 028 28(1248) -273 New York 702 012 30(1943) -323Delaware 824 058 05(0144) 1364 North Carolina 709 018 27(1644) -221DC 614 071 50(0551) -1535c North Dakota 682 061 39(0251) -598Florida 683 011 37(2446) -585 Ohio 800 017 09(0320) 1029Georgia 697 019 34(1746) -387 Oklahoma 806 030 08(0126) 1109Hawaii 620 041 49(1951) -1452 Oregon 794 028 12(0128) 947Idaho 775 045 16(0146) 692 Pennsylvania 783 015 15(0523) 794Illinois 739 016 19(1235) 190 Rhode Island 649 050 45(1051) -1050Indiana 839 024 04(0116) 1567c South Carolina 681 025 40(1850) -604Iowa 845 032 02(0120) 1647c South Dakota 701 056 31(0251) -332Kansas 713 032 24(0948) -174 Tennessee 820 023 06(0120) 1311Kentucky 886 030 01(0112) 2213c Texas 698 012 32(2043) -368Louisiana 814 029 07(0122) 1222 Utah 670 036 42(1351) -754Maine 754 045 18(0148) 395 Vermont 794 069 11(0149) 950Maryland 682 023 38(1849) -588 Virginia 694 020 35(1847) -429Massachusetts 659 020 43(2450) -910 Washington 790 022 13(0224) 897Michigan 842 019 03(0114) 1615c West Virginia 774 038 17(0142) 675Minnesota 797 025 10(0224) 995 Wisconsin 786 023 14(0227) 844Mississippi 717 034 23(0748) -110 Wyoming 698 071 33(0151) -377Missouri 702 022 29(1646) -319

Table 1923Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 436 002

High Five StatesIdaho 510 033 01(0139) 1697c

Maine 497 031 02(0141) 1396Michigan 495 012 03(0119) 1340Oklahoma 492 020 04(0128) 1276Indiana 492 016 05(0123) 1270

Low Five StatesMississippi 404 021 47(1351) -731Nevada 382 022 48(2051) -1237Colorado 369 016 49(3451) -1540c

Hawaii 352 027 50(2551) -1932c

DC 323 044 51(1551) -2601c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 440 017 24(0547) 099 Montana 435 036 27(0151) -034Alaska 414 058 38(0151) -500 Nebraska 435 027 26(0249) -032Arizona 407 014 44(2049) -664 Nevada 382 022 48(2051) -1237Arkansas 428 021 31(0649) -181 New Hampshire 454 032 19(0149) 400California 423 006 34(2244) -313 New Jersey 419 012 37(1848) -397Colorado 369 016 49(3451) -1540c New Mexico 405 025 46(0951) -706Connecticut 407 018 45(1550) -669 New York 412 008 39(2548) -554Delaware 473 039 12(0150) 855 North Carolina 420 012 35(1848) -374DC 323 044 51(1551) -2601c North Dakota 471 045 13(0150) 809Florida 412 007 40(2548) -564 Ohio 478 011 10(0123) 967Georgia 411 012 43(2049) -582 Oklahoma 492 020 04(0128) 1276Hawaii 352 027 50(2551) -1932c Oregon 465 019 15(0141) 668Idaho 510 033 01(0139) 1697c Pennsylvania 467 010 14(0427) 714Illinois 439 010 25(1341) 074 Rhode Island 455 035 18(0150) 434Indiana 492 016 05(0123) 1270 South Carolina 432 017 30(0947) -102Iowa 484 021 08(0135) 1087 South Dakota 411 039 42(0151) -580Kansas 486 023 06(0137) 1143 Tennessee 484 015 09(0126) 1087Kentucky 460 018 17(0241) 544 Texas 427 008 32(1944) -213Louisiana 451 018 21(0345) 333 Utah 433 026 28(0250) -081Maine 497 031 02(0141) 1396 Vermont 461 047 16(0151) 578Maryland 411 015 41(1749) -576 Virginia 432 013 29(1246) -092Massachusetts 423 014 33(1548) -303 Washington 452 015 20(0541) 360Michigan 495 012 03(0119) 1340 West Virginia 486 027 07(0143) 1141Minnesota 475 017 11(0132) 901 Wisconsin 443 015 23(0645) 156Mississippi 404 021 47(1351) -731 Wyoming 445 051 22(0151) 192Missouri 419 014 36(1549) -396

Table 1924Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Females

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 Areas (excluding the AlaskaNative Registry) and 112016 US population estimates based on the average of 2015 and 2016 population estimates from theUS Bureau of the CensusPrevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 24 years

b Maximum limited-duration prevalence is 24 years for 1992-2016 datac Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groupsd Cases diagnosed more than 24 years ago were estimated using the completeness index method (Capocaccia et al 1997

Merrill et al 2000)e Complete prevalence is obtained by summing 0 to lt24 and gt=24- Statistic not shown Statistic based on fewer than 5 cases estimated alive in SEER for the time interval+ Not available

Years Since Diagnosis 0 to lt5 5 to lt10 10 to lt15 15 to lt20 20 to lt24 0 to lt24b gt=24d Completee

Race Sex

All Races Both Sexes 248946 177490 117326 69109 31890 644761 49943 694704Males 135137 94173 60159 36020 16581 342069 25489 367558Females 113809 83317 57167 33089 15309 302692 24454 327146

White Both Sexes 213764 154454 101984 60537 28026 558765 49625 620368Males 116527 82172 52535 31627 14543 297404 26526 330121Females 97237 72282 49448 28910 13483 261361 23099 290247

Black Both Sexes 20500 13640 9750 5271 2215 51376 4115 55491Males 10712 7188 4768 2684 1174 26526 1911 28437Females 9789 6452 4981 2587 1041 24850 2204 27054

Asian Both Sexes 8405 5210 3415 1867 844 19741 + +Pacific Males 4548 2661 1757 1013 407 10386 + +Islander Females 3856 2549 1657 855 437 9355 + +

Hispanic Both Sexes 21339 14049 8272 4881 2136 50676 + +Males 10918 7243 4331 2617 1094 26202 + +Females 10421 6805 3941 2264 1043 24474 + +

Age Specific (Crude) Age-Adjustedc Age at Prevalence All Ages 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ All Ages

Race Sex

All Races Both Sexes 02001 00035 00139 00283 00538 01121 02352 04640 08181 10224 01738Males 02156 00044 00189 00354 00625 01293 02710 05243 09364 12449 02023Females 01850 00026 00087 00208 00450 00952 02010 04094 07196 08856 01498

White Both Sexes 02216 00035 00143 00289 00534 01148 02427 04858 08597 10738 01807Males 02380 00045 00198 00359 00622 01317 02790 05442 09778 13060 02095Females 02054 00025 00085 00214 00442 00976 02072 04317 07593 09285 01560

Black Both Sexes 01139 00029 00113 00265 00599 01027 02010 03340 05117 05333 01251Males 01226 00029 00140 00351 00696 01223 02333 03969 05849 06055 01457Females 01059 00030 00086 00178 00510 00853 01728 02836 04608 04976 01088

Asian Both Sexes 00970 00039 00133 00207 00353 00680 01409 02692 04470 06094 01032Pacific Males 01065 00044 00175 00240 00398 00744 01640 03072 05516 07472 01222Islander Females 00882 00033 00092 00175 00312 00623 01209 02384 03629 05207 00880

Hispanic Both Sexes 00887 00030 00117 00206 00398 00850 01769 03632 05888 07209 01294Males 00908 00035 00147 00256 00455 00932 01924 03940 06326 08003 01420Females 00866 00024 00086 00151 00337 00766 01616 03360 05552 06719 01185

Table 1925Non-Hodgkin Lymphoma

Estimated United States Cancer Prevalence Countsa on January 1 2016By RaceEthnicity Sex and Years Since Diagnosis

Estimated prevalence percenta on January 1 2016 of the SEER population diagnosed in the previous 24 yearsBy Age at Prevalence RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 372 452924 -05 62 18862 04 247 189692 -05 1657 244370 -05

1 Hodgkin Lymphoma 28 32262 -17 13 3927 -06 33 22556 -15 39 5779 -31

2 Non-Hodgkin lymphoma 336 409991 -03 48 14693 04 210 163591 -03 1572 231707 -042(a) Non-Hodgkin lymphoma B-cell 311 380349 -01 39 11836 14 190 148768 -02 1491 219745 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 15 16631 20 31 9416 10 07 5203 39 14 2012 252(a) 2 Mature Non-Hodgkin lymphoma B-cell 280 343965 -04 07 2271 30 174 137225 -05 1387 204469 -042(a) 21 ChronicSmallProlymphocytic 69 85601 -13 00 35 - 35 29103 -11 382 56463 -14

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 61 75061 -15 00 30 - 31 25339 -13 336 49692 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 311 19 - - - 00 72 - 02 234 262(a) 213 Mantle-cell lymphoma 08 10229 03 - - - 04 3692 02 44 6537 04

2(a) 22 Lymphoplasmacytic lymphoma 07 8651 00 - - - 03 2590 -11 41 6059 04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 03 3667 -03 - - - 01 1132 -18 17 2533 022(a) 222 Waldenstrom macroglubulinemia 04 4984 03 - - - 02 1458 -07 24 3526 06

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 72 87188 00 03 925 26 48 36480 -02 339 49783 022(a) 231 DLBCL NOSc 71 85899 -01 03 861 12 46 35469 -05 337 49569 012(a) 232 Intravascular large B-cell 00 162 - - - - 00 63 - 01 99 -

lymphoma2(a) 233 Primary effusion lymphoma 00 181 27 - - - 00 126 - 00 55 -2(a) 234 Mediastinal large B-cell 01 946 116 00 64 - 01 822 111 00 60 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 04 4692 -26 03 1028 32 04 2618 -43 07 1046 -432(a) 25 Marginal-zone lymphoma (MZL) 22 26534 00 00 137 13 14 11049 05 104 15348 -042(a) 251 Splenic MZL 02 2418 04 - - - 01 889 -08 10 1529 102(a) 252 Extranodal MZL MALTc type 13 15979 06 00 92 - 09 7148 11 59 8739 032(a) 253 Nodal MZL 07 8137 -15 00 45 - 04 3012 -05 34 5080 -20

2(a) 26 Follicular lymphoma 35 43582 -21 00 119 - 28 21725 -25 147 21738 -182(a) 27 Hairy-cell leukemia 03 3712 -16 - - - 03 2311 -19 09 1401 -122(a) 28 Plasma cell neoplasms 68 83957 08 00 24 - 39 31325 12 358 52608 062(a) 281 Plasmacytoma 04 4879 -04 00 16 - 03 2362 -06 17 2501 -032(a) 282 Multiple myeloma 64 79078 09 - - - 36 28963 14 341 50107 07

plasma-cell leukemia2(a) 29 Heavy chain disease 00 48 - - - - 00 24 - 00 23 -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 16 19753 33 00 149 27 08 6340 37 90 13264 32

Table 1926All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 23 27222 01 08 2502 18 19 13933 03 73 10787 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 616 - 01 293 - 00 272 - 00 51 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 22 26531 11 07 2207 75 19 13621 12 73 10703 -042(b) 21 Mycosis fungoidesSezary syndrome 06 6969 18 01 213 84 06 4080 23 18 2676 052(b) 211 Mycosis fungoides 06 6739 17 01 213 84 05 3990 22 17 2536 042(b) 212 Sezary syndrome 00 230 46 - - - 00 90 - 01 140 -

2(b) 22 Peripheral T-cell lymphoma 12 14531 -10 02 534 07 10 7159 -09 46 6838 -122(b) 221 Peripheral T-cell lymphoma NOSc 04 5393 -01 00 86 - 03 2489 04 19 2818 -042(b) 222 Angioimmunoblastic T-cell lymphoma 02 1902 02 - - - 01 699 -09 08 1201 072(b) 223 Subcutaneous panniculitis- 00 176 44 00 31 - 00 111 - 00 34 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 2523 -36 01 291 00 02 1450 -33 05 782 -54

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 139 - - - - 00 98 - 00 28 -2(b) 226 Enteropathy-type T-cell lymphoma 00 186 -02 - - - 00 84 - 01 101 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 2963 -07 00 59 - 02 1575 01 09 1329 -142(b) 228 Primary cutaneous anaplastic 01 1249 -41 00 51 - 01 653 -49 04 545 -39

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 03 3417 96 05 1428 101 02 1474 99 03 515 672(b) 24 NKcT-cell lymphoma nasal-type 01 985 02 00 26 - 01 659 00 02 300 05

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 120 - - - - 00 54 - 00 65 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 509 30 - - - 00 195 -05 02 309 442(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 75 - - - - 00 40 - 00 33 -2(c) Non-Hodgkin lymphoma unknown lineage 02 2420 -274 01 355 - 01 890 -216 08 1175 -2792(c) 1 Precursor lymphoblastic leukemia 01 814 -283 01 343 - 00 238 - 02 233 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 95 - - - - 00 25 - 00 69 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 1511 -274 - - - 01 627 -202 06 873 -319

lineage2() 1 Total precursor lymphomaleukemiad 16 18061 -07 33 10052 -15 08 5713 06 15 2296 -01

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 762 273 00 20 - 00 339 227 03 403 -lymphoma

4 Lymphoid neoplasm NOSc 08 9909 -55 01 222 113 04 3206 -59 43 6481 -59

Table 1926 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 461 253152 -05 70 10973 05 294 110367 -07 2122 131812 -05

1 Hodgkin Lymphoma 31 17710 -17 13 2118 -03 36 12525 -16 48 3067 -31

2 Non-Hodgkin lymphoma 419 229772 -03 56 8711 05 252 95756 -05 2017 125305 -032(a) Non-Hodgkin lymphoma B-cell 387 212247 -02 44 6786 15 227 86941 -04 1908 118520 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 16 8999 24 33 5123 11 08 2888 46 16 988 292(a) 2 Mature Non-Hodgkin lymphoma B-cell 351 192801 -05 10 1558 28 210 80417 -08 1783 110826 -042(a) 21 ChronicSmallProlymphocytic 96 52411 -15 00 21 - 47 18927 -14 539 33463 -15

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 82 44988 -17 00 19 - 40 16143 -16 464 28826 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 193 -02 - - - 00 46 - 02 145 052(a) 213 Mantle-cell lymphoma 13 7230 -01 - - - 07 2738 -01 72 4492 -01

2(a) 22 Lymphoplasmacytic lymphoma 10 5082 -05 - - - 04 1524 -08 58 3558 -04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 04 2062 -08 - - - 02 616 -12 23 1446 -072(a) 222 Waldenstrom macroglubulinemia 06 3020 -02 - - - 02 908 -06 34 2112 -02

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 88 48128 01 03 554 22 59 21824 -06 418 25750 052(a) 231 DLBCL NOSc 87 47520 00 03 519 03 57 21366 -08 416 25635 042(a) 232 Intravascular large B-cell 00 75 - - - - 00 31 - 01 44 -

lymphoma2(a) 233 Primary effusion lymphoma 00 167 26 - - - 00 123 - 01 44 -2(a) 234 Mediastinal large B-cell 01 366 155 00 35 - 01 304 142 00 27 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 06 3388 -22 05 775 31 06 1969 -46 10 644 -192(a) 25 Marginal-zone lymphoma (MZL) 22 12351 -02 01 98 - 14 5177 -02 114 7076 -012(a) 251 Splenic MZL 02 1164 14 - - - 01 434 18 12 730 112(a) 252 Extranodal MZL MALTc type 13 7268 07 00 62 - 09 3267 04 63 3939 102(a) 253 Nodal MZL 07 3919 -23 00 36 - 04 1476 -22 39 2407 -23

2(a) 26 Follicular lymphoma 39 21788 -19 01 100 - 30 11210 -25 165 10478 -152(a) 27 Hairy-cell leukemia 05 2984 -18 - - - 05 1908 -20 17 1076 -152(a) 28 Plasma cell neoplasms 85 46642 07 - - - 45 17864 11 462 28769 052(a) 281 Plasmacytoma 05 2997 -08 - - - 04 1509 -16 24 1484 -012(a) 282 Multiple myeloma 80 43645 08 - - - 41 16355 13 439 27285 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 27 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 20 10447 34 01 105 - 10 3636 40 110 6706 32

Table 1927All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 29 16118 00 11 1730 14 23 8235 02 98 6153 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 430 - 01 208 - 01 188 - 01 34 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 28 15642 11 10 1521 71 22 8022 11 97 6099 -032(b) 21 Mycosis fungoidesSezary syndrome 07 3962 19 01 135 - 06 2261 21 25 1566 092(b) 211 Mycosis fungoides 07 3831 20 01 135 - 06 2213 21 23 1483 092(b) 212 Sezary syndrome 00 131 - - - - 00 48 - 01 83 -

2(b) 22 Peripheral T-cell lymphoma 15 8438 -13 02 318 -09 12 4248 -12 62 3872 -132(b) 221 Peripheral T-cell lymphoma NOSc 06 3159 -05 00 49 - 04 1520 02 26 1590 -082(b) 222 Angioimmunoblastic T-cell lymphoma 02 1024 19 - - - 01 415 11 10 607 232(b) 223 Subcutaneous panniculitis- 00 68 - - - - 00 39 - 00 16 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 03 1549 -39 01 184 -01 02 888 -43 08 477 -45

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 98 - - - - 00 69 - 00 18 -2(b) 226 Enteropathy-type T-cell lymphoma 00 105 - - - - 00 50 - 01 54 -2(b) 227 Cutaneous T-cell lymphoma NOSc 03 1696 -12 00 32 - 02 894 -03 12 770 -172(b) 228 Primary cutaneous anaplastic 01 739 -48 00 26 - 01 373 -49 05 340 -49

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 04 2253 97 07 1047 92 03 940 98 04 266 1022(b) 24 NKcT-cell lymphoma nasal-type 01 638 -05 00 18 - 01 435 -03 03 185 -06

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 58 - - - - 00 22 - 01 36 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 01 293 45 - - - 00 116 - 03 174 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 46 - - - - 00 25 - 00 20 -2(c) Non-Hodgkin lymphoma unknown lineage 03 1407 -232 01 195 - 02 580 -184 10 632 -2302(c) 1 Precursor lymphoblastic leukemia 01 474 -228 01 187 - 00 134 - 02 153 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 49 - - - - - - - 01 36 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 02 884 -239 - - - 01 433 -175 07 443 -

lineage2() 1 Total precursor lymphomaleukemiad 18 9903 -06 35 5518 -17 09 3210 09 19 1175 05

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 435 271 - - - 01 215 - 03 207 -lymphoma

4 Lymphoid neoplasm NOSc 10 5235 -59 01 131 - 05 1871 -65 54 3233 -61

Table 1927 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 301 199772 -05 53 7889 02 202 79325 -02 1322 112558 -08

1 Hodgkin Lymphoma 24 14552 -16 12 1809 -10 29 10031 -14 32 2712 -32

2 Non-Hodgkin lymphoma 269 180219 -03 40 5982 03 170 67835 00 1251 106402 -062(a) Non-Hodgkin lymphoma B-cell 250 168102 -01 34 5050 13 154 61827 02 1190 101225 -042(a) 1 Precursor Non-Hodgkin lymphoma B-cell 14 7632 16 29 4293 09 06 2315 29 12 1024 202(a) 2 Mature Non-Hodgkin lymphoma B-cell 223 151164 -04 05 713 35 141 56808 -01 1102 93643 -072(a) 21 ChronicSmallProlymphocytic 48 33190 -13 - - - 24 10176 -05 268 23000 -16

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 43 30073 -15 - - - 22 9196 -06 243 20866 -19

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 118 - - - - 00 26 - 01 89 -2(a) 213 Mantle-cell lymphoma 04 2999 11 - - - 02 954 10 24 2045 12

2(a) 22 Lymphoplasmacytic lymphoma 05 3569 04 - - - 03 1066 -16 30 2501 11Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 02 1605 01 - - - 01 516 -25 13 1087 112(a) 222 Waldenstrom macroglubulinemia 03 1964 06 - - - 01 550 -08 17 1414 11

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 58 39060 00 02 371 33 38 14656 03 283 24033 -032(a) 231 DLBCL NOSc 57 38379 -02 02 342 27 36 14103 -01 282 23934 -032(a) 232 Intravascular large B-cell 00 87 - - - - 00 32 - 01 55 -

lymphoma2(a) 233 Primary effusion lymphoma - - - - - - - - - - - -2(a) 234 Mediastinal large B-cell 01 580 91 00 29 - 02 518 93 00 33 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 02 1304 -34 02 253 38 02 649 -37 05 402 -852(a) 25 Marginal-zone lymphoma (MZL) 21 14183 01 00 39 - 15 5872 12 98 8272 -062(a) 251 Splenic MZL 02 1254 -07 - - - 01 455 -32 10 799 072(a) 252 Extranodal MZL MALTc type 13 8711 06 00 30 - 10 3881 17 57 4800 -032(a) 253 Nodal MZL 06 4218 -07 - - - 04 1536 11 32 2673 -18

2(a) 26 Follicular lymphoma 33 21794 -24 00 19 - 27 10515 -25 134 11260 -222(a) 27 Hairy-cell leukemia 01 728 -12 - - - 01 403 -11 04 325 -122(a) 28 Plasma cell neoplasms 55 37315 08 - - - 33 13461 15 282 23839 052(a) 281 Plasmacytoma 03 1882 00 - - - 02 853 12 12 1017 -092(a) 282 Multiple myeloma 52 35433 09 - - - 30 12608 15 270 22822 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 21 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 14 9306 32 00 44 - 07 2704 32 76 6558 31

Table 1928All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 17 11104 01 05 772 29 15 5698 05 55 4634 -112(b) 1 Precursor Non-Hodgkin lymphoma T-cell 00 186 - 01 85 - 00 84 - 00 17 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 17 10889 09 05 686 83 15 5599 12 54 4604 -092(b) 21 Mycosis fungoidesSezary syndrome 05 3007 15 01 78 - 05 1819 26 13 1110 -042(b) 211 Mycosis fungoides 05 2908 12 01 78 - 05 1777 23 12 1053 -072(b) 212 Sezary syndrome 00 99 - - - - 00 42 - 01 57 -

2(b) 22 Peripheral T-cell lymphoma 09 6093 -08 01 216 30 08 2911 -06 35 2966 -142(b) 221 Peripheral T-cell lymphoma NOSc 03 2234 03 00 37 - 03 969 07 14 1228 -012(b) 222 Angioimmunoblastic T-cell lymphoma 01 878 -22 - - - 01 284 -39 07 594 -152(b) 223 Subcutaneous panniculitis- 00 108 - 00 18 - 00 72 - 00 18 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 974 -33 01 107 - 02 562 -19 04 305 -77

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 41 - - - - 00 29 - - - -2(b) 226 Enteropathy-type T-cell lymphoma 00 81 - - - - 00 34 - 01 47 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 1267 00 00 27 - 02 681 07 07 559 -102(b) 228 Primary cutaneous anaplastic 01 510 -34 00 25 - 01 280 -50 02 205 -33

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 02 1164 96 03 381 127 01 534 97 03 249 302(b) 24 NKcT-cell lymphoma nasal-type 01 347 11 - - - 01 224 - 01 115 -

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 62 - - - - 00 32 - 00 29 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 216 03 - - - 00 79 - 02 135 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 29 - - - - - - - - - -2(c) Non-Hodgkin lymphoma unknown lineage 02 1013 -341 01 160 - 01 310 - 06 543 -2(c) 1 Precursor lymphoblastic leukemia 01 340 - 01 156 - 00 104 - 01 80 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 46 - - - - - - - 00 33 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 627 - - - - 01 194 - 05 430 -

lineage2() 1 Total precursor lymphomaleukemiad 14 8158 -09 31 4534 -13 07 2503 02 13 1121 -11

3 Composite Hodgkin lymphoma and Non-Hodgkin 00 327 - - - - 00 124 - 02 196 -lymphoma

4 Lymphoid neoplasm NOSc 07 4674 -52 01 91 - 03 1335 -51 36 3248 -58

Table 1928 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 6: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Individual rates for years of death 1975-1979 available in web browser version of Cancer Statistics Reviewa US Mortality Files National Center for Health Statistics Centers for Disease Control and Prevention

Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

Year of Death1975-2016 701 880 570 732 915 596 478 613 3801975-1979 580 708 484 602 733 503 375 483 2921980 623 747 529 647 774 552 399 515 3121981 616 738 527 640 766 547 398 500 3251982 655 798 549 683 829 574 412 523 3291983 666 811 558 692 839 585 430 579 3231984 676 815 575 705 850 601 419 528 3391985 706 880 580 734 917 602 462 557 3871986 731 898 605 759 925 633 495 664 3701987 726 881 610 756 912 638 473 630 3621988 752 928 624 782 959 653 501 682 3721989 783 973 643 812 1004 671 533 710 4071990 787 997 634 816 1032 658 539 713 4171991 819 1015 674 850 1052 700 570 717 4611992 822 1030 669 853 1066 696 564 723 4451993 825 1014 686 857 1045 717 569 753 4401994 863 1075 710 900 1120 741 554 682 4561995 872 1081 716 909 1121 749 579 762 4451996 875 1094 714 909 1129 746 621 825 4741997 888 1103 725 921 1135 757 634 845 4871998 869 1085 710 903 1127 738 599 750 4891999 832 1036 685 867 1071 718 565 744 4412000 817 1020 670 854 1063 701 520 661 4172001 791 998 642 821 1031 668 561 728 4472002 765 966 619 797 1004 644 541 688 4412003 738 940 592 769 981 613 494 583 4272004 709 894 573 738 928 596 501 623 4132005 695 887 556 724 922 579 477 611 3812006 674 848 544 701 878 566 492 627 3932007 659 836 526 686 867 549 452 577 3622008 641 820 509 671 856 533 431 548 3452009 630 812 493 656 842 513 449 615 3412010 614 783 485 637 811 504 457 584 3642011 603 785 464 629 817 483 436 574 3402012 591 762 461 617 795 480 426 538 3482013 571 738 444 595 767 462 411 527 3332014 565 726 443 589 755 460 418 528 3422015 547 713 418 569 741 434 404 519 3212016 537 691 417 562 721 436 383 481 311

Table 196Non-Hodgkin Lymphoma

Age-adjusted US Deatha Rates by Year Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a SEER 21 areas Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)unless noted

b US Mortality Files National Center for Health Statistics Centers for Disease Control and PreventionRates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) unless noted

c Rates are per 100000 and are age-adjusted to the world (WHO 2000-2025) standard million- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER IncidenceAge at DiagnosisAge-Adjusted Rates 2012-2016All ages 196 239 162 206 250 170 147 177 124Under 65 94 111 78 96 113 80 91 109 7665 and over 904 1126 743 966 1199 794 532 646 461

All ages (WHO world std)c 147 177 122 154 184 127 117 140 98

Age-Specific Rates 2012-2016lt1 - - - - - - - - -1-4 08 11 05 08 11 06 06 07 -5-9 12 17 07 13 18 07 10 13 0810-14 15 20 10 14 19 10 16 21 1115-19 21 27 14 20 26 14 20 28 1220-24 27 32 22 26 31 21 28 35 2025-29 35 40 29 34 39 28 41 48 3430-34 49 56 42 48 54 41 56 67 4735-39 72 85 59 71 83 58 81 98 6640-44 99 117 80 99 117 80 108 128 9045-49 145 168 122 147 169 125 156 190 12750-54 222 256 189 229 264 194 217 250 18755-59 312 366 261 326 379 274 277 332 23060-64 445 522 376 470 548 396 363 426 31165-69 629 742 528 667 781 564 447 522 39070-74 833 997 697 890 1058 746 522 640 43975-79 1044 1287 855 1124 1384 918 588 692 52080-84 1193 1522 966 1280 1631 1031 650 791 57385+ 1079 1499 861 1146 1589 915 508 685 434

US MortalityAge at DeathAge-Adjusted Rates 2012-2016All ages 56 73 44 59 76 45 41 52 33Under 65 13 17 10 13 17 09 16 21 1265 and over 352 453 279 372 477 295 210 265 176

All ages (WHO world std)c 30 39 23 31 40 23 25 32 20

Age-Specific Rates 2012-2016lt1 - - - - - - - - -1-4 00 01 - 00 01 - - - -5-9 01 01 00 00 01 - 01 - -10-14 01 01 01 01 01 01 - - -15-19 01 02 01 01 02 01 02 02 -20-24 02 03 02 02 03 02 04 04 0325-29 04 05 03 03 04 02 05 07 0430-34 05 07 04 05 06 03 09 12 0635-39 07 09 05 06 08 04 11 14 0940-44 11 14 08 10 13 08 18 21 1545-49 18 23 13 17 22 13 24 32 1750-54 31 41 21 31 41 21 37 49 2655-59 53 71 37 54 72 36 58 74 4460-64 90 118 64 92 121 64 90 116 6965-69 142 184 105 149 192 109 116 146 9370-74 244 309 188 256 324 197 167 214 13375-79 374 473 294 397 501 312 220 275 18480-84 567 725 455 600 764 481 321 405 27485+ 751 994 624 795 1049 662 360 457 320

Table 197Non-Hodgkin Lymphoma

SEER Incidencea and US Deathb Rates Age-Adjusted and Age-Specific Rates by Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on End Results data from a series of hospital registries and one population-based registryb SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)

Based on follow-up of patients into 2016 Expected survival rates are derived from the US Annual Life Tablesc SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER programBased on follow-up of patients into 2016

d Period survival provides a 2015 estimate of survival by piecing together the most recent conditional survival estimatesfrom several cohorts It is computed here using three year calendar blocks (2010-2012 0-1 year survival)(2009-2011 1-2 year survival) (2008-2010 2-3 year survival) (2007-2009 3-4 year survival) (2006-2008 4-5 years survival)

e Stage at diagnosis is classified using SEER Summary Stage 2000 Stage distribution percentages may not sum to 100 due to roundingf The difference between 1975-1977 and 2009-2015 is statistically significant (plt05)g The standard error is between 5 and 10 percentage pointsh The standard error is greater than 10 percentage points- Statistic could not be calculated due to fewer than 25 cases during the time period

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

5-Year Relative Survival (Percent)Year of Diagnosis1960-1963a - - - 31 31 31 - - -1970-1973a - - - 41 39 43 - - -1975-1977b 465 456 475 468 463 473 486 426 553g

1978-1980b 479 461 498 479 462 495 511 469 5671981-1983b 506 503 509 508 505 511 495 492 4981984-1986b 516 501 534 521 507 537 468 445 4991987-1989b 509 476 549 513 482 552 457 413 5101990-1992b 507 467 557 515 476 564 422 384 4761993-1995b 526 487 575 533 498 577 425 359 5491996-1998b 588 570 610 595 577 615 547 531 5721999-2001b 640 614 670 650 628 676 558 490 6382002-2004b 698 686 712 710 701 721 636 611 6662005-2008b 716 706 727 728 719 738 625 578 6752009-2015b 747f 739f 757f 757f 748f 767f 695f 670f 724f

5-Year Period Survival (Percent)cd

2015 722 705 743 726 708 747 671 641 703

Stage Distribution () 2009-2015ce

All StagesNumber of cases 97737 53606 44131 80120 44109 36011 8184 4388 3796Percent 100 100 100 100 100 100 100 100 100Localized 27 27 29 27 26 28 28 25 31Regional 15 15 15 15 15 15 15 15 15Distant 50 51 48 51 52 49 51 54 48UnstagedUnknown 8 7 8 7 7 8 6 6 7

5-Year Relative Survival (Percent) 2009-2015c

Age at DiagnosisAges lt45 840 820 870 855 836 885 735 708 776Ages 45-54 810 777 859 826 795 872 687 639 750Ages 55-64 770 742 809 781 754 818 678 620 749Ages 65-74 725 706 747 731 711 755 656 623 682Ages 75+ 554 539 568 557 538 574 482 449 500Ages lt65 800 773 838 812 787 849 701 659 759Ages 65+ 638 627 649 641 628 655 584 562 598

StageeAll Stages 720 707 737 724 711 740 665 637 698Localized 840 830 850 843 833 852 810 766 850Regional 750 751 749 755 756 755 689 698 678Distant 648 633 668 657 642 677 580 557 610UnstagedUnknown 703 686 723 679 662 698 659 648 666

Table 198Non-Hodgkin Lymphoma

5-Year Relative and Period Survival (Percent) by Race Sex Diagnosis Year and Age

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Expected survival rates are derived from the US Annual Life Tables

1975- 1980- 1985- 1990-1979 1984 1989 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Survival Time

1-year 702 730 713 704 703 733 756 767 774 773 787 810 803 811 817 810 816 841 839 844 834 842 844 834 8452-year 602 637 628 622 618 659 685 700 710 714 733 760 757 760 773 769 775 790 795 796 797 800 800 7953-year 546 585 582 577 575 621 649 664 669 679 701 731 731 735 748 745 750 762 773 774 775 779 7794-year 505 546 543 544 547 587 621 636 645 655 681 712 716 715 730 726 732 744 756 752 756 7675-year 468 507 510 516 520 561 594 609 621 638 660 693 700 701 716 705 712 728 741 742 7426-year 436 475 483 492 499 541 571 583 595 621 647 680 683 688 704 688 701 718 721 7237-year 408 450 458 470 479 522 552 564 577 605 629 663 671 672 685 672 688 702 7108-year 385 428 434 450 464 504 529 552 563 589 613 651 658 666 670 661 674 6909-year 366 408 415 435 453 493 515 535 548 576 600 640 648 649 652 651 66110-year 350 389 398 421 443 481 501 522 537 563 589 632 633 638 634 63711-year 335 374 385 406 434 466 488 511 525 548 581 618 621 630 63112-year 324 360 369 395 423 457 481 501 512 535 568 600 615 61713-year 314 348 358 383 415 449 469 492 500 520 561 593 60214-year 302 335 347 372 406 443 456 485 488 513 549 58315-year 289 322 335 365 398 437 447 474 478 505 54016-year 279 312 328 356 393 437 433 472 470 49217-year 274 304 321 349 388 428 428 469 45818-year 268 296 314 341 378 420 419 46319-year 260 288 306 333 370 413 41220-year 252 280 301 329 359 408

Table 199Non-Hodgkin Lymphoma

SEERa Relative Survival (Percent)By Year of Diagnosis

All Races Males and Females

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Expected survival rates are derived from the US Annual Life Tables

1975- 1980- 1985- 1990-1979 1984 1989 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Survival Time

1-year 694 727 689 671 666 712 747 749 758 765 776 806 797 801 811 810 814 836 828 838 838 841 834 830 8352-year 594 637 605 582 583 636 672 682 691 703 713 752 749 755 762 765 778 779 781 788 798 793 786 7913-year 534 580 557 537 545 598 638 645 644 668 679 720 726 726 731 736 754 751 757 766 776 769 7644-year 493 539 516 504 515 561 610 620 615 639 657 700 709 701 711 713 734 734 737 743 756 7575-year 455 501 482 476 485 537 583 592 590 617 635 679 689 688 699 689 710 721 724 735 7426-year 426 466 455 456 469 510 561 565 562 602 620 667 669 676 684 670 696 715 706 7177-year 399 442 431 436 449 491 542 544 546 587 601 652 658 655 668 651 682 696 6968-year 378 420 410 418 433 474 520 533 536 567 582 637 645 649 650 634 665 6869-year 357 401 391 402 423 465 504 514 523 553 572 628 633 632 636 618 65210-year 340 380 377 392 416 455 489 503 515 542 560 617 617 620 613 60911-year 328 363 364 381 407 437 477 494 508 527 547 603 605 612 61212-year 319 352 351 372 395 427 472 482 498 515 537 589 601 59613-year 307 342 343 361 389 419 456 467 491 501 531 582 59114-year 295 330 332 350 378 414 444 461 480 496 521 57215-year 281 319 324 344 368 409 435 453 473 488 51216-year 272 308 316 333 361 409 426 453 471 47417-year 265 300 308 326 358 403 420 449 46218-year 261 294 302 320 350 396 410 44219-year 256 287 294 313 342 391 40320-year 250 280 291 309 332 387

Table 1910Non-Hodgkin Lymphoma

SEERa Relative Survival (Percent)By Year of Diagnosis

All Races Males

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Expected survival rates are derived from the US Annual Life Tables

1975- 1980- 1985- 1990-1979 1984 1989 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Survival Time

1-year 710 734 741 747 752 759 767 786 792 782 801 814 810 821 825 809 819 847 854 851 830 843 856 838 8572-year 611 637 656 672 664 688 701 720 734 727 758 769 765 767 786 774 772 804 812 807 796 810 817 7993-year 559 589 611 627 616 649 662 684 700 692 727 744 736 746 768 756 746 774 791 786 774 791 7974-year 519 553 576 595 590 619 634 653 681 674 710 725 724 730 751 739 729 757 778 764 755 7805-year 482 514 544 567 565 591 608 629 658 664 688 708 713 716 736 724 715 735 763 751 7426-year 446 484 517 539 540 580 583 603 635 643 679 695 699 701 727 708 707 722 738 7317-year 417 458 490 512 520 560 563 586 615 626 663 674 687 692 704 698 694 709 7268-year 392 437 463 491 505 542 539 573 596 615 649 667 672 684 693 692 684 6949-year 374 416 443 476 492 529 528 557 578 603 633 654 664 669 671 688 67110-year 360 399 424 458 480 514 516 542 562 588 625 648 651 658 659 66911-year 342 385 409 438 469 503 500 529 547 573 621 636 640 651 65312-year 329 368 390 425 460 494 493 523 529 560 606 613 632 64013-year 321 353 376 411 449 486 485 518 510 543 598 606 61514-year 310 340 365 400 442 479 470 512 497 532 582 59615-year 297 326 349 391 436 472 460 498 483 525 57416-year 287 316 342 385 435 467 441 492 468 51317-year 282 306 336 378 428 459 438 490 45218-year 274 298 327 367 413 449 428 48519-year 265 288 321 358 407 439 42220-year 254 280 312 353 395 433

Table 1911Non-Hodgkin Lymphoma

SEERa Relative Survival (Percent)By Year of Diagnosis

All Races Females

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 5222 2506 2704 3176 3627 3994 4570 4729 5325 5260 5263 5562 5775 6226 6401 6704 6998 7072 11154

SEER 9 except 4285 2088 2267 2603 2819 3091 3507 3694 4159 4249 4364 4515 4818 5209 5398 5628 5841 6015 9363SF-Oakland

San Francisco- 937 418 437 573 808 903 1063 1035 1166 1011 899 1047 957 1017 1003 1076 1157 1057 1791Oakland SMSAc

San Francisco 245 96 123 210 326 393 467 410 450 354 213 256 220 283 219 216 240 225 362CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 134 155 161 183 201 215 234 233 252 244 238 244 246 258 254 255 255 245 244

SEER 9 except 132 154 161 181 188 201 217 218 236 236 235 236 244 256 254 253 252 247 243SF-Oakland

San Francisco- 147 158 160 194 267 285 317 305 335 288 252 286 256 266 256 263 268 235 246Oakland SMSAc

San Francisco 143 144 176 293 444 519 610 523 574 448 274 325 269 354 265 257 273 252 246CityCounty

Table 1912

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males All Ages

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males All Ages

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 0-19 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 223 87 108 91 94 84 100 89 120 105 104 119 127 107 106 143 134 155 240

SEER 9 except 191 78 95 82 80 76 86 74 107 84 93 100 115 90 87 114 119 129 198SF-Oakland

San Francisco- 32 9 13 9 14 8 14 15 13 21 11 19 12 17 19 29 15 26 42Oakland SMSAc

San Francisco 9 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 5 lt4 6 lt4CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 12 12 16 14 14 13 15 13 17 14 14 15 16 14 13 18 17 20 20

SEER 9 except 12 13 16 14 14 13 15 12 17 13 14 15 17 13 13 16 17 19 19SF-Oakland

San Francisco- 14 10 15 10 16 09 15 16 13 21 11 18 12 17 19 28 14 25 27Oakland SMSAc

San Francisco 23 - - - - - - - - - - - - - - 40 - 49 -CityCounty

Table 1913

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 0-19

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 0-19

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 20-54 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 1463 687 723 958 1211 1413 1766 1830 2089 1770 1608 1696 1623 1722 1655 1693 1674 1596 2242

SEER 9 except 1208 563 588 730 827 923 1195 1294 1483 1325 1269 1327 1308 1410 1383 1401 1402 1328 1848SF-Oakland

San Francisco- 255 124 135 228 384 490 571 536 606 445 339 369 315 312 272 292 272 268 394Oakland SMSAc

San Francisco 58 29 34 105 215 288 333 303 317 225 105 115 111 111 86 75 73 71 98CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 69 79 82 104 124 136 159 156 169 138 121 124 117 123 116 118 116 111 104

SEER 9 except 69 78 81 97 103 109 131 134 144 123 115 116 112 119 115 116 115 110 103SF-Oakland

San Francisco- 69 84 89 139 226 264 295 267 298 213 156 164 139 141 123 130 118 114 110Oakland SMSAc

San Francisco 67 88 94 272 565 715 813 724 744 510 230 252 239 248 194 162 152 145 129CityCounty

Table 1914

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 20-54

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 20-54

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 55+ and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 3536 1732 1873 2127 2322 2497 2704 2810 3116 3385 3551 3747 4025 4397 4640 4868 5190 5321 8672

SEER 9 except 2886 1447 1584 1791 1912 2092 2226 2326 2569 2840 3002 3088 3395 3709 3928 4113 4320 4558 7317SF-Oakland

San Francisco- 650 285 289 336 410 405 478 484 547 545 549 659 630 688 712 755 870 763 1355Oakland SMSAc

San Francisco 178 65 88 104 109 105 132 106 130 126 106 141 108 169 131 136 164 148 261CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 451 522 540 596 633 673 701 706 761 800 811 831 858 900 901 891 899 862 871

SEER 9 except 440 521 544 601 620 667 687 692 744 797 813 813 858 901 904 891 888 874 874SF-Oakland

San Francisco- 508 528 520 571 702 703 773 783 854 821 800 932 855 894 888 890 959 800 860Oakland SMSAc

San Francisco 482 446 598 727 739 757 934 747 914 872 727 934 690 1047 764 769 889 776 826CityCounty

Table 1915

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 55+

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 55+

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 003 006 217 072 Asian 0 001 003 005 183 072

10 002 005 011 218 073 Pacific 10 002 004 009 184 073

20 003 009 021 217 073 Islander 20 003 007 015 182 073

30 006 018 042 216 073 30 005 013 029 180 073

40 012 037 082 213 074 40 008 024 057 176 073

50 025 072 139 206 074 50 017 049 101 170 073

60 049 120 177 191 075 60 034 087 139 158 072

70 080 144 - 160 072 70 056 112 - 133 068

80 085 - - 106 062 80 066 - - 091 056

White 0 001 003 006 227 075 American 0 001 002 003 116 049

10 002 005 011 228 076 Indian 10 002 002 005 117 050

20 003 009 021 227 076 Alaska 20 001 003 008 116 050

30 006 018 043 226 077 Nativea 30 003 007 022 117 051

40 012 038 085 223 077 40 004 019 041 117 052

50 026 075 147 217 078 50 016 038 078 118 053

60 052 127 187 201 078 60 024 067 105 109 055

70 085 153 - 169 076 70 048 091 - 096 055

80 090 - - 111 065 80 057 - - 064 043

Black 0 001 002 006 138 042 Hispanicb 0 001 002 005 222 073

10 002 005 011 140 043 10 001 004 009 223 074

20 003 010 022 139 043 20 003 008 019 222 074

30 006 019 041 137 043 30 005 016 040 221 074

40 013 035 068 133 043 40 011 035 078 218 074

50 023 057 093 125 043 50 024 068 133 211 074

60 037 076 102 110 042 60 046 114 173 195 074

70 047 078 - 087 038 70 075 140 - 164 070

80 044 - - 057 032 80 081 - - 112 057

Table 1916

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Both Sexes 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 004 007 243 081 Asian 0 001 003 006 213 085

10 002 006 013 244 082 Pacific 10 002 005 011 213 086

20 004 010 024 243 082 Islander 20 003 009 018 211 086

30 007 021 049 243 083 30 006 015 034 210 086

40 014 042 094 240 084 40 009 028 067 205 086

50 029 082 158 233 085 50 019 059 117 199 086

60 057 139 203 219 086 60 041 101 161 187 085

70 095 170 - 188 084 70 066 131 - 159 082

80 105 - - 130 073 80 080 - - 114 069

White 0 001 004 007 254 085 American 0 001 003 004 104 057

10 002 006 013 255 086 Indian 10 002 003 006 105 058

20 004 010 024 254 086 Alaska 20 001 004 008 103 058

30 007 020 049 253 087 Nativea 30 003 008 021 104 059

40 014 043 097 251 088 40 005 018 038 105 060

50 030 086 167 244 089 50 014 035 071 105 062

60 059 147 215 230 090 60 023 062 094 099 065

70 101 180 - 198 088 70 046 084 - 090 066

80 112 - - 136 076 80 053 - - 061 053

Black 0 001 003 007 152 046 Hispanicb 0 001 003 005 238 083

10 002 006 014 154 047 10 002 005 011 239 084

20 004 012 027 153 047 20 003 009 021 238 084

30 008 023 048 152 047 30 006 018 043 238 084

40 016 042 079 148 047 40 012 037 083 235 085

50 027 066 105 138 047 50 026 073 145 228 085

60 043 087 114 123 045 60 050 126 189 214 085

70 054 088 - 099 042 70 086 157 - 185 081

80 053 - - 070 036 80 094 - - 131 066

Table 1917

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Males 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 002 004 193 064 Asian 0 001 002 004 159 063

10 001 004 009 195 064 Pacific 10 001 004 008 160 063

20 003 007 017 194 064 Islander 20 002 006 013 159 063

30 005 015 036 192 065 30 004 011 025 157 063

40 010 031 071 189 065 40 007 021 048 153 063

50 022 062 120 182 065 50 014 042 087 148 063

60 042 103 154 168 065 60 028 074 122 136 062

70 067 123 - 138 063 70 049 099 - 114 058

80 071 - - 090 054 80 057 - - 075 047

White 0 001 002 004 203 067 American 0 000 001 002 128 043

10 001 004 009 204 067 Indian 10 001 001 004 129 044

20 002 007 017 203 067 Alaska 20 001 003 007 128 044

30 005 015 037 201 067 Nativea 30 002 006 023 129 044

40 010 032 074 198 068 40 004 021 044 129 045

50 022 065 127 192 068 50 017 042 085 129 046

60 044 109 163 177 068 60 026 072 113 118 047

70 072 130 - 146 066 70 050 097 - 102 046

80 075 - - 094 056 80 060 - - 066 037

Black 0 000 002 004 126 040 Hispanicb 0 001 002 004 210 065

10 001 004 009 128 040 10 001 004 008 211 066

20 003 008 018 127 040 20 002 007 017 211 066

30 005 015 034 125 040 30 004 014 036 209 066

40 010 029 058 122 040 40 010 032 073 206 066

50 020 049 083 115 040 50 022 064 123 198 066

60 032 068 094 102 039 60 043 104 161 182 065

70 041 071 - 080 036 70 066 127 - 149 062

80 039 - - 051 030 80 073 - - 100 051

Table 1918

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Females 2014-2016 By RaceEthnicity

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

The AAPC is the Average Annual Percent Change over the time interval The AAPCs are calculated bythe Joinpoint Regression Program Version 47 February 2019 National Cancer Institute

- Statistic not shown Rate based on less than 16 cases for the time intervalTrend based on less than 10 cases for at least one year within the time interval

a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) Trendsare based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico SeattleUtah and AtlantaThe SEER 21 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the AlaskaNative Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts

c The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 3 Joinpoints overdiagnosis years 2000-2016

d The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 5 Joinpoints overdiagnosis years 1975-2016

e Hispanic and Non-Hispanic are not mutually exclusive from whites blacks AsianPacificIslanders and American IndiansAlaska Natives Incidence data for Hispanics and Non-Hispanicsare based on NHIA and exclude cases from the Alaska Native Registry

f Incidence data for American IndianAlaska Native are based on the PurchasedReferred CareDelivery Area (PRCDA) counties

g US Mortality Files National Center for Health Statistics CDCh The 2007-2016 mortality AAPCs are based on a Joinpoint analysis using years of death 2000-2016 The APC is significantly different from zero (plt05)

SEER Incidence SEER 21 Areasb SEER 21 Areasb SEER 9 Areasb

Rate 2012-2016 Trend 2007-2016c Trend 2007-2016d

Rate per 100000 persons AAPC () AAPC ()

Total Males Females Total Males Females Total Males Females RaceEthnicity

All Races 196 239 162 -07 -09 -08 -09 -07 -08

White 206 250 170 -08 -11 -09 -09 -08 -08White Hispanice 183 212 161 -08 -03 -05 - - -White Non-Hispanice 210 256 172 -08 -06 -10 - - -

Black 147 177 124 01 00 03 00 -04 -09

AsianPacific Islander 134 164 110 00 00 -01 - - -

Amer IndAlaska Natf 113 120 106 -05 -12 00 - - -

Hispanice 179 207 157 -05 -02 03 - - -

US Mortalityg Rate 2012-2016 Trend 2007-2016h

Rate per 100000 persons AAPC ()

Total Males Females Total Males FemalesRaceEthnicity

All Races 56 73 44 -23 -20 -27

White 59 76 45 -23 -20 -27White Hispanice 51 65 40 -16 -13 -20White Non-Hispanice 59 76 46 -23 -20 -27

Black 41 52 33 -20 -19 -21

AsianPacific Islander 39 49 31 -17 -15 -19

Amer IndAlaska NatTotal US 31 40 24 -32 -20 -45PRCDA Counties 44 58 33 -21 -04 -37Non-PRCDA Counties 17 21 14 -54 -50 -60

Hispanice 48 61 38 -17 -14 -21

Table 1919Non-Hodgkin Lymphoma

SEER Incidence and US MortalityAge-Adjusted Rates and Trendsa

By RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Incidence Ratesa 2012-2016

California 1844 2241 1515 1938 2349 1591 1390 1639 1182Greater Bay Area 1957 2381 1600 2144 2601 1755 1628 1828 1436San Francisco-Oakland 1956 2421 1570 2174 2660 1765 1603 1816 1408San Jose-Monterey 1962 2311 1660 2097 2503 1742 1800 1891 1646

Los Angeles 1804 2176 1505 1951 2331 1637 1357 1659 1139Greater California 1822 2220 1489 1876 2286 1529 1314 1534 1113

Connecticut 2116 2607 1733 2154 2642 1771 1386 1829 1051Detroit 2132 2636 1742 2290 2850 1847 1620 1905 1409Georgia 1826 2244 1487 1936 2346 1588 1462 1833 1187Atlanta 1925 2381 1555 2119 2567 1736 1601 2034 1272Rural Georgia 1584 1790 1401 1953 2298 1567 807 - 988Greater Georgia 1784 2186 1459 1872 2274 1537 1380 1703 1146

Hawaii 1660 2024 1349 1958 2275 1593 - - -Idaho 1922 2267 1616 1920 2262 1618 - - -Iowa 2134 2601 1756 2148 2612 1773 1352 1602 1100Kentucky 2039 2505 1666 2070 2538 1693 1403 1788 1112Louisiana 1944 2352 1614 2106 2537 1744 1469 1769 1237Massachusetts 1810 2181 1518 1830 2214 1524 1452 1655 1299New Jersey 2155 2607 1804 2285 2765 1905 1387 1621 1222New Mexico 1550 1739 1387 1580 1798 1394 875 - -New York 2152 2620 1788 2306 2792 1915 1545 1852 1333Seattle-Puget Sound 2116 2627 1695 2177 2667 1766 1631 1973 1316Utah 1843 2233 1498 1862 2258 1513 2089 - -

SEER 9 Areasb 1992 2444 1623 2095 2551 1716 1573 1914 1298SEER 13 Areasb 1946 2373 1597 2064 2502 1700 1519 1853 1258SEER 18 Areasb 1933 2354 1590 2031 2464 1671 1449 1751 1214SEER 21 Areasb 1963 2388 1620 2061 2498 1702 1471 1771 1245

Table 1920Non-Hodgkin Lymphoma

Age-Adjusted SEER Incidence Ratesa

By Registry Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control and PreventionRates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and AtlantaThe SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Death Ratesa 2012-2016

California 533 677 423 570 726 449 417 480 367Greater Bay Area 505 671 376 561 756 408 410 491 331San Francisco-Oakland 503 667 376 555 742 409 416 490 343San Jose-Monterey 511 681 377 573 781 407 - - -

Los Angeles 541 670 443 589 728 481 424 503 371Greater California 539 682 429 564 716 447 416 455 384

Connecticut 533 705 407 547 717 421 350 510 244Detroit 639 822 505 693 895 542 443 528 384Georgia 533 697 411 580 747 450 376 503 286Atlanta 492 659 372 533 728 388 397 506 317Rural Georgia 559 731 388 670 813 507 - - -Greater Georgia 549 712 426 595 755 470 363 500 266

Hawaii 475 620 352 545 649 412 - - -Idaho 635 775 510 641 782 516 - - -Iowa 638 845 484 642 848 488 - - -Kentucky 642 886 460 655 904 470 401 557 284Louisiana 608 814 451 651 863 485 461 623 340Massachusetts 523 659 423 541 682 436 347 410 297New Jersey 545 721 419 585 780 443 372 466 314New Mexico 488 585 405 493 595 406 - - -New York 535 702 412 575 752 441 390 514 313Seattle-Puget Sound 585 749 463 604 769 480 490 562 397Utah 542 670 433 551 681 440 - - -

SEER 9 Areasb 555 719 430 586 758 454 414 522 333SEER 13 Areasb 549 705 429 586 753 457 419 521 342SEER 18 Areasb 554 717 431 589 761 456 409 518 329SEER 21 Areasb 550 712 428 584 754 453 401 513 322

Total US 562 725 436 586 755 454 408 518 330

Table 1921Non-Hodgkin Lymphoma

Age-Adjusted SEER Death Ratesa

By Registry Race and Sex

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 562 002

High Five StatesMichigan 645 011 01(0112) 1479Kentucky 642 016 02(0118) 1424Iowa 638 018 03(0120) 1367Indiana 638 013 04(0117) 1361Idaho 635 027 05(0126) 1303

Low Five StatesNevada 511 019 47(2251) -899Colorado 491 014 48(3851) -1257New Mexico 488 020 49(2851) -1317Hawaii 475 024 50(3051) -1542c

DC 444 039 51(2351) -2097c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 545 014 28(1847) -291 Montana 559 030 25(0250) -042Alaska 525 047 43(0151) -654 Nebraska 563 023 22(0548) 026Arizona 512 012 46(2950) -886 Nevada 511 019 47(2251) -899Arkansas 555 018 26(1247) -113 New Hampshire 562 027 23(0349) 014California 533 005 40(2645) -508 New Jersey 545 010 29(2045) -301Colorado 491 014 48(3851) -1257 New Mexico 488 020 49(2851) -1317Connecticut 533 016 39(1949) -505 New York 535 007 37(2446) -478Delaware 628 033 08(0139) 1174 North Carolina 541 010 35(2146) -363DC 444 039 51(2351) -2097c North Dakota 561 037 24(0151) -007Florida 535 006 38(2545) -479 Ohio 616 009 10(0220) 969Georgia 533 011 41(2248) -511 Oklahoma 630 017 06(0121) 1226Hawaii 475 024 50(3051) -1542c Oregon 612 016 11(0124) 903Idaho 635 027 05(0126) 1303 Pennsylvania 603 009 16(0622) 729Illinois 566 009 20(1634) 085 Rhode Island 542 029 32(0651) -350Indiana 638 013 04(0117) 1361 South Carolina 542 014 31(1847) -347Iowa 638 018 03(0120) 1367 South Dakota 541 033 36(0451) -364Kansas 585 019 19(0439) 420 Tennessee 629 013 07(0119) 1198Kentucky 642 016 02(0118) 1424 Texas 546 007 27(2142) -277Louisiana 608 016 14(0125) 826 Utah 542 022 33(1250) -352Maine 609 026 13(0137) 852 Vermont 605 040 15(0148) 770Maryland 524 013 44(2349) -663 Virginia 544 011 30(2046) -319Massachusetts 523 012 45(2549) -687 Washington 599 013 17(0425) 665Michigan 645 011 01(0112) 1479 West Virginia 612 022 12(0132) 894Minnesota 617 014 09(0122) 984 Wisconsin 590 013 18(0629) 507Mississippi 531 018 42(1850) -551 Wyoming 564 043 21(0151) 050Missouri 542 012 34(1947) -354

Table 1922Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males and Females

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 725 003

High Five StatesKentucky 886 030 01(0112) 2213c

Iowa 845 032 02(0120) 1647c

Michigan 842 019 03(0114) 1615c

Indiana 839 024 04(0116) 1567c

Delaware 824 058 05(0144) 1364

Low Five StatesArizona 635 019 47(3251) -1244Alaska 630 075 48(0251) -1311Hawaii 620 041 49(1951) -1452DC 614 071 50(0551) -1535c

New Mexico 585 033 51(3451) -1928c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 688 025 36(1649) -513 Montana 709 050 26(0251) -218Alaska 630 075 48(0251) -1311 Nebraska 737 040 20(0248) 165Arizona 635 019 47(3251) -1244 Nevada 653 032 44(1951) -994Arkansas 721 031 22(0747) -061 New Hampshire 710 046 25(0451) -210California 677 009 41(2846) -666 New Jersey 721 018 21(1441) -059Colorado 643 024 46(2451) -1133 New Mexico 585 033 51(3451) -1928c

Connecticut 705 028 28(1248) -273 New York 702 012 30(1943) -323Delaware 824 058 05(0144) 1364 North Carolina 709 018 27(1644) -221DC 614 071 50(0551) -1535c North Dakota 682 061 39(0251) -598Florida 683 011 37(2446) -585 Ohio 800 017 09(0320) 1029Georgia 697 019 34(1746) -387 Oklahoma 806 030 08(0126) 1109Hawaii 620 041 49(1951) -1452 Oregon 794 028 12(0128) 947Idaho 775 045 16(0146) 692 Pennsylvania 783 015 15(0523) 794Illinois 739 016 19(1235) 190 Rhode Island 649 050 45(1051) -1050Indiana 839 024 04(0116) 1567c South Carolina 681 025 40(1850) -604Iowa 845 032 02(0120) 1647c South Dakota 701 056 31(0251) -332Kansas 713 032 24(0948) -174 Tennessee 820 023 06(0120) 1311Kentucky 886 030 01(0112) 2213c Texas 698 012 32(2043) -368Louisiana 814 029 07(0122) 1222 Utah 670 036 42(1351) -754Maine 754 045 18(0148) 395 Vermont 794 069 11(0149) 950Maryland 682 023 38(1849) -588 Virginia 694 020 35(1847) -429Massachusetts 659 020 43(2450) -910 Washington 790 022 13(0224) 897Michigan 842 019 03(0114) 1615c West Virginia 774 038 17(0142) 675Minnesota 797 025 10(0224) 995 Wisconsin 786 023 14(0227) 844Mississippi 717 034 23(0748) -110 Wyoming 698 071 33(0151) -377Missouri 702 022 29(1646) -319

Table 1923Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 436 002

High Five StatesIdaho 510 033 01(0139) 1697c

Maine 497 031 02(0141) 1396Michigan 495 012 03(0119) 1340Oklahoma 492 020 04(0128) 1276Indiana 492 016 05(0123) 1270

Low Five StatesMississippi 404 021 47(1351) -731Nevada 382 022 48(2051) -1237Colorado 369 016 49(3451) -1540c

Hawaii 352 027 50(2551) -1932c

DC 323 044 51(1551) -2601c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 440 017 24(0547) 099 Montana 435 036 27(0151) -034Alaska 414 058 38(0151) -500 Nebraska 435 027 26(0249) -032Arizona 407 014 44(2049) -664 Nevada 382 022 48(2051) -1237Arkansas 428 021 31(0649) -181 New Hampshire 454 032 19(0149) 400California 423 006 34(2244) -313 New Jersey 419 012 37(1848) -397Colorado 369 016 49(3451) -1540c New Mexico 405 025 46(0951) -706Connecticut 407 018 45(1550) -669 New York 412 008 39(2548) -554Delaware 473 039 12(0150) 855 North Carolina 420 012 35(1848) -374DC 323 044 51(1551) -2601c North Dakota 471 045 13(0150) 809Florida 412 007 40(2548) -564 Ohio 478 011 10(0123) 967Georgia 411 012 43(2049) -582 Oklahoma 492 020 04(0128) 1276Hawaii 352 027 50(2551) -1932c Oregon 465 019 15(0141) 668Idaho 510 033 01(0139) 1697c Pennsylvania 467 010 14(0427) 714Illinois 439 010 25(1341) 074 Rhode Island 455 035 18(0150) 434Indiana 492 016 05(0123) 1270 South Carolina 432 017 30(0947) -102Iowa 484 021 08(0135) 1087 South Dakota 411 039 42(0151) -580Kansas 486 023 06(0137) 1143 Tennessee 484 015 09(0126) 1087Kentucky 460 018 17(0241) 544 Texas 427 008 32(1944) -213Louisiana 451 018 21(0345) 333 Utah 433 026 28(0250) -081Maine 497 031 02(0141) 1396 Vermont 461 047 16(0151) 578Maryland 411 015 41(1749) -576 Virginia 432 013 29(1246) -092Massachusetts 423 014 33(1548) -303 Washington 452 015 20(0541) 360Michigan 495 012 03(0119) 1340 West Virginia 486 027 07(0143) 1141Minnesota 475 017 11(0132) 901 Wisconsin 443 015 23(0645) 156Mississippi 404 021 47(1351) -731 Wyoming 445 051 22(0151) 192Missouri 419 014 36(1549) -396

Table 1924Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Females

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 Areas (excluding the AlaskaNative Registry) and 112016 US population estimates based on the average of 2015 and 2016 population estimates from theUS Bureau of the CensusPrevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 24 years

b Maximum limited-duration prevalence is 24 years for 1992-2016 datac Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groupsd Cases diagnosed more than 24 years ago were estimated using the completeness index method (Capocaccia et al 1997

Merrill et al 2000)e Complete prevalence is obtained by summing 0 to lt24 and gt=24- Statistic not shown Statistic based on fewer than 5 cases estimated alive in SEER for the time interval+ Not available

Years Since Diagnosis 0 to lt5 5 to lt10 10 to lt15 15 to lt20 20 to lt24 0 to lt24b gt=24d Completee

Race Sex

All Races Both Sexes 248946 177490 117326 69109 31890 644761 49943 694704Males 135137 94173 60159 36020 16581 342069 25489 367558Females 113809 83317 57167 33089 15309 302692 24454 327146

White Both Sexes 213764 154454 101984 60537 28026 558765 49625 620368Males 116527 82172 52535 31627 14543 297404 26526 330121Females 97237 72282 49448 28910 13483 261361 23099 290247

Black Both Sexes 20500 13640 9750 5271 2215 51376 4115 55491Males 10712 7188 4768 2684 1174 26526 1911 28437Females 9789 6452 4981 2587 1041 24850 2204 27054

Asian Both Sexes 8405 5210 3415 1867 844 19741 + +Pacific Males 4548 2661 1757 1013 407 10386 + +Islander Females 3856 2549 1657 855 437 9355 + +

Hispanic Both Sexes 21339 14049 8272 4881 2136 50676 + +Males 10918 7243 4331 2617 1094 26202 + +Females 10421 6805 3941 2264 1043 24474 + +

Age Specific (Crude) Age-Adjustedc Age at Prevalence All Ages 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ All Ages

Race Sex

All Races Both Sexes 02001 00035 00139 00283 00538 01121 02352 04640 08181 10224 01738Males 02156 00044 00189 00354 00625 01293 02710 05243 09364 12449 02023Females 01850 00026 00087 00208 00450 00952 02010 04094 07196 08856 01498

White Both Sexes 02216 00035 00143 00289 00534 01148 02427 04858 08597 10738 01807Males 02380 00045 00198 00359 00622 01317 02790 05442 09778 13060 02095Females 02054 00025 00085 00214 00442 00976 02072 04317 07593 09285 01560

Black Both Sexes 01139 00029 00113 00265 00599 01027 02010 03340 05117 05333 01251Males 01226 00029 00140 00351 00696 01223 02333 03969 05849 06055 01457Females 01059 00030 00086 00178 00510 00853 01728 02836 04608 04976 01088

Asian Both Sexes 00970 00039 00133 00207 00353 00680 01409 02692 04470 06094 01032Pacific Males 01065 00044 00175 00240 00398 00744 01640 03072 05516 07472 01222Islander Females 00882 00033 00092 00175 00312 00623 01209 02384 03629 05207 00880

Hispanic Both Sexes 00887 00030 00117 00206 00398 00850 01769 03632 05888 07209 01294Males 00908 00035 00147 00256 00455 00932 01924 03940 06326 08003 01420Females 00866 00024 00086 00151 00337 00766 01616 03360 05552 06719 01185

Table 1925Non-Hodgkin Lymphoma

Estimated United States Cancer Prevalence Countsa on January 1 2016By RaceEthnicity Sex and Years Since Diagnosis

Estimated prevalence percenta on January 1 2016 of the SEER population diagnosed in the previous 24 yearsBy Age at Prevalence RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 372 452924 -05 62 18862 04 247 189692 -05 1657 244370 -05

1 Hodgkin Lymphoma 28 32262 -17 13 3927 -06 33 22556 -15 39 5779 -31

2 Non-Hodgkin lymphoma 336 409991 -03 48 14693 04 210 163591 -03 1572 231707 -042(a) Non-Hodgkin lymphoma B-cell 311 380349 -01 39 11836 14 190 148768 -02 1491 219745 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 15 16631 20 31 9416 10 07 5203 39 14 2012 252(a) 2 Mature Non-Hodgkin lymphoma B-cell 280 343965 -04 07 2271 30 174 137225 -05 1387 204469 -042(a) 21 ChronicSmallProlymphocytic 69 85601 -13 00 35 - 35 29103 -11 382 56463 -14

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 61 75061 -15 00 30 - 31 25339 -13 336 49692 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 311 19 - - - 00 72 - 02 234 262(a) 213 Mantle-cell lymphoma 08 10229 03 - - - 04 3692 02 44 6537 04

2(a) 22 Lymphoplasmacytic lymphoma 07 8651 00 - - - 03 2590 -11 41 6059 04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 03 3667 -03 - - - 01 1132 -18 17 2533 022(a) 222 Waldenstrom macroglubulinemia 04 4984 03 - - - 02 1458 -07 24 3526 06

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 72 87188 00 03 925 26 48 36480 -02 339 49783 022(a) 231 DLBCL NOSc 71 85899 -01 03 861 12 46 35469 -05 337 49569 012(a) 232 Intravascular large B-cell 00 162 - - - - 00 63 - 01 99 -

lymphoma2(a) 233 Primary effusion lymphoma 00 181 27 - - - 00 126 - 00 55 -2(a) 234 Mediastinal large B-cell 01 946 116 00 64 - 01 822 111 00 60 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 04 4692 -26 03 1028 32 04 2618 -43 07 1046 -432(a) 25 Marginal-zone lymphoma (MZL) 22 26534 00 00 137 13 14 11049 05 104 15348 -042(a) 251 Splenic MZL 02 2418 04 - - - 01 889 -08 10 1529 102(a) 252 Extranodal MZL MALTc type 13 15979 06 00 92 - 09 7148 11 59 8739 032(a) 253 Nodal MZL 07 8137 -15 00 45 - 04 3012 -05 34 5080 -20

2(a) 26 Follicular lymphoma 35 43582 -21 00 119 - 28 21725 -25 147 21738 -182(a) 27 Hairy-cell leukemia 03 3712 -16 - - - 03 2311 -19 09 1401 -122(a) 28 Plasma cell neoplasms 68 83957 08 00 24 - 39 31325 12 358 52608 062(a) 281 Plasmacytoma 04 4879 -04 00 16 - 03 2362 -06 17 2501 -032(a) 282 Multiple myeloma 64 79078 09 - - - 36 28963 14 341 50107 07

plasma-cell leukemia2(a) 29 Heavy chain disease 00 48 - - - - 00 24 - 00 23 -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 16 19753 33 00 149 27 08 6340 37 90 13264 32

Table 1926All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 23 27222 01 08 2502 18 19 13933 03 73 10787 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 616 - 01 293 - 00 272 - 00 51 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 22 26531 11 07 2207 75 19 13621 12 73 10703 -042(b) 21 Mycosis fungoidesSezary syndrome 06 6969 18 01 213 84 06 4080 23 18 2676 052(b) 211 Mycosis fungoides 06 6739 17 01 213 84 05 3990 22 17 2536 042(b) 212 Sezary syndrome 00 230 46 - - - 00 90 - 01 140 -

2(b) 22 Peripheral T-cell lymphoma 12 14531 -10 02 534 07 10 7159 -09 46 6838 -122(b) 221 Peripheral T-cell lymphoma NOSc 04 5393 -01 00 86 - 03 2489 04 19 2818 -042(b) 222 Angioimmunoblastic T-cell lymphoma 02 1902 02 - - - 01 699 -09 08 1201 072(b) 223 Subcutaneous panniculitis- 00 176 44 00 31 - 00 111 - 00 34 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 2523 -36 01 291 00 02 1450 -33 05 782 -54

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 139 - - - - 00 98 - 00 28 -2(b) 226 Enteropathy-type T-cell lymphoma 00 186 -02 - - - 00 84 - 01 101 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 2963 -07 00 59 - 02 1575 01 09 1329 -142(b) 228 Primary cutaneous anaplastic 01 1249 -41 00 51 - 01 653 -49 04 545 -39

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 03 3417 96 05 1428 101 02 1474 99 03 515 672(b) 24 NKcT-cell lymphoma nasal-type 01 985 02 00 26 - 01 659 00 02 300 05

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 120 - - - - 00 54 - 00 65 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 509 30 - - - 00 195 -05 02 309 442(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 75 - - - - 00 40 - 00 33 -2(c) Non-Hodgkin lymphoma unknown lineage 02 2420 -274 01 355 - 01 890 -216 08 1175 -2792(c) 1 Precursor lymphoblastic leukemia 01 814 -283 01 343 - 00 238 - 02 233 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 95 - - - - 00 25 - 00 69 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 1511 -274 - - - 01 627 -202 06 873 -319

lineage2() 1 Total precursor lymphomaleukemiad 16 18061 -07 33 10052 -15 08 5713 06 15 2296 -01

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 762 273 00 20 - 00 339 227 03 403 -lymphoma

4 Lymphoid neoplasm NOSc 08 9909 -55 01 222 113 04 3206 -59 43 6481 -59

Table 1926 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 461 253152 -05 70 10973 05 294 110367 -07 2122 131812 -05

1 Hodgkin Lymphoma 31 17710 -17 13 2118 -03 36 12525 -16 48 3067 -31

2 Non-Hodgkin lymphoma 419 229772 -03 56 8711 05 252 95756 -05 2017 125305 -032(a) Non-Hodgkin lymphoma B-cell 387 212247 -02 44 6786 15 227 86941 -04 1908 118520 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 16 8999 24 33 5123 11 08 2888 46 16 988 292(a) 2 Mature Non-Hodgkin lymphoma B-cell 351 192801 -05 10 1558 28 210 80417 -08 1783 110826 -042(a) 21 ChronicSmallProlymphocytic 96 52411 -15 00 21 - 47 18927 -14 539 33463 -15

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 82 44988 -17 00 19 - 40 16143 -16 464 28826 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 193 -02 - - - 00 46 - 02 145 052(a) 213 Mantle-cell lymphoma 13 7230 -01 - - - 07 2738 -01 72 4492 -01

2(a) 22 Lymphoplasmacytic lymphoma 10 5082 -05 - - - 04 1524 -08 58 3558 -04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 04 2062 -08 - - - 02 616 -12 23 1446 -072(a) 222 Waldenstrom macroglubulinemia 06 3020 -02 - - - 02 908 -06 34 2112 -02

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 88 48128 01 03 554 22 59 21824 -06 418 25750 052(a) 231 DLBCL NOSc 87 47520 00 03 519 03 57 21366 -08 416 25635 042(a) 232 Intravascular large B-cell 00 75 - - - - 00 31 - 01 44 -

lymphoma2(a) 233 Primary effusion lymphoma 00 167 26 - - - 00 123 - 01 44 -2(a) 234 Mediastinal large B-cell 01 366 155 00 35 - 01 304 142 00 27 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 06 3388 -22 05 775 31 06 1969 -46 10 644 -192(a) 25 Marginal-zone lymphoma (MZL) 22 12351 -02 01 98 - 14 5177 -02 114 7076 -012(a) 251 Splenic MZL 02 1164 14 - - - 01 434 18 12 730 112(a) 252 Extranodal MZL MALTc type 13 7268 07 00 62 - 09 3267 04 63 3939 102(a) 253 Nodal MZL 07 3919 -23 00 36 - 04 1476 -22 39 2407 -23

2(a) 26 Follicular lymphoma 39 21788 -19 01 100 - 30 11210 -25 165 10478 -152(a) 27 Hairy-cell leukemia 05 2984 -18 - - - 05 1908 -20 17 1076 -152(a) 28 Plasma cell neoplasms 85 46642 07 - - - 45 17864 11 462 28769 052(a) 281 Plasmacytoma 05 2997 -08 - - - 04 1509 -16 24 1484 -012(a) 282 Multiple myeloma 80 43645 08 - - - 41 16355 13 439 27285 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 27 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 20 10447 34 01 105 - 10 3636 40 110 6706 32

Table 1927All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 29 16118 00 11 1730 14 23 8235 02 98 6153 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 430 - 01 208 - 01 188 - 01 34 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 28 15642 11 10 1521 71 22 8022 11 97 6099 -032(b) 21 Mycosis fungoidesSezary syndrome 07 3962 19 01 135 - 06 2261 21 25 1566 092(b) 211 Mycosis fungoides 07 3831 20 01 135 - 06 2213 21 23 1483 092(b) 212 Sezary syndrome 00 131 - - - - 00 48 - 01 83 -

2(b) 22 Peripheral T-cell lymphoma 15 8438 -13 02 318 -09 12 4248 -12 62 3872 -132(b) 221 Peripheral T-cell lymphoma NOSc 06 3159 -05 00 49 - 04 1520 02 26 1590 -082(b) 222 Angioimmunoblastic T-cell lymphoma 02 1024 19 - - - 01 415 11 10 607 232(b) 223 Subcutaneous panniculitis- 00 68 - - - - 00 39 - 00 16 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 03 1549 -39 01 184 -01 02 888 -43 08 477 -45

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 98 - - - - 00 69 - 00 18 -2(b) 226 Enteropathy-type T-cell lymphoma 00 105 - - - - 00 50 - 01 54 -2(b) 227 Cutaneous T-cell lymphoma NOSc 03 1696 -12 00 32 - 02 894 -03 12 770 -172(b) 228 Primary cutaneous anaplastic 01 739 -48 00 26 - 01 373 -49 05 340 -49

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 04 2253 97 07 1047 92 03 940 98 04 266 1022(b) 24 NKcT-cell lymphoma nasal-type 01 638 -05 00 18 - 01 435 -03 03 185 -06

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 58 - - - - 00 22 - 01 36 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 01 293 45 - - - 00 116 - 03 174 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 46 - - - - 00 25 - 00 20 -2(c) Non-Hodgkin lymphoma unknown lineage 03 1407 -232 01 195 - 02 580 -184 10 632 -2302(c) 1 Precursor lymphoblastic leukemia 01 474 -228 01 187 - 00 134 - 02 153 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 49 - - - - - - - 01 36 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 02 884 -239 - - - 01 433 -175 07 443 -

lineage2() 1 Total precursor lymphomaleukemiad 18 9903 -06 35 5518 -17 09 3210 09 19 1175 05

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 435 271 - - - 01 215 - 03 207 -lymphoma

4 Lymphoid neoplasm NOSc 10 5235 -59 01 131 - 05 1871 -65 54 3233 -61

Table 1927 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 301 199772 -05 53 7889 02 202 79325 -02 1322 112558 -08

1 Hodgkin Lymphoma 24 14552 -16 12 1809 -10 29 10031 -14 32 2712 -32

2 Non-Hodgkin lymphoma 269 180219 -03 40 5982 03 170 67835 00 1251 106402 -062(a) Non-Hodgkin lymphoma B-cell 250 168102 -01 34 5050 13 154 61827 02 1190 101225 -042(a) 1 Precursor Non-Hodgkin lymphoma B-cell 14 7632 16 29 4293 09 06 2315 29 12 1024 202(a) 2 Mature Non-Hodgkin lymphoma B-cell 223 151164 -04 05 713 35 141 56808 -01 1102 93643 -072(a) 21 ChronicSmallProlymphocytic 48 33190 -13 - - - 24 10176 -05 268 23000 -16

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 43 30073 -15 - - - 22 9196 -06 243 20866 -19

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 118 - - - - 00 26 - 01 89 -2(a) 213 Mantle-cell lymphoma 04 2999 11 - - - 02 954 10 24 2045 12

2(a) 22 Lymphoplasmacytic lymphoma 05 3569 04 - - - 03 1066 -16 30 2501 11Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 02 1605 01 - - - 01 516 -25 13 1087 112(a) 222 Waldenstrom macroglubulinemia 03 1964 06 - - - 01 550 -08 17 1414 11

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 58 39060 00 02 371 33 38 14656 03 283 24033 -032(a) 231 DLBCL NOSc 57 38379 -02 02 342 27 36 14103 -01 282 23934 -032(a) 232 Intravascular large B-cell 00 87 - - - - 00 32 - 01 55 -

lymphoma2(a) 233 Primary effusion lymphoma - - - - - - - - - - - -2(a) 234 Mediastinal large B-cell 01 580 91 00 29 - 02 518 93 00 33 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 02 1304 -34 02 253 38 02 649 -37 05 402 -852(a) 25 Marginal-zone lymphoma (MZL) 21 14183 01 00 39 - 15 5872 12 98 8272 -062(a) 251 Splenic MZL 02 1254 -07 - - - 01 455 -32 10 799 072(a) 252 Extranodal MZL MALTc type 13 8711 06 00 30 - 10 3881 17 57 4800 -032(a) 253 Nodal MZL 06 4218 -07 - - - 04 1536 11 32 2673 -18

2(a) 26 Follicular lymphoma 33 21794 -24 00 19 - 27 10515 -25 134 11260 -222(a) 27 Hairy-cell leukemia 01 728 -12 - - - 01 403 -11 04 325 -122(a) 28 Plasma cell neoplasms 55 37315 08 - - - 33 13461 15 282 23839 052(a) 281 Plasmacytoma 03 1882 00 - - - 02 853 12 12 1017 -092(a) 282 Multiple myeloma 52 35433 09 - - - 30 12608 15 270 22822 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 21 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 14 9306 32 00 44 - 07 2704 32 76 6558 31

Table 1928All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 17 11104 01 05 772 29 15 5698 05 55 4634 -112(b) 1 Precursor Non-Hodgkin lymphoma T-cell 00 186 - 01 85 - 00 84 - 00 17 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 17 10889 09 05 686 83 15 5599 12 54 4604 -092(b) 21 Mycosis fungoidesSezary syndrome 05 3007 15 01 78 - 05 1819 26 13 1110 -042(b) 211 Mycosis fungoides 05 2908 12 01 78 - 05 1777 23 12 1053 -072(b) 212 Sezary syndrome 00 99 - - - - 00 42 - 01 57 -

2(b) 22 Peripheral T-cell lymphoma 09 6093 -08 01 216 30 08 2911 -06 35 2966 -142(b) 221 Peripheral T-cell lymphoma NOSc 03 2234 03 00 37 - 03 969 07 14 1228 -012(b) 222 Angioimmunoblastic T-cell lymphoma 01 878 -22 - - - 01 284 -39 07 594 -152(b) 223 Subcutaneous panniculitis- 00 108 - 00 18 - 00 72 - 00 18 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 974 -33 01 107 - 02 562 -19 04 305 -77

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 41 - - - - 00 29 - - - -2(b) 226 Enteropathy-type T-cell lymphoma 00 81 - - - - 00 34 - 01 47 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 1267 00 00 27 - 02 681 07 07 559 -102(b) 228 Primary cutaneous anaplastic 01 510 -34 00 25 - 01 280 -50 02 205 -33

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 02 1164 96 03 381 127 01 534 97 03 249 302(b) 24 NKcT-cell lymphoma nasal-type 01 347 11 - - - 01 224 - 01 115 -

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 62 - - - - 00 32 - 00 29 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 216 03 - - - 00 79 - 02 135 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 29 - - - - - - - - - -2(c) Non-Hodgkin lymphoma unknown lineage 02 1013 -341 01 160 - 01 310 - 06 543 -2(c) 1 Precursor lymphoblastic leukemia 01 340 - 01 156 - 00 104 - 01 80 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 46 - - - - - - - 00 33 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 627 - - - - 01 194 - 05 430 -

lineage2() 1 Total precursor lymphomaleukemiad 14 8158 -09 31 4534 -13 07 2503 02 13 1121 -11

3 Composite Hodgkin lymphoma and Non-Hodgkin 00 327 - - - - 00 124 - 02 196 -lymphoma

4 Lymphoid neoplasm NOSc 07 4674 -52 01 91 - 03 1335 -51 36 3248 -58

Table 1928 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 7: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a SEER 21 areas Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)unless noted

b US Mortality Files National Center for Health Statistics Centers for Disease Control and PreventionRates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) unless noted

c Rates are per 100000 and are age-adjusted to the world (WHO 2000-2025) standard million- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER IncidenceAge at DiagnosisAge-Adjusted Rates 2012-2016All ages 196 239 162 206 250 170 147 177 124Under 65 94 111 78 96 113 80 91 109 7665 and over 904 1126 743 966 1199 794 532 646 461

All ages (WHO world std)c 147 177 122 154 184 127 117 140 98

Age-Specific Rates 2012-2016lt1 - - - - - - - - -1-4 08 11 05 08 11 06 06 07 -5-9 12 17 07 13 18 07 10 13 0810-14 15 20 10 14 19 10 16 21 1115-19 21 27 14 20 26 14 20 28 1220-24 27 32 22 26 31 21 28 35 2025-29 35 40 29 34 39 28 41 48 3430-34 49 56 42 48 54 41 56 67 4735-39 72 85 59 71 83 58 81 98 6640-44 99 117 80 99 117 80 108 128 9045-49 145 168 122 147 169 125 156 190 12750-54 222 256 189 229 264 194 217 250 18755-59 312 366 261 326 379 274 277 332 23060-64 445 522 376 470 548 396 363 426 31165-69 629 742 528 667 781 564 447 522 39070-74 833 997 697 890 1058 746 522 640 43975-79 1044 1287 855 1124 1384 918 588 692 52080-84 1193 1522 966 1280 1631 1031 650 791 57385+ 1079 1499 861 1146 1589 915 508 685 434

US MortalityAge at DeathAge-Adjusted Rates 2012-2016All ages 56 73 44 59 76 45 41 52 33Under 65 13 17 10 13 17 09 16 21 1265 and over 352 453 279 372 477 295 210 265 176

All ages (WHO world std)c 30 39 23 31 40 23 25 32 20

Age-Specific Rates 2012-2016lt1 - - - - - - - - -1-4 00 01 - 00 01 - - - -5-9 01 01 00 00 01 - 01 - -10-14 01 01 01 01 01 01 - - -15-19 01 02 01 01 02 01 02 02 -20-24 02 03 02 02 03 02 04 04 0325-29 04 05 03 03 04 02 05 07 0430-34 05 07 04 05 06 03 09 12 0635-39 07 09 05 06 08 04 11 14 0940-44 11 14 08 10 13 08 18 21 1545-49 18 23 13 17 22 13 24 32 1750-54 31 41 21 31 41 21 37 49 2655-59 53 71 37 54 72 36 58 74 4460-64 90 118 64 92 121 64 90 116 6965-69 142 184 105 149 192 109 116 146 9370-74 244 309 188 256 324 197 167 214 13375-79 374 473 294 397 501 312 220 275 18480-84 567 725 455 600 764 481 321 405 27485+ 751 994 624 795 1049 662 360 457 320

Table 197Non-Hodgkin Lymphoma

SEER Incidencea and US Deathb Rates Age-Adjusted and Age-Specific Rates by Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on End Results data from a series of hospital registries and one population-based registryb SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)

Based on follow-up of patients into 2016 Expected survival rates are derived from the US Annual Life Tablesc SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER programBased on follow-up of patients into 2016

d Period survival provides a 2015 estimate of survival by piecing together the most recent conditional survival estimatesfrom several cohorts It is computed here using three year calendar blocks (2010-2012 0-1 year survival)(2009-2011 1-2 year survival) (2008-2010 2-3 year survival) (2007-2009 3-4 year survival) (2006-2008 4-5 years survival)

e Stage at diagnosis is classified using SEER Summary Stage 2000 Stage distribution percentages may not sum to 100 due to roundingf The difference between 1975-1977 and 2009-2015 is statistically significant (plt05)g The standard error is between 5 and 10 percentage pointsh The standard error is greater than 10 percentage points- Statistic could not be calculated due to fewer than 25 cases during the time period

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

5-Year Relative Survival (Percent)Year of Diagnosis1960-1963a - - - 31 31 31 - - -1970-1973a - - - 41 39 43 - - -1975-1977b 465 456 475 468 463 473 486 426 553g

1978-1980b 479 461 498 479 462 495 511 469 5671981-1983b 506 503 509 508 505 511 495 492 4981984-1986b 516 501 534 521 507 537 468 445 4991987-1989b 509 476 549 513 482 552 457 413 5101990-1992b 507 467 557 515 476 564 422 384 4761993-1995b 526 487 575 533 498 577 425 359 5491996-1998b 588 570 610 595 577 615 547 531 5721999-2001b 640 614 670 650 628 676 558 490 6382002-2004b 698 686 712 710 701 721 636 611 6662005-2008b 716 706 727 728 719 738 625 578 6752009-2015b 747f 739f 757f 757f 748f 767f 695f 670f 724f

5-Year Period Survival (Percent)cd

2015 722 705 743 726 708 747 671 641 703

Stage Distribution () 2009-2015ce

All StagesNumber of cases 97737 53606 44131 80120 44109 36011 8184 4388 3796Percent 100 100 100 100 100 100 100 100 100Localized 27 27 29 27 26 28 28 25 31Regional 15 15 15 15 15 15 15 15 15Distant 50 51 48 51 52 49 51 54 48UnstagedUnknown 8 7 8 7 7 8 6 6 7

5-Year Relative Survival (Percent) 2009-2015c

Age at DiagnosisAges lt45 840 820 870 855 836 885 735 708 776Ages 45-54 810 777 859 826 795 872 687 639 750Ages 55-64 770 742 809 781 754 818 678 620 749Ages 65-74 725 706 747 731 711 755 656 623 682Ages 75+ 554 539 568 557 538 574 482 449 500Ages lt65 800 773 838 812 787 849 701 659 759Ages 65+ 638 627 649 641 628 655 584 562 598

StageeAll Stages 720 707 737 724 711 740 665 637 698Localized 840 830 850 843 833 852 810 766 850Regional 750 751 749 755 756 755 689 698 678Distant 648 633 668 657 642 677 580 557 610UnstagedUnknown 703 686 723 679 662 698 659 648 666

Table 198Non-Hodgkin Lymphoma

5-Year Relative and Period Survival (Percent) by Race Sex Diagnosis Year and Age

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Expected survival rates are derived from the US Annual Life Tables

1975- 1980- 1985- 1990-1979 1984 1989 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Survival Time

1-year 702 730 713 704 703 733 756 767 774 773 787 810 803 811 817 810 816 841 839 844 834 842 844 834 8452-year 602 637 628 622 618 659 685 700 710 714 733 760 757 760 773 769 775 790 795 796 797 800 800 7953-year 546 585 582 577 575 621 649 664 669 679 701 731 731 735 748 745 750 762 773 774 775 779 7794-year 505 546 543 544 547 587 621 636 645 655 681 712 716 715 730 726 732 744 756 752 756 7675-year 468 507 510 516 520 561 594 609 621 638 660 693 700 701 716 705 712 728 741 742 7426-year 436 475 483 492 499 541 571 583 595 621 647 680 683 688 704 688 701 718 721 7237-year 408 450 458 470 479 522 552 564 577 605 629 663 671 672 685 672 688 702 7108-year 385 428 434 450 464 504 529 552 563 589 613 651 658 666 670 661 674 6909-year 366 408 415 435 453 493 515 535 548 576 600 640 648 649 652 651 66110-year 350 389 398 421 443 481 501 522 537 563 589 632 633 638 634 63711-year 335 374 385 406 434 466 488 511 525 548 581 618 621 630 63112-year 324 360 369 395 423 457 481 501 512 535 568 600 615 61713-year 314 348 358 383 415 449 469 492 500 520 561 593 60214-year 302 335 347 372 406 443 456 485 488 513 549 58315-year 289 322 335 365 398 437 447 474 478 505 54016-year 279 312 328 356 393 437 433 472 470 49217-year 274 304 321 349 388 428 428 469 45818-year 268 296 314 341 378 420 419 46319-year 260 288 306 333 370 413 41220-year 252 280 301 329 359 408

Table 199Non-Hodgkin Lymphoma

SEERa Relative Survival (Percent)By Year of Diagnosis

All Races Males and Females

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Expected survival rates are derived from the US Annual Life Tables

1975- 1980- 1985- 1990-1979 1984 1989 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Survival Time

1-year 694 727 689 671 666 712 747 749 758 765 776 806 797 801 811 810 814 836 828 838 838 841 834 830 8352-year 594 637 605 582 583 636 672 682 691 703 713 752 749 755 762 765 778 779 781 788 798 793 786 7913-year 534 580 557 537 545 598 638 645 644 668 679 720 726 726 731 736 754 751 757 766 776 769 7644-year 493 539 516 504 515 561 610 620 615 639 657 700 709 701 711 713 734 734 737 743 756 7575-year 455 501 482 476 485 537 583 592 590 617 635 679 689 688 699 689 710 721 724 735 7426-year 426 466 455 456 469 510 561 565 562 602 620 667 669 676 684 670 696 715 706 7177-year 399 442 431 436 449 491 542 544 546 587 601 652 658 655 668 651 682 696 6968-year 378 420 410 418 433 474 520 533 536 567 582 637 645 649 650 634 665 6869-year 357 401 391 402 423 465 504 514 523 553 572 628 633 632 636 618 65210-year 340 380 377 392 416 455 489 503 515 542 560 617 617 620 613 60911-year 328 363 364 381 407 437 477 494 508 527 547 603 605 612 61212-year 319 352 351 372 395 427 472 482 498 515 537 589 601 59613-year 307 342 343 361 389 419 456 467 491 501 531 582 59114-year 295 330 332 350 378 414 444 461 480 496 521 57215-year 281 319 324 344 368 409 435 453 473 488 51216-year 272 308 316 333 361 409 426 453 471 47417-year 265 300 308 326 358 403 420 449 46218-year 261 294 302 320 350 396 410 44219-year 256 287 294 313 342 391 40320-year 250 280 291 309 332 387

Table 1910Non-Hodgkin Lymphoma

SEERa Relative Survival (Percent)By Year of Diagnosis

All Races Males

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Expected survival rates are derived from the US Annual Life Tables

1975- 1980- 1985- 1990-1979 1984 1989 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Survival Time

1-year 710 734 741 747 752 759 767 786 792 782 801 814 810 821 825 809 819 847 854 851 830 843 856 838 8572-year 611 637 656 672 664 688 701 720 734 727 758 769 765 767 786 774 772 804 812 807 796 810 817 7993-year 559 589 611 627 616 649 662 684 700 692 727 744 736 746 768 756 746 774 791 786 774 791 7974-year 519 553 576 595 590 619 634 653 681 674 710 725 724 730 751 739 729 757 778 764 755 7805-year 482 514 544 567 565 591 608 629 658 664 688 708 713 716 736 724 715 735 763 751 7426-year 446 484 517 539 540 580 583 603 635 643 679 695 699 701 727 708 707 722 738 7317-year 417 458 490 512 520 560 563 586 615 626 663 674 687 692 704 698 694 709 7268-year 392 437 463 491 505 542 539 573 596 615 649 667 672 684 693 692 684 6949-year 374 416 443 476 492 529 528 557 578 603 633 654 664 669 671 688 67110-year 360 399 424 458 480 514 516 542 562 588 625 648 651 658 659 66911-year 342 385 409 438 469 503 500 529 547 573 621 636 640 651 65312-year 329 368 390 425 460 494 493 523 529 560 606 613 632 64013-year 321 353 376 411 449 486 485 518 510 543 598 606 61514-year 310 340 365 400 442 479 470 512 497 532 582 59615-year 297 326 349 391 436 472 460 498 483 525 57416-year 287 316 342 385 435 467 441 492 468 51317-year 282 306 336 378 428 459 438 490 45218-year 274 298 327 367 413 449 428 48519-year 265 288 321 358 407 439 42220-year 254 280 312 353 395 433

Table 1911Non-Hodgkin Lymphoma

SEERa Relative Survival (Percent)By Year of Diagnosis

All Races Females

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 5222 2506 2704 3176 3627 3994 4570 4729 5325 5260 5263 5562 5775 6226 6401 6704 6998 7072 11154

SEER 9 except 4285 2088 2267 2603 2819 3091 3507 3694 4159 4249 4364 4515 4818 5209 5398 5628 5841 6015 9363SF-Oakland

San Francisco- 937 418 437 573 808 903 1063 1035 1166 1011 899 1047 957 1017 1003 1076 1157 1057 1791Oakland SMSAc

San Francisco 245 96 123 210 326 393 467 410 450 354 213 256 220 283 219 216 240 225 362CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 134 155 161 183 201 215 234 233 252 244 238 244 246 258 254 255 255 245 244

SEER 9 except 132 154 161 181 188 201 217 218 236 236 235 236 244 256 254 253 252 247 243SF-Oakland

San Francisco- 147 158 160 194 267 285 317 305 335 288 252 286 256 266 256 263 268 235 246Oakland SMSAc

San Francisco 143 144 176 293 444 519 610 523 574 448 274 325 269 354 265 257 273 252 246CityCounty

Table 1912

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males All Ages

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males All Ages

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 0-19 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 223 87 108 91 94 84 100 89 120 105 104 119 127 107 106 143 134 155 240

SEER 9 except 191 78 95 82 80 76 86 74 107 84 93 100 115 90 87 114 119 129 198SF-Oakland

San Francisco- 32 9 13 9 14 8 14 15 13 21 11 19 12 17 19 29 15 26 42Oakland SMSAc

San Francisco 9 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 5 lt4 6 lt4CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 12 12 16 14 14 13 15 13 17 14 14 15 16 14 13 18 17 20 20

SEER 9 except 12 13 16 14 14 13 15 12 17 13 14 15 17 13 13 16 17 19 19SF-Oakland

San Francisco- 14 10 15 10 16 09 15 16 13 21 11 18 12 17 19 28 14 25 27Oakland SMSAc

San Francisco 23 - - - - - - - - - - - - - - 40 - 49 -CityCounty

Table 1913

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 0-19

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 0-19

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 20-54 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 1463 687 723 958 1211 1413 1766 1830 2089 1770 1608 1696 1623 1722 1655 1693 1674 1596 2242

SEER 9 except 1208 563 588 730 827 923 1195 1294 1483 1325 1269 1327 1308 1410 1383 1401 1402 1328 1848SF-Oakland

San Francisco- 255 124 135 228 384 490 571 536 606 445 339 369 315 312 272 292 272 268 394Oakland SMSAc

San Francisco 58 29 34 105 215 288 333 303 317 225 105 115 111 111 86 75 73 71 98CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 69 79 82 104 124 136 159 156 169 138 121 124 117 123 116 118 116 111 104

SEER 9 except 69 78 81 97 103 109 131 134 144 123 115 116 112 119 115 116 115 110 103SF-Oakland

San Francisco- 69 84 89 139 226 264 295 267 298 213 156 164 139 141 123 130 118 114 110Oakland SMSAc

San Francisco 67 88 94 272 565 715 813 724 744 510 230 252 239 248 194 162 152 145 129CityCounty

Table 1914

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 20-54

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 20-54

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 55+ and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 3536 1732 1873 2127 2322 2497 2704 2810 3116 3385 3551 3747 4025 4397 4640 4868 5190 5321 8672

SEER 9 except 2886 1447 1584 1791 1912 2092 2226 2326 2569 2840 3002 3088 3395 3709 3928 4113 4320 4558 7317SF-Oakland

San Francisco- 650 285 289 336 410 405 478 484 547 545 549 659 630 688 712 755 870 763 1355Oakland SMSAc

San Francisco 178 65 88 104 109 105 132 106 130 126 106 141 108 169 131 136 164 148 261CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 451 522 540 596 633 673 701 706 761 800 811 831 858 900 901 891 899 862 871

SEER 9 except 440 521 544 601 620 667 687 692 744 797 813 813 858 901 904 891 888 874 874SF-Oakland

San Francisco- 508 528 520 571 702 703 773 783 854 821 800 932 855 894 888 890 959 800 860Oakland SMSAc

San Francisco 482 446 598 727 739 757 934 747 914 872 727 934 690 1047 764 769 889 776 826CityCounty

Table 1915

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 55+

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 55+

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 003 006 217 072 Asian 0 001 003 005 183 072

10 002 005 011 218 073 Pacific 10 002 004 009 184 073

20 003 009 021 217 073 Islander 20 003 007 015 182 073

30 006 018 042 216 073 30 005 013 029 180 073

40 012 037 082 213 074 40 008 024 057 176 073

50 025 072 139 206 074 50 017 049 101 170 073

60 049 120 177 191 075 60 034 087 139 158 072

70 080 144 - 160 072 70 056 112 - 133 068

80 085 - - 106 062 80 066 - - 091 056

White 0 001 003 006 227 075 American 0 001 002 003 116 049

10 002 005 011 228 076 Indian 10 002 002 005 117 050

20 003 009 021 227 076 Alaska 20 001 003 008 116 050

30 006 018 043 226 077 Nativea 30 003 007 022 117 051

40 012 038 085 223 077 40 004 019 041 117 052

50 026 075 147 217 078 50 016 038 078 118 053

60 052 127 187 201 078 60 024 067 105 109 055

70 085 153 - 169 076 70 048 091 - 096 055

80 090 - - 111 065 80 057 - - 064 043

Black 0 001 002 006 138 042 Hispanicb 0 001 002 005 222 073

10 002 005 011 140 043 10 001 004 009 223 074

20 003 010 022 139 043 20 003 008 019 222 074

30 006 019 041 137 043 30 005 016 040 221 074

40 013 035 068 133 043 40 011 035 078 218 074

50 023 057 093 125 043 50 024 068 133 211 074

60 037 076 102 110 042 60 046 114 173 195 074

70 047 078 - 087 038 70 075 140 - 164 070

80 044 - - 057 032 80 081 - - 112 057

Table 1916

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Both Sexes 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 004 007 243 081 Asian 0 001 003 006 213 085

10 002 006 013 244 082 Pacific 10 002 005 011 213 086

20 004 010 024 243 082 Islander 20 003 009 018 211 086

30 007 021 049 243 083 30 006 015 034 210 086

40 014 042 094 240 084 40 009 028 067 205 086

50 029 082 158 233 085 50 019 059 117 199 086

60 057 139 203 219 086 60 041 101 161 187 085

70 095 170 - 188 084 70 066 131 - 159 082

80 105 - - 130 073 80 080 - - 114 069

White 0 001 004 007 254 085 American 0 001 003 004 104 057

10 002 006 013 255 086 Indian 10 002 003 006 105 058

20 004 010 024 254 086 Alaska 20 001 004 008 103 058

30 007 020 049 253 087 Nativea 30 003 008 021 104 059

40 014 043 097 251 088 40 005 018 038 105 060

50 030 086 167 244 089 50 014 035 071 105 062

60 059 147 215 230 090 60 023 062 094 099 065

70 101 180 - 198 088 70 046 084 - 090 066

80 112 - - 136 076 80 053 - - 061 053

Black 0 001 003 007 152 046 Hispanicb 0 001 003 005 238 083

10 002 006 014 154 047 10 002 005 011 239 084

20 004 012 027 153 047 20 003 009 021 238 084

30 008 023 048 152 047 30 006 018 043 238 084

40 016 042 079 148 047 40 012 037 083 235 085

50 027 066 105 138 047 50 026 073 145 228 085

60 043 087 114 123 045 60 050 126 189 214 085

70 054 088 - 099 042 70 086 157 - 185 081

80 053 - - 070 036 80 094 - - 131 066

Table 1917

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Males 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 002 004 193 064 Asian 0 001 002 004 159 063

10 001 004 009 195 064 Pacific 10 001 004 008 160 063

20 003 007 017 194 064 Islander 20 002 006 013 159 063

30 005 015 036 192 065 30 004 011 025 157 063

40 010 031 071 189 065 40 007 021 048 153 063

50 022 062 120 182 065 50 014 042 087 148 063

60 042 103 154 168 065 60 028 074 122 136 062

70 067 123 - 138 063 70 049 099 - 114 058

80 071 - - 090 054 80 057 - - 075 047

White 0 001 002 004 203 067 American 0 000 001 002 128 043

10 001 004 009 204 067 Indian 10 001 001 004 129 044

20 002 007 017 203 067 Alaska 20 001 003 007 128 044

30 005 015 037 201 067 Nativea 30 002 006 023 129 044

40 010 032 074 198 068 40 004 021 044 129 045

50 022 065 127 192 068 50 017 042 085 129 046

60 044 109 163 177 068 60 026 072 113 118 047

70 072 130 - 146 066 70 050 097 - 102 046

80 075 - - 094 056 80 060 - - 066 037

Black 0 000 002 004 126 040 Hispanicb 0 001 002 004 210 065

10 001 004 009 128 040 10 001 004 008 211 066

20 003 008 018 127 040 20 002 007 017 211 066

30 005 015 034 125 040 30 004 014 036 209 066

40 010 029 058 122 040 40 010 032 073 206 066

50 020 049 083 115 040 50 022 064 123 198 066

60 032 068 094 102 039 60 043 104 161 182 065

70 041 071 - 080 036 70 066 127 - 149 062

80 039 - - 051 030 80 073 - - 100 051

Table 1918

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Females 2014-2016 By RaceEthnicity

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

The AAPC is the Average Annual Percent Change over the time interval The AAPCs are calculated bythe Joinpoint Regression Program Version 47 February 2019 National Cancer Institute

- Statistic not shown Rate based on less than 16 cases for the time intervalTrend based on less than 10 cases for at least one year within the time interval

a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) Trendsare based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico SeattleUtah and AtlantaThe SEER 21 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the AlaskaNative Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts

c The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 3 Joinpoints overdiagnosis years 2000-2016

d The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 5 Joinpoints overdiagnosis years 1975-2016

e Hispanic and Non-Hispanic are not mutually exclusive from whites blacks AsianPacificIslanders and American IndiansAlaska Natives Incidence data for Hispanics and Non-Hispanicsare based on NHIA and exclude cases from the Alaska Native Registry

f Incidence data for American IndianAlaska Native are based on the PurchasedReferred CareDelivery Area (PRCDA) counties

g US Mortality Files National Center for Health Statistics CDCh The 2007-2016 mortality AAPCs are based on a Joinpoint analysis using years of death 2000-2016 The APC is significantly different from zero (plt05)

SEER Incidence SEER 21 Areasb SEER 21 Areasb SEER 9 Areasb

Rate 2012-2016 Trend 2007-2016c Trend 2007-2016d

Rate per 100000 persons AAPC () AAPC ()

Total Males Females Total Males Females Total Males Females RaceEthnicity

All Races 196 239 162 -07 -09 -08 -09 -07 -08

White 206 250 170 -08 -11 -09 -09 -08 -08White Hispanice 183 212 161 -08 -03 -05 - - -White Non-Hispanice 210 256 172 -08 -06 -10 - - -

Black 147 177 124 01 00 03 00 -04 -09

AsianPacific Islander 134 164 110 00 00 -01 - - -

Amer IndAlaska Natf 113 120 106 -05 -12 00 - - -

Hispanice 179 207 157 -05 -02 03 - - -

US Mortalityg Rate 2012-2016 Trend 2007-2016h

Rate per 100000 persons AAPC ()

Total Males Females Total Males FemalesRaceEthnicity

All Races 56 73 44 -23 -20 -27

White 59 76 45 -23 -20 -27White Hispanice 51 65 40 -16 -13 -20White Non-Hispanice 59 76 46 -23 -20 -27

Black 41 52 33 -20 -19 -21

AsianPacific Islander 39 49 31 -17 -15 -19

Amer IndAlaska NatTotal US 31 40 24 -32 -20 -45PRCDA Counties 44 58 33 -21 -04 -37Non-PRCDA Counties 17 21 14 -54 -50 -60

Hispanice 48 61 38 -17 -14 -21

Table 1919Non-Hodgkin Lymphoma

SEER Incidence and US MortalityAge-Adjusted Rates and Trendsa

By RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Incidence Ratesa 2012-2016

California 1844 2241 1515 1938 2349 1591 1390 1639 1182Greater Bay Area 1957 2381 1600 2144 2601 1755 1628 1828 1436San Francisco-Oakland 1956 2421 1570 2174 2660 1765 1603 1816 1408San Jose-Monterey 1962 2311 1660 2097 2503 1742 1800 1891 1646

Los Angeles 1804 2176 1505 1951 2331 1637 1357 1659 1139Greater California 1822 2220 1489 1876 2286 1529 1314 1534 1113

Connecticut 2116 2607 1733 2154 2642 1771 1386 1829 1051Detroit 2132 2636 1742 2290 2850 1847 1620 1905 1409Georgia 1826 2244 1487 1936 2346 1588 1462 1833 1187Atlanta 1925 2381 1555 2119 2567 1736 1601 2034 1272Rural Georgia 1584 1790 1401 1953 2298 1567 807 - 988Greater Georgia 1784 2186 1459 1872 2274 1537 1380 1703 1146

Hawaii 1660 2024 1349 1958 2275 1593 - - -Idaho 1922 2267 1616 1920 2262 1618 - - -Iowa 2134 2601 1756 2148 2612 1773 1352 1602 1100Kentucky 2039 2505 1666 2070 2538 1693 1403 1788 1112Louisiana 1944 2352 1614 2106 2537 1744 1469 1769 1237Massachusetts 1810 2181 1518 1830 2214 1524 1452 1655 1299New Jersey 2155 2607 1804 2285 2765 1905 1387 1621 1222New Mexico 1550 1739 1387 1580 1798 1394 875 - -New York 2152 2620 1788 2306 2792 1915 1545 1852 1333Seattle-Puget Sound 2116 2627 1695 2177 2667 1766 1631 1973 1316Utah 1843 2233 1498 1862 2258 1513 2089 - -

SEER 9 Areasb 1992 2444 1623 2095 2551 1716 1573 1914 1298SEER 13 Areasb 1946 2373 1597 2064 2502 1700 1519 1853 1258SEER 18 Areasb 1933 2354 1590 2031 2464 1671 1449 1751 1214SEER 21 Areasb 1963 2388 1620 2061 2498 1702 1471 1771 1245

Table 1920Non-Hodgkin Lymphoma

Age-Adjusted SEER Incidence Ratesa

By Registry Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control and PreventionRates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and AtlantaThe SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Death Ratesa 2012-2016

California 533 677 423 570 726 449 417 480 367Greater Bay Area 505 671 376 561 756 408 410 491 331San Francisco-Oakland 503 667 376 555 742 409 416 490 343San Jose-Monterey 511 681 377 573 781 407 - - -

Los Angeles 541 670 443 589 728 481 424 503 371Greater California 539 682 429 564 716 447 416 455 384

Connecticut 533 705 407 547 717 421 350 510 244Detroit 639 822 505 693 895 542 443 528 384Georgia 533 697 411 580 747 450 376 503 286Atlanta 492 659 372 533 728 388 397 506 317Rural Georgia 559 731 388 670 813 507 - - -Greater Georgia 549 712 426 595 755 470 363 500 266

Hawaii 475 620 352 545 649 412 - - -Idaho 635 775 510 641 782 516 - - -Iowa 638 845 484 642 848 488 - - -Kentucky 642 886 460 655 904 470 401 557 284Louisiana 608 814 451 651 863 485 461 623 340Massachusetts 523 659 423 541 682 436 347 410 297New Jersey 545 721 419 585 780 443 372 466 314New Mexico 488 585 405 493 595 406 - - -New York 535 702 412 575 752 441 390 514 313Seattle-Puget Sound 585 749 463 604 769 480 490 562 397Utah 542 670 433 551 681 440 - - -

SEER 9 Areasb 555 719 430 586 758 454 414 522 333SEER 13 Areasb 549 705 429 586 753 457 419 521 342SEER 18 Areasb 554 717 431 589 761 456 409 518 329SEER 21 Areasb 550 712 428 584 754 453 401 513 322

Total US 562 725 436 586 755 454 408 518 330

Table 1921Non-Hodgkin Lymphoma

Age-Adjusted SEER Death Ratesa

By Registry Race and Sex

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 562 002

High Five StatesMichigan 645 011 01(0112) 1479Kentucky 642 016 02(0118) 1424Iowa 638 018 03(0120) 1367Indiana 638 013 04(0117) 1361Idaho 635 027 05(0126) 1303

Low Five StatesNevada 511 019 47(2251) -899Colorado 491 014 48(3851) -1257New Mexico 488 020 49(2851) -1317Hawaii 475 024 50(3051) -1542c

DC 444 039 51(2351) -2097c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 545 014 28(1847) -291 Montana 559 030 25(0250) -042Alaska 525 047 43(0151) -654 Nebraska 563 023 22(0548) 026Arizona 512 012 46(2950) -886 Nevada 511 019 47(2251) -899Arkansas 555 018 26(1247) -113 New Hampshire 562 027 23(0349) 014California 533 005 40(2645) -508 New Jersey 545 010 29(2045) -301Colorado 491 014 48(3851) -1257 New Mexico 488 020 49(2851) -1317Connecticut 533 016 39(1949) -505 New York 535 007 37(2446) -478Delaware 628 033 08(0139) 1174 North Carolina 541 010 35(2146) -363DC 444 039 51(2351) -2097c North Dakota 561 037 24(0151) -007Florida 535 006 38(2545) -479 Ohio 616 009 10(0220) 969Georgia 533 011 41(2248) -511 Oklahoma 630 017 06(0121) 1226Hawaii 475 024 50(3051) -1542c Oregon 612 016 11(0124) 903Idaho 635 027 05(0126) 1303 Pennsylvania 603 009 16(0622) 729Illinois 566 009 20(1634) 085 Rhode Island 542 029 32(0651) -350Indiana 638 013 04(0117) 1361 South Carolina 542 014 31(1847) -347Iowa 638 018 03(0120) 1367 South Dakota 541 033 36(0451) -364Kansas 585 019 19(0439) 420 Tennessee 629 013 07(0119) 1198Kentucky 642 016 02(0118) 1424 Texas 546 007 27(2142) -277Louisiana 608 016 14(0125) 826 Utah 542 022 33(1250) -352Maine 609 026 13(0137) 852 Vermont 605 040 15(0148) 770Maryland 524 013 44(2349) -663 Virginia 544 011 30(2046) -319Massachusetts 523 012 45(2549) -687 Washington 599 013 17(0425) 665Michigan 645 011 01(0112) 1479 West Virginia 612 022 12(0132) 894Minnesota 617 014 09(0122) 984 Wisconsin 590 013 18(0629) 507Mississippi 531 018 42(1850) -551 Wyoming 564 043 21(0151) 050Missouri 542 012 34(1947) -354

Table 1922Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males and Females

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 725 003

High Five StatesKentucky 886 030 01(0112) 2213c

Iowa 845 032 02(0120) 1647c

Michigan 842 019 03(0114) 1615c

Indiana 839 024 04(0116) 1567c

Delaware 824 058 05(0144) 1364

Low Five StatesArizona 635 019 47(3251) -1244Alaska 630 075 48(0251) -1311Hawaii 620 041 49(1951) -1452DC 614 071 50(0551) -1535c

New Mexico 585 033 51(3451) -1928c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 688 025 36(1649) -513 Montana 709 050 26(0251) -218Alaska 630 075 48(0251) -1311 Nebraska 737 040 20(0248) 165Arizona 635 019 47(3251) -1244 Nevada 653 032 44(1951) -994Arkansas 721 031 22(0747) -061 New Hampshire 710 046 25(0451) -210California 677 009 41(2846) -666 New Jersey 721 018 21(1441) -059Colorado 643 024 46(2451) -1133 New Mexico 585 033 51(3451) -1928c

Connecticut 705 028 28(1248) -273 New York 702 012 30(1943) -323Delaware 824 058 05(0144) 1364 North Carolina 709 018 27(1644) -221DC 614 071 50(0551) -1535c North Dakota 682 061 39(0251) -598Florida 683 011 37(2446) -585 Ohio 800 017 09(0320) 1029Georgia 697 019 34(1746) -387 Oklahoma 806 030 08(0126) 1109Hawaii 620 041 49(1951) -1452 Oregon 794 028 12(0128) 947Idaho 775 045 16(0146) 692 Pennsylvania 783 015 15(0523) 794Illinois 739 016 19(1235) 190 Rhode Island 649 050 45(1051) -1050Indiana 839 024 04(0116) 1567c South Carolina 681 025 40(1850) -604Iowa 845 032 02(0120) 1647c South Dakota 701 056 31(0251) -332Kansas 713 032 24(0948) -174 Tennessee 820 023 06(0120) 1311Kentucky 886 030 01(0112) 2213c Texas 698 012 32(2043) -368Louisiana 814 029 07(0122) 1222 Utah 670 036 42(1351) -754Maine 754 045 18(0148) 395 Vermont 794 069 11(0149) 950Maryland 682 023 38(1849) -588 Virginia 694 020 35(1847) -429Massachusetts 659 020 43(2450) -910 Washington 790 022 13(0224) 897Michigan 842 019 03(0114) 1615c West Virginia 774 038 17(0142) 675Minnesota 797 025 10(0224) 995 Wisconsin 786 023 14(0227) 844Mississippi 717 034 23(0748) -110 Wyoming 698 071 33(0151) -377Missouri 702 022 29(1646) -319

Table 1923Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 436 002

High Five StatesIdaho 510 033 01(0139) 1697c

Maine 497 031 02(0141) 1396Michigan 495 012 03(0119) 1340Oklahoma 492 020 04(0128) 1276Indiana 492 016 05(0123) 1270

Low Five StatesMississippi 404 021 47(1351) -731Nevada 382 022 48(2051) -1237Colorado 369 016 49(3451) -1540c

Hawaii 352 027 50(2551) -1932c

DC 323 044 51(1551) -2601c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 440 017 24(0547) 099 Montana 435 036 27(0151) -034Alaska 414 058 38(0151) -500 Nebraska 435 027 26(0249) -032Arizona 407 014 44(2049) -664 Nevada 382 022 48(2051) -1237Arkansas 428 021 31(0649) -181 New Hampshire 454 032 19(0149) 400California 423 006 34(2244) -313 New Jersey 419 012 37(1848) -397Colorado 369 016 49(3451) -1540c New Mexico 405 025 46(0951) -706Connecticut 407 018 45(1550) -669 New York 412 008 39(2548) -554Delaware 473 039 12(0150) 855 North Carolina 420 012 35(1848) -374DC 323 044 51(1551) -2601c North Dakota 471 045 13(0150) 809Florida 412 007 40(2548) -564 Ohio 478 011 10(0123) 967Georgia 411 012 43(2049) -582 Oklahoma 492 020 04(0128) 1276Hawaii 352 027 50(2551) -1932c Oregon 465 019 15(0141) 668Idaho 510 033 01(0139) 1697c Pennsylvania 467 010 14(0427) 714Illinois 439 010 25(1341) 074 Rhode Island 455 035 18(0150) 434Indiana 492 016 05(0123) 1270 South Carolina 432 017 30(0947) -102Iowa 484 021 08(0135) 1087 South Dakota 411 039 42(0151) -580Kansas 486 023 06(0137) 1143 Tennessee 484 015 09(0126) 1087Kentucky 460 018 17(0241) 544 Texas 427 008 32(1944) -213Louisiana 451 018 21(0345) 333 Utah 433 026 28(0250) -081Maine 497 031 02(0141) 1396 Vermont 461 047 16(0151) 578Maryland 411 015 41(1749) -576 Virginia 432 013 29(1246) -092Massachusetts 423 014 33(1548) -303 Washington 452 015 20(0541) 360Michigan 495 012 03(0119) 1340 West Virginia 486 027 07(0143) 1141Minnesota 475 017 11(0132) 901 Wisconsin 443 015 23(0645) 156Mississippi 404 021 47(1351) -731 Wyoming 445 051 22(0151) 192Missouri 419 014 36(1549) -396

Table 1924Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Females

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 Areas (excluding the AlaskaNative Registry) and 112016 US population estimates based on the average of 2015 and 2016 population estimates from theUS Bureau of the CensusPrevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 24 years

b Maximum limited-duration prevalence is 24 years for 1992-2016 datac Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groupsd Cases diagnosed more than 24 years ago were estimated using the completeness index method (Capocaccia et al 1997

Merrill et al 2000)e Complete prevalence is obtained by summing 0 to lt24 and gt=24- Statistic not shown Statistic based on fewer than 5 cases estimated alive in SEER for the time interval+ Not available

Years Since Diagnosis 0 to lt5 5 to lt10 10 to lt15 15 to lt20 20 to lt24 0 to lt24b gt=24d Completee

Race Sex

All Races Both Sexes 248946 177490 117326 69109 31890 644761 49943 694704Males 135137 94173 60159 36020 16581 342069 25489 367558Females 113809 83317 57167 33089 15309 302692 24454 327146

White Both Sexes 213764 154454 101984 60537 28026 558765 49625 620368Males 116527 82172 52535 31627 14543 297404 26526 330121Females 97237 72282 49448 28910 13483 261361 23099 290247

Black Both Sexes 20500 13640 9750 5271 2215 51376 4115 55491Males 10712 7188 4768 2684 1174 26526 1911 28437Females 9789 6452 4981 2587 1041 24850 2204 27054

Asian Both Sexes 8405 5210 3415 1867 844 19741 + +Pacific Males 4548 2661 1757 1013 407 10386 + +Islander Females 3856 2549 1657 855 437 9355 + +

Hispanic Both Sexes 21339 14049 8272 4881 2136 50676 + +Males 10918 7243 4331 2617 1094 26202 + +Females 10421 6805 3941 2264 1043 24474 + +

Age Specific (Crude) Age-Adjustedc Age at Prevalence All Ages 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ All Ages

Race Sex

All Races Both Sexes 02001 00035 00139 00283 00538 01121 02352 04640 08181 10224 01738Males 02156 00044 00189 00354 00625 01293 02710 05243 09364 12449 02023Females 01850 00026 00087 00208 00450 00952 02010 04094 07196 08856 01498

White Both Sexes 02216 00035 00143 00289 00534 01148 02427 04858 08597 10738 01807Males 02380 00045 00198 00359 00622 01317 02790 05442 09778 13060 02095Females 02054 00025 00085 00214 00442 00976 02072 04317 07593 09285 01560

Black Both Sexes 01139 00029 00113 00265 00599 01027 02010 03340 05117 05333 01251Males 01226 00029 00140 00351 00696 01223 02333 03969 05849 06055 01457Females 01059 00030 00086 00178 00510 00853 01728 02836 04608 04976 01088

Asian Both Sexes 00970 00039 00133 00207 00353 00680 01409 02692 04470 06094 01032Pacific Males 01065 00044 00175 00240 00398 00744 01640 03072 05516 07472 01222Islander Females 00882 00033 00092 00175 00312 00623 01209 02384 03629 05207 00880

Hispanic Both Sexes 00887 00030 00117 00206 00398 00850 01769 03632 05888 07209 01294Males 00908 00035 00147 00256 00455 00932 01924 03940 06326 08003 01420Females 00866 00024 00086 00151 00337 00766 01616 03360 05552 06719 01185

Table 1925Non-Hodgkin Lymphoma

Estimated United States Cancer Prevalence Countsa on January 1 2016By RaceEthnicity Sex and Years Since Diagnosis

Estimated prevalence percenta on January 1 2016 of the SEER population diagnosed in the previous 24 yearsBy Age at Prevalence RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 372 452924 -05 62 18862 04 247 189692 -05 1657 244370 -05

1 Hodgkin Lymphoma 28 32262 -17 13 3927 -06 33 22556 -15 39 5779 -31

2 Non-Hodgkin lymphoma 336 409991 -03 48 14693 04 210 163591 -03 1572 231707 -042(a) Non-Hodgkin lymphoma B-cell 311 380349 -01 39 11836 14 190 148768 -02 1491 219745 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 15 16631 20 31 9416 10 07 5203 39 14 2012 252(a) 2 Mature Non-Hodgkin lymphoma B-cell 280 343965 -04 07 2271 30 174 137225 -05 1387 204469 -042(a) 21 ChronicSmallProlymphocytic 69 85601 -13 00 35 - 35 29103 -11 382 56463 -14

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 61 75061 -15 00 30 - 31 25339 -13 336 49692 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 311 19 - - - 00 72 - 02 234 262(a) 213 Mantle-cell lymphoma 08 10229 03 - - - 04 3692 02 44 6537 04

2(a) 22 Lymphoplasmacytic lymphoma 07 8651 00 - - - 03 2590 -11 41 6059 04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 03 3667 -03 - - - 01 1132 -18 17 2533 022(a) 222 Waldenstrom macroglubulinemia 04 4984 03 - - - 02 1458 -07 24 3526 06

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 72 87188 00 03 925 26 48 36480 -02 339 49783 022(a) 231 DLBCL NOSc 71 85899 -01 03 861 12 46 35469 -05 337 49569 012(a) 232 Intravascular large B-cell 00 162 - - - - 00 63 - 01 99 -

lymphoma2(a) 233 Primary effusion lymphoma 00 181 27 - - - 00 126 - 00 55 -2(a) 234 Mediastinal large B-cell 01 946 116 00 64 - 01 822 111 00 60 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 04 4692 -26 03 1028 32 04 2618 -43 07 1046 -432(a) 25 Marginal-zone lymphoma (MZL) 22 26534 00 00 137 13 14 11049 05 104 15348 -042(a) 251 Splenic MZL 02 2418 04 - - - 01 889 -08 10 1529 102(a) 252 Extranodal MZL MALTc type 13 15979 06 00 92 - 09 7148 11 59 8739 032(a) 253 Nodal MZL 07 8137 -15 00 45 - 04 3012 -05 34 5080 -20

2(a) 26 Follicular lymphoma 35 43582 -21 00 119 - 28 21725 -25 147 21738 -182(a) 27 Hairy-cell leukemia 03 3712 -16 - - - 03 2311 -19 09 1401 -122(a) 28 Plasma cell neoplasms 68 83957 08 00 24 - 39 31325 12 358 52608 062(a) 281 Plasmacytoma 04 4879 -04 00 16 - 03 2362 -06 17 2501 -032(a) 282 Multiple myeloma 64 79078 09 - - - 36 28963 14 341 50107 07

plasma-cell leukemia2(a) 29 Heavy chain disease 00 48 - - - - 00 24 - 00 23 -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 16 19753 33 00 149 27 08 6340 37 90 13264 32

Table 1926All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 23 27222 01 08 2502 18 19 13933 03 73 10787 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 616 - 01 293 - 00 272 - 00 51 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 22 26531 11 07 2207 75 19 13621 12 73 10703 -042(b) 21 Mycosis fungoidesSezary syndrome 06 6969 18 01 213 84 06 4080 23 18 2676 052(b) 211 Mycosis fungoides 06 6739 17 01 213 84 05 3990 22 17 2536 042(b) 212 Sezary syndrome 00 230 46 - - - 00 90 - 01 140 -

2(b) 22 Peripheral T-cell lymphoma 12 14531 -10 02 534 07 10 7159 -09 46 6838 -122(b) 221 Peripheral T-cell lymphoma NOSc 04 5393 -01 00 86 - 03 2489 04 19 2818 -042(b) 222 Angioimmunoblastic T-cell lymphoma 02 1902 02 - - - 01 699 -09 08 1201 072(b) 223 Subcutaneous panniculitis- 00 176 44 00 31 - 00 111 - 00 34 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 2523 -36 01 291 00 02 1450 -33 05 782 -54

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 139 - - - - 00 98 - 00 28 -2(b) 226 Enteropathy-type T-cell lymphoma 00 186 -02 - - - 00 84 - 01 101 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 2963 -07 00 59 - 02 1575 01 09 1329 -142(b) 228 Primary cutaneous anaplastic 01 1249 -41 00 51 - 01 653 -49 04 545 -39

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 03 3417 96 05 1428 101 02 1474 99 03 515 672(b) 24 NKcT-cell lymphoma nasal-type 01 985 02 00 26 - 01 659 00 02 300 05

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 120 - - - - 00 54 - 00 65 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 509 30 - - - 00 195 -05 02 309 442(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 75 - - - - 00 40 - 00 33 -2(c) Non-Hodgkin lymphoma unknown lineage 02 2420 -274 01 355 - 01 890 -216 08 1175 -2792(c) 1 Precursor lymphoblastic leukemia 01 814 -283 01 343 - 00 238 - 02 233 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 95 - - - - 00 25 - 00 69 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 1511 -274 - - - 01 627 -202 06 873 -319

lineage2() 1 Total precursor lymphomaleukemiad 16 18061 -07 33 10052 -15 08 5713 06 15 2296 -01

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 762 273 00 20 - 00 339 227 03 403 -lymphoma

4 Lymphoid neoplasm NOSc 08 9909 -55 01 222 113 04 3206 -59 43 6481 -59

Table 1926 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 461 253152 -05 70 10973 05 294 110367 -07 2122 131812 -05

1 Hodgkin Lymphoma 31 17710 -17 13 2118 -03 36 12525 -16 48 3067 -31

2 Non-Hodgkin lymphoma 419 229772 -03 56 8711 05 252 95756 -05 2017 125305 -032(a) Non-Hodgkin lymphoma B-cell 387 212247 -02 44 6786 15 227 86941 -04 1908 118520 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 16 8999 24 33 5123 11 08 2888 46 16 988 292(a) 2 Mature Non-Hodgkin lymphoma B-cell 351 192801 -05 10 1558 28 210 80417 -08 1783 110826 -042(a) 21 ChronicSmallProlymphocytic 96 52411 -15 00 21 - 47 18927 -14 539 33463 -15

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 82 44988 -17 00 19 - 40 16143 -16 464 28826 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 193 -02 - - - 00 46 - 02 145 052(a) 213 Mantle-cell lymphoma 13 7230 -01 - - - 07 2738 -01 72 4492 -01

2(a) 22 Lymphoplasmacytic lymphoma 10 5082 -05 - - - 04 1524 -08 58 3558 -04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 04 2062 -08 - - - 02 616 -12 23 1446 -072(a) 222 Waldenstrom macroglubulinemia 06 3020 -02 - - - 02 908 -06 34 2112 -02

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 88 48128 01 03 554 22 59 21824 -06 418 25750 052(a) 231 DLBCL NOSc 87 47520 00 03 519 03 57 21366 -08 416 25635 042(a) 232 Intravascular large B-cell 00 75 - - - - 00 31 - 01 44 -

lymphoma2(a) 233 Primary effusion lymphoma 00 167 26 - - - 00 123 - 01 44 -2(a) 234 Mediastinal large B-cell 01 366 155 00 35 - 01 304 142 00 27 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 06 3388 -22 05 775 31 06 1969 -46 10 644 -192(a) 25 Marginal-zone lymphoma (MZL) 22 12351 -02 01 98 - 14 5177 -02 114 7076 -012(a) 251 Splenic MZL 02 1164 14 - - - 01 434 18 12 730 112(a) 252 Extranodal MZL MALTc type 13 7268 07 00 62 - 09 3267 04 63 3939 102(a) 253 Nodal MZL 07 3919 -23 00 36 - 04 1476 -22 39 2407 -23

2(a) 26 Follicular lymphoma 39 21788 -19 01 100 - 30 11210 -25 165 10478 -152(a) 27 Hairy-cell leukemia 05 2984 -18 - - - 05 1908 -20 17 1076 -152(a) 28 Plasma cell neoplasms 85 46642 07 - - - 45 17864 11 462 28769 052(a) 281 Plasmacytoma 05 2997 -08 - - - 04 1509 -16 24 1484 -012(a) 282 Multiple myeloma 80 43645 08 - - - 41 16355 13 439 27285 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 27 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 20 10447 34 01 105 - 10 3636 40 110 6706 32

Table 1927All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 29 16118 00 11 1730 14 23 8235 02 98 6153 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 430 - 01 208 - 01 188 - 01 34 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 28 15642 11 10 1521 71 22 8022 11 97 6099 -032(b) 21 Mycosis fungoidesSezary syndrome 07 3962 19 01 135 - 06 2261 21 25 1566 092(b) 211 Mycosis fungoides 07 3831 20 01 135 - 06 2213 21 23 1483 092(b) 212 Sezary syndrome 00 131 - - - - 00 48 - 01 83 -

2(b) 22 Peripheral T-cell lymphoma 15 8438 -13 02 318 -09 12 4248 -12 62 3872 -132(b) 221 Peripheral T-cell lymphoma NOSc 06 3159 -05 00 49 - 04 1520 02 26 1590 -082(b) 222 Angioimmunoblastic T-cell lymphoma 02 1024 19 - - - 01 415 11 10 607 232(b) 223 Subcutaneous panniculitis- 00 68 - - - - 00 39 - 00 16 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 03 1549 -39 01 184 -01 02 888 -43 08 477 -45

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 98 - - - - 00 69 - 00 18 -2(b) 226 Enteropathy-type T-cell lymphoma 00 105 - - - - 00 50 - 01 54 -2(b) 227 Cutaneous T-cell lymphoma NOSc 03 1696 -12 00 32 - 02 894 -03 12 770 -172(b) 228 Primary cutaneous anaplastic 01 739 -48 00 26 - 01 373 -49 05 340 -49

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 04 2253 97 07 1047 92 03 940 98 04 266 1022(b) 24 NKcT-cell lymphoma nasal-type 01 638 -05 00 18 - 01 435 -03 03 185 -06

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 58 - - - - 00 22 - 01 36 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 01 293 45 - - - 00 116 - 03 174 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 46 - - - - 00 25 - 00 20 -2(c) Non-Hodgkin lymphoma unknown lineage 03 1407 -232 01 195 - 02 580 -184 10 632 -2302(c) 1 Precursor lymphoblastic leukemia 01 474 -228 01 187 - 00 134 - 02 153 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 49 - - - - - - - 01 36 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 02 884 -239 - - - 01 433 -175 07 443 -

lineage2() 1 Total precursor lymphomaleukemiad 18 9903 -06 35 5518 -17 09 3210 09 19 1175 05

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 435 271 - - - 01 215 - 03 207 -lymphoma

4 Lymphoid neoplasm NOSc 10 5235 -59 01 131 - 05 1871 -65 54 3233 -61

Table 1927 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 301 199772 -05 53 7889 02 202 79325 -02 1322 112558 -08

1 Hodgkin Lymphoma 24 14552 -16 12 1809 -10 29 10031 -14 32 2712 -32

2 Non-Hodgkin lymphoma 269 180219 -03 40 5982 03 170 67835 00 1251 106402 -062(a) Non-Hodgkin lymphoma B-cell 250 168102 -01 34 5050 13 154 61827 02 1190 101225 -042(a) 1 Precursor Non-Hodgkin lymphoma B-cell 14 7632 16 29 4293 09 06 2315 29 12 1024 202(a) 2 Mature Non-Hodgkin lymphoma B-cell 223 151164 -04 05 713 35 141 56808 -01 1102 93643 -072(a) 21 ChronicSmallProlymphocytic 48 33190 -13 - - - 24 10176 -05 268 23000 -16

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 43 30073 -15 - - - 22 9196 -06 243 20866 -19

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 118 - - - - 00 26 - 01 89 -2(a) 213 Mantle-cell lymphoma 04 2999 11 - - - 02 954 10 24 2045 12

2(a) 22 Lymphoplasmacytic lymphoma 05 3569 04 - - - 03 1066 -16 30 2501 11Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 02 1605 01 - - - 01 516 -25 13 1087 112(a) 222 Waldenstrom macroglubulinemia 03 1964 06 - - - 01 550 -08 17 1414 11

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 58 39060 00 02 371 33 38 14656 03 283 24033 -032(a) 231 DLBCL NOSc 57 38379 -02 02 342 27 36 14103 -01 282 23934 -032(a) 232 Intravascular large B-cell 00 87 - - - - 00 32 - 01 55 -

lymphoma2(a) 233 Primary effusion lymphoma - - - - - - - - - - - -2(a) 234 Mediastinal large B-cell 01 580 91 00 29 - 02 518 93 00 33 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 02 1304 -34 02 253 38 02 649 -37 05 402 -852(a) 25 Marginal-zone lymphoma (MZL) 21 14183 01 00 39 - 15 5872 12 98 8272 -062(a) 251 Splenic MZL 02 1254 -07 - - - 01 455 -32 10 799 072(a) 252 Extranodal MZL MALTc type 13 8711 06 00 30 - 10 3881 17 57 4800 -032(a) 253 Nodal MZL 06 4218 -07 - - - 04 1536 11 32 2673 -18

2(a) 26 Follicular lymphoma 33 21794 -24 00 19 - 27 10515 -25 134 11260 -222(a) 27 Hairy-cell leukemia 01 728 -12 - - - 01 403 -11 04 325 -122(a) 28 Plasma cell neoplasms 55 37315 08 - - - 33 13461 15 282 23839 052(a) 281 Plasmacytoma 03 1882 00 - - - 02 853 12 12 1017 -092(a) 282 Multiple myeloma 52 35433 09 - - - 30 12608 15 270 22822 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 21 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 14 9306 32 00 44 - 07 2704 32 76 6558 31

Table 1928All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 17 11104 01 05 772 29 15 5698 05 55 4634 -112(b) 1 Precursor Non-Hodgkin lymphoma T-cell 00 186 - 01 85 - 00 84 - 00 17 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 17 10889 09 05 686 83 15 5599 12 54 4604 -092(b) 21 Mycosis fungoidesSezary syndrome 05 3007 15 01 78 - 05 1819 26 13 1110 -042(b) 211 Mycosis fungoides 05 2908 12 01 78 - 05 1777 23 12 1053 -072(b) 212 Sezary syndrome 00 99 - - - - 00 42 - 01 57 -

2(b) 22 Peripheral T-cell lymphoma 09 6093 -08 01 216 30 08 2911 -06 35 2966 -142(b) 221 Peripheral T-cell lymphoma NOSc 03 2234 03 00 37 - 03 969 07 14 1228 -012(b) 222 Angioimmunoblastic T-cell lymphoma 01 878 -22 - - - 01 284 -39 07 594 -152(b) 223 Subcutaneous panniculitis- 00 108 - 00 18 - 00 72 - 00 18 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 974 -33 01 107 - 02 562 -19 04 305 -77

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 41 - - - - 00 29 - - - -2(b) 226 Enteropathy-type T-cell lymphoma 00 81 - - - - 00 34 - 01 47 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 1267 00 00 27 - 02 681 07 07 559 -102(b) 228 Primary cutaneous anaplastic 01 510 -34 00 25 - 01 280 -50 02 205 -33

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 02 1164 96 03 381 127 01 534 97 03 249 302(b) 24 NKcT-cell lymphoma nasal-type 01 347 11 - - - 01 224 - 01 115 -

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 62 - - - - 00 32 - 00 29 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 216 03 - - - 00 79 - 02 135 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 29 - - - - - - - - - -2(c) Non-Hodgkin lymphoma unknown lineage 02 1013 -341 01 160 - 01 310 - 06 543 -2(c) 1 Precursor lymphoblastic leukemia 01 340 - 01 156 - 00 104 - 01 80 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 46 - - - - - - - 00 33 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 627 - - - - 01 194 - 05 430 -

lineage2() 1 Total precursor lymphomaleukemiad 14 8158 -09 31 4534 -13 07 2503 02 13 1121 -11

3 Composite Hodgkin lymphoma and Non-Hodgkin 00 327 - - - - 00 124 - 02 196 -lymphoma

4 Lymphoid neoplasm NOSc 07 4674 -52 01 91 - 03 1335 -51 36 3248 -58

Table 1928 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 8: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on End Results data from a series of hospital registries and one population-based registryb SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)

Based on follow-up of patients into 2016 Expected survival rates are derived from the US Annual Life Tablesc SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER programBased on follow-up of patients into 2016

d Period survival provides a 2015 estimate of survival by piecing together the most recent conditional survival estimatesfrom several cohorts It is computed here using three year calendar blocks (2010-2012 0-1 year survival)(2009-2011 1-2 year survival) (2008-2010 2-3 year survival) (2007-2009 3-4 year survival) (2006-2008 4-5 years survival)

e Stage at diagnosis is classified using SEER Summary Stage 2000 Stage distribution percentages may not sum to 100 due to roundingf The difference between 1975-1977 and 2009-2015 is statistically significant (plt05)g The standard error is between 5 and 10 percentage pointsh The standard error is greater than 10 percentage points- Statistic could not be calculated due to fewer than 25 cases during the time period

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

5-Year Relative Survival (Percent)Year of Diagnosis1960-1963a - - - 31 31 31 - - -1970-1973a - - - 41 39 43 - - -1975-1977b 465 456 475 468 463 473 486 426 553g

1978-1980b 479 461 498 479 462 495 511 469 5671981-1983b 506 503 509 508 505 511 495 492 4981984-1986b 516 501 534 521 507 537 468 445 4991987-1989b 509 476 549 513 482 552 457 413 5101990-1992b 507 467 557 515 476 564 422 384 4761993-1995b 526 487 575 533 498 577 425 359 5491996-1998b 588 570 610 595 577 615 547 531 5721999-2001b 640 614 670 650 628 676 558 490 6382002-2004b 698 686 712 710 701 721 636 611 6662005-2008b 716 706 727 728 719 738 625 578 6752009-2015b 747f 739f 757f 757f 748f 767f 695f 670f 724f

5-Year Period Survival (Percent)cd

2015 722 705 743 726 708 747 671 641 703

Stage Distribution () 2009-2015ce

All StagesNumber of cases 97737 53606 44131 80120 44109 36011 8184 4388 3796Percent 100 100 100 100 100 100 100 100 100Localized 27 27 29 27 26 28 28 25 31Regional 15 15 15 15 15 15 15 15 15Distant 50 51 48 51 52 49 51 54 48UnstagedUnknown 8 7 8 7 7 8 6 6 7

5-Year Relative Survival (Percent) 2009-2015c

Age at DiagnosisAges lt45 840 820 870 855 836 885 735 708 776Ages 45-54 810 777 859 826 795 872 687 639 750Ages 55-64 770 742 809 781 754 818 678 620 749Ages 65-74 725 706 747 731 711 755 656 623 682Ages 75+ 554 539 568 557 538 574 482 449 500Ages lt65 800 773 838 812 787 849 701 659 759Ages 65+ 638 627 649 641 628 655 584 562 598

StageeAll Stages 720 707 737 724 711 740 665 637 698Localized 840 830 850 843 833 852 810 766 850Regional 750 751 749 755 756 755 689 698 678Distant 648 633 668 657 642 677 580 557 610UnstagedUnknown 703 686 723 679 662 698 659 648 666

Table 198Non-Hodgkin Lymphoma

5-Year Relative and Period Survival (Percent) by Race Sex Diagnosis Year and Age

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Expected survival rates are derived from the US Annual Life Tables

1975- 1980- 1985- 1990-1979 1984 1989 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Survival Time

1-year 702 730 713 704 703 733 756 767 774 773 787 810 803 811 817 810 816 841 839 844 834 842 844 834 8452-year 602 637 628 622 618 659 685 700 710 714 733 760 757 760 773 769 775 790 795 796 797 800 800 7953-year 546 585 582 577 575 621 649 664 669 679 701 731 731 735 748 745 750 762 773 774 775 779 7794-year 505 546 543 544 547 587 621 636 645 655 681 712 716 715 730 726 732 744 756 752 756 7675-year 468 507 510 516 520 561 594 609 621 638 660 693 700 701 716 705 712 728 741 742 7426-year 436 475 483 492 499 541 571 583 595 621 647 680 683 688 704 688 701 718 721 7237-year 408 450 458 470 479 522 552 564 577 605 629 663 671 672 685 672 688 702 7108-year 385 428 434 450 464 504 529 552 563 589 613 651 658 666 670 661 674 6909-year 366 408 415 435 453 493 515 535 548 576 600 640 648 649 652 651 66110-year 350 389 398 421 443 481 501 522 537 563 589 632 633 638 634 63711-year 335 374 385 406 434 466 488 511 525 548 581 618 621 630 63112-year 324 360 369 395 423 457 481 501 512 535 568 600 615 61713-year 314 348 358 383 415 449 469 492 500 520 561 593 60214-year 302 335 347 372 406 443 456 485 488 513 549 58315-year 289 322 335 365 398 437 447 474 478 505 54016-year 279 312 328 356 393 437 433 472 470 49217-year 274 304 321 349 388 428 428 469 45818-year 268 296 314 341 378 420 419 46319-year 260 288 306 333 370 413 41220-year 252 280 301 329 359 408

Table 199Non-Hodgkin Lymphoma

SEERa Relative Survival (Percent)By Year of Diagnosis

All Races Males and Females

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Expected survival rates are derived from the US Annual Life Tables

1975- 1980- 1985- 1990-1979 1984 1989 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Survival Time

1-year 694 727 689 671 666 712 747 749 758 765 776 806 797 801 811 810 814 836 828 838 838 841 834 830 8352-year 594 637 605 582 583 636 672 682 691 703 713 752 749 755 762 765 778 779 781 788 798 793 786 7913-year 534 580 557 537 545 598 638 645 644 668 679 720 726 726 731 736 754 751 757 766 776 769 7644-year 493 539 516 504 515 561 610 620 615 639 657 700 709 701 711 713 734 734 737 743 756 7575-year 455 501 482 476 485 537 583 592 590 617 635 679 689 688 699 689 710 721 724 735 7426-year 426 466 455 456 469 510 561 565 562 602 620 667 669 676 684 670 696 715 706 7177-year 399 442 431 436 449 491 542 544 546 587 601 652 658 655 668 651 682 696 6968-year 378 420 410 418 433 474 520 533 536 567 582 637 645 649 650 634 665 6869-year 357 401 391 402 423 465 504 514 523 553 572 628 633 632 636 618 65210-year 340 380 377 392 416 455 489 503 515 542 560 617 617 620 613 60911-year 328 363 364 381 407 437 477 494 508 527 547 603 605 612 61212-year 319 352 351 372 395 427 472 482 498 515 537 589 601 59613-year 307 342 343 361 389 419 456 467 491 501 531 582 59114-year 295 330 332 350 378 414 444 461 480 496 521 57215-year 281 319 324 344 368 409 435 453 473 488 51216-year 272 308 316 333 361 409 426 453 471 47417-year 265 300 308 326 358 403 420 449 46218-year 261 294 302 320 350 396 410 44219-year 256 287 294 313 342 391 40320-year 250 280 291 309 332 387

Table 1910Non-Hodgkin Lymphoma

SEERa Relative Survival (Percent)By Year of Diagnosis

All Races Males

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Expected survival rates are derived from the US Annual Life Tables

1975- 1980- 1985- 1990-1979 1984 1989 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Survival Time

1-year 710 734 741 747 752 759 767 786 792 782 801 814 810 821 825 809 819 847 854 851 830 843 856 838 8572-year 611 637 656 672 664 688 701 720 734 727 758 769 765 767 786 774 772 804 812 807 796 810 817 7993-year 559 589 611 627 616 649 662 684 700 692 727 744 736 746 768 756 746 774 791 786 774 791 7974-year 519 553 576 595 590 619 634 653 681 674 710 725 724 730 751 739 729 757 778 764 755 7805-year 482 514 544 567 565 591 608 629 658 664 688 708 713 716 736 724 715 735 763 751 7426-year 446 484 517 539 540 580 583 603 635 643 679 695 699 701 727 708 707 722 738 7317-year 417 458 490 512 520 560 563 586 615 626 663 674 687 692 704 698 694 709 7268-year 392 437 463 491 505 542 539 573 596 615 649 667 672 684 693 692 684 6949-year 374 416 443 476 492 529 528 557 578 603 633 654 664 669 671 688 67110-year 360 399 424 458 480 514 516 542 562 588 625 648 651 658 659 66911-year 342 385 409 438 469 503 500 529 547 573 621 636 640 651 65312-year 329 368 390 425 460 494 493 523 529 560 606 613 632 64013-year 321 353 376 411 449 486 485 518 510 543 598 606 61514-year 310 340 365 400 442 479 470 512 497 532 582 59615-year 297 326 349 391 436 472 460 498 483 525 57416-year 287 316 342 385 435 467 441 492 468 51317-year 282 306 336 378 428 459 438 490 45218-year 274 298 327 367 413 449 428 48519-year 265 288 321 358 407 439 42220-year 254 280 312 353 395 433

Table 1911Non-Hodgkin Lymphoma

SEERa Relative Survival (Percent)By Year of Diagnosis

All Races Females

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 5222 2506 2704 3176 3627 3994 4570 4729 5325 5260 5263 5562 5775 6226 6401 6704 6998 7072 11154

SEER 9 except 4285 2088 2267 2603 2819 3091 3507 3694 4159 4249 4364 4515 4818 5209 5398 5628 5841 6015 9363SF-Oakland

San Francisco- 937 418 437 573 808 903 1063 1035 1166 1011 899 1047 957 1017 1003 1076 1157 1057 1791Oakland SMSAc

San Francisco 245 96 123 210 326 393 467 410 450 354 213 256 220 283 219 216 240 225 362CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 134 155 161 183 201 215 234 233 252 244 238 244 246 258 254 255 255 245 244

SEER 9 except 132 154 161 181 188 201 217 218 236 236 235 236 244 256 254 253 252 247 243SF-Oakland

San Francisco- 147 158 160 194 267 285 317 305 335 288 252 286 256 266 256 263 268 235 246Oakland SMSAc

San Francisco 143 144 176 293 444 519 610 523 574 448 274 325 269 354 265 257 273 252 246CityCounty

Table 1912

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males All Ages

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males All Ages

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 0-19 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 223 87 108 91 94 84 100 89 120 105 104 119 127 107 106 143 134 155 240

SEER 9 except 191 78 95 82 80 76 86 74 107 84 93 100 115 90 87 114 119 129 198SF-Oakland

San Francisco- 32 9 13 9 14 8 14 15 13 21 11 19 12 17 19 29 15 26 42Oakland SMSAc

San Francisco 9 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 5 lt4 6 lt4CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 12 12 16 14 14 13 15 13 17 14 14 15 16 14 13 18 17 20 20

SEER 9 except 12 13 16 14 14 13 15 12 17 13 14 15 17 13 13 16 17 19 19SF-Oakland

San Francisco- 14 10 15 10 16 09 15 16 13 21 11 18 12 17 19 28 14 25 27Oakland SMSAc

San Francisco 23 - - - - - - - - - - - - - - 40 - 49 -CityCounty

Table 1913

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 0-19

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 0-19

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 20-54 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 1463 687 723 958 1211 1413 1766 1830 2089 1770 1608 1696 1623 1722 1655 1693 1674 1596 2242

SEER 9 except 1208 563 588 730 827 923 1195 1294 1483 1325 1269 1327 1308 1410 1383 1401 1402 1328 1848SF-Oakland

San Francisco- 255 124 135 228 384 490 571 536 606 445 339 369 315 312 272 292 272 268 394Oakland SMSAc

San Francisco 58 29 34 105 215 288 333 303 317 225 105 115 111 111 86 75 73 71 98CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 69 79 82 104 124 136 159 156 169 138 121 124 117 123 116 118 116 111 104

SEER 9 except 69 78 81 97 103 109 131 134 144 123 115 116 112 119 115 116 115 110 103SF-Oakland

San Francisco- 69 84 89 139 226 264 295 267 298 213 156 164 139 141 123 130 118 114 110Oakland SMSAc

San Francisco 67 88 94 272 565 715 813 724 744 510 230 252 239 248 194 162 152 145 129CityCounty

Table 1914

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 20-54

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 20-54

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 55+ and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 3536 1732 1873 2127 2322 2497 2704 2810 3116 3385 3551 3747 4025 4397 4640 4868 5190 5321 8672

SEER 9 except 2886 1447 1584 1791 1912 2092 2226 2326 2569 2840 3002 3088 3395 3709 3928 4113 4320 4558 7317SF-Oakland

San Francisco- 650 285 289 336 410 405 478 484 547 545 549 659 630 688 712 755 870 763 1355Oakland SMSAc

San Francisco 178 65 88 104 109 105 132 106 130 126 106 141 108 169 131 136 164 148 261CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 451 522 540 596 633 673 701 706 761 800 811 831 858 900 901 891 899 862 871

SEER 9 except 440 521 544 601 620 667 687 692 744 797 813 813 858 901 904 891 888 874 874SF-Oakland

San Francisco- 508 528 520 571 702 703 773 783 854 821 800 932 855 894 888 890 959 800 860Oakland SMSAc

San Francisco 482 446 598 727 739 757 934 747 914 872 727 934 690 1047 764 769 889 776 826CityCounty

Table 1915

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 55+

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 55+

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 003 006 217 072 Asian 0 001 003 005 183 072

10 002 005 011 218 073 Pacific 10 002 004 009 184 073

20 003 009 021 217 073 Islander 20 003 007 015 182 073

30 006 018 042 216 073 30 005 013 029 180 073

40 012 037 082 213 074 40 008 024 057 176 073

50 025 072 139 206 074 50 017 049 101 170 073

60 049 120 177 191 075 60 034 087 139 158 072

70 080 144 - 160 072 70 056 112 - 133 068

80 085 - - 106 062 80 066 - - 091 056

White 0 001 003 006 227 075 American 0 001 002 003 116 049

10 002 005 011 228 076 Indian 10 002 002 005 117 050

20 003 009 021 227 076 Alaska 20 001 003 008 116 050

30 006 018 043 226 077 Nativea 30 003 007 022 117 051

40 012 038 085 223 077 40 004 019 041 117 052

50 026 075 147 217 078 50 016 038 078 118 053

60 052 127 187 201 078 60 024 067 105 109 055

70 085 153 - 169 076 70 048 091 - 096 055

80 090 - - 111 065 80 057 - - 064 043

Black 0 001 002 006 138 042 Hispanicb 0 001 002 005 222 073

10 002 005 011 140 043 10 001 004 009 223 074

20 003 010 022 139 043 20 003 008 019 222 074

30 006 019 041 137 043 30 005 016 040 221 074

40 013 035 068 133 043 40 011 035 078 218 074

50 023 057 093 125 043 50 024 068 133 211 074

60 037 076 102 110 042 60 046 114 173 195 074

70 047 078 - 087 038 70 075 140 - 164 070

80 044 - - 057 032 80 081 - - 112 057

Table 1916

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Both Sexes 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 004 007 243 081 Asian 0 001 003 006 213 085

10 002 006 013 244 082 Pacific 10 002 005 011 213 086

20 004 010 024 243 082 Islander 20 003 009 018 211 086

30 007 021 049 243 083 30 006 015 034 210 086

40 014 042 094 240 084 40 009 028 067 205 086

50 029 082 158 233 085 50 019 059 117 199 086

60 057 139 203 219 086 60 041 101 161 187 085

70 095 170 - 188 084 70 066 131 - 159 082

80 105 - - 130 073 80 080 - - 114 069

White 0 001 004 007 254 085 American 0 001 003 004 104 057

10 002 006 013 255 086 Indian 10 002 003 006 105 058

20 004 010 024 254 086 Alaska 20 001 004 008 103 058

30 007 020 049 253 087 Nativea 30 003 008 021 104 059

40 014 043 097 251 088 40 005 018 038 105 060

50 030 086 167 244 089 50 014 035 071 105 062

60 059 147 215 230 090 60 023 062 094 099 065

70 101 180 - 198 088 70 046 084 - 090 066

80 112 - - 136 076 80 053 - - 061 053

Black 0 001 003 007 152 046 Hispanicb 0 001 003 005 238 083

10 002 006 014 154 047 10 002 005 011 239 084

20 004 012 027 153 047 20 003 009 021 238 084

30 008 023 048 152 047 30 006 018 043 238 084

40 016 042 079 148 047 40 012 037 083 235 085

50 027 066 105 138 047 50 026 073 145 228 085

60 043 087 114 123 045 60 050 126 189 214 085

70 054 088 - 099 042 70 086 157 - 185 081

80 053 - - 070 036 80 094 - - 131 066

Table 1917

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Males 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 002 004 193 064 Asian 0 001 002 004 159 063

10 001 004 009 195 064 Pacific 10 001 004 008 160 063

20 003 007 017 194 064 Islander 20 002 006 013 159 063

30 005 015 036 192 065 30 004 011 025 157 063

40 010 031 071 189 065 40 007 021 048 153 063

50 022 062 120 182 065 50 014 042 087 148 063

60 042 103 154 168 065 60 028 074 122 136 062

70 067 123 - 138 063 70 049 099 - 114 058

80 071 - - 090 054 80 057 - - 075 047

White 0 001 002 004 203 067 American 0 000 001 002 128 043

10 001 004 009 204 067 Indian 10 001 001 004 129 044

20 002 007 017 203 067 Alaska 20 001 003 007 128 044

30 005 015 037 201 067 Nativea 30 002 006 023 129 044

40 010 032 074 198 068 40 004 021 044 129 045

50 022 065 127 192 068 50 017 042 085 129 046

60 044 109 163 177 068 60 026 072 113 118 047

70 072 130 - 146 066 70 050 097 - 102 046

80 075 - - 094 056 80 060 - - 066 037

Black 0 000 002 004 126 040 Hispanicb 0 001 002 004 210 065

10 001 004 009 128 040 10 001 004 008 211 066

20 003 008 018 127 040 20 002 007 017 211 066

30 005 015 034 125 040 30 004 014 036 209 066

40 010 029 058 122 040 40 010 032 073 206 066

50 020 049 083 115 040 50 022 064 123 198 066

60 032 068 094 102 039 60 043 104 161 182 065

70 041 071 - 080 036 70 066 127 - 149 062

80 039 - - 051 030 80 073 - - 100 051

Table 1918

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Females 2014-2016 By RaceEthnicity

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

The AAPC is the Average Annual Percent Change over the time interval The AAPCs are calculated bythe Joinpoint Regression Program Version 47 February 2019 National Cancer Institute

- Statistic not shown Rate based on less than 16 cases for the time intervalTrend based on less than 10 cases for at least one year within the time interval

a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) Trendsare based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico SeattleUtah and AtlantaThe SEER 21 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the AlaskaNative Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts

c The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 3 Joinpoints overdiagnosis years 2000-2016

d The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 5 Joinpoints overdiagnosis years 1975-2016

e Hispanic and Non-Hispanic are not mutually exclusive from whites blacks AsianPacificIslanders and American IndiansAlaska Natives Incidence data for Hispanics and Non-Hispanicsare based on NHIA and exclude cases from the Alaska Native Registry

f Incidence data for American IndianAlaska Native are based on the PurchasedReferred CareDelivery Area (PRCDA) counties

g US Mortality Files National Center for Health Statistics CDCh The 2007-2016 mortality AAPCs are based on a Joinpoint analysis using years of death 2000-2016 The APC is significantly different from zero (plt05)

SEER Incidence SEER 21 Areasb SEER 21 Areasb SEER 9 Areasb

Rate 2012-2016 Trend 2007-2016c Trend 2007-2016d

Rate per 100000 persons AAPC () AAPC ()

Total Males Females Total Males Females Total Males Females RaceEthnicity

All Races 196 239 162 -07 -09 -08 -09 -07 -08

White 206 250 170 -08 -11 -09 -09 -08 -08White Hispanice 183 212 161 -08 -03 -05 - - -White Non-Hispanice 210 256 172 -08 -06 -10 - - -

Black 147 177 124 01 00 03 00 -04 -09

AsianPacific Islander 134 164 110 00 00 -01 - - -

Amer IndAlaska Natf 113 120 106 -05 -12 00 - - -

Hispanice 179 207 157 -05 -02 03 - - -

US Mortalityg Rate 2012-2016 Trend 2007-2016h

Rate per 100000 persons AAPC ()

Total Males Females Total Males FemalesRaceEthnicity

All Races 56 73 44 -23 -20 -27

White 59 76 45 -23 -20 -27White Hispanice 51 65 40 -16 -13 -20White Non-Hispanice 59 76 46 -23 -20 -27

Black 41 52 33 -20 -19 -21

AsianPacific Islander 39 49 31 -17 -15 -19

Amer IndAlaska NatTotal US 31 40 24 -32 -20 -45PRCDA Counties 44 58 33 -21 -04 -37Non-PRCDA Counties 17 21 14 -54 -50 -60

Hispanice 48 61 38 -17 -14 -21

Table 1919Non-Hodgkin Lymphoma

SEER Incidence and US MortalityAge-Adjusted Rates and Trendsa

By RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Incidence Ratesa 2012-2016

California 1844 2241 1515 1938 2349 1591 1390 1639 1182Greater Bay Area 1957 2381 1600 2144 2601 1755 1628 1828 1436San Francisco-Oakland 1956 2421 1570 2174 2660 1765 1603 1816 1408San Jose-Monterey 1962 2311 1660 2097 2503 1742 1800 1891 1646

Los Angeles 1804 2176 1505 1951 2331 1637 1357 1659 1139Greater California 1822 2220 1489 1876 2286 1529 1314 1534 1113

Connecticut 2116 2607 1733 2154 2642 1771 1386 1829 1051Detroit 2132 2636 1742 2290 2850 1847 1620 1905 1409Georgia 1826 2244 1487 1936 2346 1588 1462 1833 1187Atlanta 1925 2381 1555 2119 2567 1736 1601 2034 1272Rural Georgia 1584 1790 1401 1953 2298 1567 807 - 988Greater Georgia 1784 2186 1459 1872 2274 1537 1380 1703 1146

Hawaii 1660 2024 1349 1958 2275 1593 - - -Idaho 1922 2267 1616 1920 2262 1618 - - -Iowa 2134 2601 1756 2148 2612 1773 1352 1602 1100Kentucky 2039 2505 1666 2070 2538 1693 1403 1788 1112Louisiana 1944 2352 1614 2106 2537 1744 1469 1769 1237Massachusetts 1810 2181 1518 1830 2214 1524 1452 1655 1299New Jersey 2155 2607 1804 2285 2765 1905 1387 1621 1222New Mexico 1550 1739 1387 1580 1798 1394 875 - -New York 2152 2620 1788 2306 2792 1915 1545 1852 1333Seattle-Puget Sound 2116 2627 1695 2177 2667 1766 1631 1973 1316Utah 1843 2233 1498 1862 2258 1513 2089 - -

SEER 9 Areasb 1992 2444 1623 2095 2551 1716 1573 1914 1298SEER 13 Areasb 1946 2373 1597 2064 2502 1700 1519 1853 1258SEER 18 Areasb 1933 2354 1590 2031 2464 1671 1449 1751 1214SEER 21 Areasb 1963 2388 1620 2061 2498 1702 1471 1771 1245

Table 1920Non-Hodgkin Lymphoma

Age-Adjusted SEER Incidence Ratesa

By Registry Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control and PreventionRates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and AtlantaThe SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Death Ratesa 2012-2016

California 533 677 423 570 726 449 417 480 367Greater Bay Area 505 671 376 561 756 408 410 491 331San Francisco-Oakland 503 667 376 555 742 409 416 490 343San Jose-Monterey 511 681 377 573 781 407 - - -

Los Angeles 541 670 443 589 728 481 424 503 371Greater California 539 682 429 564 716 447 416 455 384

Connecticut 533 705 407 547 717 421 350 510 244Detroit 639 822 505 693 895 542 443 528 384Georgia 533 697 411 580 747 450 376 503 286Atlanta 492 659 372 533 728 388 397 506 317Rural Georgia 559 731 388 670 813 507 - - -Greater Georgia 549 712 426 595 755 470 363 500 266

Hawaii 475 620 352 545 649 412 - - -Idaho 635 775 510 641 782 516 - - -Iowa 638 845 484 642 848 488 - - -Kentucky 642 886 460 655 904 470 401 557 284Louisiana 608 814 451 651 863 485 461 623 340Massachusetts 523 659 423 541 682 436 347 410 297New Jersey 545 721 419 585 780 443 372 466 314New Mexico 488 585 405 493 595 406 - - -New York 535 702 412 575 752 441 390 514 313Seattle-Puget Sound 585 749 463 604 769 480 490 562 397Utah 542 670 433 551 681 440 - - -

SEER 9 Areasb 555 719 430 586 758 454 414 522 333SEER 13 Areasb 549 705 429 586 753 457 419 521 342SEER 18 Areasb 554 717 431 589 761 456 409 518 329SEER 21 Areasb 550 712 428 584 754 453 401 513 322

Total US 562 725 436 586 755 454 408 518 330

Table 1921Non-Hodgkin Lymphoma

Age-Adjusted SEER Death Ratesa

By Registry Race and Sex

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 562 002

High Five StatesMichigan 645 011 01(0112) 1479Kentucky 642 016 02(0118) 1424Iowa 638 018 03(0120) 1367Indiana 638 013 04(0117) 1361Idaho 635 027 05(0126) 1303

Low Five StatesNevada 511 019 47(2251) -899Colorado 491 014 48(3851) -1257New Mexico 488 020 49(2851) -1317Hawaii 475 024 50(3051) -1542c

DC 444 039 51(2351) -2097c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 545 014 28(1847) -291 Montana 559 030 25(0250) -042Alaska 525 047 43(0151) -654 Nebraska 563 023 22(0548) 026Arizona 512 012 46(2950) -886 Nevada 511 019 47(2251) -899Arkansas 555 018 26(1247) -113 New Hampshire 562 027 23(0349) 014California 533 005 40(2645) -508 New Jersey 545 010 29(2045) -301Colorado 491 014 48(3851) -1257 New Mexico 488 020 49(2851) -1317Connecticut 533 016 39(1949) -505 New York 535 007 37(2446) -478Delaware 628 033 08(0139) 1174 North Carolina 541 010 35(2146) -363DC 444 039 51(2351) -2097c North Dakota 561 037 24(0151) -007Florida 535 006 38(2545) -479 Ohio 616 009 10(0220) 969Georgia 533 011 41(2248) -511 Oklahoma 630 017 06(0121) 1226Hawaii 475 024 50(3051) -1542c Oregon 612 016 11(0124) 903Idaho 635 027 05(0126) 1303 Pennsylvania 603 009 16(0622) 729Illinois 566 009 20(1634) 085 Rhode Island 542 029 32(0651) -350Indiana 638 013 04(0117) 1361 South Carolina 542 014 31(1847) -347Iowa 638 018 03(0120) 1367 South Dakota 541 033 36(0451) -364Kansas 585 019 19(0439) 420 Tennessee 629 013 07(0119) 1198Kentucky 642 016 02(0118) 1424 Texas 546 007 27(2142) -277Louisiana 608 016 14(0125) 826 Utah 542 022 33(1250) -352Maine 609 026 13(0137) 852 Vermont 605 040 15(0148) 770Maryland 524 013 44(2349) -663 Virginia 544 011 30(2046) -319Massachusetts 523 012 45(2549) -687 Washington 599 013 17(0425) 665Michigan 645 011 01(0112) 1479 West Virginia 612 022 12(0132) 894Minnesota 617 014 09(0122) 984 Wisconsin 590 013 18(0629) 507Mississippi 531 018 42(1850) -551 Wyoming 564 043 21(0151) 050Missouri 542 012 34(1947) -354

Table 1922Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males and Females

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 725 003

High Five StatesKentucky 886 030 01(0112) 2213c

Iowa 845 032 02(0120) 1647c

Michigan 842 019 03(0114) 1615c

Indiana 839 024 04(0116) 1567c

Delaware 824 058 05(0144) 1364

Low Five StatesArizona 635 019 47(3251) -1244Alaska 630 075 48(0251) -1311Hawaii 620 041 49(1951) -1452DC 614 071 50(0551) -1535c

New Mexico 585 033 51(3451) -1928c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 688 025 36(1649) -513 Montana 709 050 26(0251) -218Alaska 630 075 48(0251) -1311 Nebraska 737 040 20(0248) 165Arizona 635 019 47(3251) -1244 Nevada 653 032 44(1951) -994Arkansas 721 031 22(0747) -061 New Hampshire 710 046 25(0451) -210California 677 009 41(2846) -666 New Jersey 721 018 21(1441) -059Colorado 643 024 46(2451) -1133 New Mexico 585 033 51(3451) -1928c

Connecticut 705 028 28(1248) -273 New York 702 012 30(1943) -323Delaware 824 058 05(0144) 1364 North Carolina 709 018 27(1644) -221DC 614 071 50(0551) -1535c North Dakota 682 061 39(0251) -598Florida 683 011 37(2446) -585 Ohio 800 017 09(0320) 1029Georgia 697 019 34(1746) -387 Oklahoma 806 030 08(0126) 1109Hawaii 620 041 49(1951) -1452 Oregon 794 028 12(0128) 947Idaho 775 045 16(0146) 692 Pennsylvania 783 015 15(0523) 794Illinois 739 016 19(1235) 190 Rhode Island 649 050 45(1051) -1050Indiana 839 024 04(0116) 1567c South Carolina 681 025 40(1850) -604Iowa 845 032 02(0120) 1647c South Dakota 701 056 31(0251) -332Kansas 713 032 24(0948) -174 Tennessee 820 023 06(0120) 1311Kentucky 886 030 01(0112) 2213c Texas 698 012 32(2043) -368Louisiana 814 029 07(0122) 1222 Utah 670 036 42(1351) -754Maine 754 045 18(0148) 395 Vermont 794 069 11(0149) 950Maryland 682 023 38(1849) -588 Virginia 694 020 35(1847) -429Massachusetts 659 020 43(2450) -910 Washington 790 022 13(0224) 897Michigan 842 019 03(0114) 1615c West Virginia 774 038 17(0142) 675Minnesota 797 025 10(0224) 995 Wisconsin 786 023 14(0227) 844Mississippi 717 034 23(0748) -110 Wyoming 698 071 33(0151) -377Missouri 702 022 29(1646) -319

Table 1923Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 436 002

High Five StatesIdaho 510 033 01(0139) 1697c

Maine 497 031 02(0141) 1396Michigan 495 012 03(0119) 1340Oklahoma 492 020 04(0128) 1276Indiana 492 016 05(0123) 1270

Low Five StatesMississippi 404 021 47(1351) -731Nevada 382 022 48(2051) -1237Colorado 369 016 49(3451) -1540c

Hawaii 352 027 50(2551) -1932c

DC 323 044 51(1551) -2601c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 440 017 24(0547) 099 Montana 435 036 27(0151) -034Alaska 414 058 38(0151) -500 Nebraska 435 027 26(0249) -032Arizona 407 014 44(2049) -664 Nevada 382 022 48(2051) -1237Arkansas 428 021 31(0649) -181 New Hampshire 454 032 19(0149) 400California 423 006 34(2244) -313 New Jersey 419 012 37(1848) -397Colorado 369 016 49(3451) -1540c New Mexico 405 025 46(0951) -706Connecticut 407 018 45(1550) -669 New York 412 008 39(2548) -554Delaware 473 039 12(0150) 855 North Carolina 420 012 35(1848) -374DC 323 044 51(1551) -2601c North Dakota 471 045 13(0150) 809Florida 412 007 40(2548) -564 Ohio 478 011 10(0123) 967Georgia 411 012 43(2049) -582 Oklahoma 492 020 04(0128) 1276Hawaii 352 027 50(2551) -1932c Oregon 465 019 15(0141) 668Idaho 510 033 01(0139) 1697c Pennsylvania 467 010 14(0427) 714Illinois 439 010 25(1341) 074 Rhode Island 455 035 18(0150) 434Indiana 492 016 05(0123) 1270 South Carolina 432 017 30(0947) -102Iowa 484 021 08(0135) 1087 South Dakota 411 039 42(0151) -580Kansas 486 023 06(0137) 1143 Tennessee 484 015 09(0126) 1087Kentucky 460 018 17(0241) 544 Texas 427 008 32(1944) -213Louisiana 451 018 21(0345) 333 Utah 433 026 28(0250) -081Maine 497 031 02(0141) 1396 Vermont 461 047 16(0151) 578Maryland 411 015 41(1749) -576 Virginia 432 013 29(1246) -092Massachusetts 423 014 33(1548) -303 Washington 452 015 20(0541) 360Michigan 495 012 03(0119) 1340 West Virginia 486 027 07(0143) 1141Minnesota 475 017 11(0132) 901 Wisconsin 443 015 23(0645) 156Mississippi 404 021 47(1351) -731 Wyoming 445 051 22(0151) 192Missouri 419 014 36(1549) -396

Table 1924Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Females

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 Areas (excluding the AlaskaNative Registry) and 112016 US population estimates based on the average of 2015 and 2016 population estimates from theUS Bureau of the CensusPrevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 24 years

b Maximum limited-duration prevalence is 24 years for 1992-2016 datac Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groupsd Cases diagnosed more than 24 years ago were estimated using the completeness index method (Capocaccia et al 1997

Merrill et al 2000)e Complete prevalence is obtained by summing 0 to lt24 and gt=24- Statistic not shown Statistic based on fewer than 5 cases estimated alive in SEER for the time interval+ Not available

Years Since Diagnosis 0 to lt5 5 to lt10 10 to lt15 15 to lt20 20 to lt24 0 to lt24b gt=24d Completee

Race Sex

All Races Both Sexes 248946 177490 117326 69109 31890 644761 49943 694704Males 135137 94173 60159 36020 16581 342069 25489 367558Females 113809 83317 57167 33089 15309 302692 24454 327146

White Both Sexes 213764 154454 101984 60537 28026 558765 49625 620368Males 116527 82172 52535 31627 14543 297404 26526 330121Females 97237 72282 49448 28910 13483 261361 23099 290247

Black Both Sexes 20500 13640 9750 5271 2215 51376 4115 55491Males 10712 7188 4768 2684 1174 26526 1911 28437Females 9789 6452 4981 2587 1041 24850 2204 27054

Asian Both Sexes 8405 5210 3415 1867 844 19741 + +Pacific Males 4548 2661 1757 1013 407 10386 + +Islander Females 3856 2549 1657 855 437 9355 + +

Hispanic Both Sexes 21339 14049 8272 4881 2136 50676 + +Males 10918 7243 4331 2617 1094 26202 + +Females 10421 6805 3941 2264 1043 24474 + +

Age Specific (Crude) Age-Adjustedc Age at Prevalence All Ages 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ All Ages

Race Sex

All Races Both Sexes 02001 00035 00139 00283 00538 01121 02352 04640 08181 10224 01738Males 02156 00044 00189 00354 00625 01293 02710 05243 09364 12449 02023Females 01850 00026 00087 00208 00450 00952 02010 04094 07196 08856 01498

White Both Sexes 02216 00035 00143 00289 00534 01148 02427 04858 08597 10738 01807Males 02380 00045 00198 00359 00622 01317 02790 05442 09778 13060 02095Females 02054 00025 00085 00214 00442 00976 02072 04317 07593 09285 01560

Black Both Sexes 01139 00029 00113 00265 00599 01027 02010 03340 05117 05333 01251Males 01226 00029 00140 00351 00696 01223 02333 03969 05849 06055 01457Females 01059 00030 00086 00178 00510 00853 01728 02836 04608 04976 01088

Asian Both Sexes 00970 00039 00133 00207 00353 00680 01409 02692 04470 06094 01032Pacific Males 01065 00044 00175 00240 00398 00744 01640 03072 05516 07472 01222Islander Females 00882 00033 00092 00175 00312 00623 01209 02384 03629 05207 00880

Hispanic Both Sexes 00887 00030 00117 00206 00398 00850 01769 03632 05888 07209 01294Males 00908 00035 00147 00256 00455 00932 01924 03940 06326 08003 01420Females 00866 00024 00086 00151 00337 00766 01616 03360 05552 06719 01185

Table 1925Non-Hodgkin Lymphoma

Estimated United States Cancer Prevalence Countsa on January 1 2016By RaceEthnicity Sex and Years Since Diagnosis

Estimated prevalence percenta on January 1 2016 of the SEER population diagnosed in the previous 24 yearsBy Age at Prevalence RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 372 452924 -05 62 18862 04 247 189692 -05 1657 244370 -05

1 Hodgkin Lymphoma 28 32262 -17 13 3927 -06 33 22556 -15 39 5779 -31

2 Non-Hodgkin lymphoma 336 409991 -03 48 14693 04 210 163591 -03 1572 231707 -042(a) Non-Hodgkin lymphoma B-cell 311 380349 -01 39 11836 14 190 148768 -02 1491 219745 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 15 16631 20 31 9416 10 07 5203 39 14 2012 252(a) 2 Mature Non-Hodgkin lymphoma B-cell 280 343965 -04 07 2271 30 174 137225 -05 1387 204469 -042(a) 21 ChronicSmallProlymphocytic 69 85601 -13 00 35 - 35 29103 -11 382 56463 -14

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 61 75061 -15 00 30 - 31 25339 -13 336 49692 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 311 19 - - - 00 72 - 02 234 262(a) 213 Mantle-cell lymphoma 08 10229 03 - - - 04 3692 02 44 6537 04

2(a) 22 Lymphoplasmacytic lymphoma 07 8651 00 - - - 03 2590 -11 41 6059 04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 03 3667 -03 - - - 01 1132 -18 17 2533 022(a) 222 Waldenstrom macroglubulinemia 04 4984 03 - - - 02 1458 -07 24 3526 06

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 72 87188 00 03 925 26 48 36480 -02 339 49783 022(a) 231 DLBCL NOSc 71 85899 -01 03 861 12 46 35469 -05 337 49569 012(a) 232 Intravascular large B-cell 00 162 - - - - 00 63 - 01 99 -

lymphoma2(a) 233 Primary effusion lymphoma 00 181 27 - - - 00 126 - 00 55 -2(a) 234 Mediastinal large B-cell 01 946 116 00 64 - 01 822 111 00 60 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 04 4692 -26 03 1028 32 04 2618 -43 07 1046 -432(a) 25 Marginal-zone lymphoma (MZL) 22 26534 00 00 137 13 14 11049 05 104 15348 -042(a) 251 Splenic MZL 02 2418 04 - - - 01 889 -08 10 1529 102(a) 252 Extranodal MZL MALTc type 13 15979 06 00 92 - 09 7148 11 59 8739 032(a) 253 Nodal MZL 07 8137 -15 00 45 - 04 3012 -05 34 5080 -20

2(a) 26 Follicular lymphoma 35 43582 -21 00 119 - 28 21725 -25 147 21738 -182(a) 27 Hairy-cell leukemia 03 3712 -16 - - - 03 2311 -19 09 1401 -122(a) 28 Plasma cell neoplasms 68 83957 08 00 24 - 39 31325 12 358 52608 062(a) 281 Plasmacytoma 04 4879 -04 00 16 - 03 2362 -06 17 2501 -032(a) 282 Multiple myeloma 64 79078 09 - - - 36 28963 14 341 50107 07

plasma-cell leukemia2(a) 29 Heavy chain disease 00 48 - - - - 00 24 - 00 23 -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 16 19753 33 00 149 27 08 6340 37 90 13264 32

Table 1926All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 23 27222 01 08 2502 18 19 13933 03 73 10787 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 616 - 01 293 - 00 272 - 00 51 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 22 26531 11 07 2207 75 19 13621 12 73 10703 -042(b) 21 Mycosis fungoidesSezary syndrome 06 6969 18 01 213 84 06 4080 23 18 2676 052(b) 211 Mycosis fungoides 06 6739 17 01 213 84 05 3990 22 17 2536 042(b) 212 Sezary syndrome 00 230 46 - - - 00 90 - 01 140 -

2(b) 22 Peripheral T-cell lymphoma 12 14531 -10 02 534 07 10 7159 -09 46 6838 -122(b) 221 Peripheral T-cell lymphoma NOSc 04 5393 -01 00 86 - 03 2489 04 19 2818 -042(b) 222 Angioimmunoblastic T-cell lymphoma 02 1902 02 - - - 01 699 -09 08 1201 072(b) 223 Subcutaneous panniculitis- 00 176 44 00 31 - 00 111 - 00 34 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 2523 -36 01 291 00 02 1450 -33 05 782 -54

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 139 - - - - 00 98 - 00 28 -2(b) 226 Enteropathy-type T-cell lymphoma 00 186 -02 - - - 00 84 - 01 101 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 2963 -07 00 59 - 02 1575 01 09 1329 -142(b) 228 Primary cutaneous anaplastic 01 1249 -41 00 51 - 01 653 -49 04 545 -39

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 03 3417 96 05 1428 101 02 1474 99 03 515 672(b) 24 NKcT-cell lymphoma nasal-type 01 985 02 00 26 - 01 659 00 02 300 05

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 120 - - - - 00 54 - 00 65 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 509 30 - - - 00 195 -05 02 309 442(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 75 - - - - 00 40 - 00 33 -2(c) Non-Hodgkin lymphoma unknown lineage 02 2420 -274 01 355 - 01 890 -216 08 1175 -2792(c) 1 Precursor lymphoblastic leukemia 01 814 -283 01 343 - 00 238 - 02 233 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 95 - - - - 00 25 - 00 69 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 1511 -274 - - - 01 627 -202 06 873 -319

lineage2() 1 Total precursor lymphomaleukemiad 16 18061 -07 33 10052 -15 08 5713 06 15 2296 -01

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 762 273 00 20 - 00 339 227 03 403 -lymphoma

4 Lymphoid neoplasm NOSc 08 9909 -55 01 222 113 04 3206 -59 43 6481 -59

Table 1926 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 461 253152 -05 70 10973 05 294 110367 -07 2122 131812 -05

1 Hodgkin Lymphoma 31 17710 -17 13 2118 -03 36 12525 -16 48 3067 -31

2 Non-Hodgkin lymphoma 419 229772 -03 56 8711 05 252 95756 -05 2017 125305 -032(a) Non-Hodgkin lymphoma B-cell 387 212247 -02 44 6786 15 227 86941 -04 1908 118520 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 16 8999 24 33 5123 11 08 2888 46 16 988 292(a) 2 Mature Non-Hodgkin lymphoma B-cell 351 192801 -05 10 1558 28 210 80417 -08 1783 110826 -042(a) 21 ChronicSmallProlymphocytic 96 52411 -15 00 21 - 47 18927 -14 539 33463 -15

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 82 44988 -17 00 19 - 40 16143 -16 464 28826 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 193 -02 - - - 00 46 - 02 145 052(a) 213 Mantle-cell lymphoma 13 7230 -01 - - - 07 2738 -01 72 4492 -01

2(a) 22 Lymphoplasmacytic lymphoma 10 5082 -05 - - - 04 1524 -08 58 3558 -04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 04 2062 -08 - - - 02 616 -12 23 1446 -072(a) 222 Waldenstrom macroglubulinemia 06 3020 -02 - - - 02 908 -06 34 2112 -02

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 88 48128 01 03 554 22 59 21824 -06 418 25750 052(a) 231 DLBCL NOSc 87 47520 00 03 519 03 57 21366 -08 416 25635 042(a) 232 Intravascular large B-cell 00 75 - - - - 00 31 - 01 44 -

lymphoma2(a) 233 Primary effusion lymphoma 00 167 26 - - - 00 123 - 01 44 -2(a) 234 Mediastinal large B-cell 01 366 155 00 35 - 01 304 142 00 27 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 06 3388 -22 05 775 31 06 1969 -46 10 644 -192(a) 25 Marginal-zone lymphoma (MZL) 22 12351 -02 01 98 - 14 5177 -02 114 7076 -012(a) 251 Splenic MZL 02 1164 14 - - - 01 434 18 12 730 112(a) 252 Extranodal MZL MALTc type 13 7268 07 00 62 - 09 3267 04 63 3939 102(a) 253 Nodal MZL 07 3919 -23 00 36 - 04 1476 -22 39 2407 -23

2(a) 26 Follicular lymphoma 39 21788 -19 01 100 - 30 11210 -25 165 10478 -152(a) 27 Hairy-cell leukemia 05 2984 -18 - - - 05 1908 -20 17 1076 -152(a) 28 Plasma cell neoplasms 85 46642 07 - - - 45 17864 11 462 28769 052(a) 281 Plasmacytoma 05 2997 -08 - - - 04 1509 -16 24 1484 -012(a) 282 Multiple myeloma 80 43645 08 - - - 41 16355 13 439 27285 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 27 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 20 10447 34 01 105 - 10 3636 40 110 6706 32

Table 1927All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 29 16118 00 11 1730 14 23 8235 02 98 6153 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 430 - 01 208 - 01 188 - 01 34 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 28 15642 11 10 1521 71 22 8022 11 97 6099 -032(b) 21 Mycosis fungoidesSezary syndrome 07 3962 19 01 135 - 06 2261 21 25 1566 092(b) 211 Mycosis fungoides 07 3831 20 01 135 - 06 2213 21 23 1483 092(b) 212 Sezary syndrome 00 131 - - - - 00 48 - 01 83 -

2(b) 22 Peripheral T-cell lymphoma 15 8438 -13 02 318 -09 12 4248 -12 62 3872 -132(b) 221 Peripheral T-cell lymphoma NOSc 06 3159 -05 00 49 - 04 1520 02 26 1590 -082(b) 222 Angioimmunoblastic T-cell lymphoma 02 1024 19 - - - 01 415 11 10 607 232(b) 223 Subcutaneous panniculitis- 00 68 - - - - 00 39 - 00 16 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 03 1549 -39 01 184 -01 02 888 -43 08 477 -45

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 98 - - - - 00 69 - 00 18 -2(b) 226 Enteropathy-type T-cell lymphoma 00 105 - - - - 00 50 - 01 54 -2(b) 227 Cutaneous T-cell lymphoma NOSc 03 1696 -12 00 32 - 02 894 -03 12 770 -172(b) 228 Primary cutaneous anaplastic 01 739 -48 00 26 - 01 373 -49 05 340 -49

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 04 2253 97 07 1047 92 03 940 98 04 266 1022(b) 24 NKcT-cell lymphoma nasal-type 01 638 -05 00 18 - 01 435 -03 03 185 -06

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 58 - - - - 00 22 - 01 36 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 01 293 45 - - - 00 116 - 03 174 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 46 - - - - 00 25 - 00 20 -2(c) Non-Hodgkin lymphoma unknown lineage 03 1407 -232 01 195 - 02 580 -184 10 632 -2302(c) 1 Precursor lymphoblastic leukemia 01 474 -228 01 187 - 00 134 - 02 153 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 49 - - - - - - - 01 36 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 02 884 -239 - - - 01 433 -175 07 443 -

lineage2() 1 Total precursor lymphomaleukemiad 18 9903 -06 35 5518 -17 09 3210 09 19 1175 05

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 435 271 - - - 01 215 - 03 207 -lymphoma

4 Lymphoid neoplasm NOSc 10 5235 -59 01 131 - 05 1871 -65 54 3233 -61

Table 1927 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 301 199772 -05 53 7889 02 202 79325 -02 1322 112558 -08

1 Hodgkin Lymphoma 24 14552 -16 12 1809 -10 29 10031 -14 32 2712 -32

2 Non-Hodgkin lymphoma 269 180219 -03 40 5982 03 170 67835 00 1251 106402 -062(a) Non-Hodgkin lymphoma B-cell 250 168102 -01 34 5050 13 154 61827 02 1190 101225 -042(a) 1 Precursor Non-Hodgkin lymphoma B-cell 14 7632 16 29 4293 09 06 2315 29 12 1024 202(a) 2 Mature Non-Hodgkin lymphoma B-cell 223 151164 -04 05 713 35 141 56808 -01 1102 93643 -072(a) 21 ChronicSmallProlymphocytic 48 33190 -13 - - - 24 10176 -05 268 23000 -16

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 43 30073 -15 - - - 22 9196 -06 243 20866 -19

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 118 - - - - 00 26 - 01 89 -2(a) 213 Mantle-cell lymphoma 04 2999 11 - - - 02 954 10 24 2045 12

2(a) 22 Lymphoplasmacytic lymphoma 05 3569 04 - - - 03 1066 -16 30 2501 11Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 02 1605 01 - - - 01 516 -25 13 1087 112(a) 222 Waldenstrom macroglubulinemia 03 1964 06 - - - 01 550 -08 17 1414 11

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 58 39060 00 02 371 33 38 14656 03 283 24033 -032(a) 231 DLBCL NOSc 57 38379 -02 02 342 27 36 14103 -01 282 23934 -032(a) 232 Intravascular large B-cell 00 87 - - - - 00 32 - 01 55 -

lymphoma2(a) 233 Primary effusion lymphoma - - - - - - - - - - - -2(a) 234 Mediastinal large B-cell 01 580 91 00 29 - 02 518 93 00 33 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 02 1304 -34 02 253 38 02 649 -37 05 402 -852(a) 25 Marginal-zone lymphoma (MZL) 21 14183 01 00 39 - 15 5872 12 98 8272 -062(a) 251 Splenic MZL 02 1254 -07 - - - 01 455 -32 10 799 072(a) 252 Extranodal MZL MALTc type 13 8711 06 00 30 - 10 3881 17 57 4800 -032(a) 253 Nodal MZL 06 4218 -07 - - - 04 1536 11 32 2673 -18

2(a) 26 Follicular lymphoma 33 21794 -24 00 19 - 27 10515 -25 134 11260 -222(a) 27 Hairy-cell leukemia 01 728 -12 - - - 01 403 -11 04 325 -122(a) 28 Plasma cell neoplasms 55 37315 08 - - - 33 13461 15 282 23839 052(a) 281 Plasmacytoma 03 1882 00 - - - 02 853 12 12 1017 -092(a) 282 Multiple myeloma 52 35433 09 - - - 30 12608 15 270 22822 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 21 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 14 9306 32 00 44 - 07 2704 32 76 6558 31

Table 1928All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 17 11104 01 05 772 29 15 5698 05 55 4634 -112(b) 1 Precursor Non-Hodgkin lymphoma T-cell 00 186 - 01 85 - 00 84 - 00 17 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 17 10889 09 05 686 83 15 5599 12 54 4604 -092(b) 21 Mycosis fungoidesSezary syndrome 05 3007 15 01 78 - 05 1819 26 13 1110 -042(b) 211 Mycosis fungoides 05 2908 12 01 78 - 05 1777 23 12 1053 -072(b) 212 Sezary syndrome 00 99 - - - - 00 42 - 01 57 -

2(b) 22 Peripheral T-cell lymphoma 09 6093 -08 01 216 30 08 2911 -06 35 2966 -142(b) 221 Peripheral T-cell lymphoma NOSc 03 2234 03 00 37 - 03 969 07 14 1228 -012(b) 222 Angioimmunoblastic T-cell lymphoma 01 878 -22 - - - 01 284 -39 07 594 -152(b) 223 Subcutaneous panniculitis- 00 108 - 00 18 - 00 72 - 00 18 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 974 -33 01 107 - 02 562 -19 04 305 -77

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 41 - - - - 00 29 - - - -2(b) 226 Enteropathy-type T-cell lymphoma 00 81 - - - - 00 34 - 01 47 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 1267 00 00 27 - 02 681 07 07 559 -102(b) 228 Primary cutaneous anaplastic 01 510 -34 00 25 - 01 280 -50 02 205 -33

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 02 1164 96 03 381 127 01 534 97 03 249 302(b) 24 NKcT-cell lymphoma nasal-type 01 347 11 - - - 01 224 - 01 115 -

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 62 - - - - 00 32 - 00 29 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 216 03 - - - 00 79 - 02 135 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 29 - - - - - - - - - -2(c) Non-Hodgkin lymphoma unknown lineage 02 1013 -341 01 160 - 01 310 - 06 543 -2(c) 1 Precursor lymphoblastic leukemia 01 340 - 01 156 - 00 104 - 01 80 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 46 - - - - - - - 00 33 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 627 - - - - 01 194 - 05 430 -

lineage2() 1 Total precursor lymphomaleukemiad 14 8158 -09 31 4534 -13 07 2503 02 13 1121 -11

3 Composite Hodgkin lymphoma and Non-Hodgkin 00 327 - - - - 00 124 - 02 196 -lymphoma

4 Lymphoid neoplasm NOSc 07 4674 -52 01 91 - 03 1335 -51 36 3248 -58

Table 1928 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 9: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Expected survival rates are derived from the US Annual Life Tables

1975- 1980- 1985- 1990-1979 1984 1989 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Survival Time

1-year 702 730 713 704 703 733 756 767 774 773 787 810 803 811 817 810 816 841 839 844 834 842 844 834 8452-year 602 637 628 622 618 659 685 700 710 714 733 760 757 760 773 769 775 790 795 796 797 800 800 7953-year 546 585 582 577 575 621 649 664 669 679 701 731 731 735 748 745 750 762 773 774 775 779 7794-year 505 546 543 544 547 587 621 636 645 655 681 712 716 715 730 726 732 744 756 752 756 7675-year 468 507 510 516 520 561 594 609 621 638 660 693 700 701 716 705 712 728 741 742 7426-year 436 475 483 492 499 541 571 583 595 621 647 680 683 688 704 688 701 718 721 7237-year 408 450 458 470 479 522 552 564 577 605 629 663 671 672 685 672 688 702 7108-year 385 428 434 450 464 504 529 552 563 589 613 651 658 666 670 661 674 6909-year 366 408 415 435 453 493 515 535 548 576 600 640 648 649 652 651 66110-year 350 389 398 421 443 481 501 522 537 563 589 632 633 638 634 63711-year 335 374 385 406 434 466 488 511 525 548 581 618 621 630 63112-year 324 360 369 395 423 457 481 501 512 535 568 600 615 61713-year 314 348 358 383 415 449 469 492 500 520 561 593 60214-year 302 335 347 372 406 443 456 485 488 513 549 58315-year 289 322 335 365 398 437 447 474 478 505 54016-year 279 312 328 356 393 437 433 472 470 49217-year 274 304 321 349 388 428 428 469 45818-year 268 296 314 341 378 420 419 46319-year 260 288 306 333 370 413 41220-year 252 280 301 329 359 408

Table 199Non-Hodgkin Lymphoma

SEERa Relative Survival (Percent)By Year of Diagnosis

All Races Males and Females

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Expected survival rates are derived from the US Annual Life Tables

1975- 1980- 1985- 1990-1979 1984 1989 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Survival Time

1-year 694 727 689 671 666 712 747 749 758 765 776 806 797 801 811 810 814 836 828 838 838 841 834 830 8352-year 594 637 605 582 583 636 672 682 691 703 713 752 749 755 762 765 778 779 781 788 798 793 786 7913-year 534 580 557 537 545 598 638 645 644 668 679 720 726 726 731 736 754 751 757 766 776 769 7644-year 493 539 516 504 515 561 610 620 615 639 657 700 709 701 711 713 734 734 737 743 756 7575-year 455 501 482 476 485 537 583 592 590 617 635 679 689 688 699 689 710 721 724 735 7426-year 426 466 455 456 469 510 561 565 562 602 620 667 669 676 684 670 696 715 706 7177-year 399 442 431 436 449 491 542 544 546 587 601 652 658 655 668 651 682 696 6968-year 378 420 410 418 433 474 520 533 536 567 582 637 645 649 650 634 665 6869-year 357 401 391 402 423 465 504 514 523 553 572 628 633 632 636 618 65210-year 340 380 377 392 416 455 489 503 515 542 560 617 617 620 613 60911-year 328 363 364 381 407 437 477 494 508 527 547 603 605 612 61212-year 319 352 351 372 395 427 472 482 498 515 537 589 601 59613-year 307 342 343 361 389 419 456 467 491 501 531 582 59114-year 295 330 332 350 378 414 444 461 480 496 521 57215-year 281 319 324 344 368 409 435 453 473 488 51216-year 272 308 316 333 361 409 426 453 471 47417-year 265 300 308 326 358 403 420 449 46218-year 261 294 302 320 350 396 410 44219-year 256 287 294 313 342 391 40320-year 250 280 291 309 332 387

Table 1910Non-Hodgkin Lymphoma

SEERa Relative Survival (Percent)By Year of Diagnosis

All Races Males

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Expected survival rates are derived from the US Annual Life Tables

1975- 1980- 1985- 1990-1979 1984 1989 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Survival Time

1-year 710 734 741 747 752 759 767 786 792 782 801 814 810 821 825 809 819 847 854 851 830 843 856 838 8572-year 611 637 656 672 664 688 701 720 734 727 758 769 765 767 786 774 772 804 812 807 796 810 817 7993-year 559 589 611 627 616 649 662 684 700 692 727 744 736 746 768 756 746 774 791 786 774 791 7974-year 519 553 576 595 590 619 634 653 681 674 710 725 724 730 751 739 729 757 778 764 755 7805-year 482 514 544 567 565 591 608 629 658 664 688 708 713 716 736 724 715 735 763 751 7426-year 446 484 517 539 540 580 583 603 635 643 679 695 699 701 727 708 707 722 738 7317-year 417 458 490 512 520 560 563 586 615 626 663 674 687 692 704 698 694 709 7268-year 392 437 463 491 505 542 539 573 596 615 649 667 672 684 693 692 684 6949-year 374 416 443 476 492 529 528 557 578 603 633 654 664 669 671 688 67110-year 360 399 424 458 480 514 516 542 562 588 625 648 651 658 659 66911-year 342 385 409 438 469 503 500 529 547 573 621 636 640 651 65312-year 329 368 390 425 460 494 493 523 529 560 606 613 632 64013-year 321 353 376 411 449 486 485 518 510 543 598 606 61514-year 310 340 365 400 442 479 470 512 497 532 582 59615-year 297 326 349 391 436 472 460 498 483 525 57416-year 287 316 342 385 435 467 441 492 468 51317-year 282 306 336 378 428 459 438 490 45218-year 274 298 327 367 413 449 428 48519-year 265 288 321 358 407 439 42220-year 254 280 312 353 395 433

Table 1911Non-Hodgkin Lymphoma

SEERa Relative Survival (Percent)By Year of Diagnosis

All Races Females

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 5222 2506 2704 3176 3627 3994 4570 4729 5325 5260 5263 5562 5775 6226 6401 6704 6998 7072 11154

SEER 9 except 4285 2088 2267 2603 2819 3091 3507 3694 4159 4249 4364 4515 4818 5209 5398 5628 5841 6015 9363SF-Oakland

San Francisco- 937 418 437 573 808 903 1063 1035 1166 1011 899 1047 957 1017 1003 1076 1157 1057 1791Oakland SMSAc

San Francisco 245 96 123 210 326 393 467 410 450 354 213 256 220 283 219 216 240 225 362CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 134 155 161 183 201 215 234 233 252 244 238 244 246 258 254 255 255 245 244

SEER 9 except 132 154 161 181 188 201 217 218 236 236 235 236 244 256 254 253 252 247 243SF-Oakland

San Francisco- 147 158 160 194 267 285 317 305 335 288 252 286 256 266 256 263 268 235 246Oakland SMSAc

San Francisco 143 144 176 293 444 519 610 523 574 448 274 325 269 354 265 257 273 252 246CityCounty

Table 1912

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males All Ages

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males All Ages

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 0-19 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 223 87 108 91 94 84 100 89 120 105 104 119 127 107 106 143 134 155 240

SEER 9 except 191 78 95 82 80 76 86 74 107 84 93 100 115 90 87 114 119 129 198SF-Oakland

San Francisco- 32 9 13 9 14 8 14 15 13 21 11 19 12 17 19 29 15 26 42Oakland SMSAc

San Francisco 9 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 5 lt4 6 lt4CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 12 12 16 14 14 13 15 13 17 14 14 15 16 14 13 18 17 20 20

SEER 9 except 12 13 16 14 14 13 15 12 17 13 14 15 17 13 13 16 17 19 19SF-Oakland

San Francisco- 14 10 15 10 16 09 15 16 13 21 11 18 12 17 19 28 14 25 27Oakland SMSAc

San Francisco 23 - - - - - - - - - - - - - - 40 - 49 -CityCounty

Table 1913

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 0-19

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 0-19

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 20-54 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 1463 687 723 958 1211 1413 1766 1830 2089 1770 1608 1696 1623 1722 1655 1693 1674 1596 2242

SEER 9 except 1208 563 588 730 827 923 1195 1294 1483 1325 1269 1327 1308 1410 1383 1401 1402 1328 1848SF-Oakland

San Francisco- 255 124 135 228 384 490 571 536 606 445 339 369 315 312 272 292 272 268 394Oakland SMSAc

San Francisco 58 29 34 105 215 288 333 303 317 225 105 115 111 111 86 75 73 71 98CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 69 79 82 104 124 136 159 156 169 138 121 124 117 123 116 118 116 111 104

SEER 9 except 69 78 81 97 103 109 131 134 144 123 115 116 112 119 115 116 115 110 103SF-Oakland

San Francisco- 69 84 89 139 226 264 295 267 298 213 156 164 139 141 123 130 118 114 110Oakland SMSAc

San Francisco 67 88 94 272 565 715 813 724 744 510 230 252 239 248 194 162 152 145 129CityCounty

Table 1914

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 20-54

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 20-54

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 55+ and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 3536 1732 1873 2127 2322 2497 2704 2810 3116 3385 3551 3747 4025 4397 4640 4868 5190 5321 8672

SEER 9 except 2886 1447 1584 1791 1912 2092 2226 2326 2569 2840 3002 3088 3395 3709 3928 4113 4320 4558 7317SF-Oakland

San Francisco- 650 285 289 336 410 405 478 484 547 545 549 659 630 688 712 755 870 763 1355Oakland SMSAc

San Francisco 178 65 88 104 109 105 132 106 130 126 106 141 108 169 131 136 164 148 261CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 451 522 540 596 633 673 701 706 761 800 811 831 858 900 901 891 899 862 871

SEER 9 except 440 521 544 601 620 667 687 692 744 797 813 813 858 901 904 891 888 874 874SF-Oakland

San Francisco- 508 528 520 571 702 703 773 783 854 821 800 932 855 894 888 890 959 800 860Oakland SMSAc

San Francisco 482 446 598 727 739 757 934 747 914 872 727 934 690 1047 764 769 889 776 826CityCounty

Table 1915

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 55+

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 55+

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 003 006 217 072 Asian 0 001 003 005 183 072

10 002 005 011 218 073 Pacific 10 002 004 009 184 073

20 003 009 021 217 073 Islander 20 003 007 015 182 073

30 006 018 042 216 073 30 005 013 029 180 073

40 012 037 082 213 074 40 008 024 057 176 073

50 025 072 139 206 074 50 017 049 101 170 073

60 049 120 177 191 075 60 034 087 139 158 072

70 080 144 - 160 072 70 056 112 - 133 068

80 085 - - 106 062 80 066 - - 091 056

White 0 001 003 006 227 075 American 0 001 002 003 116 049

10 002 005 011 228 076 Indian 10 002 002 005 117 050

20 003 009 021 227 076 Alaska 20 001 003 008 116 050

30 006 018 043 226 077 Nativea 30 003 007 022 117 051

40 012 038 085 223 077 40 004 019 041 117 052

50 026 075 147 217 078 50 016 038 078 118 053

60 052 127 187 201 078 60 024 067 105 109 055

70 085 153 - 169 076 70 048 091 - 096 055

80 090 - - 111 065 80 057 - - 064 043

Black 0 001 002 006 138 042 Hispanicb 0 001 002 005 222 073

10 002 005 011 140 043 10 001 004 009 223 074

20 003 010 022 139 043 20 003 008 019 222 074

30 006 019 041 137 043 30 005 016 040 221 074

40 013 035 068 133 043 40 011 035 078 218 074

50 023 057 093 125 043 50 024 068 133 211 074

60 037 076 102 110 042 60 046 114 173 195 074

70 047 078 - 087 038 70 075 140 - 164 070

80 044 - - 057 032 80 081 - - 112 057

Table 1916

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Both Sexes 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 004 007 243 081 Asian 0 001 003 006 213 085

10 002 006 013 244 082 Pacific 10 002 005 011 213 086

20 004 010 024 243 082 Islander 20 003 009 018 211 086

30 007 021 049 243 083 30 006 015 034 210 086

40 014 042 094 240 084 40 009 028 067 205 086

50 029 082 158 233 085 50 019 059 117 199 086

60 057 139 203 219 086 60 041 101 161 187 085

70 095 170 - 188 084 70 066 131 - 159 082

80 105 - - 130 073 80 080 - - 114 069

White 0 001 004 007 254 085 American 0 001 003 004 104 057

10 002 006 013 255 086 Indian 10 002 003 006 105 058

20 004 010 024 254 086 Alaska 20 001 004 008 103 058

30 007 020 049 253 087 Nativea 30 003 008 021 104 059

40 014 043 097 251 088 40 005 018 038 105 060

50 030 086 167 244 089 50 014 035 071 105 062

60 059 147 215 230 090 60 023 062 094 099 065

70 101 180 - 198 088 70 046 084 - 090 066

80 112 - - 136 076 80 053 - - 061 053

Black 0 001 003 007 152 046 Hispanicb 0 001 003 005 238 083

10 002 006 014 154 047 10 002 005 011 239 084

20 004 012 027 153 047 20 003 009 021 238 084

30 008 023 048 152 047 30 006 018 043 238 084

40 016 042 079 148 047 40 012 037 083 235 085

50 027 066 105 138 047 50 026 073 145 228 085

60 043 087 114 123 045 60 050 126 189 214 085

70 054 088 - 099 042 70 086 157 - 185 081

80 053 - - 070 036 80 094 - - 131 066

Table 1917

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Males 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 002 004 193 064 Asian 0 001 002 004 159 063

10 001 004 009 195 064 Pacific 10 001 004 008 160 063

20 003 007 017 194 064 Islander 20 002 006 013 159 063

30 005 015 036 192 065 30 004 011 025 157 063

40 010 031 071 189 065 40 007 021 048 153 063

50 022 062 120 182 065 50 014 042 087 148 063

60 042 103 154 168 065 60 028 074 122 136 062

70 067 123 - 138 063 70 049 099 - 114 058

80 071 - - 090 054 80 057 - - 075 047

White 0 001 002 004 203 067 American 0 000 001 002 128 043

10 001 004 009 204 067 Indian 10 001 001 004 129 044

20 002 007 017 203 067 Alaska 20 001 003 007 128 044

30 005 015 037 201 067 Nativea 30 002 006 023 129 044

40 010 032 074 198 068 40 004 021 044 129 045

50 022 065 127 192 068 50 017 042 085 129 046

60 044 109 163 177 068 60 026 072 113 118 047

70 072 130 - 146 066 70 050 097 - 102 046

80 075 - - 094 056 80 060 - - 066 037

Black 0 000 002 004 126 040 Hispanicb 0 001 002 004 210 065

10 001 004 009 128 040 10 001 004 008 211 066

20 003 008 018 127 040 20 002 007 017 211 066

30 005 015 034 125 040 30 004 014 036 209 066

40 010 029 058 122 040 40 010 032 073 206 066

50 020 049 083 115 040 50 022 064 123 198 066

60 032 068 094 102 039 60 043 104 161 182 065

70 041 071 - 080 036 70 066 127 - 149 062

80 039 - - 051 030 80 073 - - 100 051

Table 1918

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Females 2014-2016 By RaceEthnicity

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

The AAPC is the Average Annual Percent Change over the time interval The AAPCs are calculated bythe Joinpoint Regression Program Version 47 February 2019 National Cancer Institute

- Statistic not shown Rate based on less than 16 cases for the time intervalTrend based on less than 10 cases for at least one year within the time interval

a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) Trendsare based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico SeattleUtah and AtlantaThe SEER 21 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the AlaskaNative Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts

c The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 3 Joinpoints overdiagnosis years 2000-2016

d The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 5 Joinpoints overdiagnosis years 1975-2016

e Hispanic and Non-Hispanic are not mutually exclusive from whites blacks AsianPacificIslanders and American IndiansAlaska Natives Incidence data for Hispanics and Non-Hispanicsare based on NHIA and exclude cases from the Alaska Native Registry

f Incidence data for American IndianAlaska Native are based on the PurchasedReferred CareDelivery Area (PRCDA) counties

g US Mortality Files National Center for Health Statistics CDCh The 2007-2016 mortality AAPCs are based on a Joinpoint analysis using years of death 2000-2016 The APC is significantly different from zero (plt05)

SEER Incidence SEER 21 Areasb SEER 21 Areasb SEER 9 Areasb

Rate 2012-2016 Trend 2007-2016c Trend 2007-2016d

Rate per 100000 persons AAPC () AAPC ()

Total Males Females Total Males Females Total Males Females RaceEthnicity

All Races 196 239 162 -07 -09 -08 -09 -07 -08

White 206 250 170 -08 -11 -09 -09 -08 -08White Hispanice 183 212 161 -08 -03 -05 - - -White Non-Hispanice 210 256 172 -08 -06 -10 - - -

Black 147 177 124 01 00 03 00 -04 -09

AsianPacific Islander 134 164 110 00 00 -01 - - -

Amer IndAlaska Natf 113 120 106 -05 -12 00 - - -

Hispanice 179 207 157 -05 -02 03 - - -

US Mortalityg Rate 2012-2016 Trend 2007-2016h

Rate per 100000 persons AAPC ()

Total Males Females Total Males FemalesRaceEthnicity

All Races 56 73 44 -23 -20 -27

White 59 76 45 -23 -20 -27White Hispanice 51 65 40 -16 -13 -20White Non-Hispanice 59 76 46 -23 -20 -27

Black 41 52 33 -20 -19 -21

AsianPacific Islander 39 49 31 -17 -15 -19

Amer IndAlaska NatTotal US 31 40 24 -32 -20 -45PRCDA Counties 44 58 33 -21 -04 -37Non-PRCDA Counties 17 21 14 -54 -50 -60

Hispanice 48 61 38 -17 -14 -21

Table 1919Non-Hodgkin Lymphoma

SEER Incidence and US MortalityAge-Adjusted Rates and Trendsa

By RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Incidence Ratesa 2012-2016

California 1844 2241 1515 1938 2349 1591 1390 1639 1182Greater Bay Area 1957 2381 1600 2144 2601 1755 1628 1828 1436San Francisco-Oakland 1956 2421 1570 2174 2660 1765 1603 1816 1408San Jose-Monterey 1962 2311 1660 2097 2503 1742 1800 1891 1646

Los Angeles 1804 2176 1505 1951 2331 1637 1357 1659 1139Greater California 1822 2220 1489 1876 2286 1529 1314 1534 1113

Connecticut 2116 2607 1733 2154 2642 1771 1386 1829 1051Detroit 2132 2636 1742 2290 2850 1847 1620 1905 1409Georgia 1826 2244 1487 1936 2346 1588 1462 1833 1187Atlanta 1925 2381 1555 2119 2567 1736 1601 2034 1272Rural Georgia 1584 1790 1401 1953 2298 1567 807 - 988Greater Georgia 1784 2186 1459 1872 2274 1537 1380 1703 1146

Hawaii 1660 2024 1349 1958 2275 1593 - - -Idaho 1922 2267 1616 1920 2262 1618 - - -Iowa 2134 2601 1756 2148 2612 1773 1352 1602 1100Kentucky 2039 2505 1666 2070 2538 1693 1403 1788 1112Louisiana 1944 2352 1614 2106 2537 1744 1469 1769 1237Massachusetts 1810 2181 1518 1830 2214 1524 1452 1655 1299New Jersey 2155 2607 1804 2285 2765 1905 1387 1621 1222New Mexico 1550 1739 1387 1580 1798 1394 875 - -New York 2152 2620 1788 2306 2792 1915 1545 1852 1333Seattle-Puget Sound 2116 2627 1695 2177 2667 1766 1631 1973 1316Utah 1843 2233 1498 1862 2258 1513 2089 - -

SEER 9 Areasb 1992 2444 1623 2095 2551 1716 1573 1914 1298SEER 13 Areasb 1946 2373 1597 2064 2502 1700 1519 1853 1258SEER 18 Areasb 1933 2354 1590 2031 2464 1671 1449 1751 1214SEER 21 Areasb 1963 2388 1620 2061 2498 1702 1471 1771 1245

Table 1920Non-Hodgkin Lymphoma

Age-Adjusted SEER Incidence Ratesa

By Registry Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control and PreventionRates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and AtlantaThe SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Death Ratesa 2012-2016

California 533 677 423 570 726 449 417 480 367Greater Bay Area 505 671 376 561 756 408 410 491 331San Francisco-Oakland 503 667 376 555 742 409 416 490 343San Jose-Monterey 511 681 377 573 781 407 - - -

Los Angeles 541 670 443 589 728 481 424 503 371Greater California 539 682 429 564 716 447 416 455 384

Connecticut 533 705 407 547 717 421 350 510 244Detroit 639 822 505 693 895 542 443 528 384Georgia 533 697 411 580 747 450 376 503 286Atlanta 492 659 372 533 728 388 397 506 317Rural Georgia 559 731 388 670 813 507 - - -Greater Georgia 549 712 426 595 755 470 363 500 266

Hawaii 475 620 352 545 649 412 - - -Idaho 635 775 510 641 782 516 - - -Iowa 638 845 484 642 848 488 - - -Kentucky 642 886 460 655 904 470 401 557 284Louisiana 608 814 451 651 863 485 461 623 340Massachusetts 523 659 423 541 682 436 347 410 297New Jersey 545 721 419 585 780 443 372 466 314New Mexico 488 585 405 493 595 406 - - -New York 535 702 412 575 752 441 390 514 313Seattle-Puget Sound 585 749 463 604 769 480 490 562 397Utah 542 670 433 551 681 440 - - -

SEER 9 Areasb 555 719 430 586 758 454 414 522 333SEER 13 Areasb 549 705 429 586 753 457 419 521 342SEER 18 Areasb 554 717 431 589 761 456 409 518 329SEER 21 Areasb 550 712 428 584 754 453 401 513 322

Total US 562 725 436 586 755 454 408 518 330

Table 1921Non-Hodgkin Lymphoma

Age-Adjusted SEER Death Ratesa

By Registry Race and Sex

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 562 002

High Five StatesMichigan 645 011 01(0112) 1479Kentucky 642 016 02(0118) 1424Iowa 638 018 03(0120) 1367Indiana 638 013 04(0117) 1361Idaho 635 027 05(0126) 1303

Low Five StatesNevada 511 019 47(2251) -899Colorado 491 014 48(3851) -1257New Mexico 488 020 49(2851) -1317Hawaii 475 024 50(3051) -1542c

DC 444 039 51(2351) -2097c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 545 014 28(1847) -291 Montana 559 030 25(0250) -042Alaska 525 047 43(0151) -654 Nebraska 563 023 22(0548) 026Arizona 512 012 46(2950) -886 Nevada 511 019 47(2251) -899Arkansas 555 018 26(1247) -113 New Hampshire 562 027 23(0349) 014California 533 005 40(2645) -508 New Jersey 545 010 29(2045) -301Colorado 491 014 48(3851) -1257 New Mexico 488 020 49(2851) -1317Connecticut 533 016 39(1949) -505 New York 535 007 37(2446) -478Delaware 628 033 08(0139) 1174 North Carolina 541 010 35(2146) -363DC 444 039 51(2351) -2097c North Dakota 561 037 24(0151) -007Florida 535 006 38(2545) -479 Ohio 616 009 10(0220) 969Georgia 533 011 41(2248) -511 Oklahoma 630 017 06(0121) 1226Hawaii 475 024 50(3051) -1542c Oregon 612 016 11(0124) 903Idaho 635 027 05(0126) 1303 Pennsylvania 603 009 16(0622) 729Illinois 566 009 20(1634) 085 Rhode Island 542 029 32(0651) -350Indiana 638 013 04(0117) 1361 South Carolina 542 014 31(1847) -347Iowa 638 018 03(0120) 1367 South Dakota 541 033 36(0451) -364Kansas 585 019 19(0439) 420 Tennessee 629 013 07(0119) 1198Kentucky 642 016 02(0118) 1424 Texas 546 007 27(2142) -277Louisiana 608 016 14(0125) 826 Utah 542 022 33(1250) -352Maine 609 026 13(0137) 852 Vermont 605 040 15(0148) 770Maryland 524 013 44(2349) -663 Virginia 544 011 30(2046) -319Massachusetts 523 012 45(2549) -687 Washington 599 013 17(0425) 665Michigan 645 011 01(0112) 1479 West Virginia 612 022 12(0132) 894Minnesota 617 014 09(0122) 984 Wisconsin 590 013 18(0629) 507Mississippi 531 018 42(1850) -551 Wyoming 564 043 21(0151) 050Missouri 542 012 34(1947) -354

Table 1922Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males and Females

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 725 003

High Five StatesKentucky 886 030 01(0112) 2213c

Iowa 845 032 02(0120) 1647c

Michigan 842 019 03(0114) 1615c

Indiana 839 024 04(0116) 1567c

Delaware 824 058 05(0144) 1364

Low Five StatesArizona 635 019 47(3251) -1244Alaska 630 075 48(0251) -1311Hawaii 620 041 49(1951) -1452DC 614 071 50(0551) -1535c

New Mexico 585 033 51(3451) -1928c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 688 025 36(1649) -513 Montana 709 050 26(0251) -218Alaska 630 075 48(0251) -1311 Nebraska 737 040 20(0248) 165Arizona 635 019 47(3251) -1244 Nevada 653 032 44(1951) -994Arkansas 721 031 22(0747) -061 New Hampshire 710 046 25(0451) -210California 677 009 41(2846) -666 New Jersey 721 018 21(1441) -059Colorado 643 024 46(2451) -1133 New Mexico 585 033 51(3451) -1928c

Connecticut 705 028 28(1248) -273 New York 702 012 30(1943) -323Delaware 824 058 05(0144) 1364 North Carolina 709 018 27(1644) -221DC 614 071 50(0551) -1535c North Dakota 682 061 39(0251) -598Florida 683 011 37(2446) -585 Ohio 800 017 09(0320) 1029Georgia 697 019 34(1746) -387 Oklahoma 806 030 08(0126) 1109Hawaii 620 041 49(1951) -1452 Oregon 794 028 12(0128) 947Idaho 775 045 16(0146) 692 Pennsylvania 783 015 15(0523) 794Illinois 739 016 19(1235) 190 Rhode Island 649 050 45(1051) -1050Indiana 839 024 04(0116) 1567c South Carolina 681 025 40(1850) -604Iowa 845 032 02(0120) 1647c South Dakota 701 056 31(0251) -332Kansas 713 032 24(0948) -174 Tennessee 820 023 06(0120) 1311Kentucky 886 030 01(0112) 2213c Texas 698 012 32(2043) -368Louisiana 814 029 07(0122) 1222 Utah 670 036 42(1351) -754Maine 754 045 18(0148) 395 Vermont 794 069 11(0149) 950Maryland 682 023 38(1849) -588 Virginia 694 020 35(1847) -429Massachusetts 659 020 43(2450) -910 Washington 790 022 13(0224) 897Michigan 842 019 03(0114) 1615c West Virginia 774 038 17(0142) 675Minnesota 797 025 10(0224) 995 Wisconsin 786 023 14(0227) 844Mississippi 717 034 23(0748) -110 Wyoming 698 071 33(0151) -377Missouri 702 022 29(1646) -319

Table 1923Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 436 002

High Five StatesIdaho 510 033 01(0139) 1697c

Maine 497 031 02(0141) 1396Michigan 495 012 03(0119) 1340Oklahoma 492 020 04(0128) 1276Indiana 492 016 05(0123) 1270

Low Five StatesMississippi 404 021 47(1351) -731Nevada 382 022 48(2051) -1237Colorado 369 016 49(3451) -1540c

Hawaii 352 027 50(2551) -1932c

DC 323 044 51(1551) -2601c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 440 017 24(0547) 099 Montana 435 036 27(0151) -034Alaska 414 058 38(0151) -500 Nebraska 435 027 26(0249) -032Arizona 407 014 44(2049) -664 Nevada 382 022 48(2051) -1237Arkansas 428 021 31(0649) -181 New Hampshire 454 032 19(0149) 400California 423 006 34(2244) -313 New Jersey 419 012 37(1848) -397Colorado 369 016 49(3451) -1540c New Mexico 405 025 46(0951) -706Connecticut 407 018 45(1550) -669 New York 412 008 39(2548) -554Delaware 473 039 12(0150) 855 North Carolina 420 012 35(1848) -374DC 323 044 51(1551) -2601c North Dakota 471 045 13(0150) 809Florida 412 007 40(2548) -564 Ohio 478 011 10(0123) 967Georgia 411 012 43(2049) -582 Oklahoma 492 020 04(0128) 1276Hawaii 352 027 50(2551) -1932c Oregon 465 019 15(0141) 668Idaho 510 033 01(0139) 1697c Pennsylvania 467 010 14(0427) 714Illinois 439 010 25(1341) 074 Rhode Island 455 035 18(0150) 434Indiana 492 016 05(0123) 1270 South Carolina 432 017 30(0947) -102Iowa 484 021 08(0135) 1087 South Dakota 411 039 42(0151) -580Kansas 486 023 06(0137) 1143 Tennessee 484 015 09(0126) 1087Kentucky 460 018 17(0241) 544 Texas 427 008 32(1944) -213Louisiana 451 018 21(0345) 333 Utah 433 026 28(0250) -081Maine 497 031 02(0141) 1396 Vermont 461 047 16(0151) 578Maryland 411 015 41(1749) -576 Virginia 432 013 29(1246) -092Massachusetts 423 014 33(1548) -303 Washington 452 015 20(0541) 360Michigan 495 012 03(0119) 1340 West Virginia 486 027 07(0143) 1141Minnesota 475 017 11(0132) 901 Wisconsin 443 015 23(0645) 156Mississippi 404 021 47(1351) -731 Wyoming 445 051 22(0151) 192Missouri 419 014 36(1549) -396

Table 1924Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Females

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 Areas (excluding the AlaskaNative Registry) and 112016 US population estimates based on the average of 2015 and 2016 population estimates from theUS Bureau of the CensusPrevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 24 years

b Maximum limited-duration prevalence is 24 years for 1992-2016 datac Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groupsd Cases diagnosed more than 24 years ago were estimated using the completeness index method (Capocaccia et al 1997

Merrill et al 2000)e Complete prevalence is obtained by summing 0 to lt24 and gt=24- Statistic not shown Statistic based on fewer than 5 cases estimated alive in SEER for the time interval+ Not available

Years Since Diagnosis 0 to lt5 5 to lt10 10 to lt15 15 to lt20 20 to lt24 0 to lt24b gt=24d Completee

Race Sex

All Races Both Sexes 248946 177490 117326 69109 31890 644761 49943 694704Males 135137 94173 60159 36020 16581 342069 25489 367558Females 113809 83317 57167 33089 15309 302692 24454 327146

White Both Sexes 213764 154454 101984 60537 28026 558765 49625 620368Males 116527 82172 52535 31627 14543 297404 26526 330121Females 97237 72282 49448 28910 13483 261361 23099 290247

Black Both Sexes 20500 13640 9750 5271 2215 51376 4115 55491Males 10712 7188 4768 2684 1174 26526 1911 28437Females 9789 6452 4981 2587 1041 24850 2204 27054

Asian Both Sexes 8405 5210 3415 1867 844 19741 + +Pacific Males 4548 2661 1757 1013 407 10386 + +Islander Females 3856 2549 1657 855 437 9355 + +

Hispanic Both Sexes 21339 14049 8272 4881 2136 50676 + +Males 10918 7243 4331 2617 1094 26202 + +Females 10421 6805 3941 2264 1043 24474 + +

Age Specific (Crude) Age-Adjustedc Age at Prevalence All Ages 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ All Ages

Race Sex

All Races Both Sexes 02001 00035 00139 00283 00538 01121 02352 04640 08181 10224 01738Males 02156 00044 00189 00354 00625 01293 02710 05243 09364 12449 02023Females 01850 00026 00087 00208 00450 00952 02010 04094 07196 08856 01498

White Both Sexes 02216 00035 00143 00289 00534 01148 02427 04858 08597 10738 01807Males 02380 00045 00198 00359 00622 01317 02790 05442 09778 13060 02095Females 02054 00025 00085 00214 00442 00976 02072 04317 07593 09285 01560

Black Both Sexes 01139 00029 00113 00265 00599 01027 02010 03340 05117 05333 01251Males 01226 00029 00140 00351 00696 01223 02333 03969 05849 06055 01457Females 01059 00030 00086 00178 00510 00853 01728 02836 04608 04976 01088

Asian Both Sexes 00970 00039 00133 00207 00353 00680 01409 02692 04470 06094 01032Pacific Males 01065 00044 00175 00240 00398 00744 01640 03072 05516 07472 01222Islander Females 00882 00033 00092 00175 00312 00623 01209 02384 03629 05207 00880

Hispanic Both Sexes 00887 00030 00117 00206 00398 00850 01769 03632 05888 07209 01294Males 00908 00035 00147 00256 00455 00932 01924 03940 06326 08003 01420Females 00866 00024 00086 00151 00337 00766 01616 03360 05552 06719 01185

Table 1925Non-Hodgkin Lymphoma

Estimated United States Cancer Prevalence Countsa on January 1 2016By RaceEthnicity Sex and Years Since Diagnosis

Estimated prevalence percenta on January 1 2016 of the SEER population diagnosed in the previous 24 yearsBy Age at Prevalence RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 372 452924 -05 62 18862 04 247 189692 -05 1657 244370 -05

1 Hodgkin Lymphoma 28 32262 -17 13 3927 -06 33 22556 -15 39 5779 -31

2 Non-Hodgkin lymphoma 336 409991 -03 48 14693 04 210 163591 -03 1572 231707 -042(a) Non-Hodgkin lymphoma B-cell 311 380349 -01 39 11836 14 190 148768 -02 1491 219745 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 15 16631 20 31 9416 10 07 5203 39 14 2012 252(a) 2 Mature Non-Hodgkin lymphoma B-cell 280 343965 -04 07 2271 30 174 137225 -05 1387 204469 -042(a) 21 ChronicSmallProlymphocytic 69 85601 -13 00 35 - 35 29103 -11 382 56463 -14

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 61 75061 -15 00 30 - 31 25339 -13 336 49692 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 311 19 - - - 00 72 - 02 234 262(a) 213 Mantle-cell lymphoma 08 10229 03 - - - 04 3692 02 44 6537 04

2(a) 22 Lymphoplasmacytic lymphoma 07 8651 00 - - - 03 2590 -11 41 6059 04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 03 3667 -03 - - - 01 1132 -18 17 2533 022(a) 222 Waldenstrom macroglubulinemia 04 4984 03 - - - 02 1458 -07 24 3526 06

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 72 87188 00 03 925 26 48 36480 -02 339 49783 022(a) 231 DLBCL NOSc 71 85899 -01 03 861 12 46 35469 -05 337 49569 012(a) 232 Intravascular large B-cell 00 162 - - - - 00 63 - 01 99 -

lymphoma2(a) 233 Primary effusion lymphoma 00 181 27 - - - 00 126 - 00 55 -2(a) 234 Mediastinal large B-cell 01 946 116 00 64 - 01 822 111 00 60 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 04 4692 -26 03 1028 32 04 2618 -43 07 1046 -432(a) 25 Marginal-zone lymphoma (MZL) 22 26534 00 00 137 13 14 11049 05 104 15348 -042(a) 251 Splenic MZL 02 2418 04 - - - 01 889 -08 10 1529 102(a) 252 Extranodal MZL MALTc type 13 15979 06 00 92 - 09 7148 11 59 8739 032(a) 253 Nodal MZL 07 8137 -15 00 45 - 04 3012 -05 34 5080 -20

2(a) 26 Follicular lymphoma 35 43582 -21 00 119 - 28 21725 -25 147 21738 -182(a) 27 Hairy-cell leukemia 03 3712 -16 - - - 03 2311 -19 09 1401 -122(a) 28 Plasma cell neoplasms 68 83957 08 00 24 - 39 31325 12 358 52608 062(a) 281 Plasmacytoma 04 4879 -04 00 16 - 03 2362 -06 17 2501 -032(a) 282 Multiple myeloma 64 79078 09 - - - 36 28963 14 341 50107 07

plasma-cell leukemia2(a) 29 Heavy chain disease 00 48 - - - - 00 24 - 00 23 -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 16 19753 33 00 149 27 08 6340 37 90 13264 32

Table 1926All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 23 27222 01 08 2502 18 19 13933 03 73 10787 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 616 - 01 293 - 00 272 - 00 51 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 22 26531 11 07 2207 75 19 13621 12 73 10703 -042(b) 21 Mycosis fungoidesSezary syndrome 06 6969 18 01 213 84 06 4080 23 18 2676 052(b) 211 Mycosis fungoides 06 6739 17 01 213 84 05 3990 22 17 2536 042(b) 212 Sezary syndrome 00 230 46 - - - 00 90 - 01 140 -

2(b) 22 Peripheral T-cell lymphoma 12 14531 -10 02 534 07 10 7159 -09 46 6838 -122(b) 221 Peripheral T-cell lymphoma NOSc 04 5393 -01 00 86 - 03 2489 04 19 2818 -042(b) 222 Angioimmunoblastic T-cell lymphoma 02 1902 02 - - - 01 699 -09 08 1201 072(b) 223 Subcutaneous panniculitis- 00 176 44 00 31 - 00 111 - 00 34 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 2523 -36 01 291 00 02 1450 -33 05 782 -54

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 139 - - - - 00 98 - 00 28 -2(b) 226 Enteropathy-type T-cell lymphoma 00 186 -02 - - - 00 84 - 01 101 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 2963 -07 00 59 - 02 1575 01 09 1329 -142(b) 228 Primary cutaneous anaplastic 01 1249 -41 00 51 - 01 653 -49 04 545 -39

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 03 3417 96 05 1428 101 02 1474 99 03 515 672(b) 24 NKcT-cell lymphoma nasal-type 01 985 02 00 26 - 01 659 00 02 300 05

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 120 - - - - 00 54 - 00 65 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 509 30 - - - 00 195 -05 02 309 442(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 75 - - - - 00 40 - 00 33 -2(c) Non-Hodgkin lymphoma unknown lineage 02 2420 -274 01 355 - 01 890 -216 08 1175 -2792(c) 1 Precursor lymphoblastic leukemia 01 814 -283 01 343 - 00 238 - 02 233 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 95 - - - - 00 25 - 00 69 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 1511 -274 - - - 01 627 -202 06 873 -319

lineage2() 1 Total precursor lymphomaleukemiad 16 18061 -07 33 10052 -15 08 5713 06 15 2296 -01

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 762 273 00 20 - 00 339 227 03 403 -lymphoma

4 Lymphoid neoplasm NOSc 08 9909 -55 01 222 113 04 3206 -59 43 6481 -59

Table 1926 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 461 253152 -05 70 10973 05 294 110367 -07 2122 131812 -05

1 Hodgkin Lymphoma 31 17710 -17 13 2118 -03 36 12525 -16 48 3067 -31

2 Non-Hodgkin lymphoma 419 229772 -03 56 8711 05 252 95756 -05 2017 125305 -032(a) Non-Hodgkin lymphoma B-cell 387 212247 -02 44 6786 15 227 86941 -04 1908 118520 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 16 8999 24 33 5123 11 08 2888 46 16 988 292(a) 2 Mature Non-Hodgkin lymphoma B-cell 351 192801 -05 10 1558 28 210 80417 -08 1783 110826 -042(a) 21 ChronicSmallProlymphocytic 96 52411 -15 00 21 - 47 18927 -14 539 33463 -15

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 82 44988 -17 00 19 - 40 16143 -16 464 28826 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 193 -02 - - - 00 46 - 02 145 052(a) 213 Mantle-cell lymphoma 13 7230 -01 - - - 07 2738 -01 72 4492 -01

2(a) 22 Lymphoplasmacytic lymphoma 10 5082 -05 - - - 04 1524 -08 58 3558 -04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 04 2062 -08 - - - 02 616 -12 23 1446 -072(a) 222 Waldenstrom macroglubulinemia 06 3020 -02 - - - 02 908 -06 34 2112 -02

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 88 48128 01 03 554 22 59 21824 -06 418 25750 052(a) 231 DLBCL NOSc 87 47520 00 03 519 03 57 21366 -08 416 25635 042(a) 232 Intravascular large B-cell 00 75 - - - - 00 31 - 01 44 -

lymphoma2(a) 233 Primary effusion lymphoma 00 167 26 - - - 00 123 - 01 44 -2(a) 234 Mediastinal large B-cell 01 366 155 00 35 - 01 304 142 00 27 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 06 3388 -22 05 775 31 06 1969 -46 10 644 -192(a) 25 Marginal-zone lymphoma (MZL) 22 12351 -02 01 98 - 14 5177 -02 114 7076 -012(a) 251 Splenic MZL 02 1164 14 - - - 01 434 18 12 730 112(a) 252 Extranodal MZL MALTc type 13 7268 07 00 62 - 09 3267 04 63 3939 102(a) 253 Nodal MZL 07 3919 -23 00 36 - 04 1476 -22 39 2407 -23

2(a) 26 Follicular lymphoma 39 21788 -19 01 100 - 30 11210 -25 165 10478 -152(a) 27 Hairy-cell leukemia 05 2984 -18 - - - 05 1908 -20 17 1076 -152(a) 28 Plasma cell neoplasms 85 46642 07 - - - 45 17864 11 462 28769 052(a) 281 Plasmacytoma 05 2997 -08 - - - 04 1509 -16 24 1484 -012(a) 282 Multiple myeloma 80 43645 08 - - - 41 16355 13 439 27285 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 27 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 20 10447 34 01 105 - 10 3636 40 110 6706 32

Table 1927All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 29 16118 00 11 1730 14 23 8235 02 98 6153 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 430 - 01 208 - 01 188 - 01 34 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 28 15642 11 10 1521 71 22 8022 11 97 6099 -032(b) 21 Mycosis fungoidesSezary syndrome 07 3962 19 01 135 - 06 2261 21 25 1566 092(b) 211 Mycosis fungoides 07 3831 20 01 135 - 06 2213 21 23 1483 092(b) 212 Sezary syndrome 00 131 - - - - 00 48 - 01 83 -

2(b) 22 Peripheral T-cell lymphoma 15 8438 -13 02 318 -09 12 4248 -12 62 3872 -132(b) 221 Peripheral T-cell lymphoma NOSc 06 3159 -05 00 49 - 04 1520 02 26 1590 -082(b) 222 Angioimmunoblastic T-cell lymphoma 02 1024 19 - - - 01 415 11 10 607 232(b) 223 Subcutaneous panniculitis- 00 68 - - - - 00 39 - 00 16 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 03 1549 -39 01 184 -01 02 888 -43 08 477 -45

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 98 - - - - 00 69 - 00 18 -2(b) 226 Enteropathy-type T-cell lymphoma 00 105 - - - - 00 50 - 01 54 -2(b) 227 Cutaneous T-cell lymphoma NOSc 03 1696 -12 00 32 - 02 894 -03 12 770 -172(b) 228 Primary cutaneous anaplastic 01 739 -48 00 26 - 01 373 -49 05 340 -49

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 04 2253 97 07 1047 92 03 940 98 04 266 1022(b) 24 NKcT-cell lymphoma nasal-type 01 638 -05 00 18 - 01 435 -03 03 185 -06

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 58 - - - - 00 22 - 01 36 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 01 293 45 - - - 00 116 - 03 174 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 46 - - - - 00 25 - 00 20 -2(c) Non-Hodgkin lymphoma unknown lineage 03 1407 -232 01 195 - 02 580 -184 10 632 -2302(c) 1 Precursor lymphoblastic leukemia 01 474 -228 01 187 - 00 134 - 02 153 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 49 - - - - - - - 01 36 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 02 884 -239 - - - 01 433 -175 07 443 -

lineage2() 1 Total precursor lymphomaleukemiad 18 9903 -06 35 5518 -17 09 3210 09 19 1175 05

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 435 271 - - - 01 215 - 03 207 -lymphoma

4 Lymphoid neoplasm NOSc 10 5235 -59 01 131 - 05 1871 -65 54 3233 -61

Table 1927 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 301 199772 -05 53 7889 02 202 79325 -02 1322 112558 -08

1 Hodgkin Lymphoma 24 14552 -16 12 1809 -10 29 10031 -14 32 2712 -32

2 Non-Hodgkin lymphoma 269 180219 -03 40 5982 03 170 67835 00 1251 106402 -062(a) Non-Hodgkin lymphoma B-cell 250 168102 -01 34 5050 13 154 61827 02 1190 101225 -042(a) 1 Precursor Non-Hodgkin lymphoma B-cell 14 7632 16 29 4293 09 06 2315 29 12 1024 202(a) 2 Mature Non-Hodgkin lymphoma B-cell 223 151164 -04 05 713 35 141 56808 -01 1102 93643 -072(a) 21 ChronicSmallProlymphocytic 48 33190 -13 - - - 24 10176 -05 268 23000 -16

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 43 30073 -15 - - - 22 9196 -06 243 20866 -19

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 118 - - - - 00 26 - 01 89 -2(a) 213 Mantle-cell lymphoma 04 2999 11 - - - 02 954 10 24 2045 12

2(a) 22 Lymphoplasmacytic lymphoma 05 3569 04 - - - 03 1066 -16 30 2501 11Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 02 1605 01 - - - 01 516 -25 13 1087 112(a) 222 Waldenstrom macroglubulinemia 03 1964 06 - - - 01 550 -08 17 1414 11

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 58 39060 00 02 371 33 38 14656 03 283 24033 -032(a) 231 DLBCL NOSc 57 38379 -02 02 342 27 36 14103 -01 282 23934 -032(a) 232 Intravascular large B-cell 00 87 - - - - 00 32 - 01 55 -

lymphoma2(a) 233 Primary effusion lymphoma - - - - - - - - - - - -2(a) 234 Mediastinal large B-cell 01 580 91 00 29 - 02 518 93 00 33 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 02 1304 -34 02 253 38 02 649 -37 05 402 -852(a) 25 Marginal-zone lymphoma (MZL) 21 14183 01 00 39 - 15 5872 12 98 8272 -062(a) 251 Splenic MZL 02 1254 -07 - - - 01 455 -32 10 799 072(a) 252 Extranodal MZL MALTc type 13 8711 06 00 30 - 10 3881 17 57 4800 -032(a) 253 Nodal MZL 06 4218 -07 - - - 04 1536 11 32 2673 -18

2(a) 26 Follicular lymphoma 33 21794 -24 00 19 - 27 10515 -25 134 11260 -222(a) 27 Hairy-cell leukemia 01 728 -12 - - - 01 403 -11 04 325 -122(a) 28 Plasma cell neoplasms 55 37315 08 - - - 33 13461 15 282 23839 052(a) 281 Plasmacytoma 03 1882 00 - - - 02 853 12 12 1017 -092(a) 282 Multiple myeloma 52 35433 09 - - - 30 12608 15 270 22822 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 21 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 14 9306 32 00 44 - 07 2704 32 76 6558 31

Table 1928All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 17 11104 01 05 772 29 15 5698 05 55 4634 -112(b) 1 Precursor Non-Hodgkin lymphoma T-cell 00 186 - 01 85 - 00 84 - 00 17 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 17 10889 09 05 686 83 15 5599 12 54 4604 -092(b) 21 Mycosis fungoidesSezary syndrome 05 3007 15 01 78 - 05 1819 26 13 1110 -042(b) 211 Mycosis fungoides 05 2908 12 01 78 - 05 1777 23 12 1053 -072(b) 212 Sezary syndrome 00 99 - - - - 00 42 - 01 57 -

2(b) 22 Peripheral T-cell lymphoma 09 6093 -08 01 216 30 08 2911 -06 35 2966 -142(b) 221 Peripheral T-cell lymphoma NOSc 03 2234 03 00 37 - 03 969 07 14 1228 -012(b) 222 Angioimmunoblastic T-cell lymphoma 01 878 -22 - - - 01 284 -39 07 594 -152(b) 223 Subcutaneous panniculitis- 00 108 - 00 18 - 00 72 - 00 18 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 974 -33 01 107 - 02 562 -19 04 305 -77

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 41 - - - - 00 29 - - - -2(b) 226 Enteropathy-type T-cell lymphoma 00 81 - - - - 00 34 - 01 47 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 1267 00 00 27 - 02 681 07 07 559 -102(b) 228 Primary cutaneous anaplastic 01 510 -34 00 25 - 01 280 -50 02 205 -33

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 02 1164 96 03 381 127 01 534 97 03 249 302(b) 24 NKcT-cell lymphoma nasal-type 01 347 11 - - - 01 224 - 01 115 -

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 62 - - - - 00 32 - 00 29 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 216 03 - - - 00 79 - 02 135 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 29 - - - - - - - - - -2(c) Non-Hodgkin lymphoma unknown lineage 02 1013 -341 01 160 - 01 310 - 06 543 -2(c) 1 Precursor lymphoblastic leukemia 01 340 - 01 156 - 00 104 - 01 80 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 46 - - - - - - - 00 33 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 627 - - - - 01 194 - 05 430 -

lineage2() 1 Total precursor lymphomaleukemiad 14 8158 -09 31 4534 -13 07 2503 02 13 1121 -11

3 Composite Hodgkin lymphoma and Non-Hodgkin 00 327 - - - - 00 124 - 02 196 -lymphoma

4 Lymphoid neoplasm NOSc 07 4674 -52 01 91 - 03 1335 -51 36 3248 -58

Table 1928 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 10: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Expected survival rates are derived from the US Annual Life Tables

1975- 1980- 1985- 1990-1979 1984 1989 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Survival Time

1-year 694 727 689 671 666 712 747 749 758 765 776 806 797 801 811 810 814 836 828 838 838 841 834 830 8352-year 594 637 605 582 583 636 672 682 691 703 713 752 749 755 762 765 778 779 781 788 798 793 786 7913-year 534 580 557 537 545 598 638 645 644 668 679 720 726 726 731 736 754 751 757 766 776 769 7644-year 493 539 516 504 515 561 610 620 615 639 657 700 709 701 711 713 734 734 737 743 756 7575-year 455 501 482 476 485 537 583 592 590 617 635 679 689 688 699 689 710 721 724 735 7426-year 426 466 455 456 469 510 561 565 562 602 620 667 669 676 684 670 696 715 706 7177-year 399 442 431 436 449 491 542 544 546 587 601 652 658 655 668 651 682 696 6968-year 378 420 410 418 433 474 520 533 536 567 582 637 645 649 650 634 665 6869-year 357 401 391 402 423 465 504 514 523 553 572 628 633 632 636 618 65210-year 340 380 377 392 416 455 489 503 515 542 560 617 617 620 613 60911-year 328 363 364 381 407 437 477 494 508 527 547 603 605 612 61212-year 319 352 351 372 395 427 472 482 498 515 537 589 601 59613-year 307 342 343 361 389 419 456 467 491 501 531 582 59114-year 295 330 332 350 378 414 444 461 480 496 521 57215-year 281 319 324 344 368 409 435 453 473 488 51216-year 272 308 316 333 361 409 426 453 471 47417-year 265 300 308 326 358 403 420 449 46218-year 261 294 302 320 350 396 410 44219-year 256 287 294 313 342 391 40320-year 250 280 291 309 332 387

Table 1910Non-Hodgkin Lymphoma

SEERa Relative Survival (Percent)By Year of Diagnosis

All Races Males

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Expected survival rates are derived from the US Annual Life Tables

1975- 1980- 1985- 1990-1979 1984 1989 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Survival Time

1-year 710 734 741 747 752 759 767 786 792 782 801 814 810 821 825 809 819 847 854 851 830 843 856 838 8572-year 611 637 656 672 664 688 701 720 734 727 758 769 765 767 786 774 772 804 812 807 796 810 817 7993-year 559 589 611 627 616 649 662 684 700 692 727 744 736 746 768 756 746 774 791 786 774 791 7974-year 519 553 576 595 590 619 634 653 681 674 710 725 724 730 751 739 729 757 778 764 755 7805-year 482 514 544 567 565 591 608 629 658 664 688 708 713 716 736 724 715 735 763 751 7426-year 446 484 517 539 540 580 583 603 635 643 679 695 699 701 727 708 707 722 738 7317-year 417 458 490 512 520 560 563 586 615 626 663 674 687 692 704 698 694 709 7268-year 392 437 463 491 505 542 539 573 596 615 649 667 672 684 693 692 684 6949-year 374 416 443 476 492 529 528 557 578 603 633 654 664 669 671 688 67110-year 360 399 424 458 480 514 516 542 562 588 625 648 651 658 659 66911-year 342 385 409 438 469 503 500 529 547 573 621 636 640 651 65312-year 329 368 390 425 460 494 493 523 529 560 606 613 632 64013-year 321 353 376 411 449 486 485 518 510 543 598 606 61514-year 310 340 365 400 442 479 470 512 497 532 582 59615-year 297 326 349 391 436 472 460 498 483 525 57416-year 287 316 342 385 435 467 441 492 468 51317-year 282 306 336 378 428 459 438 490 45218-year 274 298 327 367 413 449 428 48519-year 265 288 321 358 407 439 42220-year 254 280 312 353 395 433

Table 1911Non-Hodgkin Lymphoma

SEERa Relative Survival (Percent)By Year of Diagnosis

All Races Females

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 5222 2506 2704 3176 3627 3994 4570 4729 5325 5260 5263 5562 5775 6226 6401 6704 6998 7072 11154

SEER 9 except 4285 2088 2267 2603 2819 3091 3507 3694 4159 4249 4364 4515 4818 5209 5398 5628 5841 6015 9363SF-Oakland

San Francisco- 937 418 437 573 808 903 1063 1035 1166 1011 899 1047 957 1017 1003 1076 1157 1057 1791Oakland SMSAc

San Francisco 245 96 123 210 326 393 467 410 450 354 213 256 220 283 219 216 240 225 362CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 134 155 161 183 201 215 234 233 252 244 238 244 246 258 254 255 255 245 244

SEER 9 except 132 154 161 181 188 201 217 218 236 236 235 236 244 256 254 253 252 247 243SF-Oakland

San Francisco- 147 158 160 194 267 285 317 305 335 288 252 286 256 266 256 263 268 235 246Oakland SMSAc

San Francisco 143 144 176 293 444 519 610 523 574 448 274 325 269 354 265 257 273 252 246CityCounty

Table 1912

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males All Ages

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males All Ages

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 0-19 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 223 87 108 91 94 84 100 89 120 105 104 119 127 107 106 143 134 155 240

SEER 9 except 191 78 95 82 80 76 86 74 107 84 93 100 115 90 87 114 119 129 198SF-Oakland

San Francisco- 32 9 13 9 14 8 14 15 13 21 11 19 12 17 19 29 15 26 42Oakland SMSAc

San Francisco 9 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 5 lt4 6 lt4CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 12 12 16 14 14 13 15 13 17 14 14 15 16 14 13 18 17 20 20

SEER 9 except 12 13 16 14 14 13 15 12 17 13 14 15 17 13 13 16 17 19 19SF-Oakland

San Francisco- 14 10 15 10 16 09 15 16 13 21 11 18 12 17 19 28 14 25 27Oakland SMSAc

San Francisco 23 - - - - - - - - - - - - - - 40 - 49 -CityCounty

Table 1913

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 0-19

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 0-19

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 20-54 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 1463 687 723 958 1211 1413 1766 1830 2089 1770 1608 1696 1623 1722 1655 1693 1674 1596 2242

SEER 9 except 1208 563 588 730 827 923 1195 1294 1483 1325 1269 1327 1308 1410 1383 1401 1402 1328 1848SF-Oakland

San Francisco- 255 124 135 228 384 490 571 536 606 445 339 369 315 312 272 292 272 268 394Oakland SMSAc

San Francisco 58 29 34 105 215 288 333 303 317 225 105 115 111 111 86 75 73 71 98CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 69 79 82 104 124 136 159 156 169 138 121 124 117 123 116 118 116 111 104

SEER 9 except 69 78 81 97 103 109 131 134 144 123 115 116 112 119 115 116 115 110 103SF-Oakland

San Francisco- 69 84 89 139 226 264 295 267 298 213 156 164 139 141 123 130 118 114 110Oakland SMSAc

San Francisco 67 88 94 272 565 715 813 724 744 510 230 252 239 248 194 162 152 145 129CityCounty

Table 1914

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 20-54

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 20-54

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 55+ and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 3536 1732 1873 2127 2322 2497 2704 2810 3116 3385 3551 3747 4025 4397 4640 4868 5190 5321 8672

SEER 9 except 2886 1447 1584 1791 1912 2092 2226 2326 2569 2840 3002 3088 3395 3709 3928 4113 4320 4558 7317SF-Oakland

San Francisco- 650 285 289 336 410 405 478 484 547 545 549 659 630 688 712 755 870 763 1355Oakland SMSAc

San Francisco 178 65 88 104 109 105 132 106 130 126 106 141 108 169 131 136 164 148 261CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 451 522 540 596 633 673 701 706 761 800 811 831 858 900 901 891 899 862 871

SEER 9 except 440 521 544 601 620 667 687 692 744 797 813 813 858 901 904 891 888 874 874SF-Oakland

San Francisco- 508 528 520 571 702 703 773 783 854 821 800 932 855 894 888 890 959 800 860Oakland SMSAc

San Francisco 482 446 598 727 739 757 934 747 914 872 727 934 690 1047 764 769 889 776 826CityCounty

Table 1915

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 55+

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 55+

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 003 006 217 072 Asian 0 001 003 005 183 072

10 002 005 011 218 073 Pacific 10 002 004 009 184 073

20 003 009 021 217 073 Islander 20 003 007 015 182 073

30 006 018 042 216 073 30 005 013 029 180 073

40 012 037 082 213 074 40 008 024 057 176 073

50 025 072 139 206 074 50 017 049 101 170 073

60 049 120 177 191 075 60 034 087 139 158 072

70 080 144 - 160 072 70 056 112 - 133 068

80 085 - - 106 062 80 066 - - 091 056

White 0 001 003 006 227 075 American 0 001 002 003 116 049

10 002 005 011 228 076 Indian 10 002 002 005 117 050

20 003 009 021 227 076 Alaska 20 001 003 008 116 050

30 006 018 043 226 077 Nativea 30 003 007 022 117 051

40 012 038 085 223 077 40 004 019 041 117 052

50 026 075 147 217 078 50 016 038 078 118 053

60 052 127 187 201 078 60 024 067 105 109 055

70 085 153 - 169 076 70 048 091 - 096 055

80 090 - - 111 065 80 057 - - 064 043

Black 0 001 002 006 138 042 Hispanicb 0 001 002 005 222 073

10 002 005 011 140 043 10 001 004 009 223 074

20 003 010 022 139 043 20 003 008 019 222 074

30 006 019 041 137 043 30 005 016 040 221 074

40 013 035 068 133 043 40 011 035 078 218 074

50 023 057 093 125 043 50 024 068 133 211 074

60 037 076 102 110 042 60 046 114 173 195 074

70 047 078 - 087 038 70 075 140 - 164 070

80 044 - - 057 032 80 081 - - 112 057

Table 1916

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Both Sexes 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 004 007 243 081 Asian 0 001 003 006 213 085

10 002 006 013 244 082 Pacific 10 002 005 011 213 086

20 004 010 024 243 082 Islander 20 003 009 018 211 086

30 007 021 049 243 083 30 006 015 034 210 086

40 014 042 094 240 084 40 009 028 067 205 086

50 029 082 158 233 085 50 019 059 117 199 086

60 057 139 203 219 086 60 041 101 161 187 085

70 095 170 - 188 084 70 066 131 - 159 082

80 105 - - 130 073 80 080 - - 114 069

White 0 001 004 007 254 085 American 0 001 003 004 104 057

10 002 006 013 255 086 Indian 10 002 003 006 105 058

20 004 010 024 254 086 Alaska 20 001 004 008 103 058

30 007 020 049 253 087 Nativea 30 003 008 021 104 059

40 014 043 097 251 088 40 005 018 038 105 060

50 030 086 167 244 089 50 014 035 071 105 062

60 059 147 215 230 090 60 023 062 094 099 065

70 101 180 - 198 088 70 046 084 - 090 066

80 112 - - 136 076 80 053 - - 061 053

Black 0 001 003 007 152 046 Hispanicb 0 001 003 005 238 083

10 002 006 014 154 047 10 002 005 011 239 084

20 004 012 027 153 047 20 003 009 021 238 084

30 008 023 048 152 047 30 006 018 043 238 084

40 016 042 079 148 047 40 012 037 083 235 085

50 027 066 105 138 047 50 026 073 145 228 085

60 043 087 114 123 045 60 050 126 189 214 085

70 054 088 - 099 042 70 086 157 - 185 081

80 053 - - 070 036 80 094 - - 131 066

Table 1917

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Males 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 002 004 193 064 Asian 0 001 002 004 159 063

10 001 004 009 195 064 Pacific 10 001 004 008 160 063

20 003 007 017 194 064 Islander 20 002 006 013 159 063

30 005 015 036 192 065 30 004 011 025 157 063

40 010 031 071 189 065 40 007 021 048 153 063

50 022 062 120 182 065 50 014 042 087 148 063

60 042 103 154 168 065 60 028 074 122 136 062

70 067 123 - 138 063 70 049 099 - 114 058

80 071 - - 090 054 80 057 - - 075 047

White 0 001 002 004 203 067 American 0 000 001 002 128 043

10 001 004 009 204 067 Indian 10 001 001 004 129 044

20 002 007 017 203 067 Alaska 20 001 003 007 128 044

30 005 015 037 201 067 Nativea 30 002 006 023 129 044

40 010 032 074 198 068 40 004 021 044 129 045

50 022 065 127 192 068 50 017 042 085 129 046

60 044 109 163 177 068 60 026 072 113 118 047

70 072 130 - 146 066 70 050 097 - 102 046

80 075 - - 094 056 80 060 - - 066 037

Black 0 000 002 004 126 040 Hispanicb 0 001 002 004 210 065

10 001 004 009 128 040 10 001 004 008 211 066

20 003 008 018 127 040 20 002 007 017 211 066

30 005 015 034 125 040 30 004 014 036 209 066

40 010 029 058 122 040 40 010 032 073 206 066

50 020 049 083 115 040 50 022 064 123 198 066

60 032 068 094 102 039 60 043 104 161 182 065

70 041 071 - 080 036 70 066 127 - 149 062

80 039 - - 051 030 80 073 - - 100 051

Table 1918

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Females 2014-2016 By RaceEthnicity

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

The AAPC is the Average Annual Percent Change over the time interval The AAPCs are calculated bythe Joinpoint Regression Program Version 47 February 2019 National Cancer Institute

- Statistic not shown Rate based on less than 16 cases for the time intervalTrend based on less than 10 cases for at least one year within the time interval

a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) Trendsare based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico SeattleUtah and AtlantaThe SEER 21 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the AlaskaNative Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts

c The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 3 Joinpoints overdiagnosis years 2000-2016

d The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 5 Joinpoints overdiagnosis years 1975-2016

e Hispanic and Non-Hispanic are not mutually exclusive from whites blacks AsianPacificIslanders and American IndiansAlaska Natives Incidence data for Hispanics and Non-Hispanicsare based on NHIA and exclude cases from the Alaska Native Registry

f Incidence data for American IndianAlaska Native are based on the PurchasedReferred CareDelivery Area (PRCDA) counties

g US Mortality Files National Center for Health Statistics CDCh The 2007-2016 mortality AAPCs are based on a Joinpoint analysis using years of death 2000-2016 The APC is significantly different from zero (plt05)

SEER Incidence SEER 21 Areasb SEER 21 Areasb SEER 9 Areasb

Rate 2012-2016 Trend 2007-2016c Trend 2007-2016d

Rate per 100000 persons AAPC () AAPC ()

Total Males Females Total Males Females Total Males Females RaceEthnicity

All Races 196 239 162 -07 -09 -08 -09 -07 -08

White 206 250 170 -08 -11 -09 -09 -08 -08White Hispanice 183 212 161 -08 -03 -05 - - -White Non-Hispanice 210 256 172 -08 -06 -10 - - -

Black 147 177 124 01 00 03 00 -04 -09

AsianPacific Islander 134 164 110 00 00 -01 - - -

Amer IndAlaska Natf 113 120 106 -05 -12 00 - - -

Hispanice 179 207 157 -05 -02 03 - - -

US Mortalityg Rate 2012-2016 Trend 2007-2016h

Rate per 100000 persons AAPC ()

Total Males Females Total Males FemalesRaceEthnicity

All Races 56 73 44 -23 -20 -27

White 59 76 45 -23 -20 -27White Hispanice 51 65 40 -16 -13 -20White Non-Hispanice 59 76 46 -23 -20 -27

Black 41 52 33 -20 -19 -21

AsianPacific Islander 39 49 31 -17 -15 -19

Amer IndAlaska NatTotal US 31 40 24 -32 -20 -45PRCDA Counties 44 58 33 -21 -04 -37Non-PRCDA Counties 17 21 14 -54 -50 -60

Hispanice 48 61 38 -17 -14 -21

Table 1919Non-Hodgkin Lymphoma

SEER Incidence and US MortalityAge-Adjusted Rates and Trendsa

By RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Incidence Ratesa 2012-2016

California 1844 2241 1515 1938 2349 1591 1390 1639 1182Greater Bay Area 1957 2381 1600 2144 2601 1755 1628 1828 1436San Francisco-Oakland 1956 2421 1570 2174 2660 1765 1603 1816 1408San Jose-Monterey 1962 2311 1660 2097 2503 1742 1800 1891 1646

Los Angeles 1804 2176 1505 1951 2331 1637 1357 1659 1139Greater California 1822 2220 1489 1876 2286 1529 1314 1534 1113

Connecticut 2116 2607 1733 2154 2642 1771 1386 1829 1051Detroit 2132 2636 1742 2290 2850 1847 1620 1905 1409Georgia 1826 2244 1487 1936 2346 1588 1462 1833 1187Atlanta 1925 2381 1555 2119 2567 1736 1601 2034 1272Rural Georgia 1584 1790 1401 1953 2298 1567 807 - 988Greater Georgia 1784 2186 1459 1872 2274 1537 1380 1703 1146

Hawaii 1660 2024 1349 1958 2275 1593 - - -Idaho 1922 2267 1616 1920 2262 1618 - - -Iowa 2134 2601 1756 2148 2612 1773 1352 1602 1100Kentucky 2039 2505 1666 2070 2538 1693 1403 1788 1112Louisiana 1944 2352 1614 2106 2537 1744 1469 1769 1237Massachusetts 1810 2181 1518 1830 2214 1524 1452 1655 1299New Jersey 2155 2607 1804 2285 2765 1905 1387 1621 1222New Mexico 1550 1739 1387 1580 1798 1394 875 - -New York 2152 2620 1788 2306 2792 1915 1545 1852 1333Seattle-Puget Sound 2116 2627 1695 2177 2667 1766 1631 1973 1316Utah 1843 2233 1498 1862 2258 1513 2089 - -

SEER 9 Areasb 1992 2444 1623 2095 2551 1716 1573 1914 1298SEER 13 Areasb 1946 2373 1597 2064 2502 1700 1519 1853 1258SEER 18 Areasb 1933 2354 1590 2031 2464 1671 1449 1751 1214SEER 21 Areasb 1963 2388 1620 2061 2498 1702 1471 1771 1245

Table 1920Non-Hodgkin Lymphoma

Age-Adjusted SEER Incidence Ratesa

By Registry Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control and PreventionRates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and AtlantaThe SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Death Ratesa 2012-2016

California 533 677 423 570 726 449 417 480 367Greater Bay Area 505 671 376 561 756 408 410 491 331San Francisco-Oakland 503 667 376 555 742 409 416 490 343San Jose-Monterey 511 681 377 573 781 407 - - -

Los Angeles 541 670 443 589 728 481 424 503 371Greater California 539 682 429 564 716 447 416 455 384

Connecticut 533 705 407 547 717 421 350 510 244Detroit 639 822 505 693 895 542 443 528 384Georgia 533 697 411 580 747 450 376 503 286Atlanta 492 659 372 533 728 388 397 506 317Rural Georgia 559 731 388 670 813 507 - - -Greater Georgia 549 712 426 595 755 470 363 500 266

Hawaii 475 620 352 545 649 412 - - -Idaho 635 775 510 641 782 516 - - -Iowa 638 845 484 642 848 488 - - -Kentucky 642 886 460 655 904 470 401 557 284Louisiana 608 814 451 651 863 485 461 623 340Massachusetts 523 659 423 541 682 436 347 410 297New Jersey 545 721 419 585 780 443 372 466 314New Mexico 488 585 405 493 595 406 - - -New York 535 702 412 575 752 441 390 514 313Seattle-Puget Sound 585 749 463 604 769 480 490 562 397Utah 542 670 433 551 681 440 - - -

SEER 9 Areasb 555 719 430 586 758 454 414 522 333SEER 13 Areasb 549 705 429 586 753 457 419 521 342SEER 18 Areasb 554 717 431 589 761 456 409 518 329SEER 21 Areasb 550 712 428 584 754 453 401 513 322

Total US 562 725 436 586 755 454 408 518 330

Table 1921Non-Hodgkin Lymphoma

Age-Adjusted SEER Death Ratesa

By Registry Race and Sex

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 562 002

High Five StatesMichigan 645 011 01(0112) 1479Kentucky 642 016 02(0118) 1424Iowa 638 018 03(0120) 1367Indiana 638 013 04(0117) 1361Idaho 635 027 05(0126) 1303

Low Five StatesNevada 511 019 47(2251) -899Colorado 491 014 48(3851) -1257New Mexico 488 020 49(2851) -1317Hawaii 475 024 50(3051) -1542c

DC 444 039 51(2351) -2097c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 545 014 28(1847) -291 Montana 559 030 25(0250) -042Alaska 525 047 43(0151) -654 Nebraska 563 023 22(0548) 026Arizona 512 012 46(2950) -886 Nevada 511 019 47(2251) -899Arkansas 555 018 26(1247) -113 New Hampshire 562 027 23(0349) 014California 533 005 40(2645) -508 New Jersey 545 010 29(2045) -301Colorado 491 014 48(3851) -1257 New Mexico 488 020 49(2851) -1317Connecticut 533 016 39(1949) -505 New York 535 007 37(2446) -478Delaware 628 033 08(0139) 1174 North Carolina 541 010 35(2146) -363DC 444 039 51(2351) -2097c North Dakota 561 037 24(0151) -007Florida 535 006 38(2545) -479 Ohio 616 009 10(0220) 969Georgia 533 011 41(2248) -511 Oklahoma 630 017 06(0121) 1226Hawaii 475 024 50(3051) -1542c Oregon 612 016 11(0124) 903Idaho 635 027 05(0126) 1303 Pennsylvania 603 009 16(0622) 729Illinois 566 009 20(1634) 085 Rhode Island 542 029 32(0651) -350Indiana 638 013 04(0117) 1361 South Carolina 542 014 31(1847) -347Iowa 638 018 03(0120) 1367 South Dakota 541 033 36(0451) -364Kansas 585 019 19(0439) 420 Tennessee 629 013 07(0119) 1198Kentucky 642 016 02(0118) 1424 Texas 546 007 27(2142) -277Louisiana 608 016 14(0125) 826 Utah 542 022 33(1250) -352Maine 609 026 13(0137) 852 Vermont 605 040 15(0148) 770Maryland 524 013 44(2349) -663 Virginia 544 011 30(2046) -319Massachusetts 523 012 45(2549) -687 Washington 599 013 17(0425) 665Michigan 645 011 01(0112) 1479 West Virginia 612 022 12(0132) 894Minnesota 617 014 09(0122) 984 Wisconsin 590 013 18(0629) 507Mississippi 531 018 42(1850) -551 Wyoming 564 043 21(0151) 050Missouri 542 012 34(1947) -354

Table 1922Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males and Females

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 725 003

High Five StatesKentucky 886 030 01(0112) 2213c

Iowa 845 032 02(0120) 1647c

Michigan 842 019 03(0114) 1615c

Indiana 839 024 04(0116) 1567c

Delaware 824 058 05(0144) 1364

Low Five StatesArizona 635 019 47(3251) -1244Alaska 630 075 48(0251) -1311Hawaii 620 041 49(1951) -1452DC 614 071 50(0551) -1535c

New Mexico 585 033 51(3451) -1928c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 688 025 36(1649) -513 Montana 709 050 26(0251) -218Alaska 630 075 48(0251) -1311 Nebraska 737 040 20(0248) 165Arizona 635 019 47(3251) -1244 Nevada 653 032 44(1951) -994Arkansas 721 031 22(0747) -061 New Hampshire 710 046 25(0451) -210California 677 009 41(2846) -666 New Jersey 721 018 21(1441) -059Colorado 643 024 46(2451) -1133 New Mexico 585 033 51(3451) -1928c

Connecticut 705 028 28(1248) -273 New York 702 012 30(1943) -323Delaware 824 058 05(0144) 1364 North Carolina 709 018 27(1644) -221DC 614 071 50(0551) -1535c North Dakota 682 061 39(0251) -598Florida 683 011 37(2446) -585 Ohio 800 017 09(0320) 1029Georgia 697 019 34(1746) -387 Oklahoma 806 030 08(0126) 1109Hawaii 620 041 49(1951) -1452 Oregon 794 028 12(0128) 947Idaho 775 045 16(0146) 692 Pennsylvania 783 015 15(0523) 794Illinois 739 016 19(1235) 190 Rhode Island 649 050 45(1051) -1050Indiana 839 024 04(0116) 1567c South Carolina 681 025 40(1850) -604Iowa 845 032 02(0120) 1647c South Dakota 701 056 31(0251) -332Kansas 713 032 24(0948) -174 Tennessee 820 023 06(0120) 1311Kentucky 886 030 01(0112) 2213c Texas 698 012 32(2043) -368Louisiana 814 029 07(0122) 1222 Utah 670 036 42(1351) -754Maine 754 045 18(0148) 395 Vermont 794 069 11(0149) 950Maryland 682 023 38(1849) -588 Virginia 694 020 35(1847) -429Massachusetts 659 020 43(2450) -910 Washington 790 022 13(0224) 897Michigan 842 019 03(0114) 1615c West Virginia 774 038 17(0142) 675Minnesota 797 025 10(0224) 995 Wisconsin 786 023 14(0227) 844Mississippi 717 034 23(0748) -110 Wyoming 698 071 33(0151) -377Missouri 702 022 29(1646) -319

Table 1923Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 436 002

High Five StatesIdaho 510 033 01(0139) 1697c

Maine 497 031 02(0141) 1396Michigan 495 012 03(0119) 1340Oklahoma 492 020 04(0128) 1276Indiana 492 016 05(0123) 1270

Low Five StatesMississippi 404 021 47(1351) -731Nevada 382 022 48(2051) -1237Colorado 369 016 49(3451) -1540c

Hawaii 352 027 50(2551) -1932c

DC 323 044 51(1551) -2601c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 440 017 24(0547) 099 Montana 435 036 27(0151) -034Alaska 414 058 38(0151) -500 Nebraska 435 027 26(0249) -032Arizona 407 014 44(2049) -664 Nevada 382 022 48(2051) -1237Arkansas 428 021 31(0649) -181 New Hampshire 454 032 19(0149) 400California 423 006 34(2244) -313 New Jersey 419 012 37(1848) -397Colorado 369 016 49(3451) -1540c New Mexico 405 025 46(0951) -706Connecticut 407 018 45(1550) -669 New York 412 008 39(2548) -554Delaware 473 039 12(0150) 855 North Carolina 420 012 35(1848) -374DC 323 044 51(1551) -2601c North Dakota 471 045 13(0150) 809Florida 412 007 40(2548) -564 Ohio 478 011 10(0123) 967Georgia 411 012 43(2049) -582 Oklahoma 492 020 04(0128) 1276Hawaii 352 027 50(2551) -1932c Oregon 465 019 15(0141) 668Idaho 510 033 01(0139) 1697c Pennsylvania 467 010 14(0427) 714Illinois 439 010 25(1341) 074 Rhode Island 455 035 18(0150) 434Indiana 492 016 05(0123) 1270 South Carolina 432 017 30(0947) -102Iowa 484 021 08(0135) 1087 South Dakota 411 039 42(0151) -580Kansas 486 023 06(0137) 1143 Tennessee 484 015 09(0126) 1087Kentucky 460 018 17(0241) 544 Texas 427 008 32(1944) -213Louisiana 451 018 21(0345) 333 Utah 433 026 28(0250) -081Maine 497 031 02(0141) 1396 Vermont 461 047 16(0151) 578Maryland 411 015 41(1749) -576 Virginia 432 013 29(1246) -092Massachusetts 423 014 33(1548) -303 Washington 452 015 20(0541) 360Michigan 495 012 03(0119) 1340 West Virginia 486 027 07(0143) 1141Minnesota 475 017 11(0132) 901 Wisconsin 443 015 23(0645) 156Mississippi 404 021 47(1351) -731 Wyoming 445 051 22(0151) 192Missouri 419 014 36(1549) -396

Table 1924Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Females

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 Areas (excluding the AlaskaNative Registry) and 112016 US population estimates based on the average of 2015 and 2016 population estimates from theUS Bureau of the CensusPrevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 24 years

b Maximum limited-duration prevalence is 24 years for 1992-2016 datac Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groupsd Cases diagnosed more than 24 years ago were estimated using the completeness index method (Capocaccia et al 1997

Merrill et al 2000)e Complete prevalence is obtained by summing 0 to lt24 and gt=24- Statistic not shown Statistic based on fewer than 5 cases estimated alive in SEER for the time interval+ Not available

Years Since Diagnosis 0 to lt5 5 to lt10 10 to lt15 15 to lt20 20 to lt24 0 to lt24b gt=24d Completee

Race Sex

All Races Both Sexes 248946 177490 117326 69109 31890 644761 49943 694704Males 135137 94173 60159 36020 16581 342069 25489 367558Females 113809 83317 57167 33089 15309 302692 24454 327146

White Both Sexes 213764 154454 101984 60537 28026 558765 49625 620368Males 116527 82172 52535 31627 14543 297404 26526 330121Females 97237 72282 49448 28910 13483 261361 23099 290247

Black Both Sexes 20500 13640 9750 5271 2215 51376 4115 55491Males 10712 7188 4768 2684 1174 26526 1911 28437Females 9789 6452 4981 2587 1041 24850 2204 27054

Asian Both Sexes 8405 5210 3415 1867 844 19741 + +Pacific Males 4548 2661 1757 1013 407 10386 + +Islander Females 3856 2549 1657 855 437 9355 + +

Hispanic Both Sexes 21339 14049 8272 4881 2136 50676 + +Males 10918 7243 4331 2617 1094 26202 + +Females 10421 6805 3941 2264 1043 24474 + +

Age Specific (Crude) Age-Adjustedc Age at Prevalence All Ages 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ All Ages

Race Sex

All Races Both Sexes 02001 00035 00139 00283 00538 01121 02352 04640 08181 10224 01738Males 02156 00044 00189 00354 00625 01293 02710 05243 09364 12449 02023Females 01850 00026 00087 00208 00450 00952 02010 04094 07196 08856 01498

White Both Sexes 02216 00035 00143 00289 00534 01148 02427 04858 08597 10738 01807Males 02380 00045 00198 00359 00622 01317 02790 05442 09778 13060 02095Females 02054 00025 00085 00214 00442 00976 02072 04317 07593 09285 01560

Black Both Sexes 01139 00029 00113 00265 00599 01027 02010 03340 05117 05333 01251Males 01226 00029 00140 00351 00696 01223 02333 03969 05849 06055 01457Females 01059 00030 00086 00178 00510 00853 01728 02836 04608 04976 01088

Asian Both Sexes 00970 00039 00133 00207 00353 00680 01409 02692 04470 06094 01032Pacific Males 01065 00044 00175 00240 00398 00744 01640 03072 05516 07472 01222Islander Females 00882 00033 00092 00175 00312 00623 01209 02384 03629 05207 00880

Hispanic Both Sexes 00887 00030 00117 00206 00398 00850 01769 03632 05888 07209 01294Males 00908 00035 00147 00256 00455 00932 01924 03940 06326 08003 01420Females 00866 00024 00086 00151 00337 00766 01616 03360 05552 06719 01185

Table 1925Non-Hodgkin Lymphoma

Estimated United States Cancer Prevalence Countsa on January 1 2016By RaceEthnicity Sex and Years Since Diagnosis

Estimated prevalence percenta on January 1 2016 of the SEER population diagnosed in the previous 24 yearsBy Age at Prevalence RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 372 452924 -05 62 18862 04 247 189692 -05 1657 244370 -05

1 Hodgkin Lymphoma 28 32262 -17 13 3927 -06 33 22556 -15 39 5779 -31

2 Non-Hodgkin lymphoma 336 409991 -03 48 14693 04 210 163591 -03 1572 231707 -042(a) Non-Hodgkin lymphoma B-cell 311 380349 -01 39 11836 14 190 148768 -02 1491 219745 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 15 16631 20 31 9416 10 07 5203 39 14 2012 252(a) 2 Mature Non-Hodgkin lymphoma B-cell 280 343965 -04 07 2271 30 174 137225 -05 1387 204469 -042(a) 21 ChronicSmallProlymphocytic 69 85601 -13 00 35 - 35 29103 -11 382 56463 -14

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 61 75061 -15 00 30 - 31 25339 -13 336 49692 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 311 19 - - - 00 72 - 02 234 262(a) 213 Mantle-cell lymphoma 08 10229 03 - - - 04 3692 02 44 6537 04

2(a) 22 Lymphoplasmacytic lymphoma 07 8651 00 - - - 03 2590 -11 41 6059 04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 03 3667 -03 - - - 01 1132 -18 17 2533 022(a) 222 Waldenstrom macroglubulinemia 04 4984 03 - - - 02 1458 -07 24 3526 06

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 72 87188 00 03 925 26 48 36480 -02 339 49783 022(a) 231 DLBCL NOSc 71 85899 -01 03 861 12 46 35469 -05 337 49569 012(a) 232 Intravascular large B-cell 00 162 - - - - 00 63 - 01 99 -

lymphoma2(a) 233 Primary effusion lymphoma 00 181 27 - - - 00 126 - 00 55 -2(a) 234 Mediastinal large B-cell 01 946 116 00 64 - 01 822 111 00 60 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 04 4692 -26 03 1028 32 04 2618 -43 07 1046 -432(a) 25 Marginal-zone lymphoma (MZL) 22 26534 00 00 137 13 14 11049 05 104 15348 -042(a) 251 Splenic MZL 02 2418 04 - - - 01 889 -08 10 1529 102(a) 252 Extranodal MZL MALTc type 13 15979 06 00 92 - 09 7148 11 59 8739 032(a) 253 Nodal MZL 07 8137 -15 00 45 - 04 3012 -05 34 5080 -20

2(a) 26 Follicular lymphoma 35 43582 -21 00 119 - 28 21725 -25 147 21738 -182(a) 27 Hairy-cell leukemia 03 3712 -16 - - - 03 2311 -19 09 1401 -122(a) 28 Plasma cell neoplasms 68 83957 08 00 24 - 39 31325 12 358 52608 062(a) 281 Plasmacytoma 04 4879 -04 00 16 - 03 2362 -06 17 2501 -032(a) 282 Multiple myeloma 64 79078 09 - - - 36 28963 14 341 50107 07

plasma-cell leukemia2(a) 29 Heavy chain disease 00 48 - - - - 00 24 - 00 23 -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 16 19753 33 00 149 27 08 6340 37 90 13264 32

Table 1926All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 23 27222 01 08 2502 18 19 13933 03 73 10787 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 616 - 01 293 - 00 272 - 00 51 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 22 26531 11 07 2207 75 19 13621 12 73 10703 -042(b) 21 Mycosis fungoidesSezary syndrome 06 6969 18 01 213 84 06 4080 23 18 2676 052(b) 211 Mycosis fungoides 06 6739 17 01 213 84 05 3990 22 17 2536 042(b) 212 Sezary syndrome 00 230 46 - - - 00 90 - 01 140 -

2(b) 22 Peripheral T-cell lymphoma 12 14531 -10 02 534 07 10 7159 -09 46 6838 -122(b) 221 Peripheral T-cell lymphoma NOSc 04 5393 -01 00 86 - 03 2489 04 19 2818 -042(b) 222 Angioimmunoblastic T-cell lymphoma 02 1902 02 - - - 01 699 -09 08 1201 072(b) 223 Subcutaneous panniculitis- 00 176 44 00 31 - 00 111 - 00 34 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 2523 -36 01 291 00 02 1450 -33 05 782 -54

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 139 - - - - 00 98 - 00 28 -2(b) 226 Enteropathy-type T-cell lymphoma 00 186 -02 - - - 00 84 - 01 101 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 2963 -07 00 59 - 02 1575 01 09 1329 -142(b) 228 Primary cutaneous anaplastic 01 1249 -41 00 51 - 01 653 -49 04 545 -39

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 03 3417 96 05 1428 101 02 1474 99 03 515 672(b) 24 NKcT-cell lymphoma nasal-type 01 985 02 00 26 - 01 659 00 02 300 05

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 120 - - - - 00 54 - 00 65 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 509 30 - - - 00 195 -05 02 309 442(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 75 - - - - 00 40 - 00 33 -2(c) Non-Hodgkin lymphoma unknown lineage 02 2420 -274 01 355 - 01 890 -216 08 1175 -2792(c) 1 Precursor lymphoblastic leukemia 01 814 -283 01 343 - 00 238 - 02 233 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 95 - - - - 00 25 - 00 69 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 1511 -274 - - - 01 627 -202 06 873 -319

lineage2() 1 Total precursor lymphomaleukemiad 16 18061 -07 33 10052 -15 08 5713 06 15 2296 -01

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 762 273 00 20 - 00 339 227 03 403 -lymphoma

4 Lymphoid neoplasm NOSc 08 9909 -55 01 222 113 04 3206 -59 43 6481 -59

Table 1926 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 461 253152 -05 70 10973 05 294 110367 -07 2122 131812 -05

1 Hodgkin Lymphoma 31 17710 -17 13 2118 -03 36 12525 -16 48 3067 -31

2 Non-Hodgkin lymphoma 419 229772 -03 56 8711 05 252 95756 -05 2017 125305 -032(a) Non-Hodgkin lymphoma B-cell 387 212247 -02 44 6786 15 227 86941 -04 1908 118520 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 16 8999 24 33 5123 11 08 2888 46 16 988 292(a) 2 Mature Non-Hodgkin lymphoma B-cell 351 192801 -05 10 1558 28 210 80417 -08 1783 110826 -042(a) 21 ChronicSmallProlymphocytic 96 52411 -15 00 21 - 47 18927 -14 539 33463 -15

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 82 44988 -17 00 19 - 40 16143 -16 464 28826 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 193 -02 - - - 00 46 - 02 145 052(a) 213 Mantle-cell lymphoma 13 7230 -01 - - - 07 2738 -01 72 4492 -01

2(a) 22 Lymphoplasmacytic lymphoma 10 5082 -05 - - - 04 1524 -08 58 3558 -04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 04 2062 -08 - - - 02 616 -12 23 1446 -072(a) 222 Waldenstrom macroglubulinemia 06 3020 -02 - - - 02 908 -06 34 2112 -02

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 88 48128 01 03 554 22 59 21824 -06 418 25750 052(a) 231 DLBCL NOSc 87 47520 00 03 519 03 57 21366 -08 416 25635 042(a) 232 Intravascular large B-cell 00 75 - - - - 00 31 - 01 44 -

lymphoma2(a) 233 Primary effusion lymphoma 00 167 26 - - - 00 123 - 01 44 -2(a) 234 Mediastinal large B-cell 01 366 155 00 35 - 01 304 142 00 27 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 06 3388 -22 05 775 31 06 1969 -46 10 644 -192(a) 25 Marginal-zone lymphoma (MZL) 22 12351 -02 01 98 - 14 5177 -02 114 7076 -012(a) 251 Splenic MZL 02 1164 14 - - - 01 434 18 12 730 112(a) 252 Extranodal MZL MALTc type 13 7268 07 00 62 - 09 3267 04 63 3939 102(a) 253 Nodal MZL 07 3919 -23 00 36 - 04 1476 -22 39 2407 -23

2(a) 26 Follicular lymphoma 39 21788 -19 01 100 - 30 11210 -25 165 10478 -152(a) 27 Hairy-cell leukemia 05 2984 -18 - - - 05 1908 -20 17 1076 -152(a) 28 Plasma cell neoplasms 85 46642 07 - - - 45 17864 11 462 28769 052(a) 281 Plasmacytoma 05 2997 -08 - - - 04 1509 -16 24 1484 -012(a) 282 Multiple myeloma 80 43645 08 - - - 41 16355 13 439 27285 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 27 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 20 10447 34 01 105 - 10 3636 40 110 6706 32

Table 1927All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 29 16118 00 11 1730 14 23 8235 02 98 6153 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 430 - 01 208 - 01 188 - 01 34 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 28 15642 11 10 1521 71 22 8022 11 97 6099 -032(b) 21 Mycosis fungoidesSezary syndrome 07 3962 19 01 135 - 06 2261 21 25 1566 092(b) 211 Mycosis fungoides 07 3831 20 01 135 - 06 2213 21 23 1483 092(b) 212 Sezary syndrome 00 131 - - - - 00 48 - 01 83 -

2(b) 22 Peripheral T-cell lymphoma 15 8438 -13 02 318 -09 12 4248 -12 62 3872 -132(b) 221 Peripheral T-cell lymphoma NOSc 06 3159 -05 00 49 - 04 1520 02 26 1590 -082(b) 222 Angioimmunoblastic T-cell lymphoma 02 1024 19 - - - 01 415 11 10 607 232(b) 223 Subcutaneous panniculitis- 00 68 - - - - 00 39 - 00 16 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 03 1549 -39 01 184 -01 02 888 -43 08 477 -45

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 98 - - - - 00 69 - 00 18 -2(b) 226 Enteropathy-type T-cell lymphoma 00 105 - - - - 00 50 - 01 54 -2(b) 227 Cutaneous T-cell lymphoma NOSc 03 1696 -12 00 32 - 02 894 -03 12 770 -172(b) 228 Primary cutaneous anaplastic 01 739 -48 00 26 - 01 373 -49 05 340 -49

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 04 2253 97 07 1047 92 03 940 98 04 266 1022(b) 24 NKcT-cell lymphoma nasal-type 01 638 -05 00 18 - 01 435 -03 03 185 -06

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 58 - - - - 00 22 - 01 36 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 01 293 45 - - - 00 116 - 03 174 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 46 - - - - 00 25 - 00 20 -2(c) Non-Hodgkin lymphoma unknown lineage 03 1407 -232 01 195 - 02 580 -184 10 632 -2302(c) 1 Precursor lymphoblastic leukemia 01 474 -228 01 187 - 00 134 - 02 153 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 49 - - - - - - - 01 36 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 02 884 -239 - - - 01 433 -175 07 443 -

lineage2() 1 Total precursor lymphomaleukemiad 18 9903 -06 35 5518 -17 09 3210 09 19 1175 05

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 435 271 - - - 01 215 - 03 207 -lymphoma

4 Lymphoid neoplasm NOSc 10 5235 -59 01 131 - 05 1871 -65 54 3233 -61

Table 1927 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 301 199772 -05 53 7889 02 202 79325 -02 1322 112558 -08

1 Hodgkin Lymphoma 24 14552 -16 12 1809 -10 29 10031 -14 32 2712 -32

2 Non-Hodgkin lymphoma 269 180219 -03 40 5982 03 170 67835 00 1251 106402 -062(a) Non-Hodgkin lymphoma B-cell 250 168102 -01 34 5050 13 154 61827 02 1190 101225 -042(a) 1 Precursor Non-Hodgkin lymphoma B-cell 14 7632 16 29 4293 09 06 2315 29 12 1024 202(a) 2 Mature Non-Hodgkin lymphoma B-cell 223 151164 -04 05 713 35 141 56808 -01 1102 93643 -072(a) 21 ChronicSmallProlymphocytic 48 33190 -13 - - - 24 10176 -05 268 23000 -16

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 43 30073 -15 - - - 22 9196 -06 243 20866 -19

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 118 - - - - 00 26 - 01 89 -2(a) 213 Mantle-cell lymphoma 04 2999 11 - - - 02 954 10 24 2045 12

2(a) 22 Lymphoplasmacytic lymphoma 05 3569 04 - - - 03 1066 -16 30 2501 11Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 02 1605 01 - - - 01 516 -25 13 1087 112(a) 222 Waldenstrom macroglubulinemia 03 1964 06 - - - 01 550 -08 17 1414 11

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 58 39060 00 02 371 33 38 14656 03 283 24033 -032(a) 231 DLBCL NOSc 57 38379 -02 02 342 27 36 14103 -01 282 23934 -032(a) 232 Intravascular large B-cell 00 87 - - - - 00 32 - 01 55 -

lymphoma2(a) 233 Primary effusion lymphoma - - - - - - - - - - - -2(a) 234 Mediastinal large B-cell 01 580 91 00 29 - 02 518 93 00 33 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 02 1304 -34 02 253 38 02 649 -37 05 402 -852(a) 25 Marginal-zone lymphoma (MZL) 21 14183 01 00 39 - 15 5872 12 98 8272 -062(a) 251 Splenic MZL 02 1254 -07 - - - 01 455 -32 10 799 072(a) 252 Extranodal MZL MALTc type 13 8711 06 00 30 - 10 3881 17 57 4800 -032(a) 253 Nodal MZL 06 4218 -07 - - - 04 1536 11 32 2673 -18

2(a) 26 Follicular lymphoma 33 21794 -24 00 19 - 27 10515 -25 134 11260 -222(a) 27 Hairy-cell leukemia 01 728 -12 - - - 01 403 -11 04 325 -122(a) 28 Plasma cell neoplasms 55 37315 08 - - - 33 13461 15 282 23839 052(a) 281 Plasmacytoma 03 1882 00 - - - 02 853 12 12 1017 -092(a) 282 Multiple myeloma 52 35433 09 - - - 30 12608 15 270 22822 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 21 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 14 9306 32 00 44 - 07 2704 32 76 6558 31

Table 1928All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 17 11104 01 05 772 29 15 5698 05 55 4634 -112(b) 1 Precursor Non-Hodgkin lymphoma T-cell 00 186 - 01 85 - 00 84 - 00 17 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 17 10889 09 05 686 83 15 5599 12 54 4604 -092(b) 21 Mycosis fungoidesSezary syndrome 05 3007 15 01 78 - 05 1819 26 13 1110 -042(b) 211 Mycosis fungoides 05 2908 12 01 78 - 05 1777 23 12 1053 -072(b) 212 Sezary syndrome 00 99 - - - - 00 42 - 01 57 -

2(b) 22 Peripheral T-cell lymphoma 09 6093 -08 01 216 30 08 2911 -06 35 2966 -142(b) 221 Peripheral T-cell lymphoma NOSc 03 2234 03 00 37 - 03 969 07 14 1228 -012(b) 222 Angioimmunoblastic T-cell lymphoma 01 878 -22 - - - 01 284 -39 07 594 -152(b) 223 Subcutaneous panniculitis- 00 108 - 00 18 - 00 72 - 00 18 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 974 -33 01 107 - 02 562 -19 04 305 -77

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 41 - - - - 00 29 - - - -2(b) 226 Enteropathy-type T-cell lymphoma 00 81 - - - - 00 34 - 01 47 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 1267 00 00 27 - 02 681 07 07 559 -102(b) 228 Primary cutaneous anaplastic 01 510 -34 00 25 - 01 280 -50 02 205 -33

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 02 1164 96 03 381 127 01 534 97 03 249 302(b) 24 NKcT-cell lymphoma nasal-type 01 347 11 - - - 01 224 - 01 115 -

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 62 - - - - 00 32 - 00 29 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 216 03 - - - 00 79 - 02 135 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 29 - - - - - - - - - -2(c) Non-Hodgkin lymphoma unknown lineage 02 1013 -341 01 160 - 01 310 - 06 543 -2(c) 1 Precursor lymphoblastic leukemia 01 340 - 01 156 - 00 104 - 01 80 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 46 - - - - - - - 00 33 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 627 - - - - 01 194 - 05 430 -

lineage2() 1 Total precursor lymphomaleukemiad 14 8158 -09 31 4534 -13 07 2503 02 13 1121 -11

3 Composite Hodgkin lymphoma and Non-Hodgkin 00 327 - - - - 00 124 - 02 196 -lymphoma

4 Lymphoid neoplasm NOSc 07 4674 -52 01 91 - 03 1335 -51 36 3248 -58

Table 1928 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 11: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Based on the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta)Expected survival rates are derived from the US Annual Life Tables

1975- 1980- 1985- 1990-1979 1984 1989 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

Survival Time

1-year 710 734 741 747 752 759 767 786 792 782 801 814 810 821 825 809 819 847 854 851 830 843 856 838 8572-year 611 637 656 672 664 688 701 720 734 727 758 769 765 767 786 774 772 804 812 807 796 810 817 7993-year 559 589 611 627 616 649 662 684 700 692 727 744 736 746 768 756 746 774 791 786 774 791 7974-year 519 553 576 595 590 619 634 653 681 674 710 725 724 730 751 739 729 757 778 764 755 7805-year 482 514 544 567 565 591 608 629 658 664 688 708 713 716 736 724 715 735 763 751 7426-year 446 484 517 539 540 580 583 603 635 643 679 695 699 701 727 708 707 722 738 7317-year 417 458 490 512 520 560 563 586 615 626 663 674 687 692 704 698 694 709 7268-year 392 437 463 491 505 542 539 573 596 615 649 667 672 684 693 692 684 6949-year 374 416 443 476 492 529 528 557 578 603 633 654 664 669 671 688 67110-year 360 399 424 458 480 514 516 542 562 588 625 648 651 658 659 66911-year 342 385 409 438 469 503 500 529 547 573 621 636 640 651 65312-year 329 368 390 425 460 494 493 523 529 560 606 613 632 64013-year 321 353 376 411 449 486 485 518 510 543 598 606 61514-year 310 340 365 400 442 479 470 512 497 532 582 59615-year 297 326 349 391 436 472 460 498 483 525 57416-year 287 316 342 385 435 467 441 492 468 51317-year 282 306 336 378 428 459 438 490 45218-year 274 298 327 367 413 449 428 48519-year 265 288 321 358 407 439 42220-year 254 280 312 353 395 433

Table 1911Non-Hodgkin Lymphoma

SEERa Relative Survival (Percent)By Year of Diagnosis

All Races Females

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 5222 2506 2704 3176 3627 3994 4570 4729 5325 5260 5263 5562 5775 6226 6401 6704 6998 7072 11154

SEER 9 except 4285 2088 2267 2603 2819 3091 3507 3694 4159 4249 4364 4515 4818 5209 5398 5628 5841 6015 9363SF-Oakland

San Francisco- 937 418 437 573 808 903 1063 1035 1166 1011 899 1047 957 1017 1003 1076 1157 1057 1791Oakland SMSAc

San Francisco 245 96 123 210 326 393 467 410 450 354 213 256 220 283 219 216 240 225 362CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 134 155 161 183 201 215 234 233 252 244 238 244 246 258 254 255 255 245 244

SEER 9 except 132 154 161 181 188 201 217 218 236 236 235 236 244 256 254 253 252 247 243SF-Oakland

San Francisco- 147 158 160 194 267 285 317 305 335 288 252 286 256 266 256 263 268 235 246Oakland SMSAc

San Francisco 143 144 176 293 444 519 610 523 574 448 274 325 269 354 265 257 273 252 246CityCounty

Table 1912

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males All Ages

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males All Ages

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 0-19 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 223 87 108 91 94 84 100 89 120 105 104 119 127 107 106 143 134 155 240

SEER 9 except 191 78 95 82 80 76 86 74 107 84 93 100 115 90 87 114 119 129 198SF-Oakland

San Francisco- 32 9 13 9 14 8 14 15 13 21 11 19 12 17 19 29 15 26 42Oakland SMSAc

San Francisco 9 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 5 lt4 6 lt4CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 12 12 16 14 14 13 15 13 17 14 14 15 16 14 13 18 17 20 20

SEER 9 except 12 13 16 14 14 13 15 12 17 13 14 15 17 13 13 16 17 19 19SF-Oakland

San Francisco- 14 10 15 10 16 09 15 16 13 21 11 18 12 17 19 28 14 25 27Oakland SMSAc

San Francisco 23 - - - - - - - - - - - - - - 40 - 49 -CityCounty

Table 1913

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 0-19

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 0-19

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 20-54 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 1463 687 723 958 1211 1413 1766 1830 2089 1770 1608 1696 1623 1722 1655 1693 1674 1596 2242

SEER 9 except 1208 563 588 730 827 923 1195 1294 1483 1325 1269 1327 1308 1410 1383 1401 1402 1328 1848SF-Oakland

San Francisco- 255 124 135 228 384 490 571 536 606 445 339 369 315 312 272 292 272 268 394Oakland SMSAc

San Francisco 58 29 34 105 215 288 333 303 317 225 105 115 111 111 86 75 73 71 98CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 69 79 82 104 124 136 159 156 169 138 121 124 117 123 116 118 116 111 104

SEER 9 except 69 78 81 97 103 109 131 134 144 123 115 116 112 119 115 116 115 110 103SF-Oakland

San Francisco- 69 84 89 139 226 264 295 267 298 213 156 164 139 141 123 130 118 114 110Oakland SMSAc

San Francisco 67 88 94 272 565 715 813 724 744 510 230 252 239 248 194 162 152 145 129CityCounty

Table 1914

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 20-54

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 20-54

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 55+ and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 3536 1732 1873 2127 2322 2497 2704 2810 3116 3385 3551 3747 4025 4397 4640 4868 5190 5321 8672

SEER 9 except 2886 1447 1584 1791 1912 2092 2226 2326 2569 2840 3002 3088 3395 3709 3928 4113 4320 4558 7317SF-Oakland

San Francisco- 650 285 289 336 410 405 478 484 547 545 549 659 630 688 712 755 870 763 1355Oakland SMSAc

San Francisco 178 65 88 104 109 105 132 106 130 126 106 141 108 169 131 136 164 148 261CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 451 522 540 596 633 673 701 706 761 800 811 831 858 900 901 891 899 862 871

SEER 9 except 440 521 544 601 620 667 687 692 744 797 813 813 858 901 904 891 888 874 874SF-Oakland

San Francisco- 508 528 520 571 702 703 773 783 854 821 800 932 855 894 888 890 959 800 860Oakland SMSAc

San Francisco 482 446 598 727 739 757 934 747 914 872 727 934 690 1047 764 769 889 776 826CityCounty

Table 1915

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 55+

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 55+

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 003 006 217 072 Asian 0 001 003 005 183 072

10 002 005 011 218 073 Pacific 10 002 004 009 184 073

20 003 009 021 217 073 Islander 20 003 007 015 182 073

30 006 018 042 216 073 30 005 013 029 180 073

40 012 037 082 213 074 40 008 024 057 176 073

50 025 072 139 206 074 50 017 049 101 170 073

60 049 120 177 191 075 60 034 087 139 158 072

70 080 144 - 160 072 70 056 112 - 133 068

80 085 - - 106 062 80 066 - - 091 056

White 0 001 003 006 227 075 American 0 001 002 003 116 049

10 002 005 011 228 076 Indian 10 002 002 005 117 050

20 003 009 021 227 076 Alaska 20 001 003 008 116 050

30 006 018 043 226 077 Nativea 30 003 007 022 117 051

40 012 038 085 223 077 40 004 019 041 117 052

50 026 075 147 217 078 50 016 038 078 118 053

60 052 127 187 201 078 60 024 067 105 109 055

70 085 153 - 169 076 70 048 091 - 096 055

80 090 - - 111 065 80 057 - - 064 043

Black 0 001 002 006 138 042 Hispanicb 0 001 002 005 222 073

10 002 005 011 140 043 10 001 004 009 223 074

20 003 010 022 139 043 20 003 008 019 222 074

30 006 019 041 137 043 30 005 016 040 221 074

40 013 035 068 133 043 40 011 035 078 218 074

50 023 057 093 125 043 50 024 068 133 211 074

60 037 076 102 110 042 60 046 114 173 195 074

70 047 078 - 087 038 70 075 140 - 164 070

80 044 - - 057 032 80 081 - - 112 057

Table 1916

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Both Sexes 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 004 007 243 081 Asian 0 001 003 006 213 085

10 002 006 013 244 082 Pacific 10 002 005 011 213 086

20 004 010 024 243 082 Islander 20 003 009 018 211 086

30 007 021 049 243 083 30 006 015 034 210 086

40 014 042 094 240 084 40 009 028 067 205 086

50 029 082 158 233 085 50 019 059 117 199 086

60 057 139 203 219 086 60 041 101 161 187 085

70 095 170 - 188 084 70 066 131 - 159 082

80 105 - - 130 073 80 080 - - 114 069

White 0 001 004 007 254 085 American 0 001 003 004 104 057

10 002 006 013 255 086 Indian 10 002 003 006 105 058

20 004 010 024 254 086 Alaska 20 001 004 008 103 058

30 007 020 049 253 087 Nativea 30 003 008 021 104 059

40 014 043 097 251 088 40 005 018 038 105 060

50 030 086 167 244 089 50 014 035 071 105 062

60 059 147 215 230 090 60 023 062 094 099 065

70 101 180 - 198 088 70 046 084 - 090 066

80 112 - - 136 076 80 053 - - 061 053

Black 0 001 003 007 152 046 Hispanicb 0 001 003 005 238 083

10 002 006 014 154 047 10 002 005 011 239 084

20 004 012 027 153 047 20 003 009 021 238 084

30 008 023 048 152 047 30 006 018 043 238 084

40 016 042 079 148 047 40 012 037 083 235 085

50 027 066 105 138 047 50 026 073 145 228 085

60 043 087 114 123 045 60 050 126 189 214 085

70 054 088 - 099 042 70 086 157 - 185 081

80 053 - - 070 036 80 094 - - 131 066

Table 1917

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Males 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 002 004 193 064 Asian 0 001 002 004 159 063

10 001 004 009 195 064 Pacific 10 001 004 008 160 063

20 003 007 017 194 064 Islander 20 002 006 013 159 063

30 005 015 036 192 065 30 004 011 025 157 063

40 010 031 071 189 065 40 007 021 048 153 063

50 022 062 120 182 065 50 014 042 087 148 063

60 042 103 154 168 065 60 028 074 122 136 062

70 067 123 - 138 063 70 049 099 - 114 058

80 071 - - 090 054 80 057 - - 075 047

White 0 001 002 004 203 067 American 0 000 001 002 128 043

10 001 004 009 204 067 Indian 10 001 001 004 129 044

20 002 007 017 203 067 Alaska 20 001 003 007 128 044

30 005 015 037 201 067 Nativea 30 002 006 023 129 044

40 010 032 074 198 068 40 004 021 044 129 045

50 022 065 127 192 068 50 017 042 085 129 046

60 044 109 163 177 068 60 026 072 113 118 047

70 072 130 - 146 066 70 050 097 - 102 046

80 075 - - 094 056 80 060 - - 066 037

Black 0 000 002 004 126 040 Hispanicb 0 001 002 004 210 065

10 001 004 009 128 040 10 001 004 008 211 066

20 003 008 018 127 040 20 002 007 017 211 066

30 005 015 034 125 040 30 004 014 036 209 066

40 010 029 058 122 040 40 010 032 073 206 066

50 020 049 083 115 040 50 022 064 123 198 066

60 032 068 094 102 039 60 043 104 161 182 065

70 041 071 - 080 036 70 066 127 - 149 062

80 039 - - 051 030 80 073 - - 100 051

Table 1918

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Females 2014-2016 By RaceEthnicity

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

The AAPC is the Average Annual Percent Change over the time interval The AAPCs are calculated bythe Joinpoint Regression Program Version 47 February 2019 National Cancer Institute

- Statistic not shown Rate based on less than 16 cases for the time intervalTrend based on less than 10 cases for at least one year within the time interval

a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) Trendsare based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico SeattleUtah and AtlantaThe SEER 21 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the AlaskaNative Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts

c The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 3 Joinpoints overdiagnosis years 2000-2016

d The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 5 Joinpoints overdiagnosis years 1975-2016

e Hispanic and Non-Hispanic are not mutually exclusive from whites blacks AsianPacificIslanders and American IndiansAlaska Natives Incidence data for Hispanics and Non-Hispanicsare based on NHIA and exclude cases from the Alaska Native Registry

f Incidence data for American IndianAlaska Native are based on the PurchasedReferred CareDelivery Area (PRCDA) counties

g US Mortality Files National Center for Health Statistics CDCh The 2007-2016 mortality AAPCs are based on a Joinpoint analysis using years of death 2000-2016 The APC is significantly different from zero (plt05)

SEER Incidence SEER 21 Areasb SEER 21 Areasb SEER 9 Areasb

Rate 2012-2016 Trend 2007-2016c Trend 2007-2016d

Rate per 100000 persons AAPC () AAPC ()

Total Males Females Total Males Females Total Males Females RaceEthnicity

All Races 196 239 162 -07 -09 -08 -09 -07 -08

White 206 250 170 -08 -11 -09 -09 -08 -08White Hispanice 183 212 161 -08 -03 -05 - - -White Non-Hispanice 210 256 172 -08 -06 -10 - - -

Black 147 177 124 01 00 03 00 -04 -09

AsianPacific Islander 134 164 110 00 00 -01 - - -

Amer IndAlaska Natf 113 120 106 -05 -12 00 - - -

Hispanice 179 207 157 -05 -02 03 - - -

US Mortalityg Rate 2012-2016 Trend 2007-2016h

Rate per 100000 persons AAPC ()

Total Males Females Total Males FemalesRaceEthnicity

All Races 56 73 44 -23 -20 -27

White 59 76 45 -23 -20 -27White Hispanice 51 65 40 -16 -13 -20White Non-Hispanice 59 76 46 -23 -20 -27

Black 41 52 33 -20 -19 -21

AsianPacific Islander 39 49 31 -17 -15 -19

Amer IndAlaska NatTotal US 31 40 24 -32 -20 -45PRCDA Counties 44 58 33 -21 -04 -37Non-PRCDA Counties 17 21 14 -54 -50 -60

Hispanice 48 61 38 -17 -14 -21

Table 1919Non-Hodgkin Lymphoma

SEER Incidence and US MortalityAge-Adjusted Rates and Trendsa

By RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Incidence Ratesa 2012-2016

California 1844 2241 1515 1938 2349 1591 1390 1639 1182Greater Bay Area 1957 2381 1600 2144 2601 1755 1628 1828 1436San Francisco-Oakland 1956 2421 1570 2174 2660 1765 1603 1816 1408San Jose-Monterey 1962 2311 1660 2097 2503 1742 1800 1891 1646

Los Angeles 1804 2176 1505 1951 2331 1637 1357 1659 1139Greater California 1822 2220 1489 1876 2286 1529 1314 1534 1113

Connecticut 2116 2607 1733 2154 2642 1771 1386 1829 1051Detroit 2132 2636 1742 2290 2850 1847 1620 1905 1409Georgia 1826 2244 1487 1936 2346 1588 1462 1833 1187Atlanta 1925 2381 1555 2119 2567 1736 1601 2034 1272Rural Georgia 1584 1790 1401 1953 2298 1567 807 - 988Greater Georgia 1784 2186 1459 1872 2274 1537 1380 1703 1146

Hawaii 1660 2024 1349 1958 2275 1593 - - -Idaho 1922 2267 1616 1920 2262 1618 - - -Iowa 2134 2601 1756 2148 2612 1773 1352 1602 1100Kentucky 2039 2505 1666 2070 2538 1693 1403 1788 1112Louisiana 1944 2352 1614 2106 2537 1744 1469 1769 1237Massachusetts 1810 2181 1518 1830 2214 1524 1452 1655 1299New Jersey 2155 2607 1804 2285 2765 1905 1387 1621 1222New Mexico 1550 1739 1387 1580 1798 1394 875 - -New York 2152 2620 1788 2306 2792 1915 1545 1852 1333Seattle-Puget Sound 2116 2627 1695 2177 2667 1766 1631 1973 1316Utah 1843 2233 1498 1862 2258 1513 2089 - -

SEER 9 Areasb 1992 2444 1623 2095 2551 1716 1573 1914 1298SEER 13 Areasb 1946 2373 1597 2064 2502 1700 1519 1853 1258SEER 18 Areasb 1933 2354 1590 2031 2464 1671 1449 1751 1214SEER 21 Areasb 1963 2388 1620 2061 2498 1702 1471 1771 1245

Table 1920Non-Hodgkin Lymphoma

Age-Adjusted SEER Incidence Ratesa

By Registry Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control and PreventionRates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and AtlantaThe SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Death Ratesa 2012-2016

California 533 677 423 570 726 449 417 480 367Greater Bay Area 505 671 376 561 756 408 410 491 331San Francisco-Oakland 503 667 376 555 742 409 416 490 343San Jose-Monterey 511 681 377 573 781 407 - - -

Los Angeles 541 670 443 589 728 481 424 503 371Greater California 539 682 429 564 716 447 416 455 384

Connecticut 533 705 407 547 717 421 350 510 244Detroit 639 822 505 693 895 542 443 528 384Georgia 533 697 411 580 747 450 376 503 286Atlanta 492 659 372 533 728 388 397 506 317Rural Georgia 559 731 388 670 813 507 - - -Greater Georgia 549 712 426 595 755 470 363 500 266

Hawaii 475 620 352 545 649 412 - - -Idaho 635 775 510 641 782 516 - - -Iowa 638 845 484 642 848 488 - - -Kentucky 642 886 460 655 904 470 401 557 284Louisiana 608 814 451 651 863 485 461 623 340Massachusetts 523 659 423 541 682 436 347 410 297New Jersey 545 721 419 585 780 443 372 466 314New Mexico 488 585 405 493 595 406 - - -New York 535 702 412 575 752 441 390 514 313Seattle-Puget Sound 585 749 463 604 769 480 490 562 397Utah 542 670 433 551 681 440 - - -

SEER 9 Areasb 555 719 430 586 758 454 414 522 333SEER 13 Areasb 549 705 429 586 753 457 419 521 342SEER 18 Areasb 554 717 431 589 761 456 409 518 329SEER 21 Areasb 550 712 428 584 754 453 401 513 322

Total US 562 725 436 586 755 454 408 518 330

Table 1921Non-Hodgkin Lymphoma

Age-Adjusted SEER Death Ratesa

By Registry Race and Sex

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 562 002

High Five StatesMichigan 645 011 01(0112) 1479Kentucky 642 016 02(0118) 1424Iowa 638 018 03(0120) 1367Indiana 638 013 04(0117) 1361Idaho 635 027 05(0126) 1303

Low Five StatesNevada 511 019 47(2251) -899Colorado 491 014 48(3851) -1257New Mexico 488 020 49(2851) -1317Hawaii 475 024 50(3051) -1542c

DC 444 039 51(2351) -2097c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 545 014 28(1847) -291 Montana 559 030 25(0250) -042Alaska 525 047 43(0151) -654 Nebraska 563 023 22(0548) 026Arizona 512 012 46(2950) -886 Nevada 511 019 47(2251) -899Arkansas 555 018 26(1247) -113 New Hampshire 562 027 23(0349) 014California 533 005 40(2645) -508 New Jersey 545 010 29(2045) -301Colorado 491 014 48(3851) -1257 New Mexico 488 020 49(2851) -1317Connecticut 533 016 39(1949) -505 New York 535 007 37(2446) -478Delaware 628 033 08(0139) 1174 North Carolina 541 010 35(2146) -363DC 444 039 51(2351) -2097c North Dakota 561 037 24(0151) -007Florida 535 006 38(2545) -479 Ohio 616 009 10(0220) 969Georgia 533 011 41(2248) -511 Oklahoma 630 017 06(0121) 1226Hawaii 475 024 50(3051) -1542c Oregon 612 016 11(0124) 903Idaho 635 027 05(0126) 1303 Pennsylvania 603 009 16(0622) 729Illinois 566 009 20(1634) 085 Rhode Island 542 029 32(0651) -350Indiana 638 013 04(0117) 1361 South Carolina 542 014 31(1847) -347Iowa 638 018 03(0120) 1367 South Dakota 541 033 36(0451) -364Kansas 585 019 19(0439) 420 Tennessee 629 013 07(0119) 1198Kentucky 642 016 02(0118) 1424 Texas 546 007 27(2142) -277Louisiana 608 016 14(0125) 826 Utah 542 022 33(1250) -352Maine 609 026 13(0137) 852 Vermont 605 040 15(0148) 770Maryland 524 013 44(2349) -663 Virginia 544 011 30(2046) -319Massachusetts 523 012 45(2549) -687 Washington 599 013 17(0425) 665Michigan 645 011 01(0112) 1479 West Virginia 612 022 12(0132) 894Minnesota 617 014 09(0122) 984 Wisconsin 590 013 18(0629) 507Mississippi 531 018 42(1850) -551 Wyoming 564 043 21(0151) 050Missouri 542 012 34(1947) -354

Table 1922Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males and Females

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 725 003

High Five StatesKentucky 886 030 01(0112) 2213c

Iowa 845 032 02(0120) 1647c

Michigan 842 019 03(0114) 1615c

Indiana 839 024 04(0116) 1567c

Delaware 824 058 05(0144) 1364

Low Five StatesArizona 635 019 47(3251) -1244Alaska 630 075 48(0251) -1311Hawaii 620 041 49(1951) -1452DC 614 071 50(0551) -1535c

New Mexico 585 033 51(3451) -1928c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 688 025 36(1649) -513 Montana 709 050 26(0251) -218Alaska 630 075 48(0251) -1311 Nebraska 737 040 20(0248) 165Arizona 635 019 47(3251) -1244 Nevada 653 032 44(1951) -994Arkansas 721 031 22(0747) -061 New Hampshire 710 046 25(0451) -210California 677 009 41(2846) -666 New Jersey 721 018 21(1441) -059Colorado 643 024 46(2451) -1133 New Mexico 585 033 51(3451) -1928c

Connecticut 705 028 28(1248) -273 New York 702 012 30(1943) -323Delaware 824 058 05(0144) 1364 North Carolina 709 018 27(1644) -221DC 614 071 50(0551) -1535c North Dakota 682 061 39(0251) -598Florida 683 011 37(2446) -585 Ohio 800 017 09(0320) 1029Georgia 697 019 34(1746) -387 Oklahoma 806 030 08(0126) 1109Hawaii 620 041 49(1951) -1452 Oregon 794 028 12(0128) 947Idaho 775 045 16(0146) 692 Pennsylvania 783 015 15(0523) 794Illinois 739 016 19(1235) 190 Rhode Island 649 050 45(1051) -1050Indiana 839 024 04(0116) 1567c South Carolina 681 025 40(1850) -604Iowa 845 032 02(0120) 1647c South Dakota 701 056 31(0251) -332Kansas 713 032 24(0948) -174 Tennessee 820 023 06(0120) 1311Kentucky 886 030 01(0112) 2213c Texas 698 012 32(2043) -368Louisiana 814 029 07(0122) 1222 Utah 670 036 42(1351) -754Maine 754 045 18(0148) 395 Vermont 794 069 11(0149) 950Maryland 682 023 38(1849) -588 Virginia 694 020 35(1847) -429Massachusetts 659 020 43(2450) -910 Washington 790 022 13(0224) 897Michigan 842 019 03(0114) 1615c West Virginia 774 038 17(0142) 675Minnesota 797 025 10(0224) 995 Wisconsin 786 023 14(0227) 844Mississippi 717 034 23(0748) -110 Wyoming 698 071 33(0151) -377Missouri 702 022 29(1646) -319

Table 1923Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 436 002

High Five StatesIdaho 510 033 01(0139) 1697c

Maine 497 031 02(0141) 1396Michigan 495 012 03(0119) 1340Oklahoma 492 020 04(0128) 1276Indiana 492 016 05(0123) 1270

Low Five StatesMississippi 404 021 47(1351) -731Nevada 382 022 48(2051) -1237Colorado 369 016 49(3451) -1540c

Hawaii 352 027 50(2551) -1932c

DC 323 044 51(1551) -2601c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 440 017 24(0547) 099 Montana 435 036 27(0151) -034Alaska 414 058 38(0151) -500 Nebraska 435 027 26(0249) -032Arizona 407 014 44(2049) -664 Nevada 382 022 48(2051) -1237Arkansas 428 021 31(0649) -181 New Hampshire 454 032 19(0149) 400California 423 006 34(2244) -313 New Jersey 419 012 37(1848) -397Colorado 369 016 49(3451) -1540c New Mexico 405 025 46(0951) -706Connecticut 407 018 45(1550) -669 New York 412 008 39(2548) -554Delaware 473 039 12(0150) 855 North Carolina 420 012 35(1848) -374DC 323 044 51(1551) -2601c North Dakota 471 045 13(0150) 809Florida 412 007 40(2548) -564 Ohio 478 011 10(0123) 967Georgia 411 012 43(2049) -582 Oklahoma 492 020 04(0128) 1276Hawaii 352 027 50(2551) -1932c Oregon 465 019 15(0141) 668Idaho 510 033 01(0139) 1697c Pennsylvania 467 010 14(0427) 714Illinois 439 010 25(1341) 074 Rhode Island 455 035 18(0150) 434Indiana 492 016 05(0123) 1270 South Carolina 432 017 30(0947) -102Iowa 484 021 08(0135) 1087 South Dakota 411 039 42(0151) -580Kansas 486 023 06(0137) 1143 Tennessee 484 015 09(0126) 1087Kentucky 460 018 17(0241) 544 Texas 427 008 32(1944) -213Louisiana 451 018 21(0345) 333 Utah 433 026 28(0250) -081Maine 497 031 02(0141) 1396 Vermont 461 047 16(0151) 578Maryland 411 015 41(1749) -576 Virginia 432 013 29(1246) -092Massachusetts 423 014 33(1548) -303 Washington 452 015 20(0541) 360Michigan 495 012 03(0119) 1340 West Virginia 486 027 07(0143) 1141Minnesota 475 017 11(0132) 901 Wisconsin 443 015 23(0645) 156Mississippi 404 021 47(1351) -731 Wyoming 445 051 22(0151) 192Missouri 419 014 36(1549) -396

Table 1924Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Females

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 Areas (excluding the AlaskaNative Registry) and 112016 US population estimates based on the average of 2015 and 2016 population estimates from theUS Bureau of the CensusPrevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 24 years

b Maximum limited-duration prevalence is 24 years for 1992-2016 datac Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groupsd Cases diagnosed more than 24 years ago were estimated using the completeness index method (Capocaccia et al 1997

Merrill et al 2000)e Complete prevalence is obtained by summing 0 to lt24 and gt=24- Statistic not shown Statistic based on fewer than 5 cases estimated alive in SEER for the time interval+ Not available

Years Since Diagnosis 0 to lt5 5 to lt10 10 to lt15 15 to lt20 20 to lt24 0 to lt24b gt=24d Completee

Race Sex

All Races Both Sexes 248946 177490 117326 69109 31890 644761 49943 694704Males 135137 94173 60159 36020 16581 342069 25489 367558Females 113809 83317 57167 33089 15309 302692 24454 327146

White Both Sexes 213764 154454 101984 60537 28026 558765 49625 620368Males 116527 82172 52535 31627 14543 297404 26526 330121Females 97237 72282 49448 28910 13483 261361 23099 290247

Black Both Sexes 20500 13640 9750 5271 2215 51376 4115 55491Males 10712 7188 4768 2684 1174 26526 1911 28437Females 9789 6452 4981 2587 1041 24850 2204 27054

Asian Both Sexes 8405 5210 3415 1867 844 19741 + +Pacific Males 4548 2661 1757 1013 407 10386 + +Islander Females 3856 2549 1657 855 437 9355 + +

Hispanic Both Sexes 21339 14049 8272 4881 2136 50676 + +Males 10918 7243 4331 2617 1094 26202 + +Females 10421 6805 3941 2264 1043 24474 + +

Age Specific (Crude) Age-Adjustedc Age at Prevalence All Ages 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ All Ages

Race Sex

All Races Both Sexes 02001 00035 00139 00283 00538 01121 02352 04640 08181 10224 01738Males 02156 00044 00189 00354 00625 01293 02710 05243 09364 12449 02023Females 01850 00026 00087 00208 00450 00952 02010 04094 07196 08856 01498

White Both Sexes 02216 00035 00143 00289 00534 01148 02427 04858 08597 10738 01807Males 02380 00045 00198 00359 00622 01317 02790 05442 09778 13060 02095Females 02054 00025 00085 00214 00442 00976 02072 04317 07593 09285 01560

Black Both Sexes 01139 00029 00113 00265 00599 01027 02010 03340 05117 05333 01251Males 01226 00029 00140 00351 00696 01223 02333 03969 05849 06055 01457Females 01059 00030 00086 00178 00510 00853 01728 02836 04608 04976 01088

Asian Both Sexes 00970 00039 00133 00207 00353 00680 01409 02692 04470 06094 01032Pacific Males 01065 00044 00175 00240 00398 00744 01640 03072 05516 07472 01222Islander Females 00882 00033 00092 00175 00312 00623 01209 02384 03629 05207 00880

Hispanic Both Sexes 00887 00030 00117 00206 00398 00850 01769 03632 05888 07209 01294Males 00908 00035 00147 00256 00455 00932 01924 03940 06326 08003 01420Females 00866 00024 00086 00151 00337 00766 01616 03360 05552 06719 01185

Table 1925Non-Hodgkin Lymphoma

Estimated United States Cancer Prevalence Countsa on January 1 2016By RaceEthnicity Sex and Years Since Diagnosis

Estimated prevalence percenta on January 1 2016 of the SEER population diagnosed in the previous 24 yearsBy Age at Prevalence RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 372 452924 -05 62 18862 04 247 189692 -05 1657 244370 -05

1 Hodgkin Lymphoma 28 32262 -17 13 3927 -06 33 22556 -15 39 5779 -31

2 Non-Hodgkin lymphoma 336 409991 -03 48 14693 04 210 163591 -03 1572 231707 -042(a) Non-Hodgkin lymphoma B-cell 311 380349 -01 39 11836 14 190 148768 -02 1491 219745 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 15 16631 20 31 9416 10 07 5203 39 14 2012 252(a) 2 Mature Non-Hodgkin lymphoma B-cell 280 343965 -04 07 2271 30 174 137225 -05 1387 204469 -042(a) 21 ChronicSmallProlymphocytic 69 85601 -13 00 35 - 35 29103 -11 382 56463 -14

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 61 75061 -15 00 30 - 31 25339 -13 336 49692 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 311 19 - - - 00 72 - 02 234 262(a) 213 Mantle-cell lymphoma 08 10229 03 - - - 04 3692 02 44 6537 04

2(a) 22 Lymphoplasmacytic lymphoma 07 8651 00 - - - 03 2590 -11 41 6059 04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 03 3667 -03 - - - 01 1132 -18 17 2533 022(a) 222 Waldenstrom macroglubulinemia 04 4984 03 - - - 02 1458 -07 24 3526 06

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 72 87188 00 03 925 26 48 36480 -02 339 49783 022(a) 231 DLBCL NOSc 71 85899 -01 03 861 12 46 35469 -05 337 49569 012(a) 232 Intravascular large B-cell 00 162 - - - - 00 63 - 01 99 -

lymphoma2(a) 233 Primary effusion lymphoma 00 181 27 - - - 00 126 - 00 55 -2(a) 234 Mediastinal large B-cell 01 946 116 00 64 - 01 822 111 00 60 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 04 4692 -26 03 1028 32 04 2618 -43 07 1046 -432(a) 25 Marginal-zone lymphoma (MZL) 22 26534 00 00 137 13 14 11049 05 104 15348 -042(a) 251 Splenic MZL 02 2418 04 - - - 01 889 -08 10 1529 102(a) 252 Extranodal MZL MALTc type 13 15979 06 00 92 - 09 7148 11 59 8739 032(a) 253 Nodal MZL 07 8137 -15 00 45 - 04 3012 -05 34 5080 -20

2(a) 26 Follicular lymphoma 35 43582 -21 00 119 - 28 21725 -25 147 21738 -182(a) 27 Hairy-cell leukemia 03 3712 -16 - - - 03 2311 -19 09 1401 -122(a) 28 Plasma cell neoplasms 68 83957 08 00 24 - 39 31325 12 358 52608 062(a) 281 Plasmacytoma 04 4879 -04 00 16 - 03 2362 -06 17 2501 -032(a) 282 Multiple myeloma 64 79078 09 - - - 36 28963 14 341 50107 07

plasma-cell leukemia2(a) 29 Heavy chain disease 00 48 - - - - 00 24 - 00 23 -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 16 19753 33 00 149 27 08 6340 37 90 13264 32

Table 1926All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 23 27222 01 08 2502 18 19 13933 03 73 10787 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 616 - 01 293 - 00 272 - 00 51 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 22 26531 11 07 2207 75 19 13621 12 73 10703 -042(b) 21 Mycosis fungoidesSezary syndrome 06 6969 18 01 213 84 06 4080 23 18 2676 052(b) 211 Mycosis fungoides 06 6739 17 01 213 84 05 3990 22 17 2536 042(b) 212 Sezary syndrome 00 230 46 - - - 00 90 - 01 140 -

2(b) 22 Peripheral T-cell lymphoma 12 14531 -10 02 534 07 10 7159 -09 46 6838 -122(b) 221 Peripheral T-cell lymphoma NOSc 04 5393 -01 00 86 - 03 2489 04 19 2818 -042(b) 222 Angioimmunoblastic T-cell lymphoma 02 1902 02 - - - 01 699 -09 08 1201 072(b) 223 Subcutaneous panniculitis- 00 176 44 00 31 - 00 111 - 00 34 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 2523 -36 01 291 00 02 1450 -33 05 782 -54

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 139 - - - - 00 98 - 00 28 -2(b) 226 Enteropathy-type T-cell lymphoma 00 186 -02 - - - 00 84 - 01 101 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 2963 -07 00 59 - 02 1575 01 09 1329 -142(b) 228 Primary cutaneous anaplastic 01 1249 -41 00 51 - 01 653 -49 04 545 -39

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 03 3417 96 05 1428 101 02 1474 99 03 515 672(b) 24 NKcT-cell lymphoma nasal-type 01 985 02 00 26 - 01 659 00 02 300 05

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 120 - - - - 00 54 - 00 65 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 509 30 - - - 00 195 -05 02 309 442(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 75 - - - - 00 40 - 00 33 -2(c) Non-Hodgkin lymphoma unknown lineage 02 2420 -274 01 355 - 01 890 -216 08 1175 -2792(c) 1 Precursor lymphoblastic leukemia 01 814 -283 01 343 - 00 238 - 02 233 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 95 - - - - 00 25 - 00 69 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 1511 -274 - - - 01 627 -202 06 873 -319

lineage2() 1 Total precursor lymphomaleukemiad 16 18061 -07 33 10052 -15 08 5713 06 15 2296 -01

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 762 273 00 20 - 00 339 227 03 403 -lymphoma

4 Lymphoid neoplasm NOSc 08 9909 -55 01 222 113 04 3206 -59 43 6481 -59

Table 1926 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 461 253152 -05 70 10973 05 294 110367 -07 2122 131812 -05

1 Hodgkin Lymphoma 31 17710 -17 13 2118 -03 36 12525 -16 48 3067 -31

2 Non-Hodgkin lymphoma 419 229772 -03 56 8711 05 252 95756 -05 2017 125305 -032(a) Non-Hodgkin lymphoma B-cell 387 212247 -02 44 6786 15 227 86941 -04 1908 118520 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 16 8999 24 33 5123 11 08 2888 46 16 988 292(a) 2 Mature Non-Hodgkin lymphoma B-cell 351 192801 -05 10 1558 28 210 80417 -08 1783 110826 -042(a) 21 ChronicSmallProlymphocytic 96 52411 -15 00 21 - 47 18927 -14 539 33463 -15

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 82 44988 -17 00 19 - 40 16143 -16 464 28826 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 193 -02 - - - 00 46 - 02 145 052(a) 213 Mantle-cell lymphoma 13 7230 -01 - - - 07 2738 -01 72 4492 -01

2(a) 22 Lymphoplasmacytic lymphoma 10 5082 -05 - - - 04 1524 -08 58 3558 -04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 04 2062 -08 - - - 02 616 -12 23 1446 -072(a) 222 Waldenstrom macroglubulinemia 06 3020 -02 - - - 02 908 -06 34 2112 -02

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 88 48128 01 03 554 22 59 21824 -06 418 25750 052(a) 231 DLBCL NOSc 87 47520 00 03 519 03 57 21366 -08 416 25635 042(a) 232 Intravascular large B-cell 00 75 - - - - 00 31 - 01 44 -

lymphoma2(a) 233 Primary effusion lymphoma 00 167 26 - - - 00 123 - 01 44 -2(a) 234 Mediastinal large B-cell 01 366 155 00 35 - 01 304 142 00 27 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 06 3388 -22 05 775 31 06 1969 -46 10 644 -192(a) 25 Marginal-zone lymphoma (MZL) 22 12351 -02 01 98 - 14 5177 -02 114 7076 -012(a) 251 Splenic MZL 02 1164 14 - - - 01 434 18 12 730 112(a) 252 Extranodal MZL MALTc type 13 7268 07 00 62 - 09 3267 04 63 3939 102(a) 253 Nodal MZL 07 3919 -23 00 36 - 04 1476 -22 39 2407 -23

2(a) 26 Follicular lymphoma 39 21788 -19 01 100 - 30 11210 -25 165 10478 -152(a) 27 Hairy-cell leukemia 05 2984 -18 - - - 05 1908 -20 17 1076 -152(a) 28 Plasma cell neoplasms 85 46642 07 - - - 45 17864 11 462 28769 052(a) 281 Plasmacytoma 05 2997 -08 - - - 04 1509 -16 24 1484 -012(a) 282 Multiple myeloma 80 43645 08 - - - 41 16355 13 439 27285 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 27 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 20 10447 34 01 105 - 10 3636 40 110 6706 32

Table 1927All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 29 16118 00 11 1730 14 23 8235 02 98 6153 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 430 - 01 208 - 01 188 - 01 34 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 28 15642 11 10 1521 71 22 8022 11 97 6099 -032(b) 21 Mycosis fungoidesSezary syndrome 07 3962 19 01 135 - 06 2261 21 25 1566 092(b) 211 Mycosis fungoides 07 3831 20 01 135 - 06 2213 21 23 1483 092(b) 212 Sezary syndrome 00 131 - - - - 00 48 - 01 83 -

2(b) 22 Peripheral T-cell lymphoma 15 8438 -13 02 318 -09 12 4248 -12 62 3872 -132(b) 221 Peripheral T-cell lymphoma NOSc 06 3159 -05 00 49 - 04 1520 02 26 1590 -082(b) 222 Angioimmunoblastic T-cell lymphoma 02 1024 19 - - - 01 415 11 10 607 232(b) 223 Subcutaneous panniculitis- 00 68 - - - - 00 39 - 00 16 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 03 1549 -39 01 184 -01 02 888 -43 08 477 -45

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 98 - - - - 00 69 - 00 18 -2(b) 226 Enteropathy-type T-cell lymphoma 00 105 - - - - 00 50 - 01 54 -2(b) 227 Cutaneous T-cell lymphoma NOSc 03 1696 -12 00 32 - 02 894 -03 12 770 -172(b) 228 Primary cutaneous anaplastic 01 739 -48 00 26 - 01 373 -49 05 340 -49

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 04 2253 97 07 1047 92 03 940 98 04 266 1022(b) 24 NKcT-cell lymphoma nasal-type 01 638 -05 00 18 - 01 435 -03 03 185 -06

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 58 - - - - 00 22 - 01 36 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 01 293 45 - - - 00 116 - 03 174 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 46 - - - - 00 25 - 00 20 -2(c) Non-Hodgkin lymphoma unknown lineage 03 1407 -232 01 195 - 02 580 -184 10 632 -2302(c) 1 Precursor lymphoblastic leukemia 01 474 -228 01 187 - 00 134 - 02 153 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 49 - - - - - - - 01 36 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 02 884 -239 - - - 01 433 -175 07 443 -

lineage2() 1 Total precursor lymphomaleukemiad 18 9903 -06 35 5518 -17 09 3210 09 19 1175 05

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 435 271 - - - 01 215 - 03 207 -lymphoma

4 Lymphoid neoplasm NOSc 10 5235 -59 01 131 - 05 1871 -65 54 3233 -61

Table 1927 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 301 199772 -05 53 7889 02 202 79325 -02 1322 112558 -08

1 Hodgkin Lymphoma 24 14552 -16 12 1809 -10 29 10031 -14 32 2712 -32

2 Non-Hodgkin lymphoma 269 180219 -03 40 5982 03 170 67835 00 1251 106402 -062(a) Non-Hodgkin lymphoma B-cell 250 168102 -01 34 5050 13 154 61827 02 1190 101225 -042(a) 1 Precursor Non-Hodgkin lymphoma B-cell 14 7632 16 29 4293 09 06 2315 29 12 1024 202(a) 2 Mature Non-Hodgkin lymphoma B-cell 223 151164 -04 05 713 35 141 56808 -01 1102 93643 -072(a) 21 ChronicSmallProlymphocytic 48 33190 -13 - - - 24 10176 -05 268 23000 -16

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 43 30073 -15 - - - 22 9196 -06 243 20866 -19

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 118 - - - - 00 26 - 01 89 -2(a) 213 Mantle-cell lymphoma 04 2999 11 - - - 02 954 10 24 2045 12

2(a) 22 Lymphoplasmacytic lymphoma 05 3569 04 - - - 03 1066 -16 30 2501 11Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 02 1605 01 - - - 01 516 -25 13 1087 112(a) 222 Waldenstrom macroglubulinemia 03 1964 06 - - - 01 550 -08 17 1414 11

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 58 39060 00 02 371 33 38 14656 03 283 24033 -032(a) 231 DLBCL NOSc 57 38379 -02 02 342 27 36 14103 -01 282 23934 -032(a) 232 Intravascular large B-cell 00 87 - - - - 00 32 - 01 55 -

lymphoma2(a) 233 Primary effusion lymphoma - - - - - - - - - - - -2(a) 234 Mediastinal large B-cell 01 580 91 00 29 - 02 518 93 00 33 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 02 1304 -34 02 253 38 02 649 -37 05 402 -852(a) 25 Marginal-zone lymphoma (MZL) 21 14183 01 00 39 - 15 5872 12 98 8272 -062(a) 251 Splenic MZL 02 1254 -07 - - - 01 455 -32 10 799 072(a) 252 Extranodal MZL MALTc type 13 8711 06 00 30 - 10 3881 17 57 4800 -032(a) 253 Nodal MZL 06 4218 -07 - - - 04 1536 11 32 2673 -18

2(a) 26 Follicular lymphoma 33 21794 -24 00 19 - 27 10515 -25 134 11260 -222(a) 27 Hairy-cell leukemia 01 728 -12 - - - 01 403 -11 04 325 -122(a) 28 Plasma cell neoplasms 55 37315 08 - - - 33 13461 15 282 23839 052(a) 281 Plasmacytoma 03 1882 00 - - - 02 853 12 12 1017 -092(a) 282 Multiple myeloma 52 35433 09 - - - 30 12608 15 270 22822 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 21 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 14 9306 32 00 44 - 07 2704 32 76 6558 31

Table 1928All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 17 11104 01 05 772 29 15 5698 05 55 4634 -112(b) 1 Precursor Non-Hodgkin lymphoma T-cell 00 186 - 01 85 - 00 84 - 00 17 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 17 10889 09 05 686 83 15 5599 12 54 4604 -092(b) 21 Mycosis fungoidesSezary syndrome 05 3007 15 01 78 - 05 1819 26 13 1110 -042(b) 211 Mycosis fungoides 05 2908 12 01 78 - 05 1777 23 12 1053 -072(b) 212 Sezary syndrome 00 99 - - - - 00 42 - 01 57 -

2(b) 22 Peripheral T-cell lymphoma 09 6093 -08 01 216 30 08 2911 -06 35 2966 -142(b) 221 Peripheral T-cell lymphoma NOSc 03 2234 03 00 37 - 03 969 07 14 1228 -012(b) 222 Angioimmunoblastic T-cell lymphoma 01 878 -22 - - - 01 284 -39 07 594 -152(b) 223 Subcutaneous panniculitis- 00 108 - 00 18 - 00 72 - 00 18 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 974 -33 01 107 - 02 562 -19 04 305 -77

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 41 - - - - 00 29 - - - -2(b) 226 Enteropathy-type T-cell lymphoma 00 81 - - - - 00 34 - 01 47 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 1267 00 00 27 - 02 681 07 07 559 -102(b) 228 Primary cutaneous anaplastic 01 510 -34 00 25 - 01 280 -50 02 205 -33

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 02 1164 96 03 381 127 01 534 97 03 249 302(b) 24 NKcT-cell lymphoma nasal-type 01 347 11 - - - 01 224 - 01 115 -

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 62 - - - - 00 32 - 00 29 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 216 03 - - - 00 79 - 02 135 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 29 - - - - - - - - - -2(c) Non-Hodgkin lymphoma unknown lineage 02 1013 -341 01 160 - 01 310 - 06 543 -2(c) 1 Precursor lymphoblastic leukemia 01 340 - 01 156 - 00 104 - 01 80 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 46 - - - - - - - 00 33 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 627 - - - - 01 194 - 05 430 -

lineage2() 1 Total precursor lymphomaleukemiad 14 8158 -09 31 4534 -13 07 2503 02 13 1121 -11

3 Composite Hodgkin lymphoma and Non-Hodgkin 00 327 - - - - 00 124 - 02 196 -lymphoma

4 Lymphoid neoplasm NOSc 07 4674 -52 01 91 - 03 1335 -51 36 3248 -58

Table 1928 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 12: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 5222 2506 2704 3176 3627 3994 4570 4729 5325 5260 5263 5562 5775 6226 6401 6704 6998 7072 11154

SEER 9 except 4285 2088 2267 2603 2819 3091 3507 3694 4159 4249 4364 4515 4818 5209 5398 5628 5841 6015 9363SF-Oakland

San Francisco- 937 418 437 573 808 903 1063 1035 1166 1011 899 1047 957 1017 1003 1076 1157 1057 1791Oakland SMSAc

San Francisco 245 96 123 210 326 393 467 410 450 354 213 256 220 283 219 216 240 225 362CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 134 155 161 183 201 215 234 233 252 244 238 244 246 258 254 255 255 245 244

SEER 9 except 132 154 161 181 188 201 217 218 236 236 235 236 244 256 254 253 252 247 243SF-Oakland

San Francisco- 147 158 160 194 267 285 317 305 335 288 252 286 256 266 256 263 268 235 246Oakland SMSAc

San Francisco 143 144 176 293 444 519 610 523 574 448 274 325 269 354 265 257 273 252 246CityCounty

Table 1912

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males All Ages

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males All Ages

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 0-19 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 223 87 108 91 94 84 100 89 120 105 104 119 127 107 106 143 134 155 240

SEER 9 except 191 78 95 82 80 76 86 74 107 84 93 100 115 90 87 114 119 129 198SF-Oakland

San Francisco- 32 9 13 9 14 8 14 15 13 21 11 19 12 17 19 29 15 26 42Oakland SMSAc

San Francisco 9 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 5 lt4 6 lt4CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 12 12 16 14 14 13 15 13 17 14 14 15 16 14 13 18 17 20 20

SEER 9 except 12 13 16 14 14 13 15 12 17 13 14 15 17 13 13 16 17 19 19SF-Oakland

San Francisco- 14 10 15 10 16 09 15 16 13 21 11 18 12 17 19 28 14 25 27Oakland SMSAc

San Francisco 23 - - - - - - - - - - - - - - 40 - 49 -CityCounty

Table 1913

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 0-19

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 0-19

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 20-54 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 1463 687 723 958 1211 1413 1766 1830 2089 1770 1608 1696 1623 1722 1655 1693 1674 1596 2242

SEER 9 except 1208 563 588 730 827 923 1195 1294 1483 1325 1269 1327 1308 1410 1383 1401 1402 1328 1848SF-Oakland

San Francisco- 255 124 135 228 384 490 571 536 606 445 339 369 315 312 272 292 272 268 394Oakland SMSAc

San Francisco 58 29 34 105 215 288 333 303 317 225 105 115 111 111 86 75 73 71 98CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 69 79 82 104 124 136 159 156 169 138 121 124 117 123 116 118 116 111 104

SEER 9 except 69 78 81 97 103 109 131 134 144 123 115 116 112 119 115 116 115 110 103SF-Oakland

San Francisco- 69 84 89 139 226 264 295 267 298 213 156 164 139 141 123 130 118 114 110Oakland SMSAc

San Francisco 67 88 94 272 565 715 813 724 744 510 230 252 239 248 194 162 152 145 129CityCounty

Table 1914

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 20-54

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 20-54

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 55+ and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 3536 1732 1873 2127 2322 2497 2704 2810 3116 3385 3551 3747 4025 4397 4640 4868 5190 5321 8672

SEER 9 except 2886 1447 1584 1791 1912 2092 2226 2326 2569 2840 3002 3088 3395 3709 3928 4113 4320 4558 7317SF-Oakland

San Francisco- 650 285 289 336 410 405 478 484 547 545 549 659 630 688 712 755 870 763 1355Oakland SMSAc

San Francisco 178 65 88 104 109 105 132 106 130 126 106 141 108 169 131 136 164 148 261CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 451 522 540 596 633 673 701 706 761 800 811 831 858 900 901 891 899 862 871

SEER 9 except 440 521 544 601 620 667 687 692 744 797 813 813 858 901 904 891 888 874 874SF-Oakland

San Francisco- 508 528 520 571 702 703 773 783 854 821 800 932 855 894 888 890 959 800 860Oakland SMSAc

San Francisco 482 446 598 727 739 757 934 747 914 872 727 934 690 1047 764 769 889 776 826CityCounty

Table 1915

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 55+

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 55+

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 003 006 217 072 Asian 0 001 003 005 183 072

10 002 005 011 218 073 Pacific 10 002 004 009 184 073

20 003 009 021 217 073 Islander 20 003 007 015 182 073

30 006 018 042 216 073 30 005 013 029 180 073

40 012 037 082 213 074 40 008 024 057 176 073

50 025 072 139 206 074 50 017 049 101 170 073

60 049 120 177 191 075 60 034 087 139 158 072

70 080 144 - 160 072 70 056 112 - 133 068

80 085 - - 106 062 80 066 - - 091 056

White 0 001 003 006 227 075 American 0 001 002 003 116 049

10 002 005 011 228 076 Indian 10 002 002 005 117 050

20 003 009 021 227 076 Alaska 20 001 003 008 116 050

30 006 018 043 226 077 Nativea 30 003 007 022 117 051

40 012 038 085 223 077 40 004 019 041 117 052

50 026 075 147 217 078 50 016 038 078 118 053

60 052 127 187 201 078 60 024 067 105 109 055

70 085 153 - 169 076 70 048 091 - 096 055

80 090 - - 111 065 80 057 - - 064 043

Black 0 001 002 006 138 042 Hispanicb 0 001 002 005 222 073

10 002 005 011 140 043 10 001 004 009 223 074

20 003 010 022 139 043 20 003 008 019 222 074

30 006 019 041 137 043 30 005 016 040 221 074

40 013 035 068 133 043 40 011 035 078 218 074

50 023 057 093 125 043 50 024 068 133 211 074

60 037 076 102 110 042 60 046 114 173 195 074

70 047 078 - 087 038 70 075 140 - 164 070

80 044 - - 057 032 80 081 - - 112 057

Table 1916

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Both Sexes 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 004 007 243 081 Asian 0 001 003 006 213 085

10 002 006 013 244 082 Pacific 10 002 005 011 213 086

20 004 010 024 243 082 Islander 20 003 009 018 211 086

30 007 021 049 243 083 30 006 015 034 210 086

40 014 042 094 240 084 40 009 028 067 205 086

50 029 082 158 233 085 50 019 059 117 199 086

60 057 139 203 219 086 60 041 101 161 187 085

70 095 170 - 188 084 70 066 131 - 159 082

80 105 - - 130 073 80 080 - - 114 069

White 0 001 004 007 254 085 American 0 001 003 004 104 057

10 002 006 013 255 086 Indian 10 002 003 006 105 058

20 004 010 024 254 086 Alaska 20 001 004 008 103 058

30 007 020 049 253 087 Nativea 30 003 008 021 104 059

40 014 043 097 251 088 40 005 018 038 105 060

50 030 086 167 244 089 50 014 035 071 105 062

60 059 147 215 230 090 60 023 062 094 099 065

70 101 180 - 198 088 70 046 084 - 090 066

80 112 - - 136 076 80 053 - - 061 053

Black 0 001 003 007 152 046 Hispanicb 0 001 003 005 238 083

10 002 006 014 154 047 10 002 005 011 239 084

20 004 012 027 153 047 20 003 009 021 238 084

30 008 023 048 152 047 30 006 018 043 238 084

40 016 042 079 148 047 40 012 037 083 235 085

50 027 066 105 138 047 50 026 073 145 228 085

60 043 087 114 123 045 60 050 126 189 214 085

70 054 088 - 099 042 70 086 157 - 185 081

80 053 - - 070 036 80 094 - - 131 066

Table 1917

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Males 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 002 004 193 064 Asian 0 001 002 004 159 063

10 001 004 009 195 064 Pacific 10 001 004 008 160 063

20 003 007 017 194 064 Islander 20 002 006 013 159 063

30 005 015 036 192 065 30 004 011 025 157 063

40 010 031 071 189 065 40 007 021 048 153 063

50 022 062 120 182 065 50 014 042 087 148 063

60 042 103 154 168 065 60 028 074 122 136 062

70 067 123 - 138 063 70 049 099 - 114 058

80 071 - - 090 054 80 057 - - 075 047

White 0 001 002 004 203 067 American 0 000 001 002 128 043

10 001 004 009 204 067 Indian 10 001 001 004 129 044

20 002 007 017 203 067 Alaska 20 001 003 007 128 044

30 005 015 037 201 067 Nativea 30 002 006 023 129 044

40 010 032 074 198 068 40 004 021 044 129 045

50 022 065 127 192 068 50 017 042 085 129 046

60 044 109 163 177 068 60 026 072 113 118 047

70 072 130 - 146 066 70 050 097 - 102 046

80 075 - - 094 056 80 060 - - 066 037

Black 0 000 002 004 126 040 Hispanicb 0 001 002 004 210 065

10 001 004 009 128 040 10 001 004 008 211 066

20 003 008 018 127 040 20 002 007 017 211 066

30 005 015 034 125 040 30 004 014 036 209 066

40 010 029 058 122 040 40 010 032 073 206 066

50 020 049 083 115 040 50 022 064 123 198 066

60 032 068 094 102 039 60 043 104 161 182 065

70 041 071 - 080 036 70 066 127 - 149 062

80 039 - - 051 030 80 073 - - 100 051

Table 1918

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Females 2014-2016 By RaceEthnicity

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

The AAPC is the Average Annual Percent Change over the time interval The AAPCs are calculated bythe Joinpoint Regression Program Version 47 February 2019 National Cancer Institute

- Statistic not shown Rate based on less than 16 cases for the time intervalTrend based on less than 10 cases for at least one year within the time interval

a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) Trendsare based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico SeattleUtah and AtlantaThe SEER 21 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the AlaskaNative Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts

c The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 3 Joinpoints overdiagnosis years 2000-2016

d The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 5 Joinpoints overdiagnosis years 1975-2016

e Hispanic and Non-Hispanic are not mutually exclusive from whites blacks AsianPacificIslanders and American IndiansAlaska Natives Incidence data for Hispanics and Non-Hispanicsare based on NHIA and exclude cases from the Alaska Native Registry

f Incidence data for American IndianAlaska Native are based on the PurchasedReferred CareDelivery Area (PRCDA) counties

g US Mortality Files National Center for Health Statistics CDCh The 2007-2016 mortality AAPCs are based on a Joinpoint analysis using years of death 2000-2016 The APC is significantly different from zero (plt05)

SEER Incidence SEER 21 Areasb SEER 21 Areasb SEER 9 Areasb

Rate 2012-2016 Trend 2007-2016c Trend 2007-2016d

Rate per 100000 persons AAPC () AAPC ()

Total Males Females Total Males Females Total Males Females RaceEthnicity

All Races 196 239 162 -07 -09 -08 -09 -07 -08

White 206 250 170 -08 -11 -09 -09 -08 -08White Hispanice 183 212 161 -08 -03 -05 - - -White Non-Hispanice 210 256 172 -08 -06 -10 - - -

Black 147 177 124 01 00 03 00 -04 -09

AsianPacific Islander 134 164 110 00 00 -01 - - -

Amer IndAlaska Natf 113 120 106 -05 -12 00 - - -

Hispanice 179 207 157 -05 -02 03 - - -

US Mortalityg Rate 2012-2016 Trend 2007-2016h

Rate per 100000 persons AAPC ()

Total Males Females Total Males FemalesRaceEthnicity

All Races 56 73 44 -23 -20 -27

White 59 76 45 -23 -20 -27White Hispanice 51 65 40 -16 -13 -20White Non-Hispanice 59 76 46 -23 -20 -27

Black 41 52 33 -20 -19 -21

AsianPacific Islander 39 49 31 -17 -15 -19

Amer IndAlaska NatTotal US 31 40 24 -32 -20 -45PRCDA Counties 44 58 33 -21 -04 -37Non-PRCDA Counties 17 21 14 -54 -50 -60

Hispanice 48 61 38 -17 -14 -21

Table 1919Non-Hodgkin Lymphoma

SEER Incidence and US MortalityAge-Adjusted Rates and Trendsa

By RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Incidence Ratesa 2012-2016

California 1844 2241 1515 1938 2349 1591 1390 1639 1182Greater Bay Area 1957 2381 1600 2144 2601 1755 1628 1828 1436San Francisco-Oakland 1956 2421 1570 2174 2660 1765 1603 1816 1408San Jose-Monterey 1962 2311 1660 2097 2503 1742 1800 1891 1646

Los Angeles 1804 2176 1505 1951 2331 1637 1357 1659 1139Greater California 1822 2220 1489 1876 2286 1529 1314 1534 1113

Connecticut 2116 2607 1733 2154 2642 1771 1386 1829 1051Detroit 2132 2636 1742 2290 2850 1847 1620 1905 1409Georgia 1826 2244 1487 1936 2346 1588 1462 1833 1187Atlanta 1925 2381 1555 2119 2567 1736 1601 2034 1272Rural Georgia 1584 1790 1401 1953 2298 1567 807 - 988Greater Georgia 1784 2186 1459 1872 2274 1537 1380 1703 1146

Hawaii 1660 2024 1349 1958 2275 1593 - - -Idaho 1922 2267 1616 1920 2262 1618 - - -Iowa 2134 2601 1756 2148 2612 1773 1352 1602 1100Kentucky 2039 2505 1666 2070 2538 1693 1403 1788 1112Louisiana 1944 2352 1614 2106 2537 1744 1469 1769 1237Massachusetts 1810 2181 1518 1830 2214 1524 1452 1655 1299New Jersey 2155 2607 1804 2285 2765 1905 1387 1621 1222New Mexico 1550 1739 1387 1580 1798 1394 875 - -New York 2152 2620 1788 2306 2792 1915 1545 1852 1333Seattle-Puget Sound 2116 2627 1695 2177 2667 1766 1631 1973 1316Utah 1843 2233 1498 1862 2258 1513 2089 - -

SEER 9 Areasb 1992 2444 1623 2095 2551 1716 1573 1914 1298SEER 13 Areasb 1946 2373 1597 2064 2502 1700 1519 1853 1258SEER 18 Areasb 1933 2354 1590 2031 2464 1671 1449 1751 1214SEER 21 Areasb 1963 2388 1620 2061 2498 1702 1471 1771 1245

Table 1920Non-Hodgkin Lymphoma

Age-Adjusted SEER Incidence Ratesa

By Registry Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control and PreventionRates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and AtlantaThe SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Death Ratesa 2012-2016

California 533 677 423 570 726 449 417 480 367Greater Bay Area 505 671 376 561 756 408 410 491 331San Francisco-Oakland 503 667 376 555 742 409 416 490 343San Jose-Monterey 511 681 377 573 781 407 - - -

Los Angeles 541 670 443 589 728 481 424 503 371Greater California 539 682 429 564 716 447 416 455 384

Connecticut 533 705 407 547 717 421 350 510 244Detroit 639 822 505 693 895 542 443 528 384Georgia 533 697 411 580 747 450 376 503 286Atlanta 492 659 372 533 728 388 397 506 317Rural Georgia 559 731 388 670 813 507 - - -Greater Georgia 549 712 426 595 755 470 363 500 266

Hawaii 475 620 352 545 649 412 - - -Idaho 635 775 510 641 782 516 - - -Iowa 638 845 484 642 848 488 - - -Kentucky 642 886 460 655 904 470 401 557 284Louisiana 608 814 451 651 863 485 461 623 340Massachusetts 523 659 423 541 682 436 347 410 297New Jersey 545 721 419 585 780 443 372 466 314New Mexico 488 585 405 493 595 406 - - -New York 535 702 412 575 752 441 390 514 313Seattle-Puget Sound 585 749 463 604 769 480 490 562 397Utah 542 670 433 551 681 440 - - -

SEER 9 Areasb 555 719 430 586 758 454 414 522 333SEER 13 Areasb 549 705 429 586 753 457 419 521 342SEER 18 Areasb 554 717 431 589 761 456 409 518 329SEER 21 Areasb 550 712 428 584 754 453 401 513 322

Total US 562 725 436 586 755 454 408 518 330

Table 1921Non-Hodgkin Lymphoma

Age-Adjusted SEER Death Ratesa

By Registry Race and Sex

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 562 002

High Five StatesMichigan 645 011 01(0112) 1479Kentucky 642 016 02(0118) 1424Iowa 638 018 03(0120) 1367Indiana 638 013 04(0117) 1361Idaho 635 027 05(0126) 1303

Low Five StatesNevada 511 019 47(2251) -899Colorado 491 014 48(3851) -1257New Mexico 488 020 49(2851) -1317Hawaii 475 024 50(3051) -1542c

DC 444 039 51(2351) -2097c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 545 014 28(1847) -291 Montana 559 030 25(0250) -042Alaska 525 047 43(0151) -654 Nebraska 563 023 22(0548) 026Arizona 512 012 46(2950) -886 Nevada 511 019 47(2251) -899Arkansas 555 018 26(1247) -113 New Hampshire 562 027 23(0349) 014California 533 005 40(2645) -508 New Jersey 545 010 29(2045) -301Colorado 491 014 48(3851) -1257 New Mexico 488 020 49(2851) -1317Connecticut 533 016 39(1949) -505 New York 535 007 37(2446) -478Delaware 628 033 08(0139) 1174 North Carolina 541 010 35(2146) -363DC 444 039 51(2351) -2097c North Dakota 561 037 24(0151) -007Florida 535 006 38(2545) -479 Ohio 616 009 10(0220) 969Georgia 533 011 41(2248) -511 Oklahoma 630 017 06(0121) 1226Hawaii 475 024 50(3051) -1542c Oregon 612 016 11(0124) 903Idaho 635 027 05(0126) 1303 Pennsylvania 603 009 16(0622) 729Illinois 566 009 20(1634) 085 Rhode Island 542 029 32(0651) -350Indiana 638 013 04(0117) 1361 South Carolina 542 014 31(1847) -347Iowa 638 018 03(0120) 1367 South Dakota 541 033 36(0451) -364Kansas 585 019 19(0439) 420 Tennessee 629 013 07(0119) 1198Kentucky 642 016 02(0118) 1424 Texas 546 007 27(2142) -277Louisiana 608 016 14(0125) 826 Utah 542 022 33(1250) -352Maine 609 026 13(0137) 852 Vermont 605 040 15(0148) 770Maryland 524 013 44(2349) -663 Virginia 544 011 30(2046) -319Massachusetts 523 012 45(2549) -687 Washington 599 013 17(0425) 665Michigan 645 011 01(0112) 1479 West Virginia 612 022 12(0132) 894Minnesota 617 014 09(0122) 984 Wisconsin 590 013 18(0629) 507Mississippi 531 018 42(1850) -551 Wyoming 564 043 21(0151) 050Missouri 542 012 34(1947) -354

Table 1922Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males and Females

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 725 003

High Five StatesKentucky 886 030 01(0112) 2213c

Iowa 845 032 02(0120) 1647c

Michigan 842 019 03(0114) 1615c

Indiana 839 024 04(0116) 1567c

Delaware 824 058 05(0144) 1364

Low Five StatesArizona 635 019 47(3251) -1244Alaska 630 075 48(0251) -1311Hawaii 620 041 49(1951) -1452DC 614 071 50(0551) -1535c

New Mexico 585 033 51(3451) -1928c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 688 025 36(1649) -513 Montana 709 050 26(0251) -218Alaska 630 075 48(0251) -1311 Nebraska 737 040 20(0248) 165Arizona 635 019 47(3251) -1244 Nevada 653 032 44(1951) -994Arkansas 721 031 22(0747) -061 New Hampshire 710 046 25(0451) -210California 677 009 41(2846) -666 New Jersey 721 018 21(1441) -059Colorado 643 024 46(2451) -1133 New Mexico 585 033 51(3451) -1928c

Connecticut 705 028 28(1248) -273 New York 702 012 30(1943) -323Delaware 824 058 05(0144) 1364 North Carolina 709 018 27(1644) -221DC 614 071 50(0551) -1535c North Dakota 682 061 39(0251) -598Florida 683 011 37(2446) -585 Ohio 800 017 09(0320) 1029Georgia 697 019 34(1746) -387 Oklahoma 806 030 08(0126) 1109Hawaii 620 041 49(1951) -1452 Oregon 794 028 12(0128) 947Idaho 775 045 16(0146) 692 Pennsylvania 783 015 15(0523) 794Illinois 739 016 19(1235) 190 Rhode Island 649 050 45(1051) -1050Indiana 839 024 04(0116) 1567c South Carolina 681 025 40(1850) -604Iowa 845 032 02(0120) 1647c South Dakota 701 056 31(0251) -332Kansas 713 032 24(0948) -174 Tennessee 820 023 06(0120) 1311Kentucky 886 030 01(0112) 2213c Texas 698 012 32(2043) -368Louisiana 814 029 07(0122) 1222 Utah 670 036 42(1351) -754Maine 754 045 18(0148) 395 Vermont 794 069 11(0149) 950Maryland 682 023 38(1849) -588 Virginia 694 020 35(1847) -429Massachusetts 659 020 43(2450) -910 Washington 790 022 13(0224) 897Michigan 842 019 03(0114) 1615c West Virginia 774 038 17(0142) 675Minnesota 797 025 10(0224) 995 Wisconsin 786 023 14(0227) 844Mississippi 717 034 23(0748) -110 Wyoming 698 071 33(0151) -377Missouri 702 022 29(1646) -319

Table 1923Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 436 002

High Five StatesIdaho 510 033 01(0139) 1697c

Maine 497 031 02(0141) 1396Michigan 495 012 03(0119) 1340Oklahoma 492 020 04(0128) 1276Indiana 492 016 05(0123) 1270

Low Five StatesMississippi 404 021 47(1351) -731Nevada 382 022 48(2051) -1237Colorado 369 016 49(3451) -1540c

Hawaii 352 027 50(2551) -1932c

DC 323 044 51(1551) -2601c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 440 017 24(0547) 099 Montana 435 036 27(0151) -034Alaska 414 058 38(0151) -500 Nebraska 435 027 26(0249) -032Arizona 407 014 44(2049) -664 Nevada 382 022 48(2051) -1237Arkansas 428 021 31(0649) -181 New Hampshire 454 032 19(0149) 400California 423 006 34(2244) -313 New Jersey 419 012 37(1848) -397Colorado 369 016 49(3451) -1540c New Mexico 405 025 46(0951) -706Connecticut 407 018 45(1550) -669 New York 412 008 39(2548) -554Delaware 473 039 12(0150) 855 North Carolina 420 012 35(1848) -374DC 323 044 51(1551) -2601c North Dakota 471 045 13(0150) 809Florida 412 007 40(2548) -564 Ohio 478 011 10(0123) 967Georgia 411 012 43(2049) -582 Oklahoma 492 020 04(0128) 1276Hawaii 352 027 50(2551) -1932c Oregon 465 019 15(0141) 668Idaho 510 033 01(0139) 1697c Pennsylvania 467 010 14(0427) 714Illinois 439 010 25(1341) 074 Rhode Island 455 035 18(0150) 434Indiana 492 016 05(0123) 1270 South Carolina 432 017 30(0947) -102Iowa 484 021 08(0135) 1087 South Dakota 411 039 42(0151) -580Kansas 486 023 06(0137) 1143 Tennessee 484 015 09(0126) 1087Kentucky 460 018 17(0241) 544 Texas 427 008 32(1944) -213Louisiana 451 018 21(0345) 333 Utah 433 026 28(0250) -081Maine 497 031 02(0141) 1396 Vermont 461 047 16(0151) 578Maryland 411 015 41(1749) -576 Virginia 432 013 29(1246) -092Massachusetts 423 014 33(1548) -303 Washington 452 015 20(0541) 360Michigan 495 012 03(0119) 1340 West Virginia 486 027 07(0143) 1141Minnesota 475 017 11(0132) 901 Wisconsin 443 015 23(0645) 156Mississippi 404 021 47(1351) -731 Wyoming 445 051 22(0151) 192Missouri 419 014 36(1549) -396

Table 1924Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Females

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 Areas (excluding the AlaskaNative Registry) and 112016 US population estimates based on the average of 2015 and 2016 population estimates from theUS Bureau of the CensusPrevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 24 years

b Maximum limited-duration prevalence is 24 years for 1992-2016 datac Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groupsd Cases diagnosed more than 24 years ago were estimated using the completeness index method (Capocaccia et al 1997

Merrill et al 2000)e Complete prevalence is obtained by summing 0 to lt24 and gt=24- Statistic not shown Statistic based on fewer than 5 cases estimated alive in SEER for the time interval+ Not available

Years Since Diagnosis 0 to lt5 5 to lt10 10 to lt15 15 to lt20 20 to lt24 0 to lt24b gt=24d Completee

Race Sex

All Races Both Sexes 248946 177490 117326 69109 31890 644761 49943 694704Males 135137 94173 60159 36020 16581 342069 25489 367558Females 113809 83317 57167 33089 15309 302692 24454 327146

White Both Sexes 213764 154454 101984 60537 28026 558765 49625 620368Males 116527 82172 52535 31627 14543 297404 26526 330121Females 97237 72282 49448 28910 13483 261361 23099 290247

Black Both Sexes 20500 13640 9750 5271 2215 51376 4115 55491Males 10712 7188 4768 2684 1174 26526 1911 28437Females 9789 6452 4981 2587 1041 24850 2204 27054

Asian Both Sexes 8405 5210 3415 1867 844 19741 + +Pacific Males 4548 2661 1757 1013 407 10386 + +Islander Females 3856 2549 1657 855 437 9355 + +

Hispanic Both Sexes 21339 14049 8272 4881 2136 50676 + +Males 10918 7243 4331 2617 1094 26202 + +Females 10421 6805 3941 2264 1043 24474 + +

Age Specific (Crude) Age-Adjustedc Age at Prevalence All Ages 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ All Ages

Race Sex

All Races Both Sexes 02001 00035 00139 00283 00538 01121 02352 04640 08181 10224 01738Males 02156 00044 00189 00354 00625 01293 02710 05243 09364 12449 02023Females 01850 00026 00087 00208 00450 00952 02010 04094 07196 08856 01498

White Both Sexes 02216 00035 00143 00289 00534 01148 02427 04858 08597 10738 01807Males 02380 00045 00198 00359 00622 01317 02790 05442 09778 13060 02095Females 02054 00025 00085 00214 00442 00976 02072 04317 07593 09285 01560

Black Both Sexes 01139 00029 00113 00265 00599 01027 02010 03340 05117 05333 01251Males 01226 00029 00140 00351 00696 01223 02333 03969 05849 06055 01457Females 01059 00030 00086 00178 00510 00853 01728 02836 04608 04976 01088

Asian Both Sexes 00970 00039 00133 00207 00353 00680 01409 02692 04470 06094 01032Pacific Males 01065 00044 00175 00240 00398 00744 01640 03072 05516 07472 01222Islander Females 00882 00033 00092 00175 00312 00623 01209 02384 03629 05207 00880

Hispanic Both Sexes 00887 00030 00117 00206 00398 00850 01769 03632 05888 07209 01294Males 00908 00035 00147 00256 00455 00932 01924 03940 06326 08003 01420Females 00866 00024 00086 00151 00337 00766 01616 03360 05552 06719 01185

Table 1925Non-Hodgkin Lymphoma

Estimated United States Cancer Prevalence Countsa on January 1 2016By RaceEthnicity Sex and Years Since Diagnosis

Estimated prevalence percenta on January 1 2016 of the SEER population diagnosed in the previous 24 yearsBy Age at Prevalence RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 372 452924 -05 62 18862 04 247 189692 -05 1657 244370 -05

1 Hodgkin Lymphoma 28 32262 -17 13 3927 -06 33 22556 -15 39 5779 -31

2 Non-Hodgkin lymphoma 336 409991 -03 48 14693 04 210 163591 -03 1572 231707 -042(a) Non-Hodgkin lymphoma B-cell 311 380349 -01 39 11836 14 190 148768 -02 1491 219745 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 15 16631 20 31 9416 10 07 5203 39 14 2012 252(a) 2 Mature Non-Hodgkin lymphoma B-cell 280 343965 -04 07 2271 30 174 137225 -05 1387 204469 -042(a) 21 ChronicSmallProlymphocytic 69 85601 -13 00 35 - 35 29103 -11 382 56463 -14

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 61 75061 -15 00 30 - 31 25339 -13 336 49692 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 311 19 - - - 00 72 - 02 234 262(a) 213 Mantle-cell lymphoma 08 10229 03 - - - 04 3692 02 44 6537 04

2(a) 22 Lymphoplasmacytic lymphoma 07 8651 00 - - - 03 2590 -11 41 6059 04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 03 3667 -03 - - - 01 1132 -18 17 2533 022(a) 222 Waldenstrom macroglubulinemia 04 4984 03 - - - 02 1458 -07 24 3526 06

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 72 87188 00 03 925 26 48 36480 -02 339 49783 022(a) 231 DLBCL NOSc 71 85899 -01 03 861 12 46 35469 -05 337 49569 012(a) 232 Intravascular large B-cell 00 162 - - - - 00 63 - 01 99 -

lymphoma2(a) 233 Primary effusion lymphoma 00 181 27 - - - 00 126 - 00 55 -2(a) 234 Mediastinal large B-cell 01 946 116 00 64 - 01 822 111 00 60 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 04 4692 -26 03 1028 32 04 2618 -43 07 1046 -432(a) 25 Marginal-zone lymphoma (MZL) 22 26534 00 00 137 13 14 11049 05 104 15348 -042(a) 251 Splenic MZL 02 2418 04 - - - 01 889 -08 10 1529 102(a) 252 Extranodal MZL MALTc type 13 15979 06 00 92 - 09 7148 11 59 8739 032(a) 253 Nodal MZL 07 8137 -15 00 45 - 04 3012 -05 34 5080 -20

2(a) 26 Follicular lymphoma 35 43582 -21 00 119 - 28 21725 -25 147 21738 -182(a) 27 Hairy-cell leukemia 03 3712 -16 - - - 03 2311 -19 09 1401 -122(a) 28 Plasma cell neoplasms 68 83957 08 00 24 - 39 31325 12 358 52608 062(a) 281 Plasmacytoma 04 4879 -04 00 16 - 03 2362 -06 17 2501 -032(a) 282 Multiple myeloma 64 79078 09 - - - 36 28963 14 341 50107 07

plasma-cell leukemia2(a) 29 Heavy chain disease 00 48 - - - - 00 24 - 00 23 -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 16 19753 33 00 149 27 08 6340 37 90 13264 32

Table 1926All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 23 27222 01 08 2502 18 19 13933 03 73 10787 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 616 - 01 293 - 00 272 - 00 51 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 22 26531 11 07 2207 75 19 13621 12 73 10703 -042(b) 21 Mycosis fungoidesSezary syndrome 06 6969 18 01 213 84 06 4080 23 18 2676 052(b) 211 Mycosis fungoides 06 6739 17 01 213 84 05 3990 22 17 2536 042(b) 212 Sezary syndrome 00 230 46 - - - 00 90 - 01 140 -

2(b) 22 Peripheral T-cell lymphoma 12 14531 -10 02 534 07 10 7159 -09 46 6838 -122(b) 221 Peripheral T-cell lymphoma NOSc 04 5393 -01 00 86 - 03 2489 04 19 2818 -042(b) 222 Angioimmunoblastic T-cell lymphoma 02 1902 02 - - - 01 699 -09 08 1201 072(b) 223 Subcutaneous panniculitis- 00 176 44 00 31 - 00 111 - 00 34 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 2523 -36 01 291 00 02 1450 -33 05 782 -54

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 139 - - - - 00 98 - 00 28 -2(b) 226 Enteropathy-type T-cell lymphoma 00 186 -02 - - - 00 84 - 01 101 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 2963 -07 00 59 - 02 1575 01 09 1329 -142(b) 228 Primary cutaneous anaplastic 01 1249 -41 00 51 - 01 653 -49 04 545 -39

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 03 3417 96 05 1428 101 02 1474 99 03 515 672(b) 24 NKcT-cell lymphoma nasal-type 01 985 02 00 26 - 01 659 00 02 300 05

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 120 - - - - 00 54 - 00 65 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 509 30 - - - 00 195 -05 02 309 442(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 75 - - - - 00 40 - 00 33 -2(c) Non-Hodgkin lymphoma unknown lineage 02 2420 -274 01 355 - 01 890 -216 08 1175 -2792(c) 1 Precursor lymphoblastic leukemia 01 814 -283 01 343 - 00 238 - 02 233 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 95 - - - - 00 25 - 00 69 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 1511 -274 - - - 01 627 -202 06 873 -319

lineage2() 1 Total precursor lymphomaleukemiad 16 18061 -07 33 10052 -15 08 5713 06 15 2296 -01

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 762 273 00 20 - 00 339 227 03 403 -lymphoma

4 Lymphoid neoplasm NOSc 08 9909 -55 01 222 113 04 3206 -59 43 6481 -59

Table 1926 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 461 253152 -05 70 10973 05 294 110367 -07 2122 131812 -05

1 Hodgkin Lymphoma 31 17710 -17 13 2118 -03 36 12525 -16 48 3067 -31

2 Non-Hodgkin lymphoma 419 229772 -03 56 8711 05 252 95756 -05 2017 125305 -032(a) Non-Hodgkin lymphoma B-cell 387 212247 -02 44 6786 15 227 86941 -04 1908 118520 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 16 8999 24 33 5123 11 08 2888 46 16 988 292(a) 2 Mature Non-Hodgkin lymphoma B-cell 351 192801 -05 10 1558 28 210 80417 -08 1783 110826 -042(a) 21 ChronicSmallProlymphocytic 96 52411 -15 00 21 - 47 18927 -14 539 33463 -15

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 82 44988 -17 00 19 - 40 16143 -16 464 28826 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 193 -02 - - - 00 46 - 02 145 052(a) 213 Mantle-cell lymphoma 13 7230 -01 - - - 07 2738 -01 72 4492 -01

2(a) 22 Lymphoplasmacytic lymphoma 10 5082 -05 - - - 04 1524 -08 58 3558 -04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 04 2062 -08 - - - 02 616 -12 23 1446 -072(a) 222 Waldenstrom macroglubulinemia 06 3020 -02 - - - 02 908 -06 34 2112 -02

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 88 48128 01 03 554 22 59 21824 -06 418 25750 052(a) 231 DLBCL NOSc 87 47520 00 03 519 03 57 21366 -08 416 25635 042(a) 232 Intravascular large B-cell 00 75 - - - - 00 31 - 01 44 -

lymphoma2(a) 233 Primary effusion lymphoma 00 167 26 - - - 00 123 - 01 44 -2(a) 234 Mediastinal large B-cell 01 366 155 00 35 - 01 304 142 00 27 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 06 3388 -22 05 775 31 06 1969 -46 10 644 -192(a) 25 Marginal-zone lymphoma (MZL) 22 12351 -02 01 98 - 14 5177 -02 114 7076 -012(a) 251 Splenic MZL 02 1164 14 - - - 01 434 18 12 730 112(a) 252 Extranodal MZL MALTc type 13 7268 07 00 62 - 09 3267 04 63 3939 102(a) 253 Nodal MZL 07 3919 -23 00 36 - 04 1476 -22 39 2407 -23

2(a) 26 Follicular lymphoma 39 21788 -19 01 100 - 30 11210 -25 165 10478 -152(a) 27 Hairy-cell leukemia 05 2984 -18 - - - 05 1908 -20 17 1076 -152(a) 28 Plasma cell neoplasms 85 46642 07 - - - 45 17864 11 462 28769 052(a) 281 Plasmacytoma 05 2997 -08 - - - 04 1509 -16 24 1484 -012(a) 282 Multiple myeloma 80 43645 08 - - - 41 16355 13 439 27285 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 27 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 20 10447 34 01 105 - 10 3636 40 110 6706 32

Table 1927All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 29 16118 00 11 1730 14 23 8235 02 98 6153 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 430 - 01 208 - 01 188 - 01 34 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 28 15642 11 10 1521 71 22 8022 11 97 6099 -032(b) 21 Mycosis fungoidesSezary syndrome 07 3962 19 01 135 - 06 2261 21 25 1566 092(b) 211 Mycosis fungoides 07 3831 20 01 135 - 06 2213 21 23 1483 092(b) 212 Sezary syndrome 00 131 - - - - 00 48 - 01 83 -

2(b) 22 Peripheral T-cell lymphoma 15 8438 -13 02 318 -09 12 4248 -12 62 3872 -132(b) 221 Peripheral T-cell lymphoma NOSc 06 3159 -05 00 49 - 04 1520 02 26 1590 -082(b) 222 Angioimmunoblastic T-cell lymphoma 02 1024 19 - - - 01 415 11 10 607 232(b) 223 Subcutaneous panniculitis- 00 68 - - - - 00 39 - 00 16 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 03 1549 -39 01 184 -01 02 888 -43 08 477 -45

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 98 - - - - 00 69 - 00 18 -2(b) 226 Enteropathy-type T-cell lymphoma 00 105 - - - - 00 50 - 01 54 -2(b) 227 Cutaneous T-cell lymphoma NOSc 03 1696 -12 00 32 - 02 894 -03 12 770 -172(b) 228 Primary cutaneous anaplastic 01 739 -48 00 26 - 01 373 -49 05 340 -49

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 04 2253 97 07 1047 92 03 940 98 04 266 1022(b) 24 NKcT-cell lymphoma nasal-type 01 638 -05 00 18 - 01 435 -03 03 185 -06

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 58 - - - - 00 22 - 01 36 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 01 293 45 - - - 00 116 - 03 174 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 46 - - - - 00 25 - 00 20 -2(c) Non-Hodgkin lymphoma unknown lineage 03 1407 -232 01 195 - 02 580 -184 10 632 -2302(c) 1 Precursor lymphoblastic leukemia 01 474 -228 01 187 - 00 134 - 02 153 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 49 - - - - - - - 01 36 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 02 884 -239 - - - 01 433 -175 07 443 -

lineage2() 1 Total precursor lymphomaleukemiad 18 9903 -06 35 5518 -17 09 3210 09 19 1175 05

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 435 271 - - - 01 215 - 03 207 -lymphoma

4 Lymphoid neoplasm NOSc 10 5235 -59 01 131 - 05 1871 -65 54 3233 -61

Table 1927 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 301 199772 -05 53 7889 02 202 79325 -02 1322 112558 -08

1 Hodgkin Lymphoma 24 14552 -16 12 1809 -10 29 10031 -14 32 2712 -32

2 Non-Hodgkin lymphoma 269 180219 -03 40 5982 03 170 67835 00 1251 106402 -062(a) Non-Hodgkin lymphoma B-cell 250 168102 -01 34 5050 13 154 61827 02 1190 101225 -042(a) 1 Precursor Non-Hodgkin lymphoma B-cell 14 7632 16 29 4293 09 06 2315 29 12 1024 202(a) 2 Mature Non-Hodgkin lymphoma B-cell 223 151164 -04 05 713 35 141 56808 -01 1102 93643 -072(a) 21 ChronicSmallProlymphocytic 48 33190 -13 - - - 24 10176 -05 268 23000 -16

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 43 30073 -15 - - - 22 9196 -06 243 20866 -19

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 118 - - - - 00 26 - 01 89 -2(a) 213 Mantle-cell lymphoma 04 2999 11 - - - 02 954 10 24 2045 12

2(a) 22 Lymphoplasmacytic lymphoma 05 3569 04 - - - 03 1066 -16 30 2501 11Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 02 1605 01 - - - 01 516 -25 13 1087 112(a) 222 Waldenstrom macroglubulinemia 03 1964 06 - - - 01 550 -08 17 1414 11

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 58 39060 00 02 371 33 38 14656 03 283 24033 -032(a) 231 DLBCL NOSc 57 38379 -02 02 342 27 36 14103 -01 282 23934 -032(a) 232 Intravascular large B-cell 00 87 - - - - 00 32 - 01 55 -

lymphoma2(a) 233 Primary effusion lymphoma - - - - - - - - - - - -2(a) 234 Mediastinal large B-cell 01 580 91 00 29 - 02 518 93 00 33 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 02 1304 -34 02 253 38 02 649 -37 05 402 -852(a) 25 Marginal-zone lymphoma (MZL) 21 14183 01 00 39 - 15 5872 12 98 8272 -062(a) 251 Splenic MZL 02 1254 -07 - - - 01 455 -32 10 799 072(a) 252 Extranodal MZL MALTc type 13 8711 06 00 30 - 10 3881 17 57 4800 -032(a) 253 Nodal MZL 06 4218 -07 - - - 04 1536 11 32 2673 -18

2(a) 26 Follicular lymphoma 33 21794 -24 00 19 - 27 10515 -25 134 11260 -222(a) 27 Hairy-cell leukemia 01 728 -12 - - - 01 403 -11 04 325 -122(a) 28 Plasma cell neoplasms 55 37315 08 - - - 33 13461 15 282 23839 052(a) 281 Plasmacytoma 03 1882 00 - - - 02 853 12 12 1017 -092(a) 282 Multiple myeloma 52 35433 09 - - - 30 12608 15 270 22822 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 21 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 14 9306 32 00 44 - 07 2704 32 76 6558 31

Table 1928All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 17 11104 01 05 772 29 15 5698 05 55 4634 -112(b) 1 Precursor Non-Hodgkin lymphoma T-cell 00 186 - 01 85 - 00 84 - 00 17 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 17 10889 09 05 686 83 15 5599 12 54 4604 -092(b) 21 Mycosis fungoidesSezary syndrome 05 3007 15 01 78 - 05 1819 26 13 1110 -042(b) 211 Mycosis fungoides 05 2908 12 01 78 - 05 1777 23 12 1053 -072(b) 212 Sezary syndrome 00 99 - - - - 00 42 - 01 57 -

2(b) 22 Peripheral T-cell lymphoma 09 6093 -08 01 216 30 08 2911 -06 35 2966 -142(b) 221 Peripheral T-cell lymphoma NOSc 03 2234 03 00 37 - 03 969 07 14 1228 -012(b) 222 Angioimmunoblastic T-cell lymphoma 01 878 -22 - - - 01 284 -39 07 594 -152(b) 223 Subcutaneous panniculitis- 00 108 - 00 18 - 00 72 - 00 18 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 974 -33 01 107 - 02 562 -19 04 305 -77

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 41 - - - - 00 29 - - - -2(b) 226 Enteropathy-type T-cell lymphoma 00 81 - - - - 00 34 - 01 47 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 1267 00 00 27 - 02 681 07 07 559 -102(b) 228 Primary cutaneous anaplastic 01 510 -34 00 25 - 01 280 -50 02 205 -33

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 02 1164 96 03 381 127 01 534 97 03 249 302(b) 24 NKcT-cell lymphoma nasal-type 01 347 11 - - - 01 224 - 01 115 -

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 62 - - - - 00 32 - 00 29 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 216 03 - - - 00 79 - 02 135 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 29 - - - - - - - - - -2(c) Non-Hodgkin lymphoma unknown lineage 02 1013 -341 01 160 - 01 310 - 06 543 -2(c) 1 Precursor lymphoblastic leukemia 01 340 - 01 156 - 00 104 - 01 80 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 46 - - - - - - - 00 33 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 627 - - - - 01 194 - 05 430 -

lineage2() 1 Total precursor lymphomaleukemiad 14 8158 -09 31 4534 -13 07 2503 02 13 1121 -11

3 Composite Hodgkin lymphoma and Non-Hodgkin 00 327 - - - - 00 124 - 02 196 -lymphoma

4 Lymphoid neoplasm NOSc 07 4674 -52 01 91 - 03 1335 -51 36 3248 -58

Table 1928 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 13: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 0-19 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 223 87 108 91 94 84 100 89 120 105 104 119 127 107 106 143 134 155 240

SEER 9 except 191 78 95 82 80 76 86 74 107 84 93 100 115 90 87 114 119 129 198SF-Oakland

San Francisco- 32 9 13 9 14 8 14 15 13 21 11 19 12 17 19 29 15 26 42Oakland SMSAc

San Francisco 9 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 lt4 5 lt4 6 lt4CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 12 12 16 14 14 13 15 13 17 14 14 15 16 14 13 18 17 20 20

SEER 9 except 12 13 16 14 14 13 15 12 17 13 14 15 17 13 13 16 17 19 19SF-Oakland

San Francisco- 14 10 15 10 16 09 15 16 13 21 11 18 12 17 19 28 14 25 27Oakland SMSAc

San Francisco 23 - - - - - - - - - - - - - - 40 - 49 -CityCounty

Table 1913

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 0-19

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 0-19

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 20-54 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 1463 687 723 958 1211 1413 1766 1830 2089 1770 1608 1696 1623 1722 1655 1693 1674 1596 2242

SEER 9 except 1208 563 588 730 827 923 1195 1294 1483 1325 1269 1327 1308 1410 1383 1401 1402 1328 1848SF-Oakland

San Francisco- 255 124 135 228 384 490 571 536 606 445 339 369 315 312 272 292 272 268 394Oakland SMSAc

San Francisco 58 29 34 105 215 288 333 303 317 225 105 115 111 111 86 75 73 71 98CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 69 79 82 104 124 136 159 156 169 138 121 124 117 123 116 118 116 111 104

SEER 9 except 69 78 81 97 103 109 131 134 144 123 115 116 112 119 115 116 115 110 103SF-Oakland

San Francisco- 69 84 89 139 226 264 295 267 298 213 156 164 139 141 123 130 118 114 110Oakland SMSAc

San Francisco 67 88 94 272 565 715 813 724 744 510 230 252 239 248 194 162 152 145 129CityCounty

Table 1914

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 20-54

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 20-54

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 55+ and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 3536 1732 1873 2127 2322 2497 2704 2810 3116 3385 3551 3747 4025 4397 4640 4868 5190 5321 8672

SEER 9 except 2886 1447 1584 1791 1912 2092 2226 2326 2569 2840 3002 3088 3395 3709 3928 4113 4320 4558 7317SF-Oakland

San Francisco- 650 285 289 336 410 405 478 484 547 545 549 659 630 688 712 755 870 763 1355Oakland SMSAc

San Francisco 178 65 88 104 109 105 132 106 130 126 106 141 108 169 131 136 164 148 261CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 451 522 540 596 633 673 701 706 761 800 811 831 858 900 901 891 899 862 871

SEER 9 except 440 521 544 601 620 667 687 692 744 797 813 813 858 901 904 891 888 874 874SF-Oakland

San Francisco- 508 528 520 571 702 703 773 783 854 821 800 932 855 894 888 890 959 800 860Oakland SMSAc

San Francisco 482 446 598 727 739 757 934 747 914 872 727 934 690 1047 764 769 889 776 826CityCounty

Table 1915

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 55+

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 55+

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 003 006 217 072 Asian 0 001 003 005 183 072

10 002 005 011 218 073 Pacific 10 002 004 009 184 073

20 003 009 021 217 073 Islander 20 003 007 015 182 073

30 006 018 042 216 073 30 005 013 029 180 073

40 012 037 082 213 074 40 008 024 057 176 073

50 025 072 139 206 074 50 017 049 101 170 073

60 049 120 177 191 075 60 034 087 139 158 072

70 080 144 - 160 072 70 056 112 - 133 068

80 085 - - 106 062 80 066 - - 091 056

White 0 001 003 006 227 075 American 0 001 002 003 116 049

10 002 005 011 228 076 Indian 10 002 002 005 117 050

20 003 009 021 227 076 Alaska 20 001 003 008 116 050

30 006 018 043 226 077 Nativea 30 003 007 022 117 051

40 012 038 085 223 077 40 004 019 041 117 052

50 026 075 147 217 078 50 016 038 078 118 053

60 052 127 187 201 078 60 024 067 105 109 055

70 085 153 - 169 076 70 048 091 - 096 055

80 090 - - 111 065 80 057 - - 064 043

Black 0 001 002 006 138 042 Hispanicb 0 001 002 005 222 073

10 002 005 011 140 043 10 001 004 009 223 074

20 003 010 022 139 043 20 003 008 019 222 074

30 006 019 041 137 043 30 005 016 040 221 074

40 013 035 068 133 043 40 011 035 078 218 074

50 023 057 093 125 043 50 024 068 133 211 074

60 037 076 102 110 042 60 046 114 173 195 074

70 047 078 - 087 038 70 075 140 - 164 070

80 044 - - 057 032 80 081 - - 112 057

Table 1916

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Both Sexes 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 004 007 243 081 Asian 0 001 003 006 213 085

10 002 006 013 244 082 Pacific 10 002 005 011 213 086

20 004 010 024 243 082 Islander 20 003 009 018 211 086

30 007 021 049 243 083 30 006 015 034 210 086

40 014 042 094 240 084 40 009 028 067 205 086

50 029 082 158 233 085 50 019 059 117 199 086

60 057 139 203 219 086 60 041 101 161 187 085

70 095 170 - 188 084 70 066 131 - 159 082

80 105 - - 130 073 80 080 - - 114 069

White 0 001 004 007 254 085 American 0 001 003 004 104 057

10 002 006 013 255 086 Indian 10 002 003 006 105 058

20 004 010 024 254 086 Alaska 20 001 004 008 103 058

30 007 020 049 253 087 Nativea 30 003 008 021 104 059

40 014 043 097 251 088 40 005 018 038 105 060

50 030 086 167 244 089 50 014 035 071 105 062

60 059 147 215 230 090 60 023 062 094 099 065

70 101 180 - 198 088 70 046 084 - 090 066

80 112 - - 136 076 80 053 - - 061 053

Black 0 001 003 007 152 046 Hispanicb 0 001 003 005 238 083

10 002 006 014 154 047 10 002 005 011 239 084

20 004 012 027 153 047 20 003 009 021 238 084

30 008 023 048 152 047 30 006 018 043 238 084

40 016 042 079 148 047 40 012 037 083 235 085

50 027 066 105 138 047 50 026 073 145 228 085

60 043 087 114 123 045 60 050 126 189 214 085

70 054 088 - 099 042 70 086 157 - 185 081

80 053 - - 070 036 80 094 - - 131 066

Table 1917

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Males 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 002 004 193 064 Asian 0 001 002 004 159 063

10 001 004 009 195 064 Pacific 10 001 004 008 160 063

20 003 007 017 194 064 Islander 20 002 006 013 159 063

30 005 015 036 192 065 30 004 011 025 157 063

40 010 031 071 189 065 40 007 021 048 153 063

50 022 062 120 182 065 50 014 042 087 148 063

60 042 103 154 168 065 60 028 074 122 136 062

70 067 123 - 138 063 70 049 099 - 114 058

80 071 - - 090 054 80 057 - - 075 047

White 0 001 002 004 203 067 American 0 000 001 002 128 043

10 001 004 009 204 067 Indian 10 001 001 004 129 044

20 002 007 017 203 067 Alaska 20 001 003 007 128 044

30 005 015 037 201 067 Nativea 30 002 006 023 129 044

40 010 032 074 198 068 40 004 021 044 129 045

50 022 065 127 192 068 50 017 042 085 129 046

60 044 109 163 177 068 60 026 072 113 118 047

70 072 130 - 146 066 70 050 097 - 102 046

80 075 - - 094 056 80 060 - - 066 037

Black 0 000 002 004 126 040 Hispanicb 0 001 002 004 210 065

10 001 004 009 128 040 10 001 004 008 211 066

20 003 008 018 127 040 20 002 007 017 211 066

30 005 015 034 125 040 30 004 014 036 209 066

40 010 029 058 122 040 40 010 032 073 206 066

50 020 049 083 115 040 50 022 064 123 198 066

60 032 068 094 102 039 60 043 104 161 182 065

70 041 071 - 080 036 70 066 127 - 149 062

80 039 - - 051 030 80 073 - - 100 051

Table 1918

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Females 2014-2016 By RaceEthnicity

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

The AAPC is the Average Annual Percent Change over the time interval The AAPCs are calculated bythe Joinpoint Regression Program Version 47 February 2019 National Cancer Institute

- Statistic not shown Rate based on less than 16 cases for the time intervalTrend based on less than 10 cases for at least one year within the time interval

a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) Trendsare based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico SeattleUtah and AtlantaThe SEER 21 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the AlaskaNative Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts

c The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 3 Joinpoints overdiagnosis years 2000-2016

d The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 5 Joinpoints overdiagnosis years 1975-2016

e Hispanic and Non-Hispanic are not mutually exclusive from whites blacks AsianPacificIslanders and American IndiansAlaska Natives Incidence data for Hispanics and Non-Hispanicsare based on NHIA and exclude cases from the Alaska Native Registry

f Incidence data for American IndianAlaska Native are based on the PurchasedReferred CareDelivery Area (PRCDA) counties

g US Mortality Files National Center for Health Statistics CDCh The 2007-2016 mortality AAPCs are based on a Joinpoint analysis using years of death 2000-2016 The APC is significantly different from zero (plt05)

SEER Incidence SEER 21 Areasb SEER 21 Areasb SEER 9 Areasb

Rate 2012-2016 Trend 2007-2016c Trend 2007-2016d

Rate per 100000 persons AAPC () AAPC ()

Total Males Females Total Males Females Total Males Females RaceEthnicity

All Races 196 239 162 -07 -09 -08 -09 -07 -08

White 206 250 170 -08 -11 -09 -09 -08 -08White Hispanice 183 212 161 -08 -03 -05 - - -White Non-Hispanice 210 256 172 -08 -06 -10 - - -

Black 147 177 124 01 00 03 00 -04 -09

AsianPacific Islander 134 164 110 00 00 -01 - - -

Amer IndAlaska Natf 113 120 106 -05 -12 00 - - -

Hispanice 179 207 157 -05 -02 03 - - -

US Mortalityg Rate 2012-2016 Trend 2007-2016h

Rate per 100000 persons AAPC ()

Total Males Females Total Males FemalesRaceEthnicity

All Races 56 73 44 -23 -20 -27

White 59 76 45 -23 -20 -27White Hispanice 51 65 40 -16 -13 -20White Non-Hispanice 59 76 46 -23 -20 -27

Black 41 52 33 -20 -19 -21

AsianPacific Islander 39 49 31 -17 -15 -19

Amer IndAlaska NatTotal US 31 40 24 -32 -20 -45PRCDA Counties 44 58 33 -21 -04 -37Non-PRCDA Counties 17 21 14 -54 -50 -60

Hispanice 48 61 38 -17 -14 -21

Table 1919Non-Hodgkin Lymphoma

SEER Incidence and US MortalityAge-Adjusted Rates and Trendsa

By RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Incidence Ratesa 2012-2016

California 1844 2241 1515 1938 2349 1591 1390 1639 1182Greater Bay Area 1957 2381 1600 2144 2601 1755 1628 1828 1436San Francisco-Oakland 1956 2421 1570 2174 2660 1765 1603 1816 1408San Jose-Monterey 1962 2311 1660 2097 2503 1742 1800 1891 1646

Los Angeles 1804 2176 1505 1951 2331 1637 1357 1659 1139Greater California 1822 2220 1489 1876 2286 1529 1314 1534 1113

Connecticut 2116 2607 1733 2154 2642 1771 1386 1829 1051Detroit 2132 2636 1742 2290 2850 1847 1620 1905 1409Georgia 1826 2244 1487 1936 2346 1588 1462 1833 1187Atlanta 1925 2381 1555 2119 2567 1736 1601 2034 1272Rural Georgia 1584 1790 1401 1953 2298 1567 807 - 988Greater Georgia 1784 2186 1459 1872 2274 1537 1380 1703 1146

Hawaii 1660 2024 1349 1958 2275 1593 - - -Idaho 1922 2267 1616 1920 2262 1618 - - -Iowa 2134 2601 1756 2148 2612 1773 1352 1602 1100Kentucky 2039 2505 1666 2070 2538 1693 1403 1788 1112Louisiana 1944 2352 1614 2106 2537 1744 1469 1769 1237Massachusetts 1810 2181 1518 1830 2214 1524 1452 1655 1299New Jersey 2155 2607 1804 2285 2765 1905 1387 1621 1222New Mexico 1550 1739 1387 1580 1798 1394 875 - -New York 2152 2620 1788 2306 2792 1915 1545 1852 1333Seattle-Puget Sound 2116 2627 1695 2177 2667 1766 1631 1973 1316Utah 1843 2233 1498 1862 2258 1513 2089 - -

SEER 9 Areasb 1992 2444 1623 2095 2551 1716 1573 1914 1298SEER 13 Areasb 1946 2373 1597 2064 2502 1700 1519 1853 1258SEER 18 Areasb 1933 2354 1590 2031 2464 1671 1449 1751 1214SEER 21 Areasb 1963 2388 1620 2061 2498 1702 1471 1771 1245

Table 1920Non-Hodgkin Lymphoma

Age-Adjusted SEER Incidence Ratesa

By Registry Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control and PreventionRates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and AtlantaThe SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Death Ratesa 2012-2016

California 533 677 423 570 726 449 417 480 367Greater Bay Area 505 671 376 561 756 408 410 491 331San Francisco-Oakland 503 667 376 555 742 409 416 490 343San Jose-Monterey 511 681 377 573 781 407 - - -

Los Angeles 541 670 443 589 728 481 424 503 371Greater California 539 682 429 564 716 447 416 455 384

Connecticut 533 705 407 547 717 421 350 510 244Detroit 639 822 505 693 895 542 443 528 384Georgia 533 697 411 580 747 450 376 503 286Atlanta 492 659 372 533 728 388 397 506 317Rural Georgia 559 731 388 670 813 507 - - -Greater Georgia 549 712 426 595 755 470 363 500 266

Hawaii 475 620 352 545 649 412 - - -Idaho 635 775 510 641 782 516 - - -Iowa 638 845 484 642 848 488 - - -Kentucky 642 886 460 655 904 470 401 557 284Louisiana 608 814 451 651 863 485 461 623 340Massachusetts 523 659 423 541 682 436 347 410 297New Jersey 545 721 419 585 780 443 372 466 314New Mexico 488 585 405 493 595 406 - - -New York 535 702 412 575 752 441 390 514 313Seattle-Puget Sound 585 749 463 604 769 480 490 562 397Utah 542 670 433 551 681 440 - - -

SEER 9 Areasb 555 719 430 586 758 454 414 522 333SEER 13 Areasb 549 705 429 586 753 457 419 521 342SEER 18 Areasb 554 717 431 589 761 456 409 518 329SEER 21 Areasb 550 712 428 584 754 453 401 513 322

Total US 562 725 436 586 755 454 408 518 330

Table 1921Non-Hodgkin Lymphoma

Age-Adjusted SEER Death Ratesa

By Registry Race and Sex

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 562 002

High Five StatesMichigan 645 011 01(0112) 1479Kentucky 642 016 02(0118) 1424Iowa 638 018 03(0120) 1367Indiana 638 013 04(0117) 1361Idaho 635 027 05(0126) 1303

Low Five StatesNevada 511 019 47(2251) -899Colorado 491 014 48(3851) -1257New Mexico 488 020 49(2851) -1317Hawaii 475 024 50(3051) -1542c

DC 444 039 51(2351) -2097c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 545 014 28(1847) -291 Montana 559 030 25(0250) -042Alaska 525 047 43(0151) -654 Nebraska 563 023 22(0548) 026Arizona 512 012 46(2950) -886 Nevada 511 019 47(2251) -899Arkansas 555 018 26(1247) -113 New Hampshire 562 027 23(0349) 014California 533 005 40(2645) -508 New Jersey 545 010 29(2045) -301Colorado 491 014 48(3851) -1257 New Mexico 488 020 49(2851) -1317Connecticut 533 016 39(1949) -505 New York 535 007 37(2446) -478Delaware 628 033 08(0139) 1174 North Carolina 541 010 35(2146) -363DC 444 039 51(2351) -2097c North Dakota 561 037 24(0151) -007Florida 535 006 38(2545) -479 Ohio 616 009 10(0220) 969Georgia 533 011 41(2248) -511 Oklahoma 630 017 06(0121) 1226Hawaii 475 024 50(3051) -1542c Oregon 612 016 11(0124) 903Idaho 635 027 05(0126) 1303 Pennsylvania 603 009 16(0622) 729Illinois 566 009 20(1634) 085 Rhode Island 542 029 32(0651) -350Indiana 638 013 04(0117) 1361 South Carolina 542 014 31(1847) -347Iowa 638 018 03(0120) 1367 South Dakota 541 033 36(0451) -364Kansas 585 019 19(0439) 420 Tennessee 629 013 07(0119) 1198Kentucky 642 016 02(0118) 1424 Texas 546 007 27(2142) -277Louisiana 608 016 14(0125) 826 Utah 542 022 33(1250) -352Maine 609 026 13(0137) 852 Vermont 605 040 15(0148) 770Maryland 524 013 44(2349) -663 Virginia 544 011 30(2046) -319Massachusetts 523 012 45(2549) -687 Washington 599 013 17(0425) 665Michigan 645 011 01(0112) 1479 West Virginia 612 022 12(0132) 894Minnesota 617 014 09(0122) 984 Wisconsin 590 013 18(0629) 507Mississippi 531 018 42(1850) -551 Wyoming 564 043 21(0151) 050Missouri 542 012 34(1947) -354

Table 1922Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males and Females

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 725 003

High Five StatesKentucky 886 030 01(0112) 2213c

Iowa 845 032 02(0120) 1647c

Michigan 842 019 03(0114) 1615c

Indiana 839 024 04(0116) 1567c

Delaware 824 058 05(0144) 1364

Low Five StatesArizona 635 019 47(3251) -1244Alaska 630 075 48(0251) -1311Hawaii 620 041 49(1951) -1452DC 614 071 50(0551) -1535c

New Mexico 585 033 51(3451) -1928c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 688 025 36(1649) -513 Montana 709 050 26(0251) -218Alaska 630 075 48(0251) -1311 Nebraska 737 040 20(0248) 165Arizona 635 019 47(3251) -1244 Nevada 653 032 44(1951) -994Arkansas 721 031 22(0747) -061 New Hampshire 710 046 25(0451) -210California 677 009 41(2846) -666 New Jersey 721 018 21(1441) -059Colorado 643 024 46(2451) -1133 New Mexico 585 033 51(3451) -1928c

Connecticut 705 028 28(1248) -273 New York 702 012 30(1943) -323Delaware 824 058 05(0144) 1364 North Carolina 709 018 27(1644) -221DC 614 071 50(0551) -1535c North Dakota 682 061 39(0251) -598Florida 683 011 37(2446) -585 Ohio 800 017 09(0320) 1029Georgia 697 019 34(1746) -387 Oklahoma 806 030 08(0126) 1109Hawaii 620 041 49(1951) -1452 Oregon 794 028 12(0128) 947Idaho 775 045 16(0146) 692 Pennsylvania 783 015 15(0523) 794Illinois 739 016 19(1235) 190 Rhode Island 649 050 45(1051) -1050Indiana 839 024 04(0116) 1567c South Carolina 681 025 40(1850) -604Iowa 845 032 02(0120) 1647c South Dakota 701 056 31(0251) -332Kansas 713 032 24(0948) -174 Tennessee 820 023 06(0120) 1311Kentucky 886 030 01(0112) 2213c Texas 698 012 32(2043) -368Louisiana 814 029 07(0122) 1222 Utah 670 036 42(1351) -754Maine 754 045 18(0148) 395 Vermont 794 069 11(0149) 950Maryland 682 023 38(1849) -588 Virginia 694 020 35(1847) -429Massachusetts 659 020 43(2450) -910 Washington 790 022 13(0224) 897Michigan 842 019 03(0114) 1615c West Virginia 774 038 17(0142) 675Minnesota 797 025 10(0224) 995 Wisconsin 786 023 14(0227) 844Mississippi 717 034 23(0748) -110 Wyoming 698 071 33(0151) -377Missouri 702 022 29(1646) -319

Table 1923Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 436 002

High Five StatesIdaho 510 033 01(0139) 1697c

Maine 497 031 02(0141) 1396Michigan 495 012 03(0119) 1340Oklahoma 492 020 04(0128) 1276Indiana 492 016 05(0123) 1270

Low Five StatesMississippi 404 021 47(1351) -731Nevada 382 022 48(2051) -1237Colorado 369 016 49(3451) -1540c

Hawaii 352 027 50(2551) -1932c

DC 323 044 51(1551) -2601c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 440 017 24(0547) 099 Montana 435 036 27(0151) -034Alaska 414 058 38(0151) -500 Nebraska 435 027 26(0249) -032Arizona 407 014 44(2049) -664 Nevada 382 022 48(2051) -1237Arkansas 428 021 31(0649) -181 New Hampshire 454 032 19(0149) 400California 423 006 34(2244) -313 New Jersey 419 012 37(1848) -397Colorado 369 016 49(3451) -1540c New Mexico 405 025 46(0951) -706Connecticut 407 018 45(1550) -669 New York 412 008 39(2548) -554Delaware 473 039 12(0150) 855 North Carolina 420 012 35(1848) -374DC 323 044 51(1551) -2601c North Dakota 471 045 13(0150) 809Florida 412 007 40(2548) -564 Ohio 478 011 10(0123) 967Georgia 411 012 43(2049) -582 Oklahoma 492 020 04(0128) 1276Hawaii 352 027 50(2551) -1932c Oregon 465 019 15(0141) 668Idaho 510 033 01(0139) 1697c Pennsylvania 467 010 14(0427) 714Illinois 439 010 25(1341) 074 Rhode Island 455 035 18(0150) 434Indiana 492 016 05(0123) 1270 South Carolina 432 017 30(0947) -102Iowa 484 021 08(0135) 1087 South Dakota 411 039 42(0151) -580Kansas 486 023 06(0137) 1143 Tennessee 484 015 09(0126) 1087Kentucky 460 018 17(0241) 544 Texas 427 008 32(1944) -213Louisiana 451 018 21(0345) 333 Utah 433 026 28(0250) -081Maine 497 031 02(0141) 1396 Vermont 461 047 16(0151) 578Maryland 411 015 41(1749) -576 Virginia 432 013 29(1246) -092Massachusetts 423 014 33(1548) -303 Washington 452 015 20(0541) 360Michigan 495 012 03(0119) 1340 West Virginia 486 027 07(0143) 1141Minnesota 475 017 11(0132) 901 Wisconsin 443 015 23(0645) 156Mississippi 404 021 47(1351) -731 Wyoming 445 051 22(0151) 192Missouri 419 014 36(1549) -396

Table 1924Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Females

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 Areas (excluding the AlaskaNative Registry) and 112016 US population estimates based on the average of 2015 and 2016 population estimates from theUS Bureau of the CensusPrevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 24 years

b Maximum limited-duration prevalence is 24 years for 1992-2016 datac Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groupsd Cases diagnosed more than 24 years ago were estimated using the completeness index method (Capocaccia et al 1997

Merrill et al 2000)e Complete prevalence is obtained by summing 0 to lt24 and gt=24- Statistic not shown Statistic based on fewer than 5 cases estimated alive in SEER for the time interval+ Not available

Years Since Diagnosis 0 to lt5 5 to lt10 10 to lt15 15 to lt20 20 to lt24 0 to lt24b gt=24d Completee

Race Sex

All Races Both Sexes 248946 177490 117326 69109 31890 644761 49943 694704Males 135137 94173 60159 36020 16581 342069 25489 367558Females 113809 83317 57167 33089 15309 302692 24454 327146

White Both Sexes 213764 154454 101984 60537 28026 558765 49625 620368Males 116527 82172 52535 31627 14543 297404 26526 330121Females 97237 72282 49448 28910 13483 261361 23099 290247

Black Both Sexes 20500 13640 9750 5271 2215 51376 4115 55491Males 10712 7188 4768 2684 1174 26526 1911 28437Females 9789 6452 4981 2587 1041 24850 2204 27054

Asian Both Sexes 8405 5210 3415 1867 844 19741 + +Pacific Males 4548 2661 1757 1013 407 10386 + +Islander Females 3856 2549 1657 855 437 9355 + +

Hispanic Both Sexes 21339 14049 8272 4881 2136 50676 + +Males 10918 7243 4331 2617 1094 26202 + +Females 10421 6805 3941 2264 1043 24474 + +

Age Specific (Crude) Age-Adjustedc Age at Prevalence All Ages 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ All Ages

Race Sex

All Races Both Sexes 02001 00035 00139 00283 00538 01121 02352 04640 08181 10224 01738Males 02156 00044 00189 00354 00625 01293 02710 05243 09364 12449 02023Females 01850 00026 00087 00208 00450 00952 02010 04094 07196 08856 01498

White Both Sexes 02216 00035 00143 00289 00534 01148 02427 04858 08597 10738 01807Males 02380 00045 00198 00359 00622 01317 02790 05442 09778 13060 02095Females 02054 00025 00085 00214 00442 00976 02072 04317 07593 09285 01560

Black Both Sexes 01139 00029 00113 00265 00599 01027 02010 03340 05117 05333 01251Males 01226 00029 00140 00351 00696 01223 02333 03969 05849 06055 01457Females 01059 00030 00086 00178 00510 00853 01728 02836 04608 04976 01088

Asian Both Sexes 00970 00039 00133 00207 00353 00680 01409 02692 04470 06094 01032Pacific Males 01065 00044 00175 00240 00398 00744 01640 03072 05516 07472 01222Islander Females 00882 00033 00092 00175 00312 00623 01209 02384 03629 05207 00880

Hispanic Both Sexes 00887 00030 00117 00206 00398 00850 01769 03632 05888 07209 01294Males 00908 00035 00147 00256 00455 00932 01924 03940 06326 08003 01420Females 00866 00024 00086 00151 00337 00766 01616 03360 05552 06719 01185

Table 1925Non-Hodgkin Lymphoma

Estimated United States Cancer Prevalence Countsa on January 1 2016By RaceEthnicity Sex and Years Since Diagnosis

Estimated prevalence percenta on January 1 2016 of the SEER population diagnosed in the previous 24 yearsBy Age at Prevalence RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 372 452924 -05 62 18862 04 247 189692 -05 1657 244370 -05

1 Hodgkin Lymphoma 28 32262 -17 13 3927 -06 33 22556 -15 39 5779 -31

2 Non-Hodgkin lymphoma 336 409991 -03 48 14693 04 210 163591 -03 1572 231707 -042(a) Non-Hodgkin lymphoma B-cell 311 380349 -01 39 11836 14 190 148768 -02 1491 219745 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 15 16631 20 31 9416 10 07 5203 39 14 2012 252(a) 2 Mature Non-Hodgkin lymphoma B-cell 280 343965 -04 07 2271 30 174 137225 -05 1387 204469 -042(a) 21 ChronicSmallProlymphocytic 69 85601 -13 00 35 - 35 29103 -11 382 56463 -14

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 61 75061 -15 00 30 - 31 25339 -13 336 49692 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 311 19 - - - 00 72 - 02 234 262(a) 213 Mantle-cell lymphoma 08 10229 03 - - - 04 3692 02 44 6537 04

2(a) 22 Lymphoplasmacytic lymphoma 07 8651 00 - - - 03 2590 -11 41 6059 04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 03 3667 -03 - - - 01 1132 -18 17 2533 022(a) 222 Waldenstrom macroglubulinemia 04 4984 03 - - - 02 1458 -07 24 3526 06

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 72 87188 00 03 925 26 48 36480 -02 339 49783 022(a) 231 DLBCL NOSc 71 85899 -01 03 861 12 46 35469 -05 337 49569 012(a) 232 Intravascular large B-cell 00 162 - - - - 00 63 - 01 99 -

lymphoma2(a) 233 Primary effusion lymphoma 00 181 27 - - - 00 126 - 00 55 -2(a) 234 Mediastinal large B-cell 01 946 116 00 64 - 01 822 111 00 60 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 04 4692 -26 03 1028 32 04 2618 -43 07 1046 -432(a) 25 Marginal-zone lymphoma (MZL) 22 26534 00 00 137 13 14 11049 05 104 15348 -042(a) 251 Splenic MZL 02 2418 04 - - - 01 889 -08 10 1529 102(a) 252 Extranodal MZL MALTc type 13 15979 06 00 92 - 09 7148 11 59 8739 032(a) 253 Nodal MZL 07 8137 -15 00 45 - 04 3012 -05 34 5080 -20

2(a) 26 Follicular lymphoma 35 43582 -21 00 119 - 28 21725 -25 147 21738 -182(a) 27 Hairy-cell leukemia 03 3712 -16 - - - 03 2311 -19 09 1401 -122(a) 28 Plasma cell neoplasms 68 83957 08 00 24 - 39 31325 12 358 52608 062(a) 281 Plasmacytoma 04 4879 -04 00 16 - 03 2362 -06 17 2501 -032(a) 282 Multiple myeloma 64 79078 09 - - - 36 28963 14 341 50107 07

plasma-cell leukemia2(a) 29 Heavy chain disease 00 48 - - - - 00 24 - 00 23 -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 16 19753 33 00 149 27 08 6340 37 90 13264 32

Table 1926All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 23 27222 01 08 2502 18 19 13933 03 73 10787 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 616 - 01 293 - 00 272 - 00 51 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 22 26531 11 07 2207 75 19 13621 12 73 10703 -042(b) 21 Mycosis fungoidesSezary syndrome 06 6969 18 01 213 84 06 4080 23 18 2676 052(b) 211 Mycosis fungoides 06 6739 17 01 213 84 05 3990 22 17 2536 042(b) 212 Sezary syndrome 00 230 46 - - - 00 90 - 01 140 -

2(b) 22 Peripheral T-cell lymphoma 12 14531 -10 02 534 07 10 7159 -09 46 6838 -122(b) 221 Peripheral T-cell lymphoma NOSc 04 5393 -01 00 86 - 03 2489 04 19 2818 -042(b) 222 Angioimmunoblastic T-cell lymphoma 02 1902 02 - - - 01 699 -09 08 1201 072(b) 223 Subcutaneous panniculitis- 00 176 44 00 31 - 00 111 - 00 34 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 2523 -36 01 291 00 02 1450 -33 05 782 -54

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 139 - - - - 00 98 - 00 28 -2(b) 226 Enteropathy-type T-cell lymphoma 00 186 -02 - - - 00 84 - 01 101 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 2963 -07 00 59 - 02 1575 01 09 1329 -142(b) 228 Primary cutaneous anaplastic 01 1249 -41 00 51 - 01 653 -49 04 545 -39

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 03 3417 96 05 1428 101 02 1474 99 03 515 672(b) 24 NKcT-cell lymphoma nasal-type 01 985 02 00 26 - 01 659 00 02 300 05

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 120 - - - - 00 54 - 00 65 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 509 30 - - - 00 195 -05 02 309 442(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 75 - - - - 00 40 - 00 33 -2(c) Non-Hodgkin lymphoma unknown lineage 02 2420 -274 01 355 - 01 890 -216 08 1175 -2792(c) 1 Precursor lymphoblastic leukemia 01 814 -283 01 343 - 00 238 - 02 233 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 95 - - - - 00 25 - 00 69 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 1511 -274 - - - 01 627 -202 06 873 -319

lineage2() 1 Total precursor lymphomaleukemiad 16 18061 -07 33 10052 -15 08 5713 06 15 2296 -01

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 762 273 00 20 - 00 339 227 03 403 -lymphoma

4 Lymphoid neoplasm NOSc 08 9909 -55 01 222 113 04 3206 -59 43 6481 -59

Table 1926 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 461 253152 -05 70 10973 05 294 110367 -07 2122 131812 -05

1 Hodgkin Lymphoma 31 17710 -17 13 2118 -03 36 12525 -16 48 3067 -31

2 Non-Hodgkin lymphoma 419 229772 -03 56 8711 05 252 95756 -05 2017 125305 -032(a) Non-Hodgkin lymphoma B-cell 387 212247 -02 44 6786 15 227 86941 -04 1908 118520 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 16 8999 24 33 5123 11 08 2888 46 16 988 292(a) 2 Mature Non-Hodgkin lymphoma B-cell 351 192801 -05 10 1558 28 210 80417 -08 1783 110826 -042(a) 21 ChronicSmallProlymphocytic 96 52411 -15 00 21 - 47 18927 -14 539 33463 -15

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 82 44988 -17 00 19 - 40 16143 -16 464 28826 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 193 -02 - - - 00 46 - 02 145 052(a) 213 Mantle-cell lymphoma 13 7230 -01 - - - 07 2738 -01 72 4492 -01

2(a) 22 Lymphoplasmacytic lymphoma 10 5082 -05 - - - 04 1524 -08 58 3558 -04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 04 2062 -08 - - - 02 616 -12 23 1446 -072(a) 222 Waldenstrom macroglubulinemia 06 3020 -02 - - - 02 908 -06 34 2112 -02

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 88 48128 01 03 554 22 59 21824 -06 418 25750 052(a) 231 DLBCL NOSc 87 47520 00 03 519 03 57 21366 -08 416 25635 042(a) 232 Intravascular large B-cell 00 75 - - - - 00 31 - 01 44 -

lymphoma2(a) 233 Primary effusion lymphoma 00 167 26 - - - 00 123 - 01 44 -2(a) 234 Mediastinal large B-cell 01 366 155 00 35 - 01 304 142 00 27 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 06 3388 -22 05 775 31 06 1969 -46 10 644 -192(a) 25 Marginal-zone lymphoma (MZL) 22 12351 -02 01 98 - 14 5177 -02 114 7076 -012(a) 251 Splenic MZL 02 1164 14 - - - 01 434 18 12 730 112(a) 252 Extranodal MZL MALTc type 13 7268 07 00 62 - 09 3267 04 63 3939 102(a) 253 Nodal MZL 07 3919 -23 00 36 - 04 1476 -22 39 2407 -23

2(a) 26 Follicular lymphoma 39 21788 -19 01 100 - 30 11210 -25 165 10478 -152(a) 27 Hairy-cell leukemia 05 2984 -18 - - - 05 1908 -20 17 1076 -152(a) 28 Plasma cell neoplasms 85 46642 07 - - - 45 17864 11 462 28769 052(a) 281 Plasmacytoma 05 2997 -08 - - - 04 1509 -16 24 1484 -012(a) 282 Multiple myeloma 80 43645 08 - - - 41 16355 13 439 27285 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 27 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 20 10447 34 01 105 - 10 3636 40 110 6706 32

Table 1927All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 29 16118 00 11 1730 14 23 8235 02 98 6153 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 430 - 01 208 - 01 188 - 01 34 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 28 15642 11 10 1521 71 22 8022 11 97 6099 -032(b) 21 Mycosis fungoidesSezary syndrome 07 3962 19 01 135 - 06 2261 21 25 1566 092(b) 211 Mycosis fungoides 07 3831 20 01 135 - 06 2213 21 23 1483 092(b) 212 Sezary syndrome 00 131 - - - - 00 48 - 01 83 -

2(b) 22 Peripheral T-cell lymphoma 15 8438 -13 02 318 -09 12 4248 -12 62 3872 -132(b) 221 Peripheral T-cell lymphoma NOSc 06 3159 -05 00 49 - 04 1520 02 26 1590 -082(b) 222 Angioimmunoblastic T-cell lymphoma 02 1024 19 - - - 01 415 11 10 607 232(b) 223 Subcutaneous panniculitis- 00 68 - - - - 00 39 - 00 16 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 03 1549 -39 01 184 -01 02 888 -43 08 477 -45

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 98 - - - - 00 69 - 00 18 -2(b) 226 Enteropathy-type T-cell lymphoma 00 105 - - - - 00 50 - 01 54 -2(b) 227 Cutaneous T-cell lymphoma NOSc 03 1696 -12 00 32 - 02 894 -03 12 770 -172(b) 228 Primary cutaneous anaplastic 01 739 -48 00 26 - 01 373 -49 05 340 -49

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 04 2253 97 07 1047 92 03 940 98 04 266 1022(b) 24 NKcT-cell lymphoma nasal-type 01 638 -05 00 18 - 01 435 -03 03 185 -06

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 58 - - - - 00 22 - 01 36 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 01 293 45 - - - 00 116 - 03 174 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 46 - - - - 00 25 - 00 20 -2(c) Non-Hodgkin lymphoma unknown lineage 03 1407 -232 01 195 - 02 580 -184 10 632 -2302(c) 1 Precursor lymphoblastic leukemia 01 474 -228 01 187 - 00 134 - 02 153 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 49 - - - - - - - 01 36 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 02 884 -239 - - - 01 433 -175 07 443 -

lineage2() 1 Total precursor lymphomaleukemiad 18 9903 -06 35 5518 -17 09 3210 09 19 1175 05

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 435 271 - - - 01 215 - 03 207 -lymphoma

4 Lymphoid neoplasm NOSc 10 5235 -59 01 131 - 05 1871 -65 54 3233 -61

Table 1927 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 301 199772 -05 53 7889 02 202 79325 -02 1322 112558 -08

1 Hodgkin Lymphoma 24 14552 -16 12 1809 -10 29 10031 -14 32 2712 -32

2 Non-Hodgkin lymphoma 269 180219 -03 40 5982 03 170 67835 00 1251 106402 -062(a) Non-Hodgkin lymphoma B-cell 250 168102 -01 34 5050 13 154 61827 02 1190 101225 -042(a) 1 Precursor Non-Hodgkin lymphoma B-cell 14 7632 16 29 4293 09 06 2315 29 12 1024 202(a) 2 Mature Non-Hodgkin lymphoma B-cell 223 151164 -04 05 713 35 141 56808 -01 1102 93643 -072(a) 21 ChronicSmallProlymphocytic 48 33190 -13 - - - 24 10176 -05 268 23000 -16

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 43 30073 -15 - - - 22 9196 -06 243 20866 -19

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 118 - - - - 00 26 - 01 89 -2(a) 213 Mantle-cell lymphoma 04 2999 11 - - - 02 954 10 24 2045 12

2(a) 22 Lymphoplasmacytic lymphoma 05 3569 04 - - - 03 1066 -16 30 2501 11Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 02 1605 01 - - - 01 516 -25 13 1087 112(a) 222 Waldenstrom macroglubulinemia 03 1964 06 - - - 01 550 -08 17 1414 11

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 58 39060 00 02 371 33 38 14656 03 283 24033 -032(a) 231 DLBCL NOSc 57 38379 -02 02 342 27 36 14103 -01 282 23934 -032(a) 232 Intravascular large B-cell 00 87 - - - - 00 32 - 01 55 -

lymphoma2(a) 233 Primary effusion lymphoma - - - - - - - - - - - -2(a) 234 Mediastinal large B-cell 01 580 91 00 29 - 02 518 93 00 33 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 02 1304 -34 02 253 38 02 649 -37 05 402 -852(a) 25 Marginal-zone lymphoma (MZL) 21 14183 01 00 39 - 15 5872 12 98 8272 -062(a) 251 Splenic MZL 02 1254 -07 - - - 01 455 -32 10 799 072(a) 252 Extranodal MZL MALTc type 13 8711 06 00 30 - 10 3881 17 57 4800 -032(a) 253 Nodal MZL 06 4218 -07 - - - 04 1536 11 32 2673 -18

2(a) 26 Follicular lymphoma 33 21794 -24 00 19 - 27 10515 -25 134 11260 -222(a) 27 Hairy-cell leukemia 01 728 -12 - - - 01 403 -11 04 325 -122(a) 28 Plasma cell neoplasms 55 37315 08 - - - 33 13461 15 282 23839 052(a) 281 Plasmacytoma 03 1882 00 - - - 02 853 12 12 1017 -092(a) 282 Multiple myeloma 52 35433 09 - - - 30 12608 15 270 22822 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 21 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 14 9306 32 00 44 - 07 2704 32 76 6558 31

Table 1928All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 17 11104 01 05 772 29 15 5698 05 55 4634 -112(b) 1 Precursor Non-Hodgkin lymphoma T-cell 00 186 - 01 85 - 00 84 - 00 17 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 17 10889 09 05 686 83 15 5599 12 54 4604 -092(b) 21 Mycosis fungoidesSezary syndrome 05 3007 15 01 78 - 05 1819 26 13 1110 -042(b) 211 Mycosis fungoides 05 2908 12 01 78 - 05 1777 23 12 1053 -072(b) 212 Sezary syndrome 00 99 - - - - 00 42 - 01 57 -

2(b) 22 Peripheral T-cell lymphoma 09 6093 -08 01 216 30 08 2911 -06 35 2966 -142(b) 221 Peripheral T-cell lymphoma NOSc 03 2234 03 00 37 - 03 969 07 14 1228 -012(b) 222 Angioimmunoblastic T-cell lymphoma 01 878 -22 - - - 01 284 -39 07 594 -152(b) 223 Subcutaneous panniculitis- 00 108 - 00 18 - 00 72 - 00 18 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 974 -33 01 107 - 02 562 -19 04 305 -77

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 41 - - - - 00 29 - - - -2(b) 226 Enteropathy-type T-cell lymphoma 00 81 - - - - 00 34 - 01 47 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 1267 00 00 27 - 02 681 07 07 559 -102(b) 228 Primary cutaneous anaplastic 01 510 -34 00 25 - 01 280 -50 02 205 -33

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 02 1164 96 03 381 127 01 534 97 03 249 302(b) 24 NKcT-cell lymphoma nasal-type 01 347 11 - - - 01 224 - 01 115 -

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 62 - - - - 00 32 - 00 29 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 216 03 - - - 00 79 - 02 135 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 29 - - - - - - - - - -2(c) Non-Hodgkin lymphoma unknown lineage 02 1013 -341 01 160 - 01 310 - 06 543 -2(c) 1 Precursor lymphoblastic leukemia 01 340 - 01 156 - 00 104 - 01 80 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 46 - - - - - - - 00 33 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 627 - - - - 01 194 - 05 430 -

lineage2() 1 Total precursor lymphomaleukemiad 14 8158 -09 31 4534 -13 07 2503 02 13 1121 -11

3 Composite Hodgkin lymphoma and Non-Hodgkin 00 327 - - - - 00 124 - 02 196 -lymphoma

4 Lymphoid neoplasm NOSc 07 4674 -52 01 91 - 03 1335 -51 36 3248 -58

Table 1928 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 14: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 20-54 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 1463 687 723 958 1211 1413 1766 1830 2089 1770 1608 1696 1623 1722 1655 1693 1674 1596 2242

SEER 9 except 1208 563 588 730 827 923 1195 1294 1483 1325 1269 1327 1308 1410 1383 1401 1402 1328 1848SF-Oakland

San Francisco- 255 124 135 228 384 490 571 536 606 445 339 369 315 312 272 292 272 268 394Oakland SMSAc

San Francisco 58 29 34 105 215 288 333 303 317 225 105 115 111 111 86 75 73 71 98CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 69 79 82 104 124 136 159 156 169 138 121 124 117 123 116 118 116 111 104

SEER 9 except 69 78 81 97 103 109 131 134 144 123 115 116 112 119 115 116 115 110 103SF-Oakland

San Francisco- 69 84 89 139 226 264 295 267 298 213 156 164 139 141 123 130 118 114 110Oakland SMSAc

San Francisco 67 88 94 272 565 715 813 724 744 510 230 252 239 248 194 162 152 145 129CityCounty

Table 1914

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 20-54

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 20-54

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 55+ and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 3536 1732 1873 2127 2322 2497 2704 2810 3116 3385 3551 3747 4025 4397 4640 4868 5190 5321 8672

SEER 9 except 2886 1447 1584 1791 1912 2092 2226 2326 2569 2840 3002 3088 3395 3709 3928 4113 4320 4558 7317SF-Oakland

San Francisco- 650 285 289 336 410 405 478 484 547 545 549 659 630 688 712 755 870 763 1355Oakland SMSAc

San Francisco 178 65 88 104 109 105 132 106 130 126 106 141 108 169 131 136 164 148 261CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 451 522 540 596 633 673 701 706 761 800 811 831 858 900 901 891 899 862 871

SEER 9 except 440 521 544 601 620 667 687 692 744 797 813 813 858 901 904 891 888 874 874SF-Oakland

San Francisco- 508 528 520 571 702 703 773 783 854 821 800 932 855 894 888 890 959 800 860Oakland SMSAc

San Francisco 482 446 598 727 739 757 934 747 914 872 727 934 690 1047 764 769 889 776 826CityCounty

Table 1915

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 55+

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 55+

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 003 006 217 072 Asian 0 001 003 005 183 072

10 002 005 011 218 073 Pacific 10 002 004 009 184 073

20 003 009 021 217 073 Islander 20 003 007 015 182 073

30 006 018 042 216 073 30 005 013 029 180 073

40 012 037 082 213 074 40 008 024 057 176 073

50 025 072 139 206 074 50 017 049 101 170 073

60 049 120 177 191 075 60 034 087 139 158 072

70 080 144 - 160 072 70 056 112 - 133 068

80 085 - - 106 062 80 066 - - 091 056

White 0 001 003 006 227 075 American 0 001 002 003 116 049

10 002 005 011 228 076 Indian 10 002 002 005 117 050

20 003 009 021 227 076 Alaska 20 001 003 008 116 050

30 006 018 043 226 077 Nativea 30 003 007 022 117 051

40 012 038 085 223 077 40 004 019 041 117 052

50 026 075 147 217 078 50 016 038 078 118 053

60 052 127 187 201 078 60 024 067 105 109 055

70 085 153 - 169 076 70 048 091 - 096 055

80 090 - - 111 065 80 057 - - 064 043

Black 0 001 002 006 138 042 Hispanicb 0 001 002 005 222 073

10 002 005 011 140 043 10 001 004 009 223 074

20 003 010 022 139 043 20 003 008 019 222 074

30 006 019 041 137 043 30 005 016 040 221 074

40 013 035 068 133 043 40 011 035 078 218 074

50 023 057 093 125 043 50 024 068 133 211 074

60 037 076 102 110 042 60 046 114 173 195 074

70 047 078 - 087 038 70 075 140 - 164 070

80 044 - - 057 032 80 081 - - 112 057

Table 1916

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Both Sexes 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 004 007 243 081 Asian 0 001 003 006 213 085

10 002 006 013 244 082 Pacific 10 002 005 011 213 086

20 004 010 024 243 082 Islander 20 003 009 018 211 086

30 007 021 049 243 083 30 006 015 034 210 086

40 014 042 094 240 084 40 009 028 067 205 086

50 029 082 158 233 085 50 019 059 117 199 086

60 057 139 203 219 086 60 041 101 161 187 085

70 095 170 - 188 084 70 066 131 - 159 082

80 105 - - 130 073 80 080 - - 114 069

White 0 001 004 007 254 085 American 0 001 003 004 104 057

10 002 006 013 255 086 Indian 10 002 003 006 105 058

20 004 010 024 254 086 Alaska 20 001 004 008 103 058

30 007 020 049 253 087 Nativea 30 003 008 021 104 059

40 014 043 097 251 088 40 005 018 038 105 060

50 030 086 167 244 089 50 014 035 071 105 062

60 059 147 215 230 090 60 023 062 094 099 065

70 101 180 - 198 088 70 046 084 - 090 066

80 112 - - 136 076 80 053 - - 061 053

Black 0 001 003 007 152 046 Hispanicb 0 001 003 005 238 083

10 002 006 014 154 047 10 002 005 011 239 084

20 004 012 027 153 047 20 003 009 021 238 084

30 008 023 048 152 047 30 006 018 043 238 084

40 016 042 079 148 047 40 012 037 083 235 085

50 027 066 105 138 047 50 026 073 145 228 085

60 043 087 114 123 045 60 050 126 189 214 085

70 054 088 - 099 042 70 086 157 - 185 081

80 053 - - 070 036 80 094 - - 131 066

Table 1917

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Males 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 002 004 193 064 Asian 0 001 002 004 159 063

10 001 004 009 195 064 Pacific 10 001 004 008 160 063

20 003 007 017 194 064 Islander 20 002 006 013 159 063

30 005 015 036 192 065 30 004 011 025 157 063

40 010 031 071 189 065 40 007 021 048 153 063

50 022 062 120 182 065 50 014 042 087 148 063

60 042 103 154 168 065 60 028 074 122 136 062

70 067 123 - 138 063 70 049 099 - 114 058

80 071 - - 090 054 80 057 - - 075 047

White 0 001 002 004 203 067 American 0 000 001 002 128 043

10 001 004 009 204 067 Indian 10 001 001 004 129 044

20 002 007 017 203 067 Alaska 20 001 003 007 128 044

30 005 015 037 201 067 Nativea 30 002 006 023 129 044

40 010 032 074 198 068 40 004 021 044 129 045

50 022 065 127 192 068 50 017 042 085 129 046

60 044 109 163 177 068 60 026 072 113 118 047

70 072 130 - 146 066 70 050 097 - 102 046

80 075 - - 094 056 80 060 - - 066 037

Black 0 000 002 004 126 040 Hispanicb 0 001 002 004 210 065

10 001 004 009 128 040 10 001 004 008 211 066

20 003 008 018 127 040 20 002 007 017 211 066

30 005 015 034 125 040 30 004 014 036 209 066

40 010 029 058 122 040 40 010 032 073 206 066

50 020 049 083 115 040 50 022 064 123 198 066

60 032 068 094 102 039 60 043 104 161 182 065

70 041 071 - 080 036 70 066 127 - 149 062

80 039 - - 051 030 80 073 - - 100 051

Table 1918

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Females 2014-2016 By RaceEthnicity

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

The AAPC is the Average Annual Percent Change over the time interval The AAPCs are calculated bythe Joinpoint Regression Program Version 47 February 2019 National Cancer Institute

- Statistic not shown Rate based on less than 16 cases for the time intervalTrend based on less than 10 cases for at least one year within the time interval

a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) Trendsare based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico SeattleUtah and AtlantaThe SEER 21 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the AlaskaNative Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts

c The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 3 Joinpoints overdiagnosis years 2000-2016

d The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 5 Joinpoints overdiagnosis years 1975-2016

e Hispanic and Non-Hispanic are not mutually exclusive from whites blacks AsianPacificIslanders and American IndiansAlaska Natives Incidence data for Hispanics and Non-Hispanicsare based on NHIA and exclude cases from the Alaska Native Registry

f Incidence data for American IndianAlaska Native are based on the PurchasedReferred CareDelivery Area (PRCDA) counties

g US Mortality Files National Center for Health Statistics CDCh The 2007-2016 mortality AAPCs are based on a Joinpoint analysis using years of death 2000-2016 The APC is significantly different from zero (plt05)

SEER Incidence SEER 21 Areasb SEER 21 Areasb SEER 9 Areasb

Rate 2012-2016 Trend 2007-2016c Trend 2007-2016d

Rate per 100000 persons AAPC () AAPC ()

Total Males Females Total Males Females Total Males Females RaceEthnicity

All Races 196 239 162 -07 -09 -08 -09 -07 -08

White 206 250 170 -08 -11 -09 -09 -08 -08White Hispanice 183 212 161 -08 -03 -05 - - -White Non-Hispanice 210 256 172 -08 -06 -10 - - -

Black 147 177 124 01 00 03 00 -04 -09

AsianPacific Islander 134 164 110 00 00 -01 - - -

Amer IndAlaska Natf 113 120 106 -05 -12 00 - - -

Hispanice 179 207 157 -05 -02 03 - - -

US Mortalityg Rate 2012-2016 Trend 2007-2016h

Rate per 100000 persons AAPC ()

Total Males Females Total Males FemalesRaceEthnicity

All Races 56 73 44 -23 -20 -27

White 59 76 45 -23 -20 -27White Hispanice 51 65 40 -16 -13 -20White Non-Hispanice 59 76 46 -23 -20 -27

Black 41 52 33 -20 -19 -21

AsianPacific Islander 39 49 31 -17 -15 -19

Amer IndAlaska NatTotal US 31 40 24 -32 -20 -45PRCDA Counties 44 58 33 -21 -04 -37Non-PRCDA Counties 17 21 14 -54 -50 -60

Hispanice 48 61 38 -17 -14 -21

Table 1919Non-Hodgkin Lymphoma

SEER Incidence and US MortalityAge-Adjusted Rates and Trendsa

By RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Incidence Ratesa 2012-2016

California 1844 2241 1515 1938 2349 1591 1390 1639 1182Greater Bay Area 1957 2381 1600 2144 2601 1755 1628 1828 1436San Francisco-Oakland 1956 2421 1570 2174 2660 1765 1603 1816 1408San Jose-Monterey 1962 2311 1660 2097 2503 1742 1800 1891 1646

Los Angeles 1804 2176 1505 1951 2331 1637 1357 1659 1139Greater California 1822 2220 1489 1876 2286 1529 1314 1534 1113

Connecticut 2116 2607 1733 2154 2642 1771 1386 1829 1051Detroit 2132 2636 1742 2290 2850 1847 1620 1905 1409Georgia 1826 2244 1487 1936 2346 1588 1462 1833 1187Atlanta 1925 2381 1555 2119 2567 1736 1601 2034 1272Rural Georgia 1584 1790 1401 1953 2298 1567 807 - 988Greater Georgia 1784 2186 1459 1872 2274 1537 1380 1703 1146

Hawaii 1660 2024 1349 1958 2275 1593 - - -Idaho 1922 2267 1616 1920 2262 1618 - - -Iowa 2134 2601 1756 2148 2612 1773 1352 1602 1100Kentucky 2039 2505 1666 2070 2538 1693 1403 1788 1112Louisiana 1944 2352 1614 2106 2537 1744 1469 1769 1237Massachusetts 1810 2181 1518 1830 2214 1524 1452 1655 1299New Jersey 2155 2607 1804 2285 2765 1905 1387 1621 1222New Mexico 1550 1739 1387 1580 1798 1394 875 - -New York 2152 2620 1788 2306 2792 1915 1545 1852 1333Seattle-Puget Sound 2116 2627 1695 2177 2667 1766 1631 1973 1316Utah 1843 2233 1498 1862 2258 1513 2089 - -

SEER 9 Areasb 1992 2444 1623 2095 2551 1716 1573 1914 1298SEER 13 Areasb 1946 2373 1597 2064 2502 1700 1519 1853 1258SEER 18 Areasb 1933 2354 1590 2031 2464 1671 1449 1751 1214SEER 21 Areasb 1963 2388 1620 2061 2498 1702 1471 1771 1245

Table 1920Non-Hodgkin Lymphoma

Age-Adjusted SEER Incidence Ratesa

By Registry Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control and PreventionRates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and AtlantaThe SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Death Ratesa 2012-2016

California 533 677 423 570 726 449 417 480 367Greater Bay Area 505 671 376 561 756 408 410 491 331San Francisco-Oakland 503 667 376 555 742 409 416 490 343San Jose-Monterey 511 681 377 573 781 407 - - -

Los Angeles 541 670 443 589 728 481 424 503 371Greater California 539 682 429 564 716 447 416 455 384

Connecticut 533 705 407 547 717 421 350 510 244Detroit 639 822 505 693 895 542 443 528 384Georgia 533 697 411 580 747 450 376 503 286Atlanta 492 659 372 533 728 388 397 506 317Rural Georgia 559 731 388 670 813 507 - - -Greater Georgia 549 712 426 595 755 470 363 500 266

Hawaii 475 620 352 545 649 412 - - -Idaho 635 775 510 641 782 516 - - -Iowa 638 845 484 642 848 488 - - -Kentucky 642 886 460 655 904 470 401 557 284Louisiana 608 814 451 651 863 485 461 623 340Massachusetts 523 659 423 541 682 436 347 410 297New Jersey 545 721 419 585 780 443 372 466 314New Mexico 488 585 405 493 595 406 - - -New York 535 702 412 575 752 441 390 514 313Seattle-Puget Sound 585 749 463 604 769 480 490 562 397Utah 542 670 433 551 681 440 - - -

SEER 9 Areasb 555 719 430 586 758 454 414 522 333SEER 13 Areasb 549 705 429 586 753 457 419 521 342SEER 18 Areasb 554 717 431 589 761 456 409 518 329SEER 21 Areasb 550 712 428 584 754 453 401 513 322

Total US 562 725 436 586 755 454 408 518 330

Table 1921Non-Hodgkin Lymphoma

Age-Adjusted SEER Death Ratesa

By Registry Race and Sex

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 562 002

High Five StatesMichigan 645 011 01(0112) 1479Kentucky 642 016 02(0118) 1424Iowa 638 018 03(0120) 1367Indiana 638 013 04(0117) 1361Idaho 635 027 05(0126) 1303

Low Five StatesNevada 511 019 47(2251) -899Colorado 491 014 48(3851) -1257New Mexico 488 020 49(2851) -1317Hawaii 475 024 50(3051) -1542c

DC 444 039 51(2351) -2097c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 545 014 28(1847) -291 Montana 559 030 25(0250) -042Alaska 525 047 43(0151) -654 Nebraska 563 023 22(0548) 026Arizona 512 012 46(2950) -886 Nevada 511 019 47(2251) -899Arkansas 555 018 26(1247) -113 New Hampshire 562 027 23(0349) 014California 533 005 40(2645) -508 New Jersey 545 010 29(2045) -301Colorado 491 014 48(3851) -1257 New Mexico 488 020 49(2851) -1317Connecticut 533 016 39(1949) -505 New York 535 007 37(2446) -478Delaware 628 033 08(0139) 1174 North Carolina 541 010 35(2146) -363DC 444 039 51(2351) -2097c North Dakota 561 037 24(0151) -007Florida 535 006 38(2545) -479 Ohio 616 009 10(0220) 969Georgia 533 011 41(2248) -511 Oklahoma 630 017 06(0121) 1226Hawaii 475 024 50(3051) -1542c Oregon 612 016 11(0124) 903Idaho 635 027 05(0126) 1303 Pennsylvania 603 009 16(0622) 729Illinois 566 009 20(1634) 085 Rhode Island 542 029 32(0651) -350Indiana 638 013 04(0117) 1361 South Carolina 542 014 31(1847) -347Iowa 638 018 03(0120) 1367 South Dakota 541 033 36(0451) -364Kansas 585 019 19(0439) 420 Tennessee 629 013 07(0119) 1198Kentucky 642 016 02(0118) 1424 Texas 546 007 27(2142) -277Louisiana 608 016 14(0125) 826 Utah 542 022 33(1250) -352Maine 609 026 13(0137) 852 Vermont 605 040 15(0148) 770Maryland 524 013 44(2349) -663 Virginia 544 011 30(2046) -319Massachusetts 523 012 45(2549) -687 Washington 599 013 17(0425) 665Michigan 645 011 01(0112) 1479 West Virginia 612 022 12(0132) 894Minnesota 617 014 09(0122) 984 Wisconsin 590 013 18(0629) 507Mississippi 531 018 42(1850) -551 Wyoming 564 043 21(0151) 050Missouri 542 012 34(1947) -354

Table 1922Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males and Females

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 725 003

High Five StatesKentucky 886 030 01(0112) 2213c

Iowa 845 032 02(0120) 1647c

Michigan 842 019 03(0114) 1615c

Indiana 839 024 04(0116) 1567c

Delaware 824 058 05(0144) 1364

Low Five StatesArizona 635 019 47(3251) -1244Alaska 630 075 48(0251) -1311Hawaii 620 041 49(1951) -1452DC 614 071 50(0551) -1535c

New Mexico 585 033 51(3451) -1928c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 688 025 36(1649) -513 Montana 709 050 26(0251) -218Alaska 630 075 48(0251) -1311 Nebraska 737 040 20(0248) 165Arizona 635 019 47(3251) -1244 Nevada 653 032 44(1951) -994Arkansas 721 031 22(0747) -061 New Hampshire 710 046 25(0451) -210California 677 009 41(2846) -666 New Jersey 721 018 21(1441) -059Colorado 643 024 46(2451) -1133 New Mexico 585 033 51(3451) -1928c

Connecticut 705 028 28(1248) -273 New York 702 012 30(1943) -323Delaware 824 058 05(0144) 1364 North Carolina 709 018 27(1644) -221DC 614 071 50(0551) -1535c North Dakota 682 061 39(0251) -598Florida 683 011 37(2446) -585 Ohio 800 017 09(0320) 1029Georgia 697 019 34(1746) -387 Oklahoma 806 030 08(0126) 1109Hawaii 620 041 49(1951) -1452 Oregon 794 028 12(0128) 947Idaho 775 045 16(0146) 692 Pennsylvania 783 015 15(0523) 794Illinois 739 016 19(1235) 190 Rhode Island 649 050 45(1051) -1050Indiana 839 024 04(0116) 1567c South Carolina 681 025 40(1850) -604Iowa 845 032 02(0120) 1647c South Dakota 701 056 31(0251) -332Kansas 713 032 24(0948) -174 Tennessee 820 023 06(0120) 1311Kentucky 886 030 01(0112) 2213c Texas 698 012 32(2043) -368Louisiana 814 029 07(0122) 1222 Utah 670 036 42(1351) -754Maine 754 045 18(0148) 395 Vermont 794 069 11(0149) 950Maryland 682 023 38(1849) -588 Virginia 694 020 35(1847) -429Massachusetts 659 020 43(2450) -910 Washington 790 022 13(0224) 897Michigan 842 019 03(0114) 1615c West Virginia 774 038 17(0142) 675Minnesota 797 025 10(0224) 995 Wisconsin 786 023 14(0227) 844Mississippi 717 034 23(0748) -110 Wyoming 698 071 33(0151) -377Missouri 702 022 29(1646) -319

Table 1923Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 436 002

High Five StatesIdaho 510 033 01(0139) 1697c

Maine 497 031 02(0141) 1396Michigan 495 012 03(0119) 1340Oklahoma 492 020 04(0128) 1276Indiana 492 016 05(0123) 1270

Low Five StatesMississippi 404 021 47(1351) -731Nevada 382 022 48(2051) -1237Colorado 369 016 49(3451) -1540c

Hawaii 352 027 50(2551) -1932c

DC 323 044 51(1551) -2601c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 440 017 24(0547) 099 Montana 435 036 27(0151) -034Alaska 414 058 38(0151) -500 Nebraska 435 027 26(0249) -032Arizona 407 014 44(2049) -664 Nevada 382 022 48(2051) -1237Arkansas 428 021 31(0649) -181 New Hampshire 454 032 19(0149) 400California 423 006 34(2244) -313 New Jersey 419 012 37(1848) -397Colorado 369 016 49(3451) -1540c New Mexico 405 025 46(0951) -706Connecticut 407 018 45(1550) -669 New York 412 008 39(2548) -554Delaware 473 039 12(0150) 855 North Carolina 420 012 35(1848) -374DC 323 044 51(1551) -2601c North Dakota 471 045 13(0150) 809Florida 412 007 40(2548) -564 Ohio 478 011 10(0123) 967Georgia 411 012 43(2049) -582 Oklahoma 492 020 04(0128) 1276Hawaii 352 027 50(2551) -1932c Oregon 465 019 15(0141) 668Idaho 510 033 01(0139) 1697c Pennsylvania 467 010 14(0427) 714Illinois 439 010 25(1341) 074 Rhode Island 455 035 18(0150) 434Indiana 492 016 05(0123) 1270 South Carolina 432 017 30(0947) -102Iowa 484 021 08(0135) 1087 South Dakota 411 039 42(0151) -580Kansas 486 023 06(0137) 1143 Tennessee 484 015 09(0126) 1087Kentucky 460 018 17(0241) 544 Texas 427 008 32(1944) -213Louisiana 451 018 21(0345) 333 Utah 433 026 28(0250) -081Maine 497 031 02(0141) 1396 Vermont 461 047 16(0151) 578Maryland 411 015 41(1749) -576 Virginia 432 013 29(1246) -092Massachusetts 423 014 33(1548) -303 Washington 452 015 20(0541) 360Michigan 495 012 03(0119) 1340 West Virginia 486 027 07(0143) 1141Minnesota 475 017 11(0132) 901 Wisconsin 443 015 23(0645) 156Mississippi 404 021 47(1351) -731 Wyoming 445 051 22(0151) 192Missouri 419 014 36(1549) -396

Table 1924Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Females

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 Areas (excluding the AlaskaNative Registry) and 112016 US population estimates based on the average of 2015 and 2016 population estimates from theUS Bureau of the CensusPrevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 24 years

b Maximum limited-duration prevalence is 24 years for 1992-2016 datac Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groupsd Cases diagnosed more than 24 years ago were estimated using the completeness index method (Capocaccia et al 1997

Merrill et al 2000)e Complete prevalence is obtained by summing 0 to lt24 and gt=24- Statistic not shown Statistic based on fewer than 5 cases estimated alive in SEER for the time interval+ Not available

Years Since Diagnosis 0 to lt5 5 to lt10 10 to lt15 15 to lt20 20 to lt24 0 to lt24b gt=24d Completee

Race Sex

All Races Both Sexes 248946 177490 117326 69109 31890 644761 49943 694704Males 135137 94173 60159 36020 16581 342069 25489 367558Females 113809 83317 57167 33089 15309 302692 24454 327146

White Both Sexes 213764 154454 101984 60537 28026 558765 49625 620368Males 116527 82172 52535 31627 14543 297404 26526 330121Females 97237 72282 49448 28910 13483 261361 23099 290247

Black Both Sexes 20500 13640 9750 5271 2215 51376 4115 55491Males 10712 7188 4768 2684 1174 26526 1911 28437Females 9789 6452 4981 2587 1041 24850 2204 27054

Asian Both Sexes 8405 5210 3415 1867 844 19741 + +Pacific Males 4548 2661 1757 1013 407 10386 + +Islander Females 3856 2549 1657 855 437 9355 + +

Hispanic Both Sexes 21339 14049 8272 4881 2136 50676 + +Males 10918 7243 4331 2617 1094 26202 + +Females 10421 6805 3941 2264 1043 24474 + +

Age Specific (Crude) Age-Adjustedc Age at Prevalence All Ages 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ All Ages

Race Sex

All Races Both Sexes 02001 00035 00139 00283 00538 01121 02352 04640 08181 10224 01738Males 02156 00044 00189 00354 00625 01293 02710 05243 09364 12449 02023Females 01850 00026 00087 00208 00450 00952 02010 04094 07196 08856 01498

White Both Sexes 02216 00035 00143 00289 00534 01148 02427 04858 08597 10738 01807Males 02380 00045 00198 00359 00622 01317 02790 05442 09778 13060 02095Females 02054 00025 00085 00214 00442 00976 02072 04317 07593 09285 01560

Black Both Sexes 01139 00029 00113 00265 00599 01027 02010 03340 05117 05333 01251Males 01226 00029 00140 00351 00696 01223 02333 03969 05849 06055 01457Females 01059 00030 00086 00178 00510 00853 01728 02836 04608 04976 01088

Asian Both Sexes 00970 00039 00133 00207 00353 00680 01409 02692 04470 06094 01032Pacific Males 01065 00044 00175 00240 00398 00744 01640 03072 05516 07472 01222Islander Females 00882 00033 00092 00175 00312 00623 01209 02384 03629 05207 00880

Hispanic Both Sexes 00887 00030 00117 00206 00398 00850 01769 03632 05888 07209 01294Males 00908 00035 00147 00256 00455 00932 01924 03940 06326 08003 01420Females 00866 00024 00086 00151 00337 00766 01616 03360 05552 06719 01185

Table 1925Non-Hodgkin Lymphoma

Estimated United States Cancer Prevalence Countsa on January 1 2016By RaceEthnicity Sex and Years Since Diagnosis

Estimated prevalence percenta on January 1 2016 of the SEER population diagnosed in the previous 24 yearsBy Age at Prevalence RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 372 452924 -05 62 18862 04 247 189692 -05 1657 244370 -05

1 Hodgkin Lymphoma 28 32262 -17 13 3927 -06 33 22556 -15 39 5779 -31

2 Non-Hodgkin lymphoma 336 409991 -03 48 14693 04 210 163591 -03 1572 231707 -042(a) Non-Hodgkin lymphoma B-cell 311 380349 -01 39 11836 14 190 148768 -02 1491 219745 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 15 16631 20 31 9416 10 07 5203 39 14 2012 252(a) 2 Mature Non-Hodgkin lymphoma B-cell 280 343965 -04 07 2271 30 174 137225 -05 1387 204469 -042(a) 21 ChronicSmallProlymphocytic 69 85601 -13 00 35 - 35 29103 -11 382 56463 -14

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 61 75061 -15 00 30 - 31 25339 -13 336 49692 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 311 19 - - - 00 72 - 02 234 262(a) 213 Mantle-cell lymphoma 08 10229 03 - - - 04 3692 02 44 6537 04

2(a) 22 Lymphoplasmacytic lymphoma 07 8651 00 - - - 03 2590 -11 41 6059 04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 03 3667 -03 - - - 01 1132 -18 17 2533 022(a) 222 Waldenstrom macroglubulinemia 04 4984 03 - - - 02 1458 -07 24 3526 06

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 72 87188 00 03 925 26 48 36480 -02 339 49783 022(a) 231 DLBCL NOSc 71 85899 -01 03 861 12 46 35469 -05 337 49569 012(a) 232 Intravascular large B-cell 00 162 - - - - 00 63 - 01 99 -

lymphoma2(a) 233 Primary effusion lymphoma 00 181 27 - - - 00 126 - 00 55 -2(a) 234 Mediastinal large B-cell 01 946 116 00 64 - 01 822 111 00 60 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 04 4692 -26 03 1028 32 04 2618 -43 07 1046 -432(a) 25 Marginal-zone lymphoma (MZL) 22 26534 00 00 137 13 14 11049 05 104 15348 -042(a) 251 Splenic MZL 02 2418 04 - - - 01 889 -08 10 1529 102(a) 252 Extranodal MZL MALTc type 13 15979 06 00 92 - 09 7148 11 59 8739 032(a) 253 Nodal MZL 07 8137 -15 00 45 - 04 3012 -05 34 5080 -20

2(a) 26 Follicular lymphoma 35 43582 -21 00 119 - 28 21725 -25 147 21738 -182(a) 27 Hairy-cell leukemia 03 3712 -16 - - - 03 2311 -19 09 1401 -122(a) 28 Plasma cell neoplasms 68 83957 08 00 24 - 39 31325 12 358 52608 062(a) 281 Plasmacytoma 04 4879 -04 00 16 - 03 2362 -06 17 2501 -032(a) 282 Multiple myeloma 64 79078 09 - - - 36 28963 14 341 50107 07

plasma-cell leukemia2(a) 29 Heavy chain disease 00 48 - - - - 00 24 - 00 23 -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 16 19753 33 00 149 27 08 6340 37 90 13264 32

Table 1926All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 23 27222 01 08 2502 18 19 13933 03 73 10787 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 616 - 01 293 - 00 272 - 00 51 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 22 26531 11 07 2207 75 19 13621 12 73 10703 -042(b) 21 Mycosis fungoidesSezary syndrome 06 6969 18 01 213 84 06 4080 23 18 2676 052(b) 211 Mycosis fungoides 06 6739 17 01 213 84 05 3990 22 17 2536 042(b) 212 Sezary syndrome 00 230 46 - - - 00 90 - 01 140 -

2(b) 22 Peripheral T-cell lymphoma 12 14531 -10 02 534 07 10 7159 -09 46 6838 -122(b) 221 Peripheral T-cell lymphoma NOSc 04 5393 -01 00 86 - 03 2489 04 19 2818 -042(b) 222 Angioimmunoblastic T-cell lymphoma 02 1902 02 - - - 01 699 -09 08 1201 072(b) 223 Subcutaneous panniculitis- 00 176 44 00 31 - 00 111 - 00 34 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 2523 -36 01 291 00 02 1450 -33 05 782 -54

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 139 - - - - 00 98 - 00 28 -2(b) 226 Enteropathy-type T-cell lymphoma 00 186 -02 - - - 00 84 - 01 101 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 2963 -07 00 59 - 02 1575 01 09 1329 -142(b) 228 Primary cutaneous anaplastic 01 1249 -41 00 51 - 01 653 -49 04 545 -39

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 03 3417 96 05 1428 101 02 1474 99 03 515 672(b) 24 NKcT-cell lymphoma nasal-type 01 985 02 00 26 - 01 659 00 02 300 05

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 120 - - - - 00 54 - 00 65 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 509 30 - - - 00 195 -05 02 309 442(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 75 - - - - 00 40 - 00 33 -2(c) Non-Hodgkin lymphoma unknown lineage 02 2420 -274 01 355 - 01 890 -216 08 1175 -2792(c) 1 Precursor lymphoblastic leukemia 01 814 -283 01 343 - 00 238 - 02 233 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 95 - - - - 00 25 - 00 69 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 1511 -274 - - - 01 627 -202 06 873 -319

lineage2() 1 Total precursor lymphomaleukemiad 16 18061 -07 33 10052 -15 08 5713 06 15 2296 -01

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 762 273 00 20 - 00 339 227 03 403 -lymphoma

4 Lymphoid neoplasm NOSc 08 9909 -55 01 222 113 04 3206 -59 43 6481 -59

Table 1926 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 461 253152 -05 70 10973 05 294 110367 -07 2122 131812 -05

1 Hodgkin Lymphoma 31 17710 -17 13 2118 -03 36 12525 -16 48 3067 -31

2 Non-Hodgkin lymphoma 419 229772 -03 56 8711 05 252 95756 -05 2017 125305 -032(a) Non-Hodgkin lymphoma B-cell 387 212247 -02 44 6786 15 227 86941 -04 1908 118520 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 16 8999 24 33 5123 11 08 2888 46 16 988 292(a) 2 Mature Non-Hodgkin lymphoma B-cell 351 192801 -05 10 1558 28 210 80417 -08 1783 110826 -042(a) 21 ChronicSmallProlymphocytic 96 52411 -15 00 21 - 47 18927 -14 539 33463 -15

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 82 44988 -17 00 19 - 40 16143 -16 464 28826 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 193 -02 - - - 00 46 - 02 145 052(a) 213 Mantle-cell lymphoma 13 7230 -01 - - - 07 2738 -01 72 4492 -01

2(a) 22 Lymphoplasmacytic lymphoma 10 5082 -05 - - - 04 1524 -08 58 3558 -04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 04 2062 -08 - - - 02 616 -12 23 1446 -072(a) 222 Waldenstrom macroglubulinemia 06 3020 -02 - - - 02 908 -06 34 2112 -02

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 88 48128 01 03 554 22 59 21824 -06 418 25750 052(a) 231 DLBCL NOSc 87 47520 00 03 519 03 57 21366 -08 416 25635 042(a) 232 Intravascular large B-cell 00 75 - - - - 00 31 - 01 44 -

lymphoma2(a) 233 Primary effusion lymphoma 00 167 26 - - - 00 123 - 01 44 -2(a) 234 Mediastinal large B-cell 01 366 155 00 35 - 01 304 142 00 27 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 06 3388 -22 05 775 31 06 1969 -46 10 644 -192(a) 25 Marginal-zone lymphoma (MZL) 22 12351 -02 01 98 - 14 5177 -02 114 7076 -012(a) 251 Splenic MZL 02 1164 14 - - - 01 434 18 12 730 112(a) 252 Extranodal MZL MALTc type 13 7268 07 00 62 - 09 3267 04 63 3939 102(a) 253 Nodal MZL 07 3919 -23 00 36 - 04 1476 -22 39 2407 -23

2(a) 26 Follicular lymphoma 39 21788 -19 01 100 - 30 11210 -25 165 10478 -152(a) 27 Hairy-cell leukemia 05 2984 -18 - - - 05 1908 -20 17 1076 -152(a) 28 Plasma cell neoplasms 85 46642 07 - - - 45 17864 11 462 28769 052(a) 281 Plasmacytoma 05 2997 -08 - - - 04 1509 -16 24 1484 -012(a) 282 Multiple myeloma 80 43645 08 - - - 41 16355 13 439 27285 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 27 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 20 10447 34 01 105 - 10 3636 40 110 6706 32

Table 1927All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 29 16118 00 11 1730 14 23 8235 02 98 6153 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 430 - 01 208 - 01 188 - 01 34 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 28 15642 11 10 1521 71 22 8022 11 97 6099 -032(b) 21 Mycosis fungoidesSezary syndrome 07 3962 19 01 135 - 06 2261 21 25 1566 092(b) 211 Mycosis fungoides 07 3831 20 01 135 - 06 2213 21 23 1483 092(b) 212 Sezary syndrome 00 131 - - - - 00 48 - 01 83 -

2(b) 22 Peripheral T-cell lymphoma 15 8438 -13 02 318 -09 12 4248 -12 62 3872 -132(b) 221 Peripheral T-cell lymphoma NOSc 06 3159 -05 00 49 - 04 1520 02 26 1590 -082(b) 222 Angioimmunoblastic T-cell lymphoma 02 1024 19 - - - 01 415 11 10 607 232(b) 223 Subcutaneous panniculitis- 00 68 - - - - 00 39 - 00 16 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 03 1549 -39 01 184 -01 02 888 -43 08 477 -45

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 98 - - - - 00 69 - 00 18 -2(b) 226 Enteropathy-type T-cell lymphoma 00 105 - - - - 00 50 - 01 54 -2(b) 227 Cutaneous T-cell lymphoma NOSc 03 1696 -12 00 32 - 02 894 -03 12 770 -172(b) 228 Primary cutaneous anaplastic 01 739 -48 00 26 - 01 373 -49 05 340 -49

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 04 2253 97 07 1047 92 03 940 98 04 266 1022(b) 24 NKcT-cell lymphoma nasal-type 01 638 -05 00 18 - 01 435 -03 03 185 -06

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 58 - - - - 00 22 - 01 36 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 01 293 45 - - - 00 116 - 03 174 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 46 - - - - 00 25 - 00 20 -2(c) Non-Hodgkin lymphoma unknown lineage 03 1407 -232 01 195 - 02 580 -184 10 632 -2302(c) 1 Precursor lymphoblastic leukemia 01 474 -228 01 187 - 00 134 - 02 153 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 49 - - - - - - - 01 36 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 02 884 -239 - - - 01 433 -175 07 443 -

lineage2() 1 Total precursor lymphomaleukemiad 18 9903 -06 35 5518 -17 09 3210 09 19 1175 05

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 435 271 - - - 01 215 - 03 207 -lymphoma

4 Lymphoid neoplasm NOSc 10 5235 -59 01 131 - 05 1871 -65 54 3233 -61

Table 1927 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 301 199772 -05 53 7889 02 202 79325 -02 1322 112558 -08

1 Hodgkin Lymphoma 24 14552 -16 12 1809 -10 29 10031 -14 32 2712 -32

2 Non-Hodgkin lymphoma 269 180219 -03 40 5982 03 170 67835 00 1251 106402 -062(a) Non-Hodgkin lymphoma B-cell 250 168102 -01 34 5050 13 154 61827 02 1190 101225 -042(a) 1 Precursor Non-Hodgkin lymphoma B-cell 14 7632 16 29 4293 09 06 2315 29 12 1024 202(a) 2 Mature Non-Hodgkin lymphoma B-cell 223 151164 -04 05 713 35 141 56808 -01 1102 93643 -072(a) 21 ChronicSmallProlymphocytic 48 33190 -13 - - - 24 10176 -05 268 23000 -16

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 43 30073 -15 - - - 22 9196 -06 243 20866 -19

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 118 - - - - 00 26 - 01 89 -2(a) 213 Mantle-cell lymphoma 04 2999 11 - - - 02 954 10 24 2045 12

2(a) 22 Lymphoplasmacytic lymphoma 05 3569 04 - - - 03 1066 -16 30 2501 11Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 02 1605 01 - - - 01 516 -25 13 1087 112(a) 222 Waldenstrom macroglubulinemia 03 1964 06 - - - 01 550 -08 17 1414 11

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 58 39060 00 02 371 33 38 14656 03 283 24033 -032(a) 231 DLBCL NOSc 57 38379 -02 02 342 27 36 14103 -01 282 23934 -032(a) 232 Intravascular large B-cell 00 87 - - - - 00 32 - 01 55 -

lymphoma2(a) 233 Primary effusion lymphoma - - - - - - - - - - - -2(a) 234 Mediastinal large B-cell 01 580 91 00 29 - 02 518 93 00 33 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 02 1304 -34 02 253 38 02 649 -37 05 402 -852(a) 25 Marginal-zone lymphoma (MZL) 21 14183 01 00 39 - 15 5872 12 98 8272 -062(a) 251 Splenic MZL 02 1254 -07 - - - 01 455 -32 10 799 072(a) 252 Extranodal MZL MALTc type 13 8711 06 00 30 - 10 3881 17 57 4800 -032(a) 253 Nodal MZL 06 4218 -07 - - - 04 1536 11 32 2673 -18

2(a) 26 Follicular lymphoma 33 21794 -24 00 19 - 27 10515 -25 134 11260 -222(a) 27 Hairy-cell leukemia 01 728 -12 - - - 01 403 -11 04 325 -122(a) 28 Plasma cell neoplasms 55 37315 08 - - - 33 13461 15 282 23839 052(a) 281 Plasmacytoma 03 1882 00 - - - 02 853 12 12 1017 -092(a) 282 Multiple myeloma 52 35433 09 - - - 30 12608 15 270 22822 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 21 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 14 9306 32 00 44 - 07 2704 32 76 6558 31

Table 1928All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 17 11104 01 05 772 29 15 5698 05 55 4634 -112(b) 1 Precursor Non-Hodgkin lymphoma T-cell 00 186 - 01 85 - 00 84 - 00 17 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 17 10889 09 05 686 83 15 5599 12 54 4604 -092(b) 21 Mycosis fungoidesSezary syndrome 05 3007 15 01 78 - 05 1819 26 13 1110 -042(b) 211 Mycosis fungoides 05 2908 12 01 78 - 05 1777 23 12 1053 -072(b) 212 Sezary syndrome 00 99 - - - - 00 42 - 01 57 -

2(b) 22 Peripheral T-cell lymphoma 09 6093 -08 01 216 30 08 2911 -06 35 2966 -142(b) 221 Peripheral T-cell lymphoma NOSc 03 2234 03 00 37 - 03 969 07 14 1228 -012(b) 222 Angioimmunoblastic T-cell lymphoma 01 878 -22 - - - 01 284 -39 07 594 -152(b) 223 Subcutaneous panniculitis- 00 108 - 00 18 - 00 72 - 00 18 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 974 -33 01 107 - 02 562 -19 04 305 -77

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 41 - - - - 00 29 - - - -2(b) 226 Enteropathy-type T-cell lymphoma 00 81 - - - - 00 34 - 01 47 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 1267 00 00 27 - 02 681 07 07 559 -102(b) 228 Primary cutaneous anaplastic 01 510 -34 00 25 - 01 280 -50 02 205 -33

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 02 1164 96 03 381 127 01 534 97 03 249 302(b) 24 NKcT-cell lymphoma nasal-type 01 347 11 - - - 01 224 - 01 115 -

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 62 - - - - 00 32 - 00 29 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 216 03 - - - 00 79 - 02 135 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 29 - - - - - - - - - -2(c) Non-Hodgkin lymphoma unknown lineage 02 1013 -341 01 160 - 01 310 - 06 543 -2(c) 1 Precursor lymphoblastic leukemia 01 340 - 01 156 - 00 104 - 01 80 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 46 - - - - - - - 00 33 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 627 - - - - 01 194 - 05 430 -

lineage2() 1 Total precursor lymphomaleukemiad 14 8158 -09 31 4534 -13 07 2503 02 13 1121 -11

3 Composite Hodgkin lymphoma and Non-Hodgkin 00 327 - - - - 00 124 - 02 196 -lymphoma

4 Lymphoid neoplasm NOSc 07 4674 -52 01 91 - 03 1335 -51 36 3248 -58

Table 1928 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 15: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 males aged 55+ and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco-Oakland SMSA Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlantac The San Francisco-Oakland SMSA represents 15 of all persons in the SEER areas For this age group all SEER areas may not be

generalizable to the United States for Non-Hodgkin Lymphoma- Statistic not shown Rate based on less than 4 cases for the time interval

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 3536 1732 1873 2127 2322 2497 2704 2810 3116 3385 3551 3747 4025 4397 4640 4868 5190 5321 8672

SEER 9 except 2886 1447 1584 1791 1912 2092 2226 2326 2569 2840 3002 3088 3395 3709 3928 4113 4320 4558 7317SF-Oakland

San Francisco- 650 285 289 336 410 405 478 484 547 545 549 659 630 688 712 755 870 763 1355Oakland SMSAc

San Francisco 178 65 88 104 109 105 132 106 130 126 106 141 108 169 131 136 164 148 261CityCounty

SEER Location 1975- 1980- 1982- 1984- 1986- 1988- 1990- 1992- 1994- 1996- 1998- 2000- 2002- 2004- 2006- 2008- 2010- 2012- 2014-1979 1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2016

SEER 9b 451 522 540 596 633 673 701 706 761 800 811 831 858 900 901 891 899 862 871

SEER 9 except 440 521 544 601 620 667 687 692 744 797 813 813 858 901 904 891 888 874 874SF-Oakland

San Francisco- 508 528 520 571 702 703 773 783 854 821 800 932 855 894 888 890 959 800 860Oakland SMSAc

San Francisco 482 446 598 727 739 757 934 747 914 872 727 934 690 1047 764 769 889 776 826CityCounty

Table 1915

Non-Hodgkin Lymphoma

Number of Cases

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 55+

Year of Diagnosis

Age-Adjusted Cancer Incidence Ratesa

By SEER Location and Year of Diagnosis 1975-2016

All Races Males Ages 55+

Year of Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 003 006 217 072 Asian 0 001 003 005 183 072

10 002 005 011 218 073 Pacific 10 002 004 009 184 073

20 003 009 021 217 073 Islander 20 003 007 015 182 073

30 006 018 042 216 073 30 005 013 029 180 073

40 012 037 082 213 074 40 008 024 057 176 073

50 025 072 139 206 074 50 017 049 101 170 073

60 049 120 177 191 075 60 034 087 139 158 072

70 080 144 - 160 072 70 056 112 - 133 068

80 085 - - 106 062 80 066 - - 091 056

White 0 001 003 006 227 075 American 0 001 002 003 116 049

10 002 005 011 228 076 Indian 10 002 002 005 117 050

20 003 009 021 227 076 Alaska 20 001 003 008 116 050

30 006 018 043 226 077 Nativea 30 003 007 022 117 051

40 012 038 085 223 077 40 004 019 041 117 052

50 026 075 147 217 078 50 016 038 078 118 053

60 052 127 187 201 078 60 024 067 105 109 055

70 085 153 - 169 076 70 048 091 - 096 055

80 090 - - 111 065 80 057 - - 064 043

Black 0 001 002 006 138 042 Hispanicb 0 001 002 005 222 073

10 002 005 011 140 043 10 001 004 009 223 074

20 003 010 022 139 043 20 003 008 019 222 074

30 006 019 041 137 043 30 005 016 040 221 074

40 013 035 068 133 043 40 011 035 078 218 074

50 023 057 093 125 043 50 024 068 133 211 074

60 037 076 102 110 042 60 046 114 173 195 074

70 047 078 - 087 038 70 075 140 - 164 070

80 044 - - 057 032 80 081 - - 112 057

Table 1916

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Both Sexes 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 004 007 243 081 Asian 0 001 003 006 213 085

10 002 006 013 244 082 Pacific 10 002 005 011 213 086

20 004 010 024 243 082 Islander 20 003 009 018 211 086

30 007 021 049 243 083 30 006 015 034 210 086

40 014 042 094 240 084 40 009 028 067 205 086

50 029 082 158 233 085 50 019 059 117 199 086

60 057 139 203 219 086 60 041 101 161 187 085

70 095 170 - 188 084 70 066 131 - 159 082

80 105 - - 130 073 80 080 - - 114 069

White 0 001 004 007 254 085 American 0 001 003 004 104 057

10 002 006 013 255 086 Indian 10 002 003 006 105 058

20 004 010 024 254 086 Alaska 20 001 004 008 103 058

30 007 020 049 253 087 Nativea 30 003 008 021 104 059

40 014 043 097 251 088 40 005 018 038 105 060

50 030 086 167 244 089 50 014 035 071 105 062

60 059 147 215 230 090 60 023 062 094 099 065

70 101 180 - 198 088 70 046 084 - 090 066

80 112 - - 136 076 80 053 - - 061 053

Black 0 001 003 007 152 046 Hispanicb 0 001 003 005 238 083

10 002 006 014 154 047 10 002 005 011 239 084

20 004 012 027 153 047 20 003 009 021 238 084

30 008 023 048 152 047 30 006 018 043 238 084

40 016 042 079 148 047 40 012 037 083 235 085

50 027 066 105 138 047 50 026 073 145 228 085

60 043 087 114 123 045 60 050 126 189 214 085

70 054 088 - 099 042 70 086 157 - 185 081

80 053 - - 070 036 80 094 - - 131 066

Table 1917

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Males 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 002 004 193 064 Asian 0 001 002 004 159 063

10 001 004 009 195 064 Pacific 10 001 004 008 160 063

20 003 007 017 194 064 Islander 20 002 006 013 159 063

30 005 015 036 192 065 30 004 011 025 157 063

40 010 031 071 189 065 40 007 021 048 153 063

50 022 062 120 182 065 50 014 042 087 148 063

60 042 103 154 168 065 60 028 074 122 136 062

70 067 123 - 138 063 70 049 099 - 114 058

80 071 - - 090 054 80 057 - - 075 047

White 0 001 002 004 203 067 American 0 000 001 002 128 043

10 001 004 009 204 067 Indian 10 001 001 004 129 044

20 002 007 017 203 067 Alaska 20 001 003 007 128 044

30 005 015 037 201 067 Nativea 30 002 006 023 129 044

40 010 032 074 198 068 40 004 021 044 129 045

50 022 065 127 192 068 50 017 042 085 129 046

60 044 109 163 177 068 60 026 072 113 118 047

70 072 130 - 146 066 70 050 097 - 102 046

80 075 - - 094 056 80 060 - - 066 037

Black 0 000 002 004 126 040 Hispanicb 0 001 002 004 210 065

10 001 004 009 128 040 10 001 004 008 211 066

20 003 008 018 127 040 20 002 007 017 211 066

30 005 015 034 125 040 30 004 014 036 209 066

40 010 029 058 122 040 40 010 032 073 206 066

50 020 049 083 115 040 50 022 064 123 198 066

60 032 068 094 102 039 60 043 104 161 182 065

70 041 071 - 080 036 70 066 127 - 149 062

80 039 - - 051 030 80 073 - - 100 051

Table 1918

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Females 2014-2016 By RaceEthnicity

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

The AAPC is the Average Annual Percent Change over the time interval The AAPCs are calculated bythe Joinpoint Regression Program Version 47 February 2019 National Cancer Institute

- Statistic not shown Rate based on less than 16 cases for the time intervalTrend based on less than 10 cases for at least one year within the time interval

a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) Trendsare based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico SeattleUtah and AtlantaThe SEER 21 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the AlaskaNative Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts

c The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 3 Joinpoints overdiagnosis years 2000-2016

d The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 5 Joinpoints overdiagnosis years 1975-2016

e Hispanic and Non-Hispanic are not mutually exclusive from whites blacks AsianPacificIslanders and American IndiansAlaska Natives Incidence data for Hispanics and Non-Hispanicsare based on NHIA and exclude cases from the Alaska Native Registry

f Incidence data for American IndianAlaska Native are based on the PurchasedReferred CareDelivery Area (PRCDA) counties

g US Mortality Files National Center for Health Statistics CDCh The 2007-2016 mortality AAPCs are based on a Joinpoint analysis using years of death 2000-2016 The APC is significantly different from zero (plt05)

SEER Incidence SEER 21 Areasb SEER 21 Areasb SEER 9 Areasb

Rate 2012-2016 Trend 2007-2016c Trend 2007-2016d

Rate per 100000 persons AAPC () AAPC ()

Total Males Females Total Males Females Total Males Females RaceEthnicity

All Races 196 239 162 -07 -09 -08 -09 -07 -08

White 206 250 170 -08 -11 -09 -09 -08 -08White Hispanice 183 212 161 -08 -03 -05 - - -White Non-Hispanice 210 256 172 -08 -06 -10 - - -

Black 147 177 124 01 00 03 00 -04 -09

AsianPacific Islander 134 164 110 00 00 -01 - - -

Amer IndAlaska Natf 113 120 106 -05 -12 00 - - -

Hispanice 179 207 157 -05 -02 03 - - -

US Mortalityg Rate 2012-2016 Trend 2007-2016h

Rate per 100000 persons AAPC ()

Total Males Females Total Males FemalesRaceEthnicity

All Races 56 73 44 -23 -20 -27

White 59 76 45 -23 -20 -27White Hispanice 51 65 40 -16 -13 -20White Non-Hispanice 59 76 46 -23 -20 -27

Black 41 52 33 -20 -19 -21

AsianPacific Islander 39 49 31 -17 -15 -19

Amer IndAlaska NatTotal US 31 40 24 -32 -20 -45PRCDA Counties 44 58 33 -21 -04 -37Non-PRCDA Counties 17 21 14 -54 -50 -60

Hispanice 48 61 38 -17 -14 -21

Table 1919Non-Hodgkin Lymphoma

SEER Incidence and US MortalityAge-Adjusted Rates and Trendsa

By RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Incidence Ratesa 2012-2016

California 1844 2241 1515 1938 2349 1591 1390 1639 1182Greater Bay Area 1957 2381 1600 2144 2601 1755 1628 1828 1436San Francisco-Oakland 1956 2421 1570 2174 2660 1765 1603 1816 1408San Jose-Monterey 1962 2311 1660 2097 2503 1742 1800 1891 1646

Los Angeles 1804 2176 1505 1951 2331 1637 1357 1659 1139Greater California 1822 2220 1489 1876 2286 1529 1314 1534 1113

Connecticut 2116 2607 1733 2154 2642 1771 1386 1829 1051Detroit 2132 2636 1742 2290 2850 1847 1620 1905 1409Georgia 1826 2244 1487 1936 2346 1588 1462 1833 1187Atlanta 1925 2381 1555 2119 2567 1736 1601 2034 1272Rural Georgia 1584 1790 1401 1953 2298 1567 807 - 988Greater Georgia 1784 2186 1459 1872 2274 1537 1380 1703 1146

Hawaii 1660 2024 1349 1958 2275 1593 - - -Idaho 1922 2267 1616 1920 2262 1618 - - -Iowa 2134 2601 1756 2148 2612 1773 1352 1602 1100Kentucky 2039 2505 1666 2070 2538 1693 1403 1788 1112Louisiana 1944 2352 1614 2106 2537 1744 1469 1769 1237Massachusetts 1810 2181 1518 1830 2214 1524 1452 1655 1299New Jersey 2155 2607 1804 2285 2765 1905 1387 1621 1222New Mexico 1550 1739 1387 1580 1798 1394 875 - -New York 2152 2620 1788 2306 2792 1915 1545 1852 1333Seattle-Puget Sound 2116 2627 1695 2177 2667 1766 1631 1973 1316Utah 1843 2233 1498 1862 2258 1513 2089 - -

SEER 9 Areasb 1992 2444 1623 2095 2551 1716 1573 1914 1298SEER 13 Areasb 1946 2373 1597 2064 2502 1700 1519 1853 1258SEER 18 Areasb 1933 2354 1590 2031 2464 1671 1449 1751 1214SEER 21 Areasb 1963 2388 1620 2061 2498 1702 1471 1771 1245

Table 1920Non-Hodgkin Lymphoma

Age-Adjusted SEER Incidence Ratesa

By Registry Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control and PreventionRates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and AtlantaThe SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Death Ratesa 2012-2016

California 533 677 423 570 726 449 417 480 367Greater Bay Area 505 671 376 561 756 408 410 491 331San Francisco-Oakland 503 667 376 555 742 409 416 490 343San Jose-Monterey 511 681 377 573 781 407 - - -

Los Angeles 541 670 443 589 728 481 424 503 371Greater California 539 682 429 564 716 447 416 455 384

Connecticut 533 705 407 547 717 421 350 510 244Detroit 639 822 505 693 895 542 443 528 384Georgia 533 697 411 580 747 450 376 503 286Atlanta 492 659 372 533 728 388 397 506 317Rural Georgia 559 731 388 670 813 507 - - -Greater Georgia 549 712 426 595 755 470 363 500 266

Hawaii 475 620 352 545 649 412 - - -Idaho 635 775 510 641 782 516 - - -Iowa 638 845 484 642 848 488 - - -Kentucky 642 886 460 655 904 470 401 557 284Louisiana 608 814 451 651 863 485 461 623 340Massachusetts 523 659 423 541 682 436 347 410 297New Jersey 545 721 419 585 780 443 372 466 314New Mexico 488 585 405 493 595 406 - - -New York 535 702 412 575 752 441 390 514 313Seattle-Puget Sound 585 749 463 604 769 480 490 562 397Utah 542 670 433 551 681 440 - - -

SEER 9 Areasb 555 719 430 586 758 454 414 522 333SEER 13 Areasb 549 705 429 586 753 457 419 521 342SEER 18 Areasb 554 717 431 589 761 456 409 518 329SEER 21 Areasb 550 712 428 584 754 453 401 513 322

Total US 562 725 436 586 755 454 408 518 330

Table 1921Non-Hodgkin Lymphoma

Age-Adjusted SEER Death Ratesa

By Registry Race and Sex

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 562 002

High Five StatesMichigan 645 011 01(0112) 1479Kentucky 642 016 02(0118) 1424Iowa 638 018 03(0120) 1367Indiana 638 013 04(0117) 1361Idaho 635 027 05(0126) 1303

Low Five StatesNevada 511 019 47(2251) -899Colorado 491 014 48(3851) -1257New Mexico 488 020 49(2851) -1317Hawaii 475 024 50(3051) -1542c

DC 444 039 51(2351) -2097c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 545 014 28(1847) -291 Montana 559 030 25(0250) -042Alaska 525 047 43(0151) -654 Nebraska 563 023 22(0548) 026Arizona 512 012 46(2950) -886 Nevada 511 019 47(2251) -899Arkansas 555 018 26(1247) -113 New Hampshire 562 027 23(0349) 014California 533 005 40(2645) -508 New Jersey 545 010 29(2045) -301Colorado 491 014 48(3851) -1257 New Mexico 488 020 49(2851) -1317Connecticut 533 016 39(1949) -505 New York 535 007 37(2446) -478Delaware 628 033 08(0139) 1174 North Carolina 541 010 35(2146) -363DC 444 039 51(2351) -2097c North Dakota 561 037 24(0151) -007Florida 535 006 38(2545) -479 Ohio 616 009 10(0220) 969Georgia 533 011 41(2248) -511 Oklahoma 630 017 06(0121) 1226Hawaii 475 024 50(3051) -1542c Oregon 612 016 11(0124) 903Idaho 635 027 05(0126) 1303 Pennsylvania 603 009 16(0622) 729Illinois 566 009 20(1634) 085 Rhode Island 542 029 32(0651) -350Indiana 638 013 04(0117) 1361 South Carolina 542 014 31(1847) -347Iowa 638 018 03(0120) 1367 South Dakota 541 033 36(0451) -364Kansas 585 019 19(0439) 420 Tennessee 629 013 07(0119) 1198Kentucky 642 016 02(0118) 1424 Texas 546 007 27(2142) -277Louisiana 608 016 14(0125) 826 Utah 542 022 33(1250) -352Maine 609 026 13(0137) 852 Vermont 605 040 15(0148) 770Maryland 524 013 44(2349) -663 Virginia 544 011 30(2046) -319Massachusetts 523 012 45(2549) -687 Washington 599 013 17(0425) 665Michigan 645 011 01(0112) 1479 West Virginia 612 022 12(0132) 894Minnesota 617 014 09(0122) 984 Wisconsin 590 013 18(0629) 507Mississippi 531 018 42(1850) -551 Wyoming 564 043 21(0151) 050Missouri 542 012 34(1947) -354

Table 1922Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males and Females

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 725 003

High Five StatesKentucky 886 030 01(0112) 2213c

Iowa 845 032 02(0120) 1647c

Michigan 842 019 03(0114) 1615c

Indiana 839 024 04(0116) 1567c

Delaware 824 058 05(0144) 1364

Low Five StatesArizona 635 019 47(3251) -1244Alaska 630 075 48(0251) -1311Hawaii 620 041 49(1951) -1452DC 614 071 50(0551) -1535c

New Mexico 585 033 51(3451) -1928c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 688 025 36(1649) -513 Montana 709 050 26(0251) -218Alaska 630 075 48(0251) -1311 Nebraska 737 040 20(0248) 165Arizona 635 019 47(3251) -1244 Nevada 653 032 44(1951) -994Arkansas 721 031 22(0747) -061 New Hampshire 710 046 25(0451) -210California 677 009 41(2846) -666 New Jersey 721 018 21(1441) -059Colorado 643 024 46(2451) -1133 New Mexico 585 033 51(3451) -1928c

Connecticut 705 028 28(1248) -273 New York 702 012 30(1943) -323Delaware 824 058 05(0144) 1364 North Carolina 709 018 27(1644) -221DC 614 071 50(0551) -1535c North Dakota 682 061 39(0251) -598Florida 683 011 37(2446) -585 Ohio 800 017 09(0320) 1029Georgia 697 019 34(1746) -387 Oklahoma 806 030 08(0126) 1109Hawaii 620 041 49(1951) -1452 Oregon 794 028 12(0128) 947Idaho 775 045 16(0146) 692 Pennsylvania 783 015 15(0523) 794Illinois 739 016 19(1235) 190 Rhode Island 649 050 45(1051) -1050Indiana 839 024 04(0116) 1567c South Carolina 681 025 40(1850) -604Iowa 845 032 02(0120) 1647c South Dakota 701 056 31(0251) -332Kansas 713 032 24(0948) -174 Tennessee 820 023 06(0120) 1311Kentucky 886 030 01(0112) 2213c Texas 698 012 32(2043) -368Louisiana 814 029 07(0122) 1222 Utah 670 036 42(1351) -754Maine 754 045 18(0148) 395 Vermont 794 069 11(0149) 950Maryland 682 023 38(1849) -588 Virginia 694 020 35(1847) -429Massachusetts 659 020 43(2450) -910 Washington 790 022 13(0224) 897Michigan 842 019 03(0114) 1615c West Virginia 774 038 17(0142) 675Minnesota 797 025 10(0224) 995 Wisconsin 786 023 14(0227) 844Mississippi 717 034 23(0748) -110 Wyoming 698 071 33(0151) -377Missouri 702 022 29(1646) -319

Table 1923Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 436 002

High Five StatesIdaho 510 033 01(0139) 1697c

Maine 497 031 02(0141) 1396Michigan 495 012 03(0119) 1340Oklahoma 492 020 04(0128) 1276Indiana 492 016 05(0123) 1270

Low Five StatesMississippi 404 021 47(1351) -731Nevada 382 022 48(2051) -1237Colorado 369 016 49(3451) -1540c

Hawaii 352 027 50(2551) -1932c

DC 323 044 51(1551) -2601c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 440 017 24(0547) 099 Montana 435 036 27(0151) -034Alaska 414 058 38(0151) -500 Nebraska 435 027 26(0249) -032Arizona 407 014 44(2049) -664 Nevada 382 022 48(2051) -1237Arkansas 428 021 31(0649) -181 New Hampshire 454 032 19(0149) 400California 423 006 34(2244) -313 New Jersey 419 012 37(1848) -397Colorado 369 016 49(3451) -1540c New Mexico 405 025 46(0951) -706Connecticut 407 018 45(1550) -669 New York 412 008 39(2548) -554Delaware 473 039 12(0150) 855 North Carolina 420 012 35(1848) -374DC 323 044 51(1551) -2601c North Dakota 471 045 13(0150) 809Florida 412 007 40(2548) -564 Ohio 478 011 10(0123) 967Georgia 411 012 43(2049) -582 Oklahoma 492 020 04(0128) 1276Hawaii 352 027 50(2551) -1932c Oregon 465 019 15(0141) 668Idaho 510 033 01(0139) 1697c Pennsylvania 467 010 14(0427) 714Illinois 439 010 25(1341) 074 Rhode Island 455 035 18(0150) 434Indiana 492 016 05(0123) 1270 South Carolina 432 017 30(0947) -102Iowa 484 021 08(0135) 1087 South Dakota 411 039 42(0151) -580Kansas 486 023 06(0137) 1143 Tennessee 484 015 09(0126) 1087Kentucky 460 018 17(0241) 544 Texas 427 008 32(1944) -213Louisiana 451 018 21(0345) 333 Utah 433 026 28(0250) -081Maine 497 031 02(0141) 1396 Vermont 461 047 16(0151) 578Maryland 411 015 41(1749) -576 Virginia 432 013 29(1246) -092Massachusetts 423 014 33(1548) -303 Washington 452 015 20(0541) 360Michigan 495 012 03(0119) 1340 West Virginia 486 027 07(0143) 1141Minnesota 475 017 11(0132) 901 Wisconsin 443 015 23(0645) 156Mississippi 404 021 47(1351) -731 Wyoming 445 051 22(0151) 192Missouri 419 014 36(1549) -396

Table 1924Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Females

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 Areas (excluding the AlaskaNative Registry) and 112016 US population estimates based on the average of 2015 and 2016 population estimates from theUS Bureau of the CensusPrevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 24 years

b Maximum limited-duration prevalence is 24 years for 1992-2016 datac Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groupsd Cases diagnosed more than 24 years ago were estimated using the completeness index method (Capocaccia et al 1997

Merrill et al 2000)e Complete prevalence is obtained by summing 0 to lt24 and gt=24- Statistic not shown Statistic based on fewer than 5 cases estimated alive in SEER for the time interval+ Not available

Years Since Diagnosis 0 to lt5 5 to lt10 10 to lt15 15 to lt20 20 to lt24 0 to lt24b gt=24d Completee

Race Sex

All Races Both Sexes 248946 177490 117326 69109 31890 644761 49943 694704Males 135137 94173 60159 36020 16581 342069 25489 367558Females 113809 83317 57167 33089 15309 302692 24454 327146

White Both Sexes 213764 154454 101984 60537 28026 558765 49625 620368Males 116527 82172 52535 31627 14543 297404 26526 330121Females 97237 72282 49448 28910 13483 261361 23099 290247

Black Both Sexes 20500 13640 9750 5271 2215 51376 4115 55491Males 10712 7188 4768 2684 1174 26526 1911 28437Females 9789 6452 4981 2587 1041 24850 2204 27054

Asian Both Sexes 8405 5210 3415 1867 844 19741 + +Pacific Males 4548 2661 1757 1013 407 10386 + +Islander Females 3856 2549 1657 855 437 9355 + +

Hispanic Both Sexes 21339 14049 8272 4881 2136 50676 + +Males 10918 7243 4331 2617 1094 26202 + +Females 10421 6805 3941 2264 1043 24474 + +

Age Specific (Crude) Age-Adjustedc Age at Prevalence All Ages 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ All Ages

Race Sex

All Races Both Sexes 02001 00035 00139 00283 00538 01121 02352 04640 08181 10224 01738Males 02156 00044 00189 00354 00625 01293 02710 05243 09364 12449 02023Females 01850 00026 00087 00208 00450 00952 02010 04094 07196 08856 01498

White Both Sexes 02216 00035 00143 00289 00534 01148 02427 04858 08597 10738 01807Males 02380 00045 00198 00359 00622 01317 02790 05442 09778 13060 02095Females 02054 00025 00085 00214 00442 00976 02072 04317 07593 09285 01560

Black Both Sexes 01139 00029 00113 00265 00599 01027 02010 03340 05117 05333 01251Males 01226 00029 00140 00351 00696 01223 02333 03969 05849 06055 01457Females 01059 00030 00086 00178 00510 00853 01728 02836 04608 04976 01088

Asian Both Sexes 00970 00039 00133 00207 00353 00680 01409 02692 04470 06094 01032Pacific Males 01065 00044 00175 00240 00398 00744 01640 03072 05516 07472 01222Islander Females 00882 00033 00092 00175 00312 00623 01209 02384 03629 05207 00880

Hispanic Both Sexes 00887 00030 00117 00206 00398 00850 01769 03632 05888 07209 01294Males 00908 00035 00147 00256 00455 00932 01924 03940 06326 08003 01420Females 00866 00024 00086 00151 00337 00766 01616 03360 05552 06719 01185

Table 1925Non-Hodgkin Lymphoma

Estimated United States Cancer Prevalence Countsa on January 1 2016By RaceEthnicity Sex and Years Since Diagnosis

Estimated prevalence percenta on January 1 2016 of the SEER population diagnosed in the previous 24 yearsBy Age at Prevalence RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 372 452924 -05 62 18862 04 247 189692 -05 1657 244370 -05

1 Hodgkin Lymphoma 28 32262 -17 13 3927 -06 33 22556 -15 39 5779 -31

2 Non-Hodgkin lymphoma 336 409991 -03 48 14693 04 210 163591 -03 1572 231707 -042(a) Non-Hodgkin lymphoma B-cell 311 380349 -01 39 11836 14 190 148768 -02 1491 219745 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 15 16631 20 31 9416 10 07 5203 39 14 2012 252(a) 2 Mature Non-Hodgkin lymphoma B-cell 280 343965 -04 07 2271 30 174 137225 -05 1387 204469 -042(a) 21 ChronicSmallProlymphocytic 69 85601 -13 00 35 - 35 29103 -11 382 56463 -14

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 61 75061 -15 00 30 - 31 25339 -13 336 49692 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 311 19 - - - 00 72 - 02 234 262(a) 213 Mantle-cell lymphoma 08 10229 03 - - - 04 3692 02 44 6537 04

2(a) 22 Lymphoplasmacytic lymphoma 07 8651 00 - - - 03 2590 -11 41 6059 04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 03 3667 -03 - - - 01 1132 -18 17 2533 022(a) 222 Waldenstrom macroglubulinemia 04 4984 03 - - - 02 1458 -07 24 3526 06

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 72 87188 00 03 925 26 48 36480 -02 339 49783 022(a) 231 DLBCL NOSc 71 85899 -01 03 861 12 46 35469 -05 337 49569 012(a) 232 Intravascular large B-cell 00 162 - - - - 00 63 - 01 99 -

lymphoma2(a) 233 Primary effusion lymphoma 00 181 27 - - - 00 126 - 00 55 -2(a) 234 Mediastinal large B-cell 01 946 116 00 64 - 01 822 111 00 60 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 04 4692 -26 03 1028 32 04 2618 -43 07 1046 -432(a) 25 Marginal-zone lymphoma (MZL) 22 26534 00 00 137 13 14 11049 05 104 15348 -042(a) 251 Splenic MZL 02 2418 04 - - - 01 889 -08 10 1529 102(a) 252 Extranodal MZL MALTc type 13 15979 06 00 92 - 09 7148 11 59 8739 032(a) 253 Nodal MZL 07 8137 -15 00 45 - 04 3012 -05 34 5080 -20

2(a) 26 Follicular lymphoma 35 43582 -21 00 119 - 28 21725 -25 147 21738 -182(a) 27 Hairy-cell leukemia 03 3712 -16 - - - 03 2311 -19 09 1401 -122(a) 28 Plasma cell neoplasms 68 83957 08 00 24 - 39 31325 12 358 52608 062(a) 281 Plasmacytoma 04 4879 -04 00 16 - 03 2362 -06 17 2501 -032(a) 282 Multiple myeloma 64 79078 09 - - - 36 28963 14 341 50107 07

plasma-cell leukemia2(a) 29 Heavy chain disease 00 48 - - - - 00 24 - 00 23 -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 16 19753 33 00 149 27 08 6340 37 90 13264 32

Table 1926All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 23 27222 01 08 2502 18 19 13933 03 73 10787 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 616 - 01 293 - 00 272 - 00 51 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 22 26531 11 07 2207 75 19 13621 12 73 10703 -042(b) 21 Mycosis fungoidesSezary syndrome 06 6969 18 01 213 84 06 4080 23 18 2676 052(b) 211 Mycosis fungoides 06 6739 17 01 213 84 05 3990 22 17 2536 042(b) 212 Sezary syndrome 00 230 46 - - - 00 90 - 01 140 -

2(b) 22 Peripheral T-cell lymphoma 12 14531 -10 02 534 07 10 7159 -09 46 6838 -122(b) 221 Peripheral T-cell lymphoma NOSc 04 5393 -01 00 86 - 03 2489 04 19 2818 -042(b) 222 Angioimmunoblastic T-cell lymphoma 02 1902 02 - - - 01 699 -09 08 1201 072(b) 223 Subcutaneous panniculitis- 00 176 44 00 31 - 00 111 - 00 34 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 2523 -36 01 291 00 02 1450 -33 05 782 -54

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 139 - - - - 00 98 - 00 28 -2(b) 226 Enteropathy-type T-cell lymphoma 00 186 -02 - - - 00 84 - 01 101 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 2963 -07 00 59 - 02 1575 01 09 1329 -142(b) 228 Primary cutaneous anaplastic 01 1249 -41 00 51 - 01 653 -49 04 545 -39

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 03 3417 96 05 1428 101 02 1474 99 03 515 672(b) 24 NKcT-cell lymphoma nasal-type 01 985 02 00 26 - 01 659 00 02 300 05

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 120 - - - - 00 54 - 00 65 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 509 30 - - - 00 195 -05 02 309 442(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 75 - - - - 00 40 - 00 33 -2(c) Non-Hodgkin lymphoma unknown lineage 02 2420 -274 01 355 - 01 890 -216 08 1175 -2792(c) 1 Precursor lymphoblastic leukemia 01 814 -283 01 343 - 00 238 - 02 233 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 95 - - - - 00 25 - 00 69 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 1511 -274 - - - 01 627 -202 06 873 -319

lineage2() 1 Total precursor lymphomaleukemiad 16 18061 -07 33 10052 -15 08 5713 06 15 2296 -01

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 762 273 00 20 - 00 339 227 03 403 -lymphoma

4 Lymphoid neoplasm NOSc 08 9909 -55 01 222 113 04 3206 -59 43 6481 -59

Table 1926 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 461 253152 -05 70 10973 05 294 110367 -07 2122 131812 -05

1 Hodgkin Lymphoma 31 17710 -17 13 2118 -03 36 12525 -16 48 3067 -31

2 Non-Hodgkin lymphoma 419 229772 -03 56 8711 05 252 95756 -05 2017 125305 -032(a) Non-Hodgkin lymphoma B-cell 387 212247 -02 44 6786 15 227 86941 -04 1908 118520 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 16 8999 24 33 5123 11 08 2888 46 16 988 292(a) 2 Mature Non-Hodgkin lymphoma B-cell 351 192801 -05 10 1558 28 210 80417 -08 1783 110826 -042(a) 21 ChronicSmallProlymphocytic 96 52411 -15 00 21 - 47 18927 -14 539 33463 -15

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 82 44988 -17 00 19 - 40 16143 -16 464 28826 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 193 -02 - - - 00 46 - 02 145 052(a) 213 Mantle-cell lymphoma 13 7230 -01 - - - 07 2738 -01 72 4492 -01

2(a) 22 Lymphoplasmacytic lymphoma 10 5082 -05 - - - 04 1524 -08 58 3558 -04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 04 2062 -08 - - - 02 616 -12 23 1446 -072(a) 222 Waldenstrom macroglubulinemia 06 3020 -02 - - - 02 908 -06 34 2112 -02

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 88 48128 01 03 554 22 59 21824 -06 418 25750 052(a) 231 DLBCL NOSc 87 47520 00 03 519 03 57 21366 -08 416 25635 042(a) 232 Intravascular large B-cell 00 75 - - - - 00 31 - 01 44 -

lymphoma2(a) 233 Primary effusion lymphoma 00 167 26 - - - 00 123 - 01 44 -2(a) 234 Mediastinal large B-cell 01 366 155 00 35 - 01 304 142 00 27 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 06 3388 -22 05 775 31 06 1969 -46 10 644 -192(a) 25 Marginal-zone lymphoma (MZL) 22 12351 -02 01 98 - 14 5177 -02 114 7076 -012(a) 251 Splenic MZL 02 1164 14 - - - 01 434 18 12 730 112(a) 252 Extranodal MZL MALTc type 13 7268 07 00 62 - 09 3267 04 63 3939 102(a) 253 Nodal MZL 07 3919 -23 00 36 - 04 1476 -22 39 2407 -23

2(a) 26 Follicular lymphoma 39 21788 -19 01 100 - 30 11210 -25 165 10478 -152(a) 27 Hairy-cell leukemia 05 2984 -18 - - - 05 1908 -20 17 1076 -152(a) 28 Plasma cell neoplasms 85 46642 07 - - - 45 17864 11 462 28769 052(a) 281 Plasmacytoma 05 2997 -08 - - - 04 1509 -16 24 1484 -012(a) 282 Multiple myeloma 80 43645 08 - - - 41 16355 13 439 27285 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 27 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 20 10447 34 01 105 - 10 3636 40 110 6706 32

Table 1927All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 29 16118 00 11 1730 14 23 8235 02 98 6153 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 430 - 01 208 - 01 188 - 01 34 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 28 15642 11 10 1521 71 22 8022 11 97 6099 -032(b) 21 Mycosis fungoidesSezary syndrome 07 3962 19 01 135 - 06 2261 21 25 1566 092(b) 211 Mycosis fungoides 07 3831 20 01 135 - 06 2213 21 23 1483 092(b) 212 Sezary syndrome 00 131 - - - - 00 48 - 01 83 -

2(b) 22 Peripheral T-cell lymphoma 15 8438 -13 02 318 -09 12 4248 -12 62 3872 -132(b) 221 Peripheral T-cell lymphoma NOSc 06 3159 -05 00 49 - 04 1520 02 26 1590 -082(b) 222 Angioimmunoblastic T-cell lymphoma 02 1024 19 - - - 01 415 11 10 607 232(b) 223 Subcutaneous panniculitis- 00 68 - - - - 00 39 - 00 16 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 03 1549 -39 01 184 -01 02 888 -43 08 477 -45

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 98 - - - - 00 69 - 00 18 -2(b) 226 Enteropathy-type T-cell lymphoma 00 105 - - - - 00 50 - 01 54 -2(b) 227 Cutaneous T-cell lymphoma NOSc 03 1696 -12 00 32 - 02 894 -03 12 770 -172(b) 228 Primary cutaneous anaplastic 01 739 -48 00 26 - 01 373 -49 05 340 -49

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 04 2253 97 07 1047 92 03 940 98 04 266 1022(b) 24 NKcT-cell lymphoma nasal-type 01 638 -05 00 18 - 01 435 -03 03 185 -06

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 58 - - - - 00 22 - 01 36 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 01 293 45 - - - 00 116 - 03 174 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 46 - - - - 00 25 - 00 20 -2(c) Non-Hodgkin lymphoma unknown lineage 03 1407 -232 01 195 - 02 580 -184 10 632 -2302(c) 1 Precursor lymphoblastic leukemia 01 474 -228 01 187 - 00 134 - 02 153 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 49 - - - - - - - 01 36 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 02 884 -239 - - - 01 433 -175 07 443 -

lineage2() 1 Total precursor lymphomaleukemiad 18 9903 -06 35 5518 -17 09 3210 09 19 1175 05

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 435 271 - - - 01 215 - 03 207 -lymphoma

4 Lymphoid neoplasm NOSc 10 5235 -59 01 131 - 05 1871 -65 54 3233 -61

Table 1927 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 301 199772 -05 53 7889 02 202 79325 -02 1322 112558 -08

1 Hodgkin Lymphoma 24 14552 -16 12 1809 -10 29 10031 -14 32 2712 -32

2 Non-Hodgkin lymphoma 269 180219 -03 40 5982 03 170 67835 00 1251 106402 -062(a) Non-Hodgkin lymphoma B-cell 250 168102 -01 34 5050 13 154 61827 02 1190 101225 -042(a) 1 Precursor Non-Hodgkin lymphoma B-cell 14 7632 16 29 4293 09 06 2315 29 12 1024 202(a) 2 Mature Non-Hodgkin lymphoma B-cell 223 151164 -04 05 713 35 141 56808 -01 1102 93643 -072(a) 21 ChronicSmallProlymphocytic 48 33190 -13 - - - 24 10176 -05 268 23000 -16

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 43 30073 -15 - - - 22 9196 -06 243 20866 -19

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 118 - - - - 00 26 - 01 89 -2(a) 213 Mantle-cell lymphoma 04 2999 11 - - - 02 954 10 24 2045 12

2(a) 22 Lymphoplasmacytic lymphoma 05 3569 04 - - - 03 1066 -16 30 2501 11Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 02 1605 01 - - - 01 516 -25 13 1087 112(a) 222 Waldenstrom macroglubulinemia 03 1964 06 - - - 01 550 -08 17 1414 11

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 58 39060 00 02 371 33 38 14656 03 283 24033 -032(a) 231 DLBCL NOSc 57 38379 -02 02 342 27 36 14103 -01 282 23934 -032(a) 232 Intravascular large B-cell 00 87 - - - - 00 32 - 01 55 -

lymphoma2(a) 233 Primary effusion lymphoma - - - - - - - - - - - -2(a) 234 Mediastinal large B-cell 01 580 91 00 29 - 02 518 93 00 33 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 02 1304 -34 02 253 38 02 649 -37 05 402 -852(a) 25 Marginal-zone lymphoma (MZL) 21 14183 01 00 39 - 15 5872 12 98 8272 -062(a) 251 Splenic MZL 02 1254 -07 - - - 01 455 -32 10 799 072(a) 252 Extranodal MZL MALTc type 13 8711 06 00 30 - 10 3881 17 57 4800 -032(a) 253 Nodal MZL 06 4218 -07 - - - 04 1536 11 32 2673 -18

2(a) 26 Follicular lymphoma 33 21794 -24 00 19 - 27 10515 -25 134 11260 -222(a) 27 Hairy-cell leukemia 01 728 -12 - - - 01 403 -11 04 325 -122(a) 28 Plasma cell neoplasms 55 37315 08 - - - 33 13461 15 282 23839 052(a) 281 Plasmacytoma 03 1882 00 - - - 02 853 12 12 1017 -092(a) 282 Multiple myeloma 52 35433 09 - - - 30 12608 15 270 22822 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 21 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 14 9306 32 00 44 - 07 2704 32 76 6558 31

Table 1928All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 17 11104 01 05 772 29 15 5698 05 55 4634 -112(b) 1 Precursor Non-Hodgkin lymphoma T-cell 00 186 - 01 85 - 00 84 - 00 17 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 17 10889 09 05 686 83 15 5599 12 54 4604 -092(b) 21 Mycosis fungoidesSezary syndrome 05 3007 15 01 78 - 05 1819 26 13 1110 -042(b) 211 Mycosis fungoides 05 2908 12 01 78 - 05 1777 23 12 1053 -072(b) 212 Sezary syndrome 00 99 - - - - 00 42 - 01 57 -

2(b) 22 Peripheral T-cell lymphoma 09 6093 -08 01 216 30 08 2911 -06 35 2966 -142(b) 221 Peripheral T-cell lymphoma NOSc 03 2234 03 00 37 - 03 969 07 14 1228 -012(b) 222 Angioimmunoblastic T-cell lymphoma 01 878 -22 - - - 01 284 -39 07 594 -152(b) 223 Subcutaneous panniculitis- 00 108 - 00 18 - 00 72 - 00 18 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 974 -33 01 107 - 02 562 -19 04 305 -77

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 41 - - - - 00 29 - - - -2(b) 226 Enteropathy-type T-cell lymphoma 00 81 - - - - 00 34 - 01 47 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 1267 00 00 27 - 02 681 07 07 559 -102(b) 228 Primary cutaneous anaplastic 01 510 -34 00 25 - 01 280 -50 02 205 -33

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 02 1164 96 03 381 127 01 534 97 03 249 302(b) 24 NKcT-cell lymphoma nasal-type 01 347 11 - - - 01 224 - 01 115 -

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 62 - - - - 00 32 - 00 29 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 216 03 - - - 00 79 - 02 135 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 29 - - - - - - - - - -2(c) Non-Hodgkin lymphoma unknown lineage 02 1013 -341 01 160 - 01 310 - 06 543 -2(c) 1 Precursor lymphoblastic leukemia 01 340 - 01 156 - 00 104 - 01 80 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 46 - - - - - - - 00 33 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 627 - - - - 01 194 - 05 430 -

lineage2() 1 Total precursor lymphomaleukemiad 14 8158 -09 31 4534 -13 07 2503 02 13 1121 -11

3 Composite Hodgkin lymphoma and Non-Hodgkin 00 327 - - - - 00 124 - 02 196 -lymphoma

4 Lymphoid neoplasm NOSc 07 4674 -52 01 91 - 03 1335 -51 36 3248 -58

Table 1928 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 16: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 003 006 217 072 Asian 0 001 003 005 183 072

10 002 005 011 218 073 Pacific 10 002 004 009 184 073

20 003 009 021 217 073 Islander 20 003 007 015 182 073

30 006 018 042 216 073 30 005 013 029 180 073

40 012 037 082 213 074 40 008 024 057 176 073

50 025 072 139 206 074 50 017 049 101 170 073

60 049 120 177 191 075 60 034 087 139 158 072

70 080 144 - 160 072 70 056 112 - 133 068

80 085 - - 106 062 80 066 - - 091 056

White 0 001 003 006 227 075 American 0 001 002 003 116 049

10 002 005 011 228 076 Indian 10 002 002 005 117 050

20 003 009 021 227 076 Alaska 20 001 003 008 116 050

30 006 018 043 226 077 Nativea 30 003 007 022 117 051

40 012 038 085 223 077 40 004 019 041 117 052

50 026 075 147 217 078 50 016 038 078 118 053

60 052 127 187 201 078 60 024 067 105 109 055

70 085 153 - 169 076 70 048 091 - 096 055

80 090 - - 111 065 80 057 - - 064 043

Black 0 001 002 006 138 042 Hispanicb 0 001 002 005 222 073

10 002 005 011 140 043 10 001 004 009 223 074

20 003 010 022 139 043 20 003 008 019 222 074

30 006 019 041 137 043 30 005 016 040 221 074

40 013 035 068 133 043 40 011 035 078 218 074

50 023 057 093 125 043 50 024 068 133 211 074

60 037 076 102 110 042 60 046 114 173 195 074

70 047 078 - 087 038 70 075 140 - 164 070

80 044 - - 057 032 80 081 - - 112 057

Table 1916

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Both Sexes 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 004 007 243 081 Asian 0 001 003 006 213 085

10 002 006 013 244 082 Pacific 10 002 005 011 213 086

20 004 010 024 243 082 Islander 20 003 009 018 211 086

30 007 021 049 243 083 30 006 015 034 210 086

40 014 042 094 240 084 40 009 028 067 205 086

50 029 082 158 233 085 50 019 059 117 199 086

60 057 139 203 219 086 60 041 101 161 187 085

70 095 170 - 188 084 70 066 131 - 159 082

80 105 - - 130 073 80 080 - - 114 069

White 0 001 004 007 254 085 American 0 001 003 004 104 057

10 002 006 013 255 086 Indian 10 002 003 006 105 058

20 004 010 024 254 086 Alaska 20 001 004 008 103 058

30 007 020 049 253 087 Nativea 30 003 008 021 104 059

40 014 043 097 251 088 40 005 018 038 105 060

50 030 086 167 244 089 50 014 035 071 105 062

60 059 147 215 230 090 60 023 062 094 099 065

70 101 180 - 198 088 70 046 084 - 090 066

80 112 - - 136 076 80 053 - - 061 053

Black 0 001 003 007 152 046 Hispanicb 0 001 003 005 238 083

10 002 006 014 154 047 10 002 005 011 239 084

20 004 012 027 153 047 20 003 009 021 238 084

30 008 023 048 152 047 30 006 018 043 238 084

40 016 042 079 148 047 40 012 037 083 235 085

50 027 066 105 138 047 50 026 073 145 228 085

60 043 087 114 123 045 60 050 126 189 214 085

70 054 088 - 099 042 70 086 157 - 185 081

80 053 - - 070 036 80 094 - - 131 066

Table 1917

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Males 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 002 004 193 064 Asian 0 001 002 004 159 063

10 001 004 009 195 064 Pacific 10 001 004 008 160 063

20 003 007 017 194 064 Islander 20 002 006 013 159 063

30 005 015 036 192 065 30 004 011 025 157 063

40 010 031 071 189 065 40 007 021 048 153 063

50 022 062 120 182 065 50 014 042 087 148 063

60 042 103 154 168 065 60 028 074 122 136 062

70 067 123 - 138 063 70 049 099 - 114 058

80 071 - - 090 054 80 057 - - 075 047

White 0 001 002 004 203 067 American 0 000 001 002 128 043

10 001 004 009 204 067 Indian 10 001 001 004 129 044

20 002 007 017 203 067 Alaska 20 001 003 007 128 044

30 005 015 037 201 067 Nativea 30 002 006 023 129 044

40 010 032 074 198 068 40 004 021 044 129 045

50 022 065 127 192 068 50 017 042 085 129 046

60 044 109 163 177 068 60 026 072 113 118 047

70 072 130 - 146 066 70 050 097 - 102 046

80 075 - - 094 056 80 060 - - 066 037

Black 0 000 002 004 126 040 Hispanicb 0 001 002 004 210 065

10 001 004 009 128 040 10 001 004 008 211 066

20 003 008 018 127 040 20 002 007 017 211 066

30 005 015 034 125 040 30 004 014 036 209 066

40 010 029 058 122 040 40 010 032 073 206 066

50 020 049 083 115 040 50 022 064 123 198 066

60 032 068 094 102 039 60 043 104 161 182 065

70 041 071 - 080 036 70 066 127 - 149 062

80 039 - - 051 030 80 073 - - 100 051

Table 1918

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Females 2014-2016 By RaceEthnicity

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

The AAPC is the Average Annual Percent Change over the time interval The AAPCs are calculated bythe Joinpoint Regression Program Version 47 February 2019 National Cancer Institute

- Statistic not shown Rate based on less than 16 cases for the time intervalTrend based on less than 10 cases for at least one year within the time interval

a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) Trendsare based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico SeattleUtah and AtlantaThe SEER 21 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the AlaskaNative Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts

c The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 3 Joinpoints overdiagnosis years 2000-2016

d The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 5 Joinpoints overdiagnosis years 1975-2016

e Hispanic and Non-Hispanic are not mutually exclusive from whites blacks AsianPacificIslanders and American IndiansAlaska Natives Incidence data for Hispanics and Non-Hispanicsare based on NHIA and exclude cases from the Alaska Native Registry

f Incidence data for American IndianAlaska Native are based on the PurchasedReferred CareDelivery Area (PRCDA) counties

g US Mortality Files National Center for Health Statistics CDCh The 2007-2016 mortality AAPCs are based on a Joinpoint analysis using years of death 2000-2016 The APC is significantly different from zero (plt05)

SEER Incidence SEER 21 Areasb SEER 21 Areasb SEER 9 Areasb

Rate 2012-2016 Trend 2007-2016c Trend 2007-2016d

Rate per 100000 persons AAPC () AAPC ()

Total Males Females Total Males Females Total Males Females RaceEthnicity

All Races 196 239 162 -07 -09 -08 -09 -07 -08

White 206 250 170 -08 -11 -09 -09 -08 -08White Hispanice 183 212 161 -08 -03 -05 - - -White Non-Hispanice 210 256 172 -08 -06 -10 - - -

Black 147 177 124 01 00 03 00 -04 -09

AsianPacific Islander 134 164 110 00 00 -01 - - -

Amer IndAlaska Natf 113 120 106 -05 -12 00 - - -

Hispanice 179 207 157 -05 -02 03 - - -

US Mortalityg Rate 2012-2016 Trend 2007-2016h

Rate per 100000 persons AAPC ()

Total Males Females Total Males FemalesRaceEthnicity

All Races 56 73 44 -23 -20 -27

White 59 76 45 -23 -20 -27White Hispanice 51 65 40 -16 -13 -20White Non-Hispanice 59 76 46 -23 -20 -27

Black 41 52 33 -20 -19 -21

AsianPacific Islander 39 49 31 -17 -15 -19

Amer IndAlaska NatTotal US 31 40 24 -32 -20 -45PRCDA Counties 44 58 33 -21 -04 -37Non-PRCDA Counties 17 21 14 -54 -50 -60

Hispanice 48 61 38 -17 -14 -21

Table 1919Non-Hodgkin Lymphoma

SEER Incidence and US MortalityAge-Adjusted Rates and Trendsa

By RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Incidence Ratesa 2012-2016

California 1844 2241 1515 1938 2349 1591 1390 1639 1182Greater Bay Area 1957 2381 1600 2144 2601 1755 1628 1828 1436San Francisco-Oakland 1956 2421 1570 2174 2660 1765 1603 1816 1408San Jose-Monterey 1962 2311 1660 2097 2503 1742 1800 1891 1646

Los Angeles 1804 2176 1505 1951 2331 1637 1357 1659 1139Greater California 1822 2220 1489 1876 2286 1529 1314 1534 1113

Connecticut 2116 2607 1733 2154 2642 1771 1386 1829 1051Detroit 2132 2636 1742 2290 2850 1847 1620 1905 1409Georgia 1826 2244 1487 1936 2346 1588 1462 1833 1187Atlanta 1925 2381 1555 2119 2567 1736 1601 2034 1272Rural Georgia 1584 1790 1401 1953 2298 1567 807 - 988Greater Georgia 1784 2186 1459 1872 2274 1537 1380 1703 1146

Hawaii 1660 2024 1349 1958 2275 1593 - - -Idaho 1922 2267 1616 1920 2262 1618 - - -Iowa 2134 2601 1756 2148 2612 1773 1352 1602 1100Kentucky 2039 2505 1666 2070 2538 1693 1403 1788 1112Louisiana 1944 2352 1614 2106 2537 1744 1469 1769 1237Massachusetts 1810 2181 1518 1830 2214 1524 1452 1655 1299New Jersey 2155 2607 1804 2285 2765 1905 1387 1621 1222New Mexico 1550 1739 1387 1580 1798 1394 875 - -New York 2152 2620 1788 2306 2792 1915 1545 1852 1333Seattle-Puget Sound 2116 2627 1695 2177 2667 1766 1631 1973 1316Utah 1843 2233 1498 1862 2258 1513 2089 - -

SEER 9 Areasb 1992 2444 1623 2095 2551 1716 1573 1914 1298SEER 13 Areasb 1946 2373 1597 2064 2502 1700 1519 1853 1258SEER 18 Areasb 1933 2354 1590 2031 2464 1671 1449 1751 1214SEER 21 Areasb 1963 2388 1620 2061 2498 1702 1471 1771 1245

Table 1920Non-Hodgkin Lymphoma

Age-Adjusted SEER Incidence Ratesa

By Registry Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control and PreventionRates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and AtlantaThe SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Death Ratesa 2012-2016

California 533 677 423 570 726 449 417 480 367Greater Bay Area 505 671 376 561 756 408 410 491 331San Francisco-Oakland 503 667 376 555 742 409 416 490 343San Jose-Monterey 511 681 377 573 781 407 - - -

Los Angeles 541 670 443 589 728 481 424 503 371Greater California 539 682 429 564 716 447 416 455 384

Connecticut 533 705 407 547 717 421 350 510 244Detroit 639 822 505 693 895 542 443 528 384Georgia 533 697 411 580 747 450 376 503 286Atlanta 492 659 372 533 728 388 397 506 317Rural Georgia 559 731 388 670 813 507 - - -Greater Georgia 549 712 426 595 755 470 363 500 266

Hawaii 475 620 352 545 649 412 - - -Idaho 635 775 510 641 782 516 - - -Iowa 638 845 484 642 848 488 - - -Kentucky 642 886 460 655 904 470 401 557 284Louisiana 608 814 451 651 863 485 461 623 340Massachusetts 523 659 423 541 682 436 347 410 297New Jersey 545 721 419 585 780 443 372 466 314New Mexico 488 585 405 493 595 406 - - -New York 535 702 412 575 752 441 390 514 313Seattle-Puget Sound 585 749 463 604 769 480 490 562 397Utah 542 670 433 551 681 440 - - -

SEER 9 Areasb 555 719 430 586 758 454 414 522 333SEER 13 Areasb 549 705 429 586 753 457 419 521 342SEER 18 Areasb 554 717 431 589 761 456 409 518 329SEER 21 Areasb 550 712 428 584 754 453 401 513 322

Total US 562 725 436 586 755 454 408 518 330

Table 1921Non-Hodgkin Lymphoma

Age-Adjusted SEER Death Ratesa

By Registry Race and Sex

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 562 002

High Five StatesMichigan 645 011 01(0112) 1479Kentucky 642 016 02(0118) 1424Iowa 638 018 03(0120) 1367Indiana 638 013 04(0117) 1361Idaho 635 027 05(0126) 1303

Low Five StatesNevada 511 019 47(2251) -899Colorado 491 014 48(3851) -1257New Mexico 488 020 49(2851) -1317Hawaii 475 024 50(3051) -1542c

DC 444 039 51(2351) -2097c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 545 014 28(1847) -291 Montana 559 030 25(0250) -042Alaska 525 047 43(0151) -654 Nebraska 563 023 22(0548) 026Arizona 512 012 46(2950) -886 Nevada 511 019 47(2251) -899Arkansas 555 018 26(1247) -113 New Hampshire 562 027 23(0349) 014California 533 005 40(2645) -508 New Jersey 545 010 29(2045) -301Colorado 491 014 48(3851) -1257 New Mexico 488 020 49(2851) -1317Connecticut 533 016 39(1949) -505 New York 535 007 37(2446) -478Delaware 628 033 08(0139) 1174 North Carolina 541 010 35(2146) -363DC 444 039 51(2351) -2097c North Dakota 561 037 24(0151) -007Florida 535 006 38(2545) -479 Ohio 616 009 10(0220) 969Georgia 533 011 41(2248) -511 Oklahoma 630 017 06(0121) 1226Hawaii 475 024 50(3051) -1542c Oregon 612 016 11(0124) 903Idaho 635 027 05(0126) 1303 Pennsylvania 603 009 16(0622) 729Illinois 566 009 20(1634) 085 Rhode Island 542 029 32(0651) -350Indiana 638 013 04(0117) 1361 South Carolina 542 014 31(1847) -347Iowa 638 018 03(0120) 1367 South Dakota 541 033 36(0451) -364Kansas 585 019 19(0439) 420 Tennessee 629 013 07(0119) 1198Kentucky 642 016 02(0118) 1424 Texas 546 007 27(2142) -277Louisiana 608 016 14(0125) 826 Utah 542 022 33(1250) -352Maine 609 026 13(0137) 852 Vermont 605 040 15(0148) 770Maryland 524 013 44(2349) -663 Virginia 544 011 30(2046) -319Massachusetts 523 012 45(2549) -687 Washington 599 013 17(0425) 665Michigan 645 011 01(0112) 1479 West Virginia 612 022 12(0132) 894Minnesota 617 014 09(0122) 984 Wisconsin 590 013 18(0629) 507Mississippi 531 018 42(1850) -551 Wyoming 564 043 21(0151) 050Missouri 542 012 34(1947) -354

Table 1922Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males and Females

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 725 003

High Five StatesKentucky 886 030 01(0112) 2213c

Iowa 845 032 02(0120) 1647c

Michigan 842 019 03(0114) 1615c

Indiana 839 024 04(0116) 1567c

Delaware 824 058 05(0144) 1364

Low Five StatesArizona 635 019 47(3251) -1244Alaska 630 075 48(0251) -1311Hawaii 620 041 49(1951) -1452DC 614 071 50(0551) -1535c

New Mexico 585 033 51(3451) -1928c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 688 025 36(1649) -513 Montana 709 050 26(0251) -218Alaska 630 075 48(0251) -1311 Nebraska 737 040 20(0248) 165Arizona 635 019 47(3251) -1244 Nevada 653 032 44(1951) -994Arkansas 721 031 22(0747) -061 New Hampshire 710 046 25(0451) -210California 677 009 41(2846) -666 New Jersey 721 018 21(1441) -059Colorado 643 024 46(2451) -1133 New Mexico 585 033 51(3451) -1928c

Connecticut 705 028 28(1248) -273 New York 702 012 30(1943) -323Delaware 824 058 05(0144) 1364 North Carolina 709 018 27(1644) -221DC 614 071 50(0551) -1535c North Dakota 682 061 39(0251) -598Florida 683 011 37(2446) -585 Ohio 800 017 09(0320) 1029Georgia 697 019 34(1746) -387 Oklahoma 806 030 08(0126) 1109Hawaii 620 041 49(1951) -1452 Oregon 794 028 12(0128) 947Idaho 775 045 16(0146) 692 Pennsylvania 783 015 15(0523) 794Illinois 739 016 19(1235) 190 Rhode Island 649 050 45(1051) -1050Indiana 839 024 04(0116) 1567c South Carolina 681 025 40(1850) -604Iowa 845 032 02(0120) 1647c South Dakota 701 056 31(0251) -332Kansas 713 032 24(0948) -174 Tennessee 820 023 06(0120) 1311Kentucky 886 030 01(0112) 2213c Texas 698 012 32(2043) -368Louisiana 814 029 07(0122) 1222 Utah 670 036 42(1351) -754Maine 754 045 18(0148) 395 Vermont 794 069 11(0149) 950Maryland 682 023 38(1849) -588 Virginia 694 020 35(1847) -429Massachusetts 659 020 43(2450) -910 Washington 790 022 13(0224) 897Michigan 842 019 03(0114) 1615c West Virginia 774 038 17(0142) 675Minnesota 797 025 10(0224) 995 Wisconsin 786 023 14(0227) 844Mississippi 717 034 23(0748) -110 Wyoming 698 071 33(0151) -377Missouri 702 022 29(1646) -319

Table 1923Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 436 002

High Five StatesIdaho 510 033 01(0139) 1697c

Maine 497 031 02(0141) 1396Michigan 495 012 03(0119) 1340Oklahoma 492 020 04(0128) 1276Indiana 492 016 05(0123) 1270

Low Five StatesMississippi 404 021 47(1351) -731Nevada 382 022 48(2051) -1237Colorado 369 016 49(3451) -1540c

Hawaii 352 027 50(2551) -1932c

DC 323 044 51(1551) -2601c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 440 017 24(0547) 099 Montana 435 036 27(0151) -034Alaska 414 058 38(0151) -500 Nebraska 435 027 26(0249) -032Arizona 407 014 44(2049) -664 Nevada 382 022 48(2051) -1237Arkansas 428 021 31(0649) -181 New Hampshire 454 032 19(0149) 400California 423 006 34(2244) -313 New Jersey 419 012 37(1848) -397Colorado 369 016 49(3451) -1540c New Mexico 405 025 46(0951) -706Connecticut 407 018 45(1550) -669 New York 412 008 39(2548) -554Delaware 473 039 12(0150) 855 North Carolina 420 012 35(1848) -374DC 323 044 51(1551) -2601c North Dakota 471 045 13(0150) 809Florida 412 007 40(2548) -564 Ohio 478 011 10(0123) 967Georgia 411 012 43(2049) -582 Oklahoma 492 020 04(0128) 1276Hawaii 352 027 50(2551) -1932c Oregon 465 019 15(0141) 668Idaho 510 033 01(0139) 1697c Pennsylvania 467 010 14(0427) 714Illinois 439 010 25(1341) 074 Rhode Island 455 035 18(0150) 434Indiana 492 016 05(0123) 1270 South Carolina 432 017 30(0947) -102Iowa 484 021 08(0135) 1087 South Dakota 411 039 42(0151) -580Kansas 486 023 06(0137) 1143 Tennessee 484 015 09(0126) 1087Kentucky 460 018 17(0241) 544 Texas 427 008 32(1944) -213Louisiana 451 018 21(0345) 333 Utah 433 026 28(0250) -081Maine 497 031 02(0141) 1396 Vermont 461 047 16(0151) 578Maryland 411 015 41(1749) -576 Virginia 432 013 29(1246) -092Massachusetts 423 014 33(1548) -303 Washington 452 015 20(0541) 360Michigan 495 012 03(0119) 1340 West Virginia 486 027 07(0143) 1141Minnesota 475 017 11(0132) 901 Wisconsin 443 015 23(0645) 156Mississippi 404 021 47(1351) -731 Wyoming 445 051 22(0151) 192Missouri 419 014 36(1549) -396

Table 1924Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Females

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 Areas (excluding the AlaskaNative Registry) and 112016 US population estimates based on the average of 2015 and 2016 population estimates from theUS Bureau of the CensusPrevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 24 years

b Maximum limited-duration prevalence is 24 years for 1992-2016 datac Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groupsd Cases diagnosed more than 24 years ago were estimated using the completeness index method (Capocaccia et al 1997

Merrill et al 2000)e Complete prevalence is obtained by summing 0 to lt24 and gt=24- Statistic not shown Statistic based on fewer than 5 cases estimated alive in SEER for the time interval+ Not available

Years Since Diagnosis 0 to lt5 5 to lt10 10 to lt15 15 to lt20 20 to lt24 0 to lt24b gt=24d Completee

Race Sex

All Races Both Sexes 248946 177490 117326 69109 31890 644761 49943 694704Males 135137 94173 60159 36020 16581 342069 25489 367558Females 113809 83317 57167 33089 15309 302692 24454 327146

White Both Sexes 213764 154454 101984 60537 28026 558765 49625 620368Males 116527 82172 52535 31627 14543 297404 26526 330121Females 97237 72282 49448 28910 13483 261361 23099 290247

Black Both Sexes 20500 13640 9750 5271 2215 51376 4115 55491Males 10712 7188 4768 2684 1174 26526 1911 28437Females 9789 6452 4981 2587 1041 24850 2204 27054

Asian Both Sexes 8405 5210 3415 1867 844 19741 + +Pacific Males 4548 2661 1757 1013 407 10386 + +Islander Females 3856 2549 1657 855 437 9355 + +

Hispanic Both Sexes 21339 14049 8272 4881 2136 50676 + +Males 10918 7243 4331 2617 1094 26202 + +Females 10421 6805 3941 2264 1043 24474 + +

Age Specific (Crude) Age-Adjustedc Age at Prevalence All Ages 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ All Ages

Race Sex

All Races Both Sexes 02001 00035 00139 00283 00538 01121 02352 04640 08181 10224 01738Males 02156 00044 00189 00354 00625 01293 02710 05243 09364 12449 02023Females 01850 00026 00087 00208 00450 00952 02010 04094 07196 08856 01498

White Both Sexes 02216 00035 00143 00289 00534 01148 02427 04858 08597 10738 01807Males 02380 00045 00198 00359 00622 01317 02790 05442 09778 13060 02095Females 02054 00025 00085 00214 00442 00976 02072 04317 07593 09285 01560

Black Both Sexes 01139 00029 00113 00265 00599 01027 02010 03340 05117 05333 01251Males 01226 00029 00140 00351 00696 01223 02333 03969 05849 06055 01457Females 01059 00030 00086 00178 00510 00853 01728 02836 04608 04976 01088

Asian Both Sexes 00970 00039 00133 00207 00353 00680 01409 02692 04470 06094 01032Pacific Males 01065 00044 00175 00240 00398 00744 01640 03072 05516 07472 01222Islander Females 00882 00033 00092 00175 00312 00623 01209 02384 03629 05207 00880

Hispanic Both Sexes 00887 00030 00117 00206 00398 00850 01769 03632 05888 07209 01294Males 00908 00035 00147 00256 00455 00932 01924 03940 06326 08003 01420Females 00866 00024 00086 00151 00337 00766 01616 03360 05552 06719 01185

Table 1925Non-Hodgkin Lymphoma

Estimated United States Cancer Prevalence Countsa on January 1 2016By RaceEthnicity Sex and Years Since Diagnosis

Estimated prevalence percenta on January 1 2016 of the SEER population diagnosed in the previous 24 yearsBy Age at Prevalence RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 372 452924 -05 62 18862 04 247 189692 -05 1657 244370 -05

1 Hodgkin Lymphoma 28 32262 -17 13 3927 -06 33 22556 -15 39 5779 -31

2 Non-Hodgkin lymphoma 336 409991 -03 48 14693 04 210 163591 -03 1572 231707 -042(a) Non-Hodgkin lymphoma B-cell 311 380349 -01 39 11836 14 190 148768 -02 1491 219745 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 15 16631 20 31 9416 10 07 5203 39 14 2012 252(a) 2 Mature Non-Hodgkin lymphoma B-cell 280 343965 -04 07 2271 30 174 137225 -05 1387 204469 -042(a) 21 ChronicSmallProlymphocytic 69 85601 -13 00 35 - 35 29103 -11 382 56463 -14

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 61 75061 -15 00 30 - 31 25339 -13 336 49692 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 311 19 - - - 00 72 - 02 234 262(a) 213 Mantle-cell lymphoma 08 10229 03 - - - 04 3692 02 44 6537 04

2(a) 22 Lymphoplasmacytic lymphoma 07 8651 00 - - - 03 2590 -11 41 6059 04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 03 3667 -03 - - - 01 1132 -18 17 2533 022(a) 222 Waldenstrom macroglubulinemia 04 4984 03 - - - 02 1458 -07 24 3526 06

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 72 87188 00 03 925 26 48 36480 -02 339 49783 022(a) 231 DLBCL NOSc 71 85899 -01 03 861 12 46 35469 -05 337 49569 012(a) 232 Intravascular large B-cell 00 162 - - - - 00 63 - 01 99 -

lymphoma2(a) 233 Primary effusion lymphoma 00 181 27 - - - 00 126 - 00 55 -2(a) 234 Mediastinal large B-cell 01 946 116 00 64 - 01 822 111 00 60 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 04 4692 -26 03 1028 32 04 2618 -43 07 1046 -432(a) 25 Marginal-zone lymphoma (MZL) 22 26534 00 00 137 13 14 11049 05 104 15348 -042(a) 251 Splenic MZL 02 2418 04 - - - 01 889 -08 10 1529 102(a) 252 Extranodal MZL MALTc type 13 15979 06 00 92 - 09 7148 11 59 8739 032(a) 253 Nodal MZL 07 8137 -15 00 45 - 04 3012 -05 34 5080 -20

2(a) 26 Follicular lymphoma 35 43582 -21 00 119 - 28 21725 -25 147 21738 -182(a) 27 Hairy-cell leukemia 03 3712 -16 - - - 03 2311 -19 09 1401 -122(a) 28 Plasma cell neoplasms 68 83957 08 00 24 - 39 31325 12 358 52608 062(a) 281 Plasmacytoma 04 4879 -04 00 16 - 03 2362 -06 17 2501 -032(a) 282 Multiple myeloma 64 79078 09 - - - 36 28963 14 341 50107 07

plasma-cell leukemia2(a) 29 Heavy chain disease 00 48 - - - - 00 24 - 00 23 -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 16 19753 33 00 149 27 08 6340 37 90 13264 32

Table 1926All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 23 27222 01 08 2502 18 19 13933 03 73 10787 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 616 - 01 293 - 00 272 - 00 51 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 22 26531 11 07 2207 75 19 13621 12 73 10703 -042(b) 21 Mycosis fungoidesSezary syndrome 06 6969 18 01 213 84 06 4080 23 18 2676 052(b) 211 Mycosis fungoides 06 6739 17 01 213 84 05 3990 22 17 2536 042(b) 212 Sezary syndrome 00 230 46 - - - 00 90 - 01 140 -

2(b) 22 Peripheral T-cell lymphoma 12 14531 -10 02 534 07 10 7159 -09 46 6838 -122(b) 221 Peripheral T-cell lymphoma NOSc 04 5393 -01 00 86 - 03 2489 04 19 2818 -042(b) 222 Angioimmunoblastic T-cell lymphoma 02 1902 02 - - - 01 699 -09 08 1201 072(b) 223 Subcutaneous panniculitis- 00 176 44 00 31 - 00 111 - 00 34 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 2523 -36 01 291 00 02 1450 -33 05 782 -54

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 139 - - - - 00 98 - 00 28 -2(b) 226 Enteropathy-type T-cell lymphoma 00 186 -02 - - - 00 84 - 01 101 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 2963 -07 00 59 - 02 1575 01 09 1329 -142(b) 228 Primary cutaneous anaplastic 01 1249 -41 00 51 - 01 653 -49 04 545 -39

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 03 3417 96 05 1428 101 02 1474 99 03 515 672(b) 24 NKcT-cell lymphoma nasal-type 01 985 02 00 26 - 01 659 00 02 300 05

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 120 - - - - 00 54 - 00 65 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 509 30 - - - 00 195 -05 02 309 442(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 75 - - - - 00 40 - 00 33 -2(c) Non-Hodgkin lymphoma unknown lineage 02 2420 -274 01 355 - 01 890 -216 08 1175 -2792(c) 1 Precursor lymphoblastic leukemia 01 814 -283 01 343 - 00 238 - 02 233 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 95 - - - - 00 25 - 00 69 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 1511 -274 - - - 01 627 -202 06 873 -319

lineage2() 1 Total precursor lymphomaleukemiad 16 18061 -07 33 10052 -15 08 5713 06 15 2296 -01

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 762 273 00 20 - 00 339 227 03 403 -lymphoma

4 Lymphoid neoplasm NOSc 08 9909 -55 01 222 113 04 3206 -59 43 6481 -59

Table 1926 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 461 253152 -05 70 10973 05 294 110367 -07 2122 131812 -05

1 Hodgkin Lymphoma 31 17710 -17 13 2118 -03 36 12525 -16 48 3067 -31

2 Non-Hodgkin lymphoma 419 229772 -03 56 8711 05 252 95756 -05 2017 125305 -032(a) Non-Hodgkin lymphoma B-cell 387 212247 -02 44 6786 15 227 86941 -04 1908 118520 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 16 8999 24 33 5123 11 08 2888 46 16 988 292(a) 2 Mature Non-Hodgkin lymphoma B-cell 351 192801 -05 10 1558 28 210 80417 -08 1783 110826 -042(a) 21 ChronicSmallProlymphocytic 96 52411 -15 00 21 - 47 18927 -14 539 33463 -15

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 82 44988 -17 00 19 - 40 16143 -16 464 28826 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 193 -02 - - - 00 46 - 02 145 052(a) 213 Mantle-cell lymphoma 13 7230 -01 - - - 07 2738 -01 72 4492 -01

2(a) 22 Lymphoplasmacytic lymphoma 10 5082 -05 - - - 04 1524 -08 58 3558 -04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 04 2062 -08 - - - 02 616 -12 23 1446 -072(a) 222 Waldenstrom macroglubulinemia 06 3020 -02 - - - 02 908 -06 34 2112 -02

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 88 48128 01 03 554 22 59 21824 -06 418 25750 052(a) 231 DLBCL NOSc 87 47520 00 03 519 03 57 21366 -08 416 25635 042(a) 232 Intravascular large B-cell 00 75 - - - - 00 31 - 01 44 -

lymphoma2(a) 233 Primary effusion lymphoma 00 167 26 - - - 00 123 - 01 44 -2(a) 234 Mediastinal large B-cell 01 366 155 00 35 - 01 304 142 00 27 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 06 3388 -22 05 775 31 06 1969 -46 10 644 -192(a) 25 Marginal-zone lymphoma (MZL) 22 12351 -02 01 98 - 14 5177 -02 114 7076 -012(a) 251 Splenic MZL 02 1164 14 - - - 01 434 18 12 730 112(a) 252 Extranodal MZL MALTc type 13 7268 07 00 62 - 09 3267 04 63 3939 102(a) 253 Nodal MZL 07 3919 -23 00 36 - 04 1476 -22 39 2407 -23

2(a) 26 Follicular lymphoma 39 21788 -19 01 100 - 30 11210 -25 165 10478 -152(a) 27 Hairy-cell leukemia 05 2984 -18 - - - 05 1908 -20 17 1076 -152(a) 28 Plasma cell neoplasms 85 46642 07 - - - 45 17864 11 462 28769 052(a) 281 Plasmacytoma 05 2997 -08 - - - 04 1509 -16 24 1484 -012(a) 282 Multiple myeloma 80 43645 08 - - - 41 16355 13 439 27285 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 27 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 20 10447 34 01 105 - 10 3636 40 110 6706 32

Table 1927All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 29 16118 00 11 1730 14 23 8235 02 98 6153 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 430 - 01 208 - 01 188 - 01 34 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 28 15642 11 10 1521 71 22 8022 11 97 6099 -032(b) 21 Mycosis fungoidesSezary syndrome 07 3962 19 01 135 - 06 2261 21 25 1566 092(b) 211 Mycosis fungoides 07 3831 20 01 135 - 06 2213 21 23 1483 092(b) 212 Sezary syndrome 00 131 - - - - 00 48 - 01 83 -

2(b) 22 Peripheral T-cell lymphoma 15 8438 -13 02 318 -09 12 4248 -12 62 3872 -132(b) 221 Peripheral T-cell lymphoma NOSc 06 3159 -05 00 49 - 04 1520 02 26 1590 -082(b) 222 Angioimmunoblastic T-cell lymphoma 02 1024 19 - - - 01 415 11 10 607 232(b) 223 Subcutaneous panniculitis- 00 68 - - - - 00 39 - 00 16 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 03 1549 -39 01 184 -01 02 888 -43 08 477 -45

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 98 - - - - 00 69 - 00 18 -2(b) 226 Enteropathy-type T-cell lymphoma 00 105 - - - - 00 50 - 01 54 -2(b) 227 Cutaneous T-cell lymphoma NOSc 03 1696 -12 00 32 - 02 894 -03 12 770 -172(b) 228 Primary cutaneous anaplastic 01 739 -48 00 26 - 01 373 -49 05 340 -49

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 04 2253 97 07 1047 92 03 940 98 04 266 1022(b) 24 NKcT-cell lymphoma nasal-type 01 638 -05 00 18 - 01 435 -03 03 185 -06

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 58 - - - - 00 22 - 01 36 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 01 293 45 - - - 00 116 - 03 174 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 46 - - - - 00 25 - 00 20 -2(c) Non-Hodgkin lymphoma unknown lineage 03 1407 -232 01 195 - 02 580 -184 10 632 -2302(c) 1 Precursor lymphoblastic leukemia 01 474 -228 01 187 - 00 134 - 02 153 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 49 - - - - - - - 01 36 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 02 884 -239 - - - 01 433 -175 07 443 -

lineage2() 1 Total precursor lymphomaleukemiad 18 9903 -06 35 5518 -17 09 3210 09 19 1175 05

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 435 271 - - - 01 215 - 03 207 -lymphoma

4 Lymphoid neoplasm NOSc 10 5235 -59 01 131 - 05 1871 -65 54 3233 -61

Table 1927 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 301 199772 -05 53 7889 02 202 79325 -02 1322 112558 -08

1 Hodgkin Lymphoma 24 14552 -16 12 1809 -10 29 10031 -14 32 2712 -32

2 Non-Hodgkin lymphoma 269 180219 -03 40 5982 03 170 67835 00 1251 106402 -062(a) Non-Hodgkin lymphoma B-cell 250 168102 -01 34 5050 13 154 61827 02 1190 101225 -042(a) 1 Precursor Non-Hodgkin lymphoma B-cell 14 7632 16 29 4293 09 06 2315 29 12 1024 202(a) 2 Mature Non-Hodgkin lymphoma B-cell 223 151164 -04 05 713 35 141 56808 -01 1102 93643 -072(a) 21 ChronicSmallProlymphocytic 48 33190 -13 - - - 24 10176 -05 268 23000 -16

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 43 30073 -15 - - - 22 9196 -06 243 20866 -19

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 118 - - - - 00 26 - 01 89 -2(a) 213 Mantle-cell lymphoma 04 2999 11 - - - 02 954 10 24 2045 12

2(a) 22 Lymphoplasmacytic lymphoma 05 3569 04 - - - 03 1066 -16 30 2501 11Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 02 1605 01 - - - 01 516 -25 13 1087 112(a) 222 Waldenstrom macroglubulinemia 03 1964 06 - - - 01 550 -08 17 1414 11

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 58 39060 00 02 371 33 38 14656 03 283 24033 -032(a) 231 DLBCL NOSc 57 38379 -02 02 342 27 36 14103 -01 282 23934 -032(a) 232 Intravascular large B-cell 00 87 - - - - 00 32 - 01 55 -

lymphoma2(a) 233 Primary effusion lymphoma - - - - - - - - - - - -2(a) 234 Mediastinal large B-cell 01 580 91 00 29 - 02 518 93 00 33 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 02 1304 -34 02 253 38 02 649 -37 05 402 -852(a) 25 Marginal-zone lymphoma (MZL) 21 14183 01 00 39 - 15 5872 12 98 8272 -062(a) 251 Splenic MZL 02 1254 -07 - - - 01 455 -32 10 799 072(a) 252 Extranodal MZL MALTc type 13 8711 06 00 30 - 10 3881 17 57 4800 -032(a) 253 Nodal MZL 06 4218 -07 - - - 04 1536 11 32 2673 -18

2(a) 26 Follicular lymphoma 33 21794 -24 00 19 - 27 10515 -25 134 11260 -222(a) 27 Hairy-cell leukemia 01 728 -12 - - - 01 403 -11 04 325 -122(a) 28 Plasma cell neoplasms 55 37315 08 - - - 33 13461 15 282 23839 052(a) 281 Plasmacytoma 03 1882 00 - - - 02 853 12 12 1017 -092(a) 282 Multiple myeloma 52 35433 09 - - - 30 12608 15 270 22822 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 21 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 14 9306 32 00 44 - 07 2704 32 76 6558 31

Table 1928All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 17 11104 01 05 772 29 15 5698 05 55 4634 -112(b) 1 Precursor Non-Hodgkin lymphoma T-cell 00 186 - 01 85 - 00 84 - 00 17 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 17 10889 09 05 686 83 15 5599 12 54 4604 -092(b) 21 Mycosis fungoidesSezary syndrome 05 3007 15 01 78 - 05 1819 26 13 1110 -042(b) 211 Mycosis fungoides 05 2908 12 01 78 - 05 1777 23 12 1053 -072(b) 212 Sezary syndrome 00 99 - - - - 00 42 - 01 57 -

2(b) 22 Peripheral T-cell lymphoma 09 6093 -08 01 216 30 08 2911 -06 35 2966 -142(b) 221 Peripheral T-cell lymphoma NOSc 03 2234 03 00 37 - 03 969 07 14 1228 -012(b) 222 Angioimmunoblastic T-cell lymphoma 01 878 -22 - - - 01 284 -39 07 594 -152(b) 223 Subcutaneous panniculitis- 00 108 - 00 18 - 00 72 - 00 18 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 974 -33 01 107 - 02 562 -19 04 305 -77

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 41 - - - - 00 29 - - - -2(b) 226 Enteropathy-type T-cell lymphoma 00 81 - - - - 00 34 - 01 47 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 1267 00 00 27 - 02 681 07 07 559 -102(b) 228 Primary cutaneous anaplastic 01 510 -34 00 25 - 01 280 -50 02 205 -33

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 02 1164 96 03 381 127 01 534 97 03 249 302(b) 24 NKcT-cell lymphoma nasal-type 01 347 11 - - - 01 224 - 01 115 -

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 62 - - - - 00 32 - 00 29 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 216 03 - - - 00 79 - 02 135 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 29 - - - - - - - - - -2(c) Non-Hodgkin lymphoma unknown lineage 02 1013 -341 01 160 - 01 310 - 06 543 -2(c) 1 Precursor lymphoblastic leukemia 01 340 - 01 156 - 00 104 - 01 80 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 46 - - - - - - - 00 33 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 627 - - - - 01 194 - 05 430 -

lineage2() 1 Total precursor lymphomaleukemiad 14 8158 -09 31 4534 -13 07 2503 02 13 1121 -11

3 Composite Hodgkin lymphoma and Non-Hodgkin 00 327 - - - - 00 124 - 02 196 -lymphoma

4 Lymphoid neoplasm NOSc 07 4674 -52 01 91 - 03 1335 -51 36 3248 -58

Table 1928 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 17: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 004 007 243 081 Asian 0 001 003 006 213 085

10 002 006 013 244 082 Pacific 10 002 005 011 213 086

20 004 010 024 243 082 Islander 20 003 009 018 211 086

30 007 021 049 243 083 30 006 015 034 210 086

40 014 042 094 240 084 40 009 028 067 205 086

50 029 082 158 233 085 50 019 059 117 199 086

60 057 139 203 219 086 60 041 101 161 187 085

70 095 170 - 188 084 70 066 131 - 159 082

80 105 - - 130 073 80 080 - - 114 069

White 0 001 004 007 254 085 American 0 001 003 004 104 057

10 002 006 013 255 086 Indian 10 002 003 006 105 058

20 004 010 024 254 086 Alaska 20 001 004 008 103 058

30 007 020 049 253 087 Nativea 30 003 008 021 104 059

40 014 043 097 251 088 40 005 018 038 105 060

50 030 086 167 244 089 50 014 035 071 105 062

60 059 147 215 230 090 60 023 062 094 099 065

70 101 180 - 198 088 70 046 084 - 090 066

80 112 - - 136 076 80 053 - - 061 053

Black 0 001 003 007 152 046 Hispanicb 0 001 003 005 238 083

10 002 006 014 154 047 10 002 005 011 239 084

20 004 012 027 153 047 20 003 009 021 238 084

30 008 023 048 152 047 30 006 018 043 238 084

40 016 042 079 148 047 40 012 037 083 235 085

50 027 066 105 138 047 50 026 073 145 228 085

60 043 087 114 123 045 60 050 126 189 214 085

70 054 088 - 099 042 70 086 157 - 185 081

80 053 - - 070 036 80 094 - - 131 066

Table 1917

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Males 2014-2016 By RaceEthnicity

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 002 004 193 064 Asian 0 001 002 004 159 063

10 001 004 009 195 064 Pacific 10 001 004 008 160 063

20 003 007 017 194 064 Islander 20 002 006 013 159 063

30 005 015 036 192 065 30 004 011 025 157 063

40 010 031 071 189 065 40 007 021 048 153 063

50 022 062 120 182 065 50 014 042 087 148 063

60 042 103 154 168 065 60 028 074 122 136 062

70 067 123 - 138 063 70 049 099 - 114 058

80 071 - - 090 054 80 057 - - 075 047

White 0 001 002 004 203 067 American 0 000 001 002 128 043

10 001 004 009 204 067 Indian 10 001 001 004 129 044

20 002 007 017 203 067 Alaska 20 001 003 007 128 044

30 005 015 037 201 067 Nativea 30 002 006 023 129 044

40 010 032 074 198 068 40 004 021 044 129 045

50 022 065 127 192 068 50 017 042 085 129 046

60 044 109 163 177 068 60 026 072 113 118 047

70 072 130 - 146 066 70 050 097 - 102 046

80 075 - - 094 056 80 060 - - 066 037

Black 0 000 002 004 126 040 Hispanicb 0 001 002 004 210 065

10 001 004 009 128 040 10 001 004 008 211 066

20 003 008 018 127 040 20 002 007 017 211 066

30 005 015 034 125 040 30 004 014 036 209 066

40 010 029 058 122 040 40 010 032 073 206 066

50 020 049 083 115 040 50 022 064 123 198 066

60 032 068 094 102 039 60 043 104 161 182 065

70 041 071 - 080 036 70 066 127 - 149 062

80 039 - - 051 030 80 073 - - 100 051

Table 1918

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Females 2014-2016 By RaceEthnicity

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

The AAPC is the Average Annual Percent Change over the time interval The AAPCs are calculated bythe Joinpoint Regression Program Version 47 February 2019 National Cancer Institute

- Statistic not shown Rate based on less than 16 cases for the time intervalTrend based on less than 10 cases for at least one year within the time interval

a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) Trendsare based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico SeattleUtah and AtlantaThe SEER 21 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the AlaskaNative Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts

c The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 3 Joinpoints overdiagnosis years 2000-2016

d The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 5 Joinpoints overdiagnosis years 1975-2016

e Hispanic and Non-Hispanic are not mutually exclusive from whites blacks AsianPacificIslanders and American IndiansAlaska Natives Incidence data for Hispanics and Non-Hispanicsare based on NHIA and exclude cases from the Alaska Native Registry

f Incidence data for American IndianAlaska Native are based on the PurchasedReferred CareDelivery Area (PRCDA) counties

g US Mortality Files National Center for Health Statistics CDCh The 2007-2016 mortality AAPCs are based on a Joinpoint analysis using years of death 2000-2016 The APC is significantly different from zero (plt05)

SEER Incidence SEER 21 Areasb SEER 21 Areasb SEER 9 Areasb

Rate 2012-2016 Trend 2007-2016c Trend 2007-2016d

Rate per 100000 persons AAPC () AAPC ()

Total Males Females Total Males Females Total Males Females RaceEthnicity

All Races 196 239 162 -07 -09 -08 -09 -07 -08

White 206 250 170 -08 -11 -09 -09 -08 -08White Hispanice 183 212 161 -08 -03 -05 - - -White Non-Hispanice 210 256 172 -08 -06 -10 - - -

Black 147 177 124 01 00 03 00 -04 -09

AsianPacific Islander 134 164 110 00 00 -01 - - -

Amer IndAlaska Natf 113 120 106 -05 -12 00 - - -

Hispanice 179 207 157 -05 -02 03 - - -

US Mortalityg Rate 2012-2016 Trend 2007-2016h

Rate per 100000 persons AAPC ()

Total Males Females Total Males FemalesRaceEthnicity

All Races 56 73 44 -23 -20 -27

White 59 76 45 -23 -20 -27White Hispanice 51 65 40 -16 -13 -20White Non-Hispanice 59 76 46 -23 -20 -27

Black 41 52 33 -20 -19 -21

AsianPacific Islander 39 49 31 -17 -15 -19

Amer IndAlaska NatTotal US 31 40 24 -32 -20 -45PRCDA Counties 44 58 33 -21 -04 -37Non-PRCDA Counties 17 21 14 -54 -50 -60

Hispanice 48 61 38 -17 -14 -21

Table 1919Non-Hodgkin Lymphoma

SEER Incidence and US MortalityAge-Adjusted Rates and Trendsa

By RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Incidence Ratesa 2012-2016

California 1844 2241 1515 1938 2349 1591 1390 1639 1182Greater Bay Area 1957 2381 1600 2144 2601 1755 1628 1828 1436San Francisco-Oakland 1956 2421 1570 2174 2660 1765 1603 1816 1408San Jose-Monterey 1962 2311 1660 2097 2503 1742 1800 1891 1646

Los Angeles 1804 2176 1505 1951 2331 1637 1357 1659 1139Greater California 1822 2220 1489 1876 2286 1529 1314 1534 1113

Connecticut 2116 2607 1733 2154 2642 1771 1386 1829 1051Detroit 2132 2636 1742 2290 2850 1847 1620 1905 1409Georgia 1826 2244 1487 1936 2346 1588 1462 1833 1187Atlanta 1925 2381 1555 2119 2567 1736 1601 2034 1272Rural Georgia 1584 1790 1401 1953 2298 1567 807 - 988Greater Georgia 1784 2186 1459 1872 2274 1537 1380 1703 1146

Hawaii 1660 2024 1349 1958 2275 1593 - - -Idaho 1922 2267 1616 1920 2262 1618 - - -Iowa 2134 2601 1756 2148 2612 1773 1352 1602 1100Kentucky 2039 2505 1666 2070 2538 1693 1403 1788 1112Louisiana 1944 2352 1614 2106 2537 1744 1469 1769 1237Massachusetts 1810 2181 1518 1830 2214 1524 1452 1655 1299New Jersey 2155 2607 1804 2285 2765 1905 1387 1621 1222New Mexico 1550 1739 1387 1580 1798 1394 875 - -New York 2152 2620 1788 2306 2792 1915 1545 1852 1333Seattle-Puget Sound 2116 2627 1695 2177 2667 1766 1631 1973 1316Utah 1843 2233 1498 1862 2258 1513 2089 - -

SEER 9 Areasb 1992 2444 1623 2095 2551 1716 1573 1914 1298SEER 13 Areasb 1946 2373 1597 2064 2502 1700 1519 1853 1258SEER 18 Areasb 1933 2354 1590 2031 2464 1671 1449 1751 1214SEER 21 Areasb 1963 2388 1620 2061 2498 1702 1471 1771 1245

Table 1920Non-Hodgkin Lymphoma

Age-Adjusted SEER Incidence Ratesa

By Registry Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control and PreventionRates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and AtlantaThe SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Death Ratesa 2012-2016

California 533 677 423 570 726 449 417 480 367Greater Bay Area 505 671 376 561 756 408 410 491 331San Francisco-Oakland 503 667 376 555 742 409 416 490 343San Jose-Monterey 511 681 377 573 781 407 - - -

Los Angeles 541 670 443 589 728 481 424 503 371Greater California 539 682 429 564 716 447 416 455 384

Connecticut 533 705 407 547 717 421 350 510 244Detroit 639 822 505 693 895 542 443 528 384Georgia 533 697 411 580 747 450 376 503 286Atlanta 492 659 372 533 728 388 397 506 317Rural Georgia 559 731 388 670 813 507 - - -Greater Georgia 549 712 426 595 755 470 363 500 266

Hawaii 475 620 352 545 649 412 - - -Idaho 635 775 510 641 782 516 - - -Iowa 638 845 484 642 848 488 - - -Kentucky 642 886 460 655 904 470 401 557 284Louisiana 608 814 451 651 863 485 461 623 340Massachusetts 523 659 423 541 682 436 347 410 297New Jersey 545 721 419 585 780 443 372 466 314New Mexico 488 585 405 493 595 406 - - -New York 535 702 412 575 752 441 390 514 313Seattle-Puget Sound 585 749 463 604 769 480 490 562 397Utah 542 670 433 551 681 440 - - -

SEER 9 Areasb 555 719 430 586 758 454 414 522 333SEER 13 Areasb 549 705 429 586 753 457 419 521 342SEER 18 Areasb 554 717 431 589 761 456 409 518 329SEER 21 Areasb 550 712 428 584 754 453 401 513 322

Total US 562 725 436 586 755 454 408 518 330

Table 1921Non-Hodgkin Lymphoma

Age-Adjusted SEER Death Ratesa

By Registry Race and Sex

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 562 002

High Five StatesMichigan 645 011 01(0112) 1479Kentucky 642 016 02(0118) 1424Iowa 638 018 03(0120) 1367Indiana 638 013 04(0117) 1361Idaho 635 027 05(0126) 1303

Low Five StatesNevada 511 019 47(2251) -899Colorado 491 014 48(3851) -1257New Mexico 488 020 49(2851) -1317Hawaii 475 024 50(3051) -1542c

DC 444 039 51(2351) -2097c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 545 014 28(1847) -291 Montana 559 030 25(0250) -042Alaska 525 047 43(0151) -654 Nebraska 563 023 22(0548) 026Arizona 512 012 46(2950) -886 Nevada 511 019 47(2251) -899Arkansas 555 018 26(1247) -113 New Hampshire 562 027 23(0349) 014California 533 005 40(2645) -508 New Jersey 545 010 29(2045) -301Colorado 491 014 48(3851) -1257 New Mexico 488 020 49(2851) -1317Connecticut 533 016 39(1949) -505 New York 535 007 37(2446) -478Delaware 628 033 08(0139) 1174 North Carolina 541 010 35(2146) -363DC 444 039 51(2351) -2097c North Dakota 561 037 24(0151) -007Florida 535 006 38(2545) -479 Ohio 616 009 10(0220) 969Georgia 533 011 41(2248) -511 Oklahoma 630 017 06(0121) 1226Hawaii 475 024 50(3051) -1542c Oregon 612 016 11(0124) 903Idaho 635 027 05(0126) 1303 Pennsylvania 603 009 16(0622) 729Illinois 566 009 20(1634) 085 Rhode Island 542 029 32(0651) -350Indiana 638 013 04(0117) 1361 South Carolina 542 014 31(1847) -347Iowa 638 018 03(0120) 1367 South Dakota 541 033 36(0451) -364Kansas 585 019 19(0439) 420 Tennessee 629 013 07(0119) 1198Kentucky 642 016 02(0118) 1424 Texas 546 007 27(2142) -277Louisiana 608 016 14(0125) 826 Utah 542 022 33(1250) -352Maine 609 026 13(0137) 852 Vermont 605 040 15(0148) 770Maryland 524 013 44(2349) -663 Virginia 544 011 30(2046) -319Massachusetts 523 012 45(2549) -687 Washington 599 013 17(0425) 665Michigan 645 011 01(0112) 1479 West Virginia 612 022 12(0132) 894Minnesota 617 014 09(0122) 984 Wisconsin 590 013 18(0629) 507Mississippi 531 018 42(1850) -551 Wyoming 564 043 21(0151) 050Missouri 542 012 34(1947) -354

Table 1922Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males and Females

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 725 003

High Five StatesKentucky 886 030 01(0112) 2213c

Iowa 845 032 02(0120) 1647c

Michigan 842 019 03(0114) 1615c

Indiana 839 024 04(0116) 1567c

Delaware 824 058 05(0144) 1364

Low Five StatesArizona 635 019 47(3251) -1244Alaska 630 075 48(0251) -1311Hawaii 620 041 49(1951) -1452DC 614 071 50(0551) -1535c

New Mexico 585 033 51(3451) -1928c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 688 025 36(1649) -513 Montana 709 050 26(0251) -218Alaska 630 075 48(0251) -1311 Nebraska 737 040 20(0248) 165Arizona 635 019 47(3251) -1244 Nevada 653 032 44(1951) -994Arkansas 721 031 22(0747) -061 New Hampshire 710 046 25(0451) -210California 677 009 41(2846) -666 New Jersey 721 018 21(1441) -059Colorado 643 024 46(2451) -1133 New Mexico 585 033 51(3451) -1928c

Connecticut 705 028 28(1248) -273 New York 702 012 30(1943) -323Delaware 824 058 05(0144) 1364 North Carolina 709 018 27(1644) -221DC 614 071 50(0551) -1535c North Dakota 682 061 39(0251) -598Florida 683 011 37(2446) -585 Ohio 800 017 09(0320) 1029Georgia 697 019 34(1746) -387 Oklahoma 806 030 08(0126) 1109Hawaii 620 041 49(1951) -1452 Oregon 794 028 12(0128) 947Idaho 775 045 16(0146) 692 Pennsylvania 783 015 15(0523) 794Illinois 739 016 19(1235) 190 Rhode Island 649 050 45(1051) -1050Indiana 839 024 04(0116) 1567c South Carolina 681 025 40(1850) -604Iowa 845 032 02(0120) 1647c South Dakota 701 056 31(0251) -332Kansas 713 032 24(0948) -174 Tennessee 820 023 06(0120) 1311Kentucky 886 030 01(0112) 2213c Texas 698 012 32(2043) -368Louisiana 814 029 07(0122) 1222 Utah 670 036 42(1351) -754Maine 754 045 18(0148) 395 Vermont 794 069 11(0149) 950Maryland 682 023 38(1849) -588 Virginia 694 020 35(1847) -429Massachusetts 659 020 43(2450) -910 Washington 790 022 13(0224) 897Michigan 842 019 03(0114) 1615c West Virginia 774 038 17(0142) 675Minnesota 797 025 10(0224) 995 Wisconsin 786 023 14(0227) 844Mississippi 717 034 23(0748) -110 Wyoming 698 071 33(0151) -377Missouri 702 022 29(1646) -319

Table 1923Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 436 002

High Five StatesIdaho 510 033 01(0139) 1697c

Maine 497 031 02(0141) 1396Michigan 495 012 03(0119) 1340Oklahoma 492 020 04(0128) 1276Indiana 492 016 05(0123) 1270

Low Five StatesMississippi 404 021 47(1351) -731Nevada 382 022 48(2051) -1237Colorado 369 016 49(3451) -1540c

Hawaii 352 027 50(2551) -1932c

DC 323 044 51(1551) -2601c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 440 017 24(0547) 099 Montana 435 036 27(0151) -034Alaska 414 058 38(0151) -500 Nebraska 435 027 26(0249) -032Arizona 407 014 44(2049) -664 Nevada 382 022 48(2051) -1237Arkansas 428 021 31(0649) -181 New Hampshire 454 032 19(0149) 400California 423 006 34(2244) -313 New Jersey 419 012 37(1848) -397Colorado 369 016 49(3451) -1540c New Mexico 405 025 46(0951) -706Connecticut 407 018 45(1550) -669 New York 412 008 39(2548) -554Delaware 473 039 12(0150) 855 North Carolina 420 012 35(1848) -374DC 323 044 51(1551) -2601c North Dakota 471 045 13(0150) 809Florida 412 007 40(2548) -564 Ohio 478 011 10(0123) 967Georgia 411 012 43(2049) -582 Oklahoma 492 020 04(0128) 1276Hawaii 352 027 50(2551) -1932c Oregon 465 019 15(0141) 668Idaho 510 033 01(0139) 1697c Pennsylvania 467 010 14(0427) 714Illinois 439 010 25(1341) 074 Rhode Island 455 035 18(0150) 434Indiana 492 016 05(0123) 1270 South Carolina 432 017 30(0947) -102Iowa 484 021 08(0135) 1087 South Dakota 411 039 42(0151) -580Kansas 486 023 06(0137) 1143 Tennessee 484 015 09(0126) 1087Kentucky 460 018 17(0241) 544 Texas 427 008 32(1944) -213Louisiana 451 018 21(0345) 333 Utah 433 026 28(0250) -081Maine 497 031 02(0141) 1396 Vermont 461 047 16(0151) 578Maryland 411 015 41(1749) -576 Virginia 432 013 29(1246) -092Massachusetts 423 014 33(1548) -303 Washington 452 015 20(0541) 360Michigan 495 012 03(0119) 1340 West Virginia 486 027 07(0143) 1141Minnesota 475 017 11(0132) 901 Wisconsin 443 015 23(0645) 156Mississippi 404 021 47(1351) -731 Wyoming 445 051 22(0151) 192Missouri 419 014 36(1549) -396

Table 1924Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Females

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 Areas (excluding the AlaskaNative Registry) and 112016 US population estimates based on the average of 2015 and 2016 population estimates from theUS Bureau of the CensusPrevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 24 years

b Maximum limited-duration prevalence is 24 years for 1992-2016 datac Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groupsd Cases diagnosed more than 24 years ago were estimated using the completeness index method (Capocaccia et al 1997

Merrill et al 2000)e Complete prevalence is obtained by summing 0 to lt24 and gt=24- Statistic not shown Statistic based on fewer than 5 cases estimated alive in SEER for the time interval+ Not available

Years Since Diagnosis 0 to lt5 5 to lt10 10 to lt15 15 to lt20 20 to lt24 0 to lt24b gt=24d Completee

Race Sex

All Races Both Sexes 248946 177490 117326 69109 31890 644761 49943 694704Males 135137 94173 60159 36020 16581 342069 25489 367558Females 113809 83317 57167 33089 15309 302692 24454 327146

White Both Sexes 213764 154454 101984 60537 28026 558765 49625 620368Males 116527 82172 52535 31627 14543 297404 26526 330121Females 97237 72282 49448 28910 13483 261361 23099 290247

Black Both Sexes 20500 13640 9750 5271 2215 51376 4115 55491Males 10712 7188 4768 2684 1174 26526 1911 28437Females 9789 6452 4981 2587 1041 24850 2204 27054

Asian Both Sexes 8405 5210 3415 1867 844 19741 + +Pacific Males 4548 2661 1757 1013 407 10386 + +Islander Females 3856 2549 1657 855 437 9355 + +

Hispanic Both Sexes 21339 14049 8272 4881 2136 50676 + +Males 10918 7243 4331 2617 1094 26202 + +Females 10421 6805 3941 2264 1043 24474 + +

Age Specific (Crude) Age-Adjustedc Age at Prevalence All Ages 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ All Ages

Race Sex

All Races Both Sexes 02001 00035 00139 00283 00538 01121 02352 04640 08181 10224 01738Males 02156 00044 00189 00354 00625 01293 02710 05243 09364 12449 02023Females 01850 00026 00087 00208 00450 00952 02010 04094 07196 08856 01498

White Both Sexes 02216 00035 00143 00289 00534 01148 02427 04858 08597 10738 01807Males 02380 00045 00198 00359 00622 01317 02790 05442 09778 13060 02095Females 02054 00025 00085 00214 00442 00976 02072 04317 07593 09285 01560

Black Both Sexes 01139 00029 00113 00265 00599 01027 02010 03340 05117 05333 01251Males 01226 00029 00140 00351 00696 01223 02333 03969 05849 06055 01457Females 01059 00030 00086 00178 00510 00853 01728 02836 04608 04976 01088

Asian Both Sexes 00970 00039 00133 00207 00353 00680 01409 02692 04470 06094 01032Pacific Males 01065 00044 00175 00240 00398 00744 01640 03072 05516 07472 01222Islander Females 00882 00033 00092 00175 00312 00623 01209 02384 03629 05207 00880

Hispanic Both Sexes 00887 00030 00117 00206 00398 00850 01769 03632 05888 07209 01294Males 00908 00035 00147 00256 00455 00932 01924 03940 06326 08003 01420Females 00866 00024 00086 00151 00337 00766 01616 03360 05552 06719 01185

Table 1925Non-Hodgkin Lymphoma

Estimated United States Cancer Prevalence Countsa on January 1 2016By RaceEthnicity Sex and Years Since Diagnosis

Estimated prevalence percenta on January 1 2016 of the SEER population diagnosed in the previous 24 yearsBy Age at Prevalence RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 372 452924 -05 62 18862 04 247 189692 -05 1657 244370 -05

1 Hodgkin Lymphoma 28 32262 -17 13 3927 -06 33 22556 -15 39 5779 -31

2 Non-Hodgkin lymphoma 336 409991 -03 48 14693 04 210 163591 -03 1572 231707 -042(a) Non-Hodgkin lymphoma B-cell 311 380349 -01 39 11836 14 190 148768 -02 1491 219745 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 15 16631 20 31 9416 10 07 5203 39 14 2012 252(a) 2 Mature Non-Hodgkin lymphoma B-cell 280 343965 -04 07 2271 30 174 137225 -05 1387 204469 -042(a) 21 ChronicSmallProlymphocytic 69 85601 -13 00 35 - 35 29103 -11 382 56463 -14

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 61 75061 -15 00 30 - 31 25339 -13 336 49692 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 311 19 - - - 00 72 - 02 234 262(a) 213 Mantle-cell lymphoma 08 10229 03 - - - 04 3692 02 44 6537 04

2(a) 22 Lymphoplasmacytic lymphoma 07 8651 00 - - - 03 2590 -11 41 6059 04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 03 3667 -03 - - - 01 1132 -18 17 2533 022(a) 222 Waldenstrom macroglubulinemia 04 4984 03 - - - 02 1458 -07 24 3526 06

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 72 87188 00 03 925 26 48 36480 -02 339 49783 022(a) 231 DLBCL NOSc 71 85899 -01 03 861 12 46 35469 -05 337 49569 012(a) 232 Intravascular large B-cell 00 162 - - - - 00 63 - 01 99 -

lymphoma2(a) 233 Primary effusion lymphoma 00 181 27 - - - 00 126 - 00 55 -2(a) 234 Mediastinal large B-cell 01 946 116 00 64 - 01 822 111 00 60 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 04 4692 -26 03 1028 32 04 2618 -43 07 1046 -432(a) 25 Marginal-zone lymphoma (MZL) 22 26534 00 00 137 13 14 11049 05 104 15348 -042(a) 251 Splenic MZL 02 2418 04 - - - 01 889 -08 10 1529 102(a) 252 Extranodal MZL MALTc type 13 15979 06 00 92 - 09 7148 11 59 8739 032(a) 253 Nodal MZL 07 8137 -15 00 45 - 04 3012 -05 34 5080 -20

2(a) 26 Follicular lymphoma 35 43582 -21 00 119 - 28 21725 -25 147 21738 -182(a) 27 Hairy-cell leukemia 03 3712 -16 - - - 03 2311 -19 09 1401 -122(a) 28 Plasma cell neoplasms 68 83957 08 00 24 - 39 31325 12 358 52608 062(a) 281 Plasmacytoma 04 4879 -04 00 16 - 03 2362 -06 17 2501 -032(a) 282 Multiple myeloma 64 79078 09 - - - 36 28963 14 341 50107 07

plasma-cell leukemia2(a) 29 Heavy chain disease 00 48 - - - - 00 24 - 00 23 -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 16 19753 33 00 149 27 08 6340 37 90 13264 32

Table 1926All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 23 27222 01 08 2502 18 19 13933 03 73 10787 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 616 - 01 293 - 00 272 - 00 51 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 22 26531 11 07 2207 75 19 13621 12 73 10703 -042(b) 21 Mycosis fungoidesSezary syndrome 06 6969 18 01 213 84 06 4080 23 18 2676 052(b) 211 Mycosis fungoides 06 6739 17 01 213 84 05 3990 22 17 2536 042(b) 212 Sezary syndrome 00 230 46 - - - 00 90 - 01 140 -

2(b) 22 Peripheral T-cell lymphoma 12 14531 -10 02 534 07 10 7159 -09 46 6838 -122(b) 221 Peripheral T-cell lymphoma NOSc 04 5393 -01 00 86 - 03 2489 04 19 2818 -042(b) 222 Angioimmunoblastic T-cell lymphoma 02 1902 02 - - - 01 699 -09 08 1201 072(b) 223 Subcutaneous panniculitis- 00 176 44 00 31 - 00 111 - 00 34 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 2523 -36 01 291 00 02 1450 -33 05 782 -54

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 139 - - - - 00 98 - 00 28 -2(b) 226 Enteropathy-type T-cell lymphoma 00 186 -02 - - - 00 84 - 01 101 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 2963 -07 00 59 - 02 1575 01 09 1329 -142(b) 228 Primary cutaneous anaplastic 01 1249 -41 00 51 - 01 653 -49 04 545 -39

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 03 3417 96 05 1428 101 02 1474 99 03 515 672(b) 24 NKcT-cell lymphoma nasal-type 01 985 02 00 26 - 01 659 00 02 300 05

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 120 - - - - 00 54 - 00 65 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 509 30 - - - 00 195 -05 02 309 442(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 75 - - - - 00 40 - 00 33 -2(c) Non-Hodgkin lymphoma unknown lineage 02 2420 -274 01 355 - 01 890 -216 08 1175 -2792(c) 1 Precursor lymphoblastic leukemia 01 814 -283 01 343 - 00 238 - 02 233 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 95 - - - - 00 25 - 00 69 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 1511 -274 - - - 01 627 -202 06 873 -319

lineage2() 1 Total precursor lymphomaleukemiad 16 18061 -07 33 10052 -15 08 5713 06 15 2296 -01

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 762 273 00 20 - 00 339 227 03 403 -lymphoma

4 Lymphoid neoplasm NOSc 08 9909 -55 01 222 113 04 3206 -59 43 6481 -59

Table 1926 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 461 253152 -05 70 10973 05 294 110367 -07 2122 131812 -05

1 Hodgkin Lymphoma 31 17710 -17 13 2118 -03 36 12525 -16 48 3067 -31

2 Non-Hodgkin lymphoma 419 229772 -03 56 8711 05 252 95756 -05 2017 125305 -032(a) Non-Hodgkin lymphoma B-cell 387 212247 -02 44 6786 15 227 86941 -04 1908 118520 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 16 8999 24 33 5123 11 08 2888 46 16 988 292(a) 2 Mature Non-Hodgkin lymphoma B-cell 351 192801 -05 10 1558 28 210 80417 -08 1783 110826 -042(a) 21 ChronicSmallProlymphocytic 96 52411 -15 00 21 - 47 18927 -14 539 33463 -15

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 82 44988 -17 00 19 - 40 16143 -16 464 28826 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 193 -02 - - - 00 46 - 02 145 052(a) 213 Mantle-cell lymphoma 13 7230 -01 - - - 07 2738 -01 72 4492 -01

2(a) 22 Lymphoplasmacytic lymphoma 10 5082 -05 - - - 04 1524 -08 58 3558 -04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 04 2062 -08 - - - 02 616 -12 23 1446 -072(a) 222 Waldenstrom macroglubulinemia 06 3020 -02 - - - 02 908 -06 34 2112 -02

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 88 48128 01 03 554 22 59 21824 -06 418 25750 052(a) 231 DLBCL NOSc 87 47520 00 03 519 03 57 21366 -08 416 25635 042(a) 232 Intravascular large B-cell 00 75 - - - - 00 31 - 01 44 -

lymphoma2(a) 233 Primary effusion lymphoma 00 167 26 - - - 00 123 - 01 44 -2(a) 234 Mediastinal large B-cell 01 366 155 00 35 - 01 304 142 00 27 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 06 3388 -22 05 775 31 06 1969 -46 10 644 -192(a) 25 Marginal-zone lymphoma (MZL) 22 12351 -02 01 98 - 14 5177 -02 114 7076 -012(a) 251 Splenic MZL 02 1164 14 - - - 01 434 18 12 730 112(a) 252 Extranodal MZL MALTc type 13 7268 07 00 62 - 09 3267 04 63 3939 102(a) 253 Nodal MZL 07 3919 -23 00 36 - 04 1476 -22 39 2407 -23

2(a) 26 Follicular lymphoma 39 21788 -19 01 100 - 30 11210 -25 165 10478 -152(a) 27 Hairy-cell leukemia 05 2984 -18 - - - 05 1908 -20 17 1076 -152(a) 28 Plasma cell neoplasms 85 46642 07 - - - 45 17864 11 462 28769 052(a) 281 Plasmacytoma 05 2997 -08 - - - 04 1509 -16 24 1484 -012(a) 282 Multiple myeloma 80 43645 08 - - - 41 16355 13 439 27285 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 27 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 20 10447 34 01 105 - 10 3636 40 110 6706 32

Table 1927All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 29 16118 00 11 1730 14 23 8235 02 98 6153 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 430 - 01 208 - 01 188 - 01 34 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 28 15642 11 10 1521 71 22 8022 11 97 6099 -032(b) 21 Mycosis fungoidesSezary syndrome 07 3962 19 01 135 - 06 2261 21 25 1566 092(b) 211 Mycosis fungoides 07 3831 20 01 135 - 06 2213 21 23 1483 092(b) 212 Sezary syndrome 00 131 - - - - 00 48 - 01 83 -

2(b) 22 Peripheral T-cell lymphoma 15 8438 -13 02 318 -09 12 4248 -12 62 3872 -132(b) 221 Peripheral T-cell lymphoma NOSc 06 3159 -05 00 49 - 04 1520 02 26 1590 -082(b) 222 Angioimmunoblastic T-cell lymphoma 02 1024 19 - - - 01 415 11 10 607 232(b) 223 Subcutaneous panniculitis- 00 68 - - - - 00 39 - 00 16 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 03 1549 -39 01 184 -01 02 888 -43 08 477 -45

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 98 - - - - 00 69 - 00 18 -2(b) 226 Enteropathy-type T-cell lymphoma 00 105 - - - - 00 50 - 01 54 -2(b) 227 Cutaneous T-cell lymphoma NOSc 03 1696 -12 00 32 - 02 894 -03 12 770 -172(b) 228 Primary cutaneous anaplastic 01 739 -48 00 26 - 01 373 -49 05 340 -49

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 04 2253 97 07 1047 92 03 940 98 04 266 1022(b) 24 NKcT-cell lymphoma nasal-type 01 638 -05 00 18 - 01 435 -03 03 185 -06

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 58 - - - - 00 22 - 01 36 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 01 293 45 - - - 00 116 - 03 174 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 46 - - - - 00 25 - 00 20 -2(c) Non-Hodgkin lymphoma unknown lineage 03 1407 -232 01 195 - 02 580 -184 10 632 -2302(c) 1 Precursor lymphoblastic leukemia 01 474 -228 01 187 - 00 134 - 02 153 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 49 - - - - - - - 01 36 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 02 884 -239 - - - 01 433 -175 07 443 -

lineage2() 1 Total precursor lymphomaleukemiad 18 9903 -06 35 5518 -17 09 3210 09 19 1175 05

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 435 271 - - - 01 215 - 03 207 -lymphoma

4 Lymphoid neoplasm NOSc 10 5235 -59 01 131 - 05 1871 -65 54 3233 -61

Table 1927 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 301 199772 -05 53 7889 02 202 79325 -02 1322 112558 -08

1 Hodgkin Lymphoma 24 14552 -16 12 1809 -10 29 10031 -14 32 2712 -32

2 Non-Hodgkin lymphoma 269 180219 -03 40 5982 03 170 67835 00 1251 106402 -062(a) Non-Hodgkin lymphoma B-cell 250 168102 -01 34 5050 13 154 61827 02 1190 101225 -042(a) 1 Precursor Non-Hodgkin lymphoma B-cell 14 7632 16 29 4293 09 06 2315 29 12 1024 202(a) 2 Mature Non-Hodgkin lymphoma B-cell 223 151164 -04 05 713 35 141 56808 -01 1102 93643 -072(a) 21 ChronicSmallProlymphocytic 48 33190 -13 - - - 24 10176 -05 268 23000 -16

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 43 30073 -15 - - - 22 9196 -06 243 20866 -19

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 118 - - - - 00 26 - 01 89 -2(a) 213 Mantle-cell lymphoma 04 2999 11 - - - 02 954 10 24 2045 12

2(a) 22 Lymphoplasmacytic lymphoma 05 3569 04 - - - 03 1066 -16 30 2501 11Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 02 1605 01 - - - 01 516 -25 13 1087 112(a) 222 Waldenstrom macroglubulinemia 03 1964 06 - - - 01 550 -08 17 1414 11

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 58 39060 00 02 371 33 38 14656 03 283 24033 -032(a) 231 DLBCL NOSc 57 38379 -02 02 342 27 36 14103 -01 282 23934 -032(a) 232 Intravascular large B-cell 00 87 - - - - 00 32 - 01 55 -

lymphoma2(a) 233 Primary effusion lymphoma - - - - - - - - - - - -2(a) 234 Mediastinal large B-cell 01 580 91 00 29 - 02 518 93 00 33 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 02 1304 -34 02 253 38 02 649 -37 05 402 -852(a) 25 Marginal-zone lymphoma (MZL) 21 14183 01 00 39 - 15 5872 12 98 8272 -062(a) 251 Splenic MZL 02 1254 -07 - - - 01 455 -32 10 799 072(a) 252 Extranodal MZL MALTc type 13 8711 06 00 30 - 10 3881 17 57 4800 -032(a) 253 Nodal MZL 06 4218 -07 - - - 04 1536 11 32 2673 -18

2(a) 26 Follicular lymphoma 33 21794 -24 00 19 - 27 10515 -25 134 11260 -222(a) 27 Hairy-cell leukemia 01 728 -12 - - - 01 403 -11 04 325 -122(a) 28 Plasma cell neoplasms 55 37315 08 - - - 33 13461 15 282 23839 052(a) 281 Plasmacytoma 03 1882 00 - - - 02 853 12 12 1017 -092(a) 282 Multiple myeloma 52 35433 09 - - - 30 12608 15 270 22822 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 21 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 14 9306 32 00 44 - 07 2704 32 76 6558 31

Table 1928All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 17 11104 01 05 772 29 15 5698 05 55 4634 -112(b) 1 Precursor Non-Hodgkin lymphoma T-cell 00 186 - 01 85 - 00 84 - 00 17 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 17 10889 09 05 686 83 15 5599 12 54 4604 -092(b) 21 Mycosis fungoidesSezary syndrome 05 3007 15 01 78 - 05 1819 26 13 1110 -042(b) 211 Mycosis fungoides 05 2908 12 01 78 - 05 1777 23 12 1053 -072(b) 212 Sezary syndrome 00 99 - - - - 00 42 - 01 57 -

2(b) 22 Peripheral T-cell lymphoma 09 6093 -08 01 216 30 08 2911 -06 35 2966 -142(b) 221 Peripheral T-cell lymphoma NOSc 03 2234 03 00 37 - 03 969 07 14 1228 -012(b) 222 Angioimmunoblastic T-cell lymphoma 01 878 -22 - - - 01 284 -39 07 594 -152(b) 223 Subcutaneous panniculitis- 00 108 - 00 18 - 00 72 - 00 18 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 974 -33 01 107 - 02 562 -19 04 305 -77

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 41 - - - - 00 29 - - - -2(b) 226 Enteropathy-type T-cell lymphoma 00 81 - - - - 00 34 - 01 47 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 1267 00 00 27 - 02 681 07 07 559 -102(b) 228 Primary cutaneous anaplastic 01 510 -34 00 25 - 01 280 -50 02 205 -33

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 02 1164 96 03 381 127 01 534 97 03 249 302(b) 24 NKcT-cell lymphoma nasal-type 01 347 11 - - - 01 224 - 01 115 -

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 62 - - - - 00 32 - 00 29 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 216 03 - - - 00 79 - 02 135 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 29 - - - - - - - - - -2(c) Non-Hodgkin lymphoma unknown lineage 02 1013 -341 01 160 - 01 310 - 06 543 -2(c) 1 Precursor lymphoblastic leukemia 01 340 - 01 156 - 00 104 - 01 80 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 46 - - - - - - - 00 33 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 627 - - - - 01 194 - 05 430 -

lineage2() 1 Total precursor lymphomaleukemiad 14 8158 -09 31 4534 -13 07 2503 02 13 1121 -11

3 Composite Hodgkin lymphoma and Non-Hodgkin 00 327 - - - - 00 124 - 02 196 -lymphoma

4 Lymphoid neoplasm NOSc 07 4674 -52 01 91 - 03 1335 -51 36 3248 -58

Table 1928 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 18: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Devcan 677 April 2019 National Cancer Institute (httpssurveillancecancergovdevcan)Source Incidence data are from the SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta

San Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts) Mortality data are from the NCHS public use data file for the total US

a Underlying incidence and mortality data for American IndianAlaska Native are based on the PRCDA(PurchasedReferred Care DeliveryAreas) counties

b Hispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska NativesUnderlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry

- Statistic could not be calculatedA percent of 000 represents a value that is below 0005

Risk of Being Risk of Being

Race Current Diagnosed with Cancer Risk of Dying Race Current Diagnosed with Cancer Risk of Dying

Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer Ethnicity Age +10 yrs +20 yrs +30 yrs Ever from Cancer

All Races 0 001 002 004 193 064 Asian 0 001 002 004 159 063

10 001 004 009 195 064 Pacific 10 001 004 008 160 063

20 003 007 017 194 064 Islander 20 002 006 013 159 063

30 005 015 036 192 065 30 004 011 025 157 063

40 010 031 071 189 065 40 007 021 048 153 063

50 022 062 120 182 065 50 014 042 087 148 063

60 042 103 154 168 065 60 028 074 122 136 062

70 067 123 - 138 063 70 049 099 - 114 058

80 071 - - 090 054 80 057 - - 075 047

White 0 001 002 004 203 067 American 0 000 001 002 128 043

10 001 004 009 204 067 Indian 10 001 001 004 129 044

20 002 007 017 203 067 Alaska 20 001 003 007 128 044

30 005 015 037 201 067 Nativea 30 002 006 023 129 044

40 010 032 074 198 068 40 004 021 044 129 045

50 022 065 127 192 068 50 017 042 085 129 046

60 044 109 163 177 068 60 026 072 113 118 047

70 072 130 - 146 066 70 050 097 - 102 046

80 075 - - 094 056 80 060 - - 066 037

Black 0 000 002 004 126 040 Hispanicb 0 001 002 004 210 065

10 001 004 009 128 040 10 001 004 008 211 066

20 003 008 018 127 040 20 002 007 017 211 066

30 005 015 034 125 040 30 004 014 036 209 066

40 010 029 058 122 040 40 010 032 073 206 066

50 020 049 083 115 040 50 022 064 123 198 066

60 032 068 094 102 039 60 043 104 161 182 065

70 041 071 - 080 036 70 066 127 - 149 062

80 039 - - 051 030 80 073 - - 100 051

Table 1918

Non-Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10 20 and 30 Years

Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age and

Lifetime Risk of Dying from Cancer Given Alive at Current Age

Females 2014-2016 By RaceEthnicity

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

The AAPC is the Average Annual Percent Change over the time interval The AAPCs are calculated bythe Joinpoint Regression Program Version 47 February 2019 National Cancer Institute

- Statistic not shown Rate based on less than 16 cases for the time intervalTrend based on less than 10 cases for at least one year within the time interval

a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) Trendsare based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico SeattleUtah and AtlantaThe SEER 21 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the AlaskaNative Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts

c The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 3 Joinpoints overdiagnosis years 2000-2016

d The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 5 Joinpoints overdiagnosis years 1975-2016

e Hispanic and Non-Hispanic are not mutually exclusive from whites blacks AsianPacificIslanders and American IndiansAlaska Natives Incidence data for Hispanics and Non-Hispanicsare based on NHIA and exclude cases from the Alaska Native Registry

f Incidence data for American IndianAlaska Native are based on the PurchasedReferred CareDelivery Area (PRCDA) counties

g US Mortality Files National Center for Health Statistics CDCh The 2007-2016 mortality AAPCs are based on a Joinpoint analysis using years of death 2000-2016 The APC is significantly different from zero (plt05)

SEER Incidence SEER 21 Areasb SEER 21 Areasb SEER 9 Areasb

Rate 2012-2016 Trend 2007-2016c Trend 2007-2016d

Rate per 100000 persons AAPC () AAPC ()

Total Males Females Total Males Females Total Males Females RaceEthnicity

All Races 196 239 162 -07 -09 -08 -09 -07 -08

White 206 250 170 -08 -11 -09 -09 -08 -08White Hispanice 183 212 161 -08 -03 -05 - - -White Non-Hispanice 210 256 172 -08 -06 -10 - - -

Black 147 177 124 01 00 03 00 -04 -09

AsianPacific Islander 134 164 110 00 00 -01 - - -

Amer IndAlaska Natf 113 120 106 -05 -12 00 - - -

Hispanice 179 207 157 -05 -02 03 - - -

US Mortalityg Rate 2012-2016 Trend 2007-2016h

Rate per 100000 persons AAPC ()

Total Males Females Total Males FemalesRaceEthnicity

All Races 56 73 44 -23 -20 -27

White 59 76 45 -23 -20 -27White Hispanice 51 65 40 -16 -13 -20White Non-Hispanice 59 76 46 -23 -20 -27

Black 41 52 33 -20 -19 -21

AsianPacific Islander 39 49 31 -17 -15 -19

Amer IndAlaska NatTotal US 31 40 24 -32 -20 -45PRCDA Counties 44 58 33 -21 -04 -37Non-PRCDA Counties 17 21 14 -54 -50 -60

Hispanice 48 61 38 -17 -14 -21

Table 1919Non-Hodgkin Lymphoma

SEER Incidence and US MortalityAge-Adjusted Rates and Trendsa

By RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Incidence Ratesa 2012-2016

California 1844 2241 1515 1938 2349 1591 1390 1639 1182Greater Bay Area 1957 2381 1600 2144 2601 1755 1628 1828 1436San Francisco-Oakland 1956 2421 1570 2174 2660 1765 1603 1816 1408San Jose-Monterey 1962 2311 1660 2097 2503 1742 1800 1891 1646

Los Angeles 1804 2176 1505 1951 2331 1637 1357 1659 1139Greater California 1822 2220 1489 1876 2286 1529 1314 1534 1113

Connecticut 2116 2607 1733 2154 2642 1771 1386 1829 1051Detroit 2132 2636 1742 2290 2850 1847 1620 1905 1409Georgia 1826 2244 1487 1936 2346 1588 1462 1833 1187Atlanta 1925 2381 1555 2119 2567 1736 1601 2034 1272Rural Georgia 1584 1790 1401 1953 2298 1567 807 - 988Greater Georgia 1784 2186 1459 1872 2274 1537 1380 1703 1146

Hawaii 1660 2024 1349 1958 2275 1593 - - -Idaho 1922 2267 1616 1920 2262 1618 - - -Iowa 2134 2601 1756 2148 2612 1773 1352 1602 1100Kentucky 2039 2505 1666 2070 2538 1693 1403 1788 1112Louisiana 1944 2352 1614 2106 2537 1744 1469 1769 1237Massachusetts 1810 2181 1518 1830 2214 1524 1452 1655 1299New Jersey 2155 2607 1804 2285 2765 1905 1387 1621 1222New Mexico 1550 1739 1387 1580 1798 1394 875 - -New York 2152 2620 1788 2306 2792 1915 1545 1852 1333Seattle-Puget Sound 2116 2627 1695 2177 2667 1766 1631 1973 1316Utah 1843 2233 1498 1862 2258 1513 2089 - -

SEER 9 Areasb 1992 2444 1623 2095 2551 1716 1573 1914 1298SEER 13 Areasb 1946 2373 1597 2064 2502 1700 1519 1853 1258SEER 18 Areasb 1933 2354 1590 2031 2464 1671 1449 1751 1214SEER 21 Areasb 1963 2388 1620 2061 2498 1702 1471 1771 1245

Table 1920Non-Hodgkin Lymphoma

Age-Adjusted SEER Incidence Ratesa

By Registry Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control and PreventionRates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and AtlantaThe SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Death Ratesa 2012-2016

California 533 677 423 570 726 449 417 480 367Greater Bay Area 505 671 376 561 756 408 410 491 331San Francisco-Oakland 503 667 376 555 742 409 416 490 343San Jose-Monterey 511 681 377 573 781 407 - - -

Los Angeles 541 670 443 589 728 481 424 503 371Greater California 539 682 429 564 716 447 416 455 384

Connecticut 533 705 407 547 717 421 350 510 244Detroit 639 822 505 693 895 542 443 528 384Georgia 533 697 411 580 747 450 376 503 286Atlanta 492 659 372 533 728 388 397 506 317Rural Georgia 559 731 388 670 813 507 - - -Greater Georgia 549 712 426 595 755 470 363 500 266

Hawaii 475 620 352 545 649 412 - - -Idaho 635 775 510 641 782 516 - - -Iowa 638 845 484 642 848 488 - - -Kentucky 642 886 460 655 904 470 401 557 284Louisiana 608 814 451 651 863 485 461 623 340Massachusetts 523 659 423 541 682 436 347 410 297New Jersey 545 721 419 585 780 443 372 466 314New Mexico 488 585 405 493 595 406 - - -New York 535 702 412 575 752 441 390 514 313Seattle-Puget Sound 585 749 463 604 769 480 490 562 397Utah 542 670 433 551 681 440 - - -

SEER 9 Areasb 555 719 430 586 758 454 414 522 333SEER 13 Areasb 549 705 429 586 753 457 419 521 342SEER 18 Areasb 554 717 431 589 761 456 409 518 329SEER 21 Areasb 550 712 428 584 754 453 401 513 322

Total US 562 725 436 586 755 454 408 518 330

Table 1921Non-Hodgkin Lymphoma

Age-Adjusted SEER Death Ratesa

By Registry Race and Sex

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 562 002

High Five StatesMichigan 645 011 01(0112) 1479Kentucky 642 016 02(0118) 1424Iowa 638 018 03(0120) 1367Indiana 638 013 04(0117) 1361Idaho 635 027 05(0126) 1303

Low Five StatesNevada 511 019 47(2251) -899Colorado 491 014 48(3851) -1257New Mexico 488 020 49(2851) -1317Hawaii 475 024 50(3051) -1542c

DC 444 039 51(2351) -2097c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 545 014 28(1847) -291 Montana 559 030 25(0250) -042Alaska 525 047 43(0151) -654 Nebraska 563 023 22(0548) 026Arizona 512 012 46(2950) -886 Nevada 511 019 47(2251) -899Arkansas 555 018 26(1247) -113 New Hampshire 562 027 23(0349) 014California 533 005 40(2645) -508 New Jersey 545 010 29(2045) -301Colorado 491 014 48(3851) -1257 New Mexico 488 020 49(2851) -1317Connecticut 533 016 39(1949) -505 New York 535 007 37(2446) -478Delaware 628 033 08(0139) 1174 North Carolina 541 010 35(2146) -363DC 444 039 51(2351) -2097c North Dakota 561 037 24(0151) -007Florida 535 006 38(2545) -479 Ohio 616 009 10(0220) 969Georgia 533 011 41(2248) -511 Oklahoma 630 017 06(0121) 1226Hawaii 475 024 50(3051) -1542c Oregon 612 016 11(0124) 903Idaho 635 027 05(0126) 1303 Pennsylvania 603 009 16(0622) 729Illinois 566 009 20(1634) 085 Rhode Island 542 029 32(0651) -350Indiana 638 013 04(0117) 1361 South Carolina 542 014 31(1847) -347Iowa 638 018 03(0120) 1367 South Dakota 541 033 36(0451) -364Kansas 585 019 19(0439) 420 Tennessee 629 013 07(0119) 1198Kentucky 642 016 02(0118) 1424 Texas 546 007 27(2142) -277Louisiana 608 016 14(0125) 826 Utah 542 022 33(1250) -352Maine 609 026 13(0137) 852 Vermont 605 040 15(0148) 770Maryland 524 013 44(2349) -663 Virginia 544 011 30(2046) -319Massachusetts 523 012 45(2549) -687 Washington 599 013 17(0425) 665Michigan 645 011 01(0112) 1479 West Virginia 612 022 12(0132) 894Minnesota 617 014 09(0122) 984 Wisconsin 590 013 18(0629) 507Mississippi 531 018 42(1850) -551 Wyoming 564 043 21(0151) 050Missouri 542 012 34(1947) -354

Table 1922Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males and Females

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 725 003

High Five StatesKentucky 886 030 01(0112) 2213c

Iowa 845 032 02(0120) 1647c

Michigan 842 019 03(0114) 1615c

Indiana 839 024 04(0116) 1567c

Delaware 824 058 05(0144) 1364

Low Five StatesArizona 635 019 47(3251) -1244Alaska 630 075 48(0251) -1311Hawaii 620 041 49(1951) -1452DC 614 071 50(0551) -1535c

New Mexico 585 033 51(3451) -1928c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 688 025 36(1649) -513 Montana 709 050 26(0251) -218Alaska 630 075 48(0251) -1311 Nebraska 737 040 20(0248) 165Arizona 635 019 47(3251) -1244 Nevada 653 032 44(1951) -994Arkansas 721 031 22(0747) -061 New Hampshire 710 046 25(0451) -210California 677 009 41(2846) -666 New Jersey 721 018 21(1441) -059Colorado 643 024 46(2451) -1133 New Mexico 585 033 51(3451) -1928c

Connecticut 705 028 28(1248) -273 New York 702 012 30(1943) -323Delaware 824 058 05(0144) 1364 North Carolina 709 018 27(1644) -221DC 614 071 50(0551) -1535c North Dakota 682 061 39(0251) -598Florida 683 011 37(2446) -585 Ohio 800 017 09(0320) 1029Georgia 697 019 34(1746) -387 Oklahoma 806 030 08(0126) 1109Hawaii 620 041 49(1951) -1452 Oregon 794 028 12(0128) 947Idaho 775 045 16(0146) 692 Pennsylvania 783 015 15(0523) 794Illinois 739 016 19(1235) 190 Rhode Island 649 050 45(1051) -1050Indiana 839 024 04(0116) 1567c South Carolina 681 025 40(1850) -604Iowa 845 032 02(0120) 1647c South Dakota 701 056 31(0251) -332Kansas 713 032 24(0948) -174 Tennessee 820 023 06(0120) 1311Kentucky 886 030 01(0112) 2213c Texas 698 012 32(2043) -368Louisiana 814 029 07(0122) 1222 Utah 670 036 42(1351) -754Maine 754 045 18(0148) 395 Vermont 794 069 11(0149) 950Maryland 682 023 38(1849) -588 Virginia 694 020 35(1847) -429Massachusetts 659 020 43(2450) -910 Washington 790 022 13(0224) 897Michigan 842 019 03(0114) 1615c West Virginia 774 038 17(0142) 675Minnesota 797 025 10(0224) 995 Wisconsin 786 023 14(0227) 844Mississippi 717 034 23(0748) -110 Wyoming 698 071 33(0151) -377Missouri 702 022 29(1646) -319

Table 1923Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 436 002

High Five StatesIdaho 510 033 01(0139) 1697c

Maine 497 031 02(0141) 1396Michigan 495 012 03(0119) 1340Oklahoma 492 020 04(0128) 1276Indiana 492 016 05(0123) 1270

Low Five StatesMississippi 404 021 47(1351) -731Nevada 382 022 48(2051) -1237Colorado 369 016 49(3451) -1540c

Hawaii 352 027 50(2551) -1932c

DC 323 044 51(1551) -2601c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 440 017 24(0547) 099 Montana 435 036 27(0151) -034Alaska 414 058 38(0151) -500 Nebraska 435 027 26(0249) -032Arizona 407 014 44(2049) -664 Nevada 382 022 48(2051) -1237Arkansas 428 021 31(0649) -181 New Hampshire 454 032 19(0149) 400California 423 006 34(2244) -313 New Jersey 419 012 37(1848) -397Colorado 369 016 49(3451) -1540c New Mexico 405 025 46(0951) -706Connecticut 407 018 45(1550) -669 New York 412 008 39(2548) -554Delaware 473 039 12(0150) 855 North Carolina 420 012 35(1848) -374DC 323 044 51(1551) -2601c North Dakota 471 045 13(0150) 809Florida 412 007 40(2548) -564 Ohio 478 011 10(0123) 967Georgia 411 012 43(2049) -582 Oklahoma 492 020 04(0128) 1276Hawaii 352 027 50(2551) -1932c Oregon 465 019 15(0141) 668Idaho 510 033 01(0139) 1697c Pennsylvania 467 010 14(0427) 714Illinois 439 010 25(1341) 074 Rhode Island 455 035 18(0150) 434Indiana 492 016 05(0123) 1270 South Carolina 432 017 30(0947) -102Iowa 484 021 08(0135) 1087 South Dakota 411 039 42(0151) -580Kansas 486 023 06(0137) 1143 Tennessee 484 015 09(0126) 1087Kentucky 460 018 17(0241) 544 Texas 427 008 32(1944) -213Louisiana 451 018 21(0345) 333 Utah 433 026 28(0250) -081Maine 497 031 02(0141) 1396 Vermont 461 047 16(0151) 578Maryland 411 015 41(1749) -576 Virginia 432 013 29(1246) -092Massachusetts 423 014 33(1548) -303 Washington 452 015 20(0541) 360Michigan 495 012 03(0119) 1340 West Virginia 486 027 07(0143) 1141Minnesota 475 017 11(0132) 901 Wisconsin 443 015 23(0645) 156Mississippi 404 021 47(1351) -731 Wyoming 445 051 22(0151) 192Missouri 419 014 36(1549) -396

Table 1924Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Females

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 Areas (excluding the AlaskaNative Registry) and 112016 US population estimates based on the average of 2015 and 2016 population estimates from theUS Bureau of the CensusPrevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 24 years

b Maximum limited-duration prevalence is 24 years for 1992-2016 datac Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groupsd Cases diagnosed more than 24 years ago were estimated using the completeness index method (Capocaccia et al 1997

Merrill et al 2000)e Complete prevalence is obtained by summing 0 to lt24 and gt=24- Statistic not shown Statistic based on fewer than 5 cases estimated alive in SEER for the time interval+ Not available

Years Since Diagnosis 0 to lt5 5 to lt10 10 to lt15 15 to lt20 20 to lt24 0 to lt24b gt=24d Completee

Race Sex

All Races Both Sexes 248946 177490 117326 69109 31890 644761 49943 694704Males 135137 94173 60159 36020 16581 342069 25489 367558Females 113809 83317 57167 33089 15309 302692 24454 327146

White Both Sexes 213764 154454 101984 60537 28026 558765 49625 620368Males 116527 82172 52535 31627 14543 297404 26526 330121Females 97237 72282 49448 28910 13483 261361 23099 290247

Black Both Sexes 20500 13640 9750 5271 2215 51376 4115 55491Males 10712 7188 4768 2684 1174 26526 1911 28437Females 9789 6452 4981 2587 1041 24850 2204 27054

Asian Both Sexes 8405 5210 3415 1867 844 19741 + +Pacific Males 4548 2661 1757 1013 407 10386 + +Islander Females 3856 2549 1657 855 437 9355 + +

Hispanic Both Sexes 21339 14049 8272 4881 2136 50676 + +Males 10918 7243 4331 2617 1094 26202 + +Females 10421 6805 3941 2264 1043 24474 + +

Age Specific (Crude) Age-Adjustedc Age at Prevalence All Ages 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ All Ages

Race Sex

All Races Both Sexes 02001 00035 00139 00283 00538 01121 02352 04640 08181 10224 01738Males 02156 00044 00189 00354 00625 01293 02710 05243 09364 12449 02023Females 01850 00026 00087 00208 00450 00952 02010 04094 07196 08856 01498

White Both Sexes 02216 00035 00143 00289 00534 01148 02427 04858 08597 10738 01807Males 02380 00045 00198 00359 00622 01317 02790 05442 09778 13060 02095Females 02054 00025 00085 00214 00442 00976 02072 04317 07593 09285 01560

Black Both Sexes 01139 00029 00113 00265 00599 01027 02010 03340 05117 05333 01251Males 01226 00029 00140 00351 00696 01223 02333 03969 05849 06055 01457Females 01059 00030 00086 00178 00510 00853 01728 02836 04608 04976 01088

Asian Both Sexes 00970 00039 00133 00207 00353 00680 01409 02692 04470 06094 01032Pacific Males 01065 00044 00175 00240 00398 00744 01640 03072 05516 07472 01222Islander Females 00882 00033 00092 00175 00312 00623 01209 02384 03629 05207 00880

Hispanic Both Sexes 00887 00030 00117 00206 00398 00850 01769 03632 05888 07209 01294Males 00908 00035 00147 00256 00455 00932 01924 03940 06326 08003 01420Females 00866 00024 00086 00151 00337 00766 01616 03360 05552 06719 01185

Table 1925Non-Hodgkin Lymphoma

Estimated United States Cancer Prevalence Countsa on January 1 2016By RaceEthnicity Sex and Years Since Diagnosis

Estimated prevalence percenta on January 1 2016 of the SEER population diagnosed in the previous 24 yearsBy Age at Prevalence RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 372 452924 -05 62 18862 04 247 189692 -05 1657 244370 -05

1 Hodgkin Lymphoma 28 32262 -17 13 3927 -06 33 22556 -15 39 5779 -31

2 Non-Hodgkin lymphoma 336 409991 -03 48 14693 04 210 163591 -03 1572 231707 -042(a) Non-Hodgkin lymphoma B-cell 311 380349 -01 39 11836 14 190 148768 -02 1491 219745 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 15 16631 20 31 9416 10 07 5203 39 14 2012 252(a) 2 Mature Non-Hodgkin lymphoma B-cell 280 343965 -04 07 2271 30 174 137225 -05 1387 204469 -042(a) 21 ChronicSmallProlymphocytic 69 85601 -13 00 35 - 35 29103 -11 382 56463 -14

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 61 75061 -15 00 30 - 31 25339 -13 336 49692 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 311 19 - - - 00 72 - 02 234 262(a) 213 Mantle-cell lymphoma 08 10229 03 - - - 04 3692 02 44 6537 04

2(a) 22 Lymphoplasmacytic lymphoma 07 8651 00 - - - 03 2590 -11 41 6059 04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 03 3667 -03 - - - 01 1132 -18 17 2533 022(a) 222 Waldenstrom macroglubulinemia 04 4984 03 - - - 02 1458 -07 24 3526 06

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 72 87188 00 03 925 26 48 36480 -02 339 49783 022(a) 231 DLBCL NOSc 71 85899 -01 03 861 12 46 35469 -05 337 49569 012(a) 232 Intravascular large B-cell 00 162 - - - - 00 63 - 01 99 -

lymphoma2(a) 233 Primary effusion lymphoma 00 181 27 - - - 00 126 - 00 55 -2(a) 234 Mediastinal large B-cell 01 946 116 00 64 - 01 822 111 00 60 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 04 4692 -26 03 1028 32 04 2618 -43 07 1046 -432(a) 25 Marginal-zone lymphoma (MZL) 22 26534 00 00 137 13 14 11049 05 104 15348 -042(a) 251 Splenic MZL 02 2418 04 - - - 01 889 -08 10 1529 102(a) 252 Extranodal MZL MALTc type 13 15979 06 00 92 - 09 7148 11 59 8739 032(a) 253 Nodal MZL 07 8137 -15 00 45 - 04 3012 -05 34 5080 -20

2(a) 26 Follicular lymphoma 35 43582 -21 00 119 - 28 21725 -25 147 21738 -182(a) 27 Hairy-cell leukemia 03 3712 -16 - - - 03 2311 -19 09 1401 -122(a) 28 Plasma cell neoplasms 68 83957 08 00 24 - 39 31325 12 358 52608 062(a) 281 Plasmacytoma 04 4879 -04 00 16 - 03 2362 -06 17 2501 -032(a) 282 Multiple myeloma 64 79078 09 - - - 36 28963 14 341 50107 07

plasma-cell leukemia2(a) 29 Heavy chain disease 00 48 - - - - 00 24 - 00 23 -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 16 19753 33 00 149 27 08 6340 37 90 13264 32

Table 1926All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 23 27222 01 08 2502 18 19 13933 03 73 10787 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 616 - 01 293 - 00 272 - 00 51 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 22 26531 11 07 2207 75 19 13621 12 73 10703 -042(b) 21 Mycosis fungoidesSezary syndrome 06 6969 18 01 213 84 06 4080 23 18 2676 052(b) 211 Mycosis fungoides 06 6739 17 01 213 84 05 3990 22 17 2536 042(b) 212 Sezary syndrome 00 230 46 - - - 00 90 - 01 140 -

2(b) 22 Peripheral T-cell lymphoma 12 14531 -10 02 534 07 10 7159 -09 46 6838 -122(b) 221 Peripheral T-cell lymphoma NOSc 04 5393 -01 00 86 - 03 2489 04 19 2818 -042(b) 222 Angioimmunoblastic T-cell lymphoma 02 1902 02 - - - 01 699 -09 08 1201 072(b) 223 Subcutaneous panniculitis- 00 176 44 00 31 - 00 111 - 00 34 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 2523 -36 01 291 00 02 1450 -33 05 782 -54

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 139 - - - - 00 98 - 00 28 -2(b) 226 Enteropathy-type T-cell lymphoma 00 186 -02 - - - 00 84 - 01 101 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 2963 -07 00 59 - 02 1575 01 09 1329 -142(b) 228 Primary cutaneous anaplastic 01 1249 -41 00 51 - 01 653 -49 04 545 -39

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 03 3417 96 05 1428 101 02 1474 99 03 515 672(b) 24 NKcT-cell lymphoma nasal-type 01 985 02 00 26 - 01 659 00 02 300 05

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 120 - - - - 00 54 - 00 65 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 509 30 - - - 00 195 -05 02 309 442(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 75 - - - - 00 40 - 00 33 -2(c) Non-Hodgkin lymphoma unknown lineage 02 2420 -274 01 355 - 01 890 -216 08 1175 -2792(c) 1 Precursor lymphoblastic leukemia 01 814 -283 01 343 - 00 238 - 02 233 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 95 - - - - 00 25 - 00 69 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 1511 -274 - - - 01 627 -202 06 873 -319

lineage2() 1 Total precursor lymphomaleukemiad 16 18061 -07 33 10052 -15 08 5713 06 15 2296 -01

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 762 273 00 20 - 00 339 227 03 403 -lymphoma

4 Lymphoid neoplasm NOSc 08 9909 -55 01 222 113 04 3206 -59 43 6481 -59

Table 1926 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 461 253152 -05 70 10973 05 294 110367 -07 2122 131812 -05

1 Hodgkin Lymphoma 31 17710 -17 13 2118 -03 36 12525 -16 48 3067 -31

2 Non-Hodgkin lymphoma 419 229772 -03 56 8711 05 252 95756 -05 2017 125305 -032(a) Non-Hodgkin lymphoma B-cell 387 212247 -02 44 6786 15 227 86941 -04 1908 118520 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 16 8999 24 33 5123 11 08 2888 46 16 988 292(a) 2 Mature Non-Hodgkin lymphoma B-cell 351 192801 -05 10 1558 28 210 80417 -08 1783 110826 -042(a) 21 ChronicSmallProlymphocytic 96 52411 -15 00 21 - 47 18927 -14 539 33463 -15

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 82 44988 -17 00 19 - 40 16143 -16 464 28826 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 193 -02 - - - 00 46 - 02 145 052(a) 213 Mantle-cell lymphoma 13 7230 -01 - - - 07 2738 -01 72 4492 -01

2(a) 22 Lymphoplasmacytic lymphoma 10 5082 -05 - - - 04 1524 -08 58 3558 -04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 04 2062 -08 - - - 02 616 -12 23 1446 -072(a) 222 Waldenstrom macroglubulinemia 06 3020 -02 - - - 02 908 -06 34 2112 -02

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 88 48128 01 03 554 22 59 21824 -06 418 25750 052(a) 231 DLBCL NOSc 87 47520 00 03 519 03 57 21366 -08 416 25635 042(a) 232 Intravascular large B-cell 00 75 - - - - 00 31 - 01 44 -

lymphoma2(a) 233 Primary effusion lymphoma 00 167 26 - - - 00 123 - 01 44 -2(a) 234 Mediastinal large B-cell 01 366 155 00 35 - 01 304 142 00 27 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 06 3388 -22 05 775 31 06 1969 -46 10 644 -192(a) 25 Marginal-zone lymphoma (MZL) 22 12351 -02 01 98 - 14 5177 -02 114 7076 -012(a) 251 Splenic MZL 02 1164 14 - - - 01 434 18 12 730 112(a) 252 Extranodal MZL MALTc type 13 7268 07 00 62 - 09 3267 04 63 3939 102(a) 253 Nodal MZL 07 3919 -23 00 36 - 04 1476 -22 39 2407 -23

2(a) 26 Follicular lymphoma 39 21788 -19 01 100 - 30 11210 -25 165 10478 -152(a) 27 Hairy-cell leukemia 05 2984 -18 - - - 05 1908 -20 17 1076 -152(a) 28 Plasma cell neoplasms 85 46642 07 - - - 45 17864 11 462 28769 052(a) 281 Plasmacytoma 05 2997 -08 - - - 04 1509 -16 24 1484 -012(a) 282 Multiple myeloma 80 43645 08 - - - 41 16355 13 439 27285 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 27 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 20 10447 34 01 105 - 10 3636 40 110 6706 32

Table 1927All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 29 16118 00 11 1730 14 23 8235 02 98 6153 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 430 - 01 208 - 01 188 - 01 34 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 28 15642 11 10 1521 71 22 8022 11 97 6099 -032(b) 21 Mycosis fungoidesSezary syndrome 07 3962 19 01 135 - 06 2261 21 25 1566 092(b) 211 Mycosis fungoides 07 3831 20 01 135 - 06 2213 21 23 1483 092(b) 212 Sezary syndrome 00 131 - - - - 00 48 - 01 83 -

2(b) 22 Peripheral T-cell lymphoma 15 8438 -13 02 318 -09 12 4248 -12 62 3872 -132(b) 221 Peripheral T-cell lymphoma NOSc 06 3159 -05 00 49 - 04 1520 02 26 1590 -082(b) 222 Angioimmunoblastic T-cell lymphoma 02 1024 19 - - - 01 415 11 10 607 232(b) 223 Subcutaneous panniculitis- 00 68 - - - - 00 39 - 00 16 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 03 1549 -39 01 184 -01 02 888 -43 08 477 -45

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 98 - - - - 00 69 - 00 18 -2(b) 226 Enteropathy-type T-cell lymphoma 00 105 - - - - 00 50 - 01 54 -2(b) 227 Cutaneous T-cell lymphoma NOSc 03 1696 -12 00 32 - 02 894 -03 12 770 -172(b) 228 Primary cutaneous anaplastic 01 739 -48 00 26 - 01 373 -49 05 340 -49

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 04 2253 97 07 1047 92 03 940 98 04 266 1022(b) 24 NKcT-cell lymphoma nasal-type 01 638 -05 00 18 - 01 435 -03 03 185 -06

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 58 - - - - 00 22 - 01 36 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 01 293 45 - - - 00 116 - 03 174 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 46 - - - - 00 25 - 00 20 -2(c) Non-Hodgkin lymphoma unknown lineage 03 1407 -232 01 195 - 02 580 -184 10 632 -2302(c) 1 Precursor lymphoblastic leukemia 01 474 -228 01 187 - 00 134 - 02 153 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 49 - - - - - - - 01 36 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 02 884 -239 - - - 01 433 -175 07 443 -

lineage2() 1 Total precursor lymphomaleukemiad 18 9903 -06 35 5518 -17 09 3210 09 19 1175 05

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 435 271 - - - 01 215 - 03 207 -lymphoma

4 Lymphoid neoplasm NOSc 10 5235 -59 01 131 - 05 1871 -65 54 3233 -61

Table 1927 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 301 199772 -05 53 7889 02 202 79325 -02 1322 112558 -08

1 Hodgkin Lymphoma 24 14552 -16 12 1809 -10 29 10031 -14 32 2712 -32

2 Non-Hodgkin lymphoma 269 180219 -03 40 5982 03 170 67835 00 1251 106402 -062(a) Non-Hodgkin lymphoma B-cell 250 168102 -01 34 5050 13 154 61827 02 1190 101225 -042(a) 1 Precursor Non-Hodgkin lymphoma B-cell 14 7632 16 29 4293 09 06 2315 29 12 1024 202(a) 2 Mature Non-Hodgkin lymphoma B-cell 223 151164 -04 05 713 35 141 56808 -01 1102 93643 -072(a) 21 ChronicSmallProlymphocytic 48 33190 -13 - - - 24 10176 -05 268 23000 -16

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 43 30073 -15 - - - 22 9196 -06 243 20866 -19

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 118 - - - - 00 26 - 01 89 -2(a) 213 Mantle-cell lymphoma 04 2999 11 - - - 02 954 10 24 2045 12

2(a) 22 Lymphoplasmacytic lymphoma 05 3569 04 - - - 03 1066 -16 30 2501 11Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 02 1605 01 - - - 01 516 -25 13 1087 112(a) 222 Waldenstrom macroglubulinemia 03 1964 06 - - - 01 550 -08 17 1414 11

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 58 39060 00 02 371 33 38 14656 03 283 24033 -032(a) 231 DLBCL NOSc 57 38379 -02 02 342 27 36 14103 -01 282 23934 -032(a) 232 Intravascular large B-cell 00 87 - - - - 00 32 - 01 55 -

lymphoma2(a) 233 Primary effusion lymphoma - - - - - - - - - - - -2(a) 234 Mediastinal large B-cell 01 580 91 00 29 - 02 518 93 00 33 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 02 1304 -34 02 253 38 02 649 -37 05 402 -852(a) 25 Marginal-zone lymphoma (MZL) 21 14183 01 00 39 - 15 5872 12 98 8272 -062(a) 251 Splenic MZL 02 1254 -07 - - - 01 455 -32 10 799 072(a) 252 Extranodal MZL MALTc type 13 8711 06 00 30 - 10 3881 17 57 4800 -032(a) 253 Nodal MZL 06 4218 -07 - - - 04 1536 11 32 2673 -18

2(a) 26 Follicular lymphoma 33 21794 -24 00 19 - 27 10515 -25 134 11260 -222(a) 27 Hairy-cell leukemia 01 728 -12 - - - 01 403 -11 04 325 -122(a) 28 Plasma cell neoplasms 55 37315 08 - - - 33 13461 15 282 23839 052(a) 281 Plasmacytoma 03 1882 00 - - - 02 853 12 12 1017 -092(a) 282 Multiple myeloma 52 35433 09 - - - 30 12608 15 270 22822 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 21 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 14 9306 32 00 44 - 07 2704 32 76 6558 31

Table 1928All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 17 11104 01 05 772 29 15 5698 05 55 4634 -112(b) 1 Precursor Non-Hodgkin lymphoma T-cell 00 186 - 01 85 - 00 84 - 00 17 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 17 10889 09 05 686 83 15 5599 12 54 4604 -092(b) 21 Mycosis fungoidesSezary syndrome 05 3007 15 01 78 - 05 1819 26 13 1110 -042(b) 211 Mycosis fungoides 05 2908 12 01 78 - 05 1777 23 12 1053 -072(b) 212 Sezary syndrome 00 99 - - - - 00 42 - 01 57 -

2(b) 22 Peripheral T-cell lymphoma 09 6093 -08 01 216 30 08 2911 -06 35 2966 -142(b) 221 Peripheral T-cell lymphoma NOSc 03 2234 03 00 37 - 03 969 07 14 1228 -012(b) 222 Angioimmunoblastic T-cell lymphoma 01 878 -22 - - - 01 284 -39 07 594 -152(b) 223 Subcutaneous panniculitis- 00 108 - 00 18 - 00 72 - 00 18 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 974 -33 01 107 - 02 562 -19 04 305 -77

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 41 - - - - 00 29 - - - -2(b) 226 Enteropathy-type T-cell lymphoma 00 81 - - - - 00 34 - 01 47 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 1267 00 00 27 - 02 681 07 07 559 -102(b) 228 Primary cutaneous anaplastic 01 510 -34 00 25 - 01 280 -50 02 205 -33

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 02 1164 96 03 381 127 01 534 97 03 249 302(b) 24 NKcT-cell lymphoma nasal-type 01 347 11 - - - 01 224 - 01 115 -

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 62 - - - - 00 32 - 00 29 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 216 03 - - - 00 79 - 02 135 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 29 - - - - - - - - - -2(c) Non-Hodgkin lymphoma unknown lineage 02 1013 -341 01 160 - 01 310 - 06 543 -2(c) 1 Precursor lymphoblastic leukemia 01 340 - 01 156 - 00 104 - 01 80 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 46 - - - - - - - 00 33 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 627 - - - - 01 194 - 05 430 -

lineage2() 1 Total precursor lymphomaleukemiad 14 8158 -09 31 4534 -13 07 2503 02 13 1121 -11

3 Composite Hodgkin lymphoma and Non-Hodgkin 00 327 - - - - 00 124 - 02 196 -lymphoma

4 Lymphoid neoplasm NOSc 07 4674 -52 01 91 - 03 1335 -51 36 3248 -58

Table 1928 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 19: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

The AAPC is the Average Annual Percent Change over the time interval The AAPCs are calculated bythe Joinpoint Regression Program Version 47 February 2019 National Cancer Institute

- Statistic not shown Rate based on less than 16 cases for the time intervalTrend based on less than 10 cases for at least one year within the time interval

a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) Trendsare based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico SeattleUtah and AtlantaThe SEER 21 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the AlaskaNative Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts

c The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 3 Joinpoints overdiagnosis years 2000-2016

d The 2007-2016 AAPC estimates are based on a Joinpoint analysis with up to 5 Joinpoints overdiagnosis years 1975-2016

e Hispanic and Non-Hispanic are not mutually exclusive from whites blacks AsianPacificIslanders and American IndiansAlaska Natives Incidence data for Hispanics and Non-Hispanicsare based on NHIA and exclude cases from the Alaska Native Registry

f Incidence data for American IndianAlaska Native are based on the PurchasedReferred CareDelivery Area (PRCDA) counties

g US Mortality Files National Center for Health Statistics CDCh The 2007-2016 mortality AAPCs are based on a Joinpoint analysis using years of death 2000-2016 The APC is significantly different from zero (plt05)

SEER Incidence SEER 21 Areasb SEER 21 Areasb SEER 9 Areasb

Rate 2012-2016 Trend 2007-2016c Trend 2007-2016d

Rate per 100000 persons AAPC () AAPC ()

Total Males Females Total Males Females Total Males Females RaceEthnicity

All Races 196 239 162 -07 -09 -08 -09 -07 -08

White 206 250 170 -08 -11 -09 -09 -08 -08White Hispanice 183 212 161 -08 -03 -05 - - -White Non-Hispanice 210 256 172 -08 -06 -10 - - -

Black 147 177 124 01 00 03 00 -04 -09

AsianPacific Islander 134 164 110 00 00 -01 - - -

Amer IndAlaska Natf 113 120 106 -05 -12 00 - - -

Hispanice 179 207 157 -05 -02 03 - - -

US Mortalityg Rate 2012-2016 Trend 2007-2016h

Rate per 100000 persons AAPC ()

Total Males Females Total Males FemalesRaceEthnicity

All Races 56 73 44 -23 -20 -27

White 59 76 45 -23 -20 -27White Hispanice 51 65 40 -16 -13 -20White Non-Hispanice 59 76 46 -23 -20 -27

Black 41 52 33 -20 -19 -21

AsianPacific Islander 39 49 31 -17 -15 -19

Amer IndAlaska NatTotal US 31 40 24 -32 -20 -45PRCDA Counties 44 58 33 -21 -04 -37Non-PRCDA Counties 17 21 14 -54 -50 -60

Hispanice 48 61 38 -17 -14 -21

Table 1919Non-Hodgkin Lymphoma

SEER Incidence and US MortalityAge-Adjusted Rates and Trendsa

By RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Incidence Ratesa 2012-2016

California 1844 2241 1515 1938 2349 1591 1390 1639 1182Greater Bay Area 1957 2381 1600 2144 2601 1755 1628 1828 1436San Francisco-Oakland 1956 2421 1570 2174 2660 1765 1603 1816 1408San Jose-Monterey 1962 2311 1660 2097 2503 1742 1800 1891 1646

Los Angeles 1804 2176 1505 1951 2331 1637 1357 1659 1139Greater California 1822 2220 1489 1876 2286 1529 1314 1534 1113

Connecticut 2116 2607 1733 2154 2642 1771 1386 1829 1051Detroit 2132 2636 1742 2290 2850 1847 1620 1905 1409Georgia 1826 2244 1487 1936 2346 1588 1462 1833 1187Atlanta 1925 2381 1555 2119 2567 1736 1601 2034 1272Rural Georgia 1584 1790 1401 1953 2298 1567 807 - 988Greater Georgia 1784 2186 1459 1872 2274 1537 1380 1703 1146

Hawaii 1660 2024 1349 1958 2275 1593 - - -Idaho 1922 2267 1616 1920 2262 1618 - - -Iowa 2134 2601 1756 2148 2612 1773 1352 1602 1100Kentucky 2039 2505 1666 2070 2538 1693 1403 1788 1112Louisiana 1944 2352 1614 2106 2537 1744 1469 1769 1237Massachusetts 1810 2181 1518 1830 2214 1524 1452 1655 1299New Jersey 2155 2607 1804 2285 2765 1905 1387 1621 1222New Mexico 1550 1739 1387 1580 1798 1394 875 - -New York 2152 2620 1788 2306 2792 1915 1545 1852 1333Seattle-Puget Sound 2116 2627 1695 2177 2667 1766 1631 1973 1316Utah 1843 2233 1498 1862 2258 1513 2089 - -

SEER 9 Areasb 1992 2444 1623 2095 2551 1716 1573 1914 1298SEER 13 Areasb 1946 2373 1597 2064 2502 1700 1519 1853 1258SEER 18 Areasb 1933 2354 1590 2031 2464 1671 1449 1751 1214SEER 21 Areasb 1963 2388 1620 2061 2498 1702 1471 1771 1245

Table 1920Non-Hodgkin Lymphoma

Age-Adjusted SEER Incidence Ratesa

By Registry Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control and PreventionRates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and AtlantaThe SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Death Ratesa 2012-2016

California 533 677 423 570 726 449 417 480 367Greater Bay Area 505 671 376 561 756 408 410 491 331San Francisco-Oakland 503 667 376 555 742 409 416 490 343San Jose-Monterey 511 681 377 573 781 407 - - -

Los Angeles 541 670 443 589 728 481 424 503 371Greater California 539 682 429 564 716 447 416 455 384

Connecticut 533 705 407 547 717 421 350 510 244Detroit 639 822 505 693 895 542 443 528 384Georgia 533 697 411 580 747 450 376 503 286Atlanta 492 659 372 533 728 388 397 506 317Rural Georgia 559 731 388 670 813 507 - - -Greater Georgia 549 712 426 595 755 470 363 500 266

Hawaii 475 620 352 545 649 412 - - -Idaho 635 775 510 641 782 516 - - -Iowa 638 845 484 642 848 488 - - -Kentucky 642 886 460 655 904 470 401 557 284Louisiana 608 814 451 651 863 485 461 623 340Massachusetts 523 659 423 541 682 436 347 410 297New Jersey 545 721 419 585 780 443 372 466 314New Mexico 488 585 405 493 595 406 - - -New York 535 702 412 575 752 441 390 514 313Seattle-Puget Sound 585 749 463 604 769 480 490 562 397Utah 542 670 433 551 681 440 - - -

SEER 9 Areasb 555 719 430 586 758 454 414 522 333SEER 13 Areasb 549 705 429 586 753 457 419 521 342SEER 18 Areasb 554 717 431 589 761 456 409 518 329SEER 21 Areasb 550 712 428 584 754 453 401 513 322

Total US 562 725 436 586 755 454 408 518 330

Table 1921Non-Hodgkin Lymphoma

Age-Adjusted SEER Death Ratesa

By Registry Race and Sex

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 562 002

High Five StatesMichigan 645 011 01(0112) 1479Kentucky 642 016 02(0118) 1424Iowa 638 018 03(0120) 1367Indiana 638 013 04(0117) 1361Idaho 635 027 05(0126) 1303

Low Five StatesNevada 511 019 47(2251) -899Colorado 491 014 48(3851) -1257New Mexico 488 020 49(2851) -1317Hawaii 475 024 50(3051) -1542c

DC 444 039 51(2351) -2097c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 545 014 28(1847) -291 Montana 559 030 25(0250) -042Alaska 525 047 43(0151) -654 Nebraska 563 023 22(0548) 026Arizona 512 012 46(2950) -886 Nevada 511 019 47(2251) -899Arkansas 555 018 26(1247) -113 New Hampshire 562 027 23(0349) 014California 533 005 40(2645) -508 New Jersey 545 010 29(2045) -301Colorado 491 014 48(3851) -1257 New Mexico 488 020 49(2851) -1317Connecticut 533 016 39(1949) -505 New York 535 007 37(2446) -478Delaware 628 033 08(0139) 1174 North Carolina 541 010 35(2146) -363DC 444 039 51(2351) -2097c North Dakota 561 037 24(0151) -007Florida 535 006 38(2545) -479 Ohio 616 009 10(0220) 969Georgia 533 011 41(2248) -511 Oklahoma 630 017 06(0121) 1226Hawaii 475 024 50(3051) -1542c Oregon 612 016 11(0124) 903Idaho 635 027 05(0126) 1303 Pennsylvania 603 009 16(0622) 729Illinois 566 009 20(1634) 085 Rhode Island 542 029 32(0651) -350Indiana 638 013 04(0117) 1361 South Carolina 542 014 31(1847) -347Iowa 638 018 03(0120) 1367 South Dakota 541 033 36(0451) -364Kansas 585 019 19(0439) 420 Tennessee 629 013 07(0119) 1198Kentucky 642 016 02(0118) 1424 Texas 546 007 27(2142) -277Louisiana 608 016 14(0125) 826 Utah 542 022 33(1250) -352Maine 609 026 13(0137) 852 Vermont 605 040 15(0148) 770Maryland 524 013 44(2349) -663 Virginia 544 011 30(2046) -319Massachusetts 523 012 45(2549) -687 Washington 599 013 17(0425) 665Michigan 645 011 01(0112) 1479 West Virginia 612 022 12(0132) 894Minnesota 617 014 09(0122) 984 Wisconsin 590 013 18(0629) 507Mississippi 531 018 42(1850) -551 Wyoming 564 043 21(0151) 050Missouri 542 012 34(1947) -354

Table 1922Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males and Females

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 725 003

High Five StatesKentucky 886 030 01(0112) 2213c

Iowa 845 032 02(0120) 1647c

Michigan 842 019 03(0114) 1615c

Indiana 839 024 04(0116) 1567c

Delaware 824 058 05(0144) 1364

Low Five StatesArizona 635 019 47(3251) -1244Alaska 630 075 48(0251) -1311Hawaii 620 041 49(1951) -1452DC 614 071 50(0551) -1535c

New Mexico 585 033 51(3451) -1928c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 688 025 36(1649) -513 Montana 709 050 26(0251) -218Alaska 630 075 48(0251) -1311 Nebraska 737 040 20(0248) 165Arizona 635 019 47(3251) -1244 Nevada 653 032 44(1951) -994Arkansas 721 031 22(0747) -061 New Hampshire 710 046 25(0451) -210California 677 009 41(2846) -666 New Jersey 721 018 21(1441) -059Colorado 643 024 46(2451) -1133 New Mexico 585 033 51(3451) -1928c

Connecticut 705 028 28(1248) -273 New York 702 012 30(1943) -323Delaware 824 058 05(0144) 1364 North Carolina 709 018 27(1644) -221DC 614 071 50(0551) -1535c North Dakota 682 061 39(0251) -598Florida 683 011 37(2446) -585 Ohio 800 017 09(0320) 1029Georgia 697 019 34(1746) -387 Oklahoma 806 030 08(0126) 1109Hawaii 620 041 49(1951) -1452 Oregon 794 028 12(0128) 947Idaho 775 045 16(0146) 692 Pennsylvania 783 015 15(0523) 794Illinois 739 016 19(1235) 190 Rhode Island 649 050 45(1051) -1050Indiana 839 024 04(0116) 1567c South Carolina 681 025 40(1850) -604Iowa 845 032 02(0120) 1647c South Dakota 701 056 31(0251) -332Kansas 713 032 24(0948) -174 Tennessee 820 023 06(0120) 1311Kentucky 886 030 01(0112) 2213c Texas 698 012 32(2043) -368Louisiana 814 029 07(0122) 1222 Utah 670 036 42(1351) -754Maine 754 045 18(0148) 395 Vermont 794 069 11(0149) 950Maryland 682 023 38(1849) -588 Virginia 694 020 35(1847) -429Massachusetts 659 020 43(2450) -910 Washington 790 022 13(0224) 897Michigan 842 019 03(0114) 1615c West Virginia 774 038 17(0142) 675Minnesota 797 025 10(0224) 995 Wisconsin 786 023 14(0227) 844Mississippi 717 034 23(0748) -110 Wyoming 698 071 33(0151) -377Missouri 702 022 29(1646) -319

Table 1923Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 436 002

High Five StatesIdaho 510 033 01(0139) 1697c

Maine 497 031 02(0141) 1396Michigan 495 012 03(0119) 1340Oklahoma 492 020 04(0128) 1276Indiana 492 016 05(0123) 1270

Low Five StatesMississippi 404 021 47(1351) -731Nevada 382 022 48(2051) -1237Colorado 369 016 49(3451) -1540c

Hawaii 352 027 50(2551) -1932c

DC 323 044 51(1551) -2601c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 440 017 24(0547) 099 Montana 435 036 27(0151) -034Alaska 414 058 38(0151) -500 Nebraska 435 027 26(0249) -032Arizona 407 014 44(2049) -664 Nevada 382 022 48(2051) -1237Arkansas 428 021 31(0649) -181 New Hampshire 454 032 19(0149) 400California 423 006 34(2244) -313 New Jersey 419 012 37(1848) -397Colorado 369 016 49(3451) -1540c New Mexico 405 025 46(0951) -706Connecticut 407 018 45(1550) -669 New York 412 008 39(2548) -554Delaware 473 039 12(0150) 855 North Carolina 420 012 35(1848) -374DC 323 044 51(1551) -2601c North Dakota 471 045 13(0150) 809Florida 412 007 40(2548) -564 Ohio 478 011 10(0123) 967Georgia 411 012 43(2049) -582 Oklahoma 492 020 04(0128) 1276Hawaii 352 027 50(2551) -1932c Oregon 465 019 15(0141) 668Idaho 510 033 01(0139) 1697c Pennsylvania 467 010 14(0427) 714Illinois 439 010 25(1341) 074 Rhode Island 455 035 18(0150) 434Indiana 492 016 05(0123) 1270 South Carolina 432 017 30(0947) -102Iowa 484 021 08(0135) 1087 South Dakota 411 039 42(0151) -580Kansas 486 023 06(0137) 1143 Tennessee 484 015 09(0126) 1087Kentucky 460 018 17(0241) 544 Texas 427 008 32(1944) -213Louisiana 451 018 21(0345) 333 Utah 433 026 28(0250) -081Maine 497 031 02(0141) 1396 Vermont 461 047 16(0151) 578Maryland 411 015 41(1749) -576 Virginia 432 013 29(1246) -092Massachusetts 423 014 33(1548) -303 Washington 452 015 20(0541) 360Michigan 495 012 03(0119) 1340 West Virginia 486 027 07(0143) 1141Minnesota 475 017 11(0132) 901 Wisconsin 443 015 23(0645) 156Mississippi 404 021 47(1351) -731 Wyoming 445 051 22(0151) 192Missouri 419 014 36(1549) -396

Table 1924Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Females

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 Areas (excluding the AlaskaNative Registry) and 112016 US population estimates based on the average of 2015 and 2016 population estimates from theUS Bureau of the CensusPrevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 24 years

b Maximum limited-duration prevalence is 24 years for 1992-2016 datac Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groupsd Cases diagnosed more than 24 years ago were estimated using the completeness index method (Capocaccia et al 1997

Merrill et al 2000)e Complete prevalence is obtained by summing 0 to lt24 and gt=24- Statistic not shown Statistic based on fewer than 5 cases estimated alive in SEER for the time interval+ Not available

Years Since Diagnosis 0 to lt5 5 to lt10 10 to lt15 15 to lt20 20 to lt24 0 to lt24b gt=24d Completee

Race Sex

All Races Both Sexes 248946 177490 117326 69109 31890 644761 49943 694704Males 135137 94173 60159 36020 16581 342069 25489 367558Females 113809 83317 57167 33089 15309 302692 24454 327146

White Both Sexes 213764 154454 101984 60537 28026 558765 49625 620368Males 116527 82172 52535 31627 14543 297404 26526 330121Females 97237 72282 49448 28910 13483 261361 23099 290247

Black Both Sexes 20500 13640 9750 5271 2215 51376 4115 55491Males 10712 7188 4768 2684 1174 26526 1911 28437Females 9789 6452 4981 2587 1041 24850 2204 27054

Asian Both Sexes 8405 5210 3415 1867 844 19741 + +Pacific Males 4548 2661 1757 1013 407 10386 + +Islander Females 3856 2549 1657 855 437 9355 + +

Hispanic Both Sexes 21339 14049 8272 4881 2136 50676 + +Males 10918 7243 4331 2617 1094 26202 + +Females 10421 6805 3941 2264 1043 24474 + +

Age Specific (Crude) Age-Adjustedc Age at Prevalence All Ages 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ All Ages

Race Sex

All Races Both Sexes 02001 00035 00139 00283 00538 01121 02352 04640 08181 10224 01738Males 02156 00044 00189 00354 00625 01293 02710 05243 09364 12449 02023Females 01850 00026 00087 00208 00450 00952 02010 04094 07196 08856 01498

White Both Sexes 02216 00035 00143 00289 00534 01148 02427 04858 08597 10738 01807Males 02380 00045 00198 00359 00622 01317 02790 05442 09778 13060 02095Females 02054 00025 00085 00214 00442 00976 02072 04317 07593 09285 01560

Black Both Sexes 01139 00029 00113 00265 00599 01027 02010 03340 05117 05333 01251Males 01226 00029 00140 00351 00696 01223 02333 03969 05849 06055 01457Females 01059 00030 00086 00178 00510 00853 01728 02836 04608 04976 01088

Asian Both Sexes 00970 00039 00133 00207 00353 00680 01409 02692 04470 06094 01032Pacific Males 01065 00044 00175 00240 00398 00744 01640 03072 05516 07472 01222Islander Females 00882 00033 00092 00175 00312 00623 01209 02384 03629 05207 00880

Hispanic Both Sexes 00887 00030 00117 00206 00398 00850 01769 03632 05888 07209 01294Males 00908 00035 00147 00256 00455 00932 01924 03940 06326 08003 01420Females 00866 00024 00086 00151 00337 00766 01616 03360 05552 06719 01185

Table 1925Non-Hodgkin Lymphoma

Estimated United States Cancer Prevalence Countsa on January 1 2016By RaceEthnicity Sex and Years Since Diagnosis

Estimated prevalence percenta on January 1 2016 of the SEER population diagnosed in the previous 24 yearsBy Age at Prevalence RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 372 452924 -05 62 18862 04 247 189692 -05 1657 244370 -05

1 Hodgkin Lymphoma 28 32262 -17 13 3927 -06 33 22556 -15 39 5779 -31

2 Non-Hodgkin lymphoma 336 409991 -03 48 14693 04 210 163591 -03 1572 231707 -042(a) Non-Hodgkin lymphoma B-cell 311 380349 -01 39 11836 14 190 148768 -02 1491 219745 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 15 16631 20 31 9416 10 07 5203 39 14 2012 252(a) 2 Mature Non-Hodgkin lymphoma B-cell 280 343965 -04 07 2271 30 174 137225 -05 1387 204469 -042(a) 21 ChronicSmallProlymphocytic 69 85601 -13 00 35 - 35 29103 -11 382 56463 -14

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 61 75061 -15 00 30 - 31 25339 -13 336 49692 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 311 19 - - - 00 72 - 02 234 262(a) 213 Mantle-cell lymphoma 08 10229 03 - - - 04 3692 02 44 6537 04

2(a) 22 Lymphoplasmacytic lymphoma 07 8651 00 - - - 03 2590 -11 41 6059 04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 03 3667 -03 - - - 01 1132 -18 17 2533 022(a) 222 Waldenstrom macroglubulinemia 04 4984 03 - - - 02 1458 -07 24 3526 06

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 72 87188 00 03 925 26 48 36480 -02 339 49783 022(a) 231 DLBCL NOSc 71 85899 -01 03 861 12 46 35469 -05 337 49569 012(a) 232 Intravascular large B-cell 00 162 - - - - 00 63 - 01 99 -

lymphoma2(a) 233 Primary effusion lymphoma 00 181 27 - - - 00 126 - 00 55 -2(a) 234 Mediastinal large B-cell 01 946 116 00 64 - 01 822 111 00 60 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 04 4692 -26 03 1028 32 04 2618 -43 07 1046 -432(a) 25 Marginal-zone lymphoma (MZL) 22 26534 00 00 137 13 14 11049 05 104 15348 -042(a) 251 Splenic MZL 02 2418 04 - - - 01 889 -08 10 1529 102(a) 252 Extranodal MZL MALTc type 13 15979 06 00 92 - 09 7148 11 59 8739 032(a) 253 Nodal MZL 07 8137 -15 00 45 - 04 3012 -05 34 5080 -20

2(a) 26 Follicular lymphoma 35 43582 -21 00 119 - 28 21725 -25 147 21738 -182(a) 27 Hairy-cell leukemia 03 3712 -16 - - - 03 2311 -19 09 1401 -122(a) 28 Plasma cell neoplasms 68 83957 08 00 24 - 39 31325 12 358 52608 062(a) 281 Plasmacytoma 04 4879 -04 00 16 - 03 2362 -06 17 2501 -032(a) 282 Multiple myeloma 64 79078 09 - - - 36 28963 14 341 50107 07

plasma-cell leukemia2(a) 29 Heavy chain disease 00 48 - - - - 00 24 - 00 23 -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 16 19753 33 00 149 27 08 6340 37 90 13264 32

Table 1926All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 23 27222 01 08 2502 18 19 13933 03 73 10787 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 616 - 01 293 - 00 272 - 00 51 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 22 26531 11 07 2207 75 19 13621 12 73 10703 -042(b) 21 Mycosis fungoidesSezary syndrome 06 6969 18 01 213 84 06 4080 23 18 2676 052(b) 211 Mycosis fungoides 06 6739 17 01 213 84 05 3990 22 17 2536 042(b) 212 Sezary syndrome 00 230 46 - - - 00 90 - 01 140 -

2(b) 22 Peripheral T-cell lymphoma 12 14531 -10 02 534 07 10 7159 -09 46 6838 -122(b) 221 Peripheral T-cell lymphoma NOSc 04 5393 -01 00 86 - 03 2489 04 19 2818 -042(b) 222 Angioimmunoblastic T-cell lymphoma 02 1902 02 - - - 01 699 -09 08 1201 072(b) 223 Subcutaneous panniculitis- 00 176 44 00 31 - 00 111 - 00 34 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 2523 -36 01 291 00 02 1450 -33 05 782 -54

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 139 - - - - 00 98 - 00 28 -2(b) 226 Enteropathy-type T-cell lymphoma 00 186 -02 - - - 00 84 - 01 101 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 2963 -07 00 59 - 02 1575 01 09 1329 -142(b) 228 Primary cutaneous anaplastic 01 1249 -41 00 51 - 01 653 -49 04 545 -39

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 03 3417 96 05 1428 101 02 1474 99 03 515 672(b) 24 NKcT-cell lymphoma nasal-type 01 985 02 00 26 - 01 659 00 02 300 05

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 120 - - - - 00 54 - 00 65 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 509 30 - - - 00 195 -05 02 309 442(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 75 - - - - 00 40 - 00 33 -2(c) Non-Hodgkin lymphoma unknown lineage 02 2420 -274 01 355 - 01 890 -216 08 1175 -2792(c) 1 Precursor lymphoblastic leukemia 01 814 -283 01 343 - 00 238 - 02 233 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 95 - - - - 00 25 - 00 69 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 1511 -274 - - - 01 627 -202 06 873 -319

lineage2() 1 Total precursor lymphomaleukemiad 16 18061 -07 33 10052 -15 08 5713 06 15 2296 -01

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 762 273 00 20 - 00 339 227 03 403 -lymphoma

4 Lymphoid neoplasm NOSc 08 9909 -55 01 222 113 04 3206 -59 43 6481 -59

Table 1926 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 461 253152 -05 70 10973 05 294 110367 -07 2122 131812 -05

1 Hodgkin Lymphoma 31 17710 -17 13 2118 -03 36 12525 -16 48 3067 -31

2 Non-Hodgkin lymphoma 419 229772 -03 56 8711 05 252 95756 -05 2017 125305 -032(a) Non-Hodgkin lymphoma B-cell 387 212247 -02 44 6786 15 227 86941 -04 1908 118520 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 16 8999 24 33 5123 11 08 2888 46 16 988 292(a) 2 Mature Non-Hodgkin lymphoma B-cell 351 192801 -05 10 1558 28 210 80417 -08 1783 110826 -042(a) 21 ChronicSmallProlymphocytic 96 52411 -15 00 21 - 47 18927 -14 539 33463 -15

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 82 44988 -17 00 19 - 40 16143 -16 464 28826 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 193 -02 - - - 00 46 - 02 145 052(a) 213 Mantle-cell lymphoma 13 7230 -01 - - - 07 2738 -01 72 4492 -01

2(a) 22 Lymphoplasmacytic lymphoma 10 5082 -05 - - - 04 1524 -08 58 3558 -04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 04 2062 -08 - - - 02 616 -12 23 1446 -072(a) 222 Waldenstrom macroglubulinemia 06 3020 -02 - - - 02 908 -06 34 2112 -02

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 88 48128 01 03 554 22 59 21824 -06 418 25750 052(a) 231 DLBCL NOSc 87 47520 00 03 519 03 57 21366 -08 416 25635 042(a) 232 Intravascular large B-cell 00 75 - - - - 00 31 - 01 44 -

lymphoma2(a) 233 Primary effusion lymphoma 00 167 26 - - - 00 123 - 01 44 -2(a) 234 Mediastinal large B-cell 01 366 155 00 35 - 01 304 142 00 27 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 06 3388 -22 05 775 31 06 1969 -46 10 644 -192(a) 25 Marginal-zone lymphoma (MZL) 22 12351 -02 01 98 - 14 5177 -02 114 7076 -012(a) 251 Splenic MZL 02 1164 14 - - - 01 434 18 12 730 112(a) 252 Extranodal MZL MALTc type 13 7268 07 00 62 - 09 3267 04 63 3939 102(a) 253 Nodal MZL 07 3919 -23 00 36 - 04 1476 -22 39 2407 -23

2(a) 26 Follicular lymphoma 39 21788 -19 01 100 - 30 11210 -25 165 10478 -152(a) 27 Hairy-cell leukemia 05 2984 -18 - - - 05 1908 -20 17 1076 -152(a) 28 Plasma cell neoplasms 85 46642 07 - - - 45 17864 11 462 28769 052(a) 281 Plasmacytoma 05 2997 -08 - - - 04 1509 -16 24 1484 -012(a) 282 Multiple myeloma 80 43645 08 - - - 41 16355 13 439 27285 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 27 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 20 10447 34 01 105 - 10 3636 40 110 6706 32

Table 1927All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 29 16118 00 11 1730 14 23 8235 02 98 6153 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 430 - 01 208 - 01 188 - 01 34 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 28 15642 11 10 1521 71 22 8022 11 97 6099 -032(b) 21 Mycosis fungoidesSezary syndrome 07 3962 19 01 135 - 06 2261 21 25 1566 092(b) 211 Mycosis fungoides 07 3831 20 01 135 - 06 2213 21 23 1483 092(b) 212 Sezary syndrome 00 131 - - - - 00 48 - 01 83 -

2(b) 22 Peripheral T-cell lymphoma 15 8438 -13 02 318 -09 12 4248 -12 62 3872 -132(b) 221 Peripheral T-cell lymphoma NOSc 06 3159 -05 00 49 - 04 1520 02 26 1590 -082(b) 222 Angioimmunoblastic T-cell lymphoma 02 1024 19 - - - 01 415 11 10 607 232(b) 223 Subcutaneous panniculitis- 00 68 - - - - 00 39 - 00 16 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 03 1549 -39 01 184 -01 02 888 -43 08 477 -45

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 98 - - - - 00 69 - 00 18 -2(b) 226 Enteropathy-type T-cell lymphoma 00 105 - - - - 00 50 - 01 54 -2(b) 227 Cutaneous T-cell lymphoma NOSc 03 1696 -12 00 32 - 02 894 -03 12 770 -172(b) 228 Primary cutaneous anaplastic 01 739 -48 00 26 - 01 373 -49 05 340 -49

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 04 2253 97 07 1047 92 03 940 98 04 266 1022(b) 24 NKcT-cell lymphoma nasal-type 01 638 -05 00 18 - 01 435 -03 03 185 -06

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 58 - - - - 00 22 - 01 36 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 01 293 45 - - - 00 116 - 03 174 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 46 - - - - 00 25 - 00 20 -2(c) Non-Hodgkin lymphoma unknown lineage 03 1407 -232 01 195 - 02 580 -184 10 632 -2302(c) 1 Precursor lymphoblastic leukemia 01 474 -228 01 187 - 00 134 - 02 153 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 49 - - - - - - - 01 36 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 02 884 -239 - - - 01 433 -175 07 443 -

lineage2() 1 Total precursor lymphomaleukemiad 18 9903 -06 35 5518 -17 09 3210 09 19 1175 05

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 435 271 - - - 01 215 - 03 207 -lymphoma

4 Lymphoid neoplasm NOSc 10 5235 -59 01 131 - 05 1871 -65 54 3233 -61

Table 1927 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 301 199772 -05 53 7889 02 202 79325 -02 1322 112558 -08

1 Hodgkin Lymphoma 24 14552 -16 12 1809 -10 29 10031 -14 32 2712 -32

2 Non-Hodgkin lymphoma 269 180219 -03 40 5982 03 170 67835 00 1251 106402 -062(a) Non-Hodgkin lymphoma B-cell 250 168102 -01 34 5050 13 154 61827 02 1190 101225 -042(a) 1 Precursor Non-Hodgkin lymphoma B-cell 14 7632 16 29 4293 09 06 2315 29 12 1024 202(a) 2 Mature Non-Hodgkin lymphoma B-cell 223 151164 -04 05 713 35 141 56808 -01 1102 93643 -072(a) 21 ChronicSmallProlymphocytic 48 33190 -13 - - - 24 10176 -05 268 23000 -16

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 43 30073 -15 - - - 22 9196 -06 243 20866 -19

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 118 - - - - 00 26 - 01 89 -2(a) 213 Mantle-cell lymphoma 04 2999 11 - - - 02 954 10 24 2045 12

2(a) 22 Lymphoplasmacytic lymphoma 05 3569 04 - - - 03 1066 -16 30 2501 11Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 02 1605 01 - - - 01 516 -25 13 1087 112(a) 222 Waldenstrom macroglubulinemia 03 1964 06 - - - 01 550 -08 17 1414 11

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 58 39060 00 02 371 33 38 14656 03 283 24033 -032(a) 231 DLBCL NOSc 57 38379 -02 02 342 27 36 14103 -01 282 23934 -032(a) 232 Intravascular large B-cell 00 87 - - - - 00 32 - 01 55 -

lymphoma2(a) 233 Primary effusion lymphoma - - - - - - - - - - - -2(a) 234 Mediastinal large B-cell 01 580 91 00 29 - 02 518 93 00 33 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 02 1304 -34 02 253 38 02 649 -37 05 402 -852(a) 25 Marginal-zone lymphoma (MZL) 21 14183 01 00 39 - 15 5872 12 98 8272 -062(a) 251 Splenic MZL 02 1254 -07 - - - 01 455 -32 10 799 072(a) 252 Extranodal MZL MALTc type 13 8711 06 00 30 - 10 3881 17 57 4800 -032(a) 253 Nodal MZL 06 4218 -07 - - - 04 1536 11 32 2673 -18

2(a) 26 Follicular lymphoma 33 21794 -24 00 19 - 27 10515 -25 134 11260 -222(a) 27 Hairy-cell leukemia 01 728 -12 - - - 01 403 -11 04 325 -122(a) 28 Plasma cell neoplasms 55 37315 08 - - - 33 13461 15 282 23839 052(a) 281 Plasmacytoma 03 1882 00 - - - 02 853 12 12 1017 -092(a) 282 Multiple myeloma 52 35433 09 - - - 30 12608 15 270 22822 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 21 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 14 9306 32 00 44 - 07 2704 32 76 6558 31

Table 1928All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 17 11104 01 05 772 29 15 5698 05 55 4634 -112(b) 1 Precursor Non-Hodgkin lymphoma T-cell 00 186 - 01 85 - 00 84 - 00 17 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 17 10889 09 05 686 83 15 5599 12 54 4604 -092(b) 21 Mycosis fungoidesSezary syndrome 05 3007 15 01 78 - 05 1819 26 13 1110 -042(b) 211 Mycosis fungoides 05 2908 12 01 78 - 05 1777 23 12 1053 -072(b) 212 Sezary syndrome 00 99 - - - - 00 42 - 01 57 -

2(b) 22 Peripheral T-cell lymphoma 09 6093 -08 01 216 30 08 2911 -06 35 2966 -142(b) 221 Peripheral T-cell lymphoma NOSc 03 2234 03 00 37 - 03 969 07 14 1228 -012(b) 222 Angioimmunoblastic T-cell lymphoma 01 878 -22 - - - 01 284 -39 07 594 -152(b) 223 Subcutaneous panniculitis- 00 108 - 00 18 - 00 72 - 00 18 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 974 -33 01 107 - 02 562 -19 04 305 -77

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 41 - - - - 00 29 - - - -2(b) 226 Enteropathy-type T-cell lymphoma 00 81 - - - - 00 34 - 01 47 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 1267 00 00 27 - 02 681 07 07 559 -102(b) 228 Primary cutaneous anaplastic 01 510 -34 00 25 - 01 280 -50 02 205 -33

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 02 1164 96 03 381 127 01 534 97 03 249 302(b) 24 NKcT-cell lymphoma nasal-type 01 347 11 - - - 01 224 - 01 115 -

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 62 - - - - 00 32 - 00 29 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 216 03 - - - 00 79 - 02 135 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 29 - - - - - - - - - -2(c) Non-Hodgkin lymphoma unknown lineage 02 1013 -341 01 160 - 01 310 - 06 543 -2(c) 1 Precursor lymphoblastic leukemia 01 340 - 01 156 - 00 104 - 01 80 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 46 - - - - - - - 00 33 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 627 - - - - 01 194 - 05 430 -

lineage2() 1 Total precursor lymphomaleukemiad 14 8158 -09 31 4534 -13 07 2503 02 13 1121 -11

3 Composite Hodgkin lymphoma and Non-Hodgkin 00 327 - - - - 00 124 - 02 196 -lymphoma

4 Lymphoid neoplasm NOSc 07 4674 -52 01 91 - 03 1335 -51 36 3248 -58

Table 1928 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 20: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and Atlanta

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Incidence Ratesa 2012-2016

California 1844 2241 1515 1938 2349 1591 1390 1639 1182Greater Bay Area 1957 2381 1600 2144 2601 1755 1628 1828 1436San Francisco-Oakland 1956 2421 1570 2174 2660 1765 1603 1816 1408San Jose-Monterey 1962 2311 1660 2097 2503 1742 1800 1891 1646

Los Angeles 1804 2176 1505 1951 2331 1637 1357 1659 1139Greater California 1822 2220 1489 1876 2286 1529 1314 1534 1113

Connecticut 2116 2607 1733 2154 2642 1771 1386 1829 1051Detroit 2132 2636 1742 2290 2850 1847 1620 1905 1409Georgia 1826 2244 1487 1936 2346 1588 1462 1833 1187Atlanta 1925 2381 1555 2119 2567 1736 1601 2034 1272Rural Georgia 1584 1790 1401 1953 2298 1567 807 - 988Greater Georgia 1784 2186 1459 1872 2274 1537 1380 1703 1146

Hawaii 1660 2024 1349 1958 2275 1593 - - -Idaho 1922 2267 1616 1920 2262 1618 - - -Iowa 2134 2601 1756 2148 2612 1773 1352 1602 1100Kentucky 2039 2505 1666 2070 2538 1693 1403 1788 1112Louisiana 1944 2352 1614 2106 2537 1744 1469 1769 1237Massachusetts 1810 2181 1518 1830 2214 1524 1452 1655 1299New Jersey 2155 2607 1804 2285 2765 1905 1387 1621 1222New Mexico 1550 1739 1387 1580 1798 1394 875 - -New York 2152 2620 1788 2306 2792 1915 1545 1852 1333Seattle-Puget Sound 2116 2627 1695 2177 2667 1766 1631 1973 1316Utah 1843 2233 1498 1862 2258 1513 2089 - -

SEER 9 Areasb 1992 2444 1623 2095 2551 1716 1573 1914 1298SEER 13 Areasb 1946 2373 1597 2064 2502 1700 1519 1853 1258SEER 18 Areasb 1933 2354 1590 2031 2464 1671 1449 1751 1214SEER 21 Areasb 1963 2388 1620 2061 2498 1702 1471 1771 1245

Table 1920Non-Hodgkin Lymphoma

Age-Adjusted SEER Incidence Ratesa

By Registry Race and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control and PreventionRates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and AtlantaThe SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Death Ratesa 2012-2016

California 533 677 423 570 726 449 417 480 367Greater Bay Area 505 671 376 561 756 408 410 491 331San Francisco-Oakland 503 667 376 555 742 409 416 490 343San Jose-Monterey 511 681 377 573 781 407 - - -

Los Angeles 541 670 443 589 728 481 424 503 371Greater California 539 682 429 564 716 447 416 455 384

Connecticut 533 705 407 547 717 421 350 510 244Detroit 639 822 505 693 895 542 443 528 384Georgia 533 697 411 580 747 450 376 503 286Atlanta 492 659 372 533 728 388 397 506 317Rural Georgia 559 731 388 670 813 507 - - -Greater Georgia 549 712 426 595 755 470 363 500 266

Hawaii 475 620 352 545 649 412 - - -Idaho 635 775 510 641 782 516 - - -Iowa 638 845 484 642 848 488 - - -Kentucky 642 886 460 655 904 470 401 557 284Louisiana 608 814 451 651 863 485 461 623 340Massachusetts 523 659 423 541 682 436 347 410 297New Jersey 545 721 419 585 780 443 372 466 314New Mexico 488 585 405 493 595 406 - - -New York 535 702 412 575 752 441 390 514 313Seattle-Puget Sound 585 749 463 604 769 480 490 562 397Utah 542 670 433 551 681 440 - - -

SEER 9 Areasb 555 719 430 586 758 454 414 522 333SEER 13 Areasb 549 705 429 586 753 457 419 521 342SEER 18 Areasb 554 717 431 589 761 456 409 518 329SEER 21 Areasb 550 712 428 584 754 453 401 513 322

Total US 562 725 436 586 755 454 408 518 330

Table 1921Non-Hodgkin Lymphoma

Age-Adjusted SEER Death Ratesa

By Registry Race and Sex

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 562 002

High Five StatesMichigan 645 011 01(0112) 1479Kentucky 642 016 02(0118) 1424Iowa 638 018 03(0120) 1367Indiana 638 013 04(0117) 1361Idaho 635 027 05(0126) 1303

Low Five StatesNevada 511 019 47(2251) -899Colorado 491 014 48(3851) -1257New Mexico 488 020 49(2851) -1317Hawaii 475 024 50(3051) -1542c

DC 444 039 51(2351) -2097c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 545 014 28(1847) -291 Montana 559 030 25(0250) -042Alaska 525 047 43(0151) -654 Nebraska 563 023 22(0548) 026Arizona 512 012 46(2950) -886 Nevada 511 019 47(2251) -899Arkansas 555 018 26(1247) -113 New Hampshire 562 027 23(0349) 014California 533 005 40(2645) -508 New Jersey 545 010 29(2045) -301Colorado 491 014 48(3851) -1257 New Mexico 488 020 49(2851) -1317Connecticut 533 016 39(1949) -505 New York 535 007 37(2446) -478Delaware 628 033 08(0139) 1174 North Carolina 541 010 35(2146) -363DC 444 039 51(2351) -2097c North Dakota 561 037 24(0151) -007Florida 535 006 38(2545) -479 Ohio 616 009 10(0220) 969Georgia 533 011 41(2248) -511 Oklahoma 630 017 06(0121) 1226Hawaii 475 024 50(3051) -1542c Oregon 612 016 11(0124) 903Idaho 635 027 05(0126) 1303 Pennsylvania 603 009 16(0622) 729Illinois 566 009 20(1634) 085 Rhode Island 542 029 32(0651) -350Indiana 638 013 04(0117) 1361 South Carolina 542 014 31(1847) -347Iowa 638 018 03(0120) 1367 South Dakota 541 033 36(0451) -364Kansas 585 019 19(0439) 420 Tennessee 629 013 07(0119) 1198Kentucky 642 016 02(0118) 1424 Texas 546 007 27(2142) -277Louisiana 608 016 14(0125) 826 Utah 542 022 33(1250) -352Maine 609 026 13(0137) 852 Vermont 605 040 15(0148) 770Maryland 524 013 44(2349) -663 Virginia 544 011 30(2046) -319Massachusetts 523 012 45(2549) -687 Washington 599 013 17(0425) 665Michigan 645 011 01(0112) 1479 West Virginia 612 022 12(0132) 894Minnesota 617 014 09(0122) 984 Wisconsin 590 013 18(0629) 507Mississippi 531 018 42(1850) -551 Wyoming 564 043 21(0151) 050Missouri 542 012 34(1947) -354

Table 1922Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males and Females

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 725 003

High Five StatesKentucky 886 030 01(0112) 2213c

Iowa 845 032 02(0120) 1647c

Michigan 842 019 03(0114) 1615c

Indiana 839 024 04(0116) 1567c

Delaware 824 058 05(0144) 1364

Low Five StatesArizona 635 019 47(3251) -1244Alaska 630 075 48(0251) -1311Hawaii 620 041 49(1951) -1452DC 614 071 50(0551) -1535c

New Mexico 585 033 51(3451) -1928c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 688 025 36(1649) -513 Montana 709 050 26(0251) -218Alaska 630 075 48(0251) -1311 Nebraska 737 040 20(0248) 165Arizona 635 019 47(3251) -1244 Nevada 653 032 44(1951) -994Arkansas 721 031 22(0747) -061 New Hampshire 710 046 25(0451) -210California 677 009 41(2846) -666 New Jersey 721 018 21(1441) -059Colorado 643 024 46(2451) -1133 New Mexico 585 033 51(3451) -1928c

Connecticut 705 028 28(1248) -273 New York 702 012 30(1943) -323Delaware 824 058 05(0144) 1364 North Carolina 709 018 27(1644) -221DC 614 071 50(0551) -1535c North Dakota 682 061 39(0251) -598Florida 683 011 37(2446) -585 Ohio 800 017 09(0320) 1029Georgia 697 019 34(1746) -387 Oklahoma 806 030 08(0126) 1109Hawaii 620 041 49(1951) -1452 Oregon 794 028 12(0128) 947Idaho 775 045 16(0146) 692 Pennsylvania 783 015 15(0523) 794Illinois 739 016 19(1235) 190 Rhode Island 649 050 45(1051) -1050Indiana 839 024 04(0116) 1567c South Carolina 681 025 40(1850) -604Iowa 845 032 02(0120) 1647c South Dakota 701 056 31(0251) -332Kansas 713 032 24(0948) -174 Tennessee 820 023 06(0120) 1311Kentucky 886 030 01(0112) 2213c Texas 698 012 32(2043) -368Louisiana 814 029 07(0122) 1222 Utah 670 036 42(1351) -754Maine 754 045 18(0148) 395 Vermont 794 069 11(0149) 950Maryland 682 023 38(1849) -588 Virginia 694 020 35(1847) -429Massachusetts 659 020 43(2450) -910 Washington 790 022 13(0224) 897Michigan 842 019 03(0114) 1615c West Virginia 774 038 17(0142) 675Minnesota 797 025 10(0224) 995 Wisconsin 786 023 14(0227) 844Mississippi 717 034 23(0748) -110 Wyoming 698 071 33(0151) -377Missouri 702 022 29(1646) -319

Table 1923Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 436 002

High Five StatesIdaho 510 033 01(0139) 1697c

Maine 497 031 02(0141) 1396Michigan 495 012 03(0119) 1340Oklahoma 492 020 04(0128) 1276Indiana 492 016 05(0123) 1270

Low Five StatesMississippi 404 021 47(1351) -731Nevada 382 022 48(2051) -1237Colorado 369 016 49(3451) -1540c

Hawaii 352 027 50(2551) -1932c

DC 323 044 51(1551) -2601c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 440 017 24(0547) 099 Montana 435 036 27(0151) -034Alaska 414 058 38(0151) -500 Nebraska 435 027 26(0249) -032Arizona 407 014 44(2049) -664 Nevada 382 022 48(2051) -1237Arkansas 428 021 31(0649) -181 New Hampshire 454 032 19(0149) 400California 423 006 34(2244) -313 New Jersey 419 012 37(1848) -397Colorado 369 016 49(3451) -1540c New Mexico 405 025 46(0951) -706Connecticut 407 018 45(1550) -669 New York 412 008 39(2548) -554Delaware 473 039 12(0150) 855 North Carolina 420 012 35(1848) -374DC 323 044 51(1551) -2601c North Dakota 471 045 13(0150) 809Florida 412 007 40(2548) -564 Ohio 478 011 10(0123) 967Georgia 411 012 43(2049) -582 Oklahoma 492 020 04(0128) 1276Hawaii 352 027 50(2551) -1932c Oregon 465 019 15(0141) 668Idaho 510 033 01(0139) 1697c Pennsylvania 467 010 14(0427) 714Illinois 439 010 25(1341) 074 Rhode Island 455 035 18(0150) 434Indiana 492 016 05(0123) 1270 South Carolina 432 017 30(0947) -102Iowa 484 021 08(0135) 1087 South Dakota 411 039 42(0151) -580Kansas 486 023 06(0137) 1143 Tennessee 484 015 09(0126) 1087Kentucky 460 018 17(0241) 544 Texas 427 008 32(1944) -213Louisiana 451 018 21(0345) 333 Utah 433 026 28(0250) -081Maine 497 031 02(0141) 1396 Vermont 461 047 16(0151) 578Maryland 411 015 41(1749) -576 Virginia 432 013 29(1246) -092Massachusetts 423 014 33(1548) -303 Washington 452 015 20(0541) 360Michigan 495 012 03(0119) 1340 West Virginia 486 027 07(0143) 1141Minnesota 475 017 11(0132) 901 Wisconsin 443 015 23(0645) 156Mississippi 404 021 47(1351) -731 Wyoming 445 051 22(0151) 192Missouri 419 014 36(1549) -396

Table 1924Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Females

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 Areas (excluding the AlaskaNative Registry) and 112016 US population estimates based on the average of 2015 and 2016 population estimates from theUS Bureau of the CensusPrevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 24 years

b Maximum limited-duration prevalence is 24 years for 1992-2016 datac Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groupsd Cases diagnosed more than 24 years ago were estimated using the completeness index method (Capocaccia et al 1997

Merrill et al 2000)e Complete prevalence is obtained by summing 0 to lt24 and gt=24- Statistic not shown Statistic based on fewer than 5 cases estimated alive in SEER for the time interval+ Not available

Years Since Diagnosis 0 to lt5 5 to lt10 10 to lt15 15 to lt20 20 to lt24 0 to lt24b gt=24d Completee

Race Sex

All Races Both Sexes 248946 177490 117326 69109 31890 644761 49943 694704Males 135137 94173 60159 36020 16581 342069 25489 367558Females 113809 83317 57167 33089 15309 302692 24454 327146

White Both Sexes 213764 154454 101984 60537 28026 558765 49625 620368Males 116527 82172 52535 31627 14543 297404 26526 330121Females 97237 72282 49448 28910 13483 261361 23099 290247

Black Both Sexes 20500 13640 9750 5271 2215 51376 4115 55491Males 10712 7188 4768 2684 1174 26526 1911 28437Females 9789 6452 4981 2587 1041 24850 2204 27054

Asian Both Sexes 8405 5210 3415 1867 844 19741 + +Pacific Males 4548 2661 1757 1013 407 10386 + +Islander Females 3856 2549 1657 855 437 9355 + +

Hispanic Both Sexes 21339 14049 8272 4881 2136 50676 + +Males 10918 7243 4331 2617 1094 26202 + +Females 10421 6805 3941 2264 1043 24474 + +

Age Specific (Crude) Age-Adjustedc Age at Prevalence All Ages 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ All Ages

Race Sex

All Races Both Sexes 02001 00035 00139 00283 00538 01121 02352 04640 08181 10224 01738Males 02156 00044 00189 00354 00625 01293 02710 05243 09364 12449 02023Females 01850 00026 00087 00208 00450 00952 02010 04094 07196 08856 01498

White Both Sexes 02216 00035 00143 00289 00534 01148 02427 04858 08597 10738 01807Males 02380 00045 00198 00359 00622 01317 02790 05442 09778 13060 02095Females 02054 00025 00085 00214 00442 00976 02072 04317 07593 09285 01560

Black Both Sexes 01139 00029 00113 00265 00599 01027 02010 03340 05117 05333 01251Males 01226 00029 00140 00351 00696 01223 02333 03969 05849 06055 01457Females 01059 00030 00086 00178 00510 00853 01728 02836 04608 04976 01088

Asian Both Sexes 00970 00039 00133 00207 00353 00680 01409 02692 04470 06094 01032Pacific Males 01065 00044 00175 00240 00398 00744 01640 03072 05516 07472 01222Islander Females 00882 00033 00092 00175 00312 00623 01209 02384 03629 05207 00880

Hispanic Both Sexes 00887 00030 00117 00206 00398 00850 01769 03632 05888 07209 01294Males 00908 00035 00147 00256 00455 00932 01924 03940 06326 08003 01420Females 00866 00024 00086 00151 00337 00766 01616 03360 05552 06719 01185

Table 1925Non-Hodgkin Lymphoma

Estimated United States Cancer Prevalence Countsa on January 1 2016By RaceEthnicity Sex and Years Since Diagnosis

Estimated prevalence percenta on January 1 2016 of the SEER population diagnosed in the previous 24 yearsBy Age at Prevalence RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 372 452924 -05 62 18862 04 247 189692 -05 1657 244370 -05

1 Hodgkin Lymphoma 28 32262 -17 13 3927 -06 33 22556 -15 39 5779 -31

2 Non-Hodgkin lymphoma 336 409991 -03 48 14693 04 210 163591 -03 1572 231707 -042(a) Non-Hodgkin lymphoma B-cell 311 380349 -01 39 11836 14 190 148768 -02 1491 219745 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 15 16631 20 31 9416 10 07 5203 39 14 2012 252(a) 2 Mature Non-Hodgkin lymphoma B-cell 280 343965 -04 07 2271 30 174 137225 -05 1387 204469 -042(a) 21 ChronicSmallProlymphocytic 69 85601 -13 00 35 - 35 29103 -11 382 56463 -14

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 61 75061 -15 00 30 - 31 25339 -13 336 49692 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 311 19 - - - 00 72 - 02 234 262(a) 213 Mantle-cell lymphoma 08 10229 03 - - - 04 3692 02 44 6537 04

2(a) 22 Lymphoplasmacytic lymphoma 07 8651 00 - - - 03 2590 -11 41 6059 04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 03 3667 -03 - - - 01 1132 -18 17 2533 022(a) 222 Waldenstrom macroglubulinemia 04 4984 03 - - - 02 1458 -07 24 3526 06

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 72 87188 00 03 925 26 48 36480 -02 339 49783 022(a) 231 DLBCL NOSc 71 85899 -01 03 861 12 46 35469 -05 337 49569 012(a) 232 Intravascular large B-cell 00 162 - - - - 00 63 - 01 99 -

lymphoma2(a) 233 Primary effusion lymphoma 00 181 27 - - - 00 126 - 00 55 -2(a) 234 Mediastinal large B-cell 01 946 116 00 64 - 01 822 111 00 60 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 04 4692 -26 03 1028 32 04 2618 -43 07 1046 -432(a) 25 Marginal-zone lymphoma (MZL) 22 26534 00 00 137 13 14 11049 05 104 15348 -042(a) 251 Splenic MZL 02 2418 04 - - - 01 889 -08 10 1529 102(a) 252 Extranodal MZL MALTc type 13 15979 06 00 92 - 09 7148 11 59 8739 032(a) 253 Nodal MZL 07 8137 -15 00 45 - 04 3012 -05 34 5080 -20

2(a) 26 Follicular lymphoma 35 43582 -21 00 119 - 28 21725 -25 147 21738 -182(a) 27 Hairy-cell leukemia 03 3712 -16 - - - 03 2311 -19 09 1401 -122(a) 28 Plasma cell neoplasms 68 83957 08 00 24 - 39 31325 12 358 52608 062(a) 281 Plasmacytoma 04 4879 -04 00 16 - 03 2362 -06 17 2501 -032(a) 282 Multiple myeloma 64 79078 09 - - - 36 28963 14 341 50107 07

plasma-cell leukemia2(a) 29 Heavy chain disease 00 48 - - - - 00 24 - 00 23 -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 16 19753 33 00 149 27 08 6340 37 90 13264 32

Table 1926All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 23 27222 01 08 2502 18 19 13933 03 73 10787 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 616 - 01 293 - 00 272 - 00 51 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 22 26531 11 07 2207 75 19 13621 12 73 10703 -042(b) 21 Mycosis fungoidesSezary syndrome 06 6969 18 01 213 84 06 4080 23 18 2676 052(b) 211 Mycosis fungoides 06 6739 17 01 213 84 05 3990 22 17 2536 042(b) 212 Sezary syndrome 00 230 46 - - - 00 90 - 01 140 -

2(b) 22 Peripheral T-cell lymphoma 12 14531 -10 02 534 07 10 7159 -09 46 6838 -122(b) 221 Peripheral T-cell lymphoma NOSc 04 5393 -01 00 86 - 03 2489 04 19 2818 -042(b) 222 Angioimmunoblastic T-cell lymphoma 02 1902 02 - - - 01 699 -09 08 1201 072(b) 223 Subcutaneous panniculitis- 00 176 44 00 31 - 00 111 - 00 34 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 2523 -36 01 291 00 02 1450 -33 05 782 -54

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 139 - - - - 00 98 - 00 28 -2(b) 226 Enteropathy-type T-cell lymphoma 00 186 -02 - - - 00 84 - 01 101 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 2963 -07 00 59 - 02 1575 01 09 1329 -142(b) 228 Primary cutaneous anaplastic 01 1249 -41 00 51 - 01 653 -49 04 545 -39

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 03 3417 96 05 1428 101 02 1474 99 03 515 672(b) 24 NKcT-cell lymphoma nasal-type 01 985 02 00 26 - 01 659 00 02 300 05

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 120 - - - - 00 54 - 00 65 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 509 30 - - - 00 195 -05 02 309 442(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 75 - - - - 00 40 - 00 33 -2(c) Non-Hodgkin lymphoma unknown lineage 02 2420 -274 01 355 - 01 890 -216 08 1175 -2792(c) 1 Precursor lymphoblastic leukemia 01 814 -283 01 343 - 00 238 - 02 233 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 95 - - - - 00 25 - 00 69 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 1511 -274 - - - 01 627 -202 06 873 -319

lineage2() 1 Total precursor lymphomaleukemiad 16 18061 -07 33 10052 -15 08 5713 06 15 2296 -01

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 762 273 00 20 - 00 339 227 03 403 -lymphoma

4 Lymphoid neoplasm NOSc 08 9909 -55 01 222 113 04 3206 -59 43 6481 -59

Table 1926 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 461 253152 -05 70 10973 05 294 110367 -07 2122 131812 -05

1 Hodgkin Lymphoma 31 17710 -17 13 2118 -03 36 12525 -16 48 3067 -31

2 Non-Hodgkin lymphoma 419 229772 -03 56 8711 05 252 95756 -05 2017 125305 -032(a) Non-Hodgkin lymphoma B-cell 387 212247 -02 44 6786 15 227 86941 -04 1908 118520 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 16 8999 24 33 5123 11 08 2888 46 16 988 292(a) 2 Mature Non-Hodgkin lymphoma B-cell 351 192801 -05 10 1558 28 210 80417 -08 1783 110826 -042(a) 21 ChronicSmallProlymphocytic 96 52411 -15 00 21 - 47 18927 -14 539 33463 -15

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 82 44988 -17 00 19 - 40 16143 -16 464 28826 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 193 -02 - - - 00 46 - 02 145 052(a) 213 Mantle-cell lymphoma 13 7230 -01 - - - 07 2738 -01 72 4492 -01

2(a) 22 Lymphoplasmacytic lymphoma 10 5082 -05 - - - 04 1524 -08 58 3558 -04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 04 2062 -08 - - - 02 616 -12 23 1446 -072(a) 222 Waldenstrom macroglubulinemia 06 3020 -02 - - - 02 908 -06 34 2112 -02

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 88 48128 01 03 554 22 59 21824 -06 418 25750 052(a) 231 DLBCL NOSc 87 47520 00 03 519 03 57 21366 -08 416 25635 042(a) 232 Intravascular large B-cell 00 75 - - - - 00 31 - 01 44 -

lymphoma2(a) 233 Primary effusion lymphoma 00 167 26 - - - 00 123 - 01 44 -2(a) 234 Mediastinal large B-cell 01 366 155 00 35 - 01 304 142 00 27 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 06 3388 -22 05 775 31 06 1969 -46 10 644 -192(a) 25 Marginal-zone lymphoma (MZL) 22 12351 -02 01 98 - 14 5177 -02 114 7076 -012(a) 251 Splenic MZL 02 1164 14 - - - 01 434 18 12 730 112(a) 252 Extranodal MZL MALTc type 13 7268 07 00 62 - 09 3267 04 63 3939 102(a) 253 Nodal MZL 07 3919 -23 00 36 - 04 1476 -22 39 2407 -23

2(a) 26 Follicular lymphoma 39 21788 -19 01 100 - 30 11210 -25 165 10478 -152(a) 27 Hairy-cell leukemia 05 2984 -18 - - - 05 1908 -20 17 1076 -152(a) 28 Plasma cell neoplasms 85 46642 07 - - - 45 17864 11 462 28769 052(a) 281 Plasmacytoma 05 2997 -08 - - - 04 1509 -16 24 1484 -012(a) 282 Multiple myeloma 80 43645 08 - - - 41 16355 13 439 27285 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 27 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 20 10447 34 01 105 - 10 3636 40 110 6706 32

Table 1927All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 29 16118 00 11 1730 14 23 8235 02 98 6153 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 430 - 01 208 - 01 188 - 01 34 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 28 15642 11 10 1521 71 22 8022 11 97 6099 -032(b) 21 Mycosis fungoidesSezary syndrome 07 3962 19 01 135 - 06 2261 21 25 1566 092(b) 211 Mycosis fungoides 07 3831 20 01 135 - 06 2213 21 23 1483 092(b) 212 Sezary syndrome 00 131 - - - - 00 48 - 01 83 -

2(b) 22 Peripheral T-cell lymphoma 15 8438 -13 02 318 -09 12 4248 -12 62 3872 -132(b) 221 Peripheral T-cell lymphoma NOSc 06 3159 -05 00 49 - 04 1520 02 26 1590 -082(b) 222 Angioimmunoblastic T-cell lymphoma 02 1024 19 - - - 01 415 11 10 607 232(b) 223 Subcutaneous panniculitis- 00 68 - - - - 00 39 - 00 16 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 03 1549 -39 01 184 -01 02 888 -43 08 477 -45

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 98 - - - - 00 69 - 00 18 -2(b) 226 Enteropathy-type T-cell lymphoma 00 105 - - - - 00 50 - 01 54 -2(b) 227 Cutaneous T-cell lymphoma NOSc 03 1696 -12 00 32 - 02 894 -03 12 770 -172(b) 228 Primary cutaneous anaplastic 01 739 -48 00 26 - 01 373 -49 05 340 -49

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 04 2253 97 07 1047 92 03 940 98 04 266 1022(b) 24 NKcT-cell lymphoma nasal-type 01 638 -05 00 18 - 01 435 -03 03 185 -06

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 58 - - - - 00 22 - 01 36 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 01 293 45 - - - 00 116 - 03 174 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 46 - - - - 00 25 - 00 20 -2(c) Non-Hodgkin lymphoma unknown lineage 03 1407 -232 01 195 - 02 580 -184 10 632 -2302(c) 1 Precursor lymphoblastic leukemia 01 474 -228 01 187 - 00 134 - 02 153 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 49 - - - - - - - 01 36 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 02 884 -239 - - - 01 433 -175 07 443 -

lineage2() 1 Total precursor lymphomaleukemiad 18 9903 -06 35 5518 -17 09 3210 09 19 1175 05

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 435 271 - - - 01 215 - 03 207 -lymphoma

4 Lymphoid neoplasm NOSc 10 5235 -59 01 131 - 05 1871 -65 54 3233 -61

Table 1927 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 301 199772 -05 53 7889 02 202 79325 -02 1322 112558 -08

1 Hodgkin Lymphoma 24 14552 -16 12 1809 -10 29 10031 -14 32 2712 -32

2 Non-Hodgkin lymphoma 269 180219 -03 40 5982 03 170 67835 00 1251 106402 -062(a) Non-Hodgkin lymphoma B-cell 250 168102 -01 34 5050 13 154 61827 02 1190 101225 -042(a) 1 Precursor Non-Hodgkin lymphoma B-cell 14 7632 16 29 4293 09 06 2315 29 12 1024 202(a) 2 Mature Non-Hodgkin lymphoma B-cell 223 151164 -04 05 713 35 141 56808 -01 1102 93643 -072(a) 21 ChronicSmallProlymphocytic 48 33190 -13 - - - 24 10176 -05 268 23000 -16

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 43 30073 -15 - - - 22 9196 -06 243 20866 -19

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 118 - - - - 00 26 - 01 89 -2(a) 213 Mantle-cell lymphoma 04 2999 11 - - - 02 954 10 24 2045 12

2(a) 22 Lymphoplasmacytic lymphoma 05 3569 04 - - - 03 1066 -16 30 2501 11Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 02 1605 01 - - - 01 516 -25 13 1087 112(a) 222 Waldenstrom macroglubulinemia 03 1964 06 - - - 01 550 -08 17 1414 11

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 58 39060 00 02 371 33 38 14656 03 283 24033 -032(a) 231 DLBCL NOSc 57 38379 -02 02 342 27 36 14103 -01 282 23934 -032(a) 232 Intravascular large B-cell 00 87 - - - - 00 32 - 01 55 -

lymphoma2(a) 233 Primary effusion lymphoma - - - - - - - - - - - -2(a) 234 Mediastinal large B-cell 01 580 91 00 29 - 02 518 93 00 33 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 02 1304 -34 02 253 38 02 649 -37 05 402 -852(a) 25 Marginal-zone lymphoma (MZL) 21 14183 01 00 39 - 15 5872 12 98 8272 -062(a) 251 Splenic MZL 02 1254 -07 - - - 01 455 -32 10 799 072(a) 252 Extranodal MZL MALTc type 13 8711 06 00 30 - 10 3881 17 57 4800 -032(a) 253 Nodal MZL 06 4218 -07 - - - 04 1536 11 32 2673 -18

2(a) 26 Follicular lymphoma 33 21794 -24 00 19 - 27 10515 -25 134 11260 -222(a) 27 Hairy-cell leukemia 01 728 -12 - - - 01 403 -11 04 325 -122(a) 28 Plasma cell neoplasms 55 37315 08 - - - 33 13461 15 282 23839 052(a) 281 Plasmacytoma 03 1882 00 - - - 02 853 12 12 1017 -092(a) 282 Multiple myeloma 52 35433 09 - - - 30 12608 15 270 22822 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 21 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 14 9306 32 00 44 - 07 2704 32 76 6558 31

Table 1928All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 17 11104 01 05 772 29 15 5698 05 55 4634 -112(b) 1 Precursor Non-Hodgkin lymphoma T-cell 00 186 - 01 85 - 00 84 - 00 17 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 17 10889 09 05 686 83 15 5599 12 54 4604 -092(b) 21 Mycosis fungoidesSezary syndrome 05 3007 15 01 78 - 05 1819 26 13 1110 -042(b) 211 Mycosis fungoides 05 2908 12 01 78 - 05 1777 23 12 1053 -072(b) 212 Sezary syndrome 00 99 - - - - 00 42 - 01 57 -

2(b) 22 Peripheral T-cell lymphoma 09 6093 -08 01 216 30 08 2911 -06 35 2966 -142(b) 221 Peripheral T-cell lymphoma NOSc 03 2234 03 00 37 - 03 969 07 14 1228 -012(b) 222 Angioimmunoblastic T-cell lymphoma 01 878 -22 - - - 01 284 -39 07 594 -152(b) 223 Subcutaneous panniculitis- 00 108 - 00 18 - 00 72 - 00 18 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 974 -33 01 107 - 02 562 -19 04 305 -77

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 41 - - - - 00 29 - - - -2(b) 226 Enteropathy-type T-cell lymphoma 00 81 - - - - 00 34 - 01 47 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 1267 00 00 27 - 02 681 07 07 559 -102(b) 228 Primary cutaneous anaplastic 01 510 -34 00 25 - 01 280 -50 02 205 -33

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 02 1164 96 03 381 127 01 534 97 03 249 302(b) 24 NKcT-cell lymphoma nasal-type 01 347 11 - - - 01 224 - 01 115 -

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 62 - - - - 00 32 - 00 29 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 216 03 - - - 00 79 - 02 135 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 29 - - - - - - - - - -2(c) Non-Hodgkin lymphoma unknown lineage 02 1013 -341 01 160 - 01 310 - 06 543 -2(c) 1 Precursor lymphoblastic leukemia 01 340 - 01 156 - 00 104 - 01 80 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 46 - - - - - - - 00 33 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 627 - - - - 01 194 - 05 430 -

lineage2() 1 Total precursor lymphomaleukemiad 14 8158 -09 31 4534 -13 07 2503 02 13 1121 -11

3 Composite Hodgkin lymphoma and Non-Hodgkin 00 327 - - - - 00 124 - 02 196 -lymphoma

4 Lymphoid neoplasm NOSc 07 4674 -52 01 91 - 03 1335 -51 36 3248 -58

Table 1928 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 21: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control and PreventionRates are per 100000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

b The SEER 9 areas are San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah and AtlantaThe SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey Los Angeles the Alaska Native Registry and Rural GeorgiaThe SEER 18 areas comprise the SEER 13 areas plus California excluding SFSJMLA Kentucky Louisiana New Jersey and Georgiaexcluding ATLRGThe SEER 21 areas comprise the SEER 18 areas plus Idaho New York and Massachusetts

- Statistic not shown Rate based on less than 16 cases for the time interval

All Races Whites Blacks Total Males Females Total Males Females Total Males Females

SEER Death Ratesa 2012-2016

California 533 677 423 570 726 449 417 480 367Greater Bay Area 505 671 376 561 756 408 410 491 331San Francisco-Oakland 503 667 376 555 742 409 416 490 343San Jose-Monterey 511 681 377 573 781 407 - - -

Los Angeles 541 670 443 589 728 481 424 503 371Greater California 539 682 429 564 716 447 416 455 384

Connecticut 533 705 407 547 717 421 350 510 244Detroit 639 822 505 693 895 542 443 528 384Georgia 533 697 411 580 747 450 376 503 286Atlanta 492 659 372 533 728 388 397 506 317Rural Georgia 559 731 388 670 813 507 - - -Greater Georgia 549 712 426 595 755 470 363 500 266

Hawaii 475 620 352 545 649 412 - - -Idaho 635 775 510 641 782 516 - - -Iowa 638 845 484 642 848 488 - - -Kentucky 642 886 460 655 904 470 401 557 284Louisiana 608 814 451 651 863 485 461 623 340Massachusetts 523 659 423 541 682 436 347 410 297New Jersey 545 721 419 585 780 443 372 466 314New Mexico 488 585 405 493 595 406 - - -New York 535 702 412 575 752 441 390 514 313Seattle-Puget Sound 585 749 463 604 769 480 490 562 397Utah 542 670 433 551 681 440 - - -

SEER 9 Areasb 555 719 430 586 758 454 414 522 333SEER 13 Areasb 549 705 429 586 753 457 419 521 342SEER 18 Areasb 554 717 431 589 761 456 409 518 329SEER 21 Areasb 550 712 428 584 754 453 401 513 322

Total US 562 725 436 586 755 454 408 518 330

Table 1921Non-Hodgkin Lymphoma

Age-Adjusted SEER Death Ratesa

By Registry Race and Sex

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 562 002

High Five StatesMichigan 645 011 01(0112) 1479Kentucky 642 016 02(0118) 1424Iowa 638 018 03(0120) 1367Indiana 638 013 04(0117) 1361Idaho 635 027 05(0126) 1303

Low Five StatesNevada 511 019 47(2251) -899Colorado 491 014 48(3851) -1257New Mexico 488 020 49(2851) -1317Hawaii 475 024 50(3051) -1542c

DC 444 039 51(2351) -2097c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 545 014 28(1847) -291 Montana 559 030 25(0250) -042Alaska 525 047 43(0151) -654 Nebraska 563 023 22(0548) 026Arizona 512 012 46(2950) -886 Nevada 511 019 47(2251) -899Arkansas 555 018 26(1247) -113 New Hampshire 562 027 23(0349) 014California 533 005 40(2645) -508 New Jersey 545 010 29(2045) -301Colorado 491 014 48(3851) -1257 New Mexico 488 020 49(2851) -1317Connecticut 533 016 39(1949) -505 New York 535 007 37(2446) -478Delaware 628 033 08(0139) 1174 North Carolina 541 010 35(2146) -363DC 444 039 51(2351) -2097c North Dakota 561 037 24(0151) -007Florida 535 006 38(2545) -479 Ohio 616 009 10(0220) 969Georgia 533 011 41(2248) -511 Oklahoma 630 017 06(0121) 1226Hawaii 475 024 50(3051) -1542c Oregon 612 016 11(0124) 903Idaho 635 027 05(0126) 1303 Pennsylvania 603 009 16(0622) 729Illinois 566 009 20(1634) 085 Rhode Island 542 029 32(0651) -350Indiana 638 013 04(0117) 1361 South Carolina 542 014 31(1847) -347Iowa 638 018 03(0120) 1367 South Dakota 541 033 36(0451) -364Kansas 585 019 19(0439) 420 Tennessee 629 013 07(0119) 1198Kentucky 642 016 02(0118) 1424 Texas 546 007 27(2142) -277Louisiana 608 016 14(0125) 826 Utah 542 022 33(1250) -352Maine 609 026 13(0137) 852 Vermont 605 040 15(0148) 770Maryland 524 013 44(2349) -663 Virginia 544 011 30(2046) -319Massachusetts 523 012 45(2549) -687 Washington 599 013 17(0425) 665Michigan 645 011 01(0112) 1479 West Virginia 612 022 12(0132) 894Minnesota 617 014 09(0122) 984 Wisconsin 590 013 18(0629) 507Mississippi 531 018 42(1850) -551 Wyoming 564 043 21(0151) 050Missouri 542 012 34(1947) -354

Table 1922Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males and Females

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 725 003

High Five StatesKentucky 886 030 01(0112) 2213c

Iowa 845 032 02(0120) 1647c

Michigan 842 019 03(0114) 1615c

Indiana 839 024 04(0116) 1567c

Delaware 824 058 05(0144) 1364

Low Five StatesArizona 635 019 47(3251) -1244Alaska 630 075 48(0251) -1311Hawaii 620 041 49(1951) -1452DC 614 071 50(0551) -1535c

New Mexico 585 033 51(3451) -1928c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 688 025 36(1649) -513 Montana 709 050 26(0251) -218Alaska 630 075 48(0251) -1311 Nebraska 737 040 20(0248) 165Arizona 635 019 47(3251) -1244 Nevada 653 032 44(1951) -994Arkansas 721 031 22(0747) -061 New Hampshire 710 046 25(0451) -210California 677 009 41(2846) -666 New Jersey 721 018 21(1441) -059Colorado 643 024 46(2451) -1133 New Mexico 585 033 51(3451) -1928c

Connecticut 705 028 28(1248) -273 New York 702 012 30(1943) -323Delaware 824 058 05(0144) 1364 North Carolina 709 018 27(1644) -221DC 614 071 50(0551) -1535c North Dakota 682 061 39(0251) -598Florida 683 011 37(2446) -585 Ohio 800 017 09(0320) 1029Georgia 697 019 34(1746) -387 Oklahoma 806 030 08(0126) 1109Hawaii 620 041 49(1951) -1452 Oregon 794 028 12(0128) 947Idaho 775 045 16(0146) 692 Pennsylvania 783 015 15(0523) 794Illinois 739 016 19(1235) 190 Rhode Island 649 050 45(1051) -1050Indiana 839 024 04(0116) 1567c South Carolina 681 025 40(1850) -604Iowa 845 032 02(0120) 1647c South Dakota 701 056 31(0251) -332Kansas 713 032 24(0948) -174 Tennessee 820 023 06(0120) 1311Kentucky 886 030 01(0112) 2213c Texas 698 012 32(2043) -368Louisiana 814 029 07(0122) 1222 Utah 670 036 42(1351) -754Maine 754 045 18(0148) 395 Vermont 794 069 11(0149) 950Maryland 682 023 38(1849) -588 Virginia 694 020 35(1847) -429Massachusetts 659 020 43(2450) -910 Washington 790 022 13(0224) 897Michigan 842 019 03(0114) 1615c West Virginia 774 038 17(0142) 675Minnesota 797 025 10(0224) 995 Wisconsin 786 023 14(0227) 844Mississippi 717 034 23(0748) -110 Wyoming 698 071 33(0151) -377Missouri 702 022 29(1646) -319

Table 1923Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 436 002

High Five StatesIdaho 510 033 01(0139) 1697c

Maine 497 031 02(0141) 1396Michigan 495 012 03(0119) 1340Oklahoma 492 020 04(0128) 1276Indiana 492 016 05(0123) 1270

Low Five StatesMississippi 404 021 47(1351) -731Nevada 382 022 48(2051) -1237Colorado 369 016 49(3451) -1540c

Hawaii 352 027 50(2551) -1932c

DC 323 044 51(1551) -2601c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 440 017 24(0547) 099 Montana 435 036 27(0151) -034Alaska 414 058 38(0151) -500 Nebraska 435 027 26(0249) -032Arizona 407 014 44(2049) -664 Nevada 382 022 48(2051) -1237Arkansas 428 021 31(0649) -181 New Hampshire 454 032 19(0149) 400California 423 006 34(2244) -313 New Jersey 419 012 37(1848) -397Colorado 369 016 49(3451) -1540c New Mexico 405 025 46(0951) -706Connecticut 407 018 45(1550) -669 New York 412 008 39(2548) -554Delaware 473 039 12(0150) 855 North Carolina 420 012 35(1848) -374DC 323 044 51(1551) -2601c North Dakota 471 045 13(0150) 809Florida 412 007 40(2548) -564 Ohio 478 011 10(0123) 967Georgia 411 012 43(2049) -582 Oklahoma 492 020 04(0128) 1276Hawaii 352 027 50(2551) -1932c Oregon 465 019 15(0141) 668Idaho 510 033 01(0139) 1697c Pennsylvania 467 010 14(0427) 714Illinois 439 010 25(1341) 074 Rhode Island 455 035 18(0150) 434Indiana 492 016 05(0123) 1270 South Carolina 432 017 30(0947) -102Iowa 484 021 08(0135) 1087 South Dakota 411 039 42(0151) -580Kansas 486 023 06(0137) 1143 Tennessee 484 015 09(0126) 1087Kentucky 460 018 17(0241) 544 Texas 427 008 32(1944) -213Louisiana 451 018 21(0345) 333 Utah 433 026 28(0250) -081Maine 497 031 02(0141) 1396 Vermont 461 047 16(0151) 578Maryland 411 015 41(1749) -576 Virginia 432 013 29(1246) -092Massachusetts 423 014 33(1548) -303 Washington 452 015 20(0541) 360Michigan 495 012 03(0119) 1340 West Virginia 486 027 07(0143) 1141Minnesota 475 017 11(0132) 901 Wisconsin 443 015 23(0645) 156Mississippi 404 021 47(1351) -731 Wyoming 445 051 22(0151) 192Missouri 419 014 36(1549) -396

Table 1924Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Females

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 Areas (excluding the AlaskaNative Registry) and 112016 US population estimates based on the average of 2015 and 2016 population estimates from theUS Bureau of the CensusPrevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 24 years

b Maximum limited-duration prevalence is 24 years for 1992-2016 datac Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groupsd Cases diagnosed more than 24 years ago were estimated using the completeness index method (Capocaccia et al 1997

Merrill et al 2000)e Complete prevalence is obtained by summing 0 to lt24 and gt=24- Statistic not shown Statistic based on fewer than 5 cases estimated alive in SEER for the time interval+ Not available

Years Since Diagnosis 0 to lt5 5 to lt10 10 to lt15 15 to lt20 20 to lt24 0 to lt24b gt=24d Completee

Race Sex

All Races Both Sexes 248946 177490 117326 69109 31890 644761 49943 694704Males 135137 94173 60159 36020 16581 342069 25489 367558Females 113809 83317 57167 33089 15309 302692 24454 327146

White Both Sexes 213764 154454 101984 60537 28026 558765 49625 620368Males 116527 82172 52535 31627 14543 297404 26526 330121Females 97237 72282 49448 28910 13483 261361 23099 290247

Black Both Sexes 20500 13640 9750 5271 2215 51376 4115 55491Males 10712 7188 4768 2684 1174 26526 1911 28437Females 9789 6452 4981 2587 1041 24850 2204 27054

Asian Both Sexes 8405 5210 3415 1867 844 19741 + +Pacific Males 4548 2661 1757 1013 407 10386 + +Islander Females 3856 2549 1657 855 437 9355 + +

Hispanic Both Sexes 21339 14049 8272 4881 2136 50676 + +Males 10918 7243 4331 2617 1094 26202 + +Females 10421 6805 3941 2264 1043 24474 + +

Age Specific (Crude) Age-Adjustedc Age at Prevalence All Ages 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ All Ages

Race Sex

All Races Both Sexes 02001 00035 00139 00283 00538 01121 02352 04640 08181 10224 01738Males 02156 00044 00189 00354 00625 01293 02710 05243 09364 12449 02023Females 01850 00026 00087 00208 00450 00952 02010 04094 07196 08856 01498

White Both Sexes 02216 00035 00143 00289 00534 01148 02427 04858 08597 10738 01807Males 02380 00045 00198 00359 00622 01317 02790 05442 09778 13060 02095Females 02054 00025 00085 00214 00442 00976 02072 04317 07593 09285 01560

Black Both Sexes 01139 00029 00113 00265 00599 01027 02010 03340 05117 05333 01251Males 01226 00029 00140 00351 00696 01223 02333 03969 05849 06055 01457Females 01059 00030 00086 00178 00510 00853 01728 02836 04608 04976 01088

Asian Both Sexes 00970 00039 00133 00207 00353 00680 01409 02692 04470 06094 01032Pacific Males 01065 00044 00175 00240 00398 00744 01640 03072 05516 07472 01222Islander Females 00882 00033 00092 00175 00312 00623 01209 02384 03629 05207 00880

Hispanic Both Sexes 00887 00030 00117 00206 00398 00850 01769 03632 05888 07209 01294Males 00908 00035 00147 00256 00455 00932 01924 03940 06326 08003 01420Females 00866 00024 00086 00151 00337 00766 01616 03360 05552 06719 01185

Table 1925Non-Hodgkin Lymphoma

Estimated United States Cancer Prevalence Countsa on January 1 2016By RaceEthnicity Sex and Years Since Diagnosis

Estimated prevalence percenta on January 1 2016 of the SEER population diagnosed in the previous 24 yearsBy Age at Prevalence RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 372 452924 -05 62 18862 04 247 189692 -05 1657 244370 -05

1 Hodgkin Lymphoma 28 32262 -17 13 3927 -06 33 22556 -15 39 5779 -31

2 Non-Hodgkin lymphoma 336 409991 -03 48 14693 04 210 163591 -03 1572 231707 -042(a) Non-Hodgkin lymphoma B-cell 311 380349 -01 39 11836 14 190 148768 -02 1491 219745 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 15 16631 20 31 9416 10 07 5203 39 14 2012 252(a) 2 Mature Non-Hodgkin lymphoma B-cell 280 343965 -04 07 2271 30 174 137225 -05 1387 204469 -042(a) 21 ChronicSmallProlymphocytic 69 85601 -13 00 35 - 35 29103 -11 382 56463 -14

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 61 75061 -15 00 30 - 31 25339 -13 336 49692 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 311 19 - - - 00 72 - 02 234 262(a) 213 Mantle-cell lymphoma 08 10229 03 - - - 04 3692 02 44 6537 04

2(a) 22 Lymphoplasmacytic lymphoma 07 8651 00 - - - 03 2590 -11 41 6059 04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 03 3667 -03 - - - 01 1132 -18 17 2533 022(a) 222 Waldenstrom macroglubulinemia 04 4984 03 - - - 02 1458 -07 24 3526 06

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 72 87188 00 03 925 26 48 36480 -02 339 49783 022(a) 231 DLBCL NOSc 71 85899 -01 03 861 12 46 35469 -05 337 49569 012(a) 232 Intravascular large B-cell 00 162 - - - - 00 63 - 01 99 -

lymphoma2(a) 233 Primary effusion lymphoma 00 181 27 - - - 00 126 - 00 55 -2(a) 234 Mediastinal large B-cell 01 946 116 00 64 - 01 822 111 00 60 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 04 4692 -26 03 1028 32 04 2618 -43 07 1046 -432(a) 25 Marginal-zone lymphoma (MZL) 22 26534 00 00 137 13 14 11049 05 104 15348 -042(a) 251 Splenic MZL 02 2418 04 - - - 01 889 -08 10 1529 102(a) 252 Extranodal MZL MALTc type 13 15979 06 00 92 - 09 7148 11 59 8739 032(a) 253 Nodal MZL 07 8137 -15 00 45 - 04 3012 -05 34 5080 -20

2(a) 26 Follicular lymphoma 35 43582 -21 00 119 - 28 21725 -25 147 21738 -182(a) 27 Hairy-cell leukemia 03 3712 -16 - - - 03 2311 -19 09 1401 -122(a) 28 Plasma cell neoplasms 68 83957 08 00 24 - 39 31325 12 358 52608 062(a) 281 Plasmacytoma 04 4879 -04 00 16 - 03 2362 -06 17 2501 -032(a) 282 Multiple myeloma 64 79078 09 - - - 36 28963 14 341 50107 07

plasma-cell leukemia2(a) 29 Heavy chain disease 00 48 - - - - 00 24 - 00 23 -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 16 19753 33 00 149 27 08 6340 37 90 13264 32

Table 1926All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 23 27222 01 08 2502 18 19 13933 03 73 10787 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 616 - 01 293 - 00 272 - 00 51 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 22 26531 11 07 2207 75 19 13621 12 73 10703 -042(b) 21 Mycosis fungoidesSezary syndrome 06 6969 18 01 213 84 06 4080 23 18 2676 052(b) 211 Mycosis fungoides 06 6739 17 01 213 84 05 3990 22 17 2536 042(b) 212 Sezary syndrome 00 230 46 - - - 00 90 - 01 140 -

2(b) 22 Peripheral T-cell lymphoma 12 14531 -10 02 534 07 10 7159 -09 46 6838 -122(b) 221 Peripheral T-cell lymphoma NOSc 04 5393 -01 00 86 - 03 2489 04 19 2818 -042(b) 222 Angioimmunoblastic T-cell lymphoma 02 1902 02 - - - 01 699 -09 08 1201 072(b) 223 Subcutaneous panniculitis- 00 176 44 00 31 - 00 111 - 00 34 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 2523 -36 01 291 00 02 1450 -33 05 782 -54

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 139 - - - - 00 98 - 00 28 -2(b) 226 Enteropathy-type T-cell lymphoma 00 186 -02 - - - 00 84 - 01 101 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 2963 -07 00 59 - 02 1575 01 09 1329 -142(b) 228 Primary cutaneous anaplastic 01 1249 -41 00 51 - 01 653 -49 04 545 -39

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 03 3417 96 05 1428 101 02 1474 99 03 515 672(b) 24 NKcT-cell lymphoma nasal-type 01 985 02 00 26 - 01 659 00 02 300 05

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 120 - - - - 00 54 - 00 65 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 509 30 - - - 00 195 -05 02 309 442(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 75 - - - - 00 40 - 00 33 -2(c) Non-Hodgkin lymphoma unknown lineage 02 2420 -274 01 355 - 01 890 -216 08 1175 -2792(c) 1 Precursor lymphoblastic leukemia 01 814 -283 01 343 - 00 238 - 02 233 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 95 - - - - 00 25 - 00 69 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 1511 -274 - - - 01 627 -202 06 873 -319

lineage2() 1 Total precursor lymphomaleukemiad 16 18061 -07 33 10052 -15 08 5713 06 15 2296 -01

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 762 273 00 20 - 00 339 227 03 403 -lymphoma

4 Lymphoid neoplasm NOSc 08 9909 -55 01 222 113 04 3206 -59 43 6481 -59

Table 1926 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 461 253152 -05 70 10973 05 294 110367 -07 2122 131812 -05

1 Hodgkin Lymphoma 31 17710 -17 13 2118 -03 36 12525 -16 48 3067 -31

2 Non-Hodgkin lymphoma 419 229772 -03 56 8711 05 252 95756 -05 2017 125305 -032(a) Non-Hodgkin lymphoma B-cell 387 212247 -02 44 6786 15 227 86941 -04 1908 118520 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 16 8999 24 33 5123 11 08 2888 46 16 988 292(a) 2 Mature Non-Hodgkin lymphoma B-cell 351 192801 -05 10 1558 28 210 80417 -08 1783 110826 -042(a) 21 ChronicSmallProlymphocytic 96 52411 -15 00 21 - 47 18927 -14 539 33463 -15

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 82 44988 -17 00 19 - 40 16143 -16 464 28826 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 193 -02 - - - 00 46 - 02 145 052(a) 213 Mantle-cell lymphoma 13 7230 -01 - - - 07 2738 -01 72 4492 -01

2(a) 22 Lymphoplasmacytic lymphoma 10 5082 -05 - - - 04 1524 -08 58 3558 -04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 04 2062 -08 - - - 02 616 -12 23 1446 -072(a) 222 Waldenstrom macroglubulinemia 06 3020 -02 - - - 02 908 -06 34 2112 -02

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 88 48128 01 03 554 22 59 21824 -06 418 25750 052(a) 231 DLBCL NOSc 87 47520 00 03 519 03 57 21366 -08 416 25635 042(a) 232 Intravascular large B-cell 00 75 - - - - 00 31 - 01 44 -

lymphoma2(a) 233 Primary effusion lymphoma 00 167 26 - - - 00 123 - 01 44 -2(a) 234 Mediastinal large B-cell 01 366 155 00 35 - 01 304 142 00 27 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 06 3388 -22 05 775 31 06 1969 -46 10 644 -192(a) 25 Marginal-zone lymphoma (MZL) 22 12351 -02 01 98 - 14 5177 -02 114 7076 -012(a) 251 Splenic MZL 02 1164 14 - - - 01 434 18 12 730 112(a) 252 Extranodal MZL MALTc type 13 7268 07 00 62 - 09 3267 04 63 3939 102(a) 253 Nodal MZL 07 3919 -23 00 36 - 04 1476 -22 39 2407 -23

2(a) 26 Follicular lymphoma 39 21788 -19 01 100 - 30 11210 -25 165 10478 -152(a) 27 Hairy-cell leukemia 05 2984 -18 - - - 05 1908 -20 17 1076 -152(a) 28 Plasma cell neoplasms 85 46642 07 - - - 45 17864 11 462 28769 052(a) 281 Plasmacytoma 05 2997 -08 - - - 04 1509 -16 24 1484 -012(a) 282 Multiple myeloma 80 43645 08 - - - 41 16355 13 439 27285 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 27 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 20 10447 34 01 105 - 10 3636 40 110 6706 32

Table 1927All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 29 16118 00 11 1730 14 23 8235 02 98 6153 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 430 - 01 208 - 01 188 - 01 34 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 28 15642 11 10 1521 71 22 8022 11 97 6099 -032(b) 21 Mycosis fungoidesSezary syndrome 07 3962 19 01 135 - 06 2261 21 25 1566 092(b) 211 Mycosis fungoides 07 3831 20 01 135 - 06 2213 21 23 1483 092(b) 212 Sezary syndrome 00 131 - - - - 00 48 - 01 83 -

2(b) 22 Peripheral T-cell lymphoma 15 8438 -13 02 318 -09 12 4248 -12 62 3872 -132(b) 221 Peripheral T-cell lymphoma NOSc 06 3159 -05 00 49 - 04 1520 02 26 1590 -082(b) 222 Angioimmunoblastic T-cell lymphoma 02 1024 19 - - - 01 415 11 10 607 232(b) 223 Subcutaneous panniculitis- 00 68 - - - - 00 39 - 00 16 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 03 1549 -39 01 184 -01 02 888 -43 08 477 -45

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 98 - - - - 00 69 - 00 18 -2(b) 226 Enteropathy-type T-cell lymphoma 00 105 - - - - 00 50 - 01 54 -2(b) 227 Cutaneous T-cell lymphoma NOSc 03 1696 -12 00 32 - 02 894 -03 12 770 -172(b) 228 Primary cutaneous anaplastic 01 739 -48 00 26 - 01 373 -49 05 340 -49

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 04 2253 97 07 1047 92 03 940 98 04 266 1022(b) 24 NKcT-cell lymphoma nasal-type 01 638 -05 00 18 - 01 435 -03 03 185 -06

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 58 - - - - 00 22 - 01 36 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 01 293 45 - - - 00 116 - 03 174 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 46 - - - - 00 25 - 00 20 -2(c) Non-Hodgkin lymphoma unknown lineage 03 1407 -232 01 195 - 02 580 -184 10 632 -2302(c) 1 Precursor lymphoblastic leukemia 01 474 -228 01 187 - 00 134 - 02 153 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 49 - - - - - - - 01 36 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 02 884 -239 - - - 01 433 -175 07 443 -

lineage2() 1 Total precursor lymphomaleukemiad 18 9903 -06 35 5518 -17 09 3210 09 19 1175 05

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 435 271 - - - 01 215 - 03 207 -lymphoma

4 Lymphoid neoplasm NOSc 10 5235 -59 01 131 - 05 1871 -65 54 3233 -61

Table 1927 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 301 199772 -05 53 7889 02 202 79325 -02 1322 112558 -08

1 Hodgkin Lymphoma 24 14552 -16 12 1809 -10 29 10031 -14 32 2712 -32

2 Non-Hodgkin lymphoma 269 180219 -03 40 5982 03 170 67835 00 1251 106402 -062(a) Non-Hodgkin lymphoma B-cell 250 168102 -01 34 5050 13 154 61827 02 1190 101225 -042(a) 1 Precursor Non-Hodgkin lymphoma B-cell 14 7632 16 29 4293 09 06 2315 29 12 1024 202(a) 2 Mature Non-Hodgkin lymphoma B-cell 223 151164 -04 05 713 35 141 56808 -01 1102 93643 -072(a) 21 ChronicSmallProlymphocytic 48 33190 -13 - - - 24 10176 -05 268 23000 -16

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 43 30073 -15 - - - 22 9196 -06 243 20866 -19

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 118 - - - - 00 26 - 01 89 -2(a) 213 Mantle-cell lymphoma 04 2999 11 - - - 02 954 10 24 2045 12

2(a) 22 Lymphoplasmacytic lymphoma 05 3569 04 - - - 03 1066 -16 30 2501 11Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 02 1605 01 - - - 01 516 -25 13 1087 112(a) 222 Waldenstrom macroglubulinemia 03 1964 06 - - - 01 550 -08 17 1414 11

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 58 39060 00 02 371 33 38 14656 03 283 24033 -032(a) 231 DLBCL NOSc 57 38379 -02 02 342 27 36 14103 -01 282 23934 -032(a) 232 Intravascular large B-cell 00 87 - - - - 00 32 - 01 55 -

lymphoma2(a) 233 Primary effusion lymphoma - - - - - - - - - - - -2(a) 234 Mediastinal large B-cell 01 580 91 00 29 - 02 518 93 00 33 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 02 1304 -34 02 253 38 02 649 -37 05 402 -852(a) 25 Marginal-zone lymphoma (MZL) 21 14183 01 00 39 - 15 5872 12 98 8272 -062(a) 251 Splenic MZL 02 1254 -07 - - - 01 455 -32 10 799 072(a) 252 Extranodal MZL MALTc type 13 8711 06 00 30 - 10 3881 17 57 4800 -032(a) 253 Nodal MZL 06 4218 -07 - - - 04 1536 11 32 2673 -18

2(a) 26 Follicular lymphoma 33 21794 -24 00 19 - 27 10515 -25 134 11260 -222(a) 27 Hairy-cell leukemia 01 728 -12 - - - 01 403 -11 04 325 -122(a) 28 Plasma cell neoplasms 55 37315 08 - - - 33 13461 15 282 23839 052(a) 281 Plasmacytoma 03 1882 00 - - - 02 853 12 12 1017 -092(a) 282 Multiple myeloma 52 35433 09 - - - 30 12608 15 270 22822 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 21 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 14 9306 32 00 44 - 07 2704 32 76 6558 31

Table 1928All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 17 11104 01 05 772 29 15 5698 05 55 4634 -112(b) 1 Precursor Non-Hodgkin lymphoma T-cell 00 186 - 01 85 - 00 84 - 00 17 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 17 10889 09 05 686 83 15 5599 12 54 4604 -092(b) 21 Mycosis fungoidesSezary syndrome 05 3007 15 01 78 - 05 1819 26 13 1110 -042(b) 211 Mycosis fungoides 05 2908 12 01 78 - 05 1777 23 12 1053 -072(b) 212 Sezary syndrome 00 99 - - - - 00 42 - 01 57 -

2(b) 22 Peripheral T-cell lymphoma 09 6093 -08 01 216 30 08 2911 -06 35 2966 -142(b) 221 Peripheral T-cell lymphoma NOSc 03 2234 03 00 37 - 03 969 07 14 1228 -012(b) 222 Angioimmunoblastic T-cell lymphoma 01 878 -22 - - - 01 284 -39 07 594 -152(b) 223 Subcutaneous panniculitis- 00 108 - 00 18 - 00 72 - 00 18 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 974 -33 01 107 - 02 562 -19 04 305 -77

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 41 - - - - 00 29 - - - -2(b) 226 Enteropathy-type T-cell lymphoma 00 81 - - - - 00 34 - 01 47 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 1267 00 00 27 - 02 681 07 07 559 -102(b) 228 Primary cutaneous anaplastic 01 510 -34 00 25 - 01 280 -50 02 205 -33

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 02 1164 96 03 381 127 01 534 97 03 249 302(b) 24 NKcT-cell lymphoma nasal-type 01 347 11 - - - 01 224 - 01 115 -

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 62 - - - - 00 32 - 00 29 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 216 03 - - - 00 79 - 02 135 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 29 - - - - - - - - - -2(c) Non-Hodgkin lymphoma unknown lineage 02 1013 -341 01 160 - 01 310 - 06 543 -2(c) 1 Precursor lymphoblastic leukemia 01 340 - 01 156 - 00 104 - 01 80 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 46 - - - - - - - 00 33 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 627 - - - - 01 194 - 05 430 -

lineage2() 1 Total precursor lymphomaleukemiad 14 8158 -09 31 4534 -13 07 2503 02 13 1121 -11

3 Composite Hodgkin lymphoma and Non-Hodgkin 00 327 - - - - 00 124 - 02 196 -lymphoma

4 Lymphoid neoplasm NOSc 07 4674 -52 01 91 - 03 1335 -51 36 3248 -58

Table 1928 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 22: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 562 002

High Five StatesMichigan 645 011 01(0112) 1479Kentucky 642 016 02(0118) 1424Iowa 638 018 03(0120) 1367Indiana 638 013 04(0117) 1361Idaho 635 027 05(0126) 1303

Low Five StatesNevada 511 019 47(2251) -899Colorado 491 014 48(3851) -1257New Mexico 488 020 49(2851) -1317Hawaii 475 024 50(3051) -1542c

DC 444 039 51(2351) -2097c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 545 014 28(1847) -291 Montana 559 030 25(0250) -042Alaska 525 047 43(0151) -654 Nebraska 563 023 22(0548) 026Arizona 512 012 46(2950) -886 Nevada 511 019 47(2251) -899Arkansas 555 018 26(1247) -113 New Hampshire 562 027 23(0349) 014California 533 005 40(2645) -508 New Jersey 545 010 29(2045) -301Colorado 491 014 48(3851) -1257 New Mexico 488 020 49(2851) -1317Connecticut 533 016 39(1949) -505 New York 535 007 37(2446) -478Delaware 628 033 08(0139) 1174 North Carolina 541 010 35(2146) -363DC 444 039 51(2351) -2097c North Dakota 561 037 24(0151) -007Florida 535 006 38(2545) -479 Ohio 616 009 10(0220) 969Georgia 533 011 41(2248) -511 Oklahoma 630 017 06(0121) 1226Hawaii 475 024 50(3051) -1542c Oregon 612 016 11(0124) 903Idaho 635 027 05(0126) 1303 Pennsylvania 603 009 16(0622) 729Illinois 566 009 20(1634) 085 Rhode Island 542 029 32(0651) -350Indiana 638 013 04(0117) 1361 South Carolina 542 014 31(1847) -347Iowa 638 018 03(0120) 1367 South Dakota 541 033 36(0451) -364Kansas 585 019 19(0439) 420 Tennessee 629 013 07(0119) 1198Kentucky 642 016 02(0118) 1424 Texas 546 007 27(2142) -277Louisiana 608 016 14(0125) 826 Utah 542 022 33(1250) -352Maine 609 026 13(0137) 852 Vermont 605 040 15(0148) 770Maryland 524 013 44(2349) -663 Virginia 544 011 30(2046) -319Massachusetts 523 012 45(2549) -687 Washington 599 013 17(0425) 665Michigan 645 011 01(0112) 1479 West Virginia 612 022 12(0132) 894Minnesota 617 014 09(0122) 984 Wisconsin 590 013 18(0629) 507Mississippi 531 018 42(1850) -551 Wyoming 564 043 21(0151) 050Missouri 542 012 34(1947) -354

Table 1922Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males and Females

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 725 003

High Five StatesKentucky 886 030 01(0112) 2213c

Iowa 845 032 02(0120) 1647c

Michigan 842 019 03(0114) 1615c

Indiana 839 024 04(0116) 1567c

Delaware 824 058 05(0144) 1364

Low Five StatesArizona 635 019 47(3251) -1244Alaska 630 075 48(0251) -1311Hawaii 620 041 49(1951) -1452DC 614 071 50(0551) -1535c

New Mexico 585 033 51(3451) -1928c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 688 025 36(1649) -513 Montana 709 050 26(0251) -218Alaska 630 075 48(0251) -1311 Nebraska 737 040 20(0248) 165Arizona 635 019 47(3251) -1244 Nevada 653 032 44(1951) -994Arkansas 721 031 22(0747) -061 New Hampshire 710 046 25(0451) -210California 677 009 41(2846) -666 New Jersey 721 018 21(1441) -059Colorado 643 024 46(2451) -1133 New Mexico 585 033 51(3451) -1928c

Connecticut 705 028 28(1248) -273 New York 702 012 30(1943) -323Delaware 824 058 05(0144) 1364 North Carolina 709 018 27(1644) -221DC 614 071 50(0551) -1535c North Dakota 682 061 39(0251) -598Florida 683 011 37(2446) -585 Ohio 800 017 09(0320) 1029Georgia 697 019 34(1746) -387 Oklahoma 806 030 08(0126) 1109Hawaii 620 041 49(1951) -1452 Oregon 794 028 12(0128) 947Idaho 775 045 16(0146) 692 Pennsylvania 783 015 15(0523) 794Illinois 739 016 19(1235) 190 Rhode Island 649 050 45(1051) -1050Indiana 839 024 04(0116) 1567c South Carolina 681 025 40(1850) -604Iowa 845 032 02(0120) 1647c South Dakota 701 056 31(0251) -332Kansas 713 032 24(0948) -174 Tennessee 820 023 06(0120) 1311Kentucky 886 030 01(0112) 2213c Texas 698 012 32(2043) -368Louisiana 814 029 07(0122) 1222 Utah 670 036 42(1351) -754Maine 754 045 18(0148) 395 Vermont 794 069 11(0149) 950Maryland 682 023 38(1849) -588 Virginia 694 020 35(1847) -429Massachusetts 659 020 43(2450) -910 Washington 790 022 13(0224) 897Michigan 842 019 03(0114) 1615c West Virginia 774 038 17(0142) 675Minnesota 797 025 10(0224) 995 Wisconsin 786 023 14(0227) 844Mississippi 717 034 23(0748) -110 Wyoming 698 071 33(0151) -377Missouri 702 022 29(1646) -319

Table 1923Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 436 002

High Five StatesIdaho 510 033 01(0139) 1697c

Maine 497 031 02(0141) 1396Michigan 495 012 03(0119) 1340Oklahoma 492 020 04(0128) 1276Indiana 492 016 05(0123) 1270

Low Five StatesMississippi 404 021 47(1351) -731Nevada 382 022 48(2051) -1237Colorado 369 016 49(3451) -1540c

Hawaii 352 027 50(2551) -1932c

DC 323 044 51(1551) -2601c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 440 017 24(0547) 099 Montana 435 036 27(0151) -034Alaska 414 058 38(0151) -500 Nebraska 435 027 26(0249) -032Arizona 407 014 44(2049) -664 Nevada 382 022 48(2051) -1237Arkansas 428 021 31(0649) -181 New Hampshire 454 032 19(0149) 400California 423 006 34(2244) -313 New Jersey 419 012 37(1848) -397Colorado 369 016 49(3451) -1540c New Mexico 405 025 46(0951) -706Connecticut 407 018 45(1550) -669 New York 412 008 39(2548) -554Delaware 473 039 12(0150) 855 North Carolina 420 012 35(1848) -374DC 323 044 51(1551) -2601c North Dakota 471 045 13(0150) 809Florida 412 007 40(2548) -564 Ohio 478 011 10(0123) 967Georgia 411 012 43(2049) -582 Oklahoma 492 020 04(0128) 1276Hawaii 352 027 50(2551) -1932c Oregon 465 019 15(0141) 668Idaho 510 033 01(0139) 1697c Pennsylvania 467 010 14(0427) 714Illinois 439 010 25(1341) 074 Rhode Island 455 035 18(0150) 434Indiana 492 016 05(0123) 1270 South Carolina 432 017 30(0947) -102Iowa 484 021 08(0135) 1087 South Dakota 411 039 42(0151) -580Kansas 486 023 06(0137) 1143 Tennessee 484 015 09(0126) 1087Kentucky 460 018 17(0241) 544 Texas 427 008 32(1944) -213Louisiana 451 018 21(0345) 333 Utah 433 026 28(0250) -081Maine 497 031 02(0141) 1396 Vermont 461 047 16(0151) 578Maryland 411 015 41(1749) -576 Virginia 432 013 29(1246) -092Massachusetts 423 014 33(1548) -303 Washington 452 015 20(0541) 360Michigan 495 012 03(0119) 1340 West Virginia 486 027 07(0143) 1141Minnesota 475 017 11(0132) 901 Wisconsin 443 015 23(0645) 156Mississippi 404 021 47(1351) -731 Wyoming 445 051 22(0151) 192Missouri 419 014 36(1549) -396

Table 1924Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Females

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 Areas (excluding the AlaskaNative Registry) and 112016 US population estimates based on the average of 2015 and 2016 population estimates from theUS Bureau of the CensusPrevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 24 years

b Maximum limited-duration prevalence is 24 years for 1992-2016 datac Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groupsd Cases diagnosed more than 24 years ago were estimated using the completeness index method (Capocaccia et al 1997

Merrill et al 2000)e Complete prevalence is obtained by summing 0 to lt24 and gt=24- Statistic not shown Statistic based on fewer than 5 cases estimated alive in SEER for the time interval+ Not available

Years Since Diagnosis 0 to lt5 5 to lt10 10 to lt15 15 to lt20 20 to lt24 0 to lt24b gt=24d Completee

Race Sex

All Races Both Sexes 248946 177490 117326 69109 31890 644761 49943 694704Males 135137 94173 60159 36020 16581 342069 25489 367558Females 113809 83317 57167 33089 15309 302692 24454 327146

White Both Sexes 213764 154454 101984 60537 28026 558765 49625 620368Males 116527 82172 52535 31627 14543 297404 26526 330121Females 97237 72282 49448 28910 13483 261361 23099 290247

Black Both Sexes 20500 13640 9750 5271 2215 51376 4115 55491Males 10712 7188 4768 2684 1174 26526 1911 28437Females 9789 6452 4981 2587 1041 24850 2204 27054

Asian Both Sexes 8405 5210 3415 1867 844 19741 + +Pacific Males 4548 2661 1757 1013 407 10386 + +Islander Females 3856 2549 1657 855 437 9355 + +

Hispanic Both Sexes 21339 14049 8272 4881 2136 50676 + +Males 10918 7243 4331 2617 1094 26202 + +Females 10421 6805 3941 2264 1043 24474 + +

Age Specific (Crude) Age-Adjustedc Age at Prevalence All Ages 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ All Ages

Race Sex

All Races Both Sexes 02001 00035 00139 00283 00538 01121 02352 04640 08181 10224 01738Males 02156 00044 00189 00354 00625 01293 02710 05243 09364 12449 02023Females 01850 00026 00087 00208 00450 00952 02010 04094 07196 08856 01498

White Both Sexes 02216 00035 00143 00289 00534 01148 02427 04858 08597 10738 01807Males 02380 00045 00198 00359 00622 01317 02790 05442 09778 13060 02095Females 02054 00025 00085 00214 00442 00976 02072 04317 07593 09285 01560

Black Both Sexes 01139 00029 00113 00265 00599 01027 02010 03340 05117 05333 01251Males 01226 00029 00140 00351 00696 01223 02333 03969 05849 06055 01457Females 01059 00030 00086 00178 00510 00853 01728 02836 04608 04976 01088

Asian Both Sexes 00970 00039 00133 00207 00353 00680 01409 02692 04470 06094 01032Pacific Males 01065 00044 00175 00240 00398 00744 01640 03072 05516 07472 01222Islander Females 00882 00033 00092 00175 00312 00623 01209 02384 03629 05207 00880

Hispanic Both Sexes 00887 00030 00117 00206 00398 00850 01769 03632 05888 07209 01294Males 00908 00035 00147 00256 00455 00932 01924 03940 06326 08003 01420Females 00866 00024 00086 00151 00337 00766 01616 03360 05552 06719 01185

Table 1925Non-Hodgkin Lymphoma

Estimated United States Cancer Prevalence Countsa on January 1 2016By RaceEthnicity Sex and Years Since Diagnosis

Estimated prevalence percenta on January 1 2016 of the SEER population diagnosed in the previous 24 yearsBy Age at Prevalence RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 372 452924 -05 62 18862 04 247 189692 -05 1657 244370 -05

1 Hodgkin Lymphoma 28 32262 -17 13 3927 -06 33 22556 -15 39 5779 -31

2 Non-Hodgkin lymphoma 336 409991 -03 48 14693 04 210 163591 -03 1572 231707 -042(a) Non-Hodgkin lymphoma B-cell 311 380349 -01 39 11836 14 190 148768 -02 1491 219745 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 15 16631 20 31 9416 10 07 5203 39 14 2012 252(a) 2 Mature Non-Hodgkin lymphoma B-cell 280 343965 -04 07 2271 30 174 137225 -05 1387 204469 -042(a) 21 ChronicSmallProlymphocytic 69 85601 -13 00 35 - 35 29103 -11 382 56463 -14

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 61 75061 -15 00 30 - 31 25339 -13 336 49692 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 311 19 - - - 00 72 - 02 234 262(a) 213 Mantle-cell lymphoma 08 10229 03 - - - 04 3692 02 44 6537 04

2(a) 22 Lymphoplasmacytic lymphoma 07 8651 00 - - - 03 2590 -11 41 6059 04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 03 3667 -03 - - - 01 1132 -18 17 2533 022(a) 222 Waldenstrom macroglubulinemia 04 4984 03 - - - 02 1458 -07 24 3526 06

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 72 87188 00 03 925 26 48 36480 -02 339 49783 022(a) 231 DLBCL NOSc 71 85899 -01 03 861 12 46 35469 -05 337 49569 012(a) 232 Intravascular large B-cell 00 162 - - - - 00 63 - 01 99 -

lymphoma2(a) 233 Primary effusion lymphoma 00 181 27 - - - 00 126 - 00 55 -2(a) 234 Mediastinal large B-cell 01 946 116 00 64 - 01 822 111 00 60 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 04 4692 -26 03 1028 32 04 2618 -43 07 1046 -432(a) 25 Marginal-zone lymphoma (MZL) 22 26534 00 00 137 13 14 11049 05 104 15348 -042(a) 251 Splenic MZL 02 2418 04 - - - 01 889 -08 10 1529 102(a) 252 Extranodal MZL MALTc type 13 15979 06 00 92 - 09 7148 11 59 8739 032(a) 253 Nodal MZL 07 8137 -15 00 45 - 04 3012 -05 34 5080 -20

2(a) 26 Follicular lymphoma 35 43582 -21 00 119 - 28 21725 -25 147 21738 -182(a) 27 Hairy-cell leukemia 03 3712 -16 - - - 03 2311 -19 09 1401 -122(a) 28 Plasma cell neoplasms 68 83957 08 00 24 - 39 31325 12 358 52608 062(a) 281 Plasmacytoma 04 4879 -04 00 16 - 03 2362 -06 17 2501 -032(a) 282 Multiple myeloma 64 79078 09 - - - 36 28963 14 341 50107 07

plasma-cell leukemia2(a) 29 Heavy chain disease 00 48 - - - - 00 24 - 00 23 -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 16 19753 33 00 149 27 08 6340 37 90 13264 32

Table 1926All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 23 27222 01 08 2502 18 19 13933 03 73 10787 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 616 - 01 293 - 00 272 - 00 51 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 22 26531 11 07 2207 75 19 13621 12 73 10703 -042(b) 21 Mycosis fungoidesSezary syndrome 06 6969 18 01 213 84 06 4080 23 18 2676 052(b) 211 Mycosis fungoides 06 6739 17 01 213 84 05 3990 22 17 2536 042(b) 212 Sezary syndrome 00 230 46 - - - 00 90 - 01 140 -

2(b) 22 Peripheral T-cell lymphoma 12 14531 -10 02 534 07 10 7159 -09 46 6838 -122(b) 221 Peripheral T-cell lymphoma NOSc 04 5393 -01 00 86 - 03 2489 04 19 2818 -042(b) 222 Angioimmunoblastic T-cell lymphoma 02 1902 02 - - - 01 699 -09 08 1201 072(b) 223 Subcutaneous panniculitis- 00 176 44 00 31 - 00 111 - 00 34 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 2523 -36 01 291 00 02 1450 -33 05 782 -54

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 139 - - - - 00 98 - 00 28 -2(b) 226 Enteropathy-type T-cell lymphoma 00 186 -02 - - - 00 84 - 01 101 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 2963 -07 00 59 - 02 1575 01 09 1329 -142(b) 228 Primary cutaneous anaplastic 01 1249 -41 00 51 - 01 653 -49 04 545 -39

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 03 3417 96 05 1428 101 02 1474 99 03 515 672(b) 24 NKcT-cell lymphoma nasal-type 01 985 02 00 26 - 01 659 00 02 300 05

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 120 - - - - 00 54 - 00 65 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 509 30 - - - 00 195 -05 02 309 442(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 75 - - - - 00 40 - 00 33 -2(c) Non-Hodgkin lymphoma unknown lineage 02 2420 -274 01 355 - 01 890 -216 08 1175 -2792(c) 1 Precursor lymphoblastic leukemia 01 814 -283 01 343 - 00 238 - 02 233 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 95 - - - - 00 25 - 00 69 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 1511 -274 - - - 01 627 -202 06 873 -319

lineage2() 1 Total precursor lymphomaleukemiad 16 18061 -07 33 10052 -15 08 5713 06 15 2296 -01

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 762 273 00 20 - 00 339 227 03 403 -lymphoma

4 Lymphoid neoplasm NOSc 08 9909 -55 01 222 113 04 3206 -59 43 6481 -59

Table 1926 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 461 253152 -05 70 10973 05 294 110367 -07 2122 131812 -05

1 Hodgkin Lymphoma 31 17710 -17 13 2118 -03 36 12525 -16 48 3067 -31

2 Non-Hodgkin lymphoma 419 229772 -03 56 8711 05 252 95756 -05 2017 125305 -032(a) Non-Hodgkin lymphoma B-cell 387 212247 -02 44 6786 15 227 86941 -04 1908 118520 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 16 8999 24 33 5123 11 08 2888 46 16 988 292(a) 2 Mature Non-Hodgkin lymphoma B-cell 351 192801 -05 10 1558 28 210 80417 -08 1783 110826 -042(a) 21 ChronicSmallProlymphocytic 96 52411 -15 00 21 - 47 18927 -14 539 33463 -15

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 82 44988 -17 00 19 - 40 16143 -16 464 28826 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 193 -02 - - - 00 46 - 02 145 052(a) 213 Mantle-cell lymphoma 13 7230 -01 - - - 07 2738 -01 72 4492 -01

2(a) 22 Lymphoplasmacytic lymphoma 10 5082 -05 - - - 04 1524 -08 58 3558 -04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 04 2062 -08 - - - 02 616 -12 23 1446 -072(a) 222 Waldenstrom macroglubulinemia 06 3020 -02 - - - 02 908 -06 34 2112 -02

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 88 48128 01 03 554 22 59 21824 -06 418 25750 052(a) 231 DLBCL NOSc 87 47520 00 03 519 03 57 21366 -08 416 25635 042(a) 232 Intravascular large B-cell 00 75 - - - - 00 31 - 01 44 -

lymphoma2(a) 233 Primary effusion lymphoma 00 167 26 - - - 00 123 - 01 44 -2(a) 234 Mediastinal large B-cell 01 366 155 00 35 - 01 304 142 00 27 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 06 3388 -22 05 775 31 06 1969 -46 10 644 -192(a) 25 Marginal-zone lymphoma (MZL) 22 12351 -02 01 98 - 14 5177 -02 114 7076 -012(a) 251 Splenic MZL 02 1164 14 - - - 01 434 18 12 730 112(a) 252 Extranodal MZL MALTc type 13 7268 07 00 62 - 09 3267 04 63 3939 102(a) 253 Nodal MZL 07 3919 -23 00 36 - 04 1476 -22 39 2407 -23

2(a) 26 Follicular lymphoma 39 21788 -19 01 100 - 30 11210 -25 165 10478 -152(a) 27 Hairy-cell leukemia 05 2984 -18 - - - 05 1908 -20 17 1076 -152(a) 28 Plasma cell neoplasms 85 46642 07 - - - 45 17864 11 462 28769 052(a) 281 Plasmacytoma 05 2997 -08 - - - 04 1509 -16 24 1484 -012(a) 282 Multiple myeloma 80 43645 08 - - - 41 16355 13 439 27285 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 27 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 20 10447 34 01 105 - 10 3636 40 110 6706 32

Table 1927All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 29 16118 00 11 1730 14 23 8235 02 98 6153 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 430 - 01 208 - 01 188 - 01 34 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 28 15642 11 10 1521 71 22 8022 11 97 6099 -032(b) 21 Mycosis fungoidesSezary syndrome 07 3962 19 01 135 - 06 2261 21 25 1566 092(b) 211 Mycosis fungoides 07 3831 20 01 135 - 06 2213 21 23 1483 092(b) 212 Sezary syndrome 00 131 - - - - 00 48 - 01 83 -

2(b) 22 Peripheral T-cell lymphoma 15 8438 -13 02 318 -09 12 4248 -12 62 3872 -132(b) 221 Peripheral T-cell lymphoma NOSc 06 3159 -05 00 49 - 04 1520 02 26 1590 -082(b) 222 Angioimmunoblastic T-cell lymphoma 02 1024 19 - - - 01 415 11 10 607 232(b) 223 Subcutaneous panniculitis- 00 68 - - - - 00 39 - 00 16 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 03 1549 -39 01 184 -01 02 888 -43 08 477 -45

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 98 - - - - 00 69 - 00 18 -2(b) 226 Enteropathy-type T-cell lymphoma 00 105 - - - - 00 50 - 01 54 -2(b) 227 Cutaneous T-cell lymphoma NOSc 03 1696 -12 00 32 - 02 894 -03 12 770 -172(b) 228 Primary cutaneous anaplastic 01 739 -48 00 26 - 01 373 -49 05 340 -49

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 04 2253 97 07 1047 92 03 940 98 04 266 1022(b) 24 NKcT-cell lymphoma nasal-type 01 638 -05 00 18 - 01 435 -03 03 185 -06

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 58 - - - - 00 22 - 01 36 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 01 293 45 - - - 00 116 - 03 174 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 46 - - - - 00 25 - 00 20 -2(c) Non-Hodgkin lymphoma unknown lineage 03 1407 -232 01 195 - 02 580 -184 10 632 -2302(c) 1 Precursor lymphoblastic leukemia 01 474 -228 01 187 - 00 134 - 02 153 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 49 - - - - - - - 01 36 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 02 884 -239 - - - 01 433 -175 07 443 -

lineage2() 1 Total precursor lymphomaleukemiad 18 9903 -06 35 5518 -17 09 3210 09 19 1175 05

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 435 271 - - - 01 215 - 03 207 -lymphoma

4 Lymphoid neoplasm NOSc 10 5235 -59 01 131 - 05 1871 -65 54 3233 -61

Table 1927 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 301 199772 -05 53 7889 02 202 79325 -02 1322 112558 -08

1 Hodgkin Lymphoma 24 14552 -16 12 1809 -10 29 10031 -14 32 2712 -32

2 Non-Hodgkin lymphoma 269 180219 -03 40 5982 03 170 67835 00 1251 106402 -062(a) Non-Hodgkin lymphoma B-cell 250 168102 -01 34 5050 13 154 61827 02 1190 101225 -042(a) 1 Precursor Non-Hodgkin lymphoma B-cell 14 7632 16 29 4293 09 06 2315 29 12 1024 202(a) 2 Mature Non-Hodgkin lymphoma B-cell 223 151164 -04 05 713 35 141 56808 -01 1102 93643 -072(a) 21 ChronicSmallProlymphocytic 48 33190 -13 - - - 24 10176 -05 268 23000 -16

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 43 30073 -15 - - - 22 9196 -06 243 20866 -19

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 118 - - - - 00 26 - 01 89 -2(a) 213 Mantle-cell lymphoma 04 2999 11 - - - 02 954 10 24 2045 12

2(a) 22 Lymphoplasmacytic lymphoma 05 3569 04 - - - 03 1066 -16 30 2501 11Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 02 1605 01 - - - 01 516 -25 13 1087 112(a) 222 Waldenstrom macroglubulinemia 03 1964 06 - - - 01 550 -08 17 1414 11

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 58 39060 00 02 371 33 38 14656 03 283 24033 -032(a) 231 DLBCL NOSc 57 38379 -02 02 342 27 36 14103 -01 282 23934 -032(a) 232 Intravascular large B-cell 00 87 - - - - 00 32 - 01 55 -

lymphoma2(a) 233 Primary effusion lymphoma - - - - - - - - - - - -2(a) 234 Mediastinal large B-cell 01 580 91 00 29 - 02 518 93 00 33 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 02 1304 -34 02 253 38 02 649 -37 05 402 -852(a) 25 Marginal-zone lymphoma (MZL) 21 14183 01 00 39 - 15 5872 12 98 8272 -062(a) 251 Splenic MZL 02 1254 -07 - - - 01 455 -32 10 799 072(a) 252 Extranodal MZL MALTc type 13 8711 06 00 30 - 10 3881 17 57 4800 -032(a) 253 Nodal MZL 06 4218 -07 - - - 04 1536 11 32 2673 -18

2(a) 26 Follicular lymphoma 33 21794 -24 00 19 - 27 10515 -25 134 11260 -222(a) 27 Hairy-cell leukemia 01 728 -12 - - - 01 403 -11 04 325 -122(a) 28 Plasma cell neoplasms 55 37315 08 - - - 33 13461 15 282 23839 052(a) 281 Plasmacytoma 03 1882 00 - - - 02 853 12 12 1017 -092(a) 282 Multiple myeloma 52 35433 09 - - - 30 12608 15 270 22822 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 21 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 14 9306 32 00 44 - 07 2704 32 76 6558 31

Table 1928All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 17 11104 01 05 772 29 15 5698 05 55 4634 -112(b) 1 Precursor Non-Hodgkin lymphoma T-cell 00 186 - 01 85 - 00 84 - 00 17 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 17 10889 09 05 686 83 15 5599 12 54 4604 -092(b) 21 Mycosis fungoidesSezary syndrome 05 3007 15 01 78 - 05 1819 26 13 1110 -042(b) 211 Mycosis fungoides 05 2908 12 01 78 - 05 1777 23 12 1053 -072(b) 212 Sezary syndrome 00 99 - - - - 00 42 - 01 57 -

2(b) 22 Peripheral T-cell lymphoma 09 6093 -08 01 216 30 08 2911 -06 35 2966 -142(b) 221 Peripheral T-cell lymphoma NOSc 03 2234 03 00 37 - 03 969 07 14 1228 -012(b) 222 Angioimmunoblastic T-cell lymphoma 01 878 -22 - - - 01 284 -39 07 594 -152(b) 223 Subcutaneous panniculitis- 00 108 - 00 18 - 00 72 - 00 18 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 974 -33 01 107 - 02 562 -19 04 305 -77

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 41 - - - - 00 29 - - - -2(b) 226 Enteropathy-type T-cell lymphoma 00 81 - - - - 00 34 - 01 47 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 1267 00 00 27 - 02 681 07 07 559 -102(b) 228 Primary cutaneous anaplastic 01 510 -34 00 25 - 01 280 -50 02 205 -33

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 02 1164 96 03 381 127 01 534 97 03 249 302(b) 24 NKcT-cell lymphoma nasal-type 01 347 11 - - - 01 224 - 01 115 -

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 62 - - - - 00 32 - 00 29 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 216 03 - - - 00 79 - 02 135 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 29 - - - - - - - - - -2(c) Non-Hodgkin lymphoma unknown lineage 02 1013 -341 01 160 - 01 310 - 06 543 -2(c) 1 Precursor lymphoblastic leukemia 01 340 - 01 156 - 00 104 - 01 80 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 46 - - - - - - - 00 33 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 627 - - - - 01 194 - 05 430 -

lineage2() 1 Total precursor lymphomaleukemiad 14 8158 -09 31 4534 -13 07 2503 02 13 1121 -11

3 Composite Hodgkin lymphoma and Non-Hodgkin 00 327 - - - - 00 124 - 02 196 -lymphoma

4 Lymphoid neoplasm NOSc 07 4674 -52 01 91 - 03 1335 -51 36 3248 -58

Table 1928 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 23: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 725 003

High Five StatesKentucky 886 030 01(0112) 2213c

Iowa 845 032 02(0120) 1647c

Michigan 842 019 03(0114) 1615c

Indiana 839 024 04(0116) 1567c

Delaware 824 058 05(0144) 1364

Low Five StatesArizona 635 019 47(3251) -1244Alaska 630 075 48(0251) -1311Hawaii 620 041 49(1951) -1452DC 614 071 50(0551) -1535c

New Mexico 585 033 51(3451) -1928c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 688 025 36(1649) -513 Montana 709 050 26(0251) -218Alaska 630 075 48(0251) -1311 Nebraska 737 040 20(0248) 165Arizona 635 019 47(3251) -1244 Nevada 653 032 44(1951) -994Arkansas 721 031 22(0747) -061 New Hampshire 710 046 25(0451) -210California 677 009 41(2846) -666 New Jersey 721 018 21(1441) -059Colorado 643 024 46(2451) -1133 New Mexico 585 033 51(3451) -1928c

Connecticut 705 028 28(1248) -273 New York 702 012 30(1943) -323Delaware 824 058 05(0144) 1364 North Carolina 709 018 27(1644) -221DC 614 071 50(0551) -1535c North Dakota 682 061 39(0251) -598Florida 683 011 37(2446) -585 Ohio 800 017 09(0320) 1029Georgia 697 019 34(1746) -387 Oklahoma 806 030 08(0126) 1109Hawaii 620 041 49(1951) -1452 Oregon 794 028 12(0128) 947Idaho 775 045 16(0146) 692 Pennsylvania 783 015 15(0523) 794Illinois 739 016 19(1235) 190 Rhode Island 649 050 45(1051) -1050Indiana 839 024 04(0116) 1567c South Carolina 681 025 40(1850) -604Iowa 845 032 02(0120) 1647c South Dakota 701 056 31(0251) -332Kansas 713 032 24(0948) -174 Tennessee 820 023 06(0120) 1311Kentucky 886 030 01(0112) 2213c Texas 698 012 32(2043) -368Louisiana 814 029 07(0122) 1222 Utah 670 036 42(1351) -754Maine 754 045 18(0148) 395 Vermont 794 069 11(0149) 950Maryland 682 023 38(1849) -588 Virginia 694 020 35(1847) -429Massachusetts 659 020 43(2450) -910 Washington 790 022 13(0224) 897Michigan 842 019 03(0114) 1615c West Virginia 774 038 17(0142) 675Minnesota 797 025 10(0224) 995 Wisconsin 786 023 14(0227) 844Mississippi 717 034 23(0748) -110 Wyoming 698 071 33(0151) -377Missouri 702 022 29(1646) -319

Table 1923Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Males

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 436 002

High Five StatesIdaho 510 033 01(0139) 1697c

Maine 497 031 02(0141) 1396Michigan 495 012 03(0119) 1340Oklahoma 492 020 04(0128) 1276Indiana 492 016 05(0123) 1270

Low Five StatesMississippi 404 021 47(1351) -731Nevada 382 022 48(2051) -1237Colorado 369 016 49(3451) -1540c

Hawaii 352 027 50(2551) -1932c

DC 323 044 51(1551) -2601c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 440 017 24(0547) 099 Montana 435 036 27(0151) -034Alaska 414 058 38(0151) -500 Nebraska 435 027 26(0249) -032Arizona 407 014 44(2049) -664 Nevada 382 022 48(2051) -1237Arkansas 428 021 31(0649) -181 New Hampshire 454 032 19(0149) 400California 423 006 34(2244) -313 New Jersey 419 012 37(1848) -397Colorado 369 016 49(3451) -1540c New Mexico 405 025 46(0951) -706Connecticut 407 018 45(1550) -669 New York 412 008 39(2548) -554Delaware 473 039 12(0150) 855 North Carolina 420 012 35(1848) -374DC 323 044 51(1551) -2601c North Dakota 471 045 13(0150) 809Florida 412 007 40(2548) -564 Ohio 478 011 10(0123) 967Georgia 411 012 43(2049) -582 Oklahoma 492 020 04(0128) 1276Hawaii 352 027 50(2551) -1932c Oregon 465 019 15(0141) 668Idaho 510 033 01(0139) 1697c Pennsylvania 467 010 14(0427) 714Illinois 439 010 25(1341) 074 Rhode Island 455 035 18(0150) 434Indiana 492 016 05(0123) 1270 South Carolina 432 017 30(0947) -102Iowa 484 021 08(0135) 1087 South Dakota 411 039 42(0151) -580Kansas 486 023 06(0137) 1143 Tennessee 484 015 09(0126) 1087Kentucky 460 018 17(0241) 544 Texas 427 008 32(1944) -213Louisiana 451 018 21(0345) 333 Utah 433 026 28(0250) -081Maine 497 031 02(0141) 1396 Vermont 461 047 16(0151) 578Maryland 411 015 41(1749) -576 Virginia 432 013 29(1246) -092Massachusetts 423 014 33(1548) -303 Washington 452 015 20(0541) 360Michigan 495 012 03(0119) 1340 West Virginia 486 027 07(0143) 1141Minnesota 475 017 11(0132) 901 Wisconsin 443 015 23(0645) 156Mississippi 404 021 47(1351) -731 Wyoming 445 051 22(0151) 192Missouri 419 014 36(1549) -396

Table 1924Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Females

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 Areas (excluding the AlaskaNative Registry) and 112016 US population estimates based on the average of 2015 and 2016 population estimates from theUS Bureau of the CensusPrevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 24 years

b Maximum limited-duration prevalence is 24 years for 1992-2016 datac Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groupsd Cases diagnosed more than 24 years ago were estimated using the completeness index method (Capocaccia et al 1997

Merrill et al 2000)e Complete prevalence is obtained by summing 0 to lt24 and gt=24- Statistic not shown Statistic based on fewer than 5 cases estimated alive in SEER for the time interval+ Not available

Years Since Diagnosis 0 to lt5 5 to lt10 10 to lt15 15 to lt20 20 to lt24 0 to lt24b gt=24d Completee

Race Sex

All Races Both Sexes 248946 177490 117326 69109 31890 644761 49943 694704Males 135137 94173 60159 36020 16581 342069 25489 367558Females 113809 83317 57167 33089 15309 302692 24454 327146

White Both Sexes 213764 154454 101984 60537 28026 558765 49625 620368Males 116527 82172 52535 31627 14543 297404 26526 330121Females 97237 72282 49448 28910 13483 261361 23099 290247

Black Both Sexes 20500 13640 9750 5271 2215 51376 4115 55491Males 10712 7188 4768 2684 1174 26526 1911 28437Females 9789 6452 4981 2587 1041 24850 2204 27054

Asian Both Sexes 8405 5210 3415 1867 844 19741 + +Pacific Males 4548 2661 1757 1013 407 10386 + +Islander Females 3856 2549 1657 855 437 9355 + +

Hispanic Both Sexes 21339 14049 8272 4881 2136 50676 + +Males 10918 7243 4331 2617 1094 26202 + +Females 10421 6805 3941 2264 1043 24474 + +

Age Specific (Crude) Age-Adjustedc Age at Prevalence All Ages 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ All Ages

Race Sex

All Races Both Sexes 02001 00035 00139 00283 00538 01121 02352 04640 08181 10224 01738Males 02156 00044 00189 00354 00625 01293 02710 05243 09364 12449 02023Females 01850 00026 00087 00208 00450 00952 02010 04094 07196 08856 01498

White Both Sexes 02216 00035 00143 00289 00534 01148 02427 04858 08597 10738 01807Males 02380 00045 00198 00359 00622 01317 02790 05442 09778 13060 02095Females 02054 00025 00085 00214 00442 00976 02072 04317 07593 09285 01560

Black Both Sexes 01139 00029 00113 00265 00599 01027 02010 03340 05117 05333 01251Males 01226 00029 00140 00351 00696 01223 02333 03969 05849 06055 01457Females 01059 00030 00086 00178 00510 00853 01728 02836 04608 04976 01088

Asian Both Sexes 00970 00039 00133 00207 00353 00680 01409 02692 04470 06094 01032Pacific Males 01065 00044 00175 00240 00398 00744 01640 03072 05516 07472 01222Islander Females 00882 00033 00092 00175 00312 00623 01209 02384 03629 05207 00880

Hispanic Both Sexes 00887 00030 00117 00206 00398 00850 01769 03632 05888 07209 01294Males 00908 00035 00147 00256 00455 00932 01924 03940 06326 08003 01420Females 00866 00024 00086 00151 00337 00766 01616 03360 05552 06719 01185

Table 1925Non-Hodgkin Lymphoma

Estimated United States Cancer Prevalence Countsa on January 1 2016By RaceEthnicity Sex and Years Since Diagnosis

Estimated prevalence percenta on January 1 2016 of the SEER population diagnosed in the previous 24 yearsBy Age at Prevalence RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 372 452924 -05 62 18862 04 247 189692 -05 1657 244370 -05

1 Hodgkin Lymphoma 28 32262 -17 13 3927 -06 33 22556 -15 39 5779 -31

2 Non-Hodgkin lymphoma 336 409991 -03 48 14693 04 210 163591 -03 1572 231707 -042(a) Non-Hodgkin lymphoma B-cell 311 380349 -01 39 11836 14 190 148768 -02 1491 219745 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 15 16631 20 31 9416 10 07 5203 39 14 2012 252(a) 2 Mature Non-Hodgkin lymphoma B-cell 280 343965 -04 07 2271 30 174 137225 -05 1387 204469 -042(a) 21 ChronicSmallProlymphocytic 69 85601 -13 00 35 - 35 29103 -11 382 56463 -14

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 61 75061 -15 00 30 - 31 25339 -13 336 49692 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 311 19 - - - 00 72 - 02 234 262(a) 213 Mantle-cell lymphoma 08 10229 03 - - - 04 3692 02 44 6537 04

2(a) 22 Lymphoplasmacytic lymphoma 07 8651 00 - - - 03 2590 -11 41 6059 04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 03 3667 -03 - - - 01 1132 -18 17 2533 022(a) 222 Waldenstrom macroglubulinemia 04 4984 03 - - - 02 1458 -07 24 3526 06

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 72 87188 00 03 925 26 48 36480 -02 339 49783 022(a) 231 DLBCL NOSc 71 85899 -01 03 861 12 46 35469 -05 337 49569 012(a) 232 Intravascular large B-cell 00 162 - - - - 00 63 - 01 99 -

lymphoma2(a) 233 Primary effusion lymphoma 00 181 27 - - - 00 126 - 00 55 -2(a) 234 Mediastinal large B-cell 01 946 116 00 64 - 01 822 111 00 60 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 04 4692 -26 03 1028 32 04 2618 -43 07 1046 -432(a) 25 Marginal-zone lymphoma (MZL) 22 26534 00 00 137 13 14 11049 05 104 15348 -042(a) 251 Splenic MZL 02 2418 04 - - - 01 889 -08 10 1529 102(a) 252 Extranodal MZL MALTc type 13 15979 06 00 92 - 09 7148 11 59 8739 032(a) 253 Nodal MZL 07 8137 -15 00 45 - 04 3012 -05 34 5080 -20

2(a) 26 Follicular lymphoma 35 43582 -21 00 119 - 28 21725 -25 147 21738 -182(a) 27 Hairy-cell leukemia 03 3712 -16 - - - 03 2311 -19 09 1401 -122(a) 28 Plasma cell neoplasms 68 83957 08 00 24 - 39 31325 12 358 52608 062(a) 281 Plasmacytoma 04 4879 -04 00 16 - 03 2362 -06 17 2501 -032(a) 282 Multiple myeloma 64 79078 09 - - - 36 28963 14 341 50107 07

plasma-cell leukemia2(a) 29 Heavy chain disease 00 48 - - - - 00 24 - 00 23 -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 16 19753 33 00 149 27 08 6340 37 90 13264 32

Table 1926All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 23 27222 01 08 2502 18 19 13933 03 73 10787 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 616 - 01 293 - 00 272 - 00 51 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 22 26531 11 07 2207 75 19 13621 12 73 10703 -042(b) 21 Mycosis fungoidesSezary syndrome 06 6969 18 01 213 84 06 4080 23 18 2676 052(b) 211 Mycosis fungoides 06 6739 17 01 213 84 05 3990 22 17 2536 042(b) 212 Sezary syndrome 00 230 46 - - - 00 90 - 01 140 -

2(b) 22 Peripheral T-cell lymphoma 12 14531 -10 02 534 07 10 7159 -09 46 6838 -122(b) 221 Peripheral T-cell lymphoma NOSc 04 5393 -01 00 86 - 03 2489 04 19 2818 -042(b) 222 Angioimmunoblastic T-cell lymphoma 02 1902 02 - - - 01 699 -09 08 1201 072(b) 223 Subcutaneous panniculitis- 00 176 44 00 31 - 00 111 - 00 34 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 2523 -36 01 291 00 02 1450 -33 05 782 -54

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 139 - - - - 00 98 - 00 28 -2(b) 226 Enteropathy-type T-cell lymphoma 00 186 -02 - - - 00 84 - 01 101 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 2963 -07 00 59 - 02 1575 01 09 1329 -142(b) 228 Primary cutaneous anaplastic 01 1249 -41 00 51 - 01 653 -49 04 545 -39

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 03 3417 96 05 1428 101 02 1474 99 03 515 672(b) 24 NKcT-cell lymphoma nasal-type 01 985 02 00 26 - 01 659 00 02 300 05

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 120 - - - - 00 54 - 00 65 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 509 30 - - - 00 195 -05 02 309 442(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 75 - - - - 00 40 - 00 33 -2(c) Non-Hodgkin lymphoma unknown lineage 02 2420 -274 01 355 - 01 890 -216 08 1175 -2792(c) 1 Precursor lymphoblastic leukemia 01 814 -283 01 343 - 00 238 - 02 233 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 95 - - - - 00 25 - 00 69 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 1511 -274 - - - 01 627 -202 06 873 -319

lineage2() 1 Total precursor lymphomaleukemiad 16 18061 -07 33 10052 -15 08 5713 06 15 2296 -01

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 762 273 00 20 - 00 339 227 03 403 -lymphoma

4 Lymphoid neoplasm NOSc 08 9909 -55 01 222 113 04 3206 -59 43 6481 -59

Table 1926 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 461 253152 -05 70 10973 05 294 110367 -07 2122 131812 -05

1 Hodgkin Lymphoma 31 17710 -17 13 2118 -03 36 12525 -16 48 3067 -31

2 Non-Hodgkin lymphoma 419 229772 -03 56 8711 05 252 95756 -05 2017 125305 -032(a) Non-Hodgkin lymphoma B-cell 387 212247 -02 44 6786 15 227 86941 -04 1908 118520 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 16 8999 24 33 5123 11 08 2888 46 16 988 292(a) 2 Mature Non-Hodgkin lymphoma B-cell 351 192801 -05 10 1558 28 210 80417 -08 1783 110826 -042(a) 21 ChronicSmallProlymphocytic 96 52411 -15 00 21 - 47 18927 -14 539 33463 -15

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 82 44988 -17 00 19 - 40 16143 -16 464 28826 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 193 -02 - - - 00 46 - 02 145 052(a) 213 Mantle-cell lymphoma 13 7230 -01 - - - 07 2738 -01 72 4492 -01

2(a) 22 Lymphoplasmacytic lymphoma 10 5082 -05 - - - 04 1524 -08 58 3558 -04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 04 2062 -08 - - - 02 616 -12 23 1446 -072(a) 222 Waldenstrom macroglubulinemia 06 3020 -02 - - - 02 908 -06 34 2112 -02

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 88 48128 01 03 554 22 59 21824 -06 418 25750 052(a) 231 DLBCL NOSc 87 47520 00 03 519 03 57 21366 -08 416 25635 042(a) 232 Intravascular large B-cell 00 75 - - - - 00 31 - 01 44 -

lymphoma2(a) 233 Primary effusion lymphoma 00 167 26 - - - 00 123 - 01 44 -2(a) 234 Mediastinal large B-cell 01 366 155 00 35 - 01 304 142 00 27 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 06 3388 -22 05 775 31 06 1969 -46 10 644 -192(a) 25 Marginal-zone lymphoma (MZL) 22 12351 -02 01 98 - 14 5177 -02 114 7076 -012(a) 251 Splenic MZL 02 1164 14 - - - 01 434 18 12 730 112(a) 252 Extranodal MZL MALTc type 13 7268 07 00 62 - 09 3267 04 63 3939 102(a) 253 Nodal MZL 07 3919 -23 00 36 - 04 1476 -22 39 2407 -23

2(a) 26 Follicular lymphoma 39 21788 -19 01 100 - 30 11210 -25 165 10478 -152(a) 27 Hairy-cell leukemia 05 2984 -18 - - - 05 1908 -20 17 1076 -152(a) 28 Plasma cell neoplasms 85 46642 07 - - - 45 17864 11 462 28769 052(a) 281 Plasmacytoma 05 2997 -08 - - - 04 1509 -16 24 1484 -012(a) 282 Multiple myeloma 80 43645 08 - - - 41 16355 13 439 27285 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 27 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 20 10447 34 01 105 - 10 3636 40 110 6706 32

Table 1927All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 29 16118 00 11 1730 14 23 8235 02 98 6153 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 430 - 01 208 - 01 188 - 01 34 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 28 15642 11 10 1521 71 22 8022 11 97 6099 -032(b) 21 Mycosis fungoidesSezary syndrome 07 3962 19 01 135 - 06 2261 21 25 1566 092(b) 211 Mycosis fungoides 07 3831 20 01 135 - 06 2213 21 23 1483 092(b) 212 Sezary syndrome 00 131 - - - - 00 48 - 01 83 -

2(b) 22 Peripheral T-cell lymphoma 15 8438 -13 02 318 -09 12 4248 -12 62 3872 -132(b) 221 Peripheral T-cell lymphoma NOSc 06 3159 -05 00 49 - 04 1520 02 26 1590 -082(b) 222 Angioimmunoblastic T-cell lymphoma 02 1024 19 - - - 01 415 11 10 607 232(b) 223 Subcutaneous panniculitis- 00 68 - - - - 00 39 - 00 16 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 03 1549 -39 01 184 -01 02 888 -43 08 477 -45

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 98 - - - - 00 69 - 00 18 -2(b) 226 Enteropathy-type T-cell lymphoma 00 105 - - - - 00 50 - 01 54 -2(b) 227 Cutaneous T-cell lymphoma NOSc 03 1696 -12 00 32 - 02 894 -03 12 770 -172(b) 228 Primary cutaneous anaplastic 01 739 -48 00 26 - 01 373 -49 05 340 -49

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 04 2253 97 07 1047 92 03 940 98 04 266 1022(b) 24 NKcT-cell lymphoma nasal-type 01 638 -05 00 18 - 01 435 -03 03 185 -06

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 58 - - - - 00 22 - 01 36 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 01 293 45 - - - 00 116 - 03 174 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 46 - - - - 00 25 - 00 20 -2(c) Non-Hodgkin lymphoma unknown lineage 03 1407 -232 01 195 - 02 580 -184 10 632 -2302(c) 1 Precursor lymphoblastic leukemia 01 474 -228 01 187 - 00 134 - 02 153 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 49 - - - - - - - 01 36 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 02 884 -239 - - - 01 433 -175 07 443 -

lineage2() 1 Total precursor lymphomaleukemiad 18 9903 -06 35 5518 -17 09 3210 09 19 1175 05

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 435 271 - - - 01 215 - 03 207 -lymphoma

4 Lymphoid neoplasm NOSc 10 5235 -59 01 131 - 05 1871 -65 54 3233 -61

Table 1927 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 301 199772 -05 53 7889 02 202 79325 -02 1322 112558 -08

1 Hodgkin Lymphoma 24 14552 -16 12 1809 -10 29 10031 -14 32 2712 -32

2 Non-Hodgkin lymphoma 269 180219 -03 40 5982 03 170 67835 00 1251 106402 -062(a) Non-Hodgkin lymphoma B-cell 250 168102 -01 34 5050 13 154 61827 02 1190 101225 -042(a) 1 Precursor Non-Hodgkin lymphoma B-cell 14 7632 16 29 4293 09 06 2315 29 12 1024 202(a) 2 Mature Non-Hodgkin lymphoma B-cell 223 151164 -04 05 713 35 141 56808 -01 1102 93643 -072(a) 21 ChronicSmallProlymphocytic 48 33190 -13 - - - 24 10176 -05 268 23000 -16

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 43 30073 -15 - - - 22 9196 -06 243 20866 -19

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 118 - - - - 00 26 - 01 89 -2(a) 213 Mantle-cell lymphoma 04 2999 11 - - - 02 954 10 24 2045 12

2(a) 22 Lymphoplasmacytic lymphoma 05 3569 04 - - - 03 1066 -16 30 2501 11Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 02 1605 01 - - - 01 516 -25 13 1087 112(a) 222 Waldenstrom macroglubulinemia 03 1964 06 - - - 01 550 -08 17 1414 11

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 58 39060 00 02 371 33 38 14656 03 283 24033 -032(a) 231 DLBCL NOSc 57 38379 -02 02 342 27 36 14103 -01 282 23934 -032(a) 232 Intravascular large B-cell 00 87 - - - - 00 32 - 01 55 -

lymphoma2(a) 233 Primary effusion lymphoma - - - - - - - - - - - -2(a) 234 Mediastinal large B-cell 01 580 91 00 29 - 02 518 93 00 33 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 02 1304 -34 02 253 38 02 649 -37 05 402 -852(a) 25 Marginal-zone lymphoma (MZL) 21 14183 01 00 39 - 15 5872 12 98 8272 -062(a) 251 Splenic MZL 02 1254 -07 - - - 01 455 -32 10 799 072(a) 252 Extranodal MZL MALTc type 13 8711 06 00 30 - 10 3881 17 57 4800 -032(a) 253 Nodal MZL 06 4218 -07 - - - 04 1536 11 32 2673 -18

2(a) 26 Follicular lymphoma 33 21794 -24 00 19 - 27 10515 -25 134 11260 -222(a) 27 Hairy-cell leukemia 01 728 -12 - - - 01 403 -11 04 325 -122(a) 28 Plasma cell neoplasms 55 37315 08 - - - 33 13461 15 282 23839 052(a) 281 Plasmacytoma 03 1882 00 - - - 02 853 12 12 1017 -092(a) 282 Multiple myeloma 52 35433 09 - - - 30 12608 15 270 22822 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 21 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 14 9306 32 00 44 - 07 2704 32 76 6558 31

Table 1928All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 17 11104 01 05 772 29 15 5698 05 55 4634 -112(b) 1 Precursor Non-Hodgkin lymphoma T-cell 00 186 - 01 85 - 00 84 - 00 17 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 17 10889 09 05 686 83 15 5599 12 54 4604 -092(b) 21 Mycosis fungoidesSezary syndrome 05 3007 15 01 78 - 05 1819 26 13 1110 -042(b) 211 Mycosis fungoides 05 2908 12 01 78 - 05 1777 23 12 1053 -072(b) 212 Sezary syndrome 00 99 - - - - 00 42 - 01 57 -

2(b) 22 Peripheral T-cell lymphoma 09 6093 -08 01 216 30 08 2911 -06 35 2966 -142(b) 221 Peripheral T-cell lymphoma NOSc 03 2234 03 00 37 - 03 969 07 14 1228 -012(b) 222 Angioimmunoblastic T-cell lymphoma 01 878 -22 - - - 01 284 -39 07 594 -152(b) 223 Subcutaneous panniculitis- 00 108 - 00 18 - 00 72 - 00 18 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 974 -33 01 107 - 02 562 -19 04 305 -77

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 41 - - - - 00 29 - - - -2(b) 226 Enteropathy-type T-cell lymphoma 00 81 - - - - 00 34 - 01 47 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 1267 00 00 27 - 02 681 07 07 559 -102(b) 228 Primary cutaneous anaplastic 01 510 -34 00 25 - 01 280 -50 02 205 -33

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 02 1164 96 03 381 127 01 534 97 03 249 302(b) 24 NKcT-cell lymphoma nasal-type 01 347 11 - - - 01 224 - 01 115 -

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 62 - - - - 00 32 - 00 29 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 216 03 - - - 00 79 - 02 135 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 29 - - - - - - - - - -2(c) Non-Hodgkin lymphoma unknown lineage 02 1013 -341 01 160 - 01 310 - 06 543 -2(c) 1 Precursor lymphoblastic leukemia 01 340 - 01 156 - 00 104 - 01 80 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 46 - - - - - - - 00 33 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 627 - - - - 01 194 - 05 430 -

lineage2() 1 Total precursor lymphomaleukemiad 14 8158 -09 31 4534 -13 07 2503 02 13 1121 -11

3 Composite Hodgkin lymphoma and Non-Hodgkin 00 327 - - - - 00 124 - 02 196 -lymphoma

4 Lymphoid neoplasm NOSc 07 4674 -52 01 91 - 03 1335 -51 36 3248 -58

Table 1928 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 24: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

a US Mortality Files National Center for Health Statistics Centers for Disease Control andPrevention Rates are per 100000 and are age-adjusted to the 2000 US Std Population (19age groups - Census P25-1130)

b Difference between state rate and total US rate is statistically significant (plt=0002)c Absolute percent difference between state rate and total US rate is 15 or mored Rank of state level death rate and the 95 confidence intervals (low high) for the rankSE Standard error of the ratePD Percent difference between state rate and total US rate- Statistic not shown Rate based on less than 16 cases for the time interval

State Rate SE Rank(CI)d PD TOTAL US 436 002

High Five StatesIdaho 510 033 01(0139) 1697c

Maine 497 031 02(0141) 1396Michigan 495 012 03(0119) 1340Oklahoma 492 020 04(0128) 1276Indiana 492 016 05(0123) 1270

Low Five StatesMississippi 404 021 47(1351) -731Nevada 382 022 48(2051) -1237Colorado 369 016 49(3451) -1540c

Hawaii 352 027 50(2551) -1932c

DC 323 044 51(1551) -2601c

State Rate SE Rank(CI)d PD State Rate SE Rank(CI)d PD

Alabama 440 017 24(0547) 099 Montana 435 036 27(0151) -034Alaska 414 058 38(0151) -500 Nebraska 435 027 26(0249) -032Arizona 407 014 44(2049) -664 Nevada 382 022 48(2051) -1237Arkansas 428 021 31(0649) -181 New Hampshire 454 032 19(0149) 400California 423 006 34(2244) -313 New Jersey 419 012 37(1848) -397Colorado 369 016 49(3451) -1540c New Mexico 405 025 46(0951) -706Connecticut 407 018 45(1550) -669 New York 412 008 39(2548) -554Delaware 473 039 12(0150) 855 North Carolina 420 012 35(1848) -374DC 323 044 51(1551) -2601c North Dakota 471 045 13(0150) 809Florida 412 007 40(2548) -564 Ohio 478 011 10(0123) 967Georgia 411 012 43(2049) -582 Oklahoma 492 020 04(0128) 1276Hawaii 352 027 50(2551) -1932c Oregon 465 019 15(0141) 668Idaho 510 033 01(0139) 1697c Pennsylvania 467 010 14(0427) 714Illinois 439 010 25(1341) 074 Rhode Island 455 035 18(0150) 434Indiana 492 016 05(0123) 1270 South Carolina 432 017 30(0947) -102Iowa 484 021 08(0135) 1087 South Dakota 411 039 42(0151) -580Kansas 486 023 06(0137) 1143 Tennessee 484 015 09(0126) 1087Kentucky 460 018 17(0241) 544 Texas 427 008 32(1944) -213Louisiana 451 018 21(0345) 333 Utah 433 026 28(0250) -081Maine 497 031 02(0141) 1396 Vermont 461 047 16(0151) 578Maryland 411 015 41(1749) -576 Virginia 432 013 29(1246) -092Massachusetts 423 014 33(1548) -303 Washington 452 015 20(0541) 360Michigan 495 012 03(0119) 1340 West Virginia 486 027 07(0143) 1141Minnesota 475 017 11(0132) 901 Wisconsin 443 015 23(0645) 156Mississippi 404 021 47(1351) -731 Wyoming 445 051 22(0151) 192Missouri 419 014 36(1549) -396

Table 1924Non-Hodgkin Lymphoma

Age-Adjusted Cancer Deatha Rates By State All Races 2012-2016

Females

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 Areas (excluding the AlaskaNative Registry) and 112016 US population estimates based on the average of 2015 and 2016 population estimates from theUS Bureau of the CensusPrevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 24 years

b Maximum limited-duration prevalence is 24 years for 1992-2016 datac Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groupsd Cases diagnosed more than 24 years ago were estimated using the completeness index method (Capocaccia et al 1997

Merrill et al 2000)e Complete prevalence is obtained by summing 0 to lt24 and gt=24- Statistic not shown Statistic based on fewer than 5 cases estimated alive in SEER for the time interval+ Not available

Years Since Diagnosis 0 to lt5 5 to lt10 10 to lt15 15 to lt20 20 to lt24 0 to lt24b gt=24d Completee

Race Sex

All Races Both Sexes 248946 177490 117326 69109 31890 644761 49943 694704Males 135137 94173 60159 36020 16581 342069 25489 367558Females 113809 83317 57167 33089 15309 302692 24454 327146

White Both Sexes 213764 154454 101984 60537 28026 558765 49625 620368Males 116527 82172 52535 31627 14543 297404 26526 330121Females 97237 72282 49448 28910 13483 261361 23099 290247

Black Both Sexes 20500 13640 9750 5271 2215 51376 4115 55491Males 10712 7188 4768 2684 1174 26526 1911 28437Females 9789 6452 4981 2587 1041 24850 2204 27054

Asian Both Sexes 8405 5210 3415 1867 844 19741 + +Pacific Males 4548 2661 1757 1013 407 10386 + +Islander Females 3856 2549 1657 855 437 9355 + +

Hispanic Both Sexes 21339 14049 8272 4881 2136 50676 + +Males 10918 7243 4331 2617 1094 26202 + +Females 10421 6805 3941 2264 1043 24474 + +

Age Specific (Crude) Age-Adjustedc Age at Prevalence All Ages 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ All Ages

Race Sex

All Races Both Sexes 02001 00035 00139 00283 00538 01121 02352 04640 08181 10224 01738Males 02156 00044 00189 00354 00625 01293 02710 05243 09364 12449 02023Females 01850 00026 00087 00208 00450 00952 02010 04094 07196 08856 01498

White Both Sexes 02216 00035 00143 00289 00534 01148 02427 04858 08597 10738 01807Males 02380 00045 00198 00359 00622 01317 02790 05442 09778 13060 02095Females 02054 00025 00085 00214 00442 00976 02072 04317 07593 09285 01560

Black Both Sexes 01139 00029 00113 00265 00599 01027 02010 03340 05117 05333 01251Males 01226 00029 00140 00351 00696 01223 02333 03969 05849 06055 01457Females 01059 00030 00086 00178 00510 00853 01728 02836 04608 04976 01088

Asian Both Sexes 00970 00039 00133 00207 00353 00680 01409 02692 04470 06094 01032Pacific Males 01065 00044 00175 00240 00398 00744 01640 03072 05516 07472 01222Islander Females 00882 00033 00092 00175 00312 00623 01209 02384 03629 05207 00880

Hispanic Both Sexes 00887 00030 00117 00206 00398 00850 01769 03632 05888 07209 01294Males 00908 00035 00147 00256 00455 00932 01924 03940 06326 08003 01420Females 00866 00024 00086 00151 00337 00766 01616 03360 05552 06719 01185

Table 1925Non-Hodgkin Lymphoma

Estimated United States Cancer Prevalence Countsa on January 1 2016By RaceEthnicity Sex and Years Since Diagnosis

Estimated prevalence percenta on January 1 2016 of the SEER population diagnosed in the previous 24 yearsBy Age at Prevalence RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 372 452924 -05 62 18862 04 247 189692 -05 1657 244370 -05

1 Hodgkin Lymphoma 28 32262 -17 13 3927 -06 33 22556 -15 39 5779 -31

2 Non-Hodgkin lymphoma 336 409991 -03 48 14693 04 210 163591 -03 1572 231707 -042(a) Non-Hodgkin lymphoma B-cell 311 380349 -01 39 11836 14 190 148768 -02 1491 219745 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 15 16631 20 31 9416 10 07 5203 39 14 2012 252(a) 2 Mature Non-Hodgkin lymphoma B-cell 280 343965 -04 07 2271 30 174 137225 -05 1387 204469 -042(a) 21 ChronicSmallProlymphocytic 69 85601 -13 00 35 - 35 29103 -11 382 56463 -14

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 61 75061 -15 00 30 - 31 25339 -13 336 49692 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 311 19 - - - 00 72 - 02 234 262(a) 213 Mantle-cell lymphoma 08 10229 03 - - - 04 3692 02 44 6537 04

2(a) 22 Lymphoplasmacytic lymphoma 07 8651 00 - - - 03 2590 -11 41 6059 04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 03 3667 -03 - - - 01 1132 -18 17 2533 022(a) 222 Waldenstrom macroglubulinemia 04 4984 03 - - - 02 1458 -07 24 3526 06

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 72 87188 00 03 925 26 48 36480 -02 339 49783 022(a) 231 DLBCL NOSc 71 85899 -01 03 861 12 46 35469 -05 337 49569 012(a) 232 Intravascular large B-cell 00 162 - - - - 00 63 - 01 99 -

lymphoma2(a) 233 Primary effusion lymphoma 00 181 27 - - - 00 126 - 00 55 -2(a) 234 Mediastinal large B-cell 01 946 116 00 64 - 01 822 111 00 60 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 04 4692 -26 03 1028 32 04 2618 -43 07 1046 -432(a) 25 Marginal-zone lymphoma (MZL) 22 26534 00 00 137 13 14 11049 05 104 15348 -042(a) 251 Splenic MZL 02 2418 04 - - - 01 889 -08 10 1529 102(a) 252 Extranodal MZL MALTc type 13 15979 06 00 92 - 09 7148 11 59 8739 032(a) 253 Nodal MZL 07 8137 -15 00 45 - 04 3012 -05 34 5080 -20

2(a) 26 Follicular lymphoma 35 43582 -21 00 119 - 28 21725 -25 147 21738 -182(a) 27 Hairy-cell leukemia 03 3712 -16 - - - 03 2311 -19 09 1401 -122(a) 28 Plasma cell neoplasms 68 83957 08 00 24 - 39 31325 12 358 52608 062(a) 281 Plasmacytoma 04 4879 -04 00 16 - 03 2362 -06 17 2501 -032(a) 282 Multiple myeloma 64 79078 09 - - - 36 28963 14 341 50107 07

plasma-cell leukemia2(a) 29 Heavy chain disease 00 48 - - - - 00 24 - 00 23 -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 16 19753 33 00 149 27 08 6340 37 90 13264 32

Table 1926All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 23 27222 01 08 2502 18 19 13933 03 73 10787 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 616 - 01 293 - 00 272 - 00 51 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 22 26531 11 07 2207 75 19 13621 12 73 10703 -042(b) 21 Mycosis fungoidesSezary syndrome 06 6969 18 01 213 84 06 4080 23 18 2676 052(b) 211 Mycosis fungoides 06 6739 17 01 213 84 05 3990 22 17 2536 042(b) 212 Sezary syndrome 00 230 46 - - - 00 90 - 01 140 -

2(b) 22 Peripheral T-cell lymphoma 12 14531 -10 02 534 07 10 7159 -09 46 6838 -122(b) 221 Peripheral T-cell lymphoma NOSc 04 5393 -01 00 86 - 03 2489 04 19 2818 -042(b) 222 Angioimmunoblastic T-cell lymphoma 02 1902 02 - - - 01 699 -09 08 1201 072(b) 223 Subcutaneous panniculitis- 00 176 44 00 31 - 00 111 - 00 34 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 2523 -36 01 291 00 02 1450 -33 05 782 -54

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 139 - - - - 00 98 - 00 28 -2(b) 226 Enteropathy-type T-cell lymphoma 00 186 -02 - - - 00 84 - 01 101 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 2963 -07 00 59 - 02 1575 01 09 1329 -142(b) 228 Primary cutaneous anaplastic 01 1249 -41 00 51 - 01 653 -49 04 545 -39

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 03 3417 96 05 1428 101 02 1474 99 03 515 672(b) 24 NKcT-cell lymphoma nasal-type 01 985 02 00 26 - 01 659 00 02 300 05

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 120 - - - - 00 54 - 00 65 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 509 30 - - - 00 195 -05 02 309 442(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 75 - - - - 00 40 - 00 33 -2(c) Non-Hodgkin lymphoma unknown lineage 02 2420 -274 01 355 - 01 890 -216 08 1175 -2792(c) 1 Precursor lymphoblastic leukemia 01 814 -283 01 343 - 00 238 - 02 233 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 95 - - - - 00 25 - 00 69 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 1511 -274 - - - 01 627 -202 06 873 -319

lineage2() 1 Total precursor lymphomaleukemiad 16 18061 -07 33 10052 -15 08 5713 06 15 2296 -01

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 762 273 00 20 - 00 339 227 03 403 -lymphoma

4 Lymphoid neoplasm NOSc 08 9909 -55 01 222 113 04 3206 -59 43 6481 -59

Table 1926 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 461 253152 -05 70 10973 05 294 110367 -07 2122 131812 -05

1 Hodgkin Lymphoma 31 17710 -17 13 2118 -03 36 12525 -16 48 3067 -31

2 Non-Hodgkin lymphoma 419 229772 -03 56 8711 05 252 95756 -05 2017 125305 -032(a) Non-Hodgkin lymphoma B-cell 387 212247 -02 44 6786 15 227 86941 -04 1908 118520 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 16 8999 24 33 5123 11 08 2888 46 16 988 292(a) 2 Mature Non-Hodgkin lymphoma B-cell 351 192801 -05 10 1558 28 210 80417 -08 1783 110826 -042(a) 21 ChronicSmallProlymphocytic 96 52411 -15 00 21 - 47 18927 -14 539 33463 -15

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 82 44988 -17 00 19 - 40 16143 -16 464 28826 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 193 -02 - - - 00 46 - 02 145 052(a) 213 Mantle-cell lymphoma 13 7230 -01 - - - 07 2738 -01 72 4492 -01

2(a) 22 Lymphoplasmacytic lymphoma 10 5082 -05 - - - 04 1524 -08 58 3558 -04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 04 2062 -08 - - - 02 616 -12 23 1446 -072(a) 222 Waldenstrom macroglubulinemia 06 3020 -02 - - - 02 908 -06 34 2112 -02

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 88 48128 01 03 554 22 59 21824 -06 418 25750 052(a) 231 DLBCL NOSc 87 47520 00 03 519 03 57 21366 -08 416 25635 042(a) 232 Intravascular large B-cell 00 75 - - - - 00 31 - 01 44 -

lymphoma2(a) 233 Primary effusion lymphoma 00 167 26 - - - 00 123 - 01 44 -2(a) 234 Mediastinal large B-cell 01 366 155 00 35 - 01 304 142 00 27 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 06 3388 -22 05 775 31 06 1969 -46 10 644 -192(a) 25 Marginal-zone lymphoma (MZL) 22 12351 -02 01 98 - 14 5177 -02 114 7076 -012(a) 251 Splenic MZL 02 1164 14 - - - 01 434 18 12 730 112(a) 252 Extranodal MZL MALTc type 13 7268 07 00 62 - 09 3267 04 63 3939 102(a) 253 Nodal MZL 07 3919 -23 00 36 - 04 1476 -22 39 2407 -23

2(a) 26 Follicular lymphoma 39 21788 -19 01 100 - 30 11210 -25 165 10478 -152(a) 27 Hairy-cell leukemia 05 2984 -18 - - - 05 1908 -20 17 1076 -152(a) 28 Plasma cell neoplasms 85 46642 07 - - - 45 17864 11 462 28769 052(a) 281 Plasmacytoma 05 2997 -08 - - - 04 1509 -16 24 1484 -012(a) 282 Multiple myeloma 80 43645 08 - - - 41 16355 13 439 27285 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 27 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 20 10447 34 01 105 - 10 3636 40 110 6706 32

Table 1927All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 29 16118 00 11 1730 14 23 8235 02 98 6153 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 430 - 01 208 - 01 188 - 01 34 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 28 15642 11 10 1521 71 22 8022 11 97 6099 -032(b) 21 Mycosis fungoidesSezary syndrome 07 3962 19 01 135 - 06 2261 21 25 1566 092(b) 211 Mycosis fungoides 07 3831 20 01 135 - 06 2213 21 23 1483 092(b) 212 Sezary syndrome 00 131 - - - - 00 48 - 01 83 -

2(b) 22 Peripheral T-cell lymphoma 15 8438 -13 02 318 -09 12 4248 -12 62 3872 -132(b) 221 Peripheral T-cell lymphoma NOSc 06 3159 -05 00 49 - 04 1520 02 26 1590 -082(b) 222 Angioimmunoblastic T-cell lymphoma 02 1024 19 - - - 01 415 11 10 607 232(b) 223 Subcutaneous panniculitis- 00 68 - - - - 00 39 - 00 16 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 03 1549 -39 01 184 -01 02 888 -43 08 477 -45

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 98 - - - - 00 69 - 00 18 -2(b) 226 Enteropathy-type T-cell lymphoma 00 105 - - - - 00 50 - 01 54 -2(b) 227 Cutaneous T-cell lymphoma NOSc 03 1696 -12 00 32 - 02 894 -03 12 770 -172(b) 228 Primary cutaneous anaplastic 01 739 -48 00 26 - 01 373 -49 05 340 -49

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 04 2253 97 07 1047 92 03 940 98 04 266 1022(b) 24 NKcT-cell lymphoma nasal-type 01 638 -05 00 18 - 01 435 -03 03 185 -06

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 58 - - - - 00 22 - 01 36 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 01 293 45 - - - 00 116 - 03 174 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 46 - - - - 00 25 - 00 20 -2(c) Non-Hodgkin lymphoma unknown lineage 03 1407 -232 01 195 - 02 580 -184 10 632 -2302(c) 1 Precursor lymphoblastic leukemia 01 474 -228 01 187 - 00 134 - 02 153 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 49 - - - - - - - 01 36 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 02 884 -239 - - - 01 433 -175 07 443 -

lineage2() 1 Total precursor lymphomaleukemiad 18 9903 -06 35 5518 -17 09 3210 09 19 1175 05

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 435 271 - - - 01 215 - 03 207 -lymphoma

4 Lymphoid neoplasm NOSc 10 5235 -59 01 131 - 05 1871 -65 54 3233 -61

Table 1927 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 301 199772 -05 53 7889 02 202 79325 -02 1322 112558 -08

1 Hodgkin Lymphoma 24 14552 -16 12 1809 -10 29 10031 -14 32 2712 -32

2 Non-Hodgkin lymphoma 269 180219 -03 40 5982 03 170 67835 00 1251 106402 -062(a) Non-Hodgkin lymphoma B-cell 250 168102 -01 34 5050 13 154 61827 02 1190 101225 -042(a) 1 Precursor Non-Hodgkin lymphoma B-cell 14 7632 16 29 4293 09 06 2315 29 12 1024 202(a) 2 Mature Non-Hodgkin lymphoma B-cell 223 151164 -04 05 713 35 141 56808 -01 1102 93643 -072(a) 21 ChronicSmallProlymphocytic 48 33190 -13 - - - 24 10176 -05 268 23000 -16

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 43 30073 -15 - - - 22 9196 -06 243 20866 -19

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 118 - - - - 00 26 - 01 89 -2(a) 213 Mantle-cell lymphoma 04 2999 11 - - - 02 954 10 24 2045 12

2(a) 22 Lymphoplasmacytic lymphoma 05 3569 04 - - - 03 1066 -16 30 2501 11Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 02 1605 01 - - - 01 516 -25 13 1087 112(a) 222 Waldenstrom macroglubulinemia 03 1964 06 - - - 01 550 -08 17 1414 11

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 58 39060 00 02 371 33 38 14656 03 283 24033 -032(a) 231 DLBCL NOSc 57 38379 -02 02 342 27 36 14103 -01 282 23934 -032(a) 232 Intravascular large B-cell 00 87 - - - - 00 32 - 01 55 -

lymphoma2(a) 233 Primary effusion lymphoma - - - - - - - - - - - -2(a) 234 Mediastinal large B-cell 01 580 91 00 29 - 02 518 93 00 33 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 02 1304 -34 02 253 38 02 649 -37 05 402 -852(a) 25 Marginal-zone lymphoma (MZL) 21 14183 01 00 39 - 15 5872 12 98 8272 -062(a) 251 Splenic MZL 02 1254 -07 - - - 01 455 -32 10 799 072(a) 252 Extranodal MZL MALTc type 13 8711 06 00 30 - 10 3881 17 57 4800 -032(a) 253 Nodal MZL 06 4218 -07 - - - 04 1536 11 32 2673 -18

2(a) 26 Follicular lymphoma 33 21794 -24 00 19 - 27 10515 -25 134 11260 -222(a) 27 Hairy-cell leukemia 01 728 -12 - - - 01 403 -11 04 325 -122(a) 28 Plasma cell neoplasms 55 37315 08 - - - 33 13461 15 282 23839 052(a) 281 Plasmacytoma 03 1882 00 - - - 02 853 12 12 1017 -092(a) 282 Multiple myeloma 52 35433 09 - - - 30 12608 15 270 22822 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 21 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 14 9306 32 00 44 - 07 2704 32 76 6558 31

Table 1928All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 17 11104 01 05 772 29 15 5698 05 55 4634 -112(b) 1 Precursor Non-Hodgkin lymphoma T-cell 00 186 - 01 85 - 00 84 - 00 17 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 17 10889 09 05 686 83 15 5599 12 54 4604 -092(b) 21 Mycosis fungoidesSezary syndrome 05 3007 15 01 78 - 05 1819 26 13 1110 -042(b) 211 Mycosis fungoides 05 2908 12 01 78 - 05 1777 23 12 1053 -072(b) 212 Sezary syndrome 00 99 - - - - 00 42 - 01 57 -

2(b) 22 Peripheral T-cell lymphoma 09 6093 -08 01 216 30 08 2911 -06 35 2966 -142(b) 221 Peripheral T-cell lymphoma NOSc 03 2234 03 00 37 - 03 969 07 14 1228 -012(b) 222 Angioimmunoblastic T-cell lymphoma 01 878 -22 - - - 01 284 -39 07 594 -152(b) 223 Subcutaneous panniculitis- 00 108 - 00 18 - 00 72 - 00 18 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 974 -33 01 107 - 02 562 -19 04 305 -77

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 41 - - - - 00 29 - - - -2(b) 226 Enteropathy-type T-cell lymphoma 00 81 - - - - 00 34 - 01 47 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 1267 00 00 27 - 02 681 07 07 559 -102(b) 228 Primary cutaneous anaplastic 01 510 -34 00 25 - 01 280 -50 02 205 -33

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 02 1164 96 03 381 127 01 534 97 03 249 302(b) 24 NKcT-cell lymphoma nasal-type 01 347 11 - - - 01 224 - 01 115 -

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 62 - - - - 00 32 - 00 29 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 216 03 - - - 00 79 - 02 135 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 29 - - - - - - - - - -2(c) Non-Hodgkin lymphoma unknown lineage 02 1013 -341 01 160 - 01 310 - 06 543 -2(c) 1 Precursor lymphoblastic leukemia 01 340 - 01 156 - 00 104 - 01 80 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 46 - - - - - - - 00 33 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 627 - - - - 01 194 - 05 430 -

lineage2() 1 Total precursor lymphomaleukemiad 14 8158 -09 31 4534 -13 07 2503 02 13 1121 -11

3 Composite Hodgkin lymphoma and Non-Hodgkin 00 327 - - - - 00 124 - 02 196 -lymphoma

4 Lymphoid neoplasm NOSc 07 4674 -52 01 91 - 03 1335 -51 36 3248 -58

Table 1928 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 25: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a US 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 Areas (excluding the AlaskaNative Registry) and 112016 US population estimates based on the average of 2015 and 2016 population estimates from theUS Bureau of the CensusPrevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 24 years

b Maximum limited-duration prevalence is 24 years for 1992-2016 datac Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groupsd Cases diagnosed more than 24 years ago were estimated using the completeness index method (Capocaccia et al 1997

Merrill et al 2000)e Complete prevalence is obtained by summing 0 to lt24 and gt=24- Statistic not shown Statistic based on fewer than 5 cases estimated alive in SEER for the time interval+ Not available

Years Since Diagnosis 0 to lt5 5 to lt10 10 to lt15 15 to lt20 20 to lt24 0 to lt24b gt=24d Completee

Race Sex

All Races Both Sexes 248946 177490 117326 69109 31890 644761 49943 694704Males 135137 94173 60159 36020 16581 342069 25489 367558Females 113809 83317 57167 33089 15309 302692 24454 327146

White Both Sexes 213764 154454 101984 60537 28026 558765 49625 620368Males 116527 82172 52535 31627 14543 297404 26526 330121Females 97237 72282 49448 28910 13483 261361 23099 290247

Black Both Sexes 20500 13640 9750 5271 2215 51376 4115 55491Males 10712 7188 4768 2684 1174 26526 1911 28437Females 9789 6452 4981 2587 1041 24850 2204 27054

Asian Both Sexes 8405 5210 3415 1867 844 19741 + +Pacific Males 4548 2661 1757 1013 407 10386 + +Islander Females 3856 2549 1657 855 437 9355 + +

Hispanic Both Sexes 21339 14049 8272 4881 2136 50676 + +Males 10918 7243 4331 2617 1094 26202 + +Females 10421 6805 3941 2264 1043 24474 + +

Age Specific (Crude) Age-Adjustedc Age at Prevalence All Ages 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ All Ages

Race Sex

All Races Both Sexes 02001 00035 00139 00283 00538 01121 02352 04640 08181 10224 01738Males 02156 00044 00189 00354 00625 01293 02710 05243 09364 12449 02023Females 01850 00026 00087 00208 00450 00952 02010 04094 07196 08856 01498

White Both Sexes 02216 00035 00143 00289 00534 01148 02427 04858 08597 10738 01807Males 02380 00045 00198 00359 00622 01317 02790 05442 09778 13060 02095Females 02054 00025 00085 00214 00442 00976 02072 04317 07593 09285 01560

Black Both Sexes 01139 00029 00113 00265 00599 01027 02010 03340 05117 05333 01251Males 01226 00029 00140 00351 00696 01223 02333 03969 05849 06055 01457Females 01059 00030 00086 00178 00510 00853 01728 02836 04608 04976 01088

Asian Both Sexes 00970 00039 00133 00207 00353 00680 01409 02692 04470 06094 01032Pacific Males 01065 00044 00175 00240 00398 00744 01640 03072 05516 07472 01222Islander Females 00882 00033 00092 00175 00312 00623 01209 02384 03629 05207 00880

Hispanic Both Sexes 00887 00030 00117 00206 00398 00850 01769 03632 05888 07209 01294Males 00908 00035 00147 00256 00455 00932 01924 03940 06326 08003 01420Females 00866 00024 00086 00151 00337 00766 01616 03360 05552 06719 01185

Table 1925Non-Hodgkin Lymphoma

Estimated United States Cancer Prevalence Countsa on January 1 2016By RaceEthnicity Sex and Years Since Diagnosis

Estimated prevalence percenta on January 1 2016 of the SEER population diagnosed in the previous 24 yearsBy Age at Prevalence RaceEthnicity and Sex

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 372 452924 -05 62 18862 04 247 189692 -05 1657 244370 -05

1 Hodgkin Lymphoma 28 32262 -17 13 3927 -06 33 22556 -15 39 5779 -31

2 Non-Hodgkin lymphoma 336 409991 -03 48 14693 04 210 163591 -03 1572 231707 -042(a) Non-Hodgkin lymphoma B-cell 311 380349 -01 39 11836 14 190 148768 -02 1491 219745 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 15 16631 20 31 9416 10 07 5203 39 14 2012 252(a) 2 Mature Non-Hodgkin lymphoma B-cell 280 343965 -04 07 2271 30 174 137225 -05 1387 204469 -042(a) 21 ChronicSmallProlymphocytic 69 85601 -13 00 35 - 35 29103 -11 382 56463 -14

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 61 75061 -15 00 30 - 31 25339 -13 336 49692 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 311 19 - - - 00 72 - 02 234 262(a) 213 Mantle-cell lymphoma 08 10229 03 - - - 04 3692 02 44 6537 04

2(a) 22 Lymphoplasmacytic lymphoma 07 8651 00 - - - 03 2590 -11 41 6059 04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 03 3667 -03 - - - 01 1132 -18 17 2533 022(a) 222 Waldenstrom macroglubulinemia 04 4984 03 - - - 02 1458 -07 24 3526 06

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 72 87188 00 03 925 26 48 36480 -02 339 49783 022(a) 231 DLBCL NOSc 71 85899 -01 03 861 12 46 35469 -05 337 49569 012(a) 232 Intravascular large B-cell 00 162 - - - - 00 63 - 01 99 -

lymphoma2(a) 233 Primary effusion lymphoma 00 181 27 - - - 00 126 - 00 55 -2(a) 234 Mediastinal large B-cell 01 946 116 00 64 - 01 822 111 00 60 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 04 4692 -26 03 1028 32 04 2618 -43 07 1046 -432(a) 25 Marginal-zone lymphoma (MZL) 22 26534 00 00 137 13 14 11049 05 104 15348 -042(a) 251 Splenic MZL 02 2418 04 - - - 01 889 -08 10 1529 102(a) 252 Extranodal MZL MALTc type 13 15979 06 00 92 - 09 7148 11 59 8739 032(a) 253 Nodal MZL 07 8137 -15 00 45 - 04 3012 -05 34 5080 -20

2(a) 26 Follicular lymphoma 35 43582 -21 00 119 - 28 21725 -25 147 21738 -182(a) 27 Hairy-cell leukemia 03 3712 -16 - - - 03 2311 -19 09 1401 -122(a) 28 Plasma cell neoplasms 68 83957 08 00 24 - 39 31325 12 358 52608 062(a) 281 Plasmacytoma 04 4879 -04 00 16 - 03 2362 -06 17 2501 -032(a) 282 Multiple myeloma 64 79078 09 - - - 36 28963 14 341 50107 07

plasma-cell leukemia2(a) 29 Heavy chain disease 00 48 - - - - 00 24 - 00 23 -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 16 19753 33 00 149 27 08 6340 37 90 13264 32

Table 1926All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 23 27222 01 08 2502 18 19 13933 03 73 10787 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 616 - 01 293 - 00 272 - 00 51 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 22 26531 11 07 2207 75 19 13621 12 73 10703 -042(b) 21 Mycosis fungoidesSezary syndrome 06 6969 18 01 213 84 06 4080 23 18 2676 052(b) 211 Mycosis fungoides 06 6739 17 01 213 84 05 3990 22 17 2536 042(b) 212 Sezary syndrome 00 230 46 - - - 00 90 - 01 140 -

2(b) 22 Peripheral T-cell lymphoma 12 14531 -10 02 534 07 10 7159 -09 46 6838 -122(b) 221 Peripheral T-cell lymphoma NOSc 04 5393 -01 00 86 - 03 2489 04 19 2818 -042(b) 222 Angioimmunoblastic T-cell lymphoma 02 1902 02 - - - 01 699 -09 08 1201 072(b) 223 Subcutaneous panniculitis- 00 176 44 00 31 - 00 111 - 00 34 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 2523 -36 01 291 00 02 1450 -33 05 782 -54

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 139 - - - - 00 98 - 00 28 -2(b) 226 Enteropathy-type T-cell lymphoma 00 186 -02 - - - 00 84 - 01 101 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 2963 -07 00 59 - 02 1575 01 09 1329 -142(b) 228 Primary cutaneous anaplastic 01 1249 -41 00 51 - 01 653 -49 04 545 -39

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 03 3417 96 05 1428 101 02 1474 99 03 515 672(b) 24 NKcT-cell lymphoma nasal-type 01 985 02 00 26 - 01 659 00 02 300 05

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 120 - - - - 00 54 - 00 65 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 509 30 - - - 00 195 -05 02 309 442(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 75 - - - - 00 40 - 00 33 -2(c) Non-Hodgkin lymphoma unknown lineage 02 2420 -274 01 355 - 01 890 -216 08 1175 -2792(c) 1 Precursor lymphoblastic leukemia 01 814 -283 01 343 - 00 238 - 02 233 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 95 - - - - 00 25 - 00 69 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 1511 -274 - - - 01 627 -202 06 873 -319

lineage2() 1 Total precursor lymphomaleukemiad 16 18061 -07 33 10052 -15 08 5713 06 15 2296 -01

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 762 273 00 20 - 00 339 227 03 403 -lymphoma

4 Lymphoid neoplasm NOSc 08 9909 -55 01 222 113 04 3206 -59 43 6481 -59

Table 1926 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 461 253152 -05 70 10973 05 294 110367 -07 2122 131812 -05

1 Hodgkin Lymphoma 31 17710 -17 13 2118 -03 36 12525 -16 48 3067 -31

2 Non-Hodgkin lymphoma 419 229772 -03 56 8711 05 252 95756 -05 2017 125305 -032(a) Non-Hodgkin lymphoma B-cell 387 212247 -02 44 6786 15 227 86941 -04 1908 118520 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 16 8999 24 33 5123 11 08 2888 46 16 988 292(a) 2 Mature Non-Hodgkin lymphoma B-cell 351 192801 -05 10 1558 28 210 80417 -08 1783 110826 -042(a) 21 ChronicSmallProlymphocytic 96 52411 -15 00 21 - 47 18927 -14 539 33463 -15

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 82 44988 -17 00 19 - 40 16143 -16 464 28826 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 193 -02 - - - 00 46 - 02 145 052(a) 213 Mantle-cell lymphoma 13 7230 -01 - - - 07 2738 -01 72 4492 -01

2(a) 22 Lymphoplasmacytic lymphoma 10 5082 -05 - - - 04 1524 -08 58 3558 -04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 04 2062 -08 - - - 02 616 -12 23 1446 -072(a) 222 Waldenstrom macroglubulinemia 06 3020 -02 - - - 02 908 -06 34 2112 -02

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 88 48128 01 03 554 22 59 21824 -06 418 25750 052(a) 231 DLBCL NOSc 87 47520 00 03 519 03 57 21366 -08 416 25635 042(a) 232 Intravascular large B-cell 00 75 - - - - 00 31 - 01 44 -

lymphoma2(a) 233 Primary effusion lymphoma 00 167 26 - - - 00 123 - 01 44 -2(a) 234 Mediastinal large B-cell 01 366 155 00 35 - 01 304 142 00 27 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 06 3388 -22 05 775 31 06 1969 -46 10 644 -192(a) 25 Marginal-zone lymphoma (MZL) 22 12351 -02 01 98 - 14 5177 -02 114 7076 -012(a) 251 Splenic MZL 02 1164 14 - - - 01 434 18 12 730 112(a) 252 Extranodal MZL MALTc type 13 7268 07 00 62 - 09 3267 04 63 3939 102(a) 253 Nodal MZL 07 3919 -23 00 36 - 04 1476 -22 39 2407 -23

2(a) 26 Follicular lymphoma 39 21788 -19 01 100 - 30 11210 -25 165 10478 -152(a) 27 Hairy-cell leukemia 05 2984 -18 - - - 05 1908 -20 17 1076 -152(a) 28 Plasma cell neoplasms 85 46642 07 - - - 45 17864 11 462 28769 052(a) 281 Plasmacytoma 05 2997 -08 - - - 04 1509 -16 24 1484 -012(a) 282 Multiple myeloma 80 43645 08 - - - 41 16355 13 439 27285 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 27 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 20 10447 34 01 105 - 10 3636 40 110 6706 32

Table 1927All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 29 16118 00 11 1730 14 23 8235 02 98 6153 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 430 - 01 208 - 01 188 - 01 34 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 28 15642 11 10 1521 71 22 8022 11 97 6099 -032(b) 21 Mycosis fungoidesSezary syndrome 07 3962 19 01 135 - 06 2261 21 25 1566 092(b) 211 Mycosis fungoides 07 3831 20 01 135 - 06 2213 21 23 1483 092(b) 212 Sezary syndrome 00 131 - - - - 00 48 - 01 83 -

2(b) 22 Peripheral T-cell lymphoma 15 8438 -13 02 318 -09 12 4248 -12 62 3872 -132(b) 221 Peripheral T-cell lymphoma NOSc 06 3159 -05 00 49 - 04 1520 02 26 1590 -082(b) 222 Angioimmunoblastic T-cell lymphoma 02 1024 19 - - - 01 415 11 10 607 232(b) 223 Subcutaneous panniculitis- 00 68 - - - - 00 39 - 00 16 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 03 1549 -39 01 184 -01 02 888 -43 08 477 -45

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 98 - - - - 00 69 - 00 18 -2(b) 226 Enteropathy-type T-cell lymphoma 00 105 - - - - 00 50 - 01 54 -2(b) 227 Cutaneous T-cell lymphoma NOSc 03 1696 -12 00 32 - 02 894 -03 12 770 -172(b) 228 Primary cutaneous anaplastic 01 739 -48 00 26 - 01 373 -49 05 340 -49

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 04 2253 97 07 1047 92 03 940 98 04 266 1022(b) 24 NKcT-cell lymphoma nasal-type 01 638 -05 00 18 - 01 435 -03 03 185 -06

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 58 - - - - 00 22 - 01 36 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 01 293 45 - - - 00 116 - 03 174 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 46 - - - - 00 25 - 00 20 -2(c) Non-Hodgkin lymphoma unknown lineage 03 1407 -232 01 195 - 02 580 -184 10 632 -2302(c) 1 Precursor lymphoblastic leukemia 01 474 -228 01 187 - 00 134 - 02 153 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 49 - - - - - - - 01 36 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 02 884 -239 - - - 01 433 -175 07 443 -

lineage2() 1 Total precursor lymphomaleukemiad 18 9903 -06 35 5518 -17 09 3210 09 19 1175 05

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 435 271 - - - 01 215 - 03 207 -lymphoma

4 Lymphoid neoplasm NOSc 10 5235 -59 01 131 - 05 1871 -65 54 3233 -61

Table 1927 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 301 199772 -05 53 7889 02 202 79325 -02 1322 112558 -08

1 Hodgkin Lymphoma 24 14552 -16 12 1809 -10 29 10031 -14 32 2712 -32

2 Non-Hodgkin lymphoma 269 180219 -03 40 5982 03 170 67835 00 1251 106402 -062(a) Non-Hodgkin lymphoma B-cell 250 168102 -01 34 5050 13 154 61827 02 1190 101225 -042(a) 1 Precursor Non-Hodgkin lymphoma B-cell 14 7632 16 29 4293 09 06 2315 29 12 1024 202(a) 2 Mature Non-Hodgkin lymphoma B-cell 223 151164 -04 05 713 35 141 56808 -01 1102 93643 -072(a) 21 ChronicSmallProlymphocytic 48 33190 -13 - - - 24 10176 -05 268 23000 -16

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 43 30073 -15 - - - 22 9196 -06 243 20866 -19

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 118 - - - - 00 26 - 01 89 -2(a) 213 Mantle-cell lymphoma 04 2999 11 - - - 02 954 10 24 2045 12

2(a) 22 Lymphoplasmacytic lymphoma 05 3569 04 - - - 03 1066 -16 30 2501 11Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 02 1605 01 - - - 01 516 -25 13 1087 112(a) 222 Waldenstrom macroglubulinemia 03 1964 06 - - - 01 550 -08 17 1414 11

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 58 39060 00 02 371 33 38 14656 03 283 24033 -032(a) 231 DLBCL NOSc 57 38379 -02 02 342 27 36 14103 -01 282 23934 -032(a) 232 Intravascular large B-cell 00 87 - - - - 00 32 - 01 55 -

lymphoma2(a) 233 Primary effusion lymphoma - - - - - - - - - - - -2(a) 234 Mediastinal large B-cell 01 580 91 00 29 - 02 518 93 00 33 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 02 1304 -34 02 253 38 02 649 -37 05 402 -852(a) 25 Marginal-zone lymphoma (MZL) 21 14183 01 00 39 - 15 5872 12 98 8272 -062(a) 251 Splenic MZL 02 1254 -07 - - - 01 455 -32 10 799 072(a) 252 Extranodal MZL MALTc type 13 8711 06 00 30 - 10 3881 17 57 4800 -032(a) 253 Nodal MZL 06 4218 -07 - - - 04 1536 11 32 2673 -18

2(a) 26 Follicular lymphoma 33 21794 -24 00 19 - 27 10515 -25 134 11260 -222(a) 27 Hairy-cell leukemia 01 728 -12 - - - 01 403 -11 04 325 -122(a) 28 Plasma cell neoplasms 55 37315 08 - - - 33 13461 15 282 23839 052(a) 281 Plasmacytoma 03 1882 00 - - - 02 853 12 12 1017 -092(a) 282 Multiple myeloma 52 35433 09 - - - 30 12608 15 270 22822 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 21 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 14 9306 32 00 44 - 07 2704 32 76 6558 31

Table 1928All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 17 11104 01 05 772 29 15 5698 05 55 4634 -112(b) 1 Precursor Non-Hodgkin lymphoma T-cell 00 186 - 01 85 - 00 84 - 00 17 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 17 10889 09 05 686 83 15 5599 12 54 4604 -092(b) 21 Mycosis fungoidesSezary syndrome 05 3007 15 01 78 - 05 1819 26 13 1110 -042(b) 211 Mycosis fungoides 05 2908 12 01 78 - 05 1777 23 12 1053 -072(b) 212 Sezary syndrome 00 99 - - - - 00 42 - 01 57 -

2(b) 22 Peripheral T-cell lymphoma 09 6093 -08 01 216 30 08 2911 -06 35 2966 -142(b) 221 Peripheral T-cell lymphoma NOSc 03 2234 03 00 37 - 03 969 07 14 1228 -012(b) 222 Angioimmunoblastic T-cell lymphoma 01 878 -22 - - - 01 284 -39 07 594 -152(b) 223 Subcutaneous panniculitis- 00 108 - 00 18 - 00 72 - 00 18 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 974 -33 01 107 - 02 562 -19 04 305 -77

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 41 - - - - 00 29 - - - -2(b) 226 Enteropathy-type T-cell lymphoma 00 81 - - - - 00 34 - 01 47 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 1267 00 00 27 - 02 681 07 07 559 -102(b) 228 Primary cutaneous anaplastic 01 510 -34 00 25 - 01 280 -50 02 205 -33

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 02 1164 96 03 381 127 01 534 97 03 249 302(b) 24 NKcT-cell lymphoma nasal-type 01 347 11 - - - 01 224 - 01 115 -

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 62 - - - - 00 32 - 00 29 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 216 03 - - - 00 79 - 02 135 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 29 - - - - - - - - - -2(c) Non-Hodgkin lymphoma unknown lineage 02 1013 -341 01 160 - 01 310 - 06 543 -2(c) 1 Precursor lymphoblastic leukemia 01 340 - 01 156 - 00 104 - 01 80 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 46 - - - - - - - 00 33 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 627 - - - - 01 194 - 05 430 -

lineage2() 1 Total precursor lymphomaleukemiad 14 8158 -09 31 4534 -13 07 2503 02 13 1121 -11

3 Composite Hodgkin lymphoma and Non-Hodgkin 00 327 - - - - 00 124 - 02 196 -lymphoma

4 Lymphoid neoplasm NOSc 07 4674 -52 01 91 - 03 1335 -51 36 3248 -58

Table 1928 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 26: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 372 452924 -05 62 18862 04 247 189692 -05 1657 244370 -05

1 Hodgkin Lymphoma 28 32262 -17 13 3927 -06 33 22556 -15 39 5779 -31

2 Non-Hodgkin lymphoma 336 409991 -03 48 14693 04 210 163591 -03 1572 231707 -042(a) Non-Hodgkin lymphoma B-cell 311 380349 -01 39 11836 14 190 148768 -02 1491 219745 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 15 16631 20 31 9416 10 07 5203 39 14 2012 252(a) 2 Mature Non-Hodgkin lymphoma B-cell 280 343965 -04 07 2271 30 174 137225 -05 1387 204469 -042(a) 21 ChronicSmallProlymphocytic 69 85601 -13 00 35 - 35 29103 -11 382 56463 -14

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 61 75061 -15 00 30 - 31 25339 -13 336 49692 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 311 19 - - - 00 72 - 02 234 262(a) 213 Mantle-cell lymphoma 08 10229 03 - - - 04 3692 02 44 6537 04

2(a) 22 Lymphoplasmacytic lymphoma 07 8651 00 - - - 03 2590 -11 41 6059 04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 03 3667 -03 - - - 01 1132 -18 17 2533 022(a) 222 Waldenstrom macroglubulinemia 04 4984 03 - - - 02 1458 -07 24 3526 06

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 72 87188 00 03 925 26 48 36480 -02 339 49783 022(a) 231 DLBCL NOSc 71 85899 -01 03 861 12 46 35469 -05 337 49569 012(a) 232 Intravascular large B-cell 00 162 - - - - 00 63 - 01 99 -

lymphoma2(a) 233 Primary effusion lymphoma 00 181 27 - - - 00 126 - 00 55 -2(a) 234 Mediastinal large B-cell 01 946 116 00 64 - 01 822 111 00 60 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 04 4692 -26 03 1028 32 04 2618 -43 07 1046 -432(a) 25 Marginal-zone lymphoma (MZL) 22 26534 00 00 137 13 14 11049 05 104 15348 -042(a) 251 Splenic MZL 02 2418 04 - - - 01 889 -08 10 1529 102(a) 252 Extranodal MZL MALTc type 13 15979 06 00 92 - 09 7148 11 59 8739 032(a) 253 Nodal MZL 07 8137 -15 00 45 - 04 3012 -05 34 5080 -20

2(a) 26 Follicular lymphoma 35 43582 -21 00 119 - 28 21725 -25 147 21738 -182(a) 27 Hairy-cell leukemia 03 3712 -16 - - - 03 2311 -19 09 1401 -122(a) 28 Plasma cell neoplasms 68 83957 08 00 24 - 39 31325 12 358 52608 062(a) 281 Plasmacytoma 04 4879 -04 00 16 - 03 2362 -06 17 2501 -032(a) 282 Multiple myeloma 64 79078 09 - - - 36 28963 14 341 50107 07

plasma-cell leukemia2(a) 29 Heavy chain disease 00 48 - - - - 00 24 - 00 23 -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 16 19753 33 00 149 27 08 6340 37 90 13264 32

Table 1926All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 23 27222 01 08 2502 18 19 13933 03 73 10787 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 616 - 01 293 - 00 272 - 00 51 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 22 26531 11 07 2207 75 19 13621 12 73 10703 -042(b) 21 Mycosis fungoidesSezary syndrome 06 6969 18 01 213 84 06 4080 23 18 2676 052(b) 211 Mycosis fungoides 06 6739 17 01 213 84 05 3990 22 17 2536 042(b) 212 Sezary syndrome 00 230 46 - - - 00 90 - 01 140 -

2(b) 22 Peripheral T-cell lymphoma 12 14531 -10 02 534 07 10 7159 -09 46 6838 -122(b) 221 Peripheral T-cell lymphoma NOSc 04 5393 -01 00 86 - 03 2489 04 19 2818 -042(b) 222 Angioimmunoblastic T-cell lymphoma 02 1902 02 - - - 01 699 -09 08 1201 072(b) 223 Subcutaneous panniculitis- 00 176 44 00 31 - 00 111 - 00 34 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 2523 -36 01 291 00 02 1450 -33 05 782 -54

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 139 - - - - 00 98 - 00 28 -2(b) 226 Enteropathy-type T-cell lymphoma 00 186 -02 - - - 00 84 - 01 101 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 2963 -07 00 59 - 02 1575 01 09 1329 -142(b) 228 Primary cutaneous anaplastic 01 1249 -41 00 51 - 01 653 -49 04 545 -39

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 03 3417 96 05 1428 101 02 1474 99 03 515 672(b) 24 NKcT-cell lymphoma nasal-type 01 985 02 00 26 - 01 659 00 02 300 05

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 120 - - - - 00 54 - 00 65 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 509 30 - - - 00 195 -05 02 309 442(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 75 - - - - 00 40 - 00 33 -2(c) Non-Hodgkin lymphoma unknown lineage 02 2420 -274 01 355 - 01 890 -216 08 1175 -2792(c) 1 Precursor lymphoblastic leukemia 01 814 -283 01 343 - 00 238 - 02 233 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 95 - - - - 00 25 - 00 69 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 1511 -274 - - - 01 627 -202 06 873 -319

lineage2() 1 Total precursor lymphomaleukemiad 16 18061 -07 33 10052 -15 08 5713 06 15 2296 -01

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 762 273 00 20 - 00 339 227 03 403 -lymphoma

4 Lymphoid neoplasm NOSc 08 9909 -55 01 222 113 04 3206 -59 43 6481 -59

Table 1926 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 461 253152 -05 70 10973 05 294 110367 -07 2122 131812 -05

1 Hodgkin Lymphoma 31 17710 -17 13 2118 -03 36 12525 -16 48 3067 -31

2 Non-Hodgkin lymphoma 419 229772 -03 56 8711 05 252 95756 -05 2017 125305 -032(a) Non-Hodgkin lymphoma B-cell 387 212247 -02 44 6786 15 227 86941 -04 1908 118520 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 16 8999 24 33 5123 11 08 2888 46 16 988 292(a) 2 Mature Non-Hodgkin lymphoma B-cell 351 192801 -05 10 1558 28 210 80417 -08 1783 110826 -042(a) 21 ChronicSmallProlymphocytic 96 52411 -15 00 21 - 47 18927 -14 539 33463 -15

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 82 44988 -17 00 19 - 40 16143 -16 464 28826 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 193 -02 - - - 00 46 - 02 145 052(a) 213 Mantle-cell lymphoma 13 7230 -01 - - - 07 2738 -01 72 4492 -01

2(a) 22 Lymphoplasmacytic lymphoma 10 5082 -05 - - - 04 1524 -08 58 3558 -04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 04 2062 -08 - - - 02 616 -12 23 1446 -072(a) 222 Waldenstrom macroglubulinemia 06 3020 -02 - - - 02 908 -06 34 2112 -02

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 88 48128 01 03 554 22 59 21824 -06 418 25750 052(a) 231 DLBCL NOSc 87 47520 00 03 519 03 57 21366 -08 416 25635 042(a) 232 Intravascular large B-cell 00 75 - - - - 00 31 - 01 44 -

lymphoma2(a) 233 Primary effusion lymphoma 00 167 26 - - - 00 123 - 01 44 -2(a) 234 Mediastinal large B-cell 01 366 155 00 35 - 01 304 142 00 27 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 06 3388 -22 05 775 31 06 1969 -46 10 644 -192(a) 25 Marginal-zone lymphoma (MZL) 22 12351 -02 01 98 - 14 5177 -02 114 7076 -012(a) 251 Splenic MZL 02 1164 14 - - - 01 434 18 12 730 112(a) 252 Extranodal MZL MALTc type 13 7268 07 00 62 - 09 3267 04 63 3939 102(a) 253 Nodal MZL 07 3919 -23 00 36 - 04 1476 -22 39 2407 -23

2(a) 26 Follicular lymphoma 39 21788 -19 01 100 - 30 11210 -25 165 10478 -152(a) 27 Hairy-cell leukemia 05 2984 -18 - - - 05 1908 -20 17 1076 -152(a) 28 Plasma cell neoplasms 85 46642 07 - - - 45 17864 11 462 28769 052(a) 281 Plasmacytoma 05 2997 -08 - - - 04 1509 -16 24 1484 -012(a) 282 Multiple myeloma 80 43645 08 - - - 41 16355 13 439 27285 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 27 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 20 10447 34 01 105 - 10 3636 40 110 6706 32

Table 1927All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 29 16118 00 11 1730 14 23 8235 02 98 6153 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 430 - 01 208 - 01 188 - 01 34 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 28 15642 11 10 1521 71 22 8022 11 97 6099 -032(b) 21 Mycosis fungoidesSezary syndrome 07 3962 19 01 135 - 06 2261 21 25 1566 092(b) 211 Mycosis fungoides 07 3831 20 01 135 - 06 2213 21 23 1483 092(b) 212 Sezary syndrome 00 131 - - - - 00 48 - 01 83 -

2(b) 22 Peripheral T-cell lymphoma 15 8438 -13 02 318 -09 12 4248 -12 62 3872 -132(b) 221 Peripheral T-cell lymphoma NOSc 06 3159 -05 00 49 - 04 1520 02 26 1590 -082(b) 222 Angioimmunoblastic T-cell lymphoma 02 1024 19 - - - 01 415 11 10 607 232(b) 223 Subcutaneous panniculitis- 00 68 - - - - 00 39 - 00 16 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 03 1549 -39 01 184 -01 02 888 -43 08 477 -45

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 98 - - - - 00 69 - 00 18 -2(b) 226 Enteropathy-type T-cell lymphoma 00 105 - - - - 00 50 - 01 54 -2(b) 227 Cutaneous T-cell lymphoma NOSc 03 1696 -12 00 32 - 02 894 -03 12 770 -172(b) 228 Primary cutaneous anaplastic 01 739 -48 00 26 - 01 373 -49 05 340 -49

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 04 2253 97 07 1047 92 03 940 98 04 266 1022(b) 24 NKcT-cell lymphoma nasal-type 01 638 -05 00 18 - 01 435 -03 03 185 -06

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 58 - - - - 00 22 - 01 36 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 01 293 45 - - - 00 116 - 03 174 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 46 - - - - 00 25 - 00 20 -2(c) Non-Hodgkin lymphoma unknown lineage 03 1407 -232 01 195 - 02 580 -184 10 632 -2302(c) 1 Precursor lymphoblastic leukemia 01 474 -228 01 187 - 00 134 - 02 153 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 49 - - - - - - - 01 36 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 02 884 -239 - - - 01 433 -175 07 443 -

lineage2() 1 Total precursor lymphomaleukemiad 18 9903 -06 35 5518 -17 09 3210 09 19 1175 05

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 435 271 - - - 01 215 - 03 207 -lymphoma

4 Lymphoid neoplasm NOSc 10 5235 -59 01 131 - 05 1871 -65 54 3233 -61

Table 1927 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 301 199772 -05 53 7889 02 202 79325 -02 1322 112558 -08

1 Hodgkin Lymphoma 24 14552 -16 12 1809 -10 29 10031 -14 32 2712 -32

2 Non-Hodgkin lymphoma 269 180219 -03 40 5982 03 170 67835 00 1251 106402 -062(a) Non-Hodgkin lymphoma B-cell 250 168102 -01 34 5050 13 154 61827 02 1190 101225 -042(a) 1 Precursor Non-Hodgkin lymphoma B-cell 14 7632 16 29 4293 09 06 2315 29 12 1024 202(a) 2 Mature Non-Hodgkin lymphoma B-cell 223 151164 -04 05 713 35 141 56808 -01 1102 93643 -072(a) 21 ChronicSmallProlymphocytic 48 33190 -13 - - - 24 10176 -05 268 23000 -16

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 43 30073 -15 - - - 22 9196 -06 243 20866 -19

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 118 - - - - 00 26 - 01 89 -2(a) 213 Mantle-cell lymphoma 04 2999 11 - - - 02 954 10 24 2045 12

2(a) 22 Lymphoplasmacytic lymphoma 05 3569 04 - - - 03 1066 -16 30 2501 11Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 02 1605 01 - - - 01 516 -25 13 1087 112(a) 222 Waldenstrom macroglubulinemia 03 1964 06 - - - 01 550 -08 17 1414 11

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 58 39060 00 02 371 33 38 14656 03 283 24033 -032(a) 231 DLBCL NOSc 57 38379 -02 02 342 27 36 14103 -01 282 23934 -032(a) 232 Intravascular large B-cell 00 87 - - - - 00 32 - 01 55 -

lymphoma2(a) 233 Primary effusion lymphoma - - - - - - - - - - - -2(a) 234 Mediastinal large B-cell 01 580 91 00 29 - 02 518 93 00 33 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 02 1304 -34 02 253 38 02 649 -37 05 402 -852(a) 25 Marginal-zone lymphoma (MZL) 21 14183 01 00 39 - 15 5872 12 98 8272 -062(a) 251 Splenic MZL 02 1254 -07 - - - 01 455 -32 10 799 072(a) 252 Extranodal MZL MALTc type 13 8711 06 00 30 - 10 3881 17 57 4800 -032(a) 253 Nodal MZL 06 4218 -07 - - - 04 1536 11 32 2673 -18

2(a) 26 Follicular lymphoma 33 21794 -24 00 19 - 27 10515 -25 134 11260 -222(a) 27 Hairy-cell leukemia 01 728 -12 - - - 01 403 -11 04 325 -122(a) 28 Plasma cell neoplasms 55 37315 08 - - - 33 13461 15 282 23839 052(a) 281 Plasmacytoma 03 1882 00 - - - 02 853 12 12 1017 -092(a) 282 Multiple myeloma 52 35433 09 - - - 30 12608 15 270 22822 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 21 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 14 9306 32 00 44 - 07 2704 32 76 6558 31

Table 1928All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 17 11104 01 05 772 29 15 5698 05 55 4634 -112(b) 1 Precursor Non-Hodgkin lymphoma T-cell 00 186 - 01 85 - 00 84 - 00 17 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 17 10889 09 05 686 83 15 5599 12 54 4604 -092(b) 21 Mycosis fungoidesSezary syndrome 05 3007 15 01 78 - 05 1819 26 13 1110 -042(b) 211 Mycosis fungoides 05 2908 12 01 78 - 05 1777 23 12 1053 -072(b) 212 Sezary syndrome 00 99 - - - - 00 42 - 01 57 -

2(b) 22 Peripheral T-cell lymphoma 09 6093 -08 01 216 30 08 2911 -06 35 2966 -142(b) 221 Peripheral T-cell lymphoma NOSc 03 2234 03 00 37 - 03 969 07 14 1228 -012(b) 222 Angioimmunoblastic T-cell lymphoma 01 878 -22 - - - 01 284 -39 07 594 -152(b) 223 Subcutaneous panniculitis- 00 108 - 00 18 - 00 72 - 00 18 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 974 -33 01 107 - 02 562 -19 04 305 -77

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 41 - - - - 00 29 - - - -2(b) 226 Enteropathy-type T-cell lymphoma 00 81 - - - - 00 34 - 01 47 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 1267 00 00 27 - 02 681 07 07 559 -102(b) 228 Primary cutaneous anaplastic 01 510 -34 00 25 - 01 280 -50 02 205 -33

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 02 1164 96 03 381 127 01 534 97 03 249 302(b) 24 NKcT-cell lymphoma nasal-type 01 347 11 - - - 01 224 - 01 115 -

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 62 - - - - 00 32 - 00 29 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 216 03 - - - 00 79 - 02 135 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 29 - - - - - - - - - -2(c) Non-Hodgkin lymphoma unknown lineage 02 1013 -341 01 160 - 01 310 - 06 543 -2(c) 1 Precursor lymphoblastic leukemia 01 340 - 01 156 - 00 104 - 01 80 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 46 - - - - - - - 00 33 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 627 - - - - 01 194 - 05 430 -

lineage2() 1 Total precursor lymphomaleukemiad 14 8158 -09 31 4534 -13 07 2503 02 13 1121 -11

3 Composite Hodgkin lymphoma and Non-Hodgkin 00 327 - - - - 00 124 - 02 196 -lymphoma

4 Lymphoid neoplasm NOSc 07 4674 -52 01 91 - 03 1335 -51 36 3248 -58

Table 1928 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 27: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 23 27222 01 08 2502 18 19 13933 03 73 10787 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 616 - 01 293 - 00 272 - 00 51 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 22 26531 11 07 2207 75 19 13621 12 73 10703 -042(b) 21 Mycosis fungoidesSezary syndrome 06 6969 18 01 213 84 06 4080 23 18 2676 052(b) 211 Mycosis fungoides 06 6739 17 01 213 84 05 3990 22 17 2536 042(b) 212 Sezary syndrome 00 230 46 - - - 00 90 - 01 140 -

2(b) 22 Peripheral T-cell lymphoma 12 14531 -10 02 534 07 10 7159 -09 46 6838 -122(b) 221 Peripheral T-cell lymphoma NOSc 04 5393 -01 00 86 - 03 2489 04 19 2818 -042(b) 222 Angioimmunoblastic T-cell lymphoma 02 1902 02 - - - 01 699 -09 08 1201 072(b) 223 Subcutaneous panniculitis- 00 176 44 00 31 - 00 111 - 00 34 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 2523 -36 01 291 00 02 1450 -33 05 782 -54

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 139 - - - - 00 98 - 00 28 -2(b) 226 Enteropathy-type T-cell lymphoma 00 186 -02 - - - 00 84 - 01 101 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 2963 -07 00 59 - 02 1575 01 09 1329 -142(b) 228 Primary cutaneous anaplastic 01 1249 -41 00 51 - 01 653 -49 04 545 -39

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 03 3417 96 05 1428 101 02 1474 99 03 515 672(b) 24 NKcT-cell lymphoma nasal-type 01 985 02 00 26 - 01 659 00 02 300 05

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 120 - - - - 00 54 - 00 65 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 509 30 - - - 00 195 -05 02 309 442(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 75 - - - - 00 40 - 00 33 -2(c) Non-Hodgkin lymphoma unknown lineage 02 2420 -274 01 355 - 01 890 -216 08 1175 -2792(c) 1 Precursor lymphoblastic leukemia 01 814 -283 01 343 - 00 238 - 02 233 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 95 - - - - 00 25 - 00 69 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 1511 -274 - - - 01 627 -202 06 873 -319

lineage2() 1 Total precursor lymphomaleukemiad 16 18061 -07 33 10052 -15 08 5713 06 15 2296 -01

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 762 273 00 20 - 00 339 227 03 403 -lymphoma

4 Lymphoid neoplasm NOSc 08 9909 -55 01 222 113 04 3206 -59 43 6481 -59

Table 1926 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Both Sexes 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 461 253152 -05 70 10973 05 294 110367 -07 2122 131812 -05

1 Hodgkin Lymphoma 31 17710 -17 13 2118 -03 36 12525 -16 48 3067 -31

2 Non-Hodgkin lymphoma 419 229772 -03 56 8711 05 252 95756 -05 2017 125305 -032(a) Non-Hodgkin lymphoma B-cell 387 212247 -02 44 6786 15 227 86941 -04 1908 118520 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 16 8999 24 33 5123 11 08 2888 46 16 988 292(a) 2 Mature Non-Hodgkin lymphoma B-cell 351 192801 -05 10 1558 28 210 80417 -08 1783 110826 -042(a) 21 ChronicSmallProlymphocytic 96 52411 -15 00 21 - 47 18927 -14 539 33463 -15

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 82 44988 -17 00 19 - 40 16143 -16 464 28826 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 193 -02 - - - 00 46 - 02 145 052(a) 213 Mantle-cell lymphoma 13 7230 -01 - - - 07 2738 -01 72 4492 -01

2(a) 22 Lymphoplasmacytic lymphoma 10 5082 -05 - - - 04 1524 -08 58 3558 -04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 04 2062 -08 - - - 02 616 -12 23 1446 -072(a) 222 Waldenstrom macroglubulinemia 06 3020 -02 - - - 02 908 -06 34 2112 -02

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 88 48128 01 03 554 22 59 21824 -06 418 25750 052(a) 231 DLBCL NOSc 87 47520 00 03 519 03 57 21366 -08 416 25635 042(a) 232 Intravascular large B-cell 00 75 - - - - 00 31 - 01 44 -

lymphoma2(a) 233 Primary effusion lymphoma 00 167 26 - - - 00 123 - 01 44 -2(a) 234 Mediastinal large B-cell 01 366 155 00 35 - 01 304 142 00 27 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 06 3388 -22 05 775 31 06 1969 -46 10 644 -192(a) 25 Marginal-zone lymphoma (MZL) 22 12351 -02 01 98 - 14 5177 -02 114 7076 -012(a) 251 Splenic MZL 02 1164 14 - - - 01 434 18 12 730 112(a) 252 Extranodal MZL MALTc type 13 7268 07 00 62 - 09 3267 04 63 3939 102(a) 253 Nodal MZL 07 3919 -23 00 36 - 04 1476 -22 39 2407 -23

2(a) 26 Follicular lymphoma 39 21788 -19 01 100 - 30 11210 -25 165 10478 -152(a) 27 Hairy-cell leukemia 05 2984 -18 - - - 05 1908 -20 17 1076 -152(a) 28 Plasma cell neoplasms 85 46642 07 - - - 45 17864 11 462 28769 052(a) 281 Plasmacytoma 05 2997 -08 - - - 04 1509 -16 24 1484 -012(a) 282 Multiple myeloma 80 43645 08 - - - 41 16355 13 439 27285 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 27 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 20 10447 34 01 105 - 10 3636 40 110 6706 32

Table 1927All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 29 16118 00 11 1730 14 23 8235 02 98 6153 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 430 - 01 208 - 01 188 - 01 34 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 28 15642 11 10 1521 71 22 8022 11 97 6099 -032(b) 21 Mycosis fungoidesSezary syndrome 07 3962 19 01 135 - 06 2261 21 25 1566 092(b) 211 Mycosis fungoides 07 3831 20 01 135 - 06 2213 21 23 1483 092(b) 212 Sezary syndrome 00 131 - - - - 00 48 - 01 83 -

2(b) 22 Peripheral T-cell lymphoma 15 8438 -13 02 318 -09 12 4248 -12 62 3872 -132(b) 221 Peripheral T-cell lymphoma NOSc 06 3159 -05 00 49 - 04 1520 02 26 1590 -082(b) 222 Angioimmunoblastic T-cell lymphoma 02 1024 19 - - - 01 415 11 10 607 232(b) 223 Subcutaneous panniculitis- 00 68 - - - - 00 39 - 00 16 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 03 1549 -39 01 184 -01 02 888 -43 08 477 -45

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 98 - - - - 00 69 - 00 18 -2(b) 226 Enteropathy-type T-cell lymphoma 00 105 - - - - 00 50 - 01 54 -2(b) 227 Cutaneous T-cell lymphoma NOSc 03 1696 -12 00 32 - 02 894 -03 12 770 -172(b) 228 Primary cutaneous anaplastic 01 739 -48 00 26 - 01 373 -49 05 340 -49

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 04 2253 97 07 1047 92 03 940 98 04 266 1022(b) 24 NKcT-cell lymphoma nasal-type 01 638 -05 00 18 - 01 435 -03 03 185 -06

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 58 - - - - 00 22 - 01 36 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 01 293 45 - - - 00 116 - 03 174 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 46 - - - - 00 25 - 00 20 -2(c) Non-Hodgkin lymphoma unknown lineage 03 1407 -232 01 195 - 02 580 -184 10 632 -2302(c) 1 Precursor lymphoblastic leukemia 01 474 -228 01 187 - 00 134 - 02 153 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 49 - - - - - - - 01 36 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 02 884 -239 - - - 01 433 -175 07 443 -

lineage2() 1 Total precursor lymphomaleukemiad 18 9903 -06 35 5518 -17 09 3210 09 19 1175 05

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 435 271 - - - 01 215 - 03 207 -lymphoma

4 Lymphoid neoplasm NOSc 10 5235 -59 01 131 - 05 1871 -65 54 3233 -61

Table 1927 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 301 199772 -05 53 7889 02 202 79325 -02 1322 112558 -08

1 Hodgkin Lymphoma 24 14552 -16 12 1809 -10 29 10031 -14 32 2712 -32

2 Non-Hodgkin lymphoma 269 180219 -03 40 5982 03 170 67835 00 1251 106402 -062(a) Non-Hodgkin lymphoma B-cell 250 168102 -01 34 5050 13 154 61827 02 1190 101225 -042(a) 1 Precursor Non-Hodgkin lymphoma B-cell 14 7632 16 29 4293 09 06 2315 29 12 1024 202(a) 2 Mature Non-Hodgkin lymphoma B-cell 223 151164 -04 05 713 35 141 56808 -01 1102 93643 -072(a) 21 ChronicSmallProlymphocytic 48 33190 -13 - - - 24 10176 -05 268 23000 -16

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 43 30073 -15 - - - 22 9196 -06 243 20866 -19

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 118 - - - - 00 26 - 01 89 -2(a) 213 Mantle-cell lymphoma 04 2999 11 - - - 02 954 10 24 2045 12

2(a) 22 Lymphoplasmacytic lymphoma 05 3569 04 - - - 03 1066 -16 30 2501 11Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 02 1605 01 - - - 01 516 -25 13 1087 112(a) 222 Waldenstrom macroglubulinemia 03 1964 06 - - - 01 550 -08 17 1414 11

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 58 39060 00 02 371 33 38 14656 03 283 24033 -032(a) 231 DLBCL NOSc 57 38379 -02 02 342 27 36 14103 -01 282 23934 -032(a) 232 Intravascular large B-cell 00 87 - - - - 00 32 - 01 55 -

lymphoma2(a) 233 Primary effusion lymphoma - - - - - - - - - - - -2(a) 234 Mediastinal large B-cell 01 580 91 00 29 - 02 518 93 00 33 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 02 1304 -34 02 253 38 02 649 -37 05 402 -852(a) 25 Marginal-zone lymphoma (MZL) 21 14183 01 00 39 - 15 5872 12 98 8272 -062(a) 251 Splenic MZL 02 1254 -07 - - - 01 455 -32 10 799 072(a) 252 Extranodal MZL MALTc type 13 8711 06 00 30 - 10 3881 17 57 4800 -032(a) 253 Nodal MZL 06 4218 -07 - - - 04 1536 11 32 2673 -18

2(a) 26 Follicular lymphoma 33 21794 -24 00 19 - 27 10515 -25 134 11260 -222(a) 27 Hairy-cell leukemia 01 728 -12 - - - 01 403 -11 04 325 -122(a) 28 Plasma cell neoplasms 55 37315 08 - - - 33 13461 15 282 23839 052(a) 281 Plasmacytoma 03 1882 00 - - - 02 853 12 12 1017 -092(a) 282 Multiple myeloma 52 35433 09 - - - 30 12608 15 270 22822 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 21 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 14 9306 32 00 44 - 07 2704 32 76 6558 31

Table 1928All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 17 11104 01 05 772 29 15 5698 05 55 4634 -112(b) 1 Precursor Non-Hodgkin lymphoma T-cell 00 186 - 01 85 - 00 84 - 00 17 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 17 10889 09 05 686 83 15 5599 12 54 4604 -092(b) 21 Mycosis fungoidesSezary syndrome 05 3007 15 01 78 - 05 1819 26 13 1110 -042(b) 211 Mycosis fungoides 05 2908 12 01 78 - 05 1777 23 12 1053 -072(b) 212 Sezary syndrome 00 99 - - - - 00 42 - 01 57 -

2(b) 22 Peripheral T-cell lymphoma 09 6093 -08 01 216 30 08 2911 -06 35 2966 -142(b) 221 Peripheral T-cell lymphoma NOSc 03 2234 03 00 37 - 03 969 07 14 1228 -012(b) 222 Angioimmunoblastic T-cell lymphoma 01 878 -22 - - - 01 284 -39 07 594 -152(b) 223 Subcutaneous panniculitis- 00 108 - 00 18 - 00 72 - 00 18 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 974 -33 01 107 - 02 562 -19 04 305 -77

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 41 - - - - 00 29 - - - -2(b) 226 Enteropathy-type T-cell lymphoma 00 81 - - - - 00 34 - 01 47 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 1267 00 00 27 - 02 681 07 07 559 -102(b) 228 Primary cutaneous anaplastic 01 510 -34 00 25 - 01 280 -50 02 205 -33

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 02 1164 96 03 381 127 01 534 97 03 249 302(b) 24 NKcT-cell lymphoma nasal-type 01 347 11 - - - 01 224 - 01 115 -

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 62 - - - - 00 32 - 00 29 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 216 03 - - - 00 79 - 02 135 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 29 - - - - - - - - - -2(c) Non-Hodgkin lymphoma unknown lineage 02 1013 -341 01 160 - 01 310 - 06 543 -2(c) 1 Precursor lymphoblastic leukemia 01 340 - 01 156 - 00 104 - 01 80 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 46 - - - - - - - 00 33 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 627 - - - - 01 194 - 05 430 -

lineage2() 1 Total precursor lymphomaleukemiad 14 8158 -09 31 4534 -13 07 2503 02 13 1121 -11

3 Composite Hodgkin lymphoma and Non-Hodgkin 00 327 - - - - 00 124 - 02 196 -lymphoma

4 Lymphoid neoplasm NOSc 07 4674 -52 01 91 - 03 1335 -51 36 3248 -58

Table 1928 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 28: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 461 253152 -05 70 10973 05 294 110367 -07 2122 131812 -05

1 Hodgkin Lymphoma 31 17710 -17 13 2118 -03 36 12525 -16 48 3067 -31

2 Non-Hodgkin lymphoma 419 229772 -03 56 8711 05 252 95756 -05 2017 125305 -032(a) Non-Hodgkin lymphoma B-cell 387 212247 -02 44 6786 15 227 86941 -04 1908 118520 -022(a) 1 Precursor Non-Hodgkin lymphoma B-cell 16 8999 24 33 5123 11 08 2888 46 16 988 292(a) 2 Mature Non-Hodgkin lymphoma B-cell 351 192801 -05 10 1558 28 210 80417 -08 1783 110826 -042(a) 21 ChronicSmallProlymphocytic 96 52411 -15 00 21 - 47 18927 -14 539 33463 -15

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 82 44988 -17 00 19 - 40 16143 -16 464 28826 -17

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 193 -02 - - - 00 46 - 02 145 052(a) 213 Mantle-cell lymphoma 13 7230 -01 - - - 07 2738 -01 72 4492 -01

2(a) 22 Lymphoplasmacytic lymphoma 10 5082 -05 - - - 04 1524 -08 58 3558 -04Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 04 2062 -08 - - - 02 616 -12 23 1446 -072(a) 222 Waldenstrom macroglubulinemia 06 3020 -02 - - - 02 908 -06 34 2112 -02

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 88 48128 01 03 554 22 59 21824 -06 418 25750 052(a) 231 DLBCL NOSc 87 47520 00 03 519 03 57 21366 -08 416 25635 042(a) 232 Intravascular large B-cell 00 75 - - - - 00 31 - 01 44 -

lymphoma2(a) 233 Primary effusion lymphoma 00 167 26 - - - 00 123 - 01 44 -2(a) 234 Mediastinal large B-cell 01 366 155 00 35 - 01 304 142 00 27 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 06 3388 -22 05 775 31 06 1969 -46 10 644 -192(a) 25 Marginal-zone lymphoma (MZL) 22 12351 -02 01 98 - 14 5177 -02 114 7076 -012(a) 251 Splenic MZL 02 1164 14 - - - 01 434 18 12 730 112(a) 252 Extranodal MZL MALTc type 13 7268 07 00 62 - 09 3267 04 63 3939 102(a) 253 Nodal MZL 07 3919 -23 00 36 - 04 1476 -22 39 2407 -23

2(a) 26 Follicular lymphoma 39 21788 -19 01 100 - 30 11210 -25 165 10478 -152(a) 27 Hairy-cell leukemia 05 2984 -18 - - - 05 1908 -20 17 1076 -152(a) 28 Plasma cell neoplasms 85 46642 07 - - - 45 17864 11 462 28769 052(a) 281 Plasmacytoma 05 2997 -08 - - - 04 1509 -16 24 1484 -012(a) 282 Multiple myeloma 80 43645 08 - - - 41 16355 13 439 27285 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 27 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 20 10447 34 01 105 - 10 3636 40 110 6706 32

Table 1927All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 29 16118 00 11 1730 14 23 8235 02 98 6153 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 430 - 01 208 - 01 188 - 01 34 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 28 15642 11 10 1521 71 22 8022 11 97 6099 -032(b) 21 Mycosis fungoidesSezary syndrome 07 3962 19 01 135 - 06 2261 21 25 1566 092(b) 211 Mycosis fungoides 07 3831 20 01 135 - 06 2213 21 23 1483 092(b) 212 Sezary syndrome 00 131 - - - - 00 48 - 01 83 -

2(b) 22 Peripheral T-cell lymphoma 15 8438 -13 02 318 -09 12 4248 -12 62 3872 -132(b) 221 Peripheral T-cell lymphoma NOSc 06 3159 -05 00 49 - 04 1520 02 26 1590 -082(b) 222 Angioimmunoblastic T-cell lymphoma 02 1024 19 - - - 01 415 11 10 607 232(b) 223 Subcutaneous panniculitis- 00 68 - - - - 00 39 - 00 16 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 03 1549 -39 01 184 -01 02 888 -43 08 477 -45

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 98 - - - - 00 69 - 00 18 -2(b) 226 Enteropathy-type T-cell lymphoma 00 105 - - - - 00 50 - 01 54 -2(b) 227 Cutaneous T-cell lymphoma NOSc 03 1696 -12 00 32 - 02 894 -03 12 770 -172(b) 228 Primary cutaneous anaplastic 01 739 -48 00 26 - 01 373 -49 05 340 -49

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 04 2253 97 07 1047 92 03 940 98 04 266 1022(b) 24 NKcT-cell lymphoma nasal-type 01 638 -05 00 18 - 01 435 -03 03 185 -06

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 58 - - - - 00 22 - 01 36 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 01 293 45 - - - 00 116 - 03 174 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 46 - - - - 00 25 - 00 20 -2(c) Non-Hodgkin lymphoma unknown lineage 03 1407 -232 01 195 - 02 580 -184 10 632 -2302(c) 1 Precursor lymphoblastic leukemia 01 474 -228 01 187 - 00 134 - 02 153 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 49 - - - - - - - 01 36 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 02 884 -239 - - - 01 433 -175 07 443 -

lineage2() 1 Total precursor lymphomaleukemiad 18 9903 -06 35 5518 -17 09 3210 09 19 1175 05

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 435 271 - - - 01 215 - 03 207 -lymphoma

4 Lymphoid neoplasm NOSc 10 5235 -59 01 131 - 05 1871 -65 54 3233 -61

Table 1927 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 301 199772 -05 53 7889 02 202 79325 -02 1322 112558 -08

1 Hodgkin Lymphoma 24 14552 -16 12 1809 -10 29 10031 -14 32 2712 -32

2 Non-Hodgkin lymphoma 269 180219 -03 40 5982 03 170 67835 00 1251 106402 -062(a) Non-Hodgkin lymphoma B-cell 250 168102 -01 34 5050 13 154 61827 02 1190 101225 -042(a) 1 Precursor Non-Hodgkin lymphoma B-cell 14 7632 16 29 4293 09 06 2315 29 12 1024 202(a) 2 Mature Non-Hodgkin lymphoma B-cell 223 151164 -04 05 713 35 141 56808 -01 1102 93643 -072(a) 21 ChronicSmallProlymphocytic 48 33190 -13 - - - 24 10176 -05 268 23000 -16

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 43 30073 -15 - - - 22 9196 -06 243 20866 -19

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 118 - - - - 00 26 - 01 89 -2(a) 213 Mantle-cell lymphoma 04 2999 11 - - - 02 954 10 24 2045 12

2(a) 22 Lymphoplasmacytic lymphoma 05 3569 04 - - - 03 1066 -16 30 2501 11Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 02 1605 01 - - - 01 516 -25 13 1087 112(a) 222 Waldenstrom macroglubulinemia 03 1964 06 - - - 01 550 -08 17 1414 11

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 58 39060 00 02 371 33 38 14656 03 283 24033 -032(a) 231 DLBCL NOSc 57 38379 -02 02 342 27 36 14103 -01 282 23934 -032(a) 232 Intravascular large B-cell 00 87 - - - - 00 32 - 01 55 -

lymphoma2(a) 233 Primary effusion lymphoma - - - - - - - - - - - -2(a) 234 Mediastinal large B-cell 01 580 91 00 29 - 02 518 93 00 33 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 02 1304 -34 02 253 38 02 649 -37 05 402 -852(a) 25 Marginal-zone lymphoma (MZL) 21 14183 01 00 39 - 15 5872 12 98 8272 -062(a) 251 Splenic MZL 02 1254 -07 - - - 01 455 -32 10 799 072(a) 252 Extranodal MZL MALTc type 13 8711 06 00 30 - 10 3881 17 57 4800 -032(a) 253 Nodal MZL 06 4218 -07 - - - 04 1536 11 32 2673 -18

2(a) 26 Follicular lymphoma 33 21794 -24 00 19 - 27 10515 -25 134 11260 -222(a) 27 Hairy-cell leukemia 01 728 -12 - - - 01 403 -11 04 325 -122(a) 28 Plasma cell neoplasms 55 37315 08 - - - 33 13461 15 282 23839 052(a) 281 Plasmacytoma 03 1882 00 - - - 02 853 12 12 1017 -092(a) 282 Multiple myeloma 52 35433 09 - - - 30 12608 15 270 22822 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 21 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 14 9306 32 00 44 - 07 2704 32 76 6558 31

Table 1928All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 17 11104 01 05 772 29 15 5698 05 55 4634 -112(b) 1 Precursor Non-Hodgkin lymphoma T-cell 00 186 - 01 85 - 00 84 - 00 17 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 17 10889 09 05 686 83 15 5599 12 54 4604 -092(b) 21 Mycosis fungoidesSezary syndrome 05 3007 15 01 78 - 05 1819 26 13 1110 -042(b) 211 Mycosis fungoides 05 2908 12 01 78 - 05 1777 23 12 1053 -072(b) 212 Sezary syndrome 00 99 - - - - 00 42 - 01 57 -

2(b) 22 Peripheral T-cell lymphoma 09 6093 -08 01 216 30 08 2911 -06 35 2966 -142(b) 221 Peripheral T-cell lymphoma NOSc 03 2234 03 00 37 - 03 969 07 14 1228 -012(b) 222 Angioimmunoblastic T-cell lymphoma 01 878 -22 - - - 01 284 -39 07 594 -152(b) 223 Subcutaneous panniculitis- 00 108 - 00 18 - 00 72 - 00 18 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 974 -33 01 107 - 02 562 -19 04 305 -77

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 41 - - - - 00 29 - - - -2(b) 226 Enteropathy-type T-cell lymphoma 00 81 - - - - 00 34 - 01 47 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 1267 00 00 27 - 02 681 07 07 559 -102(b) 228 Primary cutaneous anaplastic 01 510 -34 00 25 - 01 280 -50 02 205 -33

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 02 1164 96 03 381 127 01 534 97 03 249 302(b) 24 NKcT-cell lymphoma nasal-type 01 347 11 - - - 01 224 - 01 115 -

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 62 - - - - 00 32 - 00 29 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 216 03 - - - 00 79 - 02 135 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 29 - - - - - - - - - -2(c) Non-Hodgkin lymphoma unknown lineage 02 1013 -341 01 160 - 01 310 - 06 543 -2(c) 1 Precursor lymphoblastic leukemia 01 340 - 01 156 - 00 104 - 01 80 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 46 - - - - - - - 00 33 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 627 - - - - 01 194 - 05 430 -

lineage2() 1 Total precursor lymphomaleukemiad 14 8158 -09 31 4534 -13 07 2503 02 13 1121 -11

3 Composite Hodgkin lymphoma and Non-Hodgkin 00 327 - - - - 00 124 - 02 196 -lymphoma

4 Lymphoid neoplasm NOSc 07 4674 -52 01 91 - 03 1335 -51 36 3248 -58

Table 1928 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 29: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 29 16118 00 11 1730 14 23 8235 02 98 6153 -062(b) 1 Precursor Non-Hodgkin lymphoma T-cell 01 430 - 01 208 - 01 188 - 01 34 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 28 15642 11 10 1521 71 22 8022 11 97 6099 -032(b) 21 Mycosis fungoidesSezary syndrome 07 3962 19 01 135 - 06 2261 21 25 1566 092(b) 211 Mycosis fungoides 07 3831 20 01 135 - 06 2213 21 23 1483 092(b) 212 Sezary syndrome 00 131 - - - - 00 48 - 01 83 -

2(b) 22 Peripheral T-cell lymphoma 15 8438 -13 02 318 -09 12 4248 -12 62 3872 -132(b) 221 Peripheral T-cell lymphoma NOSc 06 3159 -05 00 49 - 04 1520 02 26 1590 -082(b) 222 Angioimmunoblastic T-cell lymphoma 02 1024 19 - - - 01 415 11 10 607 232(b) 223 Subcutaneous panniculitis- 00 68 - - - - 00 39 - 00 16 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 03 1549 -39 01 184 -01 02 888 -43 08 477 -45

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 98 - - - - 00 69 - 00 18 -2(b) 226 Enteropathy-type T-cell lymphoma 00 105 - - - - 00 50 - 01 54 -2(b) 227 Cutaneous T-cell lymphoma NOSc 03 1696 -12 00 32 - 02 894 -03 12 770 -172(b) 228 Primary cutaneous anaplastic 01 739 -48 00 26 - 01 373 -49 05 340 -49

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 04 2253 97 07 1047 92 03 940 98 04 266 1022(b) 24 NKcT-cell lymphoma nasal-type 01 638 -05 00 18 - 01 435 -03 03 185 -06

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 58 - - - - 00 22 - 01 36 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 01 293 45 - - - 00 116 - 03 174 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 46 - - - - 00 25 - 00 20 -2(c) Non-Hodgkin lymphoma unknown lineage 03 1407 -232 01 195 - 02 580 -184 10 632 -2302(c) 1 Precursor lymphoblastic leukemia 01 474 -228 01 187 - 00 134 - 02 153 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 49 - - - - - - - 01 36 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 02 884 -239 - - - 01 433 -175 07 443 -

lineage2() 1 Total precursor lymphomaleukemiad 18 9903 -06 35 5518 -17 09 3210 09 19 1175 05

3 Composite Hodgkin lymphoma and Non-Hodgkin 01 435 271 - - - 01 215 - 03 207 -lymphoma

4 Lymphoid neoplasm NOSc 10 5235 -59 01 131 - 05 1871 -65 54 3233 -61

Table 1927 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Males 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 301 199772 -05 53 7889 02 202 79325 -02 1322 112558 -08

1 Hodgkin Lymphoma 24 14552 -16 12 1809 -10 29 10031 -14 32 2712 -32

2 Non-Hodgkin lymphoma 269 180219 -03 40 5982 03 170 67835 00 1251 106402 -062(a) Non-Hodgkin lymphoma B-cell 250 168102 -01 34 5050 13 154 61827 02 1190 101225 -042(a) 1 Precursor Non-Hodgkin lymphoma B-cell 14 7632 16 29 4293 09 06 2315 29 12 1024 202(a) 2 Mature Non-Hodgkin lymphoma B-cell 223 151164 -04 05 713 35 141 56808 -01 1102 93643 -072(a) 21 ChronicSmallProlymphocytic 48 33190 -13 - - - 24 10176 -05 268 23000 -16

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 43 30073 -15 - - - 22 9196 -06 243 20866 -19

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 118 - - - - 00 26 - 01 89 -2(a) 213 Mantle-cell lymphoma 04 2999 11 - - - 02 954 10 24 2045 12

2(a) 22 Lymphoplasmacytic lymphoma 05 3569 04 - - - 03 1066 -16 30 2501 11Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 02 1605 01 - - - 01 516 -25 13 1087 112(a) 222 Waldenstrom macroglubulinemia 03 1964 06 - - - 01 550 -08 17 1414 11

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 58 39060 00 02 371 33 38 14656 03 283 24033 -032(a) 231 DLBCL NOSc 57 38379 -02 02 342 27 36 14103 -01 282 23934 -032(a) 232 Intravascular large B-cell 00 87 - - - - 00 32 - 01 55 -

lymphoma2(a) 233 Primary effusion lymphoma - - - - - - - - - - - -2(a) 234 Mediastinal large B-cell 01 580 91 00 29 - 02 518 93 00 33 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 02 1304 -34 02 253 38 02 649 -37 05 402 -852(a) 25 Marginal-zone lymphoma (MZL) 21 14183 01 00 39 - 15 5872 12 98 8272 -062(a) 251 Splenic MZL 02 1254 -07 - - - 01 455 -32 10 799 072(a) 252 Extranodal MZL MALTc type 13 8711 06 00 30 - 10 3881 17 57 4800 -032(a) 253 Nodal MZL 06 4218 -07 - - - 04 1536 11 32 2673 -18

2(a) 26 Follicular lymphoma 33 21794 -24 00 19 - 27 10515 -25 134 11260 -222(a) 27 Hairy-cell leukemia 01 728 -12 - - - 01 403 -11 04 325 -122(a) 28 Plasma cell neoplasms 55 37315 08 - - - 33 13461 15 282 23839 052(a) 281 Plasmacytoma 03 1882 00 - - - 02 853 12 12 1017 -092(a) 282 Multiple myeloma 52 35433 09 - - - 30 12608 15 270 22822 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 21 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 14 9306 32 00 44 - 07 2704 32 76 6558 31

Table 1928All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 17 11104 01 05 772 29 15 5698 05 55 4634 -112(b) 1 Precursor Non-Hodgkin lymphoma T-cell 00 186 - 01 85 - 00 84 - 00 17 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 17 10889 09 05 686 83 15 5599 12 54 4604 -092(b) 21 Mycosis fungoidesSezary syndrome 05 3007 15 01 78 - 05 1819 26 13 1110 -042(b) 211 Mycosis fungoides 05 2908 12 01 78 - 05 1777 23 12 1053 -072(b) 212 Sezary syndrome 00 99 - - - - 00 42 - 01 57 -

2(b) 22 Peripheral T-cell lymphoma 09 6093 -08 01 216 30 08 2911 -06 35 2966 -142(b) 221 Peripheral T-cell lymphoma NOSc 03 2234 03 00 37 - 03 969 07 14 1228 -012(b) 222 Angioimmunoblastic T-cell lymphoma 01 878 -22 - - - 01 284 -39 07 594 -152(b) 223 Subcutaneous panniculitis- 00 108 - 00 18 - 00 72 - 00 18 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 974 -33 01 107 - 02 562 -19 04 305 -77

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 41 - - - - 00 29 - - - -2(b) 226 Enteropathy-type T-cell lymphoma 00 81 - - - - 00 34 - 01 47 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 1267 00 00 27 - 02 681 07 07 559 -102(b) 228 Primary cutaneous anaplastic 01 510 -34 00 25 - 01 280 -50 02 205 -33

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 02 1164 96 03 381 127 01 534 97 03 249 302(b) 24 NKcT-cell lymphoma nasal-type 01 347 11 - - - 01 224 - 01 115 -

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 62 - - - - 00 32 - 00 29 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 216 03 - - - 00 79 - 02 135 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 29 - - - - - - - - - -2(c) Non-Hodgkin lymphoma unknown lineage 02 1013 -341 01 160 - 01 310 - 06 543 -2(c) 1 Precursor lymphoblastic leukemia 01 340 - 01 156 - 00 104 - 01 80 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 46 - - - - - - - 00 33 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 627 - - - - 01 194 - 05 430 -

lineage2() 1 Total precursor lymphomaleukemiad 14 8158 -09 31 4534 -13 07 2503 02 13 1121 -11

3 Composite Hodgkin lymphoma and Non-Hodgkin 00 327 - - - - 00 124 - 02 196 -lymphoma

4 Lymphoid neoplasm NOSc 07 4674 -52 01 91 - 03 1335 -51 36 3248 -58

Table 1928 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 30: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini AS

Ruumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

Lymphoid Neoplasm 301 199772 -05 53 7889 02 202 79325 -02 1322 112558 -08

1 Hodgkin Lymphoma 24 14552 -16 12 1809 -10 29 10031 -14 32 2712 -32

2 Non-Hodgkin lymphoma 269 180219 -03 40 5982 03 170 67835 00 1251 106402 -062(a) Non-Hodgkin lymphoma B-cell 250 168102 -01 34 5050 13 154 61827 02 1190 101225 -042(a) 1 Precursor Non-Hodgkin lymphoma B-cell 14 7632 16 29 4293 09 06 2315 29 12 1024 202(a) 2 Mature Non-Hodgkin lymphoma B-cell 223 151164 -04 05 713 35 141 56808 -01 1102 93643 -072(a) 21 ChronicSmallProlymphocytic 48 33190 -13 - - - 24 10176 -05 268 23000 -16

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 43 30073 -15 - - - 22 9196 -06 243 20866 -19

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 00 118 - - - - 00 26 - 01 89 -2(a) 213 Mantle-cell lymphoma 04 2999 11 - - - 02 954 10 24 2045 12

2(a) 22 Lymphoplasmacytic lymphoma 05 3569 04 - - - 03 1066 -16 30 2501 11Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 02 1605 01 - - - 01 516 -25 13 1087 112(a) 222 Waldenstrom macroglubulinemia 03 1964 06 - - - 01 550 -08 17 1414 11

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 58 39060 00 02 371 33 38 14656 03 283 24033 -032(a) 231 DLBCL NOSc 57 38379 -02 02 342 27 36 14103 -01 282 23934 -032(a) 232 Intravascular large B-cell 00 87 - - - - 00 32 - 01 55 -

lymphoma2(a) 233 Primary effusion lymphoma - - - - - - - - - - - -2(a) 234 Mediastinal large B-cell 01 580 91 00 29 - 02 518 93 00 33 -

lymphoma2(a) 24 Burkitt lymphomaleukemia 02 1304 -34 02 253 38 02 649 -37 05 402 -852(a) 25 Marginal-zone lymphoma (MZL) 21 14183 01 00 39 - 15 5872 12 98 8272 -062(a) 251 Splenic MZL 02 1254 -07 - - - 01 455 -32 10 799 072(a) 252 Extranodal MZL MALTc type 13 8711 06 00 30 - 10 3881 17 57 4800 -032(a) 253 Nodal MZL 06 4218 -07 - - - 04 1536 11 32 2673 -18

2(a) 26 Follicular lymphoma 33 21794 -24 00 19 - 27 10515 -25 134 11260 -222(a) 27 Hairy-cell leukemia 01 728 -12 - - - 01 403 -11 04 325 -122(a) 28 Plasma cell neoplasms 55 37315 08 - - - 33 13461 15 282 23839 052(a) 281 Plasmacytoma 03 1882 00 - - - 02 853 12 12 1017 -092(a) 282 Multiple myeloma 52 35433 09 - - - 30 12608 15 270 22822 06

plasma-cell leukemia2(a) 29 Heavy chain disease 00 21 - - - - - - - - - -2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 14 9306 32 00 44 - 07 2704 32 76 6558 31

Table 1928All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 17 11104 01 05 772 29 15 5698 05 55 4634 -112(b) 1 Precursor Non-Hodgkin lymphoma T-cell 00 186 - 01 85 - 00 84 - 00 17 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 17 10889 09 05 686 83 15 5599 12 54 4604 -092(b) 21 Mycosis fungoidesSezary syndrome 05 3007 15 01 78 - 05 1819 26 13 1110 -042(b) 211 Mycosis fungoides 05 2908 12 01 78 - 05 1777 23 12 1053 -072(b) 212 Sezary syndrome 00 99 - - - - 00 42 - 01 57 -

2(b) 22 Peripheral T-cell lymphoma 09 6093 -08 01 216 30 08 2911 -06 35 2966 -142(b) 221 Peripheral T-cell lymphoma NOSc 03 2234 03 00 37 - 03 969 07 14 1228 -012(b) 222 Angioimmunoblastic T-cell lymphoma 01 878 -22 - - - 01 284 -39 07 594 -152(b) 223 Subcutaneous panniculitis- 00 108 - 00 18 - 00 72 - 00 18 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 974 -33 01 107 - 02 562 -19 04 305 -77

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 41 - - - - 00 29 - - - -2(b) 226 Enteropathy-type T-cell lymphoma 00 81 - - - - 00 34 - 01 47 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 1267 00 00 27 - 02 681 07 07 559 -102(b) 228 Primary cutaneous anaplastic 01 510 -34 00 25 - 01 280 -50 02 205 -33

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 02 1164 96 03 381 127 01 534 97 03 249 302(b) 24 NKcT-cell lymphoma nasal-type 01 347 11 - - - 01 224 - 01 115 -

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 62 - - - - 00 32 - 00 29 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 216 03 - - - 00 79 - 02 135 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 29 - - - - - - - - - -2(c) Non-Hodgkin lymphoma unknown lineage 02 1013 -341 01 160 - 01 310 - 06 543 -2(c) 1 Precursor lymphoblastic leukemia 01 340 - 01 156 - 00 104 - 01 80 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 46 - - - - - - - 00 33 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 627 - - - - 01 194 - 05 430 -

lineage2() 1 Total precursor lymphomaleukemiad 14 8158 -09 31 4534 -13 07 2503 02 13 1121 -11

3 Composite Hodgkin lymphoma and Non-Hodgkin 00 327 - - - - 00 124 - 02 196 -lymphoma

4 Lymphoid neoplasm NOSc 07 4674 -52 01 91 - 03 1335 -51 36 3248 -58

Table 1928 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 31: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

The APC is the Annual Percent Change over the time intervala Morton LM et al Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working

Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708b SEER 21 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-Monterey

Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New JerseyGeorgia excluding ATLRG Idaho New York and Massachusetts)

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1 The APC is significantly different from zero (plt05)- Statistic not shown Rate based on less than 16 cases for the time interval

Trend based on less than 10 cases for at least one year within the time interval

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Rate Count APC Rate Count APC Rate Count APC Rate Count APC

2(b) Non-Hodgkin lymphoma T-cell 17 11104 01 05 772 29 15 5698 05 55 4634 -112(b) 1 Precursor Non-Hodgkin lymphoma T-cell 00 186 - 01 85 - 00 84 - 00 17 -2(b) 2 Mature Non-Hodgkin lymphoma T-cell 17 10889 09 05 686 83 15 5599 12 54 4604 -092(b) 21 Mycosis fungoidesSezary syndrome 05 3007 15 01 78 - 05 1819 26 13 1110 -042(b) 211 Mycosis fungoides 05 2908 12 01 78 - 05 1777 23 12 1053 -072(b) 212 Sezary syndrome 00 99 - - - - 00 42 - 01 57 -

2(b) 22 Peripheral T-cell lymphoma 09 6093 -08 01 216 30 08 2911 -06 35 2966 -142(b) 221 Peripheral T-cell lymphoma NOSc 03 2234 03 00 37 - 03 969 07 14 1228 -012(b) 222 Angioimmunoblastic T-cell lymphoma 01 878 -22 - - - 01 284 -39 07 594 -152(b) 223 Subcutaneous panniculitis- 00 108 - 00 18 - 00 72 - 00 18 -

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 02 974 -33 01 107 - 02 562 -19 04 305 -77

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 00 41 - - - - 00 29 - - - -2(b) 226 Enteropathy-type T-cell lymphoma 00 81 - - - - 00 34 - 01 47 -2(b) 227 Cutaneous T-cell lymphoma NOSc 02 1267 00 00 27 - 02 681 07 07 559 -102(b) 228 Primary cutaneous anaplastic 01 510 -34 00 25 - 01 280 -50 02 205 -33

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 02 1164 96 03 381 127 01 534 97 03 249 302(b) 24 NKcT-cell lymphoma nasal-type 01 347 11 - - - 01 224 - 01 115 -

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 00 62 - - - - 00 32 - 00 29 -

leukemia2(b) 26 Prolymphocytic leukemia T-cell 00 216 03 - - - 00 79 - 02 135 -2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 00 29 - - - - - - - - - -2(c) Non-Hodgkin lymphoma unknown lineage 02 1013 -341 01 160 - 01 310 - 06 543 -2(c) 1 Precursor lymphoblastic leukemia 01 340 - 01 156 - 00 104 - 01 80 -

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 00 46 - - - - - - - 00 33 -

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 01 627 - - - - 01 194 - 05 430 -

lineage2() 1 Total precursor lymphomaleukemiad 14 8158 -09 31 4534 -13 07 2503 02 13 1121 -11

3 Composite Hodgkin lymphoma and Non-Hodgkin 00 327 - - - - 00 124 - 02 196 -lymphoma

4 Lymphoid neoplasm NOSc 07 4674 -52 01 91 - 03 1335 -51 36 3248 -58

Table 1928 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes

SEERb Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races Females 2007-2016

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 32: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 184989 713 ( 710 716) 905 ( 898 912 ) 786 ( 783 789 ) 617 ( 612 622)

1 Hodgkin Lymphoma 14589 866 ( 859 873) 973 ( 962 980 ) 900 ( 893 907 ) 580 ( 550 609)

2 Non-Hodgkin lymphoma 166396 704 ( 701 707) 888 ( 880 896 ) 772 ( 768 775 ) 624 ( 619 629)2(a) Non-Hodgkin lymphoma B-cell 154493 707 ( 704 711) 896 ( 887 904 ) 779 ( 775 783 ) 629 ( 624 634)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 8624 689 ( 677 700) 889 ( 879 899 ) 419 ( 396 442 ) 178 ( 142 218)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 137350 710 ( 707 714) 925 ( 906 940 ) 793 ( 789 797 ) 634 ( 629 640)2(a) 21 ChronicSmallProlymphocytic 33231 816 ( 808 823) 938 ( 630 991 ) 889 ( 881 896 ) 765 ( 754 775)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 29025 845 ( 838 853) 917 ( 537 988 ) 918 ( 910 926 ) 796 ( 784 807)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 90 537 ( 398 658) 1000 ( - - ) 639 ( 402 803 ) 434 ( 260 597)2(a) 213 Mantle-cell lymphoma 4116 611 ( 590 632) - ( - - ) 702 ( 674 728 ) 540 ( 509 570)

2(a) 22 Lymphoplasmacytic lymphoma 3069 828 ( 803 851) 1000 ( - - ) 896 ( 866 919 ) 789 ( 752 821)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 1363 822 ( 783 854) 1000 ( - - ) 859 ( 812 896 ) 798 ( 742 843)2(a) 222 Waldenstrom macroglubulinemia 1706 834 ( 798 863) - ( - - ) 925 ( 883 952 ) 782 ( 731 825)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 35369 632 ( 626 639) 908 ( 874 932 ) 728 ( 720 736 ) 537 ( 526 547)2(a) 231 DLBCL NOSc 34815 629 ( 623 636) 908 ( 873 934 ) 725 ( 717 733 ) 537 ( 526 547)2(a) 232 Intravascular large B-cell 69 478 ( 341 603) - ( - - ) 526 ( 341 682 ) 426 ( 232 608)

lymphoma2(a) 233 Primary effusion lymphoma 47 524 ( 357 667) - ( - - ) 506 ( 321 665 ) 542 ( 183 802)2(a) 234 Mediastinal large B-cell 438 884 ( 845 914) 899 ( 717 967 ) 903 ( 863 932 ) 479 ( 241 683)

lymphoma2(a) 24 Burkitt lymphomaleukemia 2170 641 ( 618 663) 928 ( 898 950 ) 598 ( 567 627 ) 389 ( 333 445)2(a) 25 Marginal-zone lymphoma (MZL) 10080 903 ( 892 913) 986 ( 906 998 ) 942 ( 931 951 ) 864 ( 844 882)2(a) 251 Splenic MZL 850 872 ( 828 906) - ( - - ) 900 ( 850 935 ) 852 ( 778 902)2(a) 252 Extranodal MZL MALTc type 6278 939 ( 925 950) 980 ( 863 997 ) 959 ( 946 969 ) 914 ( 887 935)2(a) 253 Nodal MZL 2952 836 ( 813 857) 1000 ( - - ) 910 ( 885 929 ) 774 ( 735 807)

2(a) 26 Follicular lymphoma 17590 884 ( 876 892) 955 ( 820 989 ) 929 ( 921 936 ) 826 ( 810 841)2(a) 27 Hairy-cell leukemia 1569 942 ( 917 959) - ( - - ) 970 ( 957 979 ) 856 ( 786 904)2(a) 28 Plasma cell neoplasms 34254 522 ( 514 529) 836 ( 488 956 ) 635 ( 625 645 ) 435 ( 425 445)2(a) 281 Plasmacytoma 2009 707 ( 678 734) 900 ( 473 985 ) 797 ( 763 826 ) 590 ( 539 637)2(a) 282 Multiple myeloma 32245 510 ( 502 518) 500 ( 06 910 ) 622 ( 611 632 ) 428 ( 417 438)

plasma-cell leukemia2(a) 29 Heavy chain disease 18 614 ( 283 828) 1000 ( - - ) 839 ( 120 986 ) 295 ( 36 638)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 8519 684 ( 669 698) 917 ( 794 968 ) 784 ( 766 802 ) 619 ( 598 640)

Table 1929All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 33: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 11325 661 ( 650 672) 856 ( 833 876 ) 702 ( 689 716 ) 522 ( 500 544)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 187 652 ( 576 718) 917 ( 833 960 ) 484 ( 366 592 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 11122 662 ( 650 672) 851 ( 826 872 ) 706 ( 693 719 ) 524 ( 501 546)2(b) 21 Mycosis fungoidesSezary syndrome 2846 909 ( 889 926) 1000 ( - - ) 931 ( 911 946 ) 858 ( 808 896)2(b) 211 Mycosis fungoides 2746 924 ( 905 940) 1000 ( - - ) 941 ( 922 956 ) 882 ( 830 919)2(b) 212 Sezary syndrome 100 454 ( 312 585) - ( - - ) 463 ( 265 640 ) 457 ( 269 628)

2(b) 22 Peripheral T-cell lymphoma 5920 584 ( 569 600) 869 ( 819 906 ) 665 ( 646 684 ) 441 ( 413 467)2(b) 221 Peripheral T-cell lymphoma NOSc 2119 400 ( 375 425) 642 ( 466 773 ) 499 ( 466 532 ) 274 ( 238 312)2(b) 222 Angioimmunoblastic T-cell 780 386 ( 344 428) 1000 ( - - ) 484 ( 419 546 ) 311 ( 256 369)

lymphoma2(b) 223 Subcutaneous panniculitis- 88 903 ( 784 958) 884 ( 406 983 ) 880 ( 729 950 ) 937 ( 320 996)

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 1110 676 ( 643 707) 896 ( 832 936 ) 716 ( 677 752 ) 456 ( 377 531)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 66 327 ( 200 459) 668 ( 53 946 ) 310 ( 174 456 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 69 93 ( 33 193) - ( - - ) 109 ( 28 254 ) 75 ( 14 210)2(b) 227 Cutaneous T-cell lymphoma NOSc 1183 847 ( 813 875) 1000 ( - - ) 888 ( 853 915 ) 771 ( 696 829)2(b) 228 Primary cutaneous anaplastic 505 881 ( 827 919) 913 ( 693 978 ) 918 ( 865 951 ) 812 ( 685 892)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1671 641 ( 613 667) 832 ( 800 859 ) 496 ( 450 540 ) 216 ( 138 304)2(b) 24 NKcT-cell lymphoma nasal-type 466 427 ( 373 479) 588 ( 325 778 ) 444 ( 382 504 ) 357 ( 247 468)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 28 638 ( 387 808) - ( - - ) 785 ( 437 931 ) 460 ( 147 731)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 191 147 ( 88 220) - ( - - ) 230 ( 134 342 ) 50 ( 10 144)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 16 443 ( 167 690) - ( - - ) 388 ( 103 673 ) 414 ( 51 770)2(c) Non-Hodgkin lymphoma unknown lineage 578 529 ( 482 574) 846 ( 743 910 ) 529 ( 461 591 ) 416 ( 336 493)2(c) 1 Precursor lymphoblastic leukemia 194 593 ( 517 662) 855 ( 751 917 ) 528 ( 392 647 ) 239 ( 123 376)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 19 384 ( 155 612) - ( - - ) - ( - - ) 299 ( 89 547)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 365 500 ( 437 559) 500 ( 06 910 ) 525 ( 446 598 ) 470 ( 371 563)

lineage2() 1 Total precursor lymphomaleukemiad 9005 686 ( 675 697) 889 ( 879 899 ) 426 ( 403 448 ) 183 ( 148 220)

3 Composite Hodgkin lymphoma and Non-Hodgkin 290 773 ( 704 828) - ( - - ) 839 ( 763 892 ) 657 ( 513 768)lymphoma

4 Lymphoid neoplasm NOSc 3714 517 ( 496 537) 847 ( 763 904 ) 669 ( 640 695 ) 400 ( 372 428)

Table 1929 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Both Sexes 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 34: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 103504 707 ( 704 711) 903 ( 893 911 ) 767 ( 763 772 ) 614 ( 607 621)

1 Hodgkin Lymphoma 8077 856 ( 846 865) 973 ( 957 983 ) 884 ( 874 894 ) 584 ( 542 623)

2 Non-Hodgkin lymphoma 93329 698 ( 694 703) 887 ( 875 897 ) 754 ( 749 759 ) 620 ( 613 627)2(a) Non-Hodgkin lymphoma B-cell 86191 703 ( 698 707) 895 ( 883 906 ) 763 ( 758 769 ) 625 ( 618 633)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 4673 683 ( 667 698) 883 ( 868 896 ) 420 ( 389 450 ) 140 ( 93 197)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 76969 706 ( 701 710) 938 ( 917 954 ) 777 ( 772 783 ) 631 ( 623 638)2(a) 21 ChronicSmallProlymphocytic 20318 804 ( 795 813) 890 ( 431 984 ) 877 ( 866 886 ) 747 ( 732 761)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 17359 839 ( 829 849) 858 ( 332 979 ) 910 ( 899 919 ) 784 ( 768 799)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 59 595 ( 420 733) - ( - - ) 688 ( 413 853 ) 490 ( 266 681)2(a) 213 Mantle-cell lymphoma 2900 598 ( 573 623) - ( - - ) 694 ( 661 725 ) 515 ( 477 552)

2(a) 22 Lymphoplasmacytic lymphoma 1783 808 ( 773 838) - ( - - ) 884 ( 841 916 ) 762 ( 710 805)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 753 805 ( 750 850) - ( - - ) 849 ( 778 899 ) 780 ( 700 841)2(a) 222 Waldenstrom macroglubulinemia 1030 811 ( 763 850) - ( - - ) 909 ( 849 946 ) 749 ( 678 806)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 19607 633 ( 624 641) 929 ( 890 955 ) 706 ( 696 717 ) 542 ( 528 557)2(a) 231 DLBCL NOSc 19365 631 ( 622 640) 932 ( 892 958 ) 705 ( 694 715 ) 543 ( 528 557)2(a) 232 Intravascular large B-cell 27 315 ( 140 507) - ( - - ) 473 ( 214 695 ) 106 ( 06 379)

lymphoma2(a) 233 Primary effusion lymphoma 42 542 ( 364 689) - ( - - ) 490 ( 304 652 ) 705 ( 224 921)2(a) 234 Mediastinal large B-cell 173 888 ( 823 931) 888 ( 617 971 ) 911 ( 841 951 ) 565 ( 224 805)

lymphoma2(a) 24 Burkitt lymphomaleukemia 1587 653 ( 626 679) 931 ( 897 954 ) 598 ( 562 631 ) 400 ( 321 477)2(a) 25 Marginal-zone lymphoma (MZL) 4689 887 ( 869 903) 1000 ( - - ) 929 ( 911 943 ) 840 ( 806 868)2(a) 251 Splenic MZL 404 844 ( 774 893) - ( - - ) 868 ( 789 919 ) 816 ( 691 894)2(a) 252 Extranodal MZL MALTc type 2853 933 ( 910 950) 1000 ( - - ) 954 ( 932 969 ) 905 ( 858 937)2(a) 253 Nodal MZL 1432 807 ( 772 838) 1000 ( - - ) 882 ( 845 911 ) 727 ( 667 778)

2(a) 26 Follicular lymphoma 8820 884 ( 872 895) 969 ( 786 996 ) 918 ( 907 928 ) 833 ( 810 854)2(a) 27 Hairy-cell leukemia 1255 947 ( 918 966) - ( - - ) 966 ( 951 977 ) 878 ( 795 929)2(a) 28 Plasma cell neoplasms 18900 521 ( 510 531) 1000 ( - - ) 619 ( 605 633 ) 439 ( 425 454)2(a) 281 Plasmacytoma 1214 694 ( 656 729) 1000 ( - - ) 775 ( 731 812 ) 576 ( 506 640)2(a) 282 Multiple myeloma 17686 508 ( 498 519) 1000 ( - - ) 604 ( 590 619 ) 433 ( 418 447)

plasma-cell leukemia2(a) 29 Heavy chain disease 10 594 ( 180 854) 1000 ( - - ) 842 ( 110 987 ) 00 ( - - )2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 4549 677 ( 656 696) 920 ( 736 978 ) 756 ( 731 780 ) 612 ( 581 642)

Table 1930All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 35: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 6775 652 ( 638 666) 857 ( 829 882 ) 671 ( 653 688 ) 528 ( 497 558)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 131 638 ( 546 717) 917 ( 811 965 ) 430 ( 294 559 ) 00 ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 6635 653 ( 638 667) 851 ( 820 877 ) 676 ( 658 693 ) 530 ( 499 561)2(b) 21 Mycosis fungoidesSezary syndrome 1633 895 ( 866 918) 1000 ( - - ) 909 ( 880 932 ) 856 ( 781 906)2(b) 211 Mycosis fungoides 1575 909 ( 880 931) 1000 ( - - ) 917 ( 888 939 ) 881 ( 802 930)2(b) 212 Sezary syndrome 58 489 ( 291 660) - ( - - ) 520 ( 233 745 ) 478 ( 225 693)

2(b) 22 Peripheral T-cell lymphoma 3446 570 ( 550 590) 857 ( 786 906 ) 633 ( 608 657 ) 442 ( 405 479)2(b) 221 Peripheral T-cell lymphoma NOSc 1268 403 ( 371 435) 690 ( 473 832 ) 488 ( 446 528 ) 272 ( 224 322)2(b) 222 Angioimmunoblastic T-cell 437 363 ( 307 418) 1000 ( - - ) 409 ( 329 488 ) 318 ( 241 398)

lymphoma2(b) 223 Subcutaneous panniculitis- 34 876 ( 633 962) 752 ( 126 962 ) 896 ( 640 973 ) - ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 680 642 ( 598 683) 886 ( 798 937 ) 677 ( 624 724 ) 427 ( 331 519)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 45 399 ( 240 553) 668 ( 53 946 ) 397 ( 219 569 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 38 97 ( 21 246) - ( - - ) 167 ( 42 365 ) 00 ( - - )2(b) 227 Cutaneous T-cell lymphoma NOSc 671 847 ( 798 884) 1000 ( - - ) 880 ( 831 916 ) 777 ( 667 854)2(b) 228 Primary cutaneous anaplastic 273 867 ( 787 918) 909 ( 508 987 ) 903 ( 819 949 ) 804 ( 623 904)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 1146 662 ( 629 692) 839 ( 801 871 ) 504 ( 449 556 ) 194 ( 97 315)2(b) 24 NKcT-cell lymphoma nasal-type 284 423 ( 353 492) 637 ( 297 845 ) 415 ( 333 495 ) 397 ( 255 534)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 12 595 ( 234 831) - ( - - ) 683 ( 186 918 ) 461 ( 45 824)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 114 178 ( 98 278) - ( - - ) 239 ( 123 375 ) 89 ( 17 236)2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 9 314 ( 40 660) - ( - - ) 271 ( 10 693 ) - ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 363 500 ( 441 557) 811 ( 666 897 ) 513 ( 432 587 ) 356 ( 252 460)2(c) 1 Precursor lymphoblastic leukemia 125 533 ( 437 620) 824 ( 676 908 ) 500 ( 324 652 ) 204 ( 88 354)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 10 496 ( 126 788) - ( - - ) - ( - - ) 383 ( 44 745)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 228 479 ( 400 553) 500 ( 06 910 ) 507 ( 416 592 ) 419 ( 278 553)

lineage2() 1 Total precursor lymphomaleukemiad 4929 678 ( 663 693) 883 ( 868 896 ) 423 ( 393 452 ) 148 ( 103 200)

3 Composite Hodgkin lymphoma and Non-Hodgkin 163 806 ( 728 863) - ( - - ) 835 ( 742 896 ) 732 ( 570 841)lymphoma

4 Lymphoid neoplasm NOSc 1935 493 ( 464 521) 836 ( 721 907 ) 600 ( 560 638 ) 386 ( 345 426)

Table 1930 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Males 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 36: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killer- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

Lymphoid Neoplasm 81485 721 ( 717 725) 908 ( 898 918 ) 813 ( 808 818 ) 621 ( 614 628)

1 Hodgkin Lymphoma 6512 878 ( 868 888) 971 ( 956 981 ) 921 ( 911 929 ) 574 ( 529 616)

2 Non-Hodgkin lymphoma 73067 711 ( 706 715) 890 ( 877 902 ) 797 ( 791 802 ) 628 ( 621 635)2(a) Non-Hodgkin lymphoma B-cell 68302 713 ( 708 718) 897 ( 883 909 ) 801 ( 795 807 ) 633 ( 626 641)2(a) 1 Precursor Non-Hodgkin lymphoma B-cell 3951 696 ( 679 712) 897 ( 882 910 ) 419 ( 383 454 ) 211 ( 159 267)2(a) 2 Mature Non-Hodgkin lymphoma B-cell 60381 716 ( 711 721) 894 ( 852 925 ) 817 ( 811 823 ) 638 ( 630 646)2(a) 21 ChronicSmallProlymphocytic 12913 833 ( 822 844) 1000 ( - - ) 913 ( 900 924 ) 789 ( 773 805)

Mantle B-cell Non-Hodgkin lymphoma2(a) 211 ChronicSmall lymphocytic 11666 854 ( 842 866) 1000 ( - - ) 934 ( 921 944 ) 810 ( 793 827)

leukemialymphoma2(a) 212 Prolymphocytic leukemia B-cell 31 396 ( 178 609) 1000 ( - - ) 349 ( 13 774 ) 334 ( 108 583)2(a) 213 Mantle-cell lymphoma 1216 642 ( 603 678) - ( - - ) 725 ( 670 773 ) 592 ( 538 642)

2(a) 22 Lymphoplasmacytic lymphoma 1286 855 ( 817 886) 1000 ( - - ) 908 ( 864 938 ) 824 ( 768 867)Waldenstrom macroglubulinemia

2(a) 221 Lymphoplasmacytic lymphoma 610 840 ( 784 883) 1000 ( - - ) 864 ( 796 910 ) 820 ( 734 880)2(a) 222 Waldenstrom macroglubulinemia 676 868 ( 811 908) - ( - - ) 949 ( 882 978 ) 826 ( 747 883)

2(a) 23 Diffuse large B-cell lymphoma (DLBCL) 15762 632 ( 622 641) 872 ( 807 916 ) 761 ( 749 773 ) 531 ( 516 545)2(a) 231 DLBCL NOSc 15450 628 ( 618 637) 868 ( 799 914 ) 756 ( 744 768 ) 531 ( 516 545)2(a) 232 Intravascular large B-cell 42 575 ( 395 719) - ( - - ) 561 ( 301 758 ) 570 ( 323 756)

lymphoma2(a) 233 Primary effusion lymphoma 5 - ( - - ) - ( - - ) - ( - - ) 00 ( - - )2(a) 234 Mediastinal large B-cell 265 881 ( 828 918) 917 ( 538 988 ) 899 ( 845 935 ) 374 ( 95 663)

lymphoma2(a) 24 Burkitt lymphomaleukemia 583 606 ( 560 649) 921 ( 842 962 ) 596 ( 533 653 ) 364 ( 282 447)2(a) 25 Marginal-zone lymphoma (MZL) 5391 916 ( 901 929) 948 ( 680 992 ) 954 ( 939 965 ) 883 ( 856 905)2(a) 251 Splenic MZL 446 893 ( 839 930) - ( - - ) 930 ( 853 967 ) 863 ( 791 911)2(a) 252 Extranodal MZL MALTc type 3425 942 ( 924 956) 938 ( 632 991 ) 963 ( 946 975 ) 919 ( 884 944)2(a) 253 Nodal MZL 1520 862 ( 830 888) 1000 ( - - ) 932 ( 897 956 ) 807 ( 756 848)

2(a) 26 Follicular lymphoma 8770 884 ( 873 895) 901 ( 469 986 ) 940 ( 929 949 ) 820 ( 798 839)2(a) 27 Hairy-cell leukemia 314 911 ( 848 949) - ( - - ) 975 ( 930 991 ) 764 ( 606 866)2(a) 28 Plasma cell neoplasms 15354 523 ( 512 534) 756 ( 324 933 ) 657 ( 642 672 ) 430 ( 415 445)2(a) 281 Plasmacytoma 795 727 ( 681 766) 857 ( 334 979 ) 832 ( 777 875 ) 599 ( 527 663)2(a) 282 Multiple myeloma 14559 512 ( 501 523) 00 ( - - ) 644 ( 628 660 ) 422 ( 407 437)

plasma-cell leukemia2(a) 29 Heavy chain disease 8 638 ( 227 873) - ( - - ) - ( - - ) 414 ( 51 770)2(a) 3 Non-Hodgkin lymphoma B-cell NOSc 3970 692 ( 670 712) 877 ( 590 968 ) 826 ( 798 850 ) 626 ( 597 654)

Table 1931All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 37: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

a Morton LM Turner JJ Cerhan JR Linet MS Treseler PA Clarke CA Jack A Cozen W Maynadieacute M Spinelli JJ Costantini ASRuumldiger T Scarpa A Zheng T Weisenburger DD Proposed classification of lymphoid neoplasms for epidemiologic research fromthe Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood 2007110695-708

b SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey andGeorgia excluding ATLRG) Expected survival rates are derived from life tables by socio-economic status geography and racedeveloped by the SEER program

c NOS = Not otherwise specified MALT = Mucosa-associated lymphoid tissue NK = Natural killerd Total precursor lymphomaleukemia is comprised of categories 2(a)1 2(b)1 and 2(c)1- Statistic not displayed due to less than 25 cases

All Ages Ages 0-19 Ages 20-64 Ages 65+ Site Count Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI ) Percent ( 95 CI )

2(b) Non-Hodgkin lymphoma T-cell 4550 674 ( 657 691) 854 ( 814 887 ) 751 ( 731 770 ) 515 ( 482 546)2(b) 1 Precursor Non-Hodgkin lymphoma T-cell 56 679 ( 537 787) 917 ( 706 979 ) 620 ( 392 783 ) - ( - - )2(b) 2 Mature Non-Hodgkin lymphoma T-cell 4487 674 ( 657 691) 850 ( 808 884 ) 753 ( 732 772 ) 516 ( 483 548)2(b) 21 Mycosis fungoidesSezary syndrome 1213 928 ( 898 949) 1000 ( - - ) 960 ( 932 976 ) 860 ( 785 910)2(b) 211 Mycosis fungoides 1171 945 ( 915 965) 1000 ( - - ) 974 ( 945 987 ) 883 ( 804 931)2(b) 212 Sezary syndrome 42 382 ( 207 555) - ( - - ) 396 ( 148 639 ) 355 ( 131 590)

2(b) 22 Peripheral T-cell lymphoma 2474 604 ( 580 627) 885 ( 803 934 ) 715 ( 685 742 ) 436 ( 396 475)2(b) 221 Peripheral T-cell lymphoma NOSc 851 395 ( 355 435) 566 ( 268 782 ) 519 ( 462 572 ) 277 ( 223 333)2(b) 222 Angioimmunoblastic T-cell 343 411 ( 346 475) - ( - - ) 604 ( 497 695 ) 301 ( 224 381)

lymphoma2(b) 223 Subcutaneous panniculitis- 54 917 ( 750 974) 1000 ( - - ) 860 ( 639 950 ) 1000 ( - - )

like T-cell lymphoma2(b) 224 Anaplastic large cell lymphoma 430 728 ( 676 773) 910 ( 794 962 ) 777 ( 714 827 ) 463 ( 361 559)

T-cell or null-cell type2(b) 225 Hepatosplenic T-cell lymphoma 21 126 ( 10 392) - ( - - ) 127 ( 10 395 ) - ( - - )2(b) 226 Enteropathy-type T-cell lymphoma 31 86 ( 16 235) - ( - - ) 00 ( - - ) 135 ( 23 343)2(b) 227 Cutaneous T-cell lymphoma NOSc 512 846 ( 794 885) 1000 ( - - ) 894 ( 839 931 ) 749 ( 642 829)2(b) 228 Primary cutaneous anaplastic 232 895 ( 812 943) 923 ( 566 989 ) 932 ( 856 968 ) 820 ( 608 924)

large cell lymphoma2(b) 23 Adult T-cell leukemialymphoma 525 596 ( 545 643) 817 ( 757 864 ) 477 ( 394 556 ) 235 ( 128 361)2(b) 24 NKcT-cell lymphoma nasal-type 182 426 ( 343 506) - ( - - ) 476 ( 380 565 ) 298 ( 149 462)

agressive NKc-cell leukemia2(b) 25 T-cell large granular lymphocytic 16 663 ( 308 867) - ( - - ) 858 ( 331 979 ) 449 ( 79 777)

leukemia2(b) 26 Prolymphocytic leukemia T-cell 77 111 ( 41 218) - ( - - ) 238 ( 89 427 ) 00 ( - - )2(b) 3 Non-Hodgkin lymphoma NOSc T-cell 7 574 ( 171 840) - ( - - ) 501 ( 111 805 ) 1000 ( - - )2(c) Non-Hodgkin lymphoma unknown lineage 215 576 ( 496 648) 902 ( 723 967 ) 567 ( 441 675 ) 469 ( 353 577)2(c) 1 Precursor lymphoblastic leukemia 69 705 ( 573 802) 902 ( 723 967 ) 565 ( 346 736 ) 341 ( 79 635)

lymphoma unknown lineage2(c) 2 Prolymphocytic leukemia unknown 9 228 ( 34 524) - ( - - ) - ( - - ) 228 ( 34 524)

lineage2(c) 3 Non-Hodgkin lymphoma NOSc unknown 137 531 ( 427 625) - ( - - ) 568 ( 411 698 ) 501 ( 369 619)

lineage2() 1 Total precursor lymphomaleukemiad 4076 696 ( 680 712) 897 ( 882 910 ) 429 ( 395 463 ) 215 ( 165 270)

3 Composite Hodgkin lymphoma and Non-Hodgkin 127 696 ( 571 791) - ( - - ) 832 ( 685 915 ) 524 ( 314 697)lymphoma

4 Lymphoid neoplasm NOSc 1779 542 ( 513 571) 863 ( 708 939 ) 758 ( 717 793 ) 412 ( 373 451)

Table 1931 - continuedAll Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races Females 2009-2015

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 38: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

0

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

5

10

15

20

25

30

35

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 20160

4

8

12

16

20

1975 1985 1995 2005 2016

Delay-Adj IncidenceDelay-Adj Incidence

Observed IncidenceObserved Incidence

MortalityMortality

SEER Observed Incidence SEER Delay Adjusted Incidence and US Death RatesNon-Hodgkin Lymphoma by Race and Sex

a

Figure 191

Source SEER 9 areas and US Mortality Files (National Center for Health Statistics CDC)Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines and APCs are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer InstituteThe APC is the Annual Percent Change for the regression line segments The APC shown on the graph is for the most recent trendThe APC is significantly different from zero (p lt 005)

a

White Male Black Male White Female Black FemaleRate per 100000 Rate per 100000 Rate per 100000 Rate per 100000

Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath Year of DiagnosisDeath

SEER Incidence APCsDelay Adj 2008-16 = -07Observed 2008-16 = -09

US Mortality APC2006-16 = -20

SEER Incidence APCsDelay Adj 1994-16 = -02Observed 1994-16 = -04

US Mortality APC1996-16 = -24

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -08

US Mortality APC2004-16 = -27

SEER Incidence APCsDelay Adj 2004-16 = -06Observed 2004-16 = -09

US Mortality APC1996-16 = -22

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 39: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

Joinpoint Analyses for Whites and Blacks from 1975-2016and for AsianPacific Islanders American IndiansAlaska Natives and Hispanics from 2000-2016

0

5

10

15

20

25

1975 1985 1995 2005 20160

5

10

15

20

25

1975 1985 1995 2005 2016

White

Black

API

AIAN

Hispanic

SEER Incidence and US Death RatesNon-Hodgkin Lymphoma Both Sexes

Figure 192

Source Incidence data for whites and blacks are from the SEER 9 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah Atlanta)Incidence data for AsianPacific Islanders American IndiansAlaska Natives and Hispanics are from the SEER 21 areas (SEER 9 areas San Jose-MontereyLos Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLA Kentucky Louisiana New Jersey Georgia excluding ATLRG Idaho New York andMassachusetts)Mortality data are from US Mortality Files National Center for Health Statistics CDCRates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103)Regression lines are calculated using the Joinpoint Regression Program Version 47 February 2019 National Cancer Institute Joinpoint analyses for Whites andBlacks during the 1975-2016 period allow a maximum of 5 joinpoints Analyses for other ethnic groups during the period 2000-2016 allow a maximum of 3 joinpointsAPI = AsianPacific IslanderAIAN = American IndianAlaska Native Rates for American IndianAlaska Native are based on the PurchasedReferred Care Delivery Area (PRCDA) countiesHispanic is not mutually exclusive from whites blacks AsianPacific Islanders and American IndiansAlaska Natives Incidence data for Hispanics are based onNHIA and exclude cases from the Alaska Native Registry

Incidence MortalityRate per 100000 Rate per 100000

Year of Diagnosis Year of Death

a

d

a

b

c

c

b

d

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 40: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

0 20 40 60 80 100

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

All Ages

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 55+

All SEER Areas

SEER 9 Areas excludingSan Francisco Registry

San Francisco Registry

San Francisco CityCounty

Ages 20-54

1980 2016

Figure 193

Non-Hodgkin LymphomaIncidence Rates 1980 vs 2016

Males by Age at Diagnosis and SEER area

Source SEER 9 areas Rates are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1103)

AgeArea

Rate per 100000

Year of DX

Ages 20-54

Ages 55+

All Ages

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 41: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

0

50

100

150

200

0-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+

1975-1977

2014-2016

Figure194

Non-Hodgkin LymphomaSEER Incidence by Age1975-1977 vs 2014-2016

All Races Males

Source SEER 9 areas Rates are age-adjusted as appropriate to the 2000 US Std Population (19 age groups - Census P25-1103)

Rate per 100000

Age at Diagnosis

SEE

R C

ancer Statistics Review

1975-2016N

ational Cancer Institute

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival
Page 42: SEER Cancer Statistics Review 1975-2016...Hispanic f 2000-16 .4*0 .4*0 .4*0 U.S. Cancer Mortality c, 1975-2016 All Races 1975-94 .2*2 1994-97 .01 1997-08 .3*-3 2008-16 .5*-2 .6*-2

Figure 195

Non-Hodgkin Lymphoma5-Year SEER Conditional Relative Survival and

95 Confidence Intervals

Source SEER 18 areas (San Francisco Connecticut Detroit Hawaii Iowa New Mexico Seattle Utah AtlantaSan Jose-Monterey Los Angeles Alaska Native Registry Rural Georgia California excluding SFSJMLAKentucky Louisiana New Jersey and Georgia excluding ATLRG)Percent surviving is not shown if based on less than 25 casesConfidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error

0

20

40

60

80

100Percent Surviving Next 5 Years

Stage at Diagnosis

Probabilty of surviving the next 5 years given the cohort has already survived 0 1 or 3 years

2000-2015 by stage at diagnosis

Survival Time Since Diagnosis

Localized Regional Distant Unstaged

0 year (at diagnosis) 1 year 3 years

SEER Cancer Statistics Review 1975-2016 National Cancer Institute

  • Trends in SEER Incidence and US Mortality Both Sexes
  • Trends in SEER Incidence and US Mortality Males
  • Trends in SEER Incidence and US Mortality Females
  • Annual Delay-adjusted Incidence Rates
  • Annual Incidence Rates
  • Annual Death Rates
  • Incidence and Mortality Rates by Age
  • 5-year Relative and Period Survival
  • Relative Survival by Year of Diagnosis Both Sexes
  • Relative Survival by Year of Diagnosis Males
  • Relative Survival by Year of Diagnosis Females
  • Number Of Cases by SEER Area Males All Ages
  • Number Of Cases by SEER Area Males Ages 0-19
  • Number Of Cases by SEER Area Males Ages 20-54
  • Number Of Cases by SEER Area Males Ages 55+
  • Risk of DevelopingDying Both Sexes
  • Risk of DevelopingDying Males
  • Risk of DevelopingDying Females
  • Rates and Trends by RaceEthnicity
  • Age-Adjusted SEER Incidence Rates by Registry
  • Age-Adjusted SEER Death Rates by Registry
  • Age-Adjusted Cancer Death Rates By State Both Sexes
  • Age-Adjusted Cancer Death Rates By State Males
  • Age-Adjusted Cancer Death Rates By State Females
  • US Prevalence Estimates
  • Incidence Rates and APC Lymphoma Subtypes Both Sexes
  • Incidence Rates and APC Lymphoma Subtypes Males
  • Incidence Rates and APC Lymphoma Subtypes Females
  • 5-Year Relative Survival Lymphoma Subtypes Both Sexes
  • 5-Year Relative Survival Lymphoma Subtypes Males
  • 5-Year Relative Survival Lymphoma Subtypes Females
  • Graph - SEER Incidence Delay Adjusted Incidence and US Death Rates by Race and Sex
  • Graph - SEER Incidence and US Death Rates by RaceEthnicity
  • Graph - SEER Incidence Rates by AgeArea Males
  • Graph - SEER Incidence Rates by Age All Races Males
  • Graph - 5-Year SEER Conditional Relative Survival